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Preamble
This thesis was accomplished in the Institut de Biologie Structurale – Jean-Pierre Ebel, Grenoble
(FRANCE), under supervision of Pr. Franck Fieschi.
Although this work is aﬃliated to Grenoble University Joseph Fourier and by the University
regulations it should be written in French language, due to the European context of the work and
my non-french nationality, it is presented in English language. However, the requirement of the title
to be in French is regarded, and the title of the thesis in English is the following:
Development of the glycomimetic antagonists of the C-type lectin
receptor DC-SIGN: a new strategy of HIV infection prevention
The work presented herein is the part of the research project of the European ITN CARMUSYS
(http://www.carmusys.iiq.csic.es/), which aims to develop inhibitors of DC-SIGN, the C-type
lectin receptor usurped by a wide range of pathogens, including HIV.
The thesis project was conducted in several collaborations with the following researchers:
✧ Pr. Anna Bernardi, Universita’ degli Studi di Milano, Dipartimento di Chimica Organica e
Industriale and CISI, Milano, ITALY.
✧ Dr. F. Javier Rojo Marcos, Instituto de Investigaciones Químicas, CSIC, Seville, SPAIN.
✧ Pr. Jitka Moravcová, Institute of Chemical Technology, Prague, CZECH REPUBLIC.
✧ Dr. Pedro Manuel Nieto Mesa, Instituto de Investigaciones Químicas, CSIC, Seville, SPAIN.
✧ Dr. Jörg Weiser, Anterio Consult & Research GMBH, Mannheim, GERMANY.
The overall structure of ITN CARMUSYS and the description of the collaborations can be found
in figure 4.1 on page 94.
The thesis is organized in four parts: Introduction, where the scientific background and the
objectives of the thesis project are presented; Matherials&Methods; Results; and Discussion
and future perspectives. The organization of the results in this thesis can be viewed in figure 7.1
on page 119. In the Appendix the articles and the relevant information is added.
The work lasted from 1st of October, 2009, untill 9thof December, 2012. During this period, I
have accomplished two secondments in the context of CARMUSYS network:
✧ a short-term secondment (15th - 19th November, 2010) in Anterio Consult & Research GMBH.
Mannheim (Germany) with Dr. Pietro Alfarano, a post-doctoral student in CARMUSYS.
There I got familiar with the docking procedures of the small molecules to DC-SIGN binding
site using Schrödinger Suite (Glide). I have also got acquainted with other applications within
Schrödinger Suite (Maestro, Primex, etc.);
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✧ a long-term secondment (26th September - 7thDecember, 2011) in Instituto de Investigaciones
Químicas, CSIC. Seville (Spain) with a PhD student Cinzia Guzzi, Dr. Jesus Angulo and Dr.
Pedro Nieto. I learnt there the basics of nuclear magnetic resonance (NMR) theory, saturation
transfer diﬀerence (STD) NMR technique and was involved in STD NMR experiments as well
as data analysis.
Additionally, I have supervised the long-term secondment (7th March 2011 - 19th May 2011) of
a PhD student Joanna Luczkowiak. During this period, we attempted to study the interaction
of pseudotyped viral particles (HIV, Ebola) with immobilized DC-SIGN using surface plasmon
resonance technique. The results of these studies are not presented in this thesis.
The work was financially supported by the Marie Curie ITN FP7 project CARMUSYS (PITN-
GA-2008-213592).
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a.a. amino acids
Ac-LDL Acetylated low density lipoprotein
AGE Advanced glycation end-product
AIDS Acquired Immunodeficiency Syndrome
APCs Antigen Presenting Cells
ARV Antiretroviral
AUC Analytical Ultracentrifugation
BCG Mycobacterium bovis Bacillus Calmette Guérin
BG Birbeck Granules
cDNA complementary DNA
CEA Carcinoembryonic antigen
CLRs C-type lectin receptors
CM CarboxyMethyl
CMV Cytomegalovirus
CRD Carbohydrate recognition domain
CRP C-reactive protein
CTLDs C-type lectin-like domains
CuAAC Cu(I) catalyzed azide−alkyne cycloaddition
DAP Diaminopimelic acid
DCs Dendritic cells
DC-SIGN DC-Specific ICAM3 Grabbing Non-integrin
DLS Dynamic Light Scattering
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
7
dNTP deoxyribonucleotide triphosphates
dsRNA double-stranded RNA
ECD Extracellular domain
ECM Extracellular matrix
EDC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
EDTA Ethylenediaminetetraacetic acid
EPO Erythropoietin
Fc Flow cell
Flt3L Fms-like tyrosine kinase 3 ligand
FPLC Fast Protein Liquid Chromatography
G- Gram-negative bacteria
G+ Gram-positive bacteria
GalNAc N-acetylgalactose amine
G-CSF Granulocyte Colony-Stimulating Factor
Gdn-HCl Guanidine hydrochloride
GlcNAc N-acetylglucose amine
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor
GPI Glycosylphosphatidyl inositol
GM-tripeptide N-acetyl-D-glucosaminyl-β(1,4)-N-acetylmuramyl-L-Ala-D-Glu
GNPs Gold nanoparticles
HAART Highly Active AntiRetroviral Treatment
HCV Hepatitis C Virus
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIV Human Immunodeficiency Virus
HRP Horse Radish Peroxidase
HSC Hematopoietic Stem Cell
HSV Herpes Simplex Virus
iDCs immature DCs
ICAM-3 InterCellular Adhesion Molecule-3
IFN Interferon
IL Interleukin
IPTG β-D-1-thiogalactopyranoside
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ITAMs Immunoreceptor Tyrosine-based Activation Motifs
ITC Isothermal Titration Calorimetry
ITIMs Immunoreceptor Tyrosine-based Inhibition Motifs
ITN Initial Training Network
LB Luria Bertani
LCs Langerhans cells
LDL Low-Density Lipoproteins
LDN-antigen GalNAcβ1-4GlcNAc-R
LDNF-antigen GalNAcβ1-4(Fucα1-3)GlcNAc-R
LPS Lipopolysaccharide
LSECtin Liver and lymph node sinusoidal endothelial cell C-type lectin
LTA Lipoteichoic acid
MØ Macrophages
ManBSA Mannosylated Bovine Serum Albumin
MARCO Macrophage receptor with a collagenous structure
MBL Mannan-Binding Lectin
M-CSF Macrophage Colony-Stimulating Factor
mDCs mature DCs
MDP Muramyl Dipeptide
MES 2-(N -morpholino)ethanesulfonic acid
MGL Macrophage Galactose-type C-type Lectin
MHC Major Histocompatibility Complex
Mo Monocytes
myDCs myeloid DCs
MWCO Molecular Weight Cut Oﬀ
NADPH Nicotinamide Adenine Dinucleotide Phosphate
Neu Neutrophils
NHS N -hydroxysuccinimide
NKs Natural killer cells
NMR Nuclear Magnetic Resonance
NOX NADPH oxidases
OAS 2’-5’-oligoadenylate synthase
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Ox-LDL Oxidized LDL
PAMPs Pathogen Associated Molecular Patterns
PBMCs Peripheral Blood Mononuclear Cells
PBS Phosphate buﬀered saline
PCR Polymerase Chain Reaction
pDCs plasmacytoid DCs
PES Polyethersulfone
PGRPs Peptidoglycan-recognition proteins
PKR Protein kinase R
PMNs Polymorphonuclear neutrophils
PRRs Pattern Recognition Receptors
psDi pseudomannobioside
psTri pseudomannotrioside
PVDF Polyvinylidene fluoride
RIG-1 Retinoid acid–inducible gene–1
RLRs RIG-1-like receptors
RNA Ribonucleic acid
ROS Reactive Oxygen Species
RU Resonance/Response Units
SAP Serum Amyloid Protein
SARS Severe Acute Respiratory Syndrome-associated
SAXS Small Angle X-ray Scattering
SCF Stem Cell Factor
SD Standard Deviation
SDS Sodium Dodecyl Sulfate
SDS-PAGE Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis
SLS Static light scattering
SPR Surface Plasmon Resonance
STI Sexually Transmitted Infections
sLewisX sulphated LewisX
ssRNA single-stranded RNA
TAE Tris-acetate-EDTA buﬀer (40mM Tris, 20mM acetic acid, 1mM EDTA)
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TCR T Cell Receptor
TE Tris-EDTA buﬀer (10mM Tris-HCl pH 8, 1mM EDTA)
TEMED Tetramethylethylenediamine
TGF Transforming Growth Factor
Th T helper cells
TIRF Total Internal Reflection Fluorescence
TLRs Toll-like receptors
TM Transmembrane domain
Tn-antigen GalNAcα1-O-Ser/Thr
TNF Tumor Necrosis Factor
TPO Thrombopoietin
TRAPs Transmembrane adaptor proteins
UGRP-1 Uteroglobin-Related Protein 1
VHMs Vaginal HIV microbicides
WB Western Blot
WNV West Nile Virus
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Les résumés en Français 
 
 
Introduction 
 
L’objet central de ce travail de recherche est DC-SIGN (Dendritic Cell Specific ICAM-3 Grabbing Non-
integrin) un récepteur lectine de type C exprimée sur les cellules dendritiques et impliqués dans les processus 
infectieux de nombreux agents pathogènes, dont le virus de l’immunodéficience humaine (VIH). Les cellules 
dendritiques (DC) sont un élément très important de l’immunité innée. Elles ont un rôle de sentinelles au sein des 
tissus périphériques pour détecter les agents pathogènes envahisseurs, les capturer et présenter des antigènes dérivés 
de ceux-ci aux lymphocytes T pour l’induction de réponses immunitaires adaptatives. 
Bien que DC-SIGN soit exploitée par de nombreux agents pathogènes comme le virus Ebola, la dengue et 
d’autres virus, mycobactéries de la tuberculose et d’autres pathogènes dangereux, ce travail de thèse se concentre 
sur les étapes de l’infection à VIH dépendantes de DC-SIGN. 
Compte tenu de ces enjeux, l’introduction de cette thèse est divisée en trois chapitres, dont chacun décrit 
brièvement ces points : l’immunité innée, la transmission sexuelle du VIH et la prévention de la transmission 
sexuelle du VIH, tandis que le quatrième chapitre présente la portée et les objectifs de ce travail de recherche. 
 
 
Chapitre 1. Un aperçu de l’immunité innée de l’homme 
 
L’immunité innée a un rôle primordial, car c’est la première ligne de défense de l’organisme contre les agents 
pathogènes et elle active dans un second temps l’immunité adaptative. Ce chapitre décrit brièvement les éléments 
les plus importants de l’immunité innée, qu’ils soient d’ordre anatomique, chimique, ou physiologique 
(température, pH, facteurs solubles). Il décrira également les acteurs cellulaires impliqués. 
La peau et les muqueuses représentent un obstacle physique pour l’invasion des pathogènes. Elles sont 
également protégées par des substances antimicrobiennes sécrétées par les kératinocytes ou des cellules épithéliales 
spécialisées, et ces substances comprennent les mucines, des enzymes et des peptides antimicrobiens. En outre, la peau 
et les muqueuses sont habités par des microorganismes non pathogènes, de la flore normale ou microbiote 
commensal, qui sont en concurrence avec les pathogènes pour les nutriments et les sites de fixation et, de cette 
façon, participent à la défense de l’organisme. La température, plus basse à la surface de la peau, le pH acide de 
la peau et des muqueuses et d’autres facteurs solubles constituent une barrière chimique physiologique. 
Les cellules de l’immunité innée fournissent une défense plus spécifique contre les infections. Ces cellules, 
chacune ayant un rôle spécifique, comprennent les macrophages, les neutrophiles, les basophiles, les éosinophiles, 
les mastocytes, les cellules tueuses (natural killer cells), et les cellules dendritiques (CD). Toutes ces cellules se 
développent, sous la stimulation par certaines cytokines, à partir de précurseurs cellulaire commun de la moelle 
osseuse, les cellule souche hématopoïétique (CSH). 
Les CDs sont constitués d’un groupe diversifié de cellules présentatrices d’antigène profes- sionnelles 
(APC). Cette diversité résultent d’une combinaison de plusieurs facteurs tels que leurs origine, leur état de 
di!érenciation, et leur localisation tissulaire. Les CDs sont particulièrement 
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importantes car elles constituent un lien entre l’immunité innée et adaptative - leur rôle principal est 
d’induire l’immunité adaptative. Les CDs immatures passent en revue les tissus périphériques et y capturent les 
micro-organismes étrangers. Cela conduit à la présentation de l’antigène dérivée des pathogènes à leur surface 
conjointement à la migration vers les organes lymphoïdes où les CDs rencontreront des cellules T naïves et les 
activer. 
L’identification des micro-organismes étrangers par l’immunité innée est basée sur la reconnais- sance des 
structures moléculaires conservés propres aux micro-organismes et absentes chez l’hôte. Ces structures sont appelées 
“motifs moléculaires associés à des pathogènes” (PAMPs en anglais). 
Les récepteurs du système immunitaire inné qui reconnaissent les PAMPs sont appelés Pattern Recognition 
Receptors (PRR). Les PRRs exercent leur fonction par la phagocytose des pathogènes, l’activation des voies de 
signalisation pro-inflammatoires, l’opsonisation, l’activation de cascades du complément et de la coagulation, et 
l’induction de l’apoptose des celluels infectées. Les PRRs peuvent être solubles, exprimées à la surface cellulaire ou 
intra-cellulaire. Les récepteurs lectine de type-C (CLRs) sont l’une des familles de PRsR. Les CLRs reconnaissent des 
groupements glucidiques spécifiques présent à la surface de ses cibles. Cette reconnaissance est dépendantes d’ions 
Ca2+ présents dans le site actif. 
 
 
Chapitre 2. Virus de l’immunodéficience humaine (VIH): l’infection par 
transmission sexuelle 
 
La transmission sexuelle par le biais des muqueuses génitales et rectales est responsable de la grande majorité 
des infections à VIH dans le monde. Les di!érentes voies d’invasion du VIH dans les muqueuses et le mécanisme 
de sa transmission puis de l’infection de sa cible cellulaire majeure, les cellules T CD4 +, sont décrite dans ce 
chapitre. 
L’infection à VIH par transmission sexuelle commence au niveau des muqueuses génitale (ou rectal) où les 
virions du VIH détournent les CDs stromales, comme des chevaux de Troie, pour at- teindre les lymphocytes T 
CD4+. Cependant, un autre sous-type de CDs, les cellules de Langerhans (CL) résidant dans la couche supérieure 
de la muqueuse épithéliale, a été découvert pour supprimer l’infection par  le  VIH. 
Il a été démontré que les récepteurs, de type CLR, impliqués dans la capture du VIH, que soit par les 
CDs stromales du derme ou les cellules de langerhans de l’épiderme, sont étroitement liés (DC-SIGN et 
langerine, respectivement). Mais la capture du VIH par DC-SIGN résulte dans une promotion de l’infection, 
alors que la reconnaissance par langérine conduit à une protection vis à vis de l’infection (élimination de 
virus). Ces deux récepteurs interagissent avec le virus au travers des nombreuses glycosylations présentes à sa 
surface sur la protéine d’enveloppe gp120. Une description détaillée de la structure et de la fonction de ces deux 
CLRs, ainsi que leur comparaison, est présentée dans ce chapitre. 
 
Chapitre 3.  VIH stratégie prévention de la transmission sexuelle 
 
Plus de 40 millions de personnes dans le monde sont infectées par le VIH. Malheureusement, il n’existe pas 
de remède pour l’infection à VIH à ce jour et le traitement de long-terme disponible, le HAART (traitement 
antirétroviral hautement actif, il combine plusieurs substances qui interfèrent à di!érentes étapes du cycle 
viral), est assez cher et accessible que pour une faible population 
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des personnes infectées. Ainsi, le développement de moyens de prévention de l’infection est d’une importance 
capitale, car ce serait le moyen le plus e!cace pour enrayer l’épidémie. 
 
Bien que la transmission sexuelle par la muqueuse génitale est la voie dominante de l’infection pour les deux 
sexes, les femmes semblent être plus sensibles à ce type d’invasion virale dans les tissus vaginaux et utérins. Les 
microbicides vaginaux anti-VIH (VHMs), des substances destinées à bloquer les événements précoces de l’infection à 
VIH, sont une alternative prometteuse pour une prévention saine et e!cace de la transmission sexuelle du VIH. 
De plus, les VHMs représentent un nouvel outil de prévention particulièrement attractif pour les femmes. En 
e"et, ils permettraient une autonomie de celles-ci dans leur protection. En e"et, dans les régions à haut 
risque de certains pays en développement les femmes ne sont pas toujours en mesure de réduire leurs risques de 
contamination, en contraignant leur partenaires, pour des raisons sociales, culturelles et économiques. Les types, le 
mode d’action et des exemples de VHMs sont détaillées dans ce chapitre. 
 
Dans la recherche de nouveaux modes de prévention du VIH, DC-SIGN a été identifié comme une cible 
thérapeutique potentielle en raison de son rôle important dans la potentialisation de l’infection à VIH et la 
di"usion dans les muqueuses. Puisque DC-SIGN est un récepteur lectine qui reconnaît des monosaccharides 
mannose et fucose dans les structures oligosaccharidiques cibles, la stratégie de synthèses de glycomimétiques 
correspondant pourrait être utilisée pour concevoir des antagonistes de DC-SIGN. 
 
Les glycomimétiques peuvent être définis comme des entités chimiques qui imitent les glucides bioactifs et se 
lient aux protéines cibles, principalement des lectines ou des enzymes modifiant des sucres, interférant ainsi avec le 
processus ciblés. Les substances médicamenteuses glycomimétique présentent plusieurs avantages par rapport aux 
ligands glucidiques naturels: elles peuvent être conçues pour avoir une plus grande a!nité et spécificité pour la 
protéine cible ainsi qu’une demi-vie plasmatique plus longue (au travers d’une résistance renforcée aux glycosidases). 
Cette stratégie de conception de glycomimétique et les exemples de réussite sont décrits dans ce chapitre. 
 
DC-SIGN reconnaît des monosaccharides de type mannose et fucose. Ainsi la  principale stratégie de 
développement de glycomimétique spécifique de DC-SIGN est de conserver le mannose ou le fucose comme ancre 
de reconnaissance primaire, tandis que d’autres parties de la molécule peut être conçu et optimisé pour atteindre la 
meilleure a!nité, et apporter de la spécificité. Les travaux préalables disponibles à propos des tentatives  de  
production  de  ligands  dirigées  contre  DC-SIGN sont détaillées dans ce chapitre. 
 
La conception de ligands monovalents pour DC-SIGN est la première étape dans le développe- ment des 
antagonistes. Cependant, dans les systèmes biologiques, les interactions entre DC-SIGN avec ses ligands, en 
particulier les PAMPs comme la glycoprotéine d’enveloppe gp120 du VIH, sont de nature multivalente. Cela 
conduit, au travers d’un phénomène d’avidité, à une a!nité globale bien supérieur à l’interaction primaire 
d’un sucre avec un site actif de DC-SIGN. Par conséquent, les ligand monovalent glycomimétiques de DC-
SIGN doivent être au final présentées en plusieurs exemplaires sur une plate-forme moléculaire donnée, afin 
d’obtenir une substance qui est capable de rivaliser, par multivalence, avec les interactions DC-SIGN/pathogen. 
Les di"érentes stratégies de développement de telles plateformes multivalentes et des exemples préalables, 
dirigés contre DC-SIGN, sont décrits dans ce chapitre. 
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Chapitre 4. La portée et les objectifs de cette thèse 
 
L’objectif principal de cette thèse est de développer des antagonistes sélectifs de DC-SIGN, et sa réalisation 
implique les tâches suivantes: 
 
! Criblage de ligand monovalent par test de compétition SPR pour: 
 
– identifier les meilleurs ligands de DC-SIGN; 
 
– évaluer le rapport de sélectivité pour DC-SIGN vis-à-vis de la langerine. 
 
! Caractérisation structurale des modes d’interactions avec DC-SIGN des composés sélectionnés par 
cristallographie aux rayons X. 
 
! Caractérisation  hydrodynamique/thermodynamique  de  l’interaction  de  DC-SIGN  avec  les composés 
d’intérêt. 
 
!  Criblage des composés multivalent par des analyses SPR: 
 
– mise au point/optimisation des tests; 
 
– détermination du pouvoir inhibiteur des dendrimers vis à vis de DC-SIGN (test de com- pétition); 
 
– l’évaluation de l’interaction directe des composés avec DC-SIGN. 
 
 
En plus de ces tâches, une partie de mon travail a été la surexpression et la purification des constructions ECD et 
CRD de DC-SIGN, nécessaires pour les approches SPR et les tests et co-cristallisation mais également pour fournir 
nos partenaires en protéines pour leurs propres expériences. 
En outre, la caractérisation de la sélectivité des composés étant une des préoccupations de cette thèse, une 
autre tâche a été le développement de la production d’autres lectines de type C, à savoir la LSECtin et MGL. 
 
 
Chapitre 5. Matériels 
 
Tous les produits chimiques, biologiques et les équipements utilisés dans ce travail sont détaillés dans ce 
chapitre. 
 
 
Chapitre 6. Méthodes 
 
Ce chapitre décrit en détail toutes les procédures expérimentales utilisées dans ce travail de recherche. 
 
 
 
Chapitre 7. L’explication de l’organisation des résultats dans cette thèse 
 
Ce chapitre décrit l’organisation du travail au sein de cette thèse et dans le contexte du réseau européen 
(résumé dans la figure 7.1). 
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Chapitre 8.  Préparation de lectines recombinantes 
 
Ce chapitre contient les résultats de la prorduction de di!érentes lectines. Pour commencer, la production de 
di!érentes constructions DC-SIGN, qui ont été utilisés pour l’évaluation composé glycomimétique structurelle 
et fonctionnelle, sont présentés dans la section 8.1. 
La production de DC-SIGN ECD a été réalisé sans obstacle majeur, et des rendements con- sidérables de 
protéines purifiées fonctionnelles ont été obtenus (habituellement 50-80 mg de 1 L de culture cellulaire). 
Étonnamment, l’ajout de StrepTag II à extrémité N-terminale de DC-SIGN ECD entraîne une nettement 
diminution du rendement de protéine purifiée principalement en raison de fortes précipitations pendant les étapes 
de repliement. Néanmoins, seules de faibles quantités de cette construction sont été nécessaires pour la préparation 
de la surface orientée pour les dosage en interaction directe par SPR. 
Les e!orts d’optimisation des rendements de production de DC-SIGN S-CRD n’ont pas aboutis. 
Cependant, la raison de la faiblesse des rendements a été révélé: lors des étapes de concentrations, la protéine forme 
des ponts disulfures non fonctionnels. 
En dehors de DC-SIGN, di!érentes constructions de deux autres lectines de type C, à savoir 
LSECtin et MGL, ont été réalisé dans le but d’étendre les outils d’analyse de la sélectivité des composés. Les 
résultats du clonage et de l’évaluation de l’expression des divers des constructions sont présentées dans la section 
8.2. 
Quatre nouvelles constructions lectine de type C ont été développés pour l’utilisation future dans le 
laboratoire: LSECtin S-CRD et S-ECD ainsi que MGL S-CRD et S-ECD. A l’exception de LSECtin S-
CRD, toutes les constructions se sont révélées capables d’exprimer e"cacement les protéines correspondantes. 
Néanmoins, LSECtin S-CRD construction est également produit mais le niveau d’expression est plus faible. 
La production de MGL S-ECD a été étudiée un peu plus loin, et les premiers essais de purifi- cation de 
cette construction ont été réalisés. Bien que des résultats prometteurs ont été obtenus, la procédure doit être 
optimisé. 
 
 
 
Chapitre 9. Les résultats de la mise au point de glycomimétique antagonistes de DC-
SIGN. 
 
Ce chapitre décrit la mise au point de composés glycomimétique, et est également divisée en deux sous-parties 
principales, dont l’une décrit le développement de glycomimétiques monovalents, et dans la seconde les 
résultats de la mise au point de composés multivalents sont présentés. 
Le développement de composé monovalent a été menée en trois axe parallèles: 
 
! L’équipe du Pr. Jitka Moravcová a développé les C-glycosides et les résultats de leur évaluation sont présentés au 
paragraphe 9.1.2. 
 
! L’équipe du Pr.   Anna équipe de Bernardi a travaillé sur deux concepts, à savoir des glycomimétiques à 
base de fucose base et à base de mannose, et la plupart des résultats de leur 
développement sont présentés sous la forme d’articles répertoriés dans le tableau 7.1. 
 
Les résultats du développement de glycomimétiques à base de fucose sont présentés dans l’article n°1. Le troisième 
axe de développement de composé glycomimétique, à base de mannose, était plus 
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élaboré. Il commence par la caractérisation fonctionnelle de deux composés glycomimétique à base de mannose, 
pseudomannobioside (psDi) et pseudomannotrioside (psTri). De ces deux composés, psTri s’est avéré avoir une 
pouvoir inhibiteur bien meilleur que le psDi. Il a été donc été utilisé pour préparer un dendron tétravalent et 
testés pour sa capacité à inhiber l’infection en trans des lymphocytes T au VIH. Plus tard, les capacités de ce 
composé à inhiber la transmission du VIH dans des explants du col de l’utérus ont pu également être étudiée 
et les résultats sont présentés dans l’article n°2. 
Les dendrimères 32-valents de psDi et psTri ont également été produit et testé en comparant les activités 
avec les psDi et psTri mono-et tétravalents dans des tests de compétition par SPR et des test d’inhibition de 
l’infection par le virus Ebola. Les résultats sont présentés dans l’article n°3. Ces études ont indiqués des 
divergences entre les caractéristiques structurelles et fonctionnelles de psTri. Ainsi, les formes monovalentes de 
psDi et psTri ont une di!érence d’un ordre de grandeur dans leurs activités en faveur de psTri, mais cet 
avantage est perdu lorsque l’on comparent les composés multivalents. Ainsi, l’interaction des deux composés 
monovalents, psDi et psTri, a été caractérisé en détail: les structures aux rayons X de ces deux composés en 
complexe avec DC-SIGN CRD ont été résolus, les propriétés structurales de l’interaction en solution a été étudiée 
par RMN, et les complexes ont été caractérisés par d’autres techniques biophysiques (ITC, ASC, DLS). Les 
résultats de ces études sont présentés dans deux documents, les article n°4 et n°5 (encore au stade de  manuscript). 
Au final, ces études ont disqualifié le psTri, mais ont révélé que le psDi possédait toutes les qualités 
souhaitables pour un composé candidat au développement. Ainsi, le développement de glycomimétique à base 
de mannose s’est poursuivi en mettant l’accent sur l’optimisation du psDi. Deux série de composés, de types 
di!érents, dérivé du psDi ont été synthétisés et évalués pour l’inhibition de DC-SIGN et leur sélectivité par 
rapport à la langérine. Les résultats de l’évaluation de l’une des deux séries (bis-benzylamides) sont présentés dans 
le document n°6, et l’analyse des autres séries (NV-type) est décrite dans le sous-paragraphe 9.1.4.6. 
Parallèlement à l’élaboration de glycomimétiques monovalents, di!érents échafaudages polyvalents ont été 
conçues et synthétisées par l’équipe du Dr Javier Rojo. Ensuite, les glycomimétiques monovalents choisis 
précédemment ont été attachés à ces échafaudages polyvalents et testé comme antagonistes de DC-SIGN. Les 
résultats de l’évaluation des composé polyvalents correspondant par SPR, tests par compétition ou et d’interaction 
directes, sont présentés aux paragraphes 9.2.2. et 9.2.3., respectivement. 
 
 
Chapitre 10.  Les composés monovalents nouvellement identifiés antagonistes de DC-
SIGN 
 
Les résultats pour l’ensemble des composés testés monovalents glycomimétiques sont résumés et comparés dans 
ce chapitre. Une proposition d’un composé optimal est proposé sur la base des résultats obtenus. 
 
 
Chapitre 11.  Le développement des échafaudages multivalents 
 
Les résultats pour l’ensemble des composés multivalents conçus sont résumés et comparés dans ce chapitre. 
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Chapitre 12. Est-ce que la forme de la courbe d’inhibition indique "le mode 
d’action" du composé? 
 
Une hypothèse sur le sens de la pente de la courbe d’inhibition est proposée, appliquée à l’ensemble des composés 
testés et discutée. Les moyens pour prouver cette hypothèse sont suggérés. 
! 
Part I.
Introduction
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1. An overview of human innate immunity
1.1. The components of innate immunity
The immune system has evolved to an amazing defense mechanism against the invasion of a broad
variety of pathogens and parasites. It is possessed by the majority of the living organisms including
such simple beings as unicellular bacteria or invertebrates, where it exists in a rudimental form
[1, 2]. In higher vertebrates, including humans, it has evolved to an extremely sophisticated system
that has the features of specificity and memory, and which is implemented by the two components –
innate and adaptive immunities. The adaptive immunity is highly specific with a unique property of
memory and it requires stimulation with an antigen prior to the response, whereas, innate immunity
is less specific and has no memory. However, innate immunity has a crucial role (fig. 1.1), as it
is the first line defense of the organism against the invading pathogens and its responses activate
the adaptive immunity. The importance of innate immunity is also highlighted by the fact that the
defects of its components are relatively rare and almost always lethal [3, 4].
Figure 1.1.: The importance of the innate immunity.
In humans with healthy immune system the infection is almost completely cleared out of the body due to the
synergistic action of innate and adaptive immunities (yellow line). If adaptive immunity is impaired, the infection
is initially stopped but can’t be cleared out and persists (green line), but if innate immunity is compromised, the
infection becomes uncontrolled since there are no innate immunity responses generated to activate the adaptive
immunity [4].
The innate immunity comprises several levels: anatomic, chemical-physiological (temperature,
pH, soluble factors), cellular, and inflammatory barriers (fig. 1.2), which are closely related and
work together to provide the eﬀective protection.
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Figure 1.2.: Diﬀerent levels of innate immunity: an example of skin infection by Staphylococcus
aureus.
A, An intact skin protects the body from pathogen invasion: the tightly packed epidermis with the uppermost corneal
layer of dead keratinocytes provides a physical barrier; normal skin microflora covers the skin and thus fills the niches
preventing pathogen attachment and growth, which is also inhibited by low temperature and pH at the skin surface;
antimicrobial peptides, secreted to the surface by underlying keratinocytes, provide an additional defense. The innate
immunity cells in dermis survey their environment for invaded pathogens. B, Once this physical barrier is breached,
an inflammation occurs: epidermal and dermal immune cells produce pro-inflammatory cytokines, chemokines and
adhesion molecules, which recruit more neutrophils from blood stream to control the infection by formation of the
abscess. Pro-inflammatory cytokines also induce the production of antimicrobial peptides. (Adapted from [5])
The anatomical barrier includes the skin and mucosa, and provides a physical obstacle for the
pathogen invasion. Its importance is obvious as in the case of the loss of the integrity of the body’s
internal epithelia, infection is a major cause of mortality and morbidity [6].
1.1.1. Anatomical and chemical-physiological barriers
The skin is composed of two layers, epidermis and dermis. The epidermis consists of several layers
of tightly packed cells, where the outer layer contains dead cells and waterproof protein keratin,
and most of the pathogens are not capable to cross such a barrier. The underlying dermis con-
tains sebaceous glands that produce oily secretion called sebum consisting of lactic acid and fatty
acids providing the acidic pH, which inhibits the growth of many pathogens. The structure and
composition of the skin makes it a formidable physical barrier, whereas mucosa does not possess as
strong physical features, but it has other properties that compensate the lack of rigidity. Mucosa is
composed of tight epithelial and the underlying connective tissue layers, and lines the conjunctiva,
the gastrointestinal, respiratory, and urogenital tracts. These linings possess numerous non-specific
defense mechanisms such as mucous secretions (tears, saliva) that wash away the microorganisms, or
viscous mucus, which entraps the potential pathogens, and specialized organelles of lung epithelial
cells, i.e. cilia, that expel the pathogens by its movement.
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The skin and mucosal surfaces are also protected by antimicrobial substances secreted by ker-
atinocytes or specialized epithelial cells. These substances include mucins (the glycoproteins that
prevent attachment and entry of the microbes), antimicrobial enzymes and peptides. Lysozyme
and phospholipase A2 are antimicrobial enzymes secreted in mucosa and responsible for the de-
struction of microbial cell walls and membranes, respectively. Antimicrobial peptides in mammals
include defensins, cathelicidins and histatins. Defensins are small amphipatic peptides possessing
a positively charged region separated from hydrophobic region. It is suggested that they function
by binding to the pathogen membranes through their positive region due to electrostatic attrac-
tion, followed by insertion of the hydrophobic region into the membrane, which results in pore
formation and pathogen destruction. Defensins are secreted by keratinocytes in epidermis, the cells
of tongue, respiratory and urogenital tracts, and by the Paneth cells of the gut into the gut lu-
men. Defensins are also secreted within the tissues by phagocytes, and they constitute one of the
components of primary granules of the neutrophils. Cathelicidins are constitutively produced by
neutrophils, macrophages, and by keratinocytes in the skin and epithelial cells in the lungs and in-
testine in response to infection. Their mechanism of action is similar to that of defensins. Histatins
are produced by the parotid, sublingual, and submandibular glands in the oral cavity. They are
short histidine-rich cationic peptides that are active against pathogenic fungi such as Cryptococcus
neoformans and Candida albicans [6].
Both skin and mucosa are inhabited by non-pathogenic microorganisms, the normal flora or
commensal microbiota, that compete with the pathogens for the nutrients and attachment sites,
and this way defend the organism. Besides, the microbiota may produce antimicrobial substances
as lactic acid or antimicrobial peptides bacteriocins [3, 6].
In the absence of wounding or disruption, despite all these defense mechanisms of the body,
some pathogens can infect by specifically adhering to and colonizing epithelial surfaces. Some
pathogens can also use surface molecules on the epithelial cells as footholds to invade the cells
or get into the underlying tissues. Once pathogens invade the body, they face an immediate re-
sponse by humoral innate immunity elements: the aforementioned antimicrobial peptides and a
circulating plasma protein complex, a complement system, which targets pathogens for lysis and
for phagocytosis by innate immunity cells (e.g. macrophages) [3, 6].
1.1.2. The cells of innate immunity
Apart from non-specific or broadly specific counter-action of physiological component of the innate
immunity, a more specific response is carried out by the innate immunity cells: macrophages,
neutrophils, basophils, eosinophils, mast cells, natural killer cells (NKs), and dendritic cells (DCs).
Moreover, the tissue intrusion by the microbes triggers inflammatory responses, which recruit more
eﬀector cells and molecules from the bloodstream to the infection site and serve to destroy, dilute
or wall oﬀ both the injurious agents and the injured tissue [7].
All cells of immune system, together with other blood cells, are believed to develop from a
common precursor in the bone marrow, a Hematopoietic Stem Cell (HSC), under the stimulation
by certain cytokines (fig. 1.3). The diﬀerentiation of the generated progenitor cells may be either
completed in the bone marrow, or the cells may mature in several stages after they leave bone
marrow [8].
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Figure 1.3.: The scheme of hematopiesis.
The blood cells are believed to be derived from a common hematopietic stem cell (HSC) via committed pro-
genitors (not shown) that give rise to the erythroid, myeloid and lymphoid lineages. The main hematopoietins
necessary for proliferation and diﬀerentiation of diﬀerent lineages and cell types are indicated: G-CSF – Gran-
ulocyte Colony-Stimulating Factor (induces the diﬀerentiation of neutrophils, which are also known as granulo-
cytes); M-CSF – Macrophage Colony-Stimulating Factor (induces the diﬀerentiation of macrophages); GM-CSF –
Granulocyte-Macrophage Colony-Stimulating Factor (induces diﬀerentiation of both granulocytes (neutrophils, ba-
sophils, eosinophils and mast cells) and macrophages). IL-3, IL-5, IL-7 and IL-15 are interleukins; Flt3L is Fms-like
tyrosine kinase 3 ligand; TPO is thrombopoietin; EPO is erythropoietin; SCF is Stem Cell Factor, which also plays
a part in the diﬀerentiation of non-hematopoietic cells. (Adapted from [8])
Basophils, mast cells and eosinophils have a special role in the protection of epithelial surfaces,
especially the mucosa of the gastrointestinal, respiratory and urogenital tracts, against the multicel-
lular parasites, such as helminthes. They all are characterized by cytoplasmic granules containing
inflammatory and cytotoxic mediators, thus they are referred to as granulocytes. Mast cells have a
sentinel role and reside in mucosal and connective tissues, while basophils and eosinophils are circu-
lating cells recruited from the bloodstream. They can recognize microorganisms either directly or
through activation by complement or lymphocyte products. These granulocytes operate by releasing
the contents of their granules to the exterior upon activation, thereby either creating an environment
hostile to invading organisms or directly killing the parasites (in the case of eosinophils). Moreover,
basophils and mast cells release molecules including histamine that are clinically important as the
mediators of allergic and pathological inflammatory responses [8, 9].
The phagocytic cells of innate immunity comprise neutrophils, macrophages and immature
DCs (iDCs). Neutrophils are the front-line eﬀector cells of innate immunity: once the diﬀerentia-
tion is complete, they circulate in a bloodstream for a few hours and after entering the tissues, they
can ingest infectious microorganisms and kill them by microbicidal substances stored in specialized
vesicles as well as by reactive oxygen species (ROS) generated by NOX family NADPH oxidases
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[10]. These vesicles appear as granules when stained, therefore neutrophils have a name of granulo-
cytes. They are also called polymorphonuclear leukocytes because of their characteristic feature of
multilobed nucleus. Neutrophils are short-lived and die after two or three days, while macrophages
are long-lived innate immunity cells that carry out immune surveillance in the tissues and play an
important part in tissue maintenance. They diﬀerentiate from blood circulating monocytes as they
leave the bloodstream. Like neutrophils, they ingest and destroy microorganisms. Macrophages also
participate as eﬀector cells in adaptive immune responses when activated by T lymphocytes or by
antibodies secreted by B cells. Both neutrophils and macrophages release inflammatory cytokines.
Macrophages and most iDCs are sentinel cells residing in tissues, and depending on the tissue
where they reside, their receptors and functional properties can vary. Apart from microbial invaders,
both of these cell types sample tissues for normal tissue debris, as they possess a variety of scavenger
receptors, specific for molecules characteristic to cells that have undergone apoptosis.
DCs form a link between innate and adaptive immunity, as their principal function is to
induce the adaptive immunity. They may develop from both lymphoid and myeloid lineages, and
a myeloid progenitor of DCs and macrophages is known as a monocyte. For a period of days
to weeks immature DCs survey the peripheral tissues and operate as phagocytes to internalize
the foreign microorganisms. This leads to diﬀerentiation into mature DCs (mDCs) that have the
antigens presented on their surface and are no longer phagocytic. They leave the peripheral tissues
to migrate into the lymphoid organs where they will encounter circulating naïve T cells and activate
them. mDCs are characterized by the long branches, for which they are named: these enable to
make contacts with several T cells simultaneously [8].
1.2. Pathogen recognition by innate immunity
The innate immune system functions using at least two recognition strategies: it is capable to
distinguish microbial non-self from missing self. These recognition events occur thanks to a range
of receptors that all cells of the innate immune system are equipped with, and through which
various signals can be triggered by cytokines, conserved components of microorganisms, complement
components and antibodies produced by B lymphocytes. The recognition of missing self is based
on the recognition of molecules expressed only on healthy uninfected host cells, which leads to
inhibition of innate immunity response, and the expression of these molecules is lost once the cells
get infected, i.e. the missing self emerges. The missing self recognition plays an important role in
the function of NK cells and complement [8, 9].
The recognition of non-self is based on the recognition of conserved molecular structures that
are unique to microorganisms and that are not produced by the host. These structures are called
Pathogen Associated Molecular Patterns (PAMPs) and include lipopolysaccharide (LPS) of gram-
negative (G-) bacteria, lipoteichoic acid (LTA) of gram-positive bacteria (G+), peptidoglycans,
lipoproteins generated by palmitoylation of the N-terminal cysteines of many bacterial cell wall
proteins, lipoarabinomannan of mycobacteria, double-stranded RNA (dsRNA) and single-stranded
RNA (ssRNA) produced by most viruses during the infection cycle, and β-glucans and mannans in
fungal cell walls [9].
41
CHAPTER 1. AN OVERVIEW OF HUMAN INNATE IMMUNITY
1.2.1. The diversity of Pattern Recognition Receptors
The receptors of the innate immune system that recognize PAMPs are called Pattern Recognition
Receptors (PRRs). The main functions of PRRs include pathogen-induced phagocytosis, activation
of pro-inflammatory signaling pathways, opsonization, activation of complement and coagulation
cascades, and induction of apoptosis [11].
All PRRs can be defined as humoral or cell associated, and the latter ones can be subdivided
to intracellular and cell surface molecules (fig. 1.4). The selected examples of PRRs and their
ligands are listed in table 1.1.
Figure 1.4.: Schematic representation of diﬀerent groups of pattern recognition receptors with se-
lected examples.
(Adapted from [12])
Secreted, or humoral, PRRs may activate complement, opsonize microbial cells to facilitate
their phagocytosis, and in some cases function as accessory proteins for PAMP recognition by
transmembrane receptors like Toll-like receptors (TLRs). Examples of humoral PRRs include
the mannan-binding lectin (MBL), C-reactive protein (CRP), serum amyloid protein (SAP) and
peptidoglycan-recognition proteins (PGRPs) [12, 11].
Cell surface PRRs may be either phagocytic/endocytic or sensor in nature. The sensor recep-
tors do not bind or internalize ligand directly, but recognize PAMPs and induce pro-inflammatory
signaling cascades, which lead to various antimicrobial eﬀector responses. They include TLRs, but
also many intracellular PRRs are sensing molecules [12]. Examples of intracellularly functioning
sensors include NOD-like receptors (NLRs), protein kinase R (PKR), 2’-5’-oligoadenylate synthase
(OAS)/RNaseL, and retinoid acid–inducible gene–1 (RIG-1)-like receptors (RLRs).
Phagocytic receptors bind and internalize ligands directly in a temperature dependent, sat-
urable and inhibitable ligand binding manner, characteristic to classical receptors. These receptors
include scavenger and C-type lectin receptors (CLRs). Scavenger receptors play several roles: they
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are important in uptake and clearance of degenerate components, such as modified host molecules
and apoptotic cells, and they bind and internalize microorganisms and their products [13]. CLRs
are a diverse family of receptors with the ability to bind to carbohydrate moieties and with variable
physiological functions from cell adhesion to pattern recognition [14].
The cellular and humoral arms of the innate immune system collaborate and maintain host
defense.
Table 1.1.: Examples of selected PRRs and their ligands.
Receptor
family
Localization Cell types Receptor Ligands Ligand origin
Collectin Humoral - MBL
Terminal mannose
residues
Bacterial surfaces
Pentraxins Humoral - CRP Phosphorylcholine Bacterial surfaces
SAP Phosphorylcholine Bacterial surfaces
Scavenger
receptors
Cell surface
MØ; DCs;
certain
endothelial cells
LPS and LTA Microbial cell walls
SR-A
Unidentified protein
ligand in serum;
activated B cells
Endogenous
β amyloid protein;
apoptotic cells;
Ox-LDL and Ac-LDL;
AGE modified proteins
Modified self
LPS Microbial cell walls
MARCO UGRP-1 Endogenous
Ac-LDL Modified self
G+, G- bacteria, yeast Microbes
SRCL-1 T and Tn antigen Endogenous
Ox-LDL Modified self
Ubiquitous Ubiquitous TLR1 Triacyl lipopeptides Mycobacteria
Envelope proteins Virus
GPI-linked proteins Trypanosomes
TLRs
Cell surface
Myeloid cells;
mast cells; NKs;
DCs; αβ and γδ
T cells
TLR2
Lipoproteins Mycobacteria
LTA G+ bacteria
Peptidoglycans G+ bacteria
Zymosan Fungi
Intracellular
(endosomal)
DCs; NKs TLR3 dsRNA Viruses
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Table 1.1.: Examples of selected PRRs and their ligands.
Receptor
family
Localization Cell types Receptor Ligands Ligand origin
Cell surface
Mo; mast cells;
Neu; γδ T cells;
Golgi in gut
epithelial cells
TLR4
Fusion protein
Respiratory syncytial
virus
Glycoinositol
phospholipids
Fungi
LPS G- bacteria
Mannan Fungi
TLRs Cell surface
Epithelial cells;
NKs; Mo; DCs
TLR5 Flagellin Bacteria
Cell surface
Myeloid cells;
mast cells; B
cells
TLR6
Diacyl lipopeptides Mycobacteria
LTA G+ bacteria
Zymosan Fungi
Intracellular
(endosomal)
DCs; B cells;
eosinophils
TLR7 ssRNA Viruses
Intracellular
(endosomal)
NKs; T cells;
myeloid cells
TLR8 ssRNA Viruses
Intracellular
(endosomal)
DCs; B cells;
surface of
tonsillar cells
TLR9 CpG-containing DNA Bacteria, protozoa, virus
Herpesvirus DNA Viruses
Cell surface DCs; B cells TLR10 Unknown Unknown
GM-tripeptide Helicobacter pylori
NLRs Intracellular
Lymphocytes,
MØ, DCs,
epithelial and
mesothelial cells
Nod1
meso-lanthionine,
meso-DAP
Shigella flexneri
γ-D-Glu-DAP
Listeria monocytogenes
Campylobacter jejuni
D-lactyl-L-Ala-γ-Glu-
meso-DAP-Gly
Enteropathogenic
Escherichia coli
heptanolyl-γ-Glu-
meso-DAP-Ala
Chlamydia pneumoniae
Pseudomonas aeruginosa
Bacillus spp.
Nod2 MDP Streptococcus pneumoniae
MurNAc-L-Ala-γ-D-
Glu-L-Lys
Listeria monocytogenes
Mycobacterium
tuberculosis
Salmonella typhimurium
Staphylococcus aureus
Shigella flexneri
44
1.2. PATHOGEN RECOGNITION BY INNATE IMMUNITY
Table 1.1.: Examples of selected PRRs and their ligands.
Receptor
family
Localization Cell types Receptor Ligands Ligand origin
Nlrc4 flagellin
Salmonella typhimurium
Legionella pneumoniae
Pseudomonas aeruginosa
NLRs
Nlrp1b anthrax lethal toxin Bacillus anthracis
Nlrp3
Bacterial and viral
RNA, viral DNA, uric
acid crystals, LPS,
LTA, MDP, silica,
asbestos
CLRs See table 1.2
Abbreviations: Ac-LDL, acetylated low density lipoprotein; AGE, advanced glycation end-product; DAP, diaminopimelic
acid; GM-tripeptide, N-acetyl-D-glucosaminyl-β(1,4)-N-acetylmuramyl-L-Ala-D-Glu; GPI, Glycosylphosphatidylinositol;
LDL, Low-Density Lipoproteins; LTA, lipoteichoic acid; MØ, macrophages; MDP, muramyl dipeptide; Mo, monocytes; Neu,
neutrophils; Ox-LDL, oxidized LDL; UGRP-1, Uteroglobin-Related Protein 1. Information collected from [11, 12, 15, 16].
1.2.2. C-type lectin receptors as PRRs
The C-type lectin family comprises a large group of Metazoan proteins that contain C-type lectin-
like domains (CTLDs). Although originally CTLDs were identified as the structures that bind
carbohydrates in a Ca2+-dependent manner (thereof the term C-type), not all the members of this
family recognize carbohydrates and not all need Ca2+ for ligand binding. Therefore, CTLDs are
referred as “C-type lectin-like domains” [17].
The mammalian C-type lectin receptors (CLRs) are divided into 17 types based on their
phylogenetic relationships and domain structures (fig. 1.5). Most of the CLR family members
function as adhesion receptors, and only CLRs of type II, V and VI are present mostly on myeloid
lineage immune cells and function as PRRs, while type III CLRs are soluble PRRs [18].
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Figure 1.5.: The structural diversity of CLR family.
CLR types are marked by roman numbers: I – lecticans, II – asialoglycoprotein receptor (ASGR) DC receptor group,
III – collectins, IV – selectins, V – NK receptors, VI – multi-CTLD endocytic receptors (macrophage mannose receptor
group), VII – Reg proteins, VIII – chondrolectin group, IX – tetranectin group, X – polycystin 1, XI – attractin, XII
– EMBP (eosinophil major basic protein), XIII –DGCR2 (the product of DiGeorge syndrome critical region gene 2),
XIV – thrombomodulin group, XV – Bimlec, XVI – SEEC (soluble protein containing SCP, EGF, EGF and CTLD
domains), XVII – CBCP (Calx-β and CTLD containing protein). (Adapted from [17])
CLRs that function as PRRs are mostly expressed by diﬀerent DC subsets (table 1.2). They
bind pathogens through the recognition of mannose, fucose, glucan and other carbohydrate struc-
tures. The combination of CLRs on DCs enables the recognition of most classes of human pathogens.
Pathogen recognition by CLRs leads to its internalization, degradation and subsequent antigen pre-
sentation [19].
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Table 1.2.: Selected examples of CLRs that function as PRRs.
Type CLR Expression
Recognized
glycans
Glycans from
pathogen
Endogenous ligands
II
(C
a2
+
-d
ep
en
de
nt
C
R
D
)
DC-SIGN
(CLEC4L,
CD209)
myDCs
High mannose and
fucose (LewisX,
LewisY, LewisA,
LewisB)
Bacteria:
Mycobacterium
tuberculosis;
Mycobacterium leprae;
BCG; Lactobacilli spp.;
Streptococcus
pneumoniae;
Leptospira interrogans;
Helicobacter pylori
Viruses:
HIV-1; measles virus;
Dengue virus; HCV;
CMV; SARS coronavirus;
HSV; H5N1; WNV; Ebola
virus and other filoviruses;
phleboviruses
Fungi:
Candida albicans;
Aspergillus fumigatus
Protozoa:
Leishmania spp.
Other:
Tick Ixodes scapularis
saliva protein Salp15;
peanut allergen Ara h1;
Schistosoma mansoni
soluble egg antigens
ICAM-2; ICAM-3;
CEACAM-1; Mac-1; CEA
DC-SIGNR
(CLEC4M,
CD299)
Endothelial
cells in
lymph-node
sinuses; liver
sinusoidal
endothelial
cells
Mannosylated
glycans, high
mannose N-glycans
HIV-1; Ebola;
Schistosoma mansoni
ICAM-1; ICAM-2;
ICAM-3
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Table 1.2.: Selected examples of CLRs that function as PRRs.
Type CLR Expression
Recognized
glycans
Glycans from
pathogen
Endogenous ligands
II
(C
a2
+
-d
ep
en
de
nt
C
R
D
)
Langerin
(CLEC4K,
CD207)
LCs; dermal
DC subset
High mannose,
fucose (LewisY,
LewisB), GlcNAc,
β-glucans,
sulphated sugars
(heparin)
Bacteria:
Mycobacterium leprae
Fungi:
Candida;
Saccharomyces cerevisiae;
Malassezia furfur
Viruses:
HSV;
Measles virus;
HIV-1
Type I pro-collagen
MGL
(CLEC10A,
CD301)
myDCs; MØ
Terminal GalNAc
(Tn, LDN and
LDNF antigens)
Filoviruses; Influenza
virus; Schistosoma
mansoni
CD45; gangliosides;
MUC-1
Dectin-2
(CLEC6A)
myDCs; pDCs;
Mo; MØ; B
cells; Neu
High mannose
Bacteria:
Mycobacterium
tuberculosis
Fungi:
Candida albicans;
Trichophyton rubrum;
Aspergillus fumigatus;
Microsporum audounii ;
Paracoccoides brasiliensis
Allergens:
House dust mite
Dermatophagoides
pteronyssinus allergens
Unknown
Mincle
(CLEC4E)
myDCs; Mo;
MØ
α-mannose
Malassezia spp.;
Mycobacteria; Candida
Damaged cells
DCIR
(CLEC4A)
myDCs; pDCs;
Mo; MØ; B
cells; Neu
Unknown HIV-1 Unknown
BDCA2
(CLEC4C,
CD303)
pDCs; Mo;
MØ; Neu
Unknown Unknown Unknown
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Table 1.2.: Selected examples of CLRs that function as PRRs.
Type CLR Expression
Recognized
glycans
Glycans from
pathogen
Endogenous ligands
V
(C
a2
+
-in
de
pe
nd
en
t
C
R
D
) Dectin-1
(CLEC7A)
myDCs; Mo;
MØ; B cells
β-1,3-glucan
Bacteria:
Mycobacterium
tuberculosis
Mycobacterium abscessus
Fungi:
Candida albicans;
Aspergillus fumigatus;
Pneumocystis carinii ;
Penicillium marneﬀei ;
Coccidioides posadasii ;
Histoplasma capsulatum
Ligand on T cells
MICL
(CLEC12A)
myDCs; Mo;
MØ; Neu
Unknown Unknown Unknown
CLEC2
(CLEC1B)
Platelets,
peripheral
blood Neu
Unknown
HIV-1; Snake venom
rhodocytin; podoplanin
Unknown
V
I
(C
a2
+
-d
ep
en
de
nt
C
R
D
)
Mannose
receptor
(CLEC13D,
CD206)
myDCs; MØ
High mannose,
fucose, sulphated
sugars (sLewisX)
Bacteria:
Mycobacterium
tuberculosis;
Mycobacterium kansasii ;
Francisella tularensis;
Klebsiella pneumoniae;
Streptococcus pneumoniae
Viruses:
HIV-1; Dengue
Fungi:
Candida albicans;
Cryptococcus neoformans;
Pneumocystis carinii
Protozoa:
Leishmania spp.
Allergens
L-selectin; MUC-1
DEC-205
(CLEC13B,
CD205)
myDCs Unknown Unknown Unknown
Abbreviations: BCG, Mycobacterium bovis Bacillus Calmette Guérin; CEA, carcinoembryonic antigen; CMV, cytomegalovirus;
GalNAc, N-acetylgalactose amine; GlcNAc, N-acetylglucose amine; HCV, hepatitis C virus; HIV, human immunodeficiency virus;
HSV, herpes simplex virus; LCs, Langerhans cells; LDN antigen, GalNAcβ1-4GlcNAc-R; LDNF antigen,
GalNAcβ1-4(Fucα1-3)GlcNAc-R; MGL, macrophage galactose-type C-type lectin; myDCs, myeloid DCs; pDCs, plasmacytoid DCs;
SARS, severe acute respiratory syndrome-associated; sLewisX, sulphated LewisX; Tn antigen, GalNAcα1-O-Ser/Thr; WNV, West
Nile virus. Information collected from [19, 20, 21, 22, 23, 24, 25].
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The CLRs can be immune activating or inhibitory depending on their ability to associate with
certain signaling molecules or the presence of specific motifs in their cytoplasmic tails. Most of
the type II CLRs are predicted to be activating as in their transmembrane regions they have a
positively charged residue which allows association with adaptor proteins. The activating CLRs
may harbour the immunoreceptor tyrosine-based activation motifs (ITAMs), which constitute two
YxxI/L motifs separated by 6-12 amino acid spacers (YxxI/Lx(6-12)YxxI/L). Upon ligand binding,
clustering of CLRs occurs and ITAMs are phosphorylated, which initiates a downstream signaling
cascade eventually leading to activation of various cellular responses. Besides, there are CLRs that
bear ITAM-like motifs (N-terminal tyrosin in YxxxL/I) in their cytoplasmic tail, for ex. dectin-1.
The activating CLRs include dectin-2, DCAR, BDCA2, Mincle and DC-SIGN [20].
The inhibitory CLRs themselves possess the immunoreceptor tyrosine-based inhibition motifs
(ITIMs: I/V/L/SxYxxI/L/V) in their cytoplasmic tails, and in this case the ligand binding to CLR
followed by phosphorylation of ITIM initiates signaling cascades that culminate at the inhibition
of cellular activation. The examples of inhibitory CLRs include DCIR and MICL. There also exist
CLRs that harbour ITIMs but mediate cellular activation [20].
1.2.2.1. The structure of C-type lectin-like domains
The common feature of all CLRs is that they possess at least one CTLD – a compact globular
structure with a characteristic fold designated “C-type lectin-like fold” that is unusual to any other
known proteins. For the majority of CLRs that function as PRRs, the CTLDs actually bind sugars,
usually in Ca2+-dependent manner, and therefore this domain is commonly called a “carbohydrate
recognition domain” (CRD) rather than CTLD.
All CRDs possess a characteristic “double-loop” fold (fig. 1.6). The whole domain can be
regarded as a loop with two flanking α helices (α1 and α2) and two antiparallel β-sheets: N- and
C-terminal β strands β1 and β5 constitute the basal β-sheet, and the top β-sheet is formed by
strands β2, β3, and β4. The long loop region enters and exits the core domain at the same location,
and is involved in Ca2+-dependent carbohydrate binding, and for some CRDs in domain-swapping
dimerization. Four highly conserved cysteins form two disulphide bridges at the bases of the loops:
C1-C4 bridge links α1 and β5, and C2-C3 bridges β3 strand and a loop upstream the β5 strand.
Another highly conserved sequence feature of the CRDs is the “WIGL” motif located within β2
strand and believed to stabilize the core of the domain.
The long loop region among diﬀerent CRDs varies, and those that possess it are designated
“canonical”, while those that lack it are called compact. The presence or absence of a short extension
at N-terminus, a β1￿-hairpin, further subdivides CRDs to long or short forms, respectively. Two
additional cysteins at the beginning of CRDs sequence are characteristic for the long form CRDs.
The corresponding disulphide bridge (C0-C0￿) stabilizes the β-hairpin.
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Figure 1.6.: A typical CRD structure (DC-SIGN CRD.
The long loop is shown in blue, disulphide bridges in yellow sticks. The three Ca-binding sites present in this lectin
presented as cyan spheres, and the location of the fourth Ca-binding site (absent in this particular structure) is shown
as a cyan circle. (pdb:1k9i; adapted from [17])
There may be up to four Ca-binding sites in the CRDs, and their occupancy depends on the
sequence of a particular CRD and on crystallization conditions. Sites 1, 2, and 3 are located within
the long loop, while the fourth site participates in the salt bridge formation between helix α2 and
β1/β5 sheet [17].
1.2.2.2. The structural basis of sugar binding within carbohydrate recognition domains
The sugar binding in the CRDs occurs at Ca2+-binding site 2, and both carbonyl sidechains co-
ordinating calcium and Ca2+ itself are involved in sugar binding. Ca2+-coordination at this site
is provided by carbonyl sidechains mainly within two characteristic motifs. One of these motifs,
EPN or QPD, resides in a long loop region and defines the monosaccharide binding specificity. The
second one, a WND motif, is contributed by β4 strand. Additionally, a carbonyl sidechain provided
by the residue preceding the second conserved cysteine, also participates in Ca2+ coordination at
site 2. The schematic representation of Ca2+ coordination and hexose binding is depicted in figure
1.7A.
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Figure 1.7.: Monosaccharide binding in Ca site 2.
A, schematic representation of Ca2+ coordination and hexose binding: a grey sphere represents Ca2+, empty circles
and ovals show the oxygens, black arrows show the direction of H-bonds in mannose group CRDs, and light grey
arrows mark changed directions in galactose-specific CRDs. B, mannose residue bound to MBP-A CRD (pdb:2msb).
C, engineered for galactose-type specificity CRD of MBP-A complexed with GalNAc (MBP-A mutant QPDWGHV
([26], pdb:1bcj). Coordination bonds are light green; H-bonds where sugar hydroxyl acts as acceptor or donor are
marked as pink or cyan dashed lines, respectively. (Adapted from [17].)
The overall network of the hydrogen-bond donors and acceptors in the site determines the
binding orientation of the carbohydrate and also which hydroxyls of the carbohydrate it can ac-
cept, i.e. the monosaccharide specificity. The EPN motif has a configuration, which accommodates
mannose group monosaccharides (fig. 1.7B), while QPD motif determines specificity for galactose
group monosaccharides (fig. 1.7C). In both of these motifs the cis-configuration of the two car-
bonyl sidechains separated by proline is crucial for Ca2+ coordination and sugar binding. Besides
the H-bond network imposed constraints, other structural elements in the binding sites introduce
selectivity to particular ligands within the mannose or galactose groups.
The other three Ca2+ binding sites play the structural stabilization role, as removal of Ca2+
increases susceptibility to proteolysis and changes physical properties of the domain. Ca2+ binding
site 2 is also important for structural stability of the domain. It has been shown that pH-induced
loss of Ca2+ causes the destabilization of the loops, which has an important physiological role for
CRDs of endocytic receptors as internalization of ligand-bound receptor to acidic lysosomes and
consequent Ca2+ loss leads to the release of the ligand for further processing, while receptor is
recycled to the cell surface [17].
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1.3. Dendritic cells and adaptive immunity initiation
Dendritic cells comprise a diverse group of professional antigen presenting cells (APCs), which share
a particular morphology, i.e. long surface membrane extensions called dendrites (fig. 1.8), and have
a common feature of being potent stimulators of T cells to induce the adaptive immunity. The
diversity of DCs is a result of a combination of several features including their origin, diﬀerentiation
state, and anatomic location. The diﬀerent subsets are identified by expression of surface markers,
but the distinction between them is often debatable. Nevertheless, DCs can be broadly divided
to myeloid (myDCs) and plasmacytoid DCs (pDCs). The latter originate from lymphoid progen-
itor, they resemble plasma cells, hence they are called “plasmacytoid”. myDCs are derived from
monocytes and diﬀerentiated from peripheral blood mononuclear cells (PBMCs). Other DC sub-
populations include Langerhan’s cells (LCs) residing in epidermis of the skin, and interstitial DCs
(iDCs) found in dermis of the skin and stromal compartments of mucosal tissues. While myDCs
are very potent at pathogen uptake and antigen presentation, the lack of CLRs and Fc receptors on
pDCs together with weak macropinocytosis suggest diﬀerent function of pDCs, which may involve
self-antigen presentation and/or it is restricted to viral antigen presentation. Besides, pDCs are the
major source of type I interferons (IFN) supporting their role in antiviral immunity [14, 27].
Figure 1.8.: Colored scanning electron micrograph of a dendritic cell.
From http://www.sciencephoto.com/media/305587/enlarge.
All DCs express PRRs on their surface including TLRs and CLRs, but each subset has its
characteristic diﬀerential expression of PRRs, therefore distinct subsets will be reactive to a certain
group of PAMPs present in particular pathogens (examples in tables 1.1 and 1.2). The diversity of
these receptors on DCs enables them to uptake multiple signals from their surroundings and finally
to transfer them for induction of appropriate adaptive immune responses [14, 28].
The immature skin and mucosal DCs form a dense network of resident cells, which sample their
environment for foreign microorganisms. Upon pathogen recognition or in response to cytokines
such as TNF-α, IL-4, GM-CSF, the maturation of DCs is triggered. This involves down-regulation
of endocytic receptors, up-regulation of maturation markers (e.g. costimulatory molecules such as
CD40, CD80 and CD86), raise in the levels of major histocompatibility complex (MHC) class II
expression, loss of adhesiveness and induction of DC migration to lymphoid organs to present the
processed antigens for T cell activation (fig. 1.9). Receptor-triggered DC responses also include
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expression of pro-inflammatory (TNF-α, IL-1, IL-6) or anti-inflammatory (IL-10) cytokines and
diﬀerential production of chemokines, which results in recruitment of diﬀerent T-cell subsets at the
site of infection [14].
Figure 1.9.: Antigen uptake, maturation and migration of dendritic cells to activate T cells.
From http://medicinembbs.blogspot.fr/2011/03/process-of-immunity-images.html.
Depending on which PRRs are triggered by pathogens, diﬀerent signaling pathways are initi-
ated in DCs. Generally, DC triggering through TLRs leads to DC activation, while PAMP recog-
nition by CLRs result in pathogen uptake, processing, antigen presentation on MHC class I or II
molecules, but also may involve modulation of DC activation [14]. On the other hand, the matura-
tion of myDCs may be inhibited by immunosuppressive cytokines such as IL-10 and TGF-β, also by
corticosteroids, cyclosporine A, and 1α,25-dihydroxyvitamin D. Such DCs may induce regulatory T
cells, which maintain tolerance to self-antigens. Thus DCs have a dual function: they either boost
the immune system, or dampen it leading to tolerance and maintenance of the immune homeostasis
[28].
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Figure 1.10.: The cross-talk between TLR and CLR signaling shape the adaptive immunity.
(From [29])
The diﬀerentially activated DCs induce naïve CD4+ T cell diﬀerentiation into distinct T helper
cells: Th1, Th2 or Th17 (fig. 1.10). These T helper cells are responsible for fighting diﬀerent types
of pathogens. Th1 produce interferon-γ (IFN-γ), which activates macrophages and cytotoxic T
cells to fight intracellular pathogens. Th2 cells secrete interleukin-4 (IL-4), IL-5, and IL-13, which
are responsible for the activation of B cells and humoral immune responses against extracellular
pathogens. Antifungal and antibacterial immunity is contributed by Th17 cells secreting IL-17,
which mobilizes phagocytes [18].
Figure 1.11.: Formation of immunological synapse.
A, Field emission scanning electron microscope image of a human dendritic cell (blue pseudo-color) in close interaction
with a lymphocyte (yellow pseudo-color). This contact may lead to the creation of an immunological synapse (from
http://microscopic.co/) B, The receptors participating in immunological synapse formation (adapted from [30]).
The information about invading pathogens or abnormal self is transferred from DCs to naïve T
lymphocytes through immunological synapse – a specialized cell–cell adhesive junction characterized
by stability and directed secretion. The formation of immunological synapse is initiated by adhesive
contacts between the two cells that are mediated by a number of adhesion receptors (fig. 1.11 A,
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B), which facilitate to form T cell receptor (TCR) and antigen-bound MHC class I or II complexes
for antigen scanning by T cells and signaling to induce appropriate adaptive immune responses [31].
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2. Human immunodeficiency virus: the
infection via sexual transmission
2.1. The mechanism of HIV entry to the host cell
The host cell infection by HIV starts by the entry of the virus into the cell. The major target cells
of HIV are CD4+ T lymphocytes, which also express chemokine receptors CCR5 and CXCR4 that
are exploited by HIV to enter the cells, hence also called HIV coreceptors. The virus entry starts
with the adhesion of the virion to the target cell and ends with the fusion of the cell and viral
membranes followed by delivery of the viral core into the cytoplasm (reviewed in [32]).
Attachment of the virion (fig. 2.1(1)) can be relatively nonspecific, for instance, HIV envelope
protein (Env, the trimer of gp120 and gp41 heterodimers, where gp41 initially is hidden) can interact
with negatively charged cell-surface heparan sulfate proteoglycans [33]. More specific adhesion
includes interactions between Env and α4β7 integrin [34, 35] or CLRs such as DC-SIGN [36]. Either
way of adhesion most likely brings Env into close proximity with the host CD4 and a coreceptor,
leading to the fusion of viral and target cell membranes (fig. 2.1) [37].
Figure 2.1.: Schematic representation of HIV entry to the target cell.
(1) HIV first attaches to the host cell via Env binding to host cell surface structures. Then binding to CD4 receptor
occurs (2), which causes conformational changes in Env, allowing coreceptor binding, which is mediated in part by
the V3 loop of Env (3). Binding to CD4 also exposes gp41 subunit and thus initiates the membrane fusion process
as the fusion peptide of gp41 inserts into the target membrane, followed by six-helix bundle formation and complete
membrane fusion (4). (From [32])
Env binding to its primary receptor CD4 (fig. 2.1(2)), a member of the immunoglobulin su-
perfamily that enhances T-cell receptor (TCR)-mediated signaling, is absolutely required for the
infection. This binding event induces rearrangements in gp120 subunit of Env, which ultimately
result in V3 loop repositioning and bridging sheet exposure that are essential for coreceptor en-
gagement (reviewed in [32]). Subsequent binding to the coreceptor (fig. 2.1(3)), CCR5 or CXCR4
depending on the virus strain R5 or R4, triggers the membrane fusion potential of Env, and usually
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is followed by the “surfing” of the virus particle to the site where productive membrane fusion may
occur. It is thought that HIV might usurp the host cell machinery to reach cell surface sites where
membrane fusion can occur [38]. Besides, HIV may need to be endocytosed by the host cell for
productive membrane fusion to occur [39].
Coreceptor-bound Env undergoes conformational changes that expose the hydrophobic gp41
fusion peptide (fig. 2.1(3)), which then inserts into the host cell membrane and folds to form six-
helix bundle (fig. 2.1(4)). The latter is the driving force that brings the opposing membranes into
close proximity, resulting in the formation of a fusion pore (reviewed in [40]).
Once the virus enters the cell, it can start its replication and productive infection, which
ultimately lead to the depletion of CD4+ T lymphocytes in the body, and thus the acquired im-
munodeficiency syndrome (AIDS).
Although the major target of HIV is CD4+ T cells, earlier studies have shown that DCs are
crucial for HIV-1 infection enhancement and dissemination in mucosa, in the case of sexual HIV
transmission, which leads to the productive infection of the CD4+ T cells and the burst of the
disease [41][42].
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2.2. Dendritic cell implication in HIV-1 sexual transmission
2.2.1. Mechanism of HIV invasion of genital mucosa
Sexual transmission through genital and rectal mucosa accounts for the vast majority of HIV-
1 infections worldwide. The viral invasion in women occurs mostly through the non-keratinized
squamous epithelium of the vagina and ectocervix, and also through the single-layer columnar
epithelium of the endocervix (figure 2.2A). Sexual transmission in men most frequently takes place
through the inner foreskin and the penile urethra as a consequence of penile–vaginal or penile–anal
intercourse (figure 2.2B). Both women and men are infected following the receptive anal intercourse
[43].
Figure 2.2.: HIV-1 sexual transmission sites in women (A) and men (B).
(From [43])
Although sexual transmission through genital mucosa is the dominating route of infection
for both genders, women appear to be more susceptible to this type of viral invasion through
cervicovaginal tissues (table 2.1) [44]. Therefore, HIV sexual transmission mechanisms in female
genital mucosa are reviewed below in more detail.
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Table 2.1.: Contribution of mucosal HIV invasion sites to global HIV infections in adults.
HIV
invasion
site
Anatomic
subloca-
tion
Type of
epithelium
Transmission
medium
Transmission
probability
per exposure
event
Estimated
contribution
to HIV cases
worldwide, n
(millions)
Female
genital tract
Vagina
Squamous,
non-keratinized
Semen
1 in 200 to 1 in
2000
12.6
Ectocervix
Squamous,
non-keratinized
Endocervix
Columnar, single
layer
Other Various epithelia
Male genital
tract
Inner foreskin
Squamous, poorly
keratinized
Cervicovaginal and
rectal secretions and
desquamations
1 in 700 to 1 in
3000
10.2
Penile
urethra
Columnar, stratified
Other Various epithelia
Intestinal
tract
Rectum
Columnar, single
layer
Semen
1 in 20 to 1 in
300
3.9
Upper gas-
trointestinal
tract
Various epithelia 1 in 2500 1.5
Human vagina and ectocervix are covered by non-keratinized squamous epithelium, which can
be abraded by shearing during sexual intercourse. The subepithelial layer of the genital mucosa is
a very favourable environment for HIV replication, since it is enriched with DCs, macrophages, and
T cells that expresses CD4, CCR5, and in lesser quantities, CXCR4 receptors, which make them
vulnerable to HIV infection. There are several pathways for HIV virions, either free or infected
donor cell-associated, to traverse the surface of female genital mucosa. Once the virus traverses the
genital mucosa it may access the vulnerable target cells in the basal epithelium and the underlying
stroma, i.e. LCs in epithelium, stromal DCs located beneath epithelium, T cells and macrophages
in stroma [43].
As illustrated in figure 2.3, HIV virions or HIV-infected donor cells can be trapped in the mucus
(fig. 2.3A), which then may lead to HIV-infected donor cell attachment to the luminal surface of
the mucosa and the attached cell may start to secret virions (fig. 2.3B). The virions can further
penetrate between epithelial cells (fig. 2.3C), where the residing LCs may capture the virions (fig.
2.3D) and internalize them to endocytic compartments (fig. 2.3E). Equally, the penetrating virions
may fuse with intraepithelial CD4+ T lymphocytes and cause the productive infection (fig. 2.3F).
The penetrating virions may also follow the transcytosis through epithelial cells (fig. 2.3G) and
result to the productive infection of the basal epithelial cells (fig. 2.3H) or internalization into their
endocytic compartments (fig. 2.3I). If not trapped to the mucus, the infected donor cells (fig. 2.3J)
and free virions (fig. 2.3K) may migrate along the abrasions into the vulnerable mucosal stroma.
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Figure 2.3.: HIV invasion pathways in the female lower genital tract mucosa.
The stromal papilla on the right illustrates a capillary through which the blood cells are supplied to the mucosa
where the monocytes diﬀerentiate to DCs or macrophages. The left side depicts an uncovered papilla, a possible site
of infection, resulting from a sharing of the outer epithelium during sexual intercourse. On the top of the figure, HIV
receptors and some phenotypic cell receptors are shown. (From[44])
Once HIV virons reach the mucosal stroma, they can cause the productive infection of stromal
DCs (fig. 2.3L) or the virions can be internalized to endocytic compartments of DCs (fig. 2.3M).
The infected stromal DCs can transfer virus to CD4+ T cells across the infectious synapse (fig.
2.3N), which then results to a massive productive infection of mucosal CD4+ T cells (fig. 2.3O) and
a productive infection of resting mucosal CD4+ memory T cells (fig. 2.3P). Productively infected
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CD4+ T cells and DCs or their conjugates can migrate to submucosa and the draining lymphatic
and venous microvessels, and thus disseminate the virus (fig. 2.3R). HIV virions may also bind and
possibly infect the stromal macrophages (fig. 2.3Q) [44].
2.2.1.1. Stromal DCs in mucosa are implicated in DC-SIGN-mediated HIV infection enhancement
DCs play particularly important role in HIV-1 infection enhancement and dissemination in epithelia
since the virus hijacks them to achieve the productive infection of the CD4+ T cells and the burst
of the disease [41, 42]. The stromal DCs that express a C-type lectin DC-SIGN (DC-Specific
ICAM3 Grabbing Non-integrin) and reside in mucosa of vagina and ectocervix, have been repeatedly
reported to be exploited by HIV-1 to enhance its infectivity of T cells. Diﬀerent mechanisms of how
DCs augment de novo infection of T cells were evaluated and suggested by several research groups
[43]. Electron microscopy 3D structural studies of the infectious synapse have shed light on this
mechanism (fig. 2.4): DCs engulf the surrounding extracellular environment, trapping virions in a
surface-accessible but protected compartment. Then CD4+ T cells may contact DCs by extending
their membrane protrusions (filopodia, cytoneme (fig. 2.5)), enriched for CD4 and coreceptor, into
the invaginated DC compartments that contain bound virions, allowing eﬃcient virion transmission
from DCs to CD4+T cells [45].
Figure 2.4.: Model of HIV transfer from DCs to CD4+ T cells.
A, HIV virions are trapped and concentrated in surface-accessible trypsin-resistand compartments of DCs. B, DCs
and CD4+T cells containing membrane protrusions, come into contact. C, CD4+T cell protrusions invade the virus-
containing compartments and eﬃciently bind HIV virions. D, HIV virions migrate toward T cell body to initiate
infection. (From [45])
The above described trans infection mechanism via infectious synapse is only one of the possible
trans infection pathways. There are several parallel mechanisms of this process (fig. 2.5), and it must
be noticed that DC-SIGN has a very important role in DC-mediated HIV infection enhancement
[36]. Following the virion binding to DC-SIGN, HIV can be endocytosed into DCs, and subsequently
the intact virions can be stored in multivesicular bodies (fig. 2.5(1)) [36, 46]. HIV can also be stored
as an integrated provirus following productive infection of DCs (fig. 2.5(2)). Likewise, HIV can be
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stored as DC-SIGN-bound virions on the cell surface and protected from degradation (fig. 2.5(3))
[47]. During the formation of the infectious synapse either case leads to accumulation of intact
virions on DC side while HIV receptors (CD4, CCR5) are presented on CD4+ T cell side. Such a
situation greatly facilitates HIV-1 passage from DCs to T cells. Indeed, it has been demonstrated
that blocking DC-SIGN prevents HIV-1 binding and subsequent trans infection of CD4+ T cells
[48, 49, 50].
Figure 2.5.: The significance of DC–T-cell interactions and DC-SIGN implication in HIV-1 trans-
mission.
(From [43])
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While trans infection is responsible for the early stage of infection (24 h after HIV exposure),
there is a diﬀerent pathway of DC-SIGN-bound HIV transmission to T lymphocytes. This pathway
is involved in long-term HIV transfer (72 h after exposure) and it occurs as an infection in cis of
DCs by transfer of DC-SIGN-bound virus to canonical HIV entry receptors, CD4 and CCR5, which
leads to productive infection of DCs and in turn presentation of increased viral load to the T cells
[51, 52]. Furthermore, DC-SIGN is not only hijacked by virus to enter the DCs, but HIV also
exploits DC-SIGN signaling for the recruitment of host transcription-elongation factors to produce
viral transcription-elongation factor Tat, which is essential for further transcription of viral genes,
and without DC-SIGN signaling only short abortive mRNAs are produced [53].
2.2.1.2. Suppressive role of epithelial LCs in HIV transmission
By contrast, another subset of dendritic cells, the LCs, plays an important preventive role in HIV
infection process. LCs express HIV receptors including CD4, CCR5 and C-type lectin langerin
[54, 55, 56]. It has been shown that epidermal LCs expressing langerin eﬃciently bind HIV virions
(fig. 2.6A), which in turn are directed to Birbeck granules (BG) for degradation (fig. 2.6B) [57].
This shows an important protective role of langerin in HIV invasion process.
Figure 2.6.: The micrograph showing an uptake of HIV-1 virions and their internalization to Birbeck
granules by immature LCs.
A, HIV-1 capture by langerin (arrows) expressed on LCs. B, HIV-1 internalization into Birbeck granules (arrow-
heads). HIV-1 p24 capsid and langerin staining are labeled by 15 nm and 10 nm gold, respectively; scale bar 100 nm.
(From [57])
The importance of langerin for the protective function of LCs can be seen very well in the
examples where the impaired presence/expression of langerin subverts this function of LCs. Firstly,
pre-incubation of LCs with anti-langerin antibody 10E2 or mannan as well as high viral loads re-
sulting in langerin saturation abrogated the LCs’ antiviral function against HIV as the virus was
transmitted to T cells [57]. The coinfection of mucosa with HSV-2 and HIV-1 increases the sus-
ceptibility to the latter infection because HSV-2 decreases the surface concentration of langerin
64
2.2. DENDRITIC CELL IMPLICATION IN HIV-1 SEXUAL TRANSMISSION
due to competition with HIV-1 for binding to langerin or through TLR-3 induced signaling, which
down-regulates expression of langerin [58]. The recent study showed that vaginal LCs may have low
or no expression of langerin, and thus they are susceptible to HIV infection [59]. Hence two CLRs,
DC-SIGN and langerin, despite the high homology of their CRDs and the overlap of ligand speci-
ficities [60] have very diﬀerent roles in HIV invasion: while DC-SIGN promotes HIV dissemination
and infection, langerin helps to prevent HIV invasion.
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2.3. Structure and function of C-type lectin receptor DC-SIGN
DC-SIGN is a type II membrane protein with a single CRD, i.e. a type II C-type lectin. It was first
cloned and identified as a C-type lectin binding to HIV glycoprotein gp120 by Curtis et al in 1992
[61] and later rediscovered and renamed by Geijtenbeek et al in 2000 when screening a library of DC-
specific monoclonal antibodies that inhibit binding to ICAM-3 (InterCellular Adhesion Molecule-3),
the T cells activating adhesion molecule [62]. DC-SIGN is present at low levels on blood monocytes
and as they leave blood to peripheral tissues and diﬀerentiate to DCs the expression of this lectin
is extremely increased. Finally, following DC maturation and migration to secondary lymphoid
tissues, DC-SIGN levels are down-regulated [62]. DC-SIGN expression is restricted to certain DC
subsets, i.e. dermal and stromal DCs, and it is not expressed on follicular DCs or on skin-resident
LCs. Other cell types that express DC-SIGN include macrophages [63, 64, 65, 66] and activated B
cells [67]. Moreover, there are reports showing the presence of soluble forms of DC-SIGN resulting
from alternative splicing [68, 69, 70].
Figure 2.7.: Primary structure of human DC-SIGN.
The sequences of cytosolic, transmembrane, neck region, and CRD domains are in blue, black, red and green letters.
The internalization motif and incomplete ITAM are highlighted in grey and green, and the conserved motifs defining
sugar specificity and Ca2+ coordination are in orange and blue. The third conserved motif, WMGL instead of WIGL
in case of DC-SIGN, is highlighted in red. The amino acid repeats (heptades) contributing to coiled-coil formation
are individually underlined, and disulphide bridges are depicted by light green lines.
The gene encoding DC-SIGN (CD209) is located on human chromosome 19p13.2-3, contains 7
exons and 6 introns, and is closely related to other CLR genes such as DC-SIGNR and CD23. The
gene encodes 404 amino acids containing protein (fig. 2.7) of 44 kDa in molecular weight [71].
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Figure 2.8.: Domain organization of DC-SIGN molecule.
(From [72])
DC-SIGN is composed of four domains: the N-terminal cytoplasmic tail, transmembrane do-
main followed by the extracellular part composed of a neck region, which contains 7 and a half
repeats of 23 amino acid residues, and the C-terminal carbohydrate recognition domain (fig. 2.7
and 2.8) [61].
2.3.1. DC-SIGN CRD structure and carbohydrate recognition
The Ca2+-dependent CRD of DC-SIGN (fig. 2.9A) has a typical long-form C-type lectin fold
sustained by four disulphide bridges, contains three occupied Ca2+-binding sites (1, 2, and 3) and
EPN motif, thus the specificity for mannose group sugars. It binds mannose residues through
equatorial 3-OH and 4-OH groups that are coordinated to Ca2+ at site 2, and the overall binding
is maintained by the hydrogen bond network formed between distinct sugar groups and amino acid
residues in the protein, which can be mediated or not by water molecules (fig. 2.9B). The interaction
with high mannose ligands is not limited to terminal mannose residues and rather involves internal
residues that stretch along the extended binding site (fig. 2.9C) [73].
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Figure 2.9.: Carbohydrate recognition by DC-SIGN CRD.
A, the structure of DC-SIGN CRD: EPN, WND and WMGL motifs are shown in orange, pink and red stick
representation; disulphide bridges depicted in yellow sticks and large cyan spheres are the three Ca2+. B, binding
of mannose residue in the CRD, the coordination bonds to Ca2+ (cyan sphere) are black solid lines and the H-
bonds are represented as black dotted lines. C, Surface representation of DC-SIGN CRD bound to GlcNAc2Man3
(oxygens and nitrogens are in red and blue, carbons of protein and of oligosaccharide are in white and yellow,
Ca2+ is green, GlcNAc2Man3 is in stick representation). D, LewisX trisaccharide (upper panel) and a structure of
lacto-N-fucopentaose bound to DC-SIGN CRD (lower panel). (A and B are from [73]; C is pdb:1k9i; D is from [74])
DC-SIGN binds N-acetylglucosamine (GlcNAc) also through equatorial 3-OH and 4-OH groups
[73], and recognizes fucosylated structures, including Lewis-type blood group antigens [74]. In this
case, fucose residue is bound in Ca-binding site 2 via equatorial 3-OH and axial 4-OH groups,
and additional tight van de Waals contacts are formed between 2-OH group of fucose and Val351
residue of the protein (fig. 2.9D). While GlcNAc residue of LewisX points away from the protein,
the terminal galactose residue interacts with the CRD at a secondary binding site through H-bonds
and van der Waals contacts with protein side chains. The observed orientation of LewisX bound to
DC-SIGN CRD suggests that other fucose-containing oligosaccharides may bind DC-SIGN primarily
through fucose in Ca2+-binding site 2 and make additional contacts with the protein at other sites
[74].
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2.3.2. Oligomeric structure of DC-SIGN
The aﬃnity of the sugars for DC-SIGN CRD is low (KD in mM range). However, the oligomerization
of the lectin to a tetrameric form aﬀorded by the neck domain [75] and the heavy glycosylation of its
ligands gives a way for high aﬃnity (KD in nM range) interactions due to the avidity phenomenon
(fig. 2.10). The other functions that can be attributed to the neck include the projection of the
CRDs further away from the cell membrane for appropriate ligand scanning and binding. The
certain positioning of the CRDs due to oligomerization provides additional means of the specificity
to the ligands [76].
Figure 2.10.: Schematic representation of lectin/pathogen interaction aﬃnity increase due to the
avidity phenomenon.
A, Low density of monomeric lectin results in weak interactions. B, Lectin binding site clustering due to oligomer-
ization and overexpression leads to strong pathogen binding. (From [77])
Oligomerization of DC-SIGN to tetramers is driven by intermolecular hydrophobic interactions
of amino acid residues of the heptad repeats (fig. 2.7 and 2.8) in the neck domains and supported by
the lateral salt bridges (fig. 2.11A): in the heptads, represented as abcdefg, a and d are hydrophobic,
and e and g are charged residues [78].
The studies of truncated DC-SIGN forms with variable length of neck region have shown
that at least 6 repeats are needed for the tetramerization, the 5.5 repeats result an equilibrium
between tetramers and dimers, and a neck of only 2 repeats leads to equilibrium between dimers
and monomers [79]. Moreover, the studies by the group, which I later joined to carry out my PhD,
have demonstrated that the state and stability of oligomerization is pH-dependent: the decrease of
pH induces dissociation of the tetramers into monomers with an approximate mid-point of transition
at about pH 5.9. It was also observed that the decrease of pH from mild alkaline (pH 7.9) to slight
acidic (pH 5.9) induces the change of the shape of DC-SIGN tetramers from elongated to more
compact [80].
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Figure 2.11.: The structure of the extracellular part of DC-SIGN.
A, a schematic representation of the coiled-coil interactions in the neck domain: each of the four circles represents
a top-view of an α-helix formed by two 23 amino acid repeats, the hydrophobic core is highlighted in grey, and the
curved double arrow represents the putative interchain salt bridge between the glutamic acid (position g) of the first
heptad and the lysine residue (position e) of the second one. B, SAXS envelop of DC-SIGN extracellular domain.
C, superimposition of DC-SIGN CRDs (pdb:1k9i) into SAXS envelop: the view from the top. The distances between
vicinal sugar-binding sites are indicated in red (measurement between the same oxygen atom of Gln147 within EPN
motif, depicted as spheres), and diagonal distances in black and green are 51.1 and 61.0Å, respectively. (Adapted
from [80])
The overall length of the extracellular part of the lectin was found to be around 32 nm with
a certain degree of flexibility observed when binding to the ligand (the length decreases to 28 nm)
[81]. This plasticity of the tetramers is likely to be furnished by a flexible CRD-neck junction [79],
and allows to adapt to the glycan structures on the ligands, thus enabling all CRDs to interact.
The global shape of the extracellular part of DC-SIGN revealed by small angle X-ray scattering
(SAXS) measurements revealed and confirmed the presumed elongated shape of the lectin with an
approximate 40Å spacing between vicinal carbohydrate binding sites (fig. 2.11B and C) [80].
2.3.3. Clustering of DC-SIGN tetramers on the surface of DCs
Regarding the organization of DC-SIGN molecules at the cell membrane level, the lectin is clustered
into microdomains in lipid rafts of the plasma membrane of DCs, and also when ectopically expressed
in fibroblasts and other cell types. This clustering occurs even in the absence of the ligands, and the
formed microdomains range from <200 nm to 1.5 ￿m as revealed by diﬀerent techniques [82, 83, 84].
Moreover, they are remarkably stable in terms of location and diﬀusion of the receptor within the
microdomain, as well as exchange between the microdomain and its surroundings in the timescale
of several minutes [85, 86]. The recent studies of the nanostructure of DC-SIGN microdomains
by super-resolution imaging technique, Blink Microscopy, indicated that DC-SIGN is organized in
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small ≈80 nm nanodomains (fig. 2.12), which are randomly distributed on the plasma membrane of
DCs and contain as few as 1-3 tetramers as a lower limit, suggesting that other proteins and lipids
occupy these nanodomains [87].
Figure 2.12.: The nanostructure of DC-SIGN microdomains.
A, DC-SIGN expression on fixed DC revealed by diﬀraction limited total internal reflection fluorescence (TIRF) illumination.
B, Super-resolution Blink image of DC-SIGN expression in the same region as in A. C, superimposition of TIRF image (in
red) and Blink image (in white). Scale bars, 500 nm; scale bar inset, 100 nm. (From [87])
The mechanism of DC-SIGN clustering on the membrane was investigated using truncated
forms of DC-SIGN and the influence of distinct DC-SIGN parts for the formation and stability of
microdomains was examined [88]. These studies indicated that the driving force of microdomain
formation is the saccharide binding to CRD, since CRD-depleted DC-SIGN or mutants of a single
amino acid required for Ca2+-coordination at sugar binding site showed a diﬀused expression over
all the membrane with no visible microdomains and high mobility. The neck domain appeared to
be responsible for the stability of the microdomains, as in case of DC-SIGN depleted of tandem
repeats the microdomains were dynamic, often moving on membrane from one position to another,
and DC-SIGN within these domains was able to exchange with other DC-SIGN molecules from the
surrounding membrane. By contrast, the removal of whole cytoplasmic domain and N-glycosylation
site at Asn80 had no significant eﬀect on microdomain formation and stability suggesting that
the clustering mechanism is not dependent on cytoskeletal structures, despite the observation that
DC-SIGN constitutively binds to scaﬀold proteins LSP1, KSR1 and CNK [89].
The finding that CRD is essential for the clustering of DC-SIGN on the membrane suggests
several mechanisms: (1) CRD directly binds to polysaccharides of the extracellular matrix (ECM),
e.g. glycosaminoglycans or glycosyl moieties of ECM proteins (fig 2.13A); (2) CRD directly binds
to transmembrane proteoglycans that link to the ECM (fig 2.13B); (3) glycosylated transmembrane
adaptor proteins (TRAPs), which are directly or indirectly linked to the membrane-apposed cy-
toskeleton and have cis interactions with DC-SIGN, serve to stabilize the microdomains (fig 2.13C).
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Figure 2.13.: Possible mechanisms of DC-SIGN microdomain formation and stability.
Microdomain formation facilitated and stabilized through DC-SIGN CRDs interactions with ECM components (A),
transmembrane proteoglycans that are linked to ECM components (B), and/or glycosylated TRAPs, having cis
interactions with DC-SIGN, link the receptor to the cytoskeleton (C). (From [88])
Such clustering of DC-SIGN into microdomains further contributes to the avidity of DC-SIGN
interactions with its ligands. Furthermore, it has been proposed that such clustering may modulate
DC-SIGN specificity by favoring carbohydrates with a certain density and spacing [90].
2.3.4. Ligand recognition by DC-SIGN
2.3.4.1. Endogeneous and exogeneous ligands of DC-SIGN.
DC-SIGN has been discovered as a C-type lectin of DCs that binds to the T cells adhesion molecules
ICAM-3, and this interaction is believed to mediate transient, antigen nonspecific adhesion of DCs
with T cells (fig. 2.14A), leading to eﬀective T cell receptor engagement and screening of the
MHC-peptide complexes [62]. DC-SIGN binds ICAM-3 through the recognition of the N-glycans
of high mannose-type oligosaccharides and, depending on the cell population, LewisX residues [91].
ICAM-2 that is expressed on endothelial cells was identified as another endogenous counterstructure
of DC-SIGN [92]. The interaction of these two molecules resists shear stresses and is involved in
DC adhesion, tethering, and rolling along the ICAM-2 expressing surfaces (fig. 2.14A). DC-SIGN
binding to ICAM-2 was shown to be strictly glycan-specific and LewisY structures on ICAM-2
were identified as the glycans possibly mediating this interaction [93]. Additionally to the adhesion
molecules ICAM-2 and ICAM-3, DC-SIGN binds to LewisX expressed on β2-integrin Mac-1 and
CEACAM1 on neutrophils (PMNs), and thus drives the interaction between DCs and neutrophils
(fig. 2.14B) [94, 95], and by binding to LewisX and LewisY sugars recognizes carcinoembryonic
antigen (CEA) overexpressed on majority of colorectal cancer cells [96]. DC-SIGN also recognizes
human semen clusterin and this binding interferes HIV capture by DCs [97].
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Figure 2.14.: The physiological role of DC-SIGN and endogeneous ligands.
A, DC-SIGN promotes transmigration of DCs from the blood vessels into lymphoid tissues by interacting with
ICAM-2 expressed on endothelial, and mediates immunological synapse initiation by binding to ICAM-3 on T cells
(from [98]). B, DC-SIGN binds Mac-1 and CEACAM on PMNs and induces PMN survival, while PMNs can induce
DC maturation (from [99]).
DC-SIGN also functions as a PRR since it is capable to recognize the glycans expressed
on various pathogens. It has been shown that DC-SIGN is implicated in antigen processing and
presentation to T cells [100]. Initially, DC-SIGN was found to bind HIV-1 through interaction
with envelope glycoprotein gp120, but soon it appeared that this lectin also captures many other
dangerous pathogens (table 1.2). Unfortunately, this recognition does not lead to infection clearance,
but rather the pathogens exploit DC-SIGN to escape immunity and facilitate their invasion and
infective processes.
2.3.4.2. Ligand-induced DC-SIGN signaling
The ligand binding to DC-SIGN triggers endocytosis and cellular signaling, which requires simul-
taneous TLR signaling and is dependent on the nature of the ligand. The cytoplasmic domain
of DC-SIGN contains di-leucine (LL) and triacidic cluster (EEE) and other internalization motifs,
which direct the DC-SIGN-bound ligands into late lysosomes or MHC class II positive endosomes
[100, 101]. However, this process is ligand-dependent since HIV-1 virions bound to DC-SIGN are
directed to early endosomes [46]. DC-SIGN-mediated internalization has been shown to occur via
clathrin-coated pits and requires membrane cholesterol and dynamin [102], but it is worth to note
that ligands, as antibodies, binding to DC-SIGN neck region induce clathrin-independent internal-
ization that directs ligands to early endosomes [103].
The cytoplasmic tail of DC-SIGN also contains an incomplete ITAM indicating the lectin’s
signaling capability [104]. Indeed, the final outcome of DC-SIGN triggering is the gene transcrip-
tion by NF-κB (reviewed in [19, 29]), despite that DC-SIGN is considered ITAM/ITIM independent
CLR. NF-κB is an important transcription factor composed of several subunits and activated by
several classes of PRRs following pathogen recognition. It regulates the expression of genes encoding
costimulatory molecules, cytokines and chemokines. However, the proper induction of gene tran-
73
CHAPTER 2. HUMAN IMMUNODEFICIENCY VIRUS: THE INFECTION VIA SEXUAL
TRANSMISSION
scription requires NF-κB translocation to nucleus, and this cannot be accomplished by triggering
DC-SIGN alone – the prior activation of NF-κB by TLR signaling is necessary. Thus, DC-SIGN
modulates the NF-κB activity and the cross-talk between DC-SIGN and TLR signaling gives the
final immune response.
Mannose-containing ligand binding to DC-SIGN induces the downstream eﬀector kinases,
which further leads to Ser/Thr protein kinase RAF1 activation (fig 2.15). The activated RAF1
then phosphorylates p65 subunit of NF-κB, which makes it a target for subsequent acetylation
and finally increases its activity (prolongs its nuclear activity, enhances transcriptional rate and
increases binding aﬃnity to DNA) on Il6, Il8, Il12a and Il12b promotors, and particularly on Il10
promotor, which strongly increases anti-inflammatory IL-10 production. Although RAF1 activation
is followed by DC-SIGN triggering and does not require TLR signaling, p65 cannot be activated
by DC-SIGN alone – DC-SIGN signaling only modulates p65 activation when it has been already
translocated to nucleus (reviewed in [29, 18]).
Figure 2.15.: TLR signaling modulation by DC-SIGN triggering induced by mannosylated ligands
bearing pathogens such as HIV-1 or Mycobacteria.
(From [18])
There is very limited knowledge about DC-SIGN signaling in response to fucose-containing
pathogen binding, and it comes only from LewisY positive and negative H. pylori infection studies
and examinations of immune responses to soluble egg antigens of the parasite Schistosoma man-
soni (reviewed in [29]). Only LewisY+ H. pylori interacts with DC-SIGN, which induces high
up-regulation of only anti-inflammatory IL-10 production. Such a response is significantly diﬀerent
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from responses to LewisY- H. pylori strain as well as to mannose-containing pathogens that induce
up-regulation of both pro-inflammatory cytokines such as IL-6 and IL-12, and anti-inflammatory
IL-10.
Thus the pathogens evolved to exploit DC-SIGN signaling for their infection promotion. The
cross-talk between DC-SIGN and TLR signaling also may explain why DC-SIGN recognition of
endogenous ligands does not lead to DC maturation and cytokine production: since there is no
simultaneous activation of PRRs by pathogens to induce NF-κB activation, DC-SIGN triggering
alone does not induce immune responses [18].
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2.4. Langerin: a specific CLR of Langerhans cells
As DC-SIGN, langerin is a type II C-type lectin, almost exclusively expressed on epidermal LCs,
but also present on dermal CD103+ DCs and lymph node resident CD8+ DCs [105, 106, 107].
LCs is a subset of DCs, whose role is not completely clear. Although initially they were assumed
to function as APCs, like dermal or stromal DCs [108], the accumulating evidence of their fail to
present antigens from various viruses and parasites to T cells activation and the observation that LCs
induce T regulatory cells supports the presumption that these cells may have an immunosuppressive,
tolerogenic role [22].
A characteristic hallmark of LCs is the Birbeck granules (fig. 2.16), and langerin has been
shown to be the main component and responsible for the formation of these tennis racquet or
rod-shaped membranous structures [105].
Figure 2.16.: Electron microscopy of a Langerhans cell from human epidermis.
Typical BGs are shown in an inset. (From [109])
Langerin has been identified as a major pathogen-capturing endocytic receptor of LCs (table
1.2) [110, 21]. It binds pathogens through the recognition of high-mannose structures [111] present
on viral envelopes, mannan and β-glucan structures on fungi [21].
As already described in sub-subsection 2.2.1.2, langerin is particularly important in protection
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against HIV infection since it captures HIV-1 virions by binding to envelope glycoprotein gp120,
and this leads to their degradation in BGs [57]. The anti-fungal function of LCs is suggested as
well, with a central protective role exerted also by langerin [21].
2.4.1. The structure and carbohydrate recognition by langerin
Langerin is a type II transmembrane receptor (328 amino acids, 37.5 kDa) with an overall molecular
organization similar to DC-SIGN and other CLRs: it consists of N-terminal cytoplasmic domain,
transmembrane domain, neck region, and a C-terminal C-type CRD (fig. 2.17) [105]. The cytoplas-
mic domain of langerin contains a proline-rich signaling motif (WPREPPP), which could function
as a docking site for signal transduction proteins, and indeed, it was demonstrated to be important
for langerin intracellular targeting [112]. Nonetheless, the role of langerin signaling is still obscure
[18].
Figure 2.17.: Primary structure of human langerin.
The sequences of cytosolic, transmembrane, neck region, and CRD domains are in blue, black, red and green let-
ters.The potential proline-rich signaling motif is highlighted in grey, and the conserved motifs defining sugar specificity
and Ca2+-coordination are in orange and blue. The conserved WIGL motif is in red. The putative heptads con-
tributing to coiled-coil formation are individually underlined, and the disulphide bridges are depicted by light green
lines.
The CRD of langerin (fig. 2.18) contains EPN motif indicating its specificity for mannose
type sugars. A glycan array analysis using truncated trimeric langerin, has revealed several types
of carbohydrates as ligands of langerin [113]. As expected, langerin bound high-mannose N-linked
oligosaccharides, however, the only fucose-based ligand of langerin was blood group B antigen
(Galα1–3(Fucα1–2)Gal). Moreover, a peculiar property of langerin to bind glycans terminating in
6-sulfated galactose was also found [113] that explained the ability of langerin to recognize keratan
sulphate [114].
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Figure 2.18.: The structure of langerin CRD.
EPN, WND and WIGL motifs are shown in orange, pink and red stick representation. Disulphide bridges depicted
in yellow sticks and a cyan sphere is the Ca2+. The flexible loop comprising residues 258-262 is shown in blue.
Structural studies of ligand recognition by langerin revealed that it binds high-mannose struc-
tures through non-reducing terminal mannoses and internal Manα1-2Man (fig. 2.19A), which has
multiple binding modes in the conventional Ca2+-dependent sugar-binding site. The binding mode
of this non-reducing mannose residue is virtually the same as mannose monosaccharide (pdb:3P7G),
except that it is 180° flipped by the axis perpendicular to C3-C4 bond. In contrast to DC-SIGN,
langerin has only a small extended binding site that contacts other sugar residues in high-mannose
oligosaccharides, and better binding aﬃnity to these oligosaccharides compared to mannose may be
a statistical eﬀect of having multiple available mannose residues, as is in case of DC-SIGN [115].
Figure 2.19.: The CRD of langerin in complex with carbohydrate ligands.
A, Manα1-2Man in a likely preferred and favored binding mode in the context of longer oligosaccharide with non-
reducing mannose coordinating to Ca2+ and oxygen atom that would be linked to the oligosaccharide shown in red
sphere (pdb: 3P5F). B, 6SO4–Galβ1–4GlcNAc (pdb:3P5I). The Ca2+ ions are shown as orange spheres.
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It was also demonstrated that langerin is unique among C-type CRDs since apart of binding
mannose/fucose type sugars, it is also able to interact with galactose-based saccharides: it rec-
ognizes 6SO4–Gal residues that are present in keratan sulfate as 6SO4–Galβ1–4GlcNAc repeating
unit[114]. In crystal structure of langerin CRD in complex with 6SO4–Galβ1–4GlcNAc (fig. 2.19B)
the galactose residue was found to make coordination to Ca2+ by axial 4-OH and equatorial 3-OH
groups, and the galactose residue packs against Ala289. Finally, the SO4 group makes salt bridges
with Lys299 and Lys313 [115].
2.4.2. Trimeric structure of langerin and its role in BG formation
The neck region of langerin is composed of the series of heptads (fig. 2.17), although these repeats
are not as obvious as the tandem 23 amino acid repeats in the neck of DC-SIGN. These heptads
are responsible for the oligomerization of langerin into trimers (fig. 2.20A) [111, 113].
Figure 2.20.: The trimeric organization of truncated langerin.
A, The side view of the trimer. B, The top view of the trimer; the spacing shown between CRDs is the average of
the distances in Å. (From [113])
The trimeric langerin is rather a rigid unit with the CRDs in fixed positions as can be seen
in the crystal structure of the truncated trimeric langerin: the CRDs make multiple contacts with
the neck region and this leads to the arrangement of primary sugar-binding sites at fixed positions
separated by a distance of 42Å (fig. 2.20B). The only significant flexibility in the CRD was observed
at the loop region comprising residues 258-262 (fig. 2.18), and results most likely due to the absence
of auxiliary Ca2+ sites that are present in many other CRDs. This kind of fixed organization of
sugar-binding sites may restrict ligand recognition by langerin [113].
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Figure 2.21.: Contribution of langerin to Birbeck granule formation.
A, The model of langerin extracellular domain. B, Stacked Birbeck granules of LC. C, two suggested macromolecular
organization models of BG stacking with langerin as a major component and the driving force. (From [112])
It has been demonstrated that the CRD of langerin is essential for BG formation [116, 112].
Based on hydrodynamic properties of extracellular domain (ECD) of langerin as a fairly elongated
protein, and sequence analysis, the group, which I later joined, has built a model of the whole ECD
(fig. 2.21A). This model, together with electron microscopy data on BGs, was used to construct
a hypothesis of a possible molecular mechanism of BG formation driven by langerin (fig. 2.21B)
[112]. However, the plausibility of such membrane zipping mechanisms and molecular details of the
process still need to be confirmed.
2.5. The comparison of the CRDs of DC-SIGN and langerin
Both DC-SIGN and langerin are lectins of type II with C-type CRDs. The sequences and the overall
structures of their CRDs are close (fig. 2.22) and correspond to the classical CRD fold (fig. 1.6).
However, several important diﬀerences can be tracked in these two CRDs.
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Figure 2.22.: The comparison of DC-SIGN and langerin CRDs.
A, An alignment of the sequences of DC-SIGN and langerin CRDs by ClustalW (amino acid color codes: red
– hydrophobic, green – polar, pink – positively charged, blue – negatively charged). B, structural alignment of
DC-SIGN and langerin CRDs (the color coding is the same as in fig. 2.9 and 2.18).
Langerin has several structural elements that are not present in DC-SIGN CRD, including
a 310 helix close to sugar-binding site, and an additional β2￿ strand (fig. 2.18). The whole CRD
structure of langerin is supported by two conserved disulphide bridges, in contrast to four S-S bonds
in DC-SIGN. Unlike DC-SIGN, langerin CRD has only one Ca2+ ion at Ca site 2 (conventional
sugar-binding site), and the lack of other Ca2+ ions in sites 1 and 3 might be the reason for the
high flexibility of the β2-β2￿ loop comprising residues 258-262, which also leads to the formation of
a large groove specific to the langerin structure.
Figure 2.23.: The diﬀerences of sugar-binding sites of DC-SIGN and langerin.
A, The alignment of DC-SIGN (blue) (pdb:2IT5) and langerin (light green) (pdb:3P5F) CRDs bound to Manα1-
2Man, shown in yellow (for DC-SIGN) and green (for langerin) sticks; the side chains of EPN and WND motifs are
shown in lines, and the most important diﬀerent amino acid residues required for sugar binding are highlighted by
stick representation; the blue and black labels correspond to DC-SIGN and langerin side chains, respectively; light
cyan spheres are Ca2+ ions. B and C are surface representations of langerin and DC-SIGN CRDs, respectively,
complexed with Manα1-2Man; the important side chains are highlighted; green sphere is Ca2+.
81
CHAPTER 2. HUMAN IMMUNODEFICIENCY VIRUS: THE INFECTION VIA SEXUAL
TRANSMISSION
However, the most relevant diﬀerence of these two lectins is in their sugar-binding site topolo-
gies. A unique feature of langerin CRD is the presence of two lysine residues (Lys299 and Lys313)
in sugar binding-site, which provide the binding site the basic character that allows langerin to
accommodate sulfated sugars in its binding site. On the other hand, while Phe313 is an impor-
tant side chain in DC-SIGN sugar-binding site as it forms stacking interactions with the sugar
ring (fig. 2.23A) [117, 73], in langerin Phe315 positioning is not suitable to participate in such
sugar binding (fig. 2.23A). Overall topology of langerin CRD composes only a small binding site
strongly constrained by Lys299 (fig. 2.23B), while DC-SIGN has a potential to adapt more extended
oligosaccharides with a widely open binding site (fig. 2.23C and 2.9C).
The CRD-neck junctions of DC-SIGN and langerin are also diﬀerent: while the flexibility in
DC-SIGN is retained, langerin trimers present CRDs in a rather rigid manner [113]. This likely
leads to diﬀerent way of ligand recognition of the two lectins.
Figure 2.24.: The micrograph of mucosal tissue.
Langerin is visualized in red, cell nuclei are in blue. (Personal communication from Dr. Jenny Valladeau-Guilemond
and Dr. Colette Dezutter-Dambuyant, Centre Léon Bérard – UMR INSERM 1052-CNRS 5286, Lyon, France)
Finally, the localization of these two lectins in mucosa is diﬀerent. Langerin is expressed on LCs
that reside in epithelia (fig. 2.24), while DC-SIGN expressing stromal DCs survey the underlying
stroma. Thus LCs with langerin are the very first barrier that pathogens encounter invading the
mucosal tissues.
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strategy
3.1. Microbicides as the means of HIV prevention
More than 40 million people around the world are infected with HIV, with an estimate of 15,000-
20,000 new infections each day [118]. However, there is no cure for HIV infection so far and
the existing life-long treatment, HAART (highly active antiretroviral treatment, a combination of
several substances that target to interfere with various stages in HIV life cycle), is rather expensive
and aﬀordable to only a limited population of those infected. Moreover, HAART has numerous
adverse eﬀects, some of which are even life threatening (reviewed in [119, 120]). This might impose
high physical and psychological burden, and part of the patients were discontinuing the therapy
within the first year [121]. Also HAART may lead to drug-induced virus resistance. Thus, the
development of the means of infection prevention is of the utmost importance as this would be the
most eﬀective way to halt the epidemic.
Unfortunately, up to date there is no eﬀective anti-HIV vaccine developed, despite extensive
research eﬀorts for more than 15 years. The only exception was RV144 trial, also called ‘Thai trial’,
which gave only modest results of 31.2% vaccine eﬃcacy [122].
The sexual transmission of HIV is a dominating route of infection (table 2.1). Women globally
comprise over 50% of all people living with HIV and they appear to be at higher risk for infection
transmission through cervicovaginal tissues (table 2.1) [44]. Moreover, in sub-Saharan Africa and
the Caribbean women make up 59% and 53% of the HIV infected population, respectively [118].
Although the simplest and indeed eﬀective means of prevention is a proper and consistent use of
condoms, the possible social, cultural, ethical and economical factors may limit their use. Therefore,
alternative means should be considered.
Vaginal HIV microbicides (VHMs) are a promising alternative for safe and eﬀective prevention
methods from sexually transmitted HIV. Furthermore, they are particularly important for women
since such microbicides would provide the way of independent self protection, as women are not
always able to lower their risks because of social, cultural and economical reasons in the high-risk
regions of the developing countries [123].
The concept of HIV prevention that would be controlled by women themselves by using a
topical vaginally applied “virucide” was introduced in 1990 by Zena A. Stein [124] and gave the
starting point for the development of VHMs.
VHMs are substances designed to inhibit or block early events in HIV infection. According
to their mode of action, the VHMs can be broadly classified to five groups (table 3.1, information
collected from [125, 126, 127]): surfactants, vaginal milieu protectors, inhibitors of entry, fusion and
reverse transcriptase [125].
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Surfactants and vaginal milieu protectors are rather non-specific protection means, while HIV
entry together with HIV reverse transcriptase inhibitors must be designed as specifically interacting
substances. Furthermore, HIV entry inhibitors can be designed to target either viral envelope or
host surface molecules implicated in the virus entry process.
To be suitable for the use as intravaginal topical microbicides, the active substances and their
formulation, apart from their eﬃcacy, must meet the following criteria (reviewed in [128]): they
must be safe and non-toxic with no inflammatory responses, resist to seminal fluid, vaginal pH and
body temperature, generally acceptable by women (i.e. easy to use, comfortable, not expensive),
and available to produce at large-scale and aﬀordable cost. VHMs can be formulated as gels/creams,
rings, foams, and films, and the mode of formulation is one of the major factors for the adherence
to a potential VHM.
Table 3.1.: The examples of diﬀerent type vaginal microbicides.
Microbicide type Mode of action Examples
Surfactants/membrane
disruptors
Disrupt membranes non-specifically and thus
provide contraceptive activity against a wide
range of potential sexually transmitted
infections (STI).
• Nonoxynol-9 (N-9);
• C31G (Savvy);
• Sodium lauryl sulfate (Invisible
Condom).
Vaginal milieu
protectors
Maintain, restore, or enhance the natural
protective mechanisms, i.e. the acidic pH
naturally maintained by lactobacilli (pH
between 4.0 and 5.8 inactivates HIV), within
vaginal canal.
• Carbopol 974P (BuﬀerGel);
• Acidform (Amphora);
• “Probiotics”: natural or
bioengineered lactobacilli .
Entry inhibitors Anionic polymers:
Negative charge causes interaction with HIV’s
viral envelope proteins (gp120 of R4 strain in
particular) and interferes with attachment to
CD4+ T cells.
• Naphthalene sulfonate (PRO2000);
• Carrageenan (Carraguard/ PC-515);
• Cellulose sulfate (Ushercell);
• Cellulose acetate phthalate (CAP);
• Dendrimers: SPL7013 (Vivagel).
CCR5 blockers
Block CCR5 coreceptor and interfere with
attachment of HIV to host cells
• PSC-RANTES;
• CMPD167.
Fusion inhibitors Prevention/inhibition of viral-host cell
membrane fusion
• C-52L (inhibits gp41-mediated
viral—cell fusion);
• Algal lectins (prevents viral-host
cell fusion by binding high mannose
residues in the HIV envelope).
Reverse transcriptase
inhibitors
Interfere with HIV reverse transcriptase • Tenofovir (PMPA, nucleotide
analogue);
• TMC120 (non-nucleoside reverse
transcriptase inhibitor (NNRTI));
• UC781 (NNRTI).
Disappointingly, for many of the clinically tested VHMs (cellulose sulphate, SAVVY, Car-
raguard, PRO 2000 and BuﬀerGel) there was no evidence found on reduction of HIV acquisition
(reviewed in [129]), some even showed toxicity (N-9, CAP) [125]. The most successful VHM can-
didate, the antiretroviral (ARV) drug tenofovir based gel, has provided clinical data to support its
eﬃcacy in CAPRISA 004 trial [130]; nonetheless, the second trial that enrolled 5000 women was
stopped early due to low likelihood of showing a protective eﬀect (reviewed in [129]). There are
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other compounds that are undergoing Phase II or III clinical trials [125], but in conclusion, up to
date there is no VHM substance to have successfully passed the Phase III.
The ARVs used for HIV therapy are increasingly investigated for the use as microbicides [131].
Moreover, in the search of the new ways of HIV-1 prevention, the human C-type lectin DC-SIGN
was identified as a potential therapeutic target because of its important role in HIV infection
enhancement and dissemination in the mucosal site (see section 2.2). There are several groups
working on the design of the compounds, mostly glycomimetic and some non-carbohydrate, that
have the ability to bind to DC-SIGN blocking its interaction with HIV (reviewed in [132]).
It is also important to notice that the discovery of eﬃcient and safe DC-SIGN antagonists
would be beneficial not only for protection from HIV infection. This lectin is usurped by numerous
pathogens, including Ebola, Dengue viruses, Mycobacteria tuberculosis and others (table 1.2), to
enhance their infective processes and survive host immunity, causing chronic diseases. This makes it
an interesting target for therapeutical intervention, and DC-SIGN antagonists could be applicable
as anti-infective agents against multiple pathogens [132].
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3.2. The concept and design of glycomimetic drugs
Glycomimetics can be defined as chemical entities that mimic the bioactive carbohydrates and bind
to target proteins, mostly lectins or sugar-modifying enzymes, thus interfering various pathological
processes. The glycomimetic drug substances present several advantages over the natural carbohy-
drate ligands: they can be designed to have higher aﬃnity and specificity for the target protein as
well as longer plasma half-life (i.e. resistance to glycosidases). Moreover, these substances may be
designed to have a lower polarity compared to carbohydrates, which would improve their pharma-
cokinetic properties [133, 132].
Figure 3.1.: The examples of the approved carbohydrate-based and glycomimetic drugs.
Voglibose, miglitol and acarbose are the drugs for diabetes treatment (glycosidase inhibitors that prevent the digestion
of carbohydrates). Zanamivir and oseltamivir are active substances for the prevention and treatment of influenza virus
infections. Fondaparinux, dalteparin, ardeparin, nardoparin and enoxaparin, which are sulphated glycosaminoglycans,
function as anticoagulants for the treatment of thrombosis. Miglustat, topiramate and sodium hyaluronate are used
to treat Gaucher’s disease, epilepsy and osteoarthritis, respectively. Trade names are in the brackets (from [133])
The glycomimetics form a new class of therapeutics and currently they cover only a small
area of the multitude of available drugs. There are several examples of already developed and
commercially available carbohydrate-derived drugs (fig. 3.1). Among them, a successful anti-
influenza prodrug oseltamivir (Tamiflu), which is metabolically converted to a viral neuraminidase
inhibitor, is a paradigm of a glycomimetic drug: it was developed from a carbohydrate lead by
systematical modifications of the molecule to finally achieve a prodrug [133].
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Generally, the rational design of a glycomimetic drug requires the explicit knowledge of the
structure–activity relationships, i.e. the molecular basis of the interaction between the carbohy-
drate epitope and its target protein receptor. To achieve that, the carbohydrate in complex with
its receptor can be studied by empirical techniques such as nuclear magnetic resonance (NMR)
spectroscopy and X-ray crystallography [134].
The aﬃnity of the designed compound can be further improved by optimizing those positions
of the molecule that are crucial for the interaction. The knowledge of the bioactive conformation
can be also very useful: the design of glycomimetics with a pre-organized favorable conformation in
solution leads to reduced entropy costs upon binding, thus increased aﬃnity [134].
The next step would be the optimization of the compound’s valency depending on the nature
of the biological interaction. In biological systems, the interactions between lectins and their carbo-
hydrate ligands are usually oligovalent due to oligomerisation of the lectin receptor, its clustering on
the cell surface or presentation of carbohydrate epitopes in a clustered manner or all of these factors
working simultaneously. Hence, in order to attain an eﬃcient compound that would be capable to
compete such interactions, the strategies of multivalent presentation must be considered and opti-
mized [133]. There are many diﬀerent platforms being used for the design of glycoclusters, and the
examples include glycodendrimers [135], gold glyconanoparticles [136], fullerene sugar balls [137],
cyclodextrin-based [138], calyx[n]arene-based [139], cyclopeptide-based glycoclusters [140] and other
scaﬀolds (reviewed in [141]).
The above described stages of the glycomimetic drug design outlines the principal workflow
and objectives of the European initial training network (ITN) CARMUSYS, which aims to develop
DC-SIGN antagonists with the purpose to block early infections of HIV as well as other pathogens.
I joined this network to carry out the PhD studies, and thus this workflow will be reflected later
throughout this thesis manuscript.
The final step in the rational design of the glycomimetic drug substance is the improvement of
the pharmacokinetic/pharmacodynamic properties of the molecule as well as optimization for the
chosen way of administration [134].
87
CHAPTER 3. HIV SEXUAL TRANSMISSION PREVENTION STRATEGY
3.3. Glycomimetics as DC-SIGN inhibitors
The strategy of glycomimetics is a rational approach for the development of DC-SIGN antagonists,
since this protein is a lectin receptor recognizing mannose or fucose-based sugars. Therefore, the
main strategy of the development of glycomimetic DC-SIGN ligands is to retain mannose or fucose
monosaccharide as an anchor, while other parts of the molecule can be designed and optimized to
attain the better aﬃnity, specificity and selectivity. Indeed, a handful of the glycomimetic DC-SIGN
ligands (tables 3.2 and 3.3) bearing both mannose or fucose anchors has been developed by several
research groups (reviewed in [128, 132]), and some of these compounds have successfully passed
cell-based in vitro tests for their anti-viral activity.
Table 3.2.: Some examples of the published monovalent mannose-based DC-SIGN glycomimetics.
Entry Potency Assay Ref.
1 K I 350 ￿M SPR competition, gp120 coated surface [142]
2
R=NH2: IC50 620 ￿M Inhibition of Ebola envelope-pseudotyped virus infection [143]
R=N3: IC50 1005 ￿M
SPR competition, mannosylated bovine serum albumin
(ManBSA) coated surface
[49]
3
IC50 125 ￿M SPR competition, ManBSA coated surface
[49]
IC50 80 ￿M Inhibition of HIV trans infection of CD4+ T cells
4
(a) IC50 6.9 ￿M
Inhibition of DC-SIGN-mediated adhesion to mannan coated
plates
[144](b) IC50 12.8 ￿M
(c) IC50 12.5 ￿M
Structures:
The strategy to design fucose-based mimics (table 3.3) is generally based on LewisX trisaccha-
ride (IC50 0.8mM in SPR competition assay with ManBSA surface [145]) (fig. 2.9D): the fucose
anchor is retained while changing the nature of the linker (GlcNAc in LewisX) and the second moiety
(galactose in LewisX) that is interacting in DC-SIGN CRD [145].
The majority of these mannose and fucose-based glycomimics (entries 2-4 in table 3.2, and
both compounds in table 3.3) were designed by Pr. Anna Bernardi’s group, who is currently our
collaborator in the ITN CARMUSYS, and they were functionally characterized (except compound
4, table 3.2) by the group of Pr. Franck Fieschi, which I later joined.
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Table 3.3.: Some examples of the published glycomimetic fucose-based DC-SIGN ligands.
Entry Potency Assay Ref.
1 IC50 350 ￿M SPR competition, ManBSA coated surface [145]
2 IC50 500 ￿M SPR competition, ManBSA coated surface [145]
Structures:
Another already applied approach for DC-SIGN ligand discovery is the screening of the non-
carbohydrate molecules that would have necessary features of the carbohydrates that bind DC-
SIGN. In such a pursuit, shikimic acid was used as a scaﬀold, and out of 192 synthesized its
derivatives a reasonable DC-SIGN binder was identified (fig. 3.2A), which was suggested as a
starting point for further optimization [146]. Furthermore, the analogue of this compound coupled
to BSA (fig. 3.2B) for multivalent presentation was found to induce cellular signaling via JNK
pathway [147].
Figure 3.2.: Examples of non-carbohydrate ligands of DC-SIGN.
A, Shikimic acid derivative [146]. B, The analogue of compound in panel A, coupled to ManBSA [147]. C, A
compound identified by high-throughput screening of two libraries [148]. D, quinoxalinone derivative [149]. A, C
and D: IC50 determined by competition assay of ManBSA binding to immobilized DC-SIGN ECD.
The other examples of non-carbohydrate DC-SIGN inhibitors include the small molecules
(IC50 values of 1.6-10 ￿M) identified by high-throughput fluorescence-based competition assay from
two commercial libraries comprising about 36 000 compounds (fig. 3.2C) [148], and the more recent
potent inhibitors (IC50 values of 0.31-329 ￿M) derived from a collection of quinoxalinones (fig. 3.2D)
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[149].
It is very important to note, that the selectivity issue is essential for the development of DC-
SIGN antagonists. As it has been described in sub-subsection 2.2.1.2, the closely related lectin
langerin has a protective role against HIV infection, and its location in mucosal surfaces makes it
the very first barrier for the invading virus. Therefore, the compounds must be designed with strict
selectivity to DC-SIGN and not langerin so that they wouldn’t interfere with this protective role of
langerin.
3.4. Multivalent presentation of the active substances
In biological systems, the interactions of DC-SIGN with its ligands, especially PAMPs, are of
multivalent nature, which results in high overall aﬃnity through the avidity eﬀects. There are
several factors that build up this multivalency. Firstly, DC-SIGN is expressed on cell surfaces in
a tetrameric form and these tetramers are further clustered into microdomains in lipid rafts (see
subsections 2.3.2 and 2.3.3), thus the binding sites are presented in a concentrated manner at the
cell surface. Secondly, the pathogens usually present their surface glycans also in a clustered way.
For instance, the high mannose type glycans of HIV envelope glycoprotein gp120 (fig. 3.3A) appear
to be clustered resulting in an unusual density (fig. 3.3B) [150].
Figure 3.3.: The glycan shield of gp120.
A, Schematic representation of gp120 N-glycan undecasaccharide showing the structure, glycosidic linkages and
identity of the D1, D2 and D3 termini of the A, B and C arms. B, molecular model of gp120 with the point of
view from the viral membrane: the glycosylation surface for oligomannose glycans, found on the densely glycosylated
outer domain, is shown in green, and in red is the glycosylation surface for complex sugars, which are distributed on
the more exposed receptor-binding sites and hypervariable loops. (Adapted from [150])
To cope with such multivalent interactions, the design of DC-SIGN inhibitors must include
the strategies of multimeric presentation of the developed monovalent ligands. The use of gold
nanoparticles (GNPs) for ligand clustering is one of the possible approaches to attain multivalency
of DC-SIGN inhibitors. Such mannose glyconanoparticles (manno-GNPs) are water-soluble nan-
oclusters with a three-dimensional display of about 100 ligands and a globular shape [151]. This
strategy was used to cluster at variable density various oligomannosides that are the structural
motifs of the gp120 undecasaccharide Man9(GlcNAc)2 (fig. 3.3A and 3.4A,B), and yielded very
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potent multivalent DC-SIGN inhibitors (table 3.4) (reviewed in [152]): Manα1-2Man based manno-
GNP had four orders of magnitude higher potency than its monovalent counterpart [151]. These
manno-GNPs (tetra-manno-GNP, fig. 3.4A) were found to be internalized into early endosomes by
immature DCs in a CLR-dependent (50%) manner [153]. However, the in vivo application of GNPs
might be limited because of potential toxicity of gold accumulation.
Figure 3.4.: The structures of multivalent presentation platforms.
A, manno-GNPs bearing diﬀerent oligosaccharides; a glucose conjugate is used to control the density of oligoman-
nosides on the manno-GNPs [154]. B, alkynyl dendrimer scaﬀolds of 1G (upper panel), 2G (middle panel) and 3G
(lower panel) [155]. C, a glycopolymer with variable α-mannose and β-galactose ratios [156]. D and E, Boltorn type
dendritic polymers of 2nd generation (2G, BoltornTMH20) in D, and 3rd generation (3G, BoltornTMH30) in E [135].
The alkynyl dendrimers (fig. 3.4B) with conjugated complex oligomannoses were shown to
be excellent inhibitors of DC-SIGN (table 3.4) [155]. However, their applicability as therapeutical
agents is limited due to high complexity of the used oligomannoses [128].
Glycopolymers with varying α-mannose and β-galactose ratios (fig. 3.4C) have been also proved
to eﬃciently bind DC-SIGN with a favor to mannose-saturated polymers (IC50 37 nM for polymer
with 100% mannose content compared to 1453 nM for 25%) [156]. The major problem for the in
vivo use of such substances would probably be caused by their relatively high viscosity, a common
feature of linear hydrophilic polymers, hindering their applicability as drug substances.
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Table 3.4.: Some multivalent DC-SIGN inhibitors and their potencies.
Entry Platform Ligand Potency Assay Ref.
1
BoltornTMH30
(valence = 32)
Mannose
IC50 337 nM
Inhibition of
DC-SIGN-mediated Ebola
infection
[157]
IC50 50 ￿M
SPR competition, gp120
coated surface
[158]
2
GNP (valence
= 22)
Tetra-manno, 50%
density
IC50 ≈0.3 nM Inhibition of
DC-SIGN-mediated HIV trans
infection
[154]
GNP (valence
= 56)
Di-manno, 50%
density
IC50 ≈2.0 nM
3
2G alkynyl
dendrimer
(valence = 9)
Man4
IC50 160 nM
Inhibition of DC-SIGN-Fc
binding to Man4 coated glass
slide
[155]
IC50 20 nM gp120/DC-SIGN-Fc ELISA
Man9
IC50 26 nM
Inhibition of DC-SIGN-Fc
binding to Man4 coated glass
slide
IC50 8 nM gp120/DC-SIGN-Fc ELISA
4
Boltorn type
dendron
(valence = 4)
Mannose IC50 50 ￿M Inhibition of
DC-SIGN-mediated HIV trans
infection
[49]
Pseudo
mannotrioside
(table 3.2, entry 3)
IC50 5 ￿M
One of the common platforms for the multivalent presentation is oﬀered by dendrimers, the
non-toxic macromolecules with suitable rheological properties, defined globular shape that provides
concentrated multiple attachment points to tether monovalent compounds [135]. Several groups
have been working on development of such glycodendritic structures. Among them Dr. Javier
Rojo group, our current collaborator in ITN CARMUSYS, suggested such glycodendritic structures
anchoring multiple mannose residues conjugated to Boltorn type dendrimers (fig. 3.4D,E) as DC-
SIGN inhibitors. They were tested in our group, and indeed, showed good inhibitory potency (table
3.4) [158]. It is noteworthy that these glycodendrimers were among the first ones demonstrated
to inhibit DC-SIGN interaction with HIV gp120 glycoprotein, i.e. shown as potential HIV early
infection inhibitors. The later collaborative studies of our group have shown that even four-valent
Boltorn type dendrons were eﬃcient inhibitors of DC-SIGN in HIV trans infection (table 3.4) [49].
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The research work on the development of DC-SIGN inhibitors has started in the team of Pr. Franck
Fieschi (later on I refer to it as “our group”) several years before I joined it to carry out PhD
studies, and has been run in collaboration with two chemist groups: the Italian team led by Pr.
Anna Bernardi (University of Milan) and the Spanish team directed by Dr. Javier Rojo (Instituto
de Investigaciones Químicas, CSIC; University of Sevilla).
During this period before my PhD started, our group has established and developed the over-
expression and purification protocols of several constructs of recombinant human lectins DC-SIGN
and Langerin. These lectins are used for the structural and functional studies of the glycomimetic
compounds carried out by our team as well as by our collaborators. Our group has also developed
Surface Plasmon Resonance (SPR) competition assay for evaluation of the interaction of the gly-
comimetic inhibitors with DC-SIGN, which allows eﬃcient identification of the lead compounds.
Our partners in Spain focus on the development of polyvalent scaﬀolds that would present diﬀerent
multivalency as well as diﬀerent geometries and spacing, and to which the selected monovalent leads
can be attached. As a start, the Boltorn type dendrimers carrying multiple mannose residues, were
challenged as DC-SIGN/gp120 inhibitors [158]. This work was among the very first attempts to
inhibit DC-SIGN/gp120 interaction using glycodendritic structures, and indeed, demonstrated that
inhibitory power of such glycodendrimers is much higher than the monovalent D-mannose, which
gave an encouragement to pursue more potent multivalent inhibitors.
On the other side, Pr. A. Bernardi’s team has been working on the design and synthesis of
monovalent mannose and fucose-based glycomimetics. Before my PhD, they have developed two
mannose-based glycomimetics, namely pseudomannobioside and pseudomannotrioside (table 3.2,
entries 2 and 3), and two LewisX trisaccharide based mimics (table 3.3), and they were assessed as
DC-SIGN inhibitors by our group and other partners [143, 49, 145].
The research work of the project continued and evolved into a successful European ITN CAR-
MUSYS. Many other research groups with high-level expertise in diﬀerent fields have joined the
project including carbohydrate chemists from Oxford (Pr. Benjamin Davis group, University of
Oxford), Berlin (Pr. Peter Seeberger group, Max Planck Institute of Colloids and Interfaces) and
Prague (Pr. Jitka Moravcová group, Institute of Chemical Technology), cell biologists and immu-
nologist from Amsterdam (Pr. Yvette van Kooyk group, VU University Medical Centre, DC4U),
Madrid (Dr. Rafael Delgado group, Laboratorio de Microbiología Molecular, Hospital Universitario
12 de Octubre) and Paris (Dr. Ali Amara group, Inserm, Institute Pasteur), nuclear magnetic
resonance (NMR) experts from Seville (Dr. Pedro Manuel Nieto Mesa group, Instituto de Investi-
gaciones Químicas, CSIC, University of Sevilla), and computational chemists from Mannheim (Dr.
Jörg Weiser group, Anterio consult & research). I have joined the network in October 2009, i.e.
nine months after it has started, at the stage when the second generation fucose-based monovalent
compound series had to be evaluated, and this PhD work is an integral part of the general workflow
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of the ITN CARMUSYS shown in figure 4.1.
ANALYSIS OF  
MONOVALENT LIGANDS 
Our team: 
Compound screening and 
interaction structural and 
functional characterization. 
Dr. P. Nieto team: 
Characterization of lead compound 
interaction with DC-SIGN in 
solution by NMR 
(Cinzia Guzzi) 
ANALYSIS OF  
MULTIVALENT COMPOUNDS 
Our team: 
Characterization of 
compound interaction  
with DC-SIGN. 
Dr. P. Nieto team: 
Characterization of compound 
interaction with DC-SIGN in 
solution by NMR 
(Cinzia Guzzi) 
BIOLOGICAL ACTIVITY STUDIES OF 
SELECTED MULTIVALENT COMPOUNDS 
Pr. Y. van Kooyk team: 
•  Compound potency to inhibit 
HIV and other infections. 
•  Compound e!ect on DC 
adhesion, maturation, cytokine 
production, antigen presentation. 
(Maurizio Perdicchio) 
VU UNIVERSITY 
MEDICAL CENTRE 
Dr. R. Delgado team: 
Compound potency to inhibit  
DC-SIGN-mediated model 
infections using recombinant  
viruses  
(Joanna Luczkowiak) 
LABORATORIO DE 
MICROBIOLOGÍA MOLECULAR 
Dr. A. Amara team: 
Compound potency to inhibit  
Flaviridae, particularly Dengue, 
infections 
(Rasika Ramdasi) 
INSTITUTE 
PASTEUR 
MULTIVALENT SCAFFOLD PREPARATION  
AND SELECTED LIGAND CONJUGATION 
Pr. B. Davis team: 
Preparation of glycodendriproteins 
functionalized with glycomimics 
(Regis Saliba and Pieter Gregoir) 
UNIVERSITY OF  
OXFORD 
INSTITUTO DE 
INVESTIGACIONES 
QUÍMICAS 
Dr. J. Rojo team: 
Preparation of various dendritic 
cores and functionalization with 
chosen monovalent ligands 
(Renato Ribeiro-Viana) 
DC4U B.V. 
Pr. Y. van Kooyk team: 
Production of natural glycoproteins 
(Martino Ambrosini) 
Pr. J. Moravcová team: 
Preparation of C-glycosides 
(Benedetta Bertolotti) 
INSTITUTE OF CHEMICAL 
TECHNOLOGY 
Pr. A. Bernardi team: 
•  mannose-based glycomimics 
(Norbert Varga) 
•  fucose-based glycomimics 
(Daniela Doknic) 
UNIVERSITA’ DEGLI  
STUDI DI MILANO!
Pr. P. Seeberger team: 
Complex oligosaccharides by 
automated synthesis  
(Oliviana Calin and Dan 
Grünstein) 
MAX PLANCK INSTITUTE OF  
COLLOIDS AND INTERFACES 
Pr. B. Davis team: 
Solution-phase and 
chemoenzymatic syntheses  
(Regis Saliba and Pieter Gregoir) 
UNIVERSITY OF  
OXFORD 
PREPARATION OF MONOVALENT LIGANDS 
Dr. J. Weiser team: 
•  Monovalent ligand 
optimization by 
computational 
techniques 
•  docking studies of 
selected compounds 
•  Modeling of 
multivalent 
compounds 
(John McGeagh) 
Figure 4.1.: The principal architecture of ITN CARMUSYS and our group involvement.
The partners, with whom we have the most relevant collaboration, are highlighted by red frames; our team highlighted
by a blue frame. The early-stage or experienced researchers (i.e. PhD or post-doc students) hired by CARMUSYS
and working on the project in corresponding groups are written in italic in the brackets.
This multidisciplinary network functions on the basis of collaboration between diﬀerent groups
with a common final goal to design new tools for the development of DC-SIGN targeting antiviral
drugs, with HIV infection being of particular interest. The principal workflow consists of several
stages (fig. 4.1).
The first stage involves the monovalent glycomimetic ligand design and optimization: the
chemist groups work on the design of the ligands with the computational aid and advices coming
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from Anterio consult & research. The series of synthesized compounds then are screened for their
activity to bind DC-SIGN and selectivity versus langerin, and this work is mainly done in our
team. The selected hits are structurally characterized for their interaction with DC-SIGN in order
to get structural information for the further rational optimization of the compounds. This work is
done also by our team (X-ray crystallography) and by Dr. P. Nieto team (NMR studies). At this
stage, Anterio consult & research also has its part in providing the results of docking studies as a
working model for the NMR team to facilitate the experimental result interpretation. On the other
hand, the X-ray structures from our team also serve for the interpretation of NMR data as well as
development of the docking protocols.
Simultaneously to the monovalent ligand development, various polyvalent scaﬀolds are de-
signed in the team led by Dr. J. Rojo with computational support from Anterio consult & research.
The suitability of these scaﬀolds, with mannose residues conjugated to them, is evaluated in our
team by SPR tests. Then the selected ligands are mounted on chosen scaﬀolds and again tested as
DC-SIGN binders in SPR tests.
The final part of the project is the evaluation of the selected multivalent compounds in bio-
logical infection inhibition assays.
Hence, the main objective of this thesis is to develop the selective DC-SIGN antagonists, and
its accomplishment involves the following main tasks:
✧ Monovalent ligand screening by SPR competition assay to:
– determine the best DC-SIGN binders;
– evaluate selectivity to DC-SIGN versus langerin.
✧ Structural characterization of lead compound binding to DC-SIGN by X-ray crystallography.
✧ Hydrodynamic/thermodynamic characterization of DC-SIGN interaction with compounds of
interest.
✧ Multivalent compound screening by SPR assays:
– set-up/optimization of assays;
– determination of compound potency to inhibit DC-SIGN (competition assay);
– evaluation of direct interaction of compounds with DC-SIGN.
Along these tasks, the part of my work is over-expression and purification of DC-SIGN ECD and
CRD constructs, required for SPR and other tests and co-crystallization as well as to provide other
partners for their experiments.
Additionally, since the compound selectivity studies are part of this thesis, one more task is
the development of production of other C-type lectins, namely LSECtin and MGL.
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5. Materials
5.1. Materials and equipment used for cloning
The enzymes NdeI, XhoI XbaI, HindIII, BsaI and Pfu DNA polymerase were from Fermentas-
Thermo Fisher Scientific Inc. The enzyme DpnI was used from QuikChange kit, Agilent
Technologies.
The buﬀers O, R, Tango, 10X Pfu, the DNA size marker “Mass Ruler DNA Ladder Mix ready-
to-use”, the dNTPs, and the “6X Orange DNA Loading Dye” were from Fermentas-Thermo
Fisher Scientific Inc. Agarose and UltraPureTM agarose were from Roche and Invitrogen,
respectively. Ethidium bromide was from Fluka.
The “Mastercycler gradient” PCR instrument from eppendorf and the “Mini Horizontal Gel
Electrophoresis System” from Major Science were used.
The kits “QIAquick PCR Purification”, “QIAprep Spin”, and “QIAquick gel purification” were
fromQIAGEN. DNA Ligation Kits were fromRoche and Fermentas-Thermo Fisher Scientific
Inc. “QuikChange Lightning: Site Directed Mutagengesis Kit” was from Agilent Technologies.
The vectors pEt20b and pEt30b were from Novagen, and vector pASK-IBA6 was from IBA.
5.2. Materials and equipment used for bacterial cultures
E.coli strains BL21(DE3) and Rosetta2(DE3) were from Novagen, and the TOP10 strain was from
Invitrogen.
LB (Lennox) broth and LB-Agar were from AthenaES and Sigma, respectively. Ampicillin,
kanamycin and IPTG were from Euromedex. Anhydrotetracycline was from Riedel-de Haën.
5.3. Materials and equipment used for protein purification and
characterization
5.3.1. SDS-PAGE
Bis-acrylamide (30%), SDS (20%) and TEMED were from Euromedex. β-mercaptoethanol was
from Carl Roth. Acetic acid, ammonium persulphate and Brilliant blue R were from Sigma.
Ethanol was from Carlo Erba Reagents. PageRuler Unstained and Prestained Protein Ladders
were from Fermentas-Thermo Fisher Scientific Inc.
Electrophoresis system and its accessories were from Bio-Rad.
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5.3.2. Western Blot
Mouse monoclonal anti-StrepTagII antibody from QIAGEN and peroxidase-labeled anti-mouse
IgG antibody from KPL-Eurobio were used. The SDS-PAGE gels were blotted on PVDF mem-
brane from Bio-Rad, and the blots were revealed using SIGMAFASTTM 3,3’-Diaminobenzidine
staining kit from Sigma.
The transfer system and its accessories were from Bio-Rad.
5.3.3. Protein purification
5.3.3.1. Materials and equipement used for inclusion body extraction and refolding
The bacterial cells were disrupted using BRANSON Digital Sonifier® from Emerson Electric Co.
The OptimaTMLE-80K ultracentrifuge with Ti45 rotor was from Beckman Coulter.
Gdn-HCl and Triton X-100 were from Euromedex and Anatrace®, respectively. Reduced
and oxidized glutathiones, urea and L-Arginine were from Sigma. “Complete EDTA-free protease
inhibitor cocktail” was from Roche.
The dialyses were carried out using Spectra/Por® dialysis membrane (3.5 kDa MWCO, 9.3mL/cm)
from Spectrum Laboratories.
5.3.3.2. Materials and equipement used for protein purification
The Mannan-Agarose (20mL) and immobilized D-galactose (5mL) were from Sigma and Pierce,
respectively. StrepTactin (5mL) and Superose12 (125mL) columns were from GE Healthcare.
D-desthiobiotin was from IBA.
The purification were performed using ÄktaFPLC system from GE Healthcare.
5.3.3.3. Protein samples concentration
VIVASPIN concentrators with PES membrane (10 kDa MWCO) from Sartorius were used to
concentrate proteins.
5.3.4. Surface Plasmon Resonance
The SPR experiments were conducted using the Biacore 3000 and Biacore X instruments from
Biacore-GE Healthcare. Sensor chips, amine coupling kit (includes EDC, NHS and ethanolamine),
HBS-P buﬀer (0.01M HEPES pH 7.4, 0.15M NaCl, 0.005% Surfactant P20), and 10% P20 were
from Biacore-GE Healthcare.
L-fucose, D-mannose, ethylen glycol and DMSO were from Sigma. LewisX, α1-3(α1-6)-
mannotriose BSA, Man α1-2 Man and Man α1-3 Man were from Dextra Laboratories Ltd.
5.3.5. Equipement and materials for ITC, AUC, SLS/DLS and NMR experiments
Equipment and materials for ITC, AUC and SLS/DLS experiments are described in article n°5.
Equipment and materials for NMR experiments are described in article n°6.
All other used reagents were from Sigma and Euromedex.
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6.1. Production of recombinant C-type lectin constructs
6.1.1. Transformation of Ca2+-competent E.coli strains
Three Ca2+-competent E.coli strains were used in this work, namely TOP10, BL21(DE3) and BL21
derivative strain Rosetta2(DE3), which are engineered for vector propagation (TOP10) and eﬃcient
recombinant protein over-expression.
The protocol of Ca2+-competent bacterial cell transformation consists of the following steps:
1. On ice, add 1 µL of plasmid DNA to 200 µL of calcium competent cells, gently shake.
2. Incubate on ice for 30min.
3. Heat-shock: 45 s in 42°C water, put back onto ice.
4. Add 1mL of Luria-Bertani (LB) broth and incubate at 37°C for 1 hour.
5. Centrifuge at 5000xg for 5min (room temperature), discard supernatant leaving a small vol-
ume in the tube.
6. Resuspend pellet in a residual volume of supernatant.
7. Plate the resuspended cells on Petri dishes with LB-Agar containing respective antibiotic and
incubate at 37°C overnight.
8. Select one clone from a plate and inoculate it to 200mL of LB with respective antibiotic.
9. Cultivate at 37°C overnight to produce the preculture.
The prepared preculture is used to start the culture for protein over-expression (in case of BL21(DE3)
or Rosetta2(DE3) cells) or to purify the vector from the cells (in case of TOP10 cells). All below de-
scribed plasmid purifications were performed using QIAprep Spin kit according to manufacturer’s
instructions, and the concentration of plasmid DNA was determined by measuring A260 of the
sample and knowing that 50 µg/mL double-stranded DNA has A260 = 1.
6.1.2. Production of DC-SIGN S-ECD, ECD, S-CRD and langerin ECD constructs
The cloning of DC-SIGN extracellular domain comprising amino acids 66-404 and containing N-
terminal StrepTag II (S-ECD) has been done previously and is described in PhD thesis of Dr.
Georges Tabarani, which can be found at http://www.sudoc.fr/137188102.
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The cloning, over-expression and purification of DC-SIGN ECD and S-CRD constructs has
been also set up previously and is published by Tabarani et al [80] and described in submitted
article by Thépaut et al (article n°4, see table 7.1), respectively.
The over-expression and purification of DC-SIGN ECD, DC-SIGN S-ECD and DC-SIGN S-
CRD are described in sub-subsections 6.1.2.1, 6.1.2.2 and 6.1.2.3. The extra-purification of DC-
SIGN ECD is described in supplementary information of paper manuscript n°5 (see table 7.1).
Langerin ECD constructs were contributed by Eric Chabrol, a PhD student in our group.
6.1.2.1. Over-expression and purification of DC-SIGN ECD
Over-expression. The E.coli strain BL21(DE3) was used for over-expression of DC-SIGN ECD.
The cells were transformed with pEt30b/DC-SIGN ECD plasmid according to protocol in subsection
6.1.1. The culture for over-expression of DC-SIGN ECD was started by inoculation of 50mL of
overnight preculture to 1 L of LB broth with 50 ￿g/mL kanamycin. The cells were grown at 37°C
for 2 h, then the protein over-expression was induced by addition of IPTG to final concentration of
1mM and the culture was continued at 37°C overnight. The cells were harvested by centrifugation
at 5000xg for 30min at 4°C, resuspended in 25mM Tris-HCl pH 8 buﬀer and again centrifuged.
Inclusion body extraction. The pellet of the cells of 1 L culture was resuspended in 30mL of the
buﬀer consisting of 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 and containing 1 tablet of
“complete EDTA-free” protease inhibitor cocktail. The cells were disrupted by freezing at -20°C
and thawing followed by sonication for two rounds at 90% amplitude for total time of 2min for
each round using 2 s long sonications and 10 s long pauses in-between and keeping cells in ice. The
inclusion bodies together with cell debris were collected by centrifugation at 100 000xg for 30min at
4°C. To isolate inclusion bodies from bacterial cell debris, the pellet was resuspended using Potter-
Elvehjem homogenizer in 30mL of buﬀer containing 25mM Tris-HCl pH 8, 150mM NaCl, 2M urea
and 1% Triton-X100, centrifuged at 100 000xg for 1 h at 4°C, then rinsed by resuspending them
in 30mL of 25mM Tris-HCl pH 8, 150mM NaCl buﬀer with Potter-Elvehjem homogenizer and
centrifuged at 100 000xg for 30min at 4°C.
Refolding. Inclusion bodies were solubilized with Potter-Elvehjem homogenizer in 30mL of buﬀer
containing 6M Gdn-HCl, 150mM NaCl, 25mM Tris-HCl pH 8 and 0.01% β-mercaptoethanol, and
centrifuged at 100 000xg for 1 h at 4°C to eliminate insoluble part. Solubilized DC-SIGN ECD
(1.9mg/mL, 135mL) was refolded by flash dilution of 5x to a buﬀer consisting of 1.25M NaCl,
25mM Tris-HCl pH 8 and 25mM CaCl2, at 4°C. The resulting protein solution was dialyzed
overnight against 3960mL of 25mM Tris-HCl pH 8 buﬀer, at 4°C. Three more dialyses (of 3 h
each at 4°C) against 4.5 L of 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 continued and
finished refolding. The precipitates were eliminated by centrifugation at 100 000xg for 1 h at 4°C.
Purification. The purification of refolded DC-SIGN ECD was performed in two steps: by an
aﬃnity chromatography followed by gel-filtration. All purifications were carried out at 4°C.
Firstly, the refolded DC-SIGN ECD solution (1450mL, 0.163mg/mL) was loaded to Mannan-
agarose column (20mL) prior equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2
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buﬀer. After washing the column with the same buﬀer (100mL), a step elution of the bound protein
was done using the same buﬀer but with CaCl2 replaced by 1mM EDTA (70mL). The flow rate
of 2.5mL/min was maintained during the purification. The whole procedure was repeated twice
using the flow-through of the prior purifications. To the eluted protein, CaCl2 was added to final
concentration of 10mM and the protein was concentrated to about 3mg/mL using VIVASPIN
concentrators.
In order to remove EDTA and recharge the protein with Ca2+, the gel-filtration was performed.
At this step, the concentrated and centrifuged (10min, 20800xg, 4°C) protein was repeatedly injected
(about 2mL each time) to Superose-12 column equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl,
4 mM CaCl2 and eluted with the same buﬀer (150mL). The flow rate of 1mL/min was maintained
during the procedure. Eluted protein fractions pooled and concentrated to 9mg/mL, 0.5mL aliquots
prepared and frozen for storage at -80°C.
6.1.2.2. Over-expression and purification of DC-SIGN S-ECD
Over-expression. The E.coli strain Rosetta2(DE3) (the strain that was previously established as
eﬃcient for over-expression of this construct) was used for over-expression of DC-SIGN S-ECD. The
cells were transformed with pEt20b/DC-SIGN S-ECD plasmid according to protocol in subsection
6.1.1. The culture for over-expression of DC-SIGN SECD was started by inoculation of 100mL of
overnight preculture to 2 L of LB broth with 0.1mg/mL ampicillin. The cells were grown at 37°C
for 2 h, then the protein over-expression was induced by addition of IPTG to final concentration of
1mM and the culture was continued at 37°C for 3 h. The cells were harvested by centrifugation at
5000xg for 30min at 4°C, resuspended in 25mM Tris-HCl pH 8 buﬀer and again centrifuged.
Inclusion body extraction. The pellet of the cells of 2 L culture was resuspended in 30mL of the
buﬀer consisting of 25mM Tris-HCl pH 8, 150mM NaCl, 4 mM CaCl2 and containing 1 tablet of
“complete EDTA-free” protease inhibitor cocktail. The cells were disrupted by freezing at -20°C
and thawing followed by sonication for two rounds at 90% amplitude for total time of 2min for
each round using 2 s long sonications and 10 s long pauses in-between and keeping cells in ice. The
inclusion bodies together with cell debris were collected by centrifugation at 100 000xg for 30min at
4°C. To isolate inclusion bodies from bacterial cell debris, the pellet was resuspended using Potter-
Elvehjem homogenizer in 30mL of buﬀer containing 25mM Tris-HCl pH 8, 150mM NaCl, 2M urea
and 1% Triton-X100, centrifuged at 100 000xg for 1 h at 4°C, then rinsed by resuspending them
in 30mL of 25mM Tris-HCl pH 8, 150mM NaCl buﬀer with Potter-Elvehjem homogenizer and
centrifuged at 100 000xg for 30min at 4°C.
Refolding. Inclusion bodies were solubilized with Potter-Elvehjem homogenizer in 30mL of buﬀer
containing 6M Gdn-HCl, 150mM NaCl, 25mM Tris-HCl pH 8 and 0.01% β-mercaptoethanol, and
centrifuged at 100 000xg for 1 h at 4°C to eliminate insoluble part. Solubilized DC-SIGN S-ECD
(30mL, 0.57mg/mL) was refolded by drop-by-drop dilution to 120mL of a buﬀer consisting of
1.25M NaCl, 25mM Tris-HCl pH 8 and 25mM CaCl2, at 4°C. The resulting protein solution was
dialyzed overnight against 880mL of 25mM Tris-HCl pH 8 buﬀer, at 4°C. Three more dialyses (of
3 h each at 4°C) against 4.5 L of 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 continued and
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finished refolding. The precipitates were eliminated by centrifugation at 100 000xg for 1 h at 4°C.
Purification. The purification of refolded DC-SIGN S-ECD was performed by two steps of aﬃnity
chromatography followed by gel-filtration. All purifications were carried out at 4°C.
Firstly, the refolded DC-SIGN S-ECD solution (260mL, 0.093mg/mL) was loaded to 5mL
StrepTactin column prior equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer.
After washing the column with the same buﬀer (100mL), a step elution of the bound protein was
done using the same buﬀer supplemented with 2.5mM desthiobiotin (70mL). The flow rate of
2.5mL/min was maintained during all procedure. The eluted protein was concentrated.
At the second purification step, the concentrated protein was centrifuged for 10min at 20800xg,
4°C, to eliminate any insoluble parts, and 1.5mL (7.6mg/mL) was injected to Mannan-Agarose
column equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2. After washing the
column with the same buﬀer (80mL), a step elution of the bound protein was done with 60mL of
buﬀer consisting of 25mM Tris-HCl pH 8, 150mM NaCl, 1mM EDTA. The flow rate of 2.5mL/min
was maintained throughout whole procedure. The eluted protein was concentrated.
In order to remove EDTA and recharge the protein with Ca2+, a gel-filtration was performed.
At this step, the concentrated and centrifuged (10min, 20800xg, 4°C) protein was injected (1mL,
7.59mg/mL) to Superose-12 column equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM
CaCl2 and eluted with the same buﬀer (150mL). The flow rate of 1mL/min was maintained during
the procedure. Eluted protein fractions pooled and concentrated to 15.08mg/mL, aliquoted to 20 µL
and frozen for storage at -80°C.
6.1.2.3. DC-SIGN S-CRD production
Over-expression. The E.coli strain BL21(DE3) was used for over-expression of DC-SIGN S-CRD
(amino acids 250-404) construct. The cells were transformed with pASK-IBA6/DC-SIGN S-CRD
plasmid according to protocol in subsection 6.1.1. The culture for over-expression of DC-SIGN
SECD was started by inoculation of 25mL of overnight preculture to 0.5 L of LB broth with
0.1mg/mL ampicillin. The cells were grown at 37°C until OD600 of 1.11 was reached, then the
protein over-expression was induced by addition of anhydrotetracycline to final concentration of
0.2 ￿g/mL and the culture was continued at 37°C overnight. The cells were harvested by centrifuga-
tion at 5000xg for 30min at 4°C, resuspended in 25mM Tris-HCl pH 8 buﬀer and again centrifuged.
Inclusion body extraction and refolding. Inclusion bodies were extracted by selective centrifu-
gation steps and solubilized in 6M Gdn-HCl buﬀer as already described for DC-SIGN ECD and
S-ECD. At this step, the screening for refolding conditions was performed. For this reason 0.2mL
protein solution (0.64mg/mL) was diluted to 0.8mL of the following buﬀers:
1. Buﬀer-1: 1.25M NaCl, 25mM Tris-HCl pH 8, 25mM CaCl2.
2. Buﬀer-2: 1.25M NaCl, 25mM Tris-HCl pH 8, 25mM CaCl2, 1mM oxidized glutathione,
10mM reduced glutathione.
3. Buﬀer-3: 1.25M NaCl, 25mM Tris-HCl pH 8, 25mM CaCl2, 0.16M L-Arginine.
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4. Buﬀer-4: 1.25M NaCl, 25mM Tris-HCl pH 8, 25mMCaCl2, 0.16M L-Arginine, 1mM oxidized
glutathione, 10mM reduced glutathione.
The UV absorbance spectra (240-500 nm) were recorded for each sample using the corresponding
buﬀer as a blank, and compared with the protein solution 5x diluted in inclusion body solubilization
buﬀer as a control sample to monitor the baseline.
Buﬀer-4 was chosen suitable and the protein (150mL, 0.64mg/mL) was refolded by drop-
by-drop dilution to 600mL of this buﬀer. First overnight dialysis was performed against 4.4 L of
25mM Tris-HCl pH 8 buﬀer. Two more dialyses for 3 hours each one were performed against 4.5 L
of 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer.
Purification. Then the protein solution was centrifuged and the supernatant was loaded to Strep-
Tactin column prior equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer, sup-
plemented with oxidized and reduced glutathiones at 1mM and 10mM. After washing the column
with the same buﬀer (300mL), a step elution of the bound protein was done using the same buﬀer
supplemented with 2.5mM desthiobiotin (70mL). The flow rate of 2.5mL/min was maintained
during all procedure at 4°C. The eluted protein was concentrated.
Mannan-Agarose column was used for the second step of purification. The concentrated elution
peak from StrepTactin was repeatedly injected (about 2mL) to Mannan-Agarose column prior
equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer. After 60mL of the buﬀer
was flown through the column, a step elution with EDTA (elution buﬀer: 25mM Tris-HCl pH 8,
150mM NaCl, 1mM EDTA) followed to eliminate the bound protein from the column. The flow
rate of 2.5mL/min was maintained during all procedure at room temperature.
6.1.3. Cloning of S-ECD and S-CRD constructs of LSECtin and MGL
6.1.3.1. Generation and amplification of LSECtin and MGL S-ECD and S-CRD coding cDNA
sequences
The plasmid pcDNA3.1 containing the cDNA encoding full-length LSECtin (liver and lymph node
sinusoidal endothelial cell C-type lectin) was kindly donated by Dr. Angel L. Corbí, and the
pRc/CMV plasmid containing the cDNA encoding full-length MGL (macrophage galactose-type
C-type lectin) isoform 2 was granted by Pr. Yvette van Kooyk.
The cDNA sequences coding S-CRD and S-ECD constructs of LSECtin and MGL were gener-
ated by PCR using corresponding plasmids as matrices and the following synthetic oligonucleotides
as primers (ordered from COGENICS) that included NdeI, XhoI cleavage sites and StrepTag II cod-
ing sequence followed by a sequence coding for factor Xa cleavage site to be placed in N-terminus
of the protein:
✧ LSECtin S-CRD:
– Forward lsec-crd-f. 5￿-GGA GAT ATA CAT ATG GCT AGC TGG AGC CAC CCG
CAG TTC GAA AAA ATC GAA GGG CGC AAC AAC TCC TGC GAG CCG TGC-3￿;
– Reverse lsec-crd-r. 5￿-GTG GTG GTG CTC GAG TCA GCA GTT GTG CCT TTT
CTC-3￿.
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✧ LSECtin S-ECD:
– Forward lsec-ecd-f. 5￿-GGA GAT ATA CAT ATG GCT AGC TGG AGC CAC CCG
CAG TTC GAA AAA ATC GAA GGG CGC AAG GCC TCC ACG GAG CGC GCG-
3￿.
✧ MGL S-CRD:
– Forward mgl-crd-f. 5￿-GGA GAT ATA CAT ATG GCT AGC TGG AGC CAC CCG
CAG TTC GAA AAA ATC GAA GGG CGC GAA GGG ACC TGC TGC CCT GTC-
3￿;
– Reverse mgl-crd-r. 5￿-GTG GTG GTG CTC GAG TCA GTG ACT CTC CTG GCT
GGT-3￿.
✧ MGL S-ECD:
– Forward mgl-ecd-f. 5￿-GGA GAT ATA CAT ATG GCT AGC TGG AGC CAC CCG
CAG TTC GAA AAA ATC GAA GGG CGC CAA AAT TCC AAA TTT CAG AGG-3￿.
The received oligonucleotides were dissolved in 50 µL of TE (10mM Tris-HCl pH 8, 1mM EDTA)
buﬀer and further diluted for PCR as shown in table 6.1.
Table 6.1.: Preparation of primers for generation of lectin constructs.
Name
Quantity,
µg
Prepared stock
conc., ￿g/￿L
Dilution factor to
obtain 100 ng/￿L
Volumes for dilution
in water (￿L)
lsec-crd-f. 112 2.24 22.4 2.23 + 47.7
lsec-crd-r. 148 2.96 29.6 1.7 + 48.3
lsec-ecd-f. 99 1.98 19.8 2.52 + 47.4
mgl-crd-f. 141 2.82 28.2 1.8 + 48
mgl-crd-r. 144 2.88 28.8 1.7 + 48.4
mgl-ecd-f. 131 2.62 26.2 1.9 + 48
The mixtures for PCR were prepared as follows: 2.5 ￿L of corresponding diluted primers
(forward+reverse), 1 ￿L of matrix (corresponding plasmid containing lectin coding cDNA), 2 ￿L
dNTP, 1 ￿L Pfu DNA polymerase; 10 ￿L 10X Pfu buﬀer, and 81 ￿L sterile water (autoclaved). The
reaction proceeded as follows (25 cycles of steps 2-4 were done):
1. 94°C, 1 min → denaturation;
2. 94°C, 45 s → denaturation;
3. 60°C, 1 min → annealing;
4. 72°C, 2 min → elongation;
5. 72°C, 10 min → elongation (to end all chains).
PCR reaction products were purified using QIAquick PCR Purification Kit as described by manu-
facturer using water for elution. The purified products were tested on 1% agarose (w/v) gel prepared
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in TAE buﬀer (40mM Tris, 20mM acetic acid, 1mM EDTA) with 2 ￿L of 10X diluted ethidium
bromide. 10 ￿L of each sample was mixed with 2 ￿L of 6X Orange DNA Loading Dye. The DNA
fragment size marker “Mass Ruler DNA Ladder Mix ready-to-use” was used. 10 ￿L of each sample
loaded to gel and TAE was used as running buﬀer.
6.1.3.2. Insertion of LSECtin and MGL S-ECD or S-CRD coding cDNA sequences to pET30b vector
The purified amplified DNA sequences of coding LSECtin and MGL S-ECD or S-CRD, and pET30b
were consecutively digested with restrictases NdeI and then XhoI. Reaction mixtures were prepared
as shown in table 6.2.
Table 6.2.: Preparation of LSECtin and MGL S-ECD or S-CRD cDNA sequences and pET30b
digestion mixtures.
For PCR products For vector
30 ￿L of corresponding PCR product 30 ￿L plasmid
3 ￿L restrictase 4 ￿L restrictase
6 ￿L buﬀer 6 ￿L buﬀer
21 ￿L water 20 ￿L water
The first digestion was done with NdeI using buﬀer O. Each reaction was conducted for 2
hours at 37°C. Reaction products were purified using QIAquick PCR Purification Kit as described
by manufacturer.
Purified samples were digested with XhoI using buﬀer R, and after digestion again purified by
the same protocol. Digested samples were analyzed in 1% agarose gel as described above.
The digested PCR products were inserted into a digested pEt30b using Rapid DNA Ligation
Kit from Roche. The reaction mixture was prepared as follows: 1 ￿L digested vector, 7 ￿L digested
PCR product, 2 ￿L dilution buﬀer, mixing of the three components, then addition of 10 ￿L of ligation
buﬀer, mixing, and 1 ￿L of ligase. The control mixture was prepared in the same way except 7 ￿L of
water was added instead of PCR product. Ligation reaction was carried out at room temperature
for 1 hour. Subsequently, the TOP10 E.coli cells were transformed with ligation reaction product
as described in subsection 6.1.1, except 5 ￿L of DNA were added to 30 ￿L of cells. The cells were
plated on Petri dish with LB-Agar in presence of 50 ￿g/mL kanamycin and grown at 37°C overnight.
From selected positive clones, pET30b/lectin construct plasmids were propagated and puri-
fied as described in section 6.1.1 and were tested by NdeI/XhoI digestion (reaction preparation in
table 6.3).
Table 6.3.: Preparation of NdeI/XhoI digestion mixtures for the test of positive cDNA insertion.
Enzyme mixture for 20 samples Reaction mixtures
20 ￿L buﬀer O 5 ￿L enzyme mixture
3.75 ￿L NdeI 5 ￿L plasmid with cDNA
(for control: 3 ￿L of empty
pEt30b + 2 ￿l H2O)
7.5 ￿L XhoI
68.75 ￿L H2O
Reaction proceeded for 1 hour at 37°C. The reaction products were visualized in 1% agarose
gel as described above. The positive samples were sent for sequencing to COGENICS.
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6.1.3.3. Insertion of LSECtin and MGL S-ECD or S-CRD coding cDNA sequences to pET20b vector
To extract the cDNA inserts, the generated pET30b plasmids containing corresponding lectin coding
cDNA sequences were digested consecutively with NdeI and XhoI. The first step reaction mixtures
contained 15 µL of pET30b/lectin cDNA, 2 µL NdeI, 3 µL buﬀer O and 10 µL water. Digestion was
carried out for 2 h at 37°C, and reaction products were purified using QIAquick PCR Purification
Kit following manufacturer’s instructions and using elution with 30 ￿l water.
The second step digestion reaction mixtures contained 30 µL of purified first step reaction
products, 2 µL XhoI, 4 µL buﬀer R and 4 µL water. Reaction of 2 h at 37°C was followed by
purification with QIAquick PCR Purification Kit using elution with 30 ￿l water.
Further, the purified digestion products were inserted into pEt20b, which was prior digested
with NdeI and XhoI in the same manner as described for pEt30b above. Ligation and subsequent
TOP10 cell transformation were performed as described above for pEt30b construct generation.
The cells were plated on Petri dish with LB-Agar in presence of 0.1mg/mL ampicillin and grown
at 37°C overnight.
After amplification and purification of the plasmids (described in subsection 6.1.1), they were
tested for positive cDNA sequence insertion as described above for pEt30b constructs. The plasmids
containing positive insertions were sent for sequencing to COGENICS.
6.1.4. Cloning of LSECtin S-CRD construct for targeting to periplasm
6.1.4.1. Construction of pEt30b vector with encoded OmpA signal sequence
OmpA coding sequence was excised from pASK-IBA6 vector by consecutive digestion with XbaI
and HindIII restrictases (fig. 6.1).
Figure 6.1.: Multiple cloning site of pASK-IBA6.
First step digestion reaction mixture contained 100 ￿L plasmid, 3 ￿L XbaI, 12 ￿L Tango buﬀer
and 5 ￿L water. In parallel, pEt30b vector was also digested with XbaI using the same reaction
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mixture composition. For the second step, the purified XbaI digests were further digested with
HindIII (reaction mixture: 45 ￿L purified XbaI digests, 4 ￿L HindIII, 7 ￿L buﬀer R and 14 ￿L water)
and subsequently purified. All digestions were performed for 2 h at 37°C, and reaction products
were purified using QIAquick PCR Purification Kit following manufacturer’s instructions and using
elution with 50 ￿L of water.
Purified digests were loaded to 1.3% UltraPure agarose gel prepared in TAE buﬀer without
ethidium bromide, other conditions as previously described. After staining the test gel in ethidium
bromide bath, the digestion products, i.e. the digested pEt30b vector or ompA sequence from
pASK-IBA6, were visualized, then excised from corresponding part of non-stained gel and purified
using QIAquick gel purification kit according to manufacturer’s instructions.
Ligation of purified ompA sequence to XbaI/HindIII digested pEt30b was performed using
ligation kit from Fermentas and the following reaction mixture: 1 ￿L pEt30b, 13 ￿L ompA, 4 ￿L 5X
buﬀer, 1 ￿L ligase. Ligation continued for 1 h at room temperature and subsequently the TOP10
cells were transformed with the reaction product by the protocol described in subsection 6.1.1. The
cells were plated on Petri dish with LB-Agar in presence of 50 ￿g/mL kanamycin and grown at 37°C
overnight. After propagating several clones and purifying plasmid as described in subsection 6.1.1,
ompA insertion was checked by 4-hours long digestion by BsaI at 37°C, and positive samples were
sent for sequencing to COGENICS.
6.1.4.2. Generation of pEt30b-ompA/LSECtin S-CRD construct
Preparation of LSECtin S-CRD cDNA sequences. At the first step, LSECtin S-CRD coding
cDNA was amplified by PCR using previously constructed pEt30b/LSECtin S-CRD vector (sub-
subsection 6.1.3.2) as a matrix and the following primers (ordered from COGENICS):
✧ Forward lsec-c-ompA-f. 5￿-CG CAG TTC GAA AAA ATC GAA GGG CGC AAC AAC
TCC TGC GAG CCG TGC-3￿;
✧ Reverese lsec-c-ompA-r. 5￿- CAG AGA CCA TGG TCC CCC TGC TCA GCA GTT GTG
CCT TTT CTC-3￿,
where sequence part in blue anneals within ompA part in pEt30b-ompA, and the red sequence
anneals to the beginning of CRD coding cDNA in pEt30b/LSECtin S-CRD. The preparation of
primers shown in table 6.4.
Table 6.4.: Preparation of primers for LSECtin S-CRD cDNA sequence amplification.
Primer
Quantity,
nmol
Dissolved
in TE, ￿L
Final
conc., ￿M
Working conc. (dilution
with water), ￿M
lsec-c-ompA-f. 17.6 196 89.8 20
lsec-c-ompA-r. 37.8 420 90 20
The mixture for PCR was prepared using reagents from QuikChange Lightning: Site Directed
Mutagengesis Kit as follows: 5 ￿L 10x buﬀer, 2 ￿L dNTP, 3 ￿L QuikSolution, 2 ￿L pEt30b/LSECtin
S-CRD vector, 2.5 ￿L of each prime (20 ￿M); 1 ￿L Pfu DNA polymerase (LQC Enzyme), and 32 ￿L
water.
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The reaction proceeded as follows (35 cycles of steps 2-4 were done):
1. 95°C, 2min;
2. 95°C, 1min;
3. 55°C, 1min;
4. 72°C, 3min;
5. 72°C, 6min.
The PCR was loaded to 1% UltraPureTM agarose gel prepared in TAE buﬀer without ethidium
bromide and other conditions were as described above. After staining in ethidium bromide bath,
the band containing PCR product was excised and purified using QIAquick gel purification kit
according to manufacturer’s instructions and rechecked on 1% agarose gel.
Insertion of LSECtin S-CRD coding cDNA sequence to pEt30b-ompA vector. This step was
accomplished by PCR using the generated LSECtin S-CRD coding cDNA as a primer and the
generated pEt30b-ompA vector as a template.
The mixture for PCR was prepared using reagents from QuikChange Lightning: Site Directed
Mutagengesis Kit and contained 5 ￿L 10X buﬀer, 1 ￿L dNTP, 3 ￿L QuikSolution, 5 ￿L pET30b-
ompA vector, 8 ￿L generated LSECtin S-CRD coding cDNA, 1 ￿L Pfu DNA polymerase (LQC
Enzyme) and 27 ￿L water.
The reaction proceeded as follows (22 cycles of steps 2-4 were done):
1. 95°C, 2min;
2. 95°C, 1min;
3. 55°C, 1min;
4. 68°C, 3min;
5. 68°C, 6min.
In order to get rid of the methylated template DNA, the PCR product was digested with DpnI
by adding 1 ￿L of the enzyme to the PCR product mix and performing reaction at 37°C for 3 h.
TOP10 cells were transformed with the reaction product as described in subsection 6.1.1 and the
cells were plated on Petri dish with LB-Agar in presence of 50 ￿g/mL kanamycin and grown at 37°C
overnight.
After propagation of several clones and plasmid purification as described in subsection 6.1.1,
the clones were checked by digestion with XbaI and HindIII (reaction mixture of 1 ￿L XbaI, 2 ￿L
HindIII, 13 ￿L 10X Tango buﬀer and 14 ￿L water; reaction for 3 h at 37°C). The positive close was
sent for sequencing to COGENICS.
6.1.5. Evaluation of LSECtin and MGL construct functionality
6.1.5.1. The functionality of pEt20b and pEt30b constructs
Over-expression of proteins. The BL21(DE3) were transformed (subsection 6.1.1) with corre-
sponding tested pEt20b or pEt30b vectors containing LSECtin S-ECD, MGL S-ECD and S-CRD
coding cDNA sequences. Overnight precultures were started in LB containing either 0.1mg/mL
ampicillin (in case of pEt20b) or 50 ￿g/mL kanamycin (in case of pEt30b). 1mL of each overnight
precultures was inoculated to 25mL of LB with the same concentrations of either ampicillin or
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kanamycin. After 3 h of cultivation at 37°C (when optical densities at 595 nm (OD595) reached ap-
proximately 0.8) and after taking 5mL samples for test, the over-expression of proteins was induced
by addition of IPTG to final concentration of 1mM and the cultures were continued for 3.5 h at
37°C. Two samples of 5mL at the end of each culture were taken to test by SDS-PAGE.
Preparation of bacterial culture samples for SDS-PAGE. For each construct, a 5mL sample
of the culture before the induction and two samples of culture after cultivation were centrifuged
at 4000xg for 20min, 4°C. The supernatants were discarded. To the pellets of the sample before
induction and one of the two samples after cultivation, 0.5mL of 6X SDS-PAGE sample loading
buﬀer (with β-mercaptoethanol) was added. After resuspending, the cells in the two samples were
disrupted by sonication for 30 s at 10% amplitude.
To the second sample with the pellet after cultivation, 0.5mL of buﬀer consisting of 25mM
Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2. The cells were resuspended and kept on ice while
sonicating for the total of 30 s at 40% amplitude with 10 s long breaks between 2 s long sonications.
Subsequently, the samples were centrifuged for 10min at 20800xg, 4°C. Both the pellet and the
supernatant were prepared for the analysis by SDS-PAGE: 0.5mL of SDS-PAGE sample loading
buﬀer was added on the pellet, which was then resuspended and heated for 5min, and equal volumes
of supernatant and SDS-PAGE sample buﬀer were mixed and heated for 5min. Typically 5 µL of
samples were loaded to gel, except the supernatant sample (10µL).
SDS-PAGE was performed according to Laemmli protocol [159] using 15% separating and 5%
stacking layers of the gel. The PageRuler Unstained Protein Ladder was used as MW marker. The
electrophoresis was run at 220V and 130mA, typically for 45-50min.
6.1.5.2. The functionality of pEt30b-ompA/LSECtin S-CRD construct
The BL21(DE3) cells were transformed with tested pEt30b-ompA/ LSECtin S-CRD vector. Overnight
preculture was started in LB containing 50 µg/mL kanamycin. 1mL of overnight preculture was
inoculated to 20mL of LB with 50 µg/mL kanamycin and the culture carried out at 25°C. Protein
expression was induced, after taking a 5mL sample for test, by addition of IPTG to final concentra-
tion of 1mM when OD600 was 0.6, and CaCl2 was also added to final concentration of 100mM. The
culture was continued at 25°C overnight. Two samples of 5mL of culture were taken for SDS-PAGE
and western blot (WB) analysis.
The samples for SDS-PAGE and WB were prepared and SDS-PAGE was performed as de-
scribed above. The WB procedure was carried out as follows:
1. Transfer of the proteins from non-stained SDS-PAGE gel to PVDF membrane at 300mA,
120V, 150W for 50min using Tris-glycine buﬀer (25mM Tris, 0.19M glycine).
2. Membrane blocking: 1 h incubation in 5% skim milk solution prepared in PBS-Tween buﬀer
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4, 0.05% Tween 20).
3. Incubation with mouse anti-StrepTagII antibody for 1 h: blocking solution replaced by 10mL
PBS-Tween buﬀer with 5 ￿L of antibody stock solution (0.2mg/mL).
4. Rinsing: 3x (for 10min each time) incubation with PBS-Tween buﬀer, each time buﬀer
changed.
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5. Incubation with anti-mouse-HRP conjugate (2 ￿L of 0.1mg/mL stock in 10mL of PBS-Tween
buﬀer) for 1 h.
6. Rinsing, same as step 4.
7. Staining: a tablet of the stainer (3,3’-Diaminobenzidine) and of urea were dissolved in 1mL
of water, then the membrane repeatedly covered with the prepared stainer.
The PageRuler Prestained Protein Ladder was used as the size marker.
6.1.6. Over-expression and purification of MGL S-ECD
Over-expression. The E.coli strain BL21(DE3) was used for over-expression of DC-SIGN S-ECD.
The cells were transformed with pEt30b/MGL S-ECD plasmid. The culture for over-expression of
MGL S-ECD was started by inoculation of 25mL of overnight preculture to 0.5 L of LB broth with
50 µg/mL kanamycin. The cells were grown at 37°C and the protein over-expression was induced
by addition of IPTG to final concentration of 1mM when OD600 was about 2.0. The culture was
continued at 37°C overnight. The cells were harvested by centrifugation at 5000xg for 30min at
4°C, rinsed with 25mM Tris-HCl pH 8 buﬀer by resuspension followed by centrifugation.
Inclusion body extraction. The pellet of the cells of 0.5 L culture was resuspended in 30mL of
the buﬀer consisting of 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 supplemented with 1
tablet of “complete EDTA-free” protease inhibitor cocktail, and all other procedures were the same
as described for DC-SIGN ECD in sub-subsection 6.1.2.1.
Refolding. Refolding of solubilized MGL S-ECD (1.3mg/mL, 150mL in Gdn-HCl) proceeded in
the same manner as described (sub-subsection 6.1.2.1).
Purification. The purification of refolded MGL S-ECD was performed by two steps of aﬃnity
chromatography. All purifications were carried out at 4°C.
Firstly, the refolded MGL S-ECD solution (860mL, 0.106mg/mL) was loaded to 5mL Strep-
Tactin column prior equilibrated in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer. After
washing the column with the same buﬀer (100mL), a step elution of the bound protein was done
using the same buﬀer supplemented with 2.5mM desthiobiotin (70mL). The flow rate of 2.5mL/min
was maintained during all procedure.
The isolation of functional protein was carried out using agarose-based medium containing
Superose12 column. Because agarose is galactose-based polymer and MGL binds galactose, this
medium could be used for aﬃnity purification. The part of the protein eluted from StrepTactin
column was concentrated and injected (1mL, 3mg/mL) to 125mL Superose 12 column prior equili-
brated in 25mM MES pH 7, 150mM NaCl, 4mM CaCl2 buﬀer, and after 170mL flow of the buﬀer
a step elution with 25mM Tris-HCl pH 8, 150mM NaCl, 1mM EDTA was done. The flow rate of
1mL/min was maintained throughout the procedure. All eluted protein species were concentrated.
Finally, to assess the functionality of purified MGL S-ECD, concentrated sample after Strep-
Tactin was injected to 5mL “immobilized D-galactose gel” column prior equilibrated in 25mM
Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer. After 25mL of buﬀer run the step elution
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was performed with 25mM Tris-HCl pH 8, 150mM NaCl, 1mM EDTA buﬀer. The flow rate of
2.5mL/min was maintained during all procedure.
6.2. Biochemical/biophysical protein characterization and
glycomimetic compound analysis assays
6.2.1. SDS-PAGE of protein samples
Protein samples for SDS-PAGE analysis were prepared by mixing equal volumes of protein solution
with SDS-PAGE sample loading buﬀer with (reducing) or without (non-reducing) β-mercaptoethanol,
and the samples were heated for 3-5min. Typically 10 µL of the samples were loaded to the gel.
The rest of the procedure was performed as already described (sub-subsection 6.1.5.1).
6.2.2. Protein concentration determination
The concentrations of protein solutions were determined measuring absorbance at 280 nm and
using extinction coeﬃcients calculated from amino acid sequence in ExPASy server (ProtParam
tool). NanoDrop 2000c spectrophotometer (from ThermoScientific) was used for protein solution
absorbance measurements.
6.2.3. Carbohydrate and glycomimetic compound preparation for SPR assays
Monovalent glycomimetic compounds were dissolved in SPR running buﬀer to final concentration of
5mM or 20mM. If the compounds had lower water solubility, they were attempted to be dissolved
by adding DMSO up to 4% of final concentration (in these cases, the DMSO concentration in
the running buﬀer was adjusted accordingly). All of the prepared compound stock solutions were
centrifuged at 13 krpm for 10min in order to separate the insoluble particles and prevent injecting
them to Biacore instrument.
The multivalent compounds were dissolved in running buﬀer to final concentration of 1mM or
5mM, and treated in same way as monovalent compounds in case of low water solubility. Typically,
100mM stock solutions in water were prepared of natural carbohydrates.
6.2.4. The SPR competition assays
6.2.4.1. Single point inhibition assay
For fast screening of compound activity and selectivity the single point inhibition assay was used.
The sensor chip CM4 surface was functionalized with α1-3(α1-6)-mannotriose BSA (ManBSA) by
amine coupling procedure. Carboxymethyl (CM) dextran matrix was activated by 50 µL injection of
0.2M EDC / 0.05M NHS mixture followed by the injection of typically 25 µL of 60µg/mL ManBSA
in 10mM sodium acetate buﬀer pH 4. The remaining unbound carboxyl groups were blocked by
the injection of 30µL of 1M ethanolamine pH 8. Finally, the surface was rinsed with 10mM HCl
injection (10 µL) and conditioned with the injection of the regeneration solution (20µL of 50mM
EDTA pH 8). The flow cell with EDC/NHS activated and ethanolamine deactivated CM-dextran
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was used as the reference surface. The HBS-P buﬀer was used as the running buﬀer and the flow
rate of 5 µL/min was maintained.
The mixtures of the lectin, DC-SIGN ECD or langerin ECD, at 20 µM and mannose-based
(150 µM) or fucose-based (300 µM) compounds were prepared in the running buﬀer composed of
25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 and 0.005% surfactant P20. The incubated
mixtures (20 µL) were injected over ManBSA surface, which was subsequently regenerated with
1min injection of 50mM EDTA pH 8. The flow rate of 5 µL/min was maintained. After subtraction
of the reference surface response, the lectin steady state binding responses were extracted from the
sensorgrams using BiaEval version 4.1 and compared with the binding responses of compound-free
lectin injections and converted to inhibition percent values.
6.2.4.2. Competition assay for IC50 determination
A range of glycomimetic compound concentrations were prepared in the presence of DC-SIGN
ECD (20 µM) or langerin ECD (15µM) and 20 µL or 13 µL of the incubated samples were injected.
Compound-free lectin injections at the same concentration were used as full activity reference and
also to monitor ManBSA surface activity. The same running buﬀer (25mM Tris-HCl pH 8, 150mM
NaCl, 4mM CaCl2 and 0.005% P20) was used, and in case of compound solubility problems it was
supplemented with 3-4% DMSO. The flow rate of 5 µL/min was maintained and all other conditions
were the same as in the single point inhibition assay.
The resulting binding responses were converted to residual lectin activity values, which were
plotted against concentration values of the compounds. The IC50 values for each compound were
determined by fitting four-parameter logistic model (eq. 6.1), and calculated using derivation of
equation 6.1 (eq. 6.2):
Res.act. = Rhi − Rhi −Rlo
1 +
￿
conc.
A1
￿A2 (6.1)
IC50 = A1
￿
Rhi −Rlo
Rhi − 50 − 1
￿ 1
A2 (6.2)
where Res.act. is the residual lectin activity, conc. is the concentration of the compounds,
Rhi and Rlo are the lowest and the highest values of percent activity, A1 and A2 are the inflection
point and the slope of the linear region of the curve, respectively. In equation 6.2, 50 stands for
50% activity of the lectin.
6.2.5. The SPR direct interaction assay
6.2.5.1. Preparation of oriented DC-SIGN surface
Sensor chips CM5 or CM3 were used. Firstly, CM-dextran was functionalized with StrepTactin by
amino coupling. Surface was activated with 50 µL injection of 0.2M EDC / 0.05M NHS mixture,
then StrepTactin (150µL injection, typically at 150 µg/mL) was covalently coupled to the activated
surface and remaining carboxyl groups were blocked by 50 µL 1M ethanolamine pH 8 injection.
HBS-P was used as the running buﬀer at 5µL/min flow rate. The prepared surface was rinsed with
10mM HCl (100µL at 100µL/min) and 50mM NaOH/1M NaCl (100µL at 100µL/min) solutions.
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The second step involved the biospecific capture of DC-SIGN S-ECD. The lectin was injected
(typically 150 µL) either with or without prior EDC/NHS reactivation of dextran-StrepTactin sur-
face. in case DC-SIGN S-ECD was injected over non-reactivated dextran/StrepTactin surface, it
was prepared in 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer, otherwise it was pre-
pared in HBS-P (Biacore) buﬀer. The prepared surface was rinsed with 5 µL of 50mM EDTA pH
8 injection. 25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 or HBS-P were used as running
buﬀers at 5 µL/min flow rate.
The CM-dextran with covalently immobilized StrepTactin (same preparation protocol as de-
scribed above) was used as a reference surface.
6.2.5.2. Establishment of regeneration conditions
Injections of 5µL of 0.5 µM ManBSA prepared in running buﬀer were used to monitor lectin surface
regeneration and activity. The following solutions were screened for surface regeneration capacity:
1. 50mM EDTA pH 8
2. 5mM NaOH/0.1M NaCl
3. 50mM NaOH/1M NaCl
4. 20% v/v ethylen glycol in 40mM EDTA pH 8
5. 50% v/v ethylen glycol in 25mM EDTA pH 8
6. 0.1M Gly-NaOH pH 11.9/0.3% TritonX100
7. 10mM Gly-NaOH pH 11.9+0.03% TritonX100
8. 50mM Gly-NaOH pH 11.9 / 0.15% TritonX100 / 25mM EDTA pH 8
The variable volumes of regeneration candidates were injected at 100µL/min flow rate, except for
EDTA (5µL/min). The flow rate of 5 µL/min was maintained of the running buﬀer composed of
25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 and 0.005% P20.
6.2.5.3. Compound interaction with oriented DC-SIGN surface
The concentration ranges (typically from submicromolar to 1mM or 2mM) of polyvalent compounds
were prepared in the running buﬀer (25mM Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 and 0.005%
P20) supplemented with 3-4% DMSO in case of compound solubility problems. 15-50 µL of prepared
compound solutions were injected over the sensor chip surfaces at 5µL/min flow rate. DC-SIGN
surface activity was monitored using ManBSA injections in the beginning and the end of each run.
The sensorgrams were reference surface (CM-dextran with immobilized StrepTactin) corrected
and analyzed in BiaEval 4.1.
6.2.6. Other biophysical assays
The experimental part of AUC, ITC and DLS experiments is described in the further presented
paper manuscript n°5 (see table 7.1 for the list of articles). The NMR experimental procedures are
described in article n°6.
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7. The explanation of the organization of the
results in this thesis.
The work of this thesis consists of two diﬀerent parts presented in two separate chapters as shown
in figure below:
Figure 7.1.: A schematic representation of the organization of the results in this thesis.
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CHAPTER 7. THE EXPLANATION OF THE ORGANIZATION OF THE RESULTS IN THIS
THESIS.
The first part includes the results of the preparation of diﬀerent lectins. To begin with,
the production of diﬀerent DC-SIGN constructs, which were used for glycomimetic compound
structural and functional evaluation, will be presented in section 8.1 on page 123. Apart from DC-
SIGN, diﬀerent constructs of two other C-type lectins, namely LSECtin and MGL, were designed
in order to expand the compound selectivity screening tools. The results of cloning and construct
expression evaluation will be presented in section 8.2 on page 133.
The second chapter describes the development of glycomimetic compounds, and is also
divided to two major subparts, one of which describes development of monovalent glycomimics ,
and in the second one the results of the development of multivalent compounds are presented.
The monovalent compound development was conducted in three parallel streams as shown
in figure 7.1. Pr. Jitka Moravcová team was developing the C-glycosides, and the results of their
evaluation are presented in subsection 9.1.2 on page 153. Pr. Anna Bernardi’s team worked on
the two concepts, namely fucose-based and mannose-based glycomimetics, and most of the results
of their development are presented as papers (table 7.1).
Table 7.1.: The list of papers presented in this thesis.
No Status Title Location
n°1
Published
article
Andreini et al. Second generation of fucose-based
DC-SIGN ligands: aﬃnity improvement and specificity
versus Langerin. Org. Biomol. Chem. 9 (2011)
5778-5786
Subsection 9.1.3 on
page 157 and
appendix on page 161
n°2
Published
article
Berzi et al. A glycomimetic compound inhibits
DC-SIGN-mediated HIV infection in cellular and
cervical explant models. AIDS 26 (2012) 127-137
Sub-subsection 9.1.4.1
on page 174 and
appendix on page 177
n°3
Published
article
Luczkowiak et al. Pseudosaccharide Functionalized
Dendrimers as Potent Inhibitors of DC-SIGN
Dependent Ebola Pseudotyped Viral Infection.
Bioconjugate chemistry 22 (2011) 1354-1365
Sub-subsection 9.1.4.2
on page 191 and
appendix on page 195
n°4
Submitteed
paper
Thépaut et al. Structure of a glycomimetic ligand in
the Carbohydrate Recognition Domain of C-type lectin
DC-SIGN. Structural requirements for selectivity and
ligand design. Submitted to JACS
Sub-subsection 9.1.4.3
on page 209 and
appendix on page 213
n°5
Paper
manuscript
Sutkevičiu¯te˙ et al. Lectin clustering by a glycomimetic
ligand without any multivalent presentation a case
study in DC-SIGN antagonist development.
Sub-subsection 9.1.4.4
on page 241 and
appendix on page 245
n°6
Article in
press
Varga et al. Selective targeting of DC-SIGN with
mannose-based glycomimetics. Synthesis and
interaction studies of bis-benzylamide derivatives of a
pseudomannobioside. Chem. Eur. J.
Sub-subsection 9.1.4.5
on page 265 and
appendix on page 271
While the results of the development of fucose-based glycomimetics are presented in article
n°1, the third stream of monovalent compound development, i.e. mannose-based glycomimics, was
more elaborated. It begins with functional characterization of two mannose-based glycomimetic
compounds, pseudomannobioside (psDi) and pseudomannotrioside (psTri) [49]. From these two
compounds, psTri turned out to have much better inhibitory eﬃciency than psDi, hence it was
used to prepare a tetravalent dendron and tested for capacity to inhibit HIV trans infection of T
120
lymphocytes [49]. Later on, the potency of this compound to inhibit HIV transmission in cervical
explants was also studied and the results are presented in the article n°2.
The 32-valent forms of psDi and psTri were also generated and tested comparing the activities
with the mono- and tetravalent psDi and psTri compounds in SPR competition and Ebola virus
infection inhibition assays. The results are presented in article n°3. The latter studies of the
compounds indicated discrepancies regarding psTri structural and functional characteristics, i.e.
monovalent forms of psDi and psTri had an order of magnitude diﬀerence in their activities in favor
for psTri, but this diﬀerence was lost comparing multivalent compounds. Therefore, the interaction
of both monovalent compounds was characterized in detail: the X-ray structures of both compounds
in complex with DC-SIGN CRD were solved, structural properties of the interaction in solution was
studied by NMR, and the complexes were characterized by other biophysical techniques (ITC, AUC,
DLS). The results of these studies are presented in two papers, i.e. submitted article n°4 and paper
manuscript n°5.
Finally, these studies disapproved psTri as the best lead compound, but revealed psDi to
possess all the desirable qualities of a compound for further development. Thus the development
of mannose-based glycomimics continued with a focus on psDi optimization. Two diﬀerent types of
psDi-based compound series were synthesized and evaluated for inhibition and selectivity to DC-
SIGN versus langerin. The results of the evaluation of one of the two series (bis-benzylamides)
are presented in paper n°6, and the analysis of the other series (NV -type) is described in sub-
subsection 9.1.4.6 on page 290.
Simultaneously to the development of monovalent glycomimics, various polyvalent scaﬀolds
were designed and synthesized by the team of Dr. Javier Rojo. Then the chosen monovalent
glycomimics were tethered to these polyvalent scaﬀolds and tested as DC-SIGN antagonists. The
results of corresponding polyvalent compound evaluation by SPR competition and direct interaction
assays are presented in subsections 9.2.2 and 9.2.3, respectively.
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8. Results of preparation of recombinant
lectins
8.1. Preparation of diﬀerent DC-SIGN constructs
Three diﬀerent constructs of DC-SIGN were used in this work (fig. 8.1):
✧ DC-SIGN ECD (a.a. 66-404);
✧ DC-SIGN S-CRD (a.a. 250-404 and includes N-terminal StrepTag: MASWSHPQFEKIEGR,
where green, red and blue parts correspond to linker, StrepTag II and Factor Xa cleavage site
sequences, respectively);
✧ DC-SIGN S-ECD (a.a. 66-404 and includes N-terminal StrepTag).
Figure 8.1.: The DC-SIGN constructs used in this thesis.
TM stands for transmembrane domain, a.a. – amino acids, MW – molecular weight (in Da), pI – isoelectric point.
The shown MW and pI values are theoretical, calculated from corresponding amino acid sequences with ProtParam
tool in ExPASy server.
DC-SIGN ECD in this thesis is used mainly in SPR competition assay, and also was used in
ITC, AUC and DLS experiments. The CRD construct of DC-SIGN is used only for co-crystallization
with selected compounds. Because monomeric CRD doesn’t have high aﬃnity to sugars, the Strep-
Tag was included in order to facilitate the purification of the protein by the means of the aﬃnity
chromatography using the StrepTactin column. There were diﬀerent reasons to add StrepTag to
the ECD construct of DC-SIGN: this tag served for the preparation of oriented DC-SIGN surfaces
for SPR direct interaction assay, where the lectin construct is captured by covalently immobilized
StrepTactin; StrepTag also aided the purification of this construct.
All of the three constructs were designed and their production was developed before I started
my PhD.
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8.1.1. DC-SIGN ECD over-expression and purification results
DC-SIGN ECD (38.7 kDa) pEt30b construct was expressed in BL21(DE3) E.coli strain (fig. 8.2)
and purified from 1L of culture.
Figure 8.2.: The SDS-PAGE analysis of DC-SIGN ECD expression.
Samples before (I 0) and after induction containing whole disrupted cells (I+), supernatant (S) and pellet (P) were
loaded. Red ticks mark the target protein bands.
The inclusion bodies were isolated by several steps of selective centrifugations, then solubilized
in 6M Gdn-HCl buﬀer and refolded by flash dilution and subsequent dialyses. The functional protein
was recovered by an aﬃnity chromatography step using Mannan-Agarose column followed by gel-
filtration on Superose12 column to eliminate EDTA and recharge the lectin with Ca2+ ions. The
examples of the results of DC-SIGN ECD purification on Mannan-Agarose and Superose12 columns
are shown in figure 8.3.
Figure 8.3.: The chromatograms of DC-SIGN ECD purification.
A, Loading and elution from Mannan-Agarose column; B, Gel-filtration on Superose12 column with diﬀerent forms
of protein marked: ‘peak 1’ - possibly higher size oligomers, ‘pool’ highlighted in orange – the collected well-folded
protein, and the ‘peak 3’ – possibly lower size protein form.
The typical yield of the protein from 1L of bacterial cell culture evolved as follows: 237mg of
protein was loaded to Mannan-Agarose column and 78.4mg were eluted from the column; after all
injections to Superose12 column and concentration of pooled fractions the total amount of protein
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was 52.4mg. All steps of the purification were monitored by SDS-PAGE, and the results of reduced
and non-reduced DC-SIGN ECD samples from diﬀerent purification stages are shown in figure 8.4.
Figure 8.4.: The SDS-PAGE analysis of DC-SIGN ECD purification.
Reduced or non-reduced samples after refolding (i.e. before Mannan-Agarose, marked Mannan ‘0’), concentrated
samples of protein eluted from Mannan-Agarose column (marked Mannan ‘+’) and diﬀerent samples from Superose12
as shown in fig. 8.3B (peak 1 marked ‘P.1’, peak 3 marked ‘P.3’) were loaded to the gel.
DC-SIGN ECD forms disulphide-linked oligomers, which comprise nearly a half of all DC-
SIGN ECD sample after refolding, and the following steps of purification gradually remove the
major part of those high oligomers. It is possible that the size-exclusion column is not capable to
separate these disulphide-linked oligomers because well-folded protein is a tetramer (155 kDa), thus
both disulphide-linked oligomers and well-folded DC-SIGN ECD are eluted at the same volume.
The ‘peak 1’, which is excluded from the major pool of DC-SIGN ECD, contains disulphide-linked
oligomers of high size, while ‘peak 3’ doesn’t have disulphide-linked oligomers at all, and the lower
size of this DC-SIGN ECD form could result from folding into dimers or trimers but not tetramers.
It is also noticeable that the sample also contains smaller fragments, which are linked to correct size
or higher oligomers of DC-SIGN ECD by disulphide bridges, since the lower MW bands in SDS-
PAGE that are visible in reduced sample disappear at non-reducing conditions. Nevertheless, the
vast majority of the functional protein has the correct size as seen in SDS-PAGE at both reducing
and non-reducing conditions.
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8.1.2. DC-SIGN S-ECD over-expression and purification results
DC-SIGN S-ECD (40.4 kDa) pEt20b construct was expressed in Rosetta(DE3) E.coli strain (fig.
8.5), which was previously chosen among several strains as the most optimal in terms of expression
capacity, and purified from 2L of culture due to relatively low expression level.
Figure 8.5.: The expression of DC-SIGN S-ECD.
The left and right panels show SDS-PAGE and WB analyses, respectively, of DC-SIGN S-ECD expression. Lanes
marked I 0 and I+ corresponded to loaded samples before and after induction. The WB was revealed using anti-
StrepTag II antibody.
DC-SIGN S-ECD was “leaking”, i.e. a band corresponding to target protein is seen before
induction, due to not as tight expression control as in case of pEt30b.
The inclusion bodies were extracted and refolded in the same manner as for DC-SIGN ECD
construct. The functional protein was recovered by two-step aﬃnity purification followed by gel-
filtration: at first the protein was captured and concentrated on StrepTactin column, then the
functional protein was isolated using Mannan-Agarose column, and finally the EDTA from elution
buﬀer of previous purification step was eliminated and the lectin was recharged with Ca2+ ions using
Superose12 column. The results of DC-SIGN S-ECD purification on StrepTactin, Mannan-Agarose
and Superose12 columns are shown in figure 8.6.
Figure 8.6.: The chromatograms of DC-SIGN S-ECD purification.
The chromatograms of DC-SIGN S-ECD purification. A, Loading and elution from StrepTactin column. B, Injection
and elution from Mannan-Agarose column. C, Gel-filtration on Superose12 column.
The yield of the protein evolved as follows: 25.6mg of protein was loaded to StrepTactin and
13.4mg were eluted from the column → 11.4mg were injected to Mannan-Agarose column and
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7.6mg were eluted → 7.4mg were injected to Superose12 and 5.4mg were eluted. Thus the general
yield of DC-SIGN S-ECD is 5.4mg from 2L of bacterial culture.
The purification was monitored by SDS-PAGE of reduced (R) or non-reduced (NR) DC-SIGN
S-ECD samples from diﬀerent purification stages (fig. 8.7).
Figure 8.7.: The SDS-PAGE analysis of DC-SIGN S-ECD purification.
Reduced (R) or non-reduced (NR) samples after refolding (i.e. before StrepTactin), concentrated samples of protein
eluted from StrepTactin column (i.e. after StrepTactin), from Mannan-Agarose (i.e. Mannan) and from Superose12
(i.e. Superose) were loaded to the gel.
As DC-SIGN ECD, the S-ECD construct of DC-SIGN also forms disulphide-linked oligomers,
and the distribution of these oligomers has the same pattern as in case of DC-SIGN ECD, with the
vast majority of the functional protein of a correct size.
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8.1.3. DC-SIGN S-CRD refolding optimization results
The S-CRD construct of DC-SIGN is required for co-crystallization with selected glycomimetic
compounds. Moreover, this construct could be a valuable tool in SPR assays for the following
reasons. Because of their low MW and low aﬃnity (thus high bulk responses when injecting high
compound concentrations), the monovalent glycomimetic compounds cannot be assessed for binding
aﬃnity to the surface functionalized with DC-SIGN. The soluble tetrameric DC-SIGN ECD, which
is used in SPR competition assay, does not allow to determine solution aﬃnity of the compounds
because of the presence of four binding sites within one protein entity that binds to the surface.
But CRD has only one binding site meaning that this construct could be successfully used in SPR
solution aﬃnity assay.
The over-expression of DC-SIGN S-CRD is very eﬃcient (fig. 8.9) giving a promising potential
to obtain high yields of purified protein. However, all of the protein is expressed as inclusion bodies
and must be refolded. Although the protocol of DC-SIGN S-CRD purification was set-up and used
before my PhD, it gives low yields of protein mainly because of extensive precipitation during the
refolding step. Additionally, a high proportion of the protein was found to exists as functional
disulfide-linked dimers (peak 4 (pk.4 ) in fig. 8.8), therefore a double mutant construct where the
first and the last cysteine residues (responsible for C0-C0￿ disulfide bridge formation at the base of
CRD, fig. 1.6 on page 51) were changed to serines (see figure 2.7 on page 66). Unfortunately, this
construct did not yield any improvements in DC-SIGN S-CRD purification.
Figure 8.8.: The chromatograms showing elution profiles of DC-SIGN S-CRD purification on
Mannan-Agarose column.
A, The best-case scenario of DC-SIGN S-CRD sample preparation (the result from previous experiments before my
PhD): the first peak (pk.1 ) was assumed to be desthiobiotin coming from previous purification on StrepTactin column
mixed with non-functional/contaminant proteins; pk.2 and pk.3 (a delayed peak) were assumed to be monomeric
misfolded and functional DC-SIGN S-CRD, respectively; and pk.4 was found to be a disulfide-linked DC-SIGN S-
CRD dimers that were functional since EDTA was required to detach mannan-bound CRDs. B, A typical elution
profile on Mannan-Agarose column of DC-SIGN S-CRD (injection of non-concentrated sample prior purified using
StrepTactin column).
Hence, the refolding step was targeted for optimization in order to improve the yield of the
functional monomeric DC-SIGN S-CRD.
This lectin (19.4 kDa) was expressed in BL21(DE3) E.coli strain (fig. 8.9), and inclusion bodies
were extracted from 0.5 L of culture in the same manner as for DC-SIGN ECD and S-ECD. After
solubilization in Gdn-HCl buﬀer, the estimated amount of the protein was 95mg.
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Figure 8.9.: The SDS-PAGE analysis of DC-SIGN S-CRD production.
Samples before (I 0 ) and after induction containing whole disrupted cells (I+), supernatant (S) and pellet (P) were
loaded. Red ticks mark the target protein bands.
Then the refolding of solubilized DC-SIGN S-CRD inclusion bodies was tested in 4 diﬀerent
buﬀers:
1. “Usual buﬀer” consisting of 1.25M NaCl, 25mM Tris-HCl pH 8, 25mM CaCl2 (sample 1 );
2. Usual buﬀer supplemented with glutathiones (1mM oxidized / 10mM reduced) (sample 2 );
3. Usual buﬀer supplemented with 0.16M L-arginine (sample 3 );
4. Usual buﬀer supplemented with glutathiones (as 2.) and 0.16M L-arginine (sample 4 ).
The absorbance spectra of each sample and a control (same concentration of protein in inclusion
body solubilization buﬀer) were recorded and compared (fig. 8.10).
Figure 8.10.: The absorbance spectra of DC-SIGN S-CRD refolding samples.
As can be seen from figure 8.10, samples 2 and 4 superimposed with the control meaning no
precipitation. Both of the buﬀers of these two samples contained glutathiones, which suggests that
precipitation in other samples might have occurred due to the formation of disulphide-linked ag-
gregates. Buﬀer 4, which contains both glutathiones and arginine that helps to minimize aggregate
formation through hydrophobic patches, was selected for refolding of the whole batch of solubilized
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inclusion bodies. No precipitation was observed even after the dialyses, however, after centrifuging
a gel-like pellet formed. SDS-PAGE analysis (fig. 8.11, gel 1 ) of non-reduced sample of the super-
natant showed the presence of big disulphide-linked aggregates that couldn’t enter the gel (a band
at the bottom of the well). The analysis of this pellet (fig. 8.11, gel 2 ) showed that it contained a
considerable amount of DC-SIGN S-CRD.
Figure 8.11.: The SDS-PAGE analysis of diﬀerent purification stages of DC-SIGN S-CRD.
Gel 1 shows reduced (R) and non-reduced (NR) DC-SIGN S-CRD samples after refolding (the supernatant before
loading to StrepTactin, Before Strep.). Gel 2 shows reduced sample of gel-like pellet after DC-SIGN S-CRD refolding
(Ref.p.) and samples of elution peak from StrepTactin (Strep.).
The refolded DC-SIGN S-CRD was loaded to StrepTactin column in the continued presence
of glutathiones (fig. 8.12A), which were added in order to decrease the formation of disulfide-linked
oligomers. The flow-through was reloaded to StrepTactin two more times (results not shown) to
increase the yield of the purified protein. In total, 15.2mg of DC-SIGN S-CRD was recovered in
elution peaks from StrepTactin column.
Figure 8.12.: The chromatograms of DC-SIGN S-CRD purification.
A, An example of loading and elution from StrepTactin column. B, An example of elution profile of DC-SIGN
S-CRD (injection of 1.8mL at 1.8mg/mL) on Mannan-Agarose column with absorbance changes monitored at 280 nm
(blue line) and 260 nm (red line).
The SDS-PAGE analysis of StrepTactin elution peak showed that the sample was composed
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of nearly equal amounts of monomeric and disulfide-linked dimeric DC-SIGN S-CRD, but also
contained high oligomers as a band was visible at the interface of stacking and running layers of the
gel (fig. 8.11, gel 2 ). Comparing DC-SIGN S-CRD samples before loading to StrepTactin, when
the majority of the protein was monomeric (fig. 8.11, gel 1 ), and the elution peak, it becomes clear
that the concentrating of the protein influenced by binding to the column catalyzed the formation of
aberrant disulfides even in the presence of glutathiones. Nevertheless, the addition of glutathiones
had a slight improvement of the yield of monomeric protein as can be seen in SDS-PAGE analysis
of previous DC-SIGN S-CRD purification on StrepTactin column in the absence of glutathiones,
where the dimeric DC-SIGN S-CRD and higher oligomers were dominant (fig. 8.13).
Figure 8.13.: The SDS-PAGE analysis of DC-SIGN S-CRD purification on StrepTactin column in
the absence of glutathiones.
The lectin was refolded and purified on StrepTactin column under “conventional” conditions, i.e. in the same way
as described for DC-SIGN ECD and S-ECD. The reduced (R) and non-reduced (NR) samples, as indicated, were
analyzed.
The purification of DC-SIGN S-CRD (refolded in optimized conditions) continued, and the
concentrated elution peak from StrepTactin was injected to Mannan-Agarose column (fig. 8.12B).
All the peaks present in the elution profile (fig. 8.12B) were analyzed by SDS-PAGE (fig. 8.14).
Figure 8.14.: The SDS-PAGE analysis of DC-SIGN S-CRD purification on Mannan-Agarose col-
umn.
The reduced (R) and non-reduced (NR) samples of the corresponding peaks from Mannan-Agarose column (Man.,
pk.), as indicated in fig. 8.12B, were analyzed. “Man., pk.3 conc.” is a concentrated sample of peak 3 from Mannan-
Agarose.
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It appeared that the first peak after Mannan-Agarose (pk.1 ) was composed mainly of high
oligomers of DC-SIGN S-CRD formed due to aberrant intermolecular disulfide formation: in re-
ducing conditions the major part of the protein is in the band corresponding to the correct size of
DC-SIGN S-CRD, but the major part of non-reduced sample stays in the interface of stacking and
running layers of the gel (fig. 8.14, Man., pk1.).
Initially, the second peak (pk.2 ) and the third broad peak (pk.3 ) were considered to be
monomeric misfolded and correctly folded DC-SIGN S-CRD species, respectively. The SDS-PAGE
analysis showed that although pk.2 contained a small amount of monomeric protein, it is majorly
composed of dimers and high oligomers as indicated by the band present in the interface of stacking
and running layers of the gel (fig. 8.14, Man., pk.2 ). Moreover, in addition to standard 280 nm, the
absorbance during the purification on Mannan-Agarose was monitored at 260 nm and appeared to
be stronger than at 280 nm, which means that this sample contained residual amounts of nucleic
acids (absorbance maxima for nucleic acids is at 260 nm). Thus pk.2 and pk.3 are probably con-
tributed by the same species of the protein (later referred as pk.2/pk.3 ), but the presence of nucleic
acids influences the emergence of pk.2 as a separate peak.
The last EDTA elution peak (pk.4 ) contains active protein as deduced from requirement of
EDTA to detach the protein from the column. SDS-PAGE analysis of pk.4 (fig. 8.14, Man., pk.4 )
showed that this sample was composed of disulfide-linked dimers of DC-SIGN S-CRD, which are
functional, explaining the increased aﬃnity of the lectin to mannan.
Considering a very broad shape of pk.2/pk.3, it is possible that the protein species in pk.2/pk.3
were slowly “leaking” and did not completely leave the column prior to the switch to elution buﬀer,
which means that the pk.4 is composed of the same protein species as pk.2/pk.3.
The fractions making up pk.3 were pooled and also analyzed by SDS-PAGE (fig. 8.14, Man.,
pk.3 ). The analysis revealed that this sample is homogeneous and contains monomeric DC-SIGN
S-CRD. The pooled protein was concentrated and again analyzed in reducing and non-reducing
conditions (fig. 8.14, Man., pk.3 conc.). It appeared that concentrating forced the monomeric
DC-SIGN S-CRD to form disulfide-linked dimers leaving only a negligible amount of monomeric
protein, a very disappointing outcome of these experiments.
In summary, these studies showed that the presence of multiple cysteine residues in DC-SIGN
S-CRD is the limiting factor for the preparation of purified samples of this lectin construct. Even
though the refolding can be achieved keeping nearly all protein soluble, the subsequent purification
includes concentrating steps and this forced the formation of disulfide-linked DC-SIGN S-CRD
oligomers dramatically reducing the quantity of functional monomeric protein.
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8.2. Generation of recombinant LSECtin and MGL S-ECD and
S-CRD constructs
8.2.1. General information about LSECtin and MGL
In order to expand the tools for glycomimetic compound selectivity screening, the extracellular and
carbohydrate recognition domains of LSECtin and MGL were constructed. Both of these type II
membrane proteins are also type II C-type lectins as DC-SIGN and langerin.
LSECtin LSECtin is encoded in the same gene cluster as DC-SIGN and DC-SIGNR (Liu:2004p28).
It also contains an EPN motif in its CRD and it was found to have an overlapping specificity
for mannose and GlcNAc containing oligosaccharides [25] with the most eﬀective glycan ligand, a
disaccharide GlcNAcβ1–2Man [160]. This lectin presumably exists as a dimer stabilized by two
disulphide bonds in its neck region (fig. 8.15) [160]. LSECtin is predominantly expressed on
sinusoidal endothelial cells of human liver and lymph node (thereof its name), but it has been also
found to be present on macrophages, DCs and Kupﬀer cells [161, 162], where it functions as an
endocytic receptor, although the physiological role of this lectin is not yet fully clear. LSECtin was
reported to serve as an attachment factor for enveloped viruses such as Ebola, Marburg and SARS
coronavirus [161, 163, 164, 160], and in case of Ebola virus LSECtin was reported to mediate the
infection [163]. In contrast to DC-SIGN, LSECtin does not bind lentiviral particles such as HIV or
HCV viruses [161].
Figure 8.15.: The structure of LSECtin.
A, The amino acid sequence of full length LSECtin with cytosolic, transmembrane, neck region, and CRD parts
in blue, black, red and green letters (domain organization based on information from UniProtKB); the potential
coiled-coil region in the neck domain is underlined (based on information from UniProtKB); the conserved motifs
defining sugar specificity and Ca2+-coordination are highlighted in orange and blue, and the third conserved motif,
WLGL instead of WIGL in case of LSECtin, is highlighted in red; all cysteine residues highlighted in yellow. B, The
presumed organization of full length LSECtin (from [160]). The beginning of ECD and CRD sequences chosen for
cloning are marked by blue and black sticks.
For cloning, amino acids 55-293 were chosen to produce LSECtin ECD construct, and CRD
construct comprised amino acids 159-293.
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MGL Although MGL, a macrophage galactose-type C-type lectin (also called DC-asialoglycoprotein
receptor (DC-ASGP-R) or human macrophage lectin (HML)), has a diﬀerent sugar specificity than
DC-SIGN since it contains galactose specificity determining QPD motif in its CRD, it is a general
interest to have this lectin as an extended means for compound selectivity screening. Like DC-
SIGN, MGL is a type II membrane protein that contains a single C-type CRD, and it is expressed
on macrophages and immature myDCs [165], and it is likely a sole galactose-type CLR on DCs [166].
Presumably, MGL exists as trimers although dimeric forms could be identified too [167]. Although
initially MGL was reported to recognize galactose and GalNAc sugars [165], recombinantly in bac-
teria expressed MGL bound only GalNAc [167], and later studies found MGL strongly specific to
α- or β-linked GalNAc, including Tn (GalNAcα1-O-Ser/Thr, carcinoma-associated antigen), LDN
(GalNAcβ1-4GlcNAc-R) and LDNF (GalNAcβ1-4(Fucα1-3)GlcNAc-R) antigens (although present
in humans, LDN and LDNF are abundantly expressed by human helminth parasite Schistosoma
mansoni), and not to galactose-containing sugar analogues [168]. Such carbohydrate specificity sug-
gests that MGL may have a role in tolerance to self-gangliosides, recognition of tumor antigens and
the eggs of human helminth parasite S. mansoni [168]. MGL has been also found to promote cellu-
lar entry of filoviruses like Ebola and Marburg virus [169], and together with macrophage mannose
receptor was shown to be implicated in influenza infection of macrophages [170].
Figure 8.16.: ClustalW sequence alignment of canonical MGL and isoform 2.
Cytosolic, transmembrane, neck region, and CRD parts are in blue, black, red and green letters (domain organization
based on information from UniProtKB); the putative coiled-coil region in the neck domain is underlined (based on
information from UniProtKB); the endocytosis signal motif is highlighted in green; the conserved motifs defining
sugar specificity and Ca2+-coordination are highlighted in orange and blue, and the third conserved motif, WMGL
instead of WIGL in case of MGL, is highlighted in red; all cysteine residues in extracellular part of isoform 2 are
highlighted in yellow. The beginning of ECD and CRD sequences chosen for cloning are marked by blue and black
sticks.
Three alternative splicing variants of MGL are known: isoform 1, also called “canonical” is the
longest one; isoform 2 has a deletion of amino acids 118-144 and an insertion of GEE after N173
with respect to canonical MGL; and isoform 3 has two deletions (118-144, and 284-316 amino acids
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with respect to canonical MGL), the same insertion as isoform 2 and the sequence replacement
at position 226-283 (NFVQKYLGSA ... HGLGGGEDCA → VRASGTQFLR ... IQRNISKLLS).
Isoform 2 of MGL was chosen for cloning (fig. 8.16).
To clone ECD and CRD parts of MGL isoform 2, the sequences comprising amino acids 61-292
and 153-292, respectively, were chosen.
To all of the cloned constructs, LSECtin or MGL, N-terminal tag was included:
MASWSHPQFEKIEGR (5￿-ATG GCT AGC TGG AGC CAC CCG CAG TTC GAA AAA
ATC GAA GGG CGC-3￿), where green, red and blue parts correspond to linker, StrepTag II and
Factor Xa cleavage site sequences, respectively.
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8.2.2. Results of LSECtin and MGL S-ECD and S-CRD construct cloning into
pEt20b and pEt30b vectors
8.2.2.1. Generation of pEt20b and pEt30b constructs of LSECtin and MGL S-ECD and S-CRD
LSECtin and MGL S-ECD and S-CRD pEt20b and pEt30b constructs were generated by a general
strategy represented in figure 8.17.
Figure 8.17.: The strategy of LSECtin and MGL S-ECD and S-CRD cloning.
Upper panel shows the generation of corresponding lectin constructs coding cDNA sequences; lower panel illustrates
generated cDNA insertion into selected vectors. Black, green red and blue tag colors correspond to methionine, linker
region, StrepTag II and Factor Xa cleavage site, respectively.
The PCR products (fig. 8.18) were inserted at first into pEt30b then pEt20b vectors between
XhoI and NdeI restriction sites, and the results of insertion to pEt30b vector are shown in figure
8.19.
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Figure 8.18.: The results of generation of LSECtin and MGL S-ECD and S-CRD coding cDNA
sequences by PCR.
The agarose gel of amplified corresponding cDNA: lane 1 – LSECtin S-CRD, lane 2 – LSECtin S-ECD, lane 3 – MGL
S-ECD, lane 4 – MGL S-CRD.
Figure 8.19.: The results of insertion of LSECtin and MGL S-ECD and S-CRD coding cDNA
sequences to pEt30b vector.
The agarose gels of XhoI/NdeI digested corresponding plasmids: left panel shows empty pEt30b vector and
pEt30b/LSECtin S-ECD; right panel shows digested pEt30b vector containing corresponding lectin coding cDNA (as
marked in the figure) extracted from 4 diﬀerent clones in each case. The target inserts are marked by red arrows,
and the clones marked by blue circles were sequence checked.
Most of the clones contained the target cDNA inserts. The shown clone of LSECtin S-ECD,
and LSECtin S-CRD clone 1, MGL S-CRD clone 3 and MGL S-ECD clone 1 were sequence checked
and proved to be correct, thus chosen for further investigation.
The results of generated lectin cDNA insertion to pEt20b vector are shown in figure 8.20.
Figure 8.20.: The results of insertion of LSECtin and MGL S-ECD and S-CRD coding cDNA
sequences to pEt20b vector.
The agarose gels of XhoI/NdeI digested prepared plasmids: both panels show digested pEt20b vector containing
corresponding lectin cDNA (as marked in the figure) extracted from 4 diﬀerent clones in each case, and an empty
digested pEt20b vector. The target inserts are marked by red arrows, and the clones marked by blue circles were
sequence checked.
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Most of the clones contained the target cDNA inserts. LSECtin S-ECD clone 2, and LSECtin
S-CRD clone 1, MGL S-CRD clone 1 and MGL S-ECD clone 2 were sequence checked and proved
to be correct, thus chosen for further investigation.
8.2.2.2. Results of LSECtin and MGL S-ECD and S-CRD pEt20b and pEt30b construct functionality
evaluation
The capability of generated lectin constructs to express corresponding proteins was tested in E.coli
BL21(DE3) strain. The protein expression location was also checked by preparing samples of total
expression (whole cells), inclusion bodies (the pellet after cell disruption) and cytoplasm/periplasm
(supernatant after cell disruption). The results of expression test of pEt30b constructs are shown in
figure 8.21 (the expected molecular weights are 28 kDa and 17.8 kDa for MGL S-ECD and S-CRD
constructs, and 28.3 kDa and 17 kDa for LSECtin S-ECD and S-CRD constructs, respectively).
Figure 8.21.: The results of LSECtin and MGL S-ECD and S-CRD production by pEt30b con-
structs.
The left panel shows total expression results with loaded samples as marked in the figure (I 0 and I+ notations corre-
spond to samples before and after induction, respectively), and the right panel shows protein expression localization
(S and P notations correspond to supernatant and pellet of disrupted cells, respectively). Red ticks mark the target
protein bands.
All of the pEt30b constructs, except for LSECtin S-CRD, appeared to express corresponding
lectins at high quantities in inclusion bodies. No expression at all was observed for LSECtin S-CRD
construct. Similar results were obtained for pEt20b constructs (fig. 8.22).
Figure 8.22.: The results of LSECtin and MGL S-ECD and S-CRD production by pEt20b con-
structs.
The left panel shows total expression results with loaded samples as marked in the figure, and the right panel shows
protein expression localization. Notations are same as in figure 8.21. Red ticks mark the target protein bands.
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As expected, pEt20b constructs had a “leaking” expression. Similarly as pEt30b constructs,
the lectins were expressed at relatively high quantities in inclusion bodies, except for LSECtin S-
CRD, which showed apparently no expression. Therefore, a diﬀerent LSECtin S-CRD construct
had to be designed.
8.2.3. Results of generation of LSECtin S-CRD construct to direct expression to
periplasm
8.2.3.1. The results of LSECtin S-CRD construct cloning
Although it was not clear what were the underlying reasons for the absence of LSECtin S-CRD
expression in pEt20b and pEt30b constructs, it was chosen to design a new construct, which would
be directed to the periplasm of E.coli. This strategy was based on the use of OmpA protein signal
sequence in pEt30b vector. Because OmpA signal peptide coding sequence (ompA, 213 bp) is not
included in commercially available pEt30b vector, it was cleaved out from pASK-IBA6 vector using
HindIII and XbaI restrictases as shown in figure 6.1 on page 108 (results of excision in fig. 8.23),
and then inserted to pEt30b vector between HindIII and XbaI cleavage sites.
Figure 8.23.: The results of design of pEt30b vector containing OmpA signal peptide coding se-
quence.
The left panel: an agarose gel showing ompA (213 bp) cleaved out from pASK-IBA6 vector by HindIII/XbaI restric-
tases. The middle and right panels correspond to BsaI digested and non-digested pEt30b-ompA vector, respectively.
The success of the excised ompA sequence insertion into pEt30b vector was checked by diges-
tion with BsaI restrictase: since BsaI site is present only in ompA sequence, the cleavage would relax
plasmid DNA as it would become linear and thus result in a single band in agarose gel compared to
multiple bands of supercoiled non-cleaved plasmid. Indeed, the digested pEt30b-ompA vector gave
a single band (fig. 8.23) and after sequence checking the insertion approved to be correct.
The next step was the insertion of LSECtin S-CRD coding cDNA into the constructed pEt30b-
ompA vector. This was accomplished by site-directed mutagenesis. At first, LSECtin S-CRD
coding cDNA (455 bp) was amplified by PCR from previously constructed pEt30b/LSECtin S-CRD
construct using primers that included a part annealing to ompA sequence (at StrepTag site) and
another part annealing to the beginning of CRD coding sequence. PCR results are shown in figure
8.24. Then this new LSECtin S-CRD coding cDNA sequence was used as a primer in the following
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PCR to insert it into pEt30b-ompA vector (used as a template DNA in the PCR).
Figure 8.24.: The PCR results of LSECtin S-CRD coding cDNA that included ompA-annealing
sequences (455 bp) amplification.
The resulting construct was tested by XbaI/HindIII digestion, and after sequence checking
proved to be correct (the results of digestion are not shown because the intensity of the corresponding
band was too low to be visible in the scan of the gel photo).
8.2.3.2. The results of pEt30b-ompA/LSECtin S-CRD construct functionality evaluation
The capability of constructed pEt30b-ompA/LSECtin S-CRD vector to express LSECtin S-CRD
together with expression location was tested in BL21(DE3) E.coli strains. The samples before
induction (I 0), after induction whole disrupted cells (I+), insoluble (P) and soluble parts (S ) of
disrupted cells were analyzed by SDS-PAGE. Because the presence of protein expression was not
evident on the gel (fig. 8.25 left panel), it was blotted on PVDF membrane and protein was
visualized using anti-StrepTag II antibodies (fig. 8.25 right panel).
Figure 8.25.: The functionality of pEt30b-ompA/LSECtin S-CRD construct to express LSECtin
S-CRD.
The left and right panels show SDS-PAGE and WB results, respectively, with the corresponding samples as marked
on the figure. The WB was revealed using anti-StrepTag II antibody.
It appeared that LSECtin S-CRD was expressed in inclusion bodies but not as a soluble
protein. Because the presence of protein expression is poorly seen on the gel, it is possible that
earlier pEt20b and pEt30b constructs also express lectin but at low quantities (protein expression
presence wasn’t analyzed by WB).
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8.2.4. MGL S-ECD over-expression and purification results
The expression level of MGL S-ECD (28 kDa) was high (Figure 8.26). The lectin was purified from
two batches of 0.5 L cell culture.
Figure 8.26.: The SDS-PAGE analysis of MGL S-ECD expression.
Samples before (I 0) and after induction containing whole disrupted cells (I+), supernatant (S) and pellet (P) were
loaded.
Inclusion bodies were extracted, solubilized in Gdn-HCl and refolded in the same manner as
DC-SIGN ECD and S-ECD. During refolding of solubilized inclusion bodies, extensive precipitation
was observed. The refolded protein was purified in two steps. At first the protein solution (860mL,
0.106mg/mL) was loaded to StrepTactin column and eluted with 2.5mM desthiobiotin (fig. 8.27).
Figure 8.27.: The chromatogram of MGL S-ECD elution by desthiobiotin from StrepTactin column.
The next step of purification was performed to isolate functional protein. Because of MGL
specificity to galactose, Superose12 column, which contains galactose-based polymer agarose, could
be used as a combination of an aﬃnity and size-exclusion column. The sample of MGL S-ECD
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eluted from StrepTactin, was concentrated to 3mg/mL and injected (1mL) to 125mL Superose12
column (fig. 8.28).
Figure 8.28.: The chromatograms of MGL S-ECD injection to 125mL Superose12 column.
A, The elution profile in running buﬀer. B, The retained protein elution with buﬀer containing 1mM EDTA (brown
line represents conductivity changes).
Two major species of MGL S-ECD migrating through the column could be observed (fig.
8.28A), and deduced from elution time they both contained most likely non-functional incorrectly
folded protein of various sizes. However, the activity of part of MGL S-ECD preparation was
suggested by the observation that using buﬀer containing EDTA, the bound protein, i.e. functional,
was washed out (fig. 8.28B).
To confirm the functionality of purified MGL S-ECD, a column with immobilized galactose
(later refered “galactose column”) was used. The sample of MGL S-ECD eluted from StrepTactin
was concentrated and injected (1mL) to the galactose column (fig. 8.29).
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Figure 8.29.: The chromatogram of MGL S-ECD elution profile on immobilized galactose column.
Blue and pink lines represent absorbance changes and the switch from running to elution buﬀer (from 0% to 100%
of buﬀer containing 1mM EDTA), respectively.
It turned out that the vast majority of the MGL S-ECD sample eluted from StrepTactin column
was functional as almost of the all injected protein left the column in EDTA elution peak. Thus
the sample heterogeneity observed on Superose12 column (fig. 8.28) is likely caused by diﬀerent
oligomeric forms of probably active MGL S-ECD.
Figure 8.30.: The SDS-PAGE analysis of MGL S-ECD purification steps.
Reduced (R) or non-reduced (NR) samples were loaded. Markings: the gel “Before StrepTactin” shows samples
after refolding, i.e. the reduced sample of precipitate after refolding (P) and supernatant (R and NR); the middle
gel shows concentrated reduced sample of protein eluted from StrepTactin column (i.e. “Strep.”) and concentrated
reduced samples from Superose12 (fig. 8.28); the gel “Galactose column” shows samples eluted from galactose column.
All the purification steps were monitored by SDS-PAGE loading reduced (R) or non-reduced
(NR) MGL S-ECD samples (fig. 8.30). The major part of the precipitate after refolding contained
MGL S-ECD. The Superose12 purification with EDTA elution seems to have worked well since
the resulting sample (fig. 8.28, “EDTA Peak ”) is rather homogeneous; the “Peak 1 ” and “Peak
2 ” samples contain various size contaminants, partially explaining the elution profile heterogeneity,
though the major part of the samples is comprised by MGL S-ECD. The faster migration of the non-
reduced sample after galactose column might indicate that intramolecular disulphide bonds render
the molecule more compact compared to disulphide-free molecule allowing the faster migration. It
is also noticeable that the sample eluted from galactose column contains disulphide-linked oligomers
of various sizes (the blue trail above the major band).
The yield of the protein evolved as follows: 91mg of total protein after refolding were loaded to
StrepTactin and 29mg were recovered from the column in a desthiobiotin elution peak. From 3mg
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of protein injected to Superose12 column, 0.2mg were eluted (EDTA peak) as homogeneous active
protein. From these results it can be extrapolated that the injection of 29mg could be expected to
yield 1.9mg of pure protein and this quantity could be considered as the yield from 1L culture.
Generally, the MGL S-ECD production process should be improved most importantly at the
refolding stage, and the buﬀer formulation to stabilize protein should be found (the purified samples
were precipitating). The order of purification procedure should be also changed: first purification
on StrepTactin column followed by aﬃnity purification on galactose column and finally gel-filtration
using the column with the media, for which MGL doesn’t have aﬃnity. Also the loading to Strep-
Tactin seemed to over-saturate the column, as judged from absorbance and peak profile, thus loading
in smaller portions or loading the flow-through could probably help to get a higher yield of purified
protein. It is also possible that StrepTactin column is not necessary at all, since the ECD con-
struct presents three CRDs and may have suﬃcient aﬃnity for galactose column at the first step of
purification.
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8.3. Concluding remarks on diﬀerent lectin production
The production of DC-SIGN ECD construct is eﬃcient without any major bottleneck, and consid-
erable yields of purified functional protein are obtained (typically 50-80mg from 1L of cell culture).
Surprisingly, the addition of StrepTag II at N-terminus of DC-SIGN ECD markedly decreases the
yield of purified protein mainly due to strong precipitation during refolding. Nevertheless, only
low quantities of this construct are required for the preparation of oriented surface for SPR direct
interaction assay.
Unfortunately, the eﬀorts to optimize DC-SIGN S-CRD production yield did not give any
improvements. However, the reason for low yields was revealed: while being concentrated, the
protein forms nonfunctional disulfide-linked oligomers.
Four new C-type lectin constructs were developed for the use in the laboratory in the future:
LSECtin S-CRD and S-ECDs as well as MGL S-CRD and S-ECDs. Only with the exception for
LSECtin S-CRD, all other constructs were capable to eﬃciently over-express corresponding proteins.
Nonetheless, LSECtin S-CRD construct is also produced but expression level is lower.
The production of MGL S-ECD was investigated a step further, and the first trials of purifica-
tion of this construct were performed. Although the promising results were obtained, the procedure
should be optimized.
The development of these four new constructs discontinued when the first series of the gly-
comimetic compounds were synthesized. From then on, the SPR analysis of the glycomimetic
compounds, which were continuously synthesized and sent for analysis by diﬀerent chemists groups,
became the priority of the work. From that point, only DC-SIGN and langerin ECD constructs
were used for the studies (I have been preparing DC-SIGN, and langerin ECD was prepared by
another PhD student in the group, Eric Chabrol).
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9. The results of the development of
glycomimetic DC-SIGN antagonists
9.1. Development of monovalent glycomimics
9.1.1. The SPR competition assay characteristics
The monovalent glycomimetic compounds were evaluated as DC-SIGN binders by SPR competition
assay, which allows to assess and compare the capacities of the compounds to block DC-SIGN ECD
interaction with ManBSA, used as an artificial ligand of DC-SIGN due to its lower cost as compared
to gp120. All of the compounds were prepared and analyzed in the running buﬀer without DMSO
(see subsection 6.2.3 on page 113), and if DMSO was required, the concentration used will be noted.
9.1.1.1. The experimental design of SPR competition assay
Figure 9.1 illustrates the principal design of the SPR competition assay. ManBSA, bearing 12
branched trisaccharides (α1-3, α1-6 mannotriose) per BSA molecule in average, was immobilized
on the CM-dextran surface of the sensor chip via amine coupling chemistry, and the quantity of
immobilized ManBSA varied from 1200RU to 5000RU. Then the samples containing a constant
amount of lectin and varying concentrations of the compound were injected over the reference
(activated/deactivated CM-dextran) and ManBSA surfaces.
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Figure 9.1.: The SPR competition assay.
The top part illustrates the experimental design of the assay, and the bottom part demonstrates the overlaid reference
surface corrected sensorgrams showing the binding responses of DC-SIGN ECD (20 ￿M) in the presence of a compound
at diﬀerent concentrations (the red bar on the sensorgrams indicates an approximate interval, over which the binding
responses were extracted, and the arrow shows the point of EDTA injection to regenerate the surface), and the
corresponding inhibition curve.
The residual lectin activity values were calculated by normalizing the binding responses at
equilibrium (extracted from reference surface corrected sensorgrams) with respect to the response
of lectin alone sample, which was assigned a 100% activity value. Subsequently, the IC50 for each
compound were calculated by fitting eq. 6.2 (see sub-subsection 6.2.4.2 on page 114) to the plots
of residual activity versus compound concentration.
In a few cases a simpler set-up of competition assay, so-called single-point assay, was used:
only a single concentration of monovalent compounds (150 ￿M for mannose-based or 300 ￿M for
fucose-based compounds) in a mixture with the lectin was used, and lectin binding responses in the
presence of individual compounds were compared to lectin alone binding.
All of the sensorgrams and inhibition curves are presented in appendix.
9.1.1.2. The surface activity control during the experiment
The activity of ManBSA surface in the course of the experiment was monitored in two ways. Firstly,
the apparent aﬃnity of DC-SIGN ECD to ManBSA surface was determined before and after the
competition assay by fitting the steady state aﬃnity model (eq. 9.1) to the plots of DC-SIGN
binding responses versus concentration (fig. 9.2), and the apparent KD values were compared. For
all experiments very close aﬃnities (KD 0.8-1.5 ￿M) were obtained.
Req =
KA·C·Rmax
1 +KA
(9.1)
where Req is equilibrium binding response, KA equilibrium association constant (KD=1/KA),
C – concentration of the injected analyte, and Rmax – surface binding capacity (the maximum
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binding response that can be achieved for a given analyte with a given surface).
Figure 9.2.: The ManBSA surface titration with DC-SIGN ECD.
A, Reference surface corrected sensorgrams showing the binding of DC-SIGN ECD at concentrations ranging from
0.82 ￿M to 52.7 ￿M (with respect to binding sites). B, The plot of the corresponding DC-SIGN ECD binding responses
as a function of DC-SIGN monomer concentration. The experimental points ( ) and the fit of eq. 9.1 (solid line)
are shown. ManBSA was immobilized to 1700RU, and the calculated apparent KD 1.3 ￿M for the whole tetrameric
ECD.
In parallel, a second approach was used to monitor surface activity. In this case, the same
sample of the lectin alone was injected in the beginning, in the middle and in the end of the
experiment, and the binding responses were compared. Typically, 50-90 cycles of sample injections
followed by surface regenerations were performed per experiment, and in the end of a such run the
surface retained at least 95% of its primary activity.
Additional control of the experiments was done by including a reference compound (e.g. D-
mannose, L-fucose) to the run and comparing the obtained IC50 values between diﬀerent experi-
ments.
9.1.1.3. The evaluation of the variation of IC50 values
The variation of IC50 values was evaluated comparing the values obtained for the same compound
in several diﬀerent experiments (table 9.1) where the ManBSA surface densities and DC-SIGN ECD
preparations were diﬀerent, and some of the experiments were performed by diﬀerent operators.
Table 9.1.: Evaluation of variation of IC50 values.
Compound Mean IC50± SD, mM Number of measurements
D-mannose 3.29 ± 0.34 8
Man α1-2 Man 0.95 ± 0.11 7
psDi (fig. 9.14 on page 173) 1.02 ± 0.11 14
psTri (fig. 9.14 on page 173) 0.145 ± 0.083 9
4h (fig. 9.17 on page 265) 0.31 ± 0.04 24
L-fucose 2.06 ± 0.18 6
LewisX 0.77 ± 0.10 6
10b (fig. 9.13 on page 172) 0.395 ± 0.043 7
10b-azide1 (fig. 9.13 on page 172) 0.328 ± 0.043 9
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Under these conditions, the calculated standard deviations (SD), when normalized to the IC50
mean value, varied at 10-13% range over a total of up to 24 measurements.
Interestingly, very high variation of IC50 values for psTri was observed. This might be related
to the ability of this compound to bridge DC-SIGN tetramers (see manuscript n°5), which could
lead to the sensitivity of the DC-SIGN ECD preparation, i.e. number of active CRDs per tetramer.
9.1.1.4. The set-up of the evaluation of compound selectivity to DC-SIGN versus langerin
The same principle of competition assay was used to determine the compounds’ capacities to in-
hibit langerin ECD (15 ￿M, the concentration was lower than DC-SIGN ECD due to the limited
availability of this lectin) binding to Man-BSA surface. However, langerin strongly interacted with
the CM-dextran surface (fig. 9.3).
Figure 9.3.: The raw sensorgams representing titration of diﬀerence surfaces with langerin ECD.
A range of langerin ECD concentrations was injected over the following surfaces: A, unmodified CM-dextran sur-
face; B, activated/deactivated CM-dextran surface; and C, immobilized ManBSA (5000RU) surface (the beginning
of sensorgrams was not normalized to 0RU to take into account the accumulation of protein not fully removed by
regeneration after each cycle). D, a surface saturation curve by langerin ECD titration: binding responses corre-
sponding to sensorgrams in panel C were plotted against langerin monomer concentration; the solid line represents
the fit of eq. 9.1 to the experimental points and yielded an apparent KD of 2.4 ￿M for the whole trimeric ECD. The
blue arrows mark the injection of surface regeneration solution, 50mM EDTA pH 8.
Eﬀorts were made to eliminate or significantly reduce this binding by preparing the reference
surface with high amount of immobilized BSA in order to shield the dextran (fig. 9.4B), or by
performing several cycles of CM-dextran activation/deactivation to decrease the carboxyl groups in
order to reduce possible electrostatic interactions (fig. 9.4C).
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Figure 9.4.: The sensorgrams comparing langerin interaction with ManBSA and reference surfaces.
Langerin ECD (15 ￿M, 50 ￿M and 16 ￿M for A, B and C, respectively) injections over corresponding reference (red
lines) and ManBSA surfaces (green lines). A, the reference surface was EDC/NHS activated and ethanolamine
deactivated CM-dextran, and Man-BSA was immobilized 1900RU. B, the reference surface was coated with BSA
(3300RU) and Man-BSA was immobilized to 2000RU. C, the reference and Man-BSA surfaces were pretreated with
four alternating injections (50 ￿L) of EDC/NHS followed by ethanolamine, then 300RU of Man-BSA was immobilized
on the active surface; the high bulk response of langerin injection arose due to the diﬀerence in running (4% DMSO)
and sample (no DMSO) buﬀers. The blue arrows mark the injection of surface regeneration solution, 50mM EDTA
pH 8.
All of these eﬀorts did not give any plausible results. However, as can be seen from figures
9.3 and 9.4, the injection of EDTA abolished the interaction of langerin with the surface suggesting
that this binding was Ca2+-dependent and sugar determined, i.e. the interacting entity was the
CRD of langerin. Indeed, langerin recognizes maltose [60], hence its specificity to dextran matrix
is not surprising.
Finally, ManBSA/dextran surface was considered as a combined ligand of langerin. No ref-
erence surface subtraction was performed prior to extraction of binding responses, which were
calculated using similar intervals as in case of DC-SIGN (fig. 9.1) just after the end of the injection
in order to avoid bulk responses. Moreover, it appeared that the inhibition of langerin binding
is highly dependent on ManBSA surface density, which was in the contrary to DC-SIGN, since it
didn’t show such dependency (an example from studies in article n°4 are shown figure 9.5).
Figure 9.5.: The langerin inhibition dependence on ManBSA surface density.
A, IC50 values of langerin and DC-SIGN inhibition by indicated compounds that were obtained on high density
(Fc-HD, 5000RU of immobilized ManBSA) and low density (Fc-LD, 1100RU of immobilized ManBSA) surfaces. B,
the corresponding selectivities of Man α1-2 Man and psDi calculated according to eq. 9.2. C, the corresponding
selectivity gains achieved by changing Man α1-2 Man to psDi, calculated according to eq. 9.3.
Despite high diﬀerences in absolute IC50 values for diﬀerent density surfaces, the general
pattern of IC50 value distribution among the compounds remained the same.
In order to get a more tangible evaluation of the selectivity of the compounds, the following
approach was envisioned. The absolute selectivity of a particular compound (selcomp.) for DC-SIGN
vs langerin can be defined as a following ratio:
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selcomp. =
IC50Langerin
IC50DC−SIGN
(9.2)
This means that selcomp. > 1 indicates a selectivity of the compound in favor for DC-SIGN.
However, selcomp. term is still entirely surface density-dependent (fig. 9.5B). To exclude this eﬀect,
a selectivity gain (sel.g) achieved by switching from one compound (reference, comp.1 ) to another
(comp.2 ) can be considered:
sel.gcomp.1→comp.2 =
selcomp.2
selcomp.1
(9.3)
This term also provides a relative comparison of the selectivity improvement between the two
lectins when switching from one compound to another, i.e. it answers the question “how much the
selectivity of compound 2 is better than compound 1”, and sel.gcomp.1→comp.2 > 1 means a gain
of selectivity to DC-SIGN vs langerin for compound 2 compared to compound 1, while values <1
mean a loss of selectivity for DC-SIGN. Indeed, the sel.g values are no longer dependent on surface
density as can be seen in the example in figure 9.5C, which tells that chemically modifying a natural
Manα1-2Man disaccharide, improved a selectivity to DC-SIGN of the resulting compound psDi by
a factor of 3.5.
152
9.1. DEVELOPMENT OF MONOVALENT GLYCOMIMICS
9.1.2. C-glycoside development
In order to generate compounds with higher resistance to the cleavage by glycosidases, the C-
glycosides were constructed and assayed for their binding to DC-SIGN (C-glycosides are sugars
where the anomeric oxygen is replaced by a carbon). The design and synthesis of these C-glycosides
was conducted in the group of Pr. J. Moravcová by PhD student Benedetta Bertolotti.
The first trials were made with D-mannose (BB112) and L-fucose (BB133) (fig. 9.6 top panel)
with the short linkers attached by C-glycosidic bond were synthesized. Then various disaccharides
(fig. 9.6 middle and bottom panels) were synthesized and tested. All of the disaccharides, except
ZL1(D), ZL2(L), were analyzed in the presence of 4% DMSO; ZL1(D) and ZL2(L) were analyzed
in the absence of DMSO.
Figure 9.6.: The structures of C-glycosides.
Top panel shows the structure of D-mannose (BB112) and L-fucose (BB133) with the short linkers attached by C-
glycosidic bond. Middle and bottom panels show the structures of mannose- and fucose-based pseudo-disaccharides,
respectively.
All of these compounds were tested by SPR competition assay to assess their capacity of
inhibiting DC-SIGN ECD binding to ManBSA surface and compared with the available natural
counterparts, i.e. D-mannose, L-fucose, Manα1-2Man and Manα1-3Man.
Surprisingly, the L-fucose C-glycoside BB133 appeared to have 2-fold better activity of DC-
SIGN inhibition than the natural L-fucose (fig. 9.7), although the underlying structural basis for
such results is not clear. The mannose C-glycoside had exactly the same activity as D-mannose.
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Figure 9.7.: DC-SIGN inhibition activities of D-mannose and L-fucose C-glycosidic monosaccha-
rides compared to their natural counterparts.
D-mannose and L-fucose IC50 values are the means as shown in table 9.1; the error bars are standard deviations (over
two measurements of BB112 and BB133).
Among the pseudo-disaccharides, there were compounds that had very low solubility (i.e.
BB178 and BO). They were solubilized in the running buﬀer containing 4% DMSO, and thus the
assay was performed in DMSO (4%) presence.
The results of mannose-based pseudo-disaccharides showed that these compounds have similar
activity as D-mannose (fig. 9.8).
Figure 9.8.: DC-SIGN inhibition activities of D-mannose C-glycosidic pseudo-disaccharides com-
pared to D-mannose, Manα1-2Man and Manα1-3Man.
D-mannose and Manα1-2Man IC50 values are the means as shown in table 9.1; the error bars are standard deviations
(over two measurements of Manα1-3Man and ZL1(D), other compounds run only once).
Only BB203, which has an elongated linker between two mannose moieties connected via
anomeric carbons, showed a better activity than mannose. All other compounds had the same
(BB207, BB213) or lower (ZL1(D)) activity as D-mannose suggesting that only non-reducing man-
nose moiety was interacting with the lectin and the second moiety had either no eﬀect on binding
or probably imposed some kind of hindrance for the binding (in case of ZL1(D)). Manα1-3Man has
more than 2-fold lower activity than Manα1-2Man, and none of Manα1-3Man mimics had higher
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activity than the natural disaccharide.
Interestingly, all of the fucose-based pseudo-disaccharides had a better apparent aﬃnity to
DC-SIGN than L-fucose (fig. 9.9).
Figure 9.9.: DC-SIGN inhibition activities of L-fucose C-glycosidic pseudo-disaccharides compared
to L-fucose and LewisX.
L-fucose and LewisX IC50 values are the means as shown in table 9.1; the error bars are standard deviations (over
two measurements for BO, other compounds run only once).
Similarly to mannose-based pseudo-disaccharides, the best activity in these fucose-based com-
pound series belonged to the compound with an elongated alkyl linker between two L-fucose moieties
attached via anomeric carbons, i.e. compound BB178. The activity of this compound was even
higher than of LewisX trisaccharide. It is noteworthy that BB178 was the least soluble compound
(part of the compound remained non-dissolved when final concentration of 20mM (7mg/mL) was
aimed) meaning that its activity is underestimated. However, low water solubility is a disadvantage
in the development of drug candidates.
The other three fucose-based pseudo-disaccharides had about 2-fold better activity than L-
fucose suggesting that the addition of corresponding moieties to L-fucose improved their aﬃnity to
DC-SIGN.
It is interesting to notice that among mannose-based pseudo-disaccharides, there was a com-
pound, namely ZL2(L), with a bizarre eﬀect observed (fig. 9.10). The presence of higher concentra-
tions (≥2mM) of ZL2(L) seemed to trigger DC-SIGN binding to dextran surface (fig. 9.10B), since
10mM ZL2(L) alone did not show interaction with the reference surface, but slightly interacted
with ManBSA surface (100RU bound) bound (fig. 9.10C). The same binding to ManBSA surface
was also observed for compound ZL1(D) (fig. 9.10D), which did not have such eﬀect as ZL2(L).
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Figure 9.10.: Sensorgrams illustrating the eﬀect of compound ZL2(L) for DC-SIGN ECD binding
to CM-dextran and ManBSA surfaces.
A, Reference surface corrected sensorgrams of injections of ZL2(L) (at concentrations as shown in figure legend)
in presence of 20 ￿M DC-SIGN ECD, over ManBSA surface (5300RU immobilized). B, Raw sensorgrams of same
injections as in panel A, over a reference surface (activated/deactivated CM-dextran). C, Raw sensorgrams showing
injection of 10mM ZL2(L) alone over reference (Fc1) and ManBSA (Fc2) surfaces. D, Raw sensorgrams showing
injection of 5mM ZL1(D) alone over reference (Fc1) and ManBSA (Fc2) surfaces. E, Raw sensorgrams showing 9mM
(red) and 6mM (green) ZL1(D) with 20 ￿M DC-SIGN ECD injected over a reference surface; samples with 9mM and
6mM ZL1(D) were incubated at room temperature for 2 and 15 hours, respectively.
Moreover, the sensorgrams deviated from a usual shape, which has a characteristic rapid
association phase of DC-SIGN ECD binding to ManBSA surface with binding plateau reached
immediately after the injection is started, and a rapid dissociation phase (fig. 9.2 on page 149A).
In the presence of higher concentrations of ZL2(L) this behavior was distorted: the association
does not reach plateau and binding continues, while dissociation phase is markedly stabilized (fig.
9.10A). However, the interaction was Ca2+-dependant (EDTA was capable to remove the bound
material). In terms of binding responses, about 850RU bound to the reference surface after 18mM
ZL2(L)/20 ￿M DC-SIGN ECD mixture was injected. This high response is unlikely just for a
disaccharide molecule. Furthermore, this eﬀect was dependent on incubation time of ZL2(L)/DC-
SIGN ECD mixture: the longer the incubation, the more visible the eﬀect (fig. 9.10E). The reason
of such behavior of compound ZL2(L) is not clear.
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9.1.3. Development of fucose-based glycomimetic compounds
The research work on fucose-based glycomimetic DC-SIGN antagonists, conducted by our team
in collaboration with Pr. A. Bernardi group, has been started few years before the beginning of
my PhD. Based on the structural knowledge of LewisX binding to DC-SIGN CRD (described in
subsection 2.3.1 on page 67, fig. 2.9 on page 68D), two α-fucosylamides, 2a and 17 (fig. 9.11),
were designed, which conserved the L-fucose anchor for directing them to CRD of DC-SIGN, but
GlcNAc and D-galactose moieties of LewisX were changed in order to improve binding aﬃnity to
DC-SIGN. These compounds were evaluated as DC-SIGN inhibitors, and indeed showed slightly
better aﬃnity to DC-SIGN than LewisX trisaccharide [145]. However, the results suggested that
this type of compounds could be further improved.
Figure 9.11.: The structures of previously designed fucose-based compounds 2a and 17 .
Keeping the same concept, several series of α-fucosylamides (fig. 9.12), all of which possess
a β-amino acid tether and a fucosylamide anchor (general formula shown in figure 9.12A), were
generated by a PhD student Daniela Doknic and tested in SPR competition assay, and the results
are outlined in the following article.
Figure 9.12.: The structures of newly synthesized fucose-based compounds.
A, The general formula of all compounds. B, The substituents, R, of the compounds. C, The general formulas of
diﬀerent series. All the structures and their names are the same as in article n°1 (the individual compound names
are derived writing series number followed by the letter of a relevant substituent).
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Additionally to the evaluation of the potency of these compounds to inhibit DC-SIGN binding
to immobilized ManBSA, they were also tested against langerin, a C-type lectin expressed by Langer-
hans cells and demonstrated to have protective role against HIV infection (see sub-subsection 2.2.1.2
on page 64). All of the compounds appeared to have low aﬃnity to langerin, a desirable result in
the development of selective DC-SIGN antagonists.
The compound 10b was identified as the most active and selective ligand in these series.
The main outcome of these studies:
✧ Most of the LewisX trisaccharide mimicking compounds have a similar activity towards DC-
SIGN as the latter sugar.
✧ For the first time the selectivity to DC-SIGN vs langerin was addressed; as could be expected,
fucose-based compounds had low aﬃnity to langerin, thus good selectivity to DC-SIGN.
Contributions:
All of the compounds were designed and synthesized by the group of Pr. A. Bernardi. The
described modeling and docking studies were conducted by Pr. A. Bernardi group in collaboration
with Dr. J. Weiser team. Langerin used in SPR assays were produced in our team.
My contribution to this study:
I have prepared DC-SIGN required for SPR experiments, set up the competition assay with
langerin and performed all of the described SPR assays, analyzed the data, and participated in the
preparation of the paper manuscript.
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specificity versus Langerin
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DC-SIGN and Langerin are two C-type lectins involved in the initial steps of HIV infections: the
former acts as a viral attachment factor and facilitates viral invasion of the immune system, the latter
has a protective effect. Potential antiviral compounds targeted against DC-SIGN were synthesized
using a common fucosylamide anchor. Their DC-SIGN affinity was tested by SPR and found to be
similar to that of the natural ligand Lewis-X (LeX). The compounds were also found to be selective for
DC-SIGN and to interact only weakly with Langerin. These molecules are potentially useful
therapeutic tools against sexually transmitted HIV infection.
Introduction
Dendritic Cells (DCs) are instrumental in the development
of pathogen-specific immune responses.1 DCs are professional
antigen-presenting cells that capture microbes entering skin or
mucosal tissues and process them to form MHC-peptide com-
plexes. After antigen uptake, immature DCs acquire the capacity
to migrate to lymph nodes where they present processed antigens
to T-cells, initiating adaptive immune responses. DCs express a
repertoire of pathogen-recognition receptors (PRRs), including
Toll Like Receptors (TLRs) and C-type lectins that mediate
both signaling by self antigens and, in some cases, pathogen
recognition.2 C-type lectins represent a large family of Ca2+
dependent lectins and recognize pathogen-derived carbohydrate
structures. Many different C-type lectins expressed by DCs have
been described,3 including DC-SIGN.
DC-SIGN (DC-Specific ICAM-3 Grabbing Nonintegrin; CD
209) was originally defined as an intercellular adhesionmolecule-3
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(ICAM-3) receptor that plays an important role in establishing the
first contact between DC and resting T cells.4 It is a type II trans-
membrane C-type lectin with a single C-terminal Carbohydrate
Recognition Domain (CRD) within its sequence. In the cellular
membrane, DC-SIGN is assembled as a tetramer, thanks to an
extended coiled-coil region that allows simultaneous presentation
of fourCRDs.5 This oligomerization influences the lectin avidity in
binding events. DC-SIGN appears to promote dissemination of a
number of viruses (e.g., HIV, hepatitis C virus, Ebola virus)6 and to
participate in suppressing immune responses to some pathogens,
(e.g.,Mycobacterium tuberculosis and Helicobacter pylori).7
The various roles attributed to DC-SIGN have generated much
interest towards the identification of ligands that can be used
to explore its different functions and/or to inhibit pathogen
binding.8 However, generation of specific ligands for DC-SIGN
is a challenging task, since many other C-type lectins exist and
share important structural features with DC-SIGN binding site.
Among the list of C-type lectin receptors closely related to DC-
SIGN, Langerin, which is also expressed at the cell surface of
antigen presenting cells, and L-SIGN, expressed on endothelial
liver cell, placenta and lymph nodes, are particularly likely to
interfere with DC-SIGN recognition.9,10 These three lectins are all
calcium-dependent carbohydrate-binding proteins and share the
ability to bind high-mannose oligosaccharides. On the other hand,
the three lectins show different specificity towards fucosylated
oligosaccharides, a fact which may be used to design DC-SIGN
specific ligands. Indeed, contrary to L-SIGN, DC-SIGN is known
to bind the Lewis X (LeX) epitope (Galb4[Fuca3]GlcNAc, 1 in
Fig. 1), as illustrated in the recognition mode of Schistosoma
mansoni egg by these lectins.5d,7,11 Moreover, both DC-SIGN and
Langerin appear to recognize blood group B antigen through its
fucose residue12,13 in the primary Ca2+ binding site, but again the
LeX antigen is specific for DC-SIGN relative to Langerin. As
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Fig. 1 The known fucose-based DC-SIGN ligands 1–3a and the general
structure 4 of the library described in this paper. (IC50 from ref. 14).
shown by X-ray structures,12,13 in addition to binding the fucose
residue on the Ca2+ site, DC-SIGN is uniquely able to stabilize LeX
galactose residue in a second binding area due to key residues that
are absent in Langerin.
The existence of a secondary binding site is also suggested by
a glycan array study of over 100 glycan structures.12 This study
demonstrated that the presence of a terminal fucose residue is not
sufficient for DC-SIGN binding, but 14 fucose-bearing glycans
with the structure of Lewis epitopes were found to bind selectively
to DC-SIGN relative to L-SIGN.
Wehave recently described the first fucose-based artificial ligand
of DC-SIGN (compound 2, Fig. 1), designed to mimic this
trisaccharide.14 The ligand was built by using an a-fucosylamide
anchor to drive the molecule to the DC-SIGN primary binding
site and connecting it to a galactose mimic using a cyclic cis-b-
amino acid ((1S,2R)-2-amino-cyclohexanecarboxylic acid, Fig. 1).
The layout of these residues and more specifically the linker b-
amino acid allowed the molecule to adopt a three-dimensional
shape similar to the LeX trisaccharide (Fig. 1).15 Amide bonds
were chosen to connect the three elements of ligand 2 to achieve
synthetic simplicity as well as chemical and metabolic stability
of the target molecule. DC-SIGN binding studies performed by
SPR showed that ligand 2 and surprisingly its simplified version
3a, which does not contain the galactose-mimic moiety, inhibit
DC-SIGN better than the natural ligand 1 (IC50 = 0.35 mM,
0.5 mM and 0.8 mM, respectively).14 The weak difference of
affinity between 2 and 3a, however, suggested that the galactose-
like fragment in 2 gives a limited contribution to the binding
interaction. Building on this knowledge, the goals of the work
we report in this paper were: 1) to establish a minimal structure
easily accessible in large scale and able to engage the receptor
with an affinity similar to that of the natural ligand LeX; 2) to
improve the binding affinity of the fucosylamides by optimizing
the interactions in the secondary binding site. To achieve these
goals, a library of ca. 40 derivatives of general formula 4 was
designed, synthesized and assayed by SPR to determine the ability
of the compounds to inhibit DC-SIGN binding to immobilized
mannosylated Bovine Serum Albumin (Man-BSA). Moreover,
a preliminary selectivity screening was introduced to test some
library members for inhibition of Langerin, using SPR. Selectivity
for DC-SIGN versus Langerin is specially important to develop
inhibitors of sexually transmitted HIV infections. As discussed
above, interaction with DC-SIGN on mucosal DC is used by
the virus to invade the host immune system. On the contrary,
Langerin is suggested to have protective effects against HIV
infection.16 Indeed, some of the fucosylamides examined displayed
an interestingDC-SIGN selectivity and have the potential of being
developed as antiviral agents.
Results and discussion
In order to select reasonable ligand candidates, the properties of
the protein surface in the vicinity of the Ca2+ site in the LewisX-
DC-SIGN complex (1SL5)12 were examined using GRID.17 Both
the DRY probe and the WATER probe were used to identify
hydrophilic and lipophilic regions of the binding site. The molec-
ular representations shown in Fig. 2 were obtained with the
Maestro graphical interface. Various minima for the WATER
probe were identified in the vicinity of the Ca2+-binding region:
in the crystal structure, they are occupied by crystallographic
water molecules W13, W34 and W36 (Fig. 2a). W13 and W36
are located in two well-defined low interaction energy sites, both
below -11 kcal mol-1. W13 is in the vicinity of the fucose
residue and mediates the interaction of Fuc-O2 with Glu354 and
Lys368, and of Gal-O6 with Asp367 (Fig. 2a). W36 mediates the
interaction of Gal-O4 with Glu358. The W36 site is occupied
by a crystallographic water molecule also in 3 out of 4 known
X-ray structures of DC-SIGN in complex with oligomannosides
(1SL4,12 1K9I,18 2IT519) and it is replaced by one sugar hydroxyl
group in the fourth one (2IT619). The W34 site belongs to a larger
isoenergetic area with a less favorable GRID interaction energy
(ca. -7 kcal mol-1), occupied by water molecules in 2 out of 4
oligomannoside-DC-SIGN complexes (1SL4, 1K9I) and loosely
Fig. 2 Energetic maps of GRID interactions (the Ca2+ ion is shown in yellow) in the structure of the DC-SIGN- LeX complex (pdb code : 1SL5, from
ref. 11). a) WATER probe, -7.0 kcal mol-1 isosurface, showing the binding sites for crystallographic water molecules W13, W34 and W36 in 1SL5. b)
DRY probe, -0.5 kcal mol-1 isosurface, showing hydrophobic areas near the binding region and the groove formed by Phe313 and Leu 371.
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Scheme 1 Retrosynthetic analysis of fucosyl derivative 3.
replaced by mannose hydroxyl groups in the other 2 (2IT5 and
2IT6). In the 1SL5 structure, W34 mediates binding of Gal-O4 to
Ser360 and, together with W36, contributes to the creation of a
secondary binding site involving Leu371, Asp367, Lys373, Glu358
and flanked by Phe313 (Fig. 2a).
GRID analysis with the DRY probe allowed identification of
the hydrophobic areas near the binding region, which are shown in
Fig. 2b. Two of them, formed by Val351 and Asn362/Asn344, are
in the immediate vicinity of theCa2+-binding site and establishVan
der Waals contact with the ligand. Phe313 and Leu371/Lys368
side chains form a major hydrophobic groove which flank the
W36 crystallographic site.
Docking of mimic 2 in the 1SL5 structure was obtained using
Glide.20 The complex, which included protein, ligand and the two
water molecules W13 and W36, was prepared with the standard
Preparation Wizard routine of Glide, but the final minimization
was performed in implicit (GB/SA21) water with the AMBER*
force field. It was found that this procedure allowed achievement
of a better orientation of the water molecules and optimization
of their hydrogen bonding pattern, which in turn avoided steric
clashes in the following re-docking step. Docking obtained with
this model suggested that optimal interaction is reached with
the ligand in an extended conformation, which would allow the
galactose mimic to place two hydroxyl groups in a hydrophilic
patch of the protein near the side chain of Phe313 while nesting
the cyclohexane ring in the groove formed by Phe313 and Leu371
(Fig. 3).
Fig. 3 Docking of mimic 2 in 1SL5. (the Ca2+ ion is shown in yellow).
Based on this model, interesting candidates to replace the
galactose moiety should be molecules able to take advantage
of lipophilic interactions and to interact specifically with the
secondary hydrophilic regions. Further docking experiments sug-
gested that favorable interactions could also be established by
positively charged groups in the ligands and the negatively charged
regions of the protein created by Asp 367 and Glu 358 side
chains. Following this analysis, candidates for the R group in
4 were selected among commercially available carboxylic acids
featuring aromatic groups and/or hydroxyl groups, amino groups
or acetamides.
The initial set of compounds were synthesized starting from
amine 5,14 which in turn was obtained from tri-O-acetyl-L-
fucosylazide 6 and the protected (1S,2R)-b-amino acid 7, as we
have previously described (Scheme 1).14
The coupling reactions between amine 5 and the acid partners
(RCO2H, Scheme 2) were performed using either HBTU, acid
chloride or EDC/HOBt activation, as described in the Supple-
mentary Information. These conditions afforded the protected
ligands 8 in variable yields (between 43 and 80%) after isolation by
solid phase extraction and chromatographic purification.Removal
of the protecting groups under standard Zemplen’s conditions
gave the required compounds 3. If the acid partner carried a Boc
protection, this was first removed using a mixture of TFA/CH2Cl2
(1/5). In this way ca. 30 different compounds were prepared (see
Supplementary Information for the structure and characterization
of the entire library). Scheme 2 shows the structure of those that
will be used in the following discussion.
Scheme 2 Coupling reaction of amine 5 with acid partners.
DC-SIGN affinity for the entire set of 30 compounds of general
formula 3 was estimated using a surface plasmon resonance
(SPR) biosensor in a competition assay which we have previously
described.14 The assay allows an affinity evaluation of all ligands
relative to one another on the basis of their percentage inhibition
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Fig. 4 The dependency of DC-SIGN ECD percent activity on concentrations of corresponding compounds. (see original sensorgrams in SI-Fig.4).
of DC-SIGN binding to immobilized mannosylated bovine serum
albumin (Man-BSA). The commercially available Man-BSA used
in these assays contain an average of 12 glycosylation sites
displaying the Mana1-3[Mana1-6]Man branched trisaccharide.
Man-BSA was covalently attached to a carboxymethyl dextran-
functionalized gold SPR sensor chip CM4. Inhibition studies
were then performed using extracellular domain (ECD) of DC-
SIGN (20 mM) injected alone or in the presence of a constant
concentration (300 mM) of the ligands. At this concentration,
for the particular chip used in the assay, LeX exhibited 25%
of inhibition. All the molecules 3 synthesized showed a similar
efficiency, independent of the nature of the R group, and none
improved significantly over the activity of 3a. To confirm these
data, complete inhibition curves were obtained and IC50 values
were estimated for the selected group of compounds 3a–h shown
in Scheme 2. The results were totally consistent with the previous
observation (Fig. 4).
Interestingly,when ananalogous groupof compounds 9 (Fig. 5),
obtained by reaction of fucosylazide 6 with b-alanine rather than
with 7, was examined in SPR single point assays at 300 mM
concentration, similar inhibition values (25–30%) were obtained.
Thus, these simple a-fucosyl-b-alanyl amides showed a similar
affinity forDC-SIGNas LeX and all the compounds 3 synthesized.
Fig. 5 b-Alanine derivatives 9.
These observations, that are in striking contrast with the
expectations derived from docking studies, strongly suggest that
the R substituent in 3 is not reaching the secondary binding site
identified by the docking algorithm and may not be interacting
at all with the protein. The unexpected results obtained with a-
fucosyl-b-alanyl amides 9, whilst providing us with very simple
ligands of high efficiency,22 confirm that the (1S,2R)-2-amino-
cyclohexanecarboxylic acid scaffold selected for the synthesis of 3
does not enforce optimal interaction of the secondary residue with
the protein. NMR studies are currently in progress to assess the
structural details of the interaction of DC-SIGNwith compounds
3.23 To further explore the role of the b-amino acid structure
in defining ligand–protein interaction, the configuration of the
scaffold was varied systematically and a third set of compounds
was synthesized, where the R fragment was kept unchanged and
the b-configuration was systematically permutated.
The new set of compounds 10–12 (Fig. 6) were synthesized
starting from b-amino acids 13–15 (Fig. 6) using the synthetic
sequence employed for 3 and shown in Schemes 1 and 2. The
syntheses of the enantiomerically pure isomeric amino acids
13–15 and of the corresponding fucosylamide derivatives 10–12
are described in the Supplementary Information. The IC50 ob-
tained by SPR analysis of 10–12 are collected in Fig. 7 and
compared to selected data obtained for 3, for LeX and for L-fucose
(see SI-Fig 5 for original sensorgrams).
The IC50 values obtained for 3a and 3b are consistent with
previous measurements (Fig. 4). The data confirm that the activity
of most fucosylamides is close to that of LeX. The series of
compounds 10a–d show a larger increase of the affinity (a factor
of 3) on passing from the acetamide 10a (R =Me) to the aromatic
amides 10b–d, suggesting a possible role of the aromatic group
in the interaction with the protein. This series, which is built on
the (1R,2S)-2-amino-cyclohexanecarboxylic acid scaffold 13, also
contains the strongest ligands so far, the hydroxybenzoic acid
derivatives 10b and 10c (IC50 470 mM) and is therefore the best
current candidate for further optimization.
To analyze the selectivity properties of the compounds screened,
we developed an additional SPR analysis for Langerin binding
properties. As for DC-SIGN, the ability of Langerin to bind to a
surface functionalized with Man-BSA was tested. In the case of
Langerin, binding to Man-BSA as well as to the dextran matrix
(SI-Fig 1)was observed. Therefore, the dextran/Man-BSA surface
was considered as a combined ligand of Langerin ECD. Upon
titration of the surface with Langerin, a similar saturation curve
than for DC-SIGN was obtained (SI-Fig. 2 and 3). Langerin
displayed an apparent Kd for this surface of 10.3 mM. Indeed,
the two lectins exhibited comparable affinity for this surface, thus
the same fixed concentration of Langerin was used in the SPR-
based competition assay, which allowed a direct comparison of
the binding inhibition properties of the compounds for Langerin
versus DC-SIGN.
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Fig. 6 Library of compounds with different stereochemistry in the cyclohexane scaffold.
Fig. 7 The IC50 values obtained for compounds 10–12 by SPR inhibition assay. IC50 of L-fucose, LeX, 3a and 3b measured in the same conditions are
shown for comparison.
Compounds initially tested for their DC-SIGN inhibitory
potency (Fig. 7) were evaluated with Langerin ECD. The results
are shown in Fig. 8A (see also SI-Fig.6). The inhibitory potency
of the fucosylated mimics is so low against Langerin that it
was not possible to determine an IC50. A crude comparison of
the inhibitors’ properties towards DC-SIGN and Langerin was
obtained by comparing the residual activity of both lectins at the
highest concentration tested for each compound (Fig. 8B).
The data show that many of the fucosylamides tested display a
larger DC-SIGN selectivity than LeX and confirm 10b as one of
the most interesting elements of this group, both for its DC-SIGN
affinity and for its specificity.
Conclusions
In this paper, we have presented a new library of fucose-based
ligands of DC-SIGN, all characterized by the presence of a b-
amino acid tether and of a fucosylamide anchor, able to direct the
molecules to the DC-SIGN CRD binding site. We were able to
identify many compounds that, compared to the natural ligand
LeX and its previously reported mimic 2, display a similar DC-
SIGN inhibition efficiency at a fraction of the synthetic cost.
In particular, a-fucosylamides 9, derived from b-alanine, are
interesting candidates for polyvalent presentations8d–k due to their
high synthetic accessibility and good ligand efficiency.22 A second
group of compounds, a-fucosylamides 10 derived from (1R,2S)-
2-amino-cyclohexanecarboxylic acid 13, were also of interest
because they yielded the most active and selective ligand of this
group (10b). Indeed, it may be important that molecules directed
to block the action of DC-SIGN do not interfere with the action
of other lectins. We have recently shown that a-N-fucosylamides
of general formula 3 and 9 interact strongly with the L-fucose
binding lectin PA-IIL of Pseudomonas aeruginosa.24 In particular,
to develop inhibitors of sexually transmittedHIV infections it may
be necessary to select DC-SIGN antagonists that do not interfere
with the action of Langerin. Like DC-SIGN, Langerin is a
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Fig. 8 A) Inhibition of Langerin ECD binding to Man-BSA immobilized on the dextran surface. B) Residual lectin activity at the highest tested
concentration of the ligands (4.6 mM). Langerin, white bars; DC-SIGN, black bars.
membrane C-type lectin known to bind to HIV-1. However, whilst
interaction with DC-SIGN is used by the virus to invade the host
immune system, Langerin is suggested to have protective effects
against HIV infection.16,25 Indeed, Langerhans cells, which are the
first dendritic cells to encounterHIV via genitalmucosa, have been
described as a natural barrier for HIV-1 transmission, which is
dependent on Langerin expression.15 The importance of Langerin
in HIV protection has been again emphasized in the context of
HIV-1/Herpes Simplex Virus type II (HSV-2) co-infection.26 In
this last case, it has been demonstrated that HIV susceptibility
of Langerhans cells, and the subsequent virus transmission,
could be promoted by HSV-2-dependent abrogation of Langerin’s
functions. Conversely, DC-SIGN has a well-established role in
dendritic cells-mediatedHIV-1 transmission.6 Thus, the selectivity
of the ligands for DC-SIGN relative to Langerin was also tested.
Indeed, we described here for the first time, simultaneous screening
of artificial compounds towards both lectins. In agreement with
literature data on the natural ligands of these lectins, a low
inhibitory potency of LeX towards Langerin has been observed
in contrast to DC-SIGN. The capacity of LeX and of the other
fucosylated derivatives to inhibit Langerin binding is so low that
we could not perform a full inhibition curve in a reasonable range
of concentration. Therefore, selectivity of the fucose-based ligands
tested was assessed by comparing residual lectin activity at the
highest ligand concentration tested. Most of the a-fucosylamides
assayed were found to be more DC-SIGN selective than the
natural ligand LeX and therefore they are more likely to be turned
into therapeutically useful tools against sexually transmitted HIV
infection.8
Experimental
Langerin and DC-SIGN ECD expression and purification
Langerin ECD constructs (comprising residue 68–328) have been
overexpressed using a pET30b derived vector in BL21(DE3) as
described previously.27 The protein was expressed as inclusion
body, refolded and purified to homogeneity in a functional form
as already described.22 DC-SIGN ECD protein (residue 66–404)
has been overexpressed and purified as described previously.5a
Surface plasmon resonance analysis
All experiments were performed on a Biacore 3000 using func-
tionalized CM4 sensor chips and the corresponding reagents
from Biacore. Two flow cells were activated as previously
described.28 Flow cell one was then blocked with 30 mL of
1 M ethanolamine and used as a control surface. The sec-
ond one was treated with BSA-Mana1-3[Mana1-6]Man (Man-
BSA, Dextra) (60 mg mL-1) in 10 mM acetate buffer, pH 4.
Remaining activated groups were blocked with 30 mL of 1 M
ethanolamine. The final density immobilized on the surface of
the second flow cell was 2000 RU. The Man-BSA used to func-
tionalize CM4 chip harbours 12 glycosylation sites according to
manufacturer.
Two types of SPR tests were set up for the evaluation of
glycomimic compounds. The single point inhibition assay was
used for fast screening of compound selectivity. Here, either DC-
SIGN or Langerin at concentration of 20 mMwere incubated with
corresponding compounds (300 mMfinal concentration) and 20 ml
of the samples were co-injected over Man-BSA surface. The lectin
steady state binding responses were extracted from the sensor-
grams and compared with the responses of compound-free lectin
injections and converted to inhibition percent values. In the case of
Langerin inhibition assay, even with parallel functionalization of
the reference surfacewith non-glycosylated BSA, some interaction
of Langerin with the dextran matrix still remains. Indeed, the
dextran/Man-BSA surface has been considered as a combined
ligandofLangerinECD(see Supplementary Information formore
details).
The second type of SPR test was used to estimate the
relative compound affinity to the lectins on the basis of their
IC50 values. This was accomplished in the same manner as in
the single point inhibition assay, except that both lectins were
incubated with increasing concentrations (from 0 to 5000 mM)
of the corresponding compounds, the injected sample volumes
were 13 ml, and the resulting binding responses were con-
verted to residual lectin activity values, which were plotted
against concentration values of the compounds. The relative
IC50 values for each compound were determined by fitting
four parameter logistic model (eqn (1)) to the experimental
data.
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where y is the percent activity, x is the corresponding concentra-
tion, bot and top are the lowest and the highest values of percent
activity, respectively.
In both type of experiments 5 ml flow rate was used and the
running buffer was 25 mM Tris-HCl, pH 8, 150 mM NaCl,
4 mMCaCl2, and 0.005% of P20 surfactant. All the samples were
prepared in the running buffer.
The stability of the surface during a campaign was evaluated
by DC-SIGN ECD binding capacity as a function of the number
of cycles. The chip surfaces demonstrated a strong stability with
negligible decrease of the binding capacity of only 0.06% per cycle
(see data in the Supplementary Information).
Modeling
Grid analysis. The properties of the protein surface in the
vicinity of the Ca2+ site were determined using the protein crystal
structure derived from the complex DC-SIGN-LeX (pdb code
1SL512) and the program GRID17 (version 22). In particular
the DRY probe and the WATER probe were used to identify
hydrophilic and lipophilic regions of the binding site. The accom-
panying program GREAT was used to check the crystal structure
file and to prepare the file of coordinates in standard PDB format,
which is used as an input for the program GRIN. This program,
which prepares the input for the main program GRID, was used
to automatically assign atom types and charges for every atom
of the protein, using provided standard parameters. Calculations
of the interaction energy between the probe and each atom of the
proteinwere performed on a box (36.6 A˚ ¥ 23.0 A˚ ¥ 16.6 A˚ per side)
centered on the protein, with a grid spacing of 0.2 A˚ (NPLA = 5)
and its valuewas evaluated at each grid point. A dielectric constant
of 80 was used to simulate a bulk aqueous phase, while a dielectric
constant of 4 was assigned to the interior of the protein.
The output, which consists of an array of interaction energies,
can be visualized as contour surfaces at appropriate energy
levels together with the protein structure. Contours at negative
energy levels delineate regions of attraction between probe and
protein, whereas positive energy levels define the surface of the
protein. Visual inspection of the contour surfaces superimposed
on the active site of DC-SIGN enabled the identification of the
most favored hydrophilic and lipophilic regions, facilitating the
interpretation of protein–ligand interaction.Moreover interaction
energy values between the WATER probe and the protein were
used to identify the important structural water molecules out of
all the crystallized water molecules found in the X-ray structure.
An arbitrary cut-off of -10.42 kcal mol-1 (the most negative
energy value was -14.97 kcal mol-1) was chosen to detect the most
favorable hot spots for a water molecule. This cut off allowed us to
identify two important structural water molecules, corresponding
to W13 and W36 in the crystal structure of DC-SIGN-LeX
complex (1SL5). The DC-SIGN crystal structure including these
twowatermolecules was subsequently used for additional docking
runs.
Docking calculations. Docking calculations were performed
using the program GLIDE 4.5.20 The initial setup for the
receptor preparation before docking runs was performed using
Schro¨dinger’s ‘Protein Preparation Wizard’, starting from the
X-ray crystal structure of the DC-SIGN-LeX complex. All crys-
tallographic water molecules, except for W13 and W36, were
deleted, bond orders assigned and hydrogen atoms added. The
assignments of protonation states for basic and acidic residues
were based on the optimization of hydrogen bonding patterns.
The final minimization of the complex was not performed with
the Preparation Wizard default, but the complex was minimized
(500 steps, Truncated Newton Conjugate Gradient method) in
implicit water (GB/SA21 model) using MacroModel29 with the
AMBER* force field (dielectric constant 1, cut off extended,
convergence on gradient with threshold of 0.05). The oxygen
atoms of W13 and W36 as well as the Ca2+ ion were an-
chored to the original position through a harmonic potential
during minimization. At the end of the minimization, the root-
mean-square deviation (RMSD) of all heavy atoms was within
0.34 A˚ of the crystallographic positions. Docking calculations
were performed in Standard Precision mode with standard
OPLS-AA(2001)30 force field; non-planar conformations of amide
bonds were penalized, Van der Waals radii were scaled by 0.80
and the partial charge cut off was fixed to 0.15. The shape
and properties of the binding site were mapped onto grids with
dimensions of 36 A˚ (enclosing box) and 14 A˚ (ligand diameter
midpoint box), centered on the ligand in the X-ray structure of
the DC-SIGN-LeX complex. Docking was constrained in the Ca2+
binding site by specifying a reference core corresponding to the
C1–C6 carbon andO3–O4–O5 oxygen atoms of the fucose residue
of the reference ligand in the X-ray structure of theDC-SIGN-LeX
complex: ligands that feature the same coremoiety as the reference
ligand are subject to the constraint. The RMSD tolerance for the
position of the core was set to 3.5 A˚. This parameter enforces the
fucosemoiety to be locatedwithin 3.5 A˚ of the fucose residue in the
reference ligand: ligand poses that do notmatch this constraint are
screened out. These constraints allow coordination of the Ca2+ ion
by the hydroxy groups OH-2 and OH-3 of fucose, as observed in
several crystal structure of C-type lectins complexed with fucose-
containing ligands. The RMSD tolerance of 3.5 A˚ was selected
to allow docking poses to explore both possible binding modes
of the vicinal diol. Indeed, crystallographic and NMR data on
DC-SIGN show that the monosaccharide moiety of ligands can
coordinate the Ca2+ ion with the vicinal hydroxyl groups in two
possible orientations, differing by a 180◦ rotation. The quality of
this docking protocol was validated by re-docking the LeX ligand
in the DC-SIGN-LeX complex, which yielded a ligand pose that
could be superimposed with crystalline LeX with RMSD of 1.71 A˚
(0.31 A˚ for the fucose residue).
Synthesis
Solvents were dried by standard procedures: dichloromethane,
methanol, N,N-diisopropylethylamine and triethylamine were
dried over calcium hydride, chloroform and pyridine were dried
over activated molecular sieves. Reactions requiring anhydrous
conditions were performed under nitrogen. 1H, 13C and 31P-
NMR spectra were recorded at 400 MHz on a Bruker AVANCE-
400 instrument. Chemical shifts (d) for 1H and 13C spectra are
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expressed in ppm relative to internal Me4Si as standard. Signals
are abbreviated as s, singlet; bs, broad singlet; d, doublet; t, triplet;
q, quartet; m,multiplet.Mass spectra were obtained with a Bruker
ion-trap Esquire 3000 apparatus (ESI ionization) or an Autospec
Fission Instrument (FAB ionization). HRMS (FT-ICR, ESI) were
obtained with an Apex II instrument. Thin layer chromatography
(TLC) was carried out with pre-coatedMerck F254 silica gel plates.
Flash chromatography (FC) was carried out with Macherey-
Nagel silica gel 60 (230–400 mesh). The libraries were synthesized
through the common approach shown in Scheme 1.14 All synthetic
schemes and procedures, the synthesis and characterization of new
intermediates, the synthesis and characterization of the full library
of ligands (3, 9, 11 and 12) as well as their 1H- and 13C-NMR
spectra are collected in the Supplementary Information. Below we
report the characterization of compounds 10a–d (from (1R,2S)-
2-aminocyclohexanecarboxylic acid). Compounds 3a and 5 were
previously described.14
N-((1R,2S)-2-Acetamido-cyclohexanecarboxyl)-a-L-fucopyrano-
sylamine (10a)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was used in the general acetylation
method (see Supplementary Information). The product was puri-
fied by flash chromatography on silica gel (AcOEt,Rf 0.29). Yield:
27 mg (82%). Zemplen deprotection and flash chromatography
(85 : 15 CHCl3 :MeOH,Rf 0.18) afforded 10a. Yield: 13 mg (65%).
1H-NMR (400 MHz, CD3OD): d (ppm) = 1.18 (d, 3H, J5-6 =
6.5 Hz, HF6), 1.32–1.50 (m, 2H, HCy4ax and HCy5ax), 1.55 –1.68 (m,
3H, HCy6ax, HC3ax and HC4eq or HC5eq), 1.73–1.78 (m, 1H, HCy4eq or
HCy5eq), 1.83–1.92 (m, 1H, HCy3eq and HC6eq), 1.94 (s, 3H, Ac-Me),
2.71–2.75 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74 (dd, J3-4 =
3.3 Hz, J3-2 = 10.3 Hz, 1H, HF3), 3.79 (q, J5-6 = 6.5 Hz, 1H, HF5),
3.94 (dd, J1-2 = 5.6 Hz, J2-3 = 10.2 Hz, 1H, HF2), 4.18–4.25 (m,
1H, HCy2), 5.51 (d, 1H, J1-2 = 5.6 Hz, HF1). 13C-NMR (100 MHz,
CD3OD): d (ppm) = 17.0 (CF6), 23.0 (Ac-Me), 23.6 (CCy4 or CCy5),
24.2 (CCy4 or CCy5), 26.8 (CCy6), 30.7 (CCy3), 40.3 (CCy1), 46.4 (CCy2),
68.3 (CF2), 68.8 (CF5), 71.8 (CF3), 73.3 (CF4), 78.3 (CF1), 173.1
(NHCO), 177.5 (NHCO). HRMS (FT-ICR, ESI): m/z calcd for
C15H26N2O6: 353.16831 [M + Na]+; found: 353.16838. [a]D -77.5
(c 0.35, EtOH)
N-[(1R,2S)-2-(3-Hydroxybenzamido)cyclohexanecarboxyl]-a-L-
fucopyranosylamine (10b)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was coupled with 3-hydroxybenzoic
acid using the HBTU general procedure (see Supplementary
Information) and the product was purified by flash chromatog-
raphy (6 : 4 AcOEt : petroleum ether, Rf 0.38). Yield: 13 mg
(31%). Zemplen deprotection and flash chromatography (85 : 15
chloroform :methanol, Rf 0.17) afforded 10b. Yield: 8 mg (89%).
1H-NMR(400MHz,CD3OD): d (ppm)= 1.18 (d, 3H, J5-6 = 6.5Hz,
HF6), 1.42–1.55 (m, 2H,HCy4ax andHCy5ax), 1.61–1.76 (m, 4H,HCy6ax,
HCy3ax, HCy4eq and HCy5eq), 1.94–2.02 (m, 1H, HCy6eq), 2.16–2.24 (m,
1H, HCy3eq), 2.86–2.91 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74–
3.80 (m, 2H, HF5 and HF3), 3.91–3.95 (m, 1H, HF2), 4.28–4.33 (m,
1H,HCy2), 5.52–5.54 (m, 1H,HF1) 6.90–6.95 (m, 1H,Ar), 7.18–7.28
(m, 3H, Ar). 13C-NMR (100MHz, CD3OD): d (ppm) = 17.0 (CF6),
23.8 (CCy4 or CCy5), 24.2 (CCy4 or CCy5), 27.8 (CCy6), 30.4 (CCy3), 46.2
(CCy1), 50.2 (CCy2), 68.2 (CF2), 68.8 (CF5), 71.7 (CF3), 73.3 (CF4),
78.4 (CF1), 115.3 (Ar), 119.4 (Ar), 119.7 (Ar), 130.8 (Ar), 137.5
(Cquart.Ar.), 158.9 (Cquart.Ar.), 170.0 (NHCO), 178.0 (NHCO). HRMS
(FT-ICR, ESI): m/z calcd for C20H28N2O7: 431.17887 [M + Na]+;
found: 431.17948. [a]D -53.1 (c 0.25, MeOH)
N-[(1R,2S)-2-(3,5-Dihydroxybenzamido)cyclohexanecarboxyl]-a-
L-fucopyranosylamine (10c)
The crude hydrogenation product of 28 (see Supple-
mentary Information–SI-Scheme 3) was coupled with 3,5-
dihydroxybenzoic acid using the HBTU general procedure (see
Supplementary Information) and the product was purified by
flash chromatography (7 : 3 ethyl acetate : n-hexane,Rf 0.43).Yield:
17 mg (37%). Zemplen deprotection and flash chromatography
(85 : 15 chloroform :methanol,Rf 0.14) afforded 10c. Yield: 10 mg
(91%). 1H-NMR (400 MHz, CD3OD): d (ppm) = 1.19 (d, 3H,
J5-6 = 6.5 Hz, HF6), 1.42–1.55 (m, 2H, HCy4ax and HCy5ax), 1.61–1.73
(m, 4H, HC6ax, HCy3ax, HCy4eq and HCyeq), 1.92–2.02 (m, 1H, HCy6eq),
2.16–2.22 (m, 1H, HCy3eq), 2.85–2.90 (m, 1H, HCy1), 3.64–3.66 (m,
1H, HF4), 3.77 (dd, J3-4 = 3.3 Hz, J2-3 = 10.3 Hz, 1H, HF3), 3.79
(q, J5-6 = 6.5 Hz, 1H, HF5), 3.95 (dd, 1H, J1-2 = 5.6 Hz, J2-3 =
10.3 Hz, HF2), 4.25–4.30 (m, 1H, HCy2), 5.55 (d, 1H, J1-2 = 5.6 Hz,
HF1) 6.39 (bs, 1H, Ar), 6.68 (bs, 2H, Ar). 13C-NMR (100 MHz,
CD3OD): d (ppm) = 17.0 (CF6), 23.8 (CCy4 or CCy5), 24.1 (CCy4 or
CCy5), 27.9 (CCy6), 30.4 (CCy3), 46.2 (CCy1), 50.2 (CCy2), 68.2 (CF2),
68.8 (CF3 or CF5), 71.7 (CF3 or CF5), 73.3 (CF4), 78.4 (CF1), 106.8
(Ar), 106.8 (Ar), 138.1 (Cquart., Ar.), 160.0 (Cquart., Ar.), 170.0
(NHCO), 178.0 (NHCO). HRMS (FT-ICR, ESI): m/z calcd for
C20H28N2O8: 447.17379 [M + Na]+; found: 447.17407. [a]D -65.7
(c 0.20, MeOH)
N-[(1R,2S)-2-(3-Pyridinecarboxamido)cyclohexanecarboxyl]-a-
L-fucopyranosylamine (10d)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was coupled with nicotinic acid us-
ing the HBTU general procedure (see Supplementary Infor-
mation) and the product was purified by flash chromatogra-
phy (97 : 3 ethyl acetate : triethyl amine, Rf 0.17). Yield: 19 mg
(50%) Zemplen deprotection and flash chromatography (85 : 15
chloroform :methanol, Rf 0.17) afforded 10d. Yield: 6 mg (43%).
1H-NMR(400MHz,CD3OD): d (ppm)= 1.19 (d, 3H, J5-6 = 6.5Hz,
HF6), 1.43–1.55 (m, 2H,HCy4ax andHCy5ax), 1.67–1.78 (m, 4H,HCy6ax,
HCy3ax, HCy4eq and HC5eq), 1.94–2.04 (m, 1H, HCy3eq), 2.14–2.21 (m,
1H, HCy6eq), 2.88–2.92 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74
(dd, J3-4 = 3.4 Hz, J2-3 = 10.3 Hz, 1H, HF3), 3.78 (q, J5-6 = 6.5 Hz,
1H,HF5), 3.93 (dd, 1H, J1-2 = 5.6Hz, J2-3 = 10.2Hz, HF2), 4.37–4.42
(m, 1H, HCy2), 5.53 (d, 1H, J1-2 = 5.6 Hz, HF1), 7.50–7.53 (m, 1H,
HAr5), 8.20 (d, 1H, JAr5-JAr6 = 8.0 Hz, HAr6), 8.65 (d, 1H, JAr4-JAr5 =
4.5 Hz, HAr4), 8.92 (s, 1H, HAr2). 13C-NMR (100 MHz, CD3OD):
d (ppm) = 17.0 (CF6), 23.7 (CCy4 and CCy5), 24.1 (CCy3), 27.4 (CCy6),
30.4 (CCy1), 50.4 (CCy2), 68.2 (CF2), 68.8 (CF5), 71.7 (CF3), 73.3 (CF4),
78.3 (CF1), 125.1 (CAr5), 132.7 (Cquart.Ar), 137.4 (CAr6), 149.5 (CAr2),
152.5 (CAr4), 167.95 (NHCO), 177.76 (NHCO). HRMS (FT-ICR,
ESI): m/z calcd for C19H27N3O6: 416.17921 [M + Na]+; found:
416.17934. [a]D -81.9 (c 0.15, MeOH)
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 5778–5786 | 5785
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Additional studies. After the latter studies were published, a couple of modifications were intro-
duced to compound 10b yielding compounds 10b-azide1 and 10b-azide2, shown in figure 9.13A
(an ethylazide linker was introduced in order to make it possible to tether these ligands on poly-
valent scaﬀolds). They were also tested in SPR competition assay for DC-SIGN inhibition and the
results are shown in figure 9.13B.
Figure 9.13.: The structures and activities of compound 10b and its derivatives.
A, The structures of the three compounds. B, The IC50 values of DC-SIGN inhibition by the corresponding
compounds; the error bars show standard deviations (for 10b and 10b-azide1 values are as in table 9.1, for 10b-
azide2 values are from 3 measurements).
The addition of a meta hydroxyl and the azide linker to yield compound 10b-azide1 appar-
ently had no significant eﬀect on the activity of the compound as compared to 10b. However, the
swapping positions of hydroxyl and the azide linker groups in 10b-azide1 leading to compound
10b-azide2 resulted in a dramatic decrease of the activity of this compound, probably suggesting
the steric hindrances imposed to the binding by the following swap.
Compound 10b-azide1 was selected for further development to tether it on a multivalent
scaﬀold.
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9.1.4. Development of mannose-based glycomimetic compounds
Two mannose-based glycomimetic compounds, psDi [143] and psTri [49] (fig. 9.14), were designed
and evaluated as DC-SIGN inhibitors before my PhD started, and psTri appeared to have an order
of magnitude better inhibitory potency than psDi [49]. Hence it was chosen to generate the first
multivalent (tetravalent dendron) glycomimetic compound and tested in cell-based HIV infection
inhibition assay [49].
Figure 9.14.: The structures of previously designed mannose-based glycomimics psDi and psTri.
The results of these cellular studies were promising, thus psTri dendron later was also as-
sessed for the potency to inhibit HIV infection in cervical explants (article n°2), a real-life closer
experimental set-up.
When my PhD started, in addition to psTri, polyvalent form of psDi were also generated,
and one of my very first tasks was the evaluation of these multivalent compounds as DC-SIGN
inhibitors in SPR competition assay. Simultaneously, the same compounds were evaluated by our
collaborators in Spain, Dr. Rafael Delgado team, in a cell-based assay as Ebola virus infection
inhibitors (article n°3).
Although in all of these studies psTri was observed as markedly more potent DC-SIGN inhibitor
than psDi, there was also a discrepancy in the results observed as psTri was the better inhibitor
only in monovalent form, and the potencies of both psDi and psTri were very similar once they
were tethered to multivalent scaﬀolds. Therefore the eﬀorts were invested to study the interaction
with DC-SIGN of these both compounds in more detail. After solving the structures of DC-SIGN
in complex with psDi and psTri (papers n°4 and n°5), even more discrepancy arose: despite rather
diﬀerent activities of these two compounds, they had virtually the same binding modes within DC-
SIGN CRD. In addition, the NMR studies of psDi interaction with DC-SIGN indicated a unique
binding mode for this compound, which was in a good agreement with X-ray data, while NMR
data for psTri showed complex interaction properties (results not shown). Thermodynamic and
hydrodynamic characterization of the interaction of both compounds with the whole extracellular
domain of DC-SIGN was also performed. These studies revealed that the higher potency of psTri
was an artifact resulting from a competition assay set-up: soluble DC-SIGN tetramers are used in
this assay and psTri molecule showed a unique capability to bridge the protein tetramers.
These studies disapproved psTri as the best lead compound. On the other hand, they revealed
that synthetically simpler psDi had all the desirable qualities of a compound for further development
as a drug candidate: a well-defined unique binding mode to DC-SIGN, favorable selectivity to
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DC-SIGN combined with a good synthetic availability. Hence, further design of mannose-based
glycomimetics went on using psDi as a starting scaﬀold and the structural knowledge of its binding
to DC-SIGN. Two diﬀerent types of psDi-based compound series were synthesized and evaluated
for inhibition and selectivity to DC-SIGN versus langerin. The first series included the aromatic
bis-benzylamide substituents on the cyclohexane ring of psDi in place of methyls (paper n°6). From
this series, one compound, namely 4h, was identified as a new lead compound. The second psDi-
based series (NV -type, sub-subsection 9.1.4.6 on page 290) had diﬀerent substituents at position 6
of non-reducing mannose of psDi.
9.1.4.1. Evaluation of tetravalent psTri to inhibit HIV infection in human cervicovaginal explants, and
estimation of monovalent psTri selectivity to DC-SIGN versus langerin
The previous encouraging results of tetravalent psTri dendron (fig. 9.15 on page 191) tested in cell-
based HIV trans infection assay [49] prompted to evaluate this compound in a more biologically
relevant assay. The following article by Berzi et al. presents the characterization of this compound
as the inhibitor of HIV infection of cervicovaginal explants. The dendron proved to be non-toxic
at used concentrations, it was capable to significantly reduce R5-tropic HIV infection and had a
moderate activity against X4-tropic virus. It also induced the production of anti-HIV activity
possessing β-chemokines.
Because Langerhans cells are present in the endothelial layer of the cervix, it was interesting to
assess the selectivity of psTri to DC-SIGN versus langerin. Therefore SPR competition assay with
soluble DC-SIGN and langerin was performed and showed that monovalent psTri, as compared to
D-mannose, had a desirable increased selectivity to DC-SIGN.
The main outcome of these studies:
✧ The strategy of HIV infection inhibition using glycomimetics works not only in a cell-based
assay but also in a more relevant ex vivo assay.
✧ psTri had better selectivity to DC-SIGN than langerin (sel.g.mannose→psTri = 5.4 ± 0.9, not
presented in the article).
Contributions:
In the article presented dendrons and dendrimers were synthesized by the group of Dr. J.
Rojo. The assays of HIV infection of cervicovaginal explants were carried out by the group of Pr.
Mario Clerici.
My contribution to this study:
I have conducted the SPR assay and analyzed the data.
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Paper no2: A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular
and cervical explant models
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A glycomimetic compound inhibits DC-SIGN-
mediated HIV infection in cellular
and cervical explant models
Angela Berzia, Jose´ J. Reinad, Roberta Ottriad, Ieva Sutkeviciutee,f,g,
Patrizio Antonazzoi, Macarena Sanchez-Navarroj, Eric Chabrole,f,g,
Mara Biasina, Daria Trabattonia, Irene Cetini, Javier Rojoj,
Franck Fieschie,f,g,h, Anna Bernardid,k and Mario Clericib,c
Objective: Dendritic cell-specific intercellular adhesion molecule (ICAM)-3 grabbing
nonintegrin (DC-SIGN) participates in the initial stages of sexually transmitted HIV-1
infection by recognizing highly mannosylated structures presented in multiple copies
on HIV-1 gp120 and promoting virus dissemination. Inhibition of HIV interaction with
DC-SIGN thus represents a potential therapeutic approach for viral entry inhibition at
the mucosal level.
Design: Herein we evaluate the efficacy in inhibiting HIV-1 infection and the potential
toxicity of a multimeric glycomimetic DC-SIGN ligand (Dendron 12).
Methods: The ability of Dendron 12 to block HIV-1 infection was assessed in cellular
and human cervical explant models. Selectivity of Dendron 12 towards DC-SIGN and
langerin was evaluated by surface plasmon resonance studies. b chemokine production
following stimulation with Dendron 12 was also analyzed. Toxicity of the compound
was evaluated in cellular and tissue models.
Results: Dendron 12 averted HIV-1 trans infection of CD4þ T lymphocytes in presence
of elevated viral loads and prevented HIV-1 infection of human cervical tissues, under
conditions mimicking compromised epithelial integrity, by multiple clades of R5 and
X4 tropic viruses. Treatment with Dendron 12 did not interfere with the activity of
langerin and also significantly elicited the production of the b chemokines MIP-1a,
MIP-1b and RANTES.
Conclusion: Dendron 12 thus inhibits HIV-1 infection by competition with binding of
HIV to DC-SIGN and stimulation of b-chemokine production. Dendron 12 represents a
promising lead compound for the development of anti-HIV topical microbicides.
! 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2012, 26:127–137
Keywords: cervical explants, DC-SIGN, glycomimetic drugs, HIV, topical
microbicides
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Introduction
HIV remains one of the leading causes of mortality and
morbidity [1]. As the vast majority of HIV-1 infections
occur via sexual transmission through mucosal surfaces,
the development of vaginal and rectal topical micro-
bicides represents a promising approach to prevent
sexually transmitted HIV-1 infection.
Dendritic cell-specific intercellular adhesion molecule-3
grabbing nonintegrin (DC-SIGN) is involved in the
initial step of HIV-1 sexually transmitted infection
and it may be considered a promising therapeutic target
[2,3].
Myeloid immature dendritic cells located in mucosal
tissue of vagina, cervix and rectum express DC-SIGN and
are among the first cells to encounter sexually transmitted
HIV [4–6]. UponHIV-1 binding to DC-SIGN, the virus
escapes (at least partially) degradation into lysosomes.
Rather, it is internalized into endosomes and multi-
vescicolar bodies, in which it is protected from
degradation and retained in a high infective state [7–
9]. Dendritic cells transmit the virus in trans to adjacent
CD4þ T lymphocytes in genital mucosae or, after
migration to lymphoid tissue, to CD4þ T lymphocytes
resident in lymphoid tissue, promoting HIV-1 dissemina-
tion [10,11]. DC-SIGN, facilitating HIV-1 interaction
with CD4 and co-receptors, also enhances dendritic cell
infection in cis, that results in long-term transmission of
HIV [12,13].
In addition, binding of HIV-1 to DC-SIGN activates
signaling pathways that modulate Toll-like receptor
signaling, inducing immunosuppressive responses
and triggering HIV replication and transmission [14–
17].
DC-SIGN specifically recognizes the high mannose
glycan (Man9), presented in multiple copies on HIV-1
gp120 [8,18]. Fragments of Man9 terminated by a di-
mannoside or a tri-mannoside bind to DC-SIGN almost
as efficiently as the entire Man9 [19]. Chemically
synthesized analogs of (Man)9 terminal di-saccharides
and tri-saccharides are more resistant to hydrolysis by
glycosydases than the corresponding natural oligosac-
charides and interact efficiently with DC-SIGN [20].
These analogs can be linked to tetravalent (dendrons)
scaffolds to obtain compounds endowed with stronger
binding affinities to DC-SIGN [21,22]. Such compounds
can compete with binding of HIV gp120 to DC-SIGN
and are suitable for the development of new anti-
HIV microbicides.
We recently demonstrated that a tetravalent dendron
containing four copies of a linear pseudo-mannotrioside
(Dendron 12) was able to inhibit HIV-1 trans infection of
CD4þ T lymphocytes [23].
Experimental models based on infection with HIV of
explants taken from human uterine cervix, albeit with
some limitations, allow a better approximation of the
conditions in vivo compared to cellular models [24–27].
Thus, in this study a cervical explant model was exploited
to assess the efficacy in inhibiting HIV-1 infection and the
toxicity of Dendron 12, with the purpose of evaluating if
the compound is a suitable candidate for the development
as topical microbicide.
Material and methods
Cell culture
B-THP1 and B-THP1/DC-SIGN cells (contributed by
Drs Li Wu and Vinet N. KevalRamani) were cultured as
described [23].
Virus
The following HIV-1 strains were used: BaL (contributed
by Drs. S. Gartner, M. Popovic and R. Gallo; DU174
(Source: Dr L Morris); the R5 and X4 tropic primary
isolates 8 g and DPMVF (provided by Professor Stefano
Aquaro).
Inhibition of HIV infection in trans
Human CD4þ T lymphocytes were purified from
peripheral blood of volunteer healthy donors following
written consent, and activated as described [23]. Dendron
12, synthesized as described [23], was diluted to
desired concentration into culture medium [Roswell
Park Memorial Institute (RPMI) 160 with 20% fetal
bovine serum (FBS), penicillin and streptomycin and
L-glutamine, all from Euroclone, Siziano, Italy]. B-
THP1/DC-SIGN or B-THP1 cells (106 cells/ml) were
preincubated with Dendron 12 (250mmol/l), or culture
medium alone for 30min prior to exposure to BaL (virus
titer ranging from 5 TCID50 to 80 TCID50), in the
continued presence of the inhibitor 3 h at 378C. After
extensive washing, B-THP1/DC-SIGN cells were
co-cultured with activated human CD4þ T cells as
previously described [23].
Human cervical explants infection
Cervical tissue was obtained, following written informed
consent, from premenopausal women, HIV, hepatitis B
virus (HBV) and hepatitis C virus (HCV) seronegative
and without current genital infection, undergoing
therapeutic hysterectomy at Unit of Obstetrics and
Gynaecology of Sacco Hospital (Milan, Italy). The study
was approved by the local ethic committee and conducted
in compliance with international guidelines and local
laws. Endocervical 3mm" 3mm explant biopsies com-
prised both epithelium and stromal tissue.
Within 1 h after obtaining tissues the explants
were extensively washed. Then explants were either
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immediately treated with the Dendron 12 and infected
with R5 tropic strains or were prestimulated for 2 days
in presence of IL-2 (R&D systems, Minneapolis,
Minnesota, USA) and phytohaemagglutinin (PHA)
(Sigma–Aldrich, Saint Louis, Missouri, USA) prior to
X4 tropic DPMVF exposure.
Explants were pretreated 30min at 378C with different
concentrations of Dendron 12. Afterwards explants were
exposed to HIV-1 BaL, DU174 (both 2.6" 104
TCID50), 8 g or DPMVF (both 10
4 TCID50) in the
continued presence of the compound 3 h at 378C.
Subsequently explants were washed with RPMI.
Unstimulated explants were cultured in RPMI medium
supplemented with 20% FBS, penicillin and streptomy-
cin, L-glutamine (Euroclone) and gentamycin (Sigma–
Aldrich) at 378C and 5% CO2. Stimulated explants were
cultured under the same conditions in presence of IL-2.
Supernatants were collected 3 and 7 days post infection.
p24 ELISA
p24 concentration in the supernatants was assayed by
Alliance HIV-1 p24 Antigen kit (Perkin Elmer, Waltham,
Massachusetts, USA). Plates were read using the IMark
microplate reader equipped with Microplate Manager
6 software (Biorad, Segrate, Italy).
Toxicity on peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC), purified
from peripheral blood of healthy donors as described
[23], were incubated with different concentrations of
Dendron 12 for 3 or 7 days. The apoptosis was monitored
evaluating the percentage of dead cells by staining with
7-AAD (Beckman Coulter, Fullerton, California, USA).
Flow cytometric analyses were performed using a
CYTOMICS FC-500 flow cytometer interfaced with
CXP21 software (Beckman Coulter).
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay
Toxicity of Dendron 12 was determined by a 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-
based assay (Sigma–Aldrich). Viable explants reduceMTT
to formazan crystals. Explants were cultured with
increasing concentration of Dendron 12 diluted in
medium culture for 3 and 7 days. The 50% of medium
culture (containing the different concentration of
Dendron 12) was changed at day 3. After culturing,
explants were washed and incubated in medium RPMI
without phenol red and 10% FBS and MTT. Formazan
was dissolved by MTT solubilization solution and
formazan absorbance was measured at 595 nm.
Differentiation and treatment of monocyte-
derived dendritic cells
CD14þ monocytes were separated from PBMCs
using the CD14þmicrobeads (Miltenyi Biotech, Bergisch
Gladbach,Germany) followingmanufacturer’s instruction.
Monocytes were differentiated into iDCs by culturing
them in presence of IL-4 (20 ng/ml) and granulocyte-
macrophage colony-stimulating factor (20 ng/ml) (R&D
Systems) for 6 days. DC-SIGN expression was checked by
staining with anti human DC-SIGN-PE monoclonal
antibody (clone AZND1, Beckman Coulter) and flow
cytometric analysis. Monocyte-derived dendritic cells
(MDDCs) were treated with Dendron 12. Supernatants
were harvested and RNA extracted from cells after 3,
24 and 72h. b chemokine concentration in culture
supernatants was evaluated using DuoSet kits (R&D
Systems).
RNA extraction and real-time PCR
RNA was extracted using the acid guanidium thiocya-
nate–phenol–chloroform method and purified from
genomic DNA with RNase-free DNase (RQ1 DNase,
Promega, Madison, Wisconsin, USA). RNAwas reverse-
transcribed using random examer primers and M-MLV
reverse transcriptase (Clontech, Palo Alto, California,
USA). cDNA quantification for macrophage inflamma-
tory protein (MIP)-1a, MIP-1b, RANTES (regulated
upon activation, normal T-cell expressed, and secre-
ted) and glycerAldehyde 3-phosphate dehydrogenase
(GAPDH) was performed by real-time PCR (DNA
Engine Opticon 2; MJ Research, Ramsey, Minnesota,
USA). Reactions were performed using a SYBR
Green PCR mix (Finnzymes, Espoo, Finland). Results
were expressed as DDCt and presented as ratios between
the target gene and the GAPDH housekeeping
mRNA.
Surface plasmon resonance analysis
Extracellular domain (ECD) of langerin (residue 68–328)
and DC-SIGN (residue 66–404) was overexpressed and
purified as described [28,29]. Surface plasmon resonance
(SPR) experiments were performed on a Biacore 3000
using functionalized CM4 sensor chips and the corre-
sponding reagents from Biacore. Two flow cells were
activated as described [30]. Flow cell one was blocked
with ethanolamine and used as a control surface. The
second one was treated with BSA-Mana1–3[Mana1–6]
Man (Man-BSA, Dextra) (60 mg/ml) in 10mmol/l
acetate buffer, pH 4. Remaining activated groups were
blocked with ethanolamine. The final density immobil-
ized on the surface of the second flow cell was 5200 RU.
The Man-BSA used to functionalize CM4 chip harbors
12 glycosylation sites. The affinities for DC-SIGN
ECD and langerin ECD of pseudo-mannotrioside and
D-mannose were estimated by an inhibition assay, as
described [22,31]. Each lectin was injected onto theMan-
BSA surface, at 20 mmol/l alone or in presence of an
increasing concentration of compounds. Injections were
performed at 5 ml/min using 25 mM Tris-HCl, pH 8,
150 mM NaCl, 4 mmol/l CaCl2, and 0.005% of P20
surfactant as running buffer. The surface was regenerated
by 1’ injection of 50 mmol/l EDTA, pH 8. The IC50
values were determined as described [22,31].
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Results
Dendron 12 inhibits trans infection in presence
of HIV-1 elevated viral load
We firstly examined whether the Dendron 12 was able to
inhibit the trans infection in the presence of elevated viral
load. B-THP1/DC-SIGN cells were used as model to
mimic HIV transmission to CD4þ T cells, as previously
described [6,23,32]. B-THP1/DC-SIGN cells were
preincubated 30min in the presence or in absence of
Dendron 12 and then exposed to different inoculums of
HIV-1 Bal. Then, B-THP1/DC-SIGN cells were
washed and co-cultured with activated CD4þ T cells.
At lower viral concentration inhibition of BaL trans-
mission to CD4þ T cells was almost complete. Even at
higher viral load (40 and 80 TCID50) the Dendron 12was
able to counteract the transmission of the virus to CD4þ
T lymphocytes (more than 92% of inhibition) (Fig. 1a).
Selectivity towards DC-SIGN
Both langerin and DC-SIGN recognize Man9 on gp120,
but have distinct specificities towards complex
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Fig. 1. Evaluation of Dendron 12 ability to inhibit HIV-1 Bal trans infection in presence of increasing amounts of the virus (a) and
selectivity to DC-SIGN (b,c). (a) After pretreatment with Dendron 12 (250mm) or medium culture, B-THP-1/DC-SIGN cells were
pulsed with BaL for 3 h. After washing cells were co-cultured 3 days with CD4þ T lymphocytes from healthy donors. Levels of
infection were quantified by measuring p24 in the supernatants of co-cultures by ELISA. Data were obtained from three different
healthy donors. Each donor was tested in duplicate. Values are mean# SD. (b, c) SPR experiment results of DC-SIGN ECD and
langerin ECD binding to Man-BSA/dextran surface inhibition by pseudo-mannotrioside (psTri) and D-mannose. (b) Inhibition
curves, and (c) lectin selectivity histograms.
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oligosaccharides [33–36]. Specificity of pseudo-manno-
trioside ligand for langerin and DC-SIGN was tested by
competition experiments using SPR, as previously
described [37]. A CM4 sensor chip was functionalized
with BSA-mannotriose and a fixed amount of the
extracellular domain of DC-SIGN and langerin was
injected over the surface in the presence or absence of
pseudo-mannotrioside or mannose (control). From the
inhibition curves (Fig. 1b), an IC50 of the two ligands
towards each lectins was evaluated (Fig. 1c). A limited
difference in favor of DC-SIGN was observed for
mannose. On the contrary, pseudo-mannotrioside is 20
times more potent toward DC-SIGN than against
langerin. Moreover, pseudo-mannotrioside is 14 times
more potent than D-mannose towards DC-SIGN.
Indeed, the use of pseudo-mannotrioside allows real
improvement in affinity and in selectivity.
Inhibition of HIV-1 infection of human cervical
tissue by Dendron 12
Endocervical tissue was obtained from premenopausal
women, HIV, HBV and HCV seronegative, undergoing
planned therapeutic hysterectomy. Explants were exposed
to HIV-1 in a nonpolarized manner, analogous to
condition of compromised epithelium in vivo. As the
laboratory adapted R5 strain HIV-1 BaL is able to infect
resting tissue [25], explants were not activated to mimic
physiological conditions.
Explants were pretreated 30min in absence or in presence
of increasing concentration of Dendron 12 and then were
exposed to BaL in the continued presence of compound.
After washing to remove unbound Dendron 12 and virus,
explants were maintained in culture up to 7 days. Data
represent p24 levels and are presented as the mean of five
independent experiments, using explants from separate
donors. Dendron 12 inhibited cervical explants BaL
infection in dose-dependent manner (Fig. 2). At the
higher concentration tested, Dendron 12 reduced the
infection by about 80%, at 3 and 7 days post infection.
The ability of Dendron 12 to avert explant infection
mediated by primary HIV-1 isolates was also verified. R5
tropic isolate 8 g was able to infect unstimulated tissue, but
X4 tropic isolate DPMVF needed preactivation to induce
infection (not shown). Explants unstimulated or pre-
activated 2 days with IL-2 and PHAwere pretreated with
increasing concentration of Dendron 12 and infected,
respectively, with 8 g or DPMVF, as described before.
Infection inhibition was dose-dependent. At the con-
centration of 1mmol/l, infection by both isolates was
reduced by more than 85%. At 0.05mmol/l Dendron 12
decreases by 56% (day 3) and by 40% (day 7) the infection
mediated by 8 g (Fig. 3a and b), but the inhibitory effect
against DPMVF was largely lost (Fig. 3c and d).
Furthermore we evaluated the capability of Dendron
12 to block explant infection by Clade C R5 tropic
strain DU174. Unstimulated explants were pretreated
with the compound, exposed to DU174 and cultured as
described. Dendron 12 reduced DU174 infection in
dose-dependent manner and by about 90% at 1mM
(Fig. 3e and f).
Induction of b1 chemokines production by
Dendron 12
We wondered if, in addition to competitive inhibition of
DC-SIGN, other mechanisms account for the antiviral
effect of the compound 12. Sowe investigated if Dendron
12 stimulates the production of factors interfering with
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Fig. 2. Inhibition of endocervical tissue infection mediated by HIV-1 Bal. After a 30min pretreatment with the Dendron 12 or
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Fig. 3. Inhibition of endocervical infection induced by HIV-1 primary isolates (8 g and DPMVF) and HIV-1clade C DU174.
(a, b, e, f) Unstimulated explants were pretreated 30’ with Dendron 12 or medium culture and challenged with 8 g or DU174.
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HIV infection. Due to difficulty of isolating sufficient
amounts of primary mucosal dendritic cells, immature
monocyte-derived dendritic cells (iMDDCs) that share
with mucosal dendritic cells similar features and DC-
SIGN expression, were used as a model [38]. iMDDCs
were treated with Dendron 12 for 3, 24 and 72 h.
Expression and production of b chemokines MIP-1a,
MIP-1b, and RANTES following stimulation were
analyzed by quantitative real-time PCR and ELISA. The
treatment increased expression level of mRNA specific
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for MIP-1a, MIP-1b and RANTES (Fig. 4a-c) after 3 h.
Also MIP-1a, MIP-1b and RANTES production
increased after 24 and 72 h of stimulation (Fig. 4d-f).
Evaluation of Dendron 12 toxicity
Cytotoxicity against PBMCs was evaluated by labeling
with 7-amino-actinomycin D (7-AAD) that identifies
nonviable cells after Dendron 12 treatment. Compound
exposure for 3 and 7 days did not alter significantly the
viability of PBMCs (Fig. 5a and b).
To assess toxicity of Dendron 12 towards cervical tissue,
effect of nonpolarized exposure of the compound on
explants viability was monitored (Fig. 5c). After 3 and
7 days treatment in absence or in presence of different
concentration of Dendron 12, viability was evaluated by a
MTT-based assay. Viability of the compound treated
explants was compared to viability of untreated control.
No significant difference between control and treated
explants was observed up to a concentration of 1mM (the
higher concentration tested in assessment of compound
efficacy against HIV-1 infection).
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Fig. 5. Toxicity of compound 12. (a, b) Percentage of 7-AAD-positive (nonviable) PBMCs after 3 or 7 days of incubation with
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Discussion
Three decades after HIV discovery HIV-AIDS pandemic
continues and millions of people are infected every year.
Thus, the development of effective, nontoxic and low-
cost topical microbicides represents a valid alternative
approach to prevent the sexual transmission of HIV [3].
However, so far almost all compounds failed to prevent
HIV transmission in efficacy trials. A recent exception
was a vaginal gel formulation of tenofovir that reduced
HIV infection by 50% [39].
Tenofovir and other topical microbicides can prevent
localized infection of target cells in genital mucosae.
However, dendritic cells DC-SIGNþ internalize and
transport HIV to secondary lymphoid organs, rendering
the virus inaccessible to inhibitory effect of the
microbicides. Therefore inhibition of DC-SIGN is
essential to block HIV-1 uptake and dissemination from
migratory dendritic cells.
We have previously reported that the tetravalent Dendron
12 was able to block almost completely the HIV-1 trans
infection of CD4þ T cells at micromolar range [23]. This
compound exerts its activity by competitive inhibition of
HIV-1 gp120 binding to DC-SIGN. In our initial
experiments we demonstrated that Dendron 12 (at the
same concentration previously assayed) even in presence
of higher viral loads retains its ability to inhibit HIV-1
trans infection. This potent inhibitory activity is due both
to elevate affinity for DC-SIGN of Dendron 12 pseudo-
trisaccharide units and to high avidity of binding,
guaranteed by the tetravalent presentation on the
compound scaffold.
Different DC-SIGN inhibitors have been described so
far. Dendrons displaying complex oligomannoses in high
density inhibited binding of gp120 to DC-SIGN with
IC50 in nanomolar range [40]. Nevertheless the complex-
ity of the oligosaccharides used limits the possibility
of a therapeutic application. Gold nanoparticles display-
ing mannosyl oligosaccharides are potent inhibitors of
DC-SIGN-mediated HIV-1 trans infection of human
PBMCs [41], but may have toxic effects because of
gold accumulation.
Unlike DC-SIGN, the C-type lectin langerin, expressed
on Langerhans cells, appears to play a protective role
against HIV infection. Langerhans cells are located in the
stratified mucosal epithelia of female and male genital
tissue. Both DC-SIGN and langerin recognize high
mannose glycans on gp120 through their carbohydrate
recognition domain (CRD). Recent data demonstrate
that langerin prevents HIV transmission by Langerhans
cells, at least in the presence of low concentration of the
virus, promoting rapid degradation and clearance of HIV-
1 [32,33]. Using a biosensor with a SPR detection
method we showed that the Dendron 12 is much more
selective for DC-SIGN than for langerin. Considering
the similarity between the CRD of DC-SIGN and
langerin, the fact that the Dendron 12 does not interfere
with langerin function is a remarkable advantage in view
of developing new microbicides.
The efficacy and the safety of the Dendron 12 were
evaluated in a human cervical explant model. Endocervix
is more susceptible to HIV-1, being lined by a single layer
of columnar epithelium, and contains dendritic cell DC-
SIGNþ in the subepithelial region [4,5,24]. Explants were
exposed to HIV-1 to mimic a condition of compromised
epithelium in vivo; condition that highly increases the risk
of HIV infection.
R5-tropic virus strains predominate during HIV-1
transmission in vivo and cause the majority of new
infections [42]. The results obtained showed that
Dendron 12 strongly reduced the infection of cervical
explants by different HIV-1R5 tropic strains, such as BaL,
the primary isolate 8 g and the Clade CDU174. This may
have a great impact, considering that Clade C is the most
abundant subtype in all countries of Southern Africa and
in some countries of eastern Africa and Asia, areas where
the majority of HIV-1-infected people resides [43,44].
Rare cases of HIV-1 infection by X4-tropic strains were
observed in CCR5D32 homozygotes and X4-tropic
strain can infect immune activate human cervical tissue
[25,42]. Dendron 12was able to inhibit DPMVF primary
X4-tropic strain infection at higher concentration
assayed, but this effect was in part lost at lower
concentrations of the compound.
Data obtained suggest that Dendron 12 might have
additional mechanisms of action apart from competitive
inhibition of HIV-1 binding to DC-SIGN. Flow
cytometric studies indicate that treatment with Dendron
12 reduces DC-SIGN expression on B-THP1/DC-
SIGNþ cells [23]. This effect may be due to increased
internalization of the receptor after binding of the
compound to DC-SIGN.
Furthermore, Dendron 12 induced an increase of the
production of b chemokines, such as MIP-1a, MIP-1b
and RANTES, by iMDDCs. These b chemokines,
natural ligands of CCR5, suppress HIV-1 R5 tropic strain
replication, competing with the binding of the virus to
CCR5 or inducing receptor internalization [45–47].
The Dendron 12, enhancing b chemokines production,
could interfere, at least partially, with the direct infection
of CCR5þ CD4þ T lymphocytes and macrophages
located in genital mucosae.
The Dendron 12 does not reduce the vitality of PBMCs
and of explants. However, additional experiments, such as
rabbit vaginal irritation assay [48], would be needed for a
more accurate evaluation of potential toxic effects.
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Vaginal epithelium has limited permeability to particles
greater than 30 nm [2]. However, the diameter of
Dendron 12 is certainly below that threshold, so the
compound could enter and diffuse into intact mucosal
tissue. Furthermore the Dendron 12 scaffold can be easily
modified to improve absorption of the compound,
without decreasing affinity to DC-SIGN.
The tetravalent Dendron 12 prevents HIV trans infection
of CD4þ T lymphocytes at micromolar range, even in
presence of elevated viral load, and displays high solubility
in physiological media, a neglectable toxicity and a long-
lasting effect. Moreover it inhibits in dose-dependent
manner HIV-1 infection of human cervical explants.
These features make the Dendron 12 a good candidate as
a lead compound to develop new microbicide drugs.
However, the Dendron 12 inhibits 80–90% of cervical
explants HIV-1 infection, but cannot block it completely.
To overcome these limitations, the structure of this
compound can be improved in both the scaffold and the
active pseudo-saccharide ligand to develop new ligands of
DC-SIGN more effective and easier to synthesize.
Furthermore, Dendron 12 (or its derivatives) can be
used in combination with other molecules directed
against different HIV targets. In particular multivalent
structures, presenting on the same scaffold multiple copies
of DC-SIGN and HIV co-receptor inhibitors, simul-
taneously blocking different HIV targets, could protect
against different routes of HIV transmission.
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9.1. DEVELOPMENT OF MONOVALENT GLYCOMIMICS
9.1.4.2. Evaluation of psDi and psTri as DC-SIGN antagonists presented in monovalent and
multivalent manner using Ebola infection inhibition and SPR competition assays
The glycodendritic structures based on hyperbranched Boltorn type dendrimers (fig. 9.15) func-
tionalized with D-mannose (BH30sucMan) have been previously explored as DC-SIGN inhibitors
by our group with our collaborators Dr. J. Rojo and Dr. R. Delgado [157, 158]. The following
article by Luczkowiak et al. for the first time addresses these dendritic structures functionalized
with glycomimetic ligands, i.e. psDi and psTri (fig. 9.14) as Ebola infection inhibitors.
Figure 9.15.: The structures of the scaﬀolds of tetravalent dendron and multivalent Boltorn type
dendrimer.
The yellow spheres mark attachment points of psDi or psTri (fig. 9.14 on page 173). The grey sphere represents
Boltorn type 3rd generation dendrimer with the shown structure. The dendrimers with psDi and psTri are further
called G3(pseudodi)32 and G3(pseudotri)32, respectively.
Indeed, such glycodendrimers have an order of magnitude higher potency (IC50 values range
0.02 ￿M – 0.06 ￿M) to inhibit DC-SIGN-mediated Ebola infection than the analogous BH30sucMan
dendrimer (IC50 0.3 ￿M [157]). The tetravalent dendrons with psDi and psTri tethers were also
tested, and as expected, had lower potencies to inhibit DC-SIGN-mediated Ebola infection.
The same compounds were analyzed in SPR competition assay. The absolute IC50 values from
SPR competition assay were 2 orders of magnitude higher than values in Ebola infection inhibition
assay, however, the general pattern of IC50 values for the compounds corresponded in both types of
experiments.
The main outcome of these studies:
✧ The multivalent glycomimetic compounds were tested as the inhibitors of another type pathogen,
the Ebola virus, and proved to be eﬃcient in inhibiting the infection.
✧ psTri showed a discrepancy when comparing results for monovalent psDi and psTri compounds
and the multivalent forms.
Contributions:
In the article presented dendrons and dendrimers were synthesized by the group of Dr. J.
Rojo. The assays of DC-SIGN-mediated Ebola infection in cis and in trans were performed in the
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group of Dr. R. Delgado by a PhD student Joanna Luczkowiak. DC-SIGN used in SPR assay was
produced in our team by Dr. Michel Thépaut.
My contribution to this study:
I have performed all of the described SPR assays, analyzed the data, and participated in the
preparation of the paper manuscript.
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’ INTRODUCTION
Carbohydrates are involved in several biological processes
including cell-diﬀerentiation, migration, tumor progression and
metastasis, inﬂammation, pathogen infection, and so forth.1 Carbo-
hydrates participate in these events through complex and selective
recognition processes triggered by interaction with receptors.
One of the processes that initialize immune response to
pathogen invasion is the interaction of the pathogen surface glycans
with C-type lectin receptors expressed on the antigen-presenting
cells (APCs), such as dendritic cells (DCs). Although usually indi-
vidual carbohydrate unit binding to lectin is weak (KD in millimolar
range), the clustered organization of these receptors as well as high
glycosylation of their ligands create the conditions for more speciﬁc
multivalent interactions, and thus overcome low aﬃnity prob-
lems.2!5 The use of scaﬀolds to prepare carbohydrate multivalent
systems is nowadays a very useful and common approach to develop
tools to understand and intervene in these biological processes
where carbohydrates play a key role.6,7
The lack of design in thesemultivalent systems is partly a result of
the often scarce information about the structural details of the
multivalent presentation of the corresponding receptors at the cell
surface. However, even if these details were known, topological
design of large, multivalent molecules would still not be straightfor-
ward and the valency and 3D structures required to achieve a strong
cluster eﬀect on a given receptor cannot be estimated a priori. These
facts explain the huge number of examples illustrating diﬀerent
strategies to target cellular receptors in a multivalent manner. In this
context, our research is focused on the development of glycoden-
drimers to block a C-type lectin, DC-SIGN, which recognizes
glycoconjugates present on the surfaces of several pathogens includ-
ing viruses (HIV, Ebola, Cytomegalovirus, Dengue, SARS), bacteria
(M. tuberculosis, S. pneumoniae) fungi (C. albicans, A. fumigatus), and
Received: January 21, 2011
Revised: March 31, 2011
ABSTRACT: The development of compounds with strong
aﬃnity for the receptor DC-SIGN is a topic of remarkable
interest due to the role that this lectin plays in several pathogen
infection processes and in the modulation of the immune
response. DC-SIGN recognizes mannosylated and fucosylated
oligosaccharides in a multivalent manner. Therefore, multi-
valent carbohydrate systems are required to interact in an
eﬃcient manner with this receptor and compete with the
natural ligands. We have previously demonstrated that linear
pseudodi- and pseudotrisaccharides are adequate ligands for
DC-SIGN. In this work, we show that multivalent presentations
of these glycomimetics based on polyester dendrons and
dendrimers lead to very potent inhibitors (in the nanomolar
range) of cell infection by Ebola pseudotyped viral particles by blocking DC-SIGN receptor. Furthermore, SPR model experiments
conﬁrm that the described multivalent glycomimetic compounds compete in a very eﬃcient manner with polymannosylated ligands
for binding to DC-SIGN.
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parasites (Leishmania, S. mansoni).8!14 It has been proven that this
lectin plays a key role in the early stages of the infection processes
caused by some of these pathogens. Therefore, DC-SIGN can be
selected as a new therapeutic target for the design of antiviral
drugs.15!18 Previous results from our groups indicate that glyco-
dendrimers based on Boltorn-type structures bearing mannoses
exhibit a strong antiviral activity in a pseudotype Ebola viral particles
infection model both for in cis and in trans infection.19!21 Addi-
tionally, we have demonstrated that carbohydrate mimics such as a
pseudomannobioside present an activity around 1 order of magni-
tude higher than mannose in such infection studies.22,23 These new
glycomimetics are more stable against enzymatic degradation than
the corresponding natural counterparts, and therefore, they are
more adequate compounds to be used in clinical applications.
In this study, we combined the improved binding properties of
these new pseudomannoside ligands with the potency of multi-
valent presentation on Boltorn scaﬀolds. Indeed, nanomolar
inhibition levels have been reached in a pseudotyped Ebola viral
particles infection model. Binding properties between these
compounds and their receptor, DC-SIGN, have been analyzed
at the molecular level using biosensors with surface plasmon
resonance (SPR) detection method. Altogether, this work opens
road to new compounds in antiviral strategy.
’MATERIALS AND METHODS
Reagents were purchased from Sigma-Aldrich, Senn Chemi-
cals, Flucka and were used without puriﬁcation. Solvents were
dried by standard procedures. Reactions requiring anhydrous condi-
tions were performed under nitrogen. Synthetic compounds were
puriﬁed by ﬂash chromatography using medium or ﬁne silica gel or
by Sephadex (LH20, G25). Thin layer chromatography (TLC) was
carried out with precoated Merck F254 silica gel plates. Flash
chromatography (FC) was carried out with Macherey-Nagel silica
gel 60 (230!400mesh). Reaction completionwas observed byTLC
using as development reagents phosphomolibdic acid, 10% sulfuric
acid in methanol or anisaldehyde. 1H and 13C spectra were recorded
at 400 MHz on Bruker Avance DPX 300, DRX 400, and DRX 500
MHz spectrometers. Chemical shifts (δ) for 1H and 13C spectra are
expressed in ppm relative to internal TMS (tetramethylsilane) using
manufacturer indirect referencing method. Signals were abbreviated
as s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; and m,
multiplet. Mass spectra were obtained with a Bruker ion-trap Esquire
3000 or 6000 apparatus (ESI ionization) and Microﬂex apparatus
(MALDI ionization) from Bruker. HRMS (FT-ICR, ESI) were
obtained with an Apex II instrument. Infrared spectra were recorded
with a Bruker Vector 22 FT-IR spectrometer. Elemental analyses
were obtained with a Leco CNHS instrument. All hydrogenation
reactions were carried out under H2 atmosphere at atmospheric
pressure.
Synthesis of Compounds. Compounds G1(Bn)4,
24 G1-
(OH)8,
25 1,26 2,27 3,28 6,29 11,23 13,22 and 14!1523 were prepared
as described previously in the literature.
Synthesis of G2(Bn)8. G1(OH)8 (100 mg, 0.17 mmol) and
DMAP (70 mg) were dissolved in dry pyridine (1 mL) and then
dilutedwithCH2Cl2 (2mL). Anhydride 1 (812mg, 2.04mmol) was
added and the reaction mixture was stirred at room temperature for
15 h. Then, the excess of anhydride 1 was quenched by stirring the
reaction mixture with 1 mL of pyridine/H2O (1:1) solution over-
night. The organic phase was diluted with CH2Cl2 (100 mL), and
washed with NaHSO4 1 M (2 " 40 mL), Na2CO3 (10%) (2 "
40 mL), and NaCl sat. (40 mL). The organic phase was dried using
MgSO4 anh., and the solvent was evaporated under vacuum. The
residue was recrystallized from CH2Cl2/hexane to give G2(Bn)8
(370 mg, 97%) as white crystals. 1H NMR (300 MHz, CDCl3): δ
(ppm) 7.40!7.38 (m, 16 H, HAr), 7.32!7.26 (m, 30H, HAr), 5.36
(s, 8H, 8" CHBn), 4.53 (d, 16H, J = 11.7 Hz, CH2G2), 4.36 (d, 8H,
J = 11.4 Hz, CH2G1), 4.29 (d, 8H, J = 11.4 Hz, CH2G1), 3.89 (s, 8H,
CH2Pentaerythritol), 3.52 (d, 16H, J = 11.7 Hz, CH2G2), 1.15 (s, 12H,
CH3G1), 0.88 (s, 24H, CH3G1);
13C NMR (100 MHz, CDCl3) δ
(ppm) 175.9 (COOG2), 174.1 (COOG1), 140.2 (CPh), 131.2 (CPh),
130.4 (CHPh), 128.5 (CHPh), 104.0 (CHBn), 75.7, 75.7, 67.2, 63.6,
49.2, 44.8, 36.2, 20.0 (CH3G2), 19.9 (CH3 G1); ESI-MS for
C121H140O40; calcd 2232.9 [M]
þ; found 2256.7 [MþNa]þ and
1139.8 [Mþ2Na]2þ; Elemental analysis calcd (%) forC121H140O40:
C, 65.04%; H, 6.32%; found: C, 65.32%; H, 6.31%.
Synthesis of G2(OH)16. G2(Bn)8 (3.8 g, 1.70 mmol) was
dissolved in CH2Cl2 (50 mL) and diluted with MeOH (50 mL).
A catalytic amount of Pd(C) was added to the solution and the
reaction mixture was hydrogenated under vigorous stirring for 12 h.
Then, the reaction mixture was ﬁltered over a pad of Celite. The
solvent was evaporated to giveG2(OH)16 (860mg, 95%) as a white
solid. 1HNMR(300MHz, CD3OD):δ (ppm) 4.39 (d, 8H, J= 11.1
Hz, CH2G1), 4.30 (d, 8H, J = 11.1 Hz, CH2G1), 4.29 (s, 8H,
CH2Pentaerythritol), 3.70 (d, 16H, J = 10.8 Hz, CH2G2), 3.61 (d, 16H,
J = 10.8 Hz, CH2G2), 1.35 (s, 12H, CH3G1), 1.17 (s, 24H, CH3G2);
13C NMR (75 MHz, CD3OD): δ (ppm) 176.0 (COOG2), 173.8
(COOG1), 66.1 (CH2Pentaerythritol), 65.9 (CH2G2), 63.6 (CG2), 51.8
(CH2G1), 44.3 (CG1), 18.3 (CH3G1), 17.4 (CH3G2); ESI-MS for
C65H108O40; calcd: 1528.6 [M]
þ; found: 1551.4 [MþNa]þ.
Synthesis of G3(Bn)16. G2)OH)16 (1.00 g, 0.654 mmol)
andDMAP (445mg) were dissolved in dry pyridine (20mL) and
then diluted with CH2Cl2 (40 mL). Anhydride 1 (6.02 g, 14.13
mmol) was added, and the reaction mixture was stirred at room
temperature for 15 h. Then, the excess of anhydride 1was quenched
by stirring the reaction mixture with 20 mL of pyridine/H2O (1:1)
solution overnight. The organic phase was diluted with CH2Cl2
(300 mL), and washed with NaHSO4 1M (2" 150 mL), Na2CO3
(10%) (2" 150 mL), and NaCl sat. (150 mL). The organic phase
was dried using MgSO4 anh., and the solvent was evaporated under
vacuum.The residuewas recrystallized fromCH2Cl2/MeOH to give
G3(Bn)16 (2.7 g, 97%) as white crystals.
1H NMR (500 MHz,
CDCl3):δ (ppm) 7.37!7.34 (m, 32H,CHPh), 7.27!7.21 (m, 48H,
CHPh), 5.32 (s, 16H, CHBn), 4.49 (d, 32H, CH2G3), 4.34!4.25 (m,
32H, 2 " 16 CH2G2), 4.12 (d, 8H, CH2G1), 4.11 (s, 8H,
CH2Pentaerythritol), 4.02 (d, 8H,CH2G1), 3.55!3.51 (m, 32H,CH2G3),
1.18 (s, 24H, CH3G2), 1.08 (s, 12H, CH3G1), 0.88 (s, 48H, CH3G3);
13C NMR (125 MHz, CDCl3): δ (ppm) 173.2 (COOG3), 171.9
(COOG2), 171.5 (COOG1), 138.0 (CPh), 128.8 (CHPh), 128.1
(CHPh), 126.2 (CHPh), 101.6 (CHBn), 73.4, 73.3, 64.9, 46.9, 46.6,
42.5 (CH2G3), 34.0, 25.0, 17.7 (CH3G2), 17.6 (CH3G3), 17.2
(CH3G1); ESI-MS for C257H300O88; calcd: 4793.9 [M]
þ; found:
2420.5 [Mþ2Na]2þ and 1621.8 [Mþ3Na]3þ; Elemental analysis
calcd (%) for C257H300O88: C, 64.34%;H, 6.30%; found: C, 64.07%;
H, 6.46%.
Synthesis of G3(OH)32. G3(Bn)16 (1.7 g, 0.354 mmol) was
dissolved in CH2Cl2 (30 mL) and diluted with MeOH (30 mL).
A catalytic amount of Pd(C) was added to the solution and the
reaction mixture was hydrogenated under vigorous stirring for 12 h.
Then, the reaction mixture was ﬁltered over a pad of Celite. The
solvent was evaporated to give G3(OH)32 (1.14 g, 95%) as a white
solid. 1HNMR(500MHz,CD3OD):δ (ppm) 4.36!4.22 (m, 56H,
CH2PentaerythritolþCH2G1þCH2G2), 3.68 (m, 32H,CH2G3), 3.58 (d,
32H, J = 10.0 Hz, CH2G3), 3.39 (s, 32H, CH2OH), 1.34 (s, 12H,
1356 dx.doi.org/10.1021/bc2000403 |Bioconjugate Chem. 2011, 22, 1354–1365
Bioconjugate Chemistry ARTICLE
CH3G1), 1.30 (s, 24H,CH3G2), 1.12 (s, 48H,CH3G3);
13CNMR(75
MHz, CD3OD): δ (ppm) 176.0 (COOG2), 173.8 (COOG1), 66.1
(CH2Pentaerythritol), 65.9 (CH2G2), 63.6 (CG2), 51.8 (CH2G1), 44.3
(CG1), 18.3 (CH3G1), 17.8 (CH3G3), 17.4 (CH3G2); ESI-MS for
C65H108O40; calcd: 3385.4 [M]
þ; found: 1716.0 [Mþ2Na]2þ and
1151.0 [Mþ3Na]3þ.
Synthesis of G3(sucBn)32. (460 mg, 1.36 mmol), succinic
acid derivate 2 (1.086 g, 5.22 mmol) and DPTS (512 mg,
1.74 mmol) were disolved in CH2Cl2 (15 mL) under argon
atmosphere. DCC (1.433 g, 6.96 mmol) was added and the
reaction mixture was stirred for 24 h at room temperature.
Then, the reaction mixture was diluted with (6 mL), ﬁltered
over a pad of Celite, and the solvent was evaporated. The residue
was puriﬁed by ﬂash chromatography on silica gel (Hex-AcOEt,
1:1.2), to aﬀord G3(sucBn)32 (1.10 g, 81%) as an oil.
1H NMR
(500 MHz, CDCl3): δ (ppm) 7.41!7.33 (m, 160H, CHAr), 5.13
(bs, 64H, CH2Bn), 4.50!4.21 (m, 120H, CH2dendrimer), 2.63 (bs,
128H, CH2suc), 1.39 (bs, 12H, CH3G1), 1.31 (bs, 24H, CH3G2),
1.23 (bs, 48H, CH3G3);
13C NMR (125 MHz, CDCl3) δ (ppm)
171.9 (COOG3), 171.7 (COOG2), 171.6 (COOG1), 135.9 (CArBn),
128.5 (CHArBn), 128.4 (CHArBn), 128.2 (CHArBn), 66.4 (CH2Bn),
65.1, 64.9 (CH2dendrimer), 46.7 (CG1), 46.6 (CG2), 46.3 (CG3),
28.9 (CH2suc), 28.8 (CH2suc), 17.7 (CH3G3), 17.6 (CH3G2), 17.4
(CH3G1); ESI-MS for C497H556O184; calcd: 9467.4 [M]
þ;
found: 4758.5 [Mþ2Na]2þ and 3185.3 [Mþ3Na]3þ; Elemental
analysis calcd (%) for C497H556O184: C, 63.01%; H, 5.92%;
found: C, 62.54%; H, 6.00%.
Synthesis of G3(suc)32. G3(sucBn)32 (87 mg, 9.19 " 10!3
mmol) was dissolved in CH2Cl2 (3 mL) and diluted withMeOH
(6 mL). A catalytic amount of Pd(C) was added to the solution and
the reactionmixture was hydrogenated under vigorous stirring for 12
h. Then, the reaction mixture was ﬁltered over a pad of Celite. The
solvent was evaporated to giveG3(suc)32 (79mg, quant.) as a white
solid. 1H NMR (300 MHz, D2O): δ (ppm) 4.50!4.20 (m, 120,
60" CH2OCO), 2.70!257 (m, 128H, 64" CH2suc), 1.42 (s, 12H,
4" CH3G1), 1.35 (s, 32H, 8" CH3G2), 1.28 (s, 52H, 16" CH3G3);
13C NMR (125 MHz, CD3CN): δ (ppm) 174.2 (COO), 173.0
(COO), 172.9 (COO), 66.3 (CH2O), 47.4 (C), 29.1 (CH2suc), 17.9
(CH3).
G3(pseudodi)32. To a solution of G3(suc)32 (3.5 mg, 5.31"
10!4 mmol, 1 equiv) in dry DMA (100 μL) under nitrogen
atmosphere, HATU (13 mg, 0.034 mmol, 64 equiv) and DIPEA
(12μL, 0.068mmol, 128 equiv) were added. After 15min a solution
of 13 (16.0 mg, 0.037 mmol, 69 equiv) in dry DMA (170 μL) was
added. The reaction was stirred at room temperature for 1 day.
MALDI mass analysis of a sample of the reaction mixture showed
the completion of the reaction. The reaction mixture was diluted in
methanol and charged directly onto a Sephadex LH-20 column in
methanol. Slow elution led to the purification of the product
G3(pseudodi)32 that was isolated in good yield (9.2 mg, 88%).
1HNMR(400MHz,D2O):δ (ppm) 5.00 (s,H1M), 4.43!4.14 (m,
CH2OG1 þ CH2OG2 þ CH2OG3), 4.02!3.95 (m, HD2 þ H2M),
3.92 (s,H2M), 3.86 (d, J = 11.2 Hz,H6MB), 3.81 (dd, J = 3.2 and 8.8
Hz,H3M), 3.78!3.56 (m,H6MAþHD1þH4MþH5MþH7), 3.69
(s, COOCH3), 3.69 (s, COOCH3), 3.42!3.32 (m,H8), 2.97!2.81
(m, HD4 þ HD5), 2.72!2.61 (m, CH2COO), 2.61!2.49 (m,
CH2CONH), 2.16!2.03 (m, HD6eq þ HD3eq), 1.89!1.71 (m,
HD6axþ HD3ax), 1.39!1.18 (m, CH3G1þ CH3G2þ CH3G3); 13C
NMR (100 MHz, D2O): 177.1, 176.8, 173.4 (COOCH3,
COOCH2, CONH), 98.7 (C1M), 73.9 (CD1), 73.6 (C4M), 71.1
(CD2), 70.6 (C2Mþ C3M), 67.1 (C7), 66.9 (C5M), 65.5 (CH2OG1
þCH2OG2þCH2OG3), 61.1 (C6M), 52.5 (CH3O), 46.5 (CquatG1
þ CquatG2 þ CquatG3), 39.5 (C8), 39.1 (CD4, CD5), 30.2
(CH2CONH), 29.3 (CH2COO), 27.3, 26.9 (CD6, CD3), 17.3
(CH3G1 þ CH3G2 þ CH3G3); MALDI-ToF MS (matrix, SA):
distribution centered on 31 sugar loaded, for 31 sugars [MþNa]þ
calculated: 19614.8, found: 19689.5.
G3(pseudotri)32. To a solution ofG3(suc)32 (7.6 mg, 1.15"
10!3 mmol, 1 equiv) in 100 μL of dry DMA under nitrogen
atmosphere, HATU (28.1 mg, 0.074 mmol, 64 equiv) and DIPEA
(26μL, 0.148mmol, 128 equiv) were added. After 15min, a solution
of 15 (35.7 mg, 0.06 mmol, 52 equiv) in dry DMA (230 μL) was
added. The reaction was stirred at room temperature for 2 days.
MALDImass analysis of a sample of the reactionmixture showed the
completion of the reaction. The reaction mixture was diluted in
methanol and charged directly onto a Sephadex LH-20 column in
methanol. Slow elution led to the purification of the product
G3(pseudotri)32 that was isolated in good yield (25.5 mg, 88%
yield). 1H NMR (400 MHz, D2O): δ (ppm) 5.00 (s, H1M0 ), 4.84
(s, H1M), 4.40!4.10 (m, CH2OG1 þ CH2OG2 þ CH2OG3), 4.04
(s, HD2), 3.97 (bs, H2M0 ), 3.92 (s, H2M), 3.89!3.53 (m, H3M0 þ
H6M0 BþH6MBþHD1þH6M0 AþH6MAþH3MþH4MþH4M0 þ
H7 þ H5M þ H5M0 ), 3.69 (s, COOCH3), 3.68 (s, COOCH3),
3.49!3.34 (m, H8), 3.00!2.85 (m, HD4 þ HD5), 2.73!2.59 (m,
CH2COO), 2.59!2.46 (m, CH2CONH), 2.27!2.03 (m, HD6eqþ
HD3eq), 1.89!1.71 (m, HD6ax þ HD3ax), 1.40!1.15 (m, CH3G1 þ
CH3G2 þ CH3G3); 13C NMR (100 MHz, D2O): δ (ppm) 177.3,
177.0, 173.5, 173.0 (COOCH3, COOCH2, CONH), 99.9 (C1M),
98.7 (C1M0 ), 74.7 (CD1), 73.5, 72.2 (C4M þ C4M0 ), 71.0 (CD2),
70.9, 70.7, 70.6 (C2M0 þ C3M þ C3M0 ), 70.2 (C2M), 68.2 (C6M),
67.1, 66.9 (C5Mþ C5M0 ), 66.2 (C7), 65.4 (CH2OG1þ CH2OG2þ
CH2OG3); 61.1 (C6M0 ), 52.6 (CH3O), 46.4 (CquatG1þ CquatG2þ
CquatG3), 39.1, (CD4, CD5), 39.0 (C8), 30.1 (CH2CONH), 29.2
(CH2COO), 27.2, 26.9 (CD6, CD3), 17.3 (CH3G1 þ CH3G2 þ
CH3G3). MALDI-ToF MS (matrix: SA): distribution centered
on 31 sugar loaded, for 31 sugar [C1041H1612N32O664Na]
þ
calcd: 25222.75, found: 25227.9.
2-Azidoethyl Isopropylidene-2,2-bis(oxymethyl)propio-
nate (4). 2-Bromoethanol (1.2 mL, 17.0 mmol) and DMAP
(0.325 g, 2.6 mmol) were dissolved in pyridine (25 mL), followed
by the addition of CH2Cl2 (70 mL). The anhydride of isopropyli-
dene-2,2-bis(oxymethyl)propionic acid 6 (7.4 g, 22.4 mmol) was
added slowly.The solutionwas stirred at room temperature overnight
and then was quenched with water (1 mL) under vigorous stirring,
followed by dilution with of CH2Cl2 (200mL), and the solution was
washed with 10% of NaHSO4 (3" 40 mL), 10% of Na2CO3 (3"
40 mL), and brine (20 mL). The organic phase was dried with
MgSO4, filtered, and concentrated. The crude product was purified
by flash chromatography on silica gel, eluting with hexane (100 mL)
and gradually increasing the polarity to EtOAc/hexane (9:1; 6:1) to
give 2-bromoethyl isopropylidene-2,2-bis(oxymethyl)propionate as
colorless oil (4.9 g, 86%). This bromo derivative (4.9 g, 14.6 mmol)
and NaN3 (2.6 g, 40.0 mmol) were dissolved in dry DMF (50 mL)
and the reactionmixturewas stirred at 50 !Cfor 15h.The solventwas
removed under high vacuum and AcOEt was added to the residue.
The NaN3 on excess was taken off by filtration, and the solvent was
removed to obtain 4 as colorless oil (3.53 g, 99%). 1H NMR (300
MHz, CDCl3) δ: 4.30 (t, 2H, J = 5.1 Hz, CH2CH2N3), 4.18 (d, 2H,
J =11.9Hz,CH2OCO), 3.64 (d, 2H, J =11.9Hz,CH2OCO), 3.67 (t,
2H, J = 5.1 Hz, CH2CH2N3), 1.41 (s, 3H, CH3), 1.36 (s, 3H, CH3),
1.19 (s, 6H, 2 " CH3); 13C NMR (100 MHz, CDCl3) δ: 173.8
(COO), 98.0 (Cipr), 65.8 (CH2OCO), 63.5 (CH2CH2N3), 49.7
(CH2CH2N3), 41.9 (C), 24.8, 22.2 (CH3), 17.7 (CH3); ESI-MS for
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C9H15N3O4; calcd: 243.1, [M]
þ; found 266.1 [MþNa]þ. IR
(υ, cm!1): 3448 (bs), 2992, 2940, 2105, 1734, 1638.
2-Azidoethyl 2,2-Bis(hydroxymethyl)propionate (5). Azi-
do derivative 4 (11.0 g, 45.2 mmol) was dissolved in MeOH
(50 mL). One teaspoon of a Dowex, Hþ resin was added, and the
reaction mixture was stirred at 40 !C until complete disappearance
of starting material. When the reaction was complete, the Dowex
Hþ resin was filtered off in a glass filter and carefully washed with
methanol. The methanol was evaporated to give 5 as colorless oil
(9.0 g, 98%). 1H NMR (CDCl3, 300 MHz) δ: 4.34 (t, 2H, J = 5.1
Hz,CH2CH2N3), 3.92 (d, 2H, J = 11.2Hz,CH2OCO), 3.74 (d, 2H,
J = 11.2 Hz, CH2OCO), 3.52 (t, 2H, J = 5.1 Hz, CH2CH2N3), 3.02
(bs, 2H,OH), 1.12 (s, 3H,CH3);
13CNMR (CDCl3, 100MHz) δ:
175.3 (COO), 67.8 (CH2OCO), 63.5 (CH2CH2N3), 49.8
(CH2CH2N3), 49.4 (C), 17.0 (CH3); ESI-MS for C7H13N3O4;
calcd: 203.1 [M]þ; found: 226.0 [MþNa]þ. IR (υ, cm!1): 3405
(bs), 2945, 2885, 2105, 1729, 1660, 1459. Elemental analysis calcd.
(%) for C7H13N3O4: C, 41.38%, H, 6.45%; N, 20.68%; found: C,
41.83%; H, 6.79%; N, 20.50%.
Compound 7. Azido derivative 5 (2.4 g, 11.8 mmol) and
DMAP (0.43 g, 3.54 mmol) were dissolved in pyridine (6 mL),
followed by the addition of CH2Cl2 (12 mL). The anhydride of
isopropylidene-2,2-bis(hydroxymethyl)propionic acid 6 (9.3 g,
30.7 mmol) was added slowly. The solution was stirred at room
temperature until completion. The reaction was quenched with
water (1 mL) under vigorous stirring, followed by dilution with
CH2Cl2 (50 mL), and the solution was washed with 10% of
NaHSO4 (3 " 20 mL), 10% of Na2CO3 (3 " 20 mL), and brine
(10 mL). The organic phase was dried with MgSO4, filtered, and
concentrated. The crude product was purified by flash chromatog-
raphy on silica, eluting with hexane (100 mL) and gradually
increasing the polarity to EtOAc/hexane (1:3) to give 7 as colorless
oil (4.4 g, 73%). 1HNMR(CDCl3, 300MHz)δ: 1.17 (s, 6H,CH3),
1.34 (s, 3H, CH3), 1.38 (s, 6H, CH3), 1.43 (s, 6H, CH3), 3.51 (t, J =
5.1 Hz, 2H, CH2CH2N3), 3.64 (d, J = 11.9 Hz, 4H, CH2OCO),
4.17 (d, J = 11.8 Hz, 4H, CH2OCO), 4.34!4.28 (t, J = 5.1 Hz, 2H,
CH2CH2N3), 4.36 (s, 4H, CH2OCO);
13C NMR (CDCl3, 75.5
MHz) δ: 173.5, 172.3 (COO), 98.1 (Cipr), 66.0, 66.0, 65.3
(CH2OCO), 63.9 (CH2CH2N3), 49.6 (CH2CH2N3), 46.9, 42.1
(C), 25.3, 22.0 (CH3
ipr), 18.0, 17.0 (CH3); ESI-EM calc for
C23H37N3O10(m/z): 515.2; found 538.2 [MþNa]þ. IR
(υ, cm!1): 3453 (bs), 2991, 2940, 2876, 2106, 1738, 1643, 1455.
Compound 8. Azido derivative 7 (4.3 g, 8.4 mmol) was
dissolved in MeOH (20 mL). One teaspoon of a Dowex Hþ
resin was added, and the reaction mixture was stirred at 40 !C until
complete disappearance of starting material by TLC. When the
reaction was complete, the Dowex Hþ resin was filtered off in a
glass filter and carefully washed with methanol. The methanol was
evaporated to give 8 as colorless oil (3.5 g, 97%). 1HNMR (CDCl3,
300 MHz) δ: 4.46 (d, J = 11.1 Hz, 2H, CH2OCO), 4.36!4.26 (m,
4H, CH2OCO, CH2CH2N3), 3.90!3.78 (m, 4H, CH2OCO),
3.76!3.67 (m, 4H, CH2OCO), 3.51 (t, J = 5.1 Hz, 2H,
CH2CH2N3), 3.19!2.87 (bs, 4H), 1.36 (s, 3H, CH3), 1.08 (s,
6H, CH3);
13C NMR (CDCl3, 75.5 MHz) δ: 175.0, 175.0, 172.8
(COO), 67.3, 67.2, 67.2, 64.8 (CH2OCO), 64.0 (CH2CH2N3),
49.8 (CH2CH2N3), 49.8, 49.6 (C), 18.0, 17.0 (CH3); ESI-EM calcd
for C17H29N3O10 (m/z): 435.2; found 458.2 [MþNa]þ. IR
(υ, cm!1): 3405 (bs), 2943, 2886, 2108, 1731, 1469.
Compound 10. 4-Oxo-4-(2-(trimethylsilyl)ethoxy)butanoic
acid (9) (1.43 g, 6.57 mmol), tetraol 8 (0.50 g, 1.09 mmol), and
DPTS (0.65 g, 2.18 mmol) were mixed in CH2Cl2 anhydrous
(10 mL). Then, the reaction flask was flushed with argon and
DCC (1.35 g, 6.57 mmol) was added. Stirring at 40 !C was
continued for 15 h under argon atmosphere. Once the reaction
was complete, the formed urea was filtered off on a glass filter and
washed with a small volume of CH2Cl2. The crude product was
purified by liquid chromatography Sephadex LH20 (CH2Cl2/
MeOH; 1:1) to give 10 as colorless viscous oil (1.11 g, 81%). 1H
NMR (CDCl3, 300 MHz) δ: 4.43!3.97 (m, 14H, 4 CH2G1, 8
CH2G2, 2 CH2CH2N3, 8 CH2CH2COCH2), 3.53!3.43 (t, J = 5.1
Hz, 2H, CH2CH2N3), 2.65!2.47 (m, 16H, CH2suc), 1.26 (s, 3H,
CH3 G"1), 1.20 (s, 6H, CH3 G"2), 1.00!0.88 (t, J = 8.5 Hz, 8H, CH2-
TMS), 0.00 (s, 36H,CH3TMS);
13CNMR(CDCl3, 75.5MHz) δ:
172.1, 171.9, 171.9, 171.7 (COO), 65.6, 65.3, 64.0, 62.9 (CH2OCO,
CH2CH2N3, CH2CH2COCH2), 49.6 (CH2CH2N3), 46.7, 46.4
(CCH2O), 29.1, 28.8 (CH2suc), 17.7, 17.4 (CH2-TMS,CH3), 17.2,
!1.5,!1.9 (CH3TMS); ESI-HRMS calcd for C53H93N3O22Si4Na
(m/z): 1258.5291; found: 1258.5226. IR (υ, cm!1): 2955, 2898,
2104, 1730, 1471.
Compound 11. TFA (5 mL) was added to a solution of 10
(142 mg, 0.115 mmol) in CH2Cl2 (5 mL). The mixture was
stirred at room temperature for 2 h. After complete conversion, the
solventwas evaporated and dried in high vacuum to afford 11 as pale
yellow syrup (96 mg, 100%). The compound was used in the next
step without purification. 1H NMR (MeOH-d4, 400 MHz) δ: 4.30
(m, 28H, 4CH2 G1 8CH2 G2, 2CH2CH2N3), 3.57 (t, J = 5.1Hz, 2H,
CH2CH2N3), 2.62 (m, 16H, CH2CONH, CH2COO), 1.34 (s, 3H,
CH3G10), 1.27 (s, 6H, CH3G20);
13C NMR (CDCl3, 100 MHz) δ:
174.4, 172.2, 172.2, 172.0 (COO), 65.5, 65.3, 65.2, 64.0 (CH2OCO,
CH2CH2N3, CH2CH2COCH2), 49.4 (CH2CH2N3), 46.9, 46.5,
46.3 (CCH2O), 28.6, 28.5, 28.3, 28.2 (CH2CONH, CH2COO),
16.7, 16.5 (CH3); ESI-HRMS calcd for [MþNa] C33H45N3O22Na
(m/z): 858.2392; found: 858.2435.
Compound 12. To a solution of the scaffold dendron 11 (6.0
mg, 0.00718 mmol, 1 equiv) in 150 μL of dry DMA under
nitrogen atmosphere, HATU (22 mg, 0.0575 mmol, 8 equiv) and
DIPEA (20 μL, 0.1157mmol, 16 equiv) were added. After 15min, a
solution of 13 (23.4 mg, 0.05349 mmol, 8 equiv) in dry DMA
(210 μL) was added. The reaction was stirred at room temperature
for 3 days. MALDI mass analysis of a sample of the reaction mixture
showed the completion of the reaction. The reaction mixture was
diluted in methanol and charged directly onto a Sephadex LH-20
column (methanol). Slow elution led to the purification of the
product 12 that was isolated in good yield (16.9mg, 94%). 1HNMR
(400 MHz, D2O): δ (ppm) 4.93 (s, 4H, H1), 4.27 (bs, 6H,
OCH2CH2N3, CH2OG1), 4.18 (bs, 8H, CH2OG2), 3.91 (bs, 8H,
D2, H2), 3.78 (d, 4H, H6B, J = 12 Hz), 3.76!3.71 (m, 4H, H3),
3.69!3.59 (m, 8H,H6A,HD1), 3.63 (s, 24H,OCH3), 3.59!3.49 (m,
18H, H4, H5, H7, CH2N3), 3.30 (bt, 8H, H8), 2.91!2.72 (m, 8H,
HD4, HD5), 2.65!2.56 (m, 8H, CH2COO), 2.54!2.45 (m, 8H,
CH2CONH), 2.10!1.99 (m, 8H, HD6eq, HD3eq), 1.81!1.64 (m,
8H, HD6ax, HD3ax), 1.26 (s, 3H, CH3G10 ), 1.19 (s, 6H, CH3G20 );
13C
NMR (100 MHz, D2O): 177.4, 177.2, 174.1, 174.0, 173.8, 173.7
(COOCH3, COOCH2, CONH), 98.6 (C1M), 73.8 (CD1), 73.5
(C4M), 71.0, 70.5 (CD2, C2M, C3M), 66.9 (C7), 66.8 (C5M), 65.9
(OCH2G1, OCH2G2), 64.8 (OCH2CH2N3), 61.0 (C6M); 52.6
(CH3O); 49.4 (CH2N3); 46.6, 46.4 (Cquat G1, G2); 39.4 (C8);
39.0 (CD4, CD5); 30.1 (CH2CONH); 29.3 (CH2COO); 27.0,
26.7 (CD6, CD3); 16.9 (CH3G1,G2); ESI-MS calcd for [C105H161-
N7O62Na2]
þ2 1279.7, found: 1279.2; MALDI-ToF MS (matrix
DHB) [C105H161N7O62Na]
þ calcd: 2536.4, found: 2537.2.
Production of Recombinant Viruses. Recombinant viruses
were produced in 293 T cells. The viral construction was pseudo-
typed with Ebola virus envelope glycoprotein (EboGP) and
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expressed luciferase as a reporter of the infection. The infection of
Jurkat cells (a CDþT-lymphocyte cell line) by EboGP is absolutely
dependent on virus envelope interaction with DC-SIGN. As a
control of DC-SIGN independent infection, we produced recom-
binant viruses pseudotyped with vesicular stomatitis virus envelope
glycoprotein (VSV-G).
One day (18!24 h) before transfection, 6 " 106 293 T cells
were seeded onto 10 cm plates. Cells were cultured in DMEM
medium supplemented with 10% heat-inactivated FBS, 25 mg
Gentamicin, and 2 mM L-glutamine. Few minutes before transfec-
tion, the medium on transfection plates was changed to 9 mL
DMEM and 25 μM chloroquine. Transfection reaction with all
reagents at room temperature (r.t.) was prepared in 15 mL tubes:
183 μL of 2 M CaCl2, 450 ng of Ebola virus envelope, 21 μg of
pNL4!3 luc, and 1200 μL of H2O. Next, 1.5 mL of 2"HBS
(Hepes Buﬀer Saline) pH 7.00 was added quickly to the tubes and
bubbled for 30 s. HBS/DNA solution was dropwise added onto
medium. After 8 h of incubation at 37 !Cwith 5%CO2, medium on
transfection plates was changed to 10 mL DMEM and once again
one day after transfection to 7 mL DMEM. Transfection super-
natants were harvested after 48 h, centrifuged at 1200 rpm for 10
min at r.t. to remove cell debris, and stored frozen at !80 !C.
Infection Assay. Infection in cis. Infection was performed on
Jurkat cells expressing DC-SIGN. Since Ebola virus does not
infect T-lymphocytes, its entry into Jurkat cells is absolutely
dependent on the interaction with DC-SIGN.30
DC-SIGNþ Jurkat cells (2.5 " 105) were incubated with
carbohydrate multivalent compounds on 24-well suspension
plates for 30 min at r.t. and then challenged with 10 000 tissue
culture infective dose (TCID) of recombinant viruses. After 48 h
of incubation, cells were washed twice with PBS and lysed with
100 μL of 1" Lysis Buﬀer for luciferase assay (Promega).
Infection control experiment was performed with VSV-G
pseudoviruses under the same conditions.
Infection in trans. DC-SIGNþ Jurkat cells (2.5 " 105) were
preincubated for 20 min at r.t. with carbohydrate multivalent
compounds. Then, they were challenged with 10 000 TCID of
recombinant viruses and incubated for 2 h at r.t. with rotation. After
2 h, cells were centrifuged at 1000 rpm for 5 min and washed twice
with 1 mL of PBS supplemented with 0.5% bovine serum albumin
(BSA) and 1mMCaCl2.DC-SIGN
þ Jurkat cells were resuspended
in 500 μL of RPMI medium and co-cultivated with adherent HeLa
cells (105 cells/well) on 24-well plate. After 48 h, supernatant was
removed and monolayer of HeLa was washed twice with 1 mL of
PBS and lysed with 100 μL of 1" Lysis Buffer for luciferase assay.
As control experiment, trans-infection test with VSV-G pseu-
doviruses was performed.
Surface Plasmon Resonance. Extracellular domain (ECD)
of DC-SIGN protein (residue 66!404) has been overexpressed
and purified as described previously.31 All experiments were
performed on a Biacore 3000 using functionalized CM4 sensor
chips and the corresponding reagents from BIAcore. Two flow
Scheme 1. Synthesis of Compound G3(suc)32 from Pentaerythritol
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cells were activated as previously described.32 Flow cell one was
then blocked with 30 μL of 1 M ethanolamine and used as a
control surface. The second one was treated with BSA-ManR1!
3[ManR1!6]Man (BSA-Mannotriose, Dextra) (60 μg/mL) in
10 mM acetate buffer, pH 4. Remaining activated groups were
blocked with 30 μL of 1 M ethanolamine. The final density
immobilized on the surface of the second flow cell was 1200 RU.
The BSA-Mannotriose used to functionalize CM4 chip harbors
12 glycosylation sites according to manufacturer. The affinity of
the various sugars and mimics was then estimated through a DC-
SIGN ECD binding inhibition assay. The ECD of DC-SIGN was
injected onto the BSA-Mannotriose surface, at 20 μM alone or in
presence of an increasing concentration of the sugar derivatives.
Injections were performed at 20 μL/min using 25 mMTris-HCl,
pH 8, 150 mMNaCl, 4 mMCaCl2, and 0.005% of P20 surfactant
as running buffer. The original sensorgrams are reported as
Supporting Information.
To determine IC50 values for sugar derivatives, the steady state
binding responses of DC-SIGN ECD to BSA-Mannotriose sur-
face were obtained from sensorgrams and converted to relative
residual activity values. Relative IC50 values were determined
from the plots of sugar derivative concentration vs relative
residual DC-SIGNECD activity by ﬁtting four-parameter logistic
model (see eq 1 in SI) to the experimental data.
’RESULTS
In previous works, we have demonstrated that the commer-
cially available and very cheap third generation of a Boltorn
Scheme 2. Synthesis of Tetravalent Compounds 12 and 14
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dendritic polymer was a very convenient platform for a multi-
valent presentation of carbohydrates.19 This polydisperse den-
dritic polymer, bearing 32 copies of mannose, exhibited a high
antiviral activity (IC50 = 0.3 μM) in an Ebola infection model.
20
The polydispersity of the commercial Boltorn scaﬀold is a major
drawback of this strategy. On the basis of these preliminary
results, we decided to prepare a Boltorn-type polyester dendri-
mer in a completely monodisperse manner. To approach this
synthesis, we used a divergent strategy based on the anhydride 1
as a building block monomer and pentaerythritol as a central
core, a strategy previously used to prepare polyester dendrons.26
A sequential set of two reactions was employed as described in
Scheme 1. A coupling reaction with anhydride 1 to grow to the
next generation, followed by hydrogenolysis using palladium on
carbon as catalyst to remove the benzylidene protecting groups,
yielded the ﬁrst (G1(OH)8), second (G2(OH)16), and third
(G3(OH)32) generations of the polyester dendrimers in a very
eﬃcient way and with complete monodispersity, as shown by mass
spectrometry. These dendrimers were prepared in multigram-scale
and puriﬁed by recrystallization in a very straightforward way.
Carboxylic acids were introduced as functional groups at the
surface of the third-generation dendrimer G3(OH)32 to allow
coupling with conveniently functionalized ligands by the formation
of amide bonds. In contrast to our previous experience, where the
carboxylic acids were introduced by reaction of G3(OH)32 with a
large excess of succinic anhydride, succinic acidmonobenzyl ester and
DCC were used for the coupling reaction (Scheme 1). Using this
strategy, the resulting compoundG3(sucBn)32was soluble in organic
solvents and very easy to purify by ﬂash chromatography on silica gel.
Again, a complete analysis of the compound, especially by MS,
conﬁrmed themonodispersity of the molecule. After a simple step of
benzyl ester deprotection by hydrogenolysis at atmospheric pressure
using Pd(C) (10%) at room temperature, the dendrimer G3(suc)32
with 32 carboxylic acids was obtained almost quantitatively.
To evaluate the importance of the valency, a tetravalent system
also based on 2,20-bis(hydroxymethyl) propionic acid (bis-MPA)
(Scheme 2) was considered as a scaﬀold for presentation of four
copies of selected ligands.
Starting from the isopropylidene-2,2-bis(methoxy)propionic
acid (3) prepared as reported in the literature28 and following the
experimental procedure described in Scheme 2, we obtained 4 in
good yields with adequate functionalization. As a protecting group of
the carboxylic acid, the azidoethanol was used. This terminal azide
has been used in our laboratory in a convergent strategy to create
higher valency compounds applying a click chemistry Cu catalyzed
cycloaddition (unpublished results). Compound 4 was prepared in
good yields by reaction of 3 with 2-bromoethanol in the presence of
DCCand4-(dimethylamino)pyridinum4-toluenesulfonate (DPTS)
followed by treatment with sodium azide in DMF at 40 !C. After
deprotectionof the hydroxyl groups using an acidic resin inmethanol,
the tetraol 8 was prepared using a two-step synthetic sequence
reported in the literature to prepare similar polyester dendrons.28,29,33
This synthetic sequence begun coupling 5 with 2 equiv of anhydride
6 which, in turn, was prepared in one step from acid 3 using DCC,29
in pyridine and dimethylaminopyridine as catalyst. The second step
was the deprotection of the isopropylidene acetals of 7 using Dowex
Hþ. Tetraol 8 was obtained in good yield after chromatographic
puriﬁcation. The introduction of the carboxylic acid linkers on 8 was
performed using the trimethylsilylethanol monosuccinate 9 prepared
by ring-opening of succinic anhydride by trimethylsilylethanol as
described in the literature.34 In thisway, the silyl protected compound
was prepared in good yields and easily puriﬁed. After deprotection
using triﬂuoroacetic acid at room temperature, the tetraacid 11 was
obtained in very good yield andwas used in the next stepwithout any
further puriﬁcation.
Our previous studies have demonstrated that compounds 13
and 15, linear glycomimetics of the disaccharide ManR1,2Man
and of the trisaccharideManR1,2ManR1,6Man, respectively, were
Scheme 3. Coupling of Glycomimetics 13 and 15 on G3(suc)32
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very adequate ligands for DC-SIGN providing better stability
against enzymatic degradation than the corresponding natural
counterparts. The synthesis of these glycomimetics has been
previously described.22,23
Conjugation of 13 and 15 on the tetra- and multivalent
scaﬀolds was performed using HATU as an activating reagent in
the presence of DIPEA at room temperature and aﬀorded the
correspondingmultivalent systemswith high yields after puriﬁcation
by size exclusion chromatography as described in Schemes 2 and 3.
The tetravalent compoundswere fully characterized byNMR, IR,
and MS analysis. MALDI-MS of the compounds G3(pseudodi)32
and G3(pseudotri)32 using sinapinic acid (SA) as matrix allowed to
observe a complex signal centered on the molecular weight
corresponding to the 31-loaded dendrimer both for pseudodi-
and pseudotrimultivalent systems (see SI for MS spectra). This
is consistent with the number of 30!32 ligands which could be
estimated based on the integration of signiﬁcant signals in the
1H NMR spectrum (see SI). Although the MS spectra were not
conclusive, we concluded that almost all the reactive sites of the
scaﬀold were conjugated with ligands to obtain a high load
narrowly disperse system.
Infection Studies. The antiviral activity of these tetra- and
multivalent systems was tested using pseudotyped viral particles
presenting the EboGP and Jurkat cell line expressing DC-SIGN
on the surface. Two kinds of experiments were set up: a cis-
infection assay of DC-SIGNþ Jurkat cells with this artificial
Ebola virus, and a trans-infection experiment of HeLa cells using
DC-SIGNþ Jurkat cells as viral particle transporters.
We have used these infection models previously to test the
activity of mannosylated Boltorn-type hyperbranched dendritic
polymers.20 The DC-SIGN blocking eﬃciency has been evaluated
as dependence of multivalency and of the diﬀerent pseudomanno-
side ligands used in the compounds synthesized. The infection
inhibition analysis has been done as a function of compound
concentration. All compounds were used in at least 3 independent
experiments. The results of the infection assays are represented as a
percentage of infection inhibition compared with DC-SIGNþ
Jurkat cells infected by pseudoviruses without addition of any
compound (blank experiment). The IC50 values were calculated
with the 95% conﬁdence intervals. Control experiment with VSV-G
pseudoviruses was performed with ﬁnal concentrations of 10 nM
and 10 μM (negative control).
The results obtained in the cis infection experiments indicate
that the tetravalent systems presenting four copies of the pseudo-
mannotrioside, 14, show an IC50 1 order of magnitude lower than
the system with four pseudomannobiosides, 12 (Figure 1). In a
previous publication, we have shown that the tetravalent system 14
bearing four copies of linear pseudomannotrioside 15 was an
eﬀective inhibitor of T-cell trans infection by HIV.23
Multivalent systems with an average of 30!32 copies of
glycomimetic ligands were tested. In this case, no signiﬁcant
diﬀerences were found as a function of the pseudosaccharide
presented. The IC50 values found for the multivalent systems
were around 20 nM (around 0.5 μM, based on ligand con-
centration), which shows that their inhibitory potency is between
Figure 1. Infection results of the cis-experiments using 12, 14, G3(pseudodi)32, and G3(pseudotri)32 compounds as inhibitors. Concentrations are
expressed based on ligand concentration.
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1 to 2 orders of magnitude higher than that of the corresponding
tetravalent systems.
Similar results were obtained in the trans infection experi-
ments (Figure 2). The IC50 of 32-valent systems bearing
pseudomannobioside 13 or pseudomannotrioside 15 were
62 nM and 31.5 nM, respectively (2 and 1 μM, based on ligand
concentration, respectively). The tetravalent dendron 14 with
four copies of pseudomannotrioside showed an IC50 of 203 nM
(0.8 μM, based on ligand concentration), and the tetravalent
dendron 12with four copies of pseudomannobioside was 1 order
of magnitude less potent with an IC50 of 1.22 μM(4.9 μM, based
on ligand concentration) (Figure 2).
SPR Studies. Competition experiments using Biacore SPR
were performed to analyze the interaction of these glycomimetic
tetra- and multivalent systems with the receptor DC-SIGN and
to characterize the interaction at the molecular level.
For this aim, Biacore CM4 sensor chip was functionalized
as described in the experimental section with BSA-Mannotriose.
A ﬁxed amount of DC-SIGN ECD was injected over the
sensor chip ﬂow cells in the presence or absence of diﬀerent
concentrations of the glycodendritic compounds to be evaluated.
Analysis of the sensorgrams (see Supporting Information)
allowed estimating IC50 for the monovalent, tetravalent,
and multivalent compounds. At the monovalent level, strong
diﬀerences were found (almost 1 order of magnitude) between
the IC50 of monovalent pseudodi- and pseudotrisaccharides
(IC50 1.19 mM for the pseudodisaccharide 13 and 0.16 mM for the
pseudotrisaccharide15).However, these diﬀerences decrease notably
when the ligands are presented on the tetravalent scaﬀold (IC50
227 μM for the tetravalent pseudodi 12 and 120 μM for the
tetravalent pseudotri 14) and are very similar when a dendrimer
of third generation is used as multivalent platform (IC50 2 μM for
the multivalent pseudodi G3(pseudodi)32 and 1.25 μM for the
multivalent pseudotri G3(pseudotri)32. (Figure 3)
These data show that tetravalent presentation of the pseudo-
disaccharide 13 on dendron 12 aﬀords a very modest (1.3 per
pseudosugar), if any, polyvalency eﬀect (β), which improves
signiﬁcantly (18 per pseudosugar) in the full dendrimer G3-
(pseudodi)32. Strikingly, the tetravalent presentation of the
pseudotrisaccharide 15 on dendron 14 does not aﬀord any
aﬃnity increase (β = 0.3 per pseudosugar) and only a modest
improvement (4 per pseudosugar) is observed for the full
dendrimer G3(pseudotri)32.
’DISCUSSION
DC-SIGN is considered a very interesting therapeutic target for
the design of new antiviral drugs. In addition, the ability of DC-SIGN
to trigger signaling pathways that lead to a speciﬁc immune response
has attracted attention on this lectin.35!42 The development of
speciﬁc tools to interact with and to understand the role and function
of this lectin is of great interest. Furthermore, speciﬁc ligands designed
to block the carbohydrate recognition domain of this lectin could be
good candidates to be tested as antimicrobial agents.
Figure 2. Infection results of the trans experiments using 12, 14, G3(pseudodi)32, and G3(pseudotri)32 compounds as inhibitors. Concentrations are
expressed based on ligand concentration.
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In this context, we have selected two linear pseudosaccharides
13 and 15 with good aﬃnity for this receptor. The aﬃnity has been
remarkably enhanced via amultivalent presentation of these ligands.
Tetra- andmultivalent scaﬀolds based on bis-MPA as building block
have been prepared with adequate functionalization on the surface
for attachment of the selected ligands. The corresponding glyco-
conjugates with 4 and 32 copies of these ligands were prepared in
good yields and were characterized using typical spectroscopic
methods. MS analysis demonstrated the monodispersity of the
tetravalent systems (compounds 12 and 14). Higher valency
systems obtained from monodisperse G3 Boltorn-type dendrimer
G3(OH)32 did not give good MS spectra and by analysis of the
NMR spectra could only be described as systems with 30!32
ligands as an average loading; therefore, themonodispersity of these
systems was not conﬁrmed.
These tetra- and multivalent systems were tested in vitro as
antiviral compounds in a well-established infection model based
on pseudotyped viral particles with the Ebola virus envelope
glycoprotein GP1. This infection system is a very eﬃcient and
“clean” model where the infection is exclusively dependent on
DC-SIGN.20 Cells that do not express the receptor and viruses
able to infect the cells independently of DC-SIGN have been
used as controls in these experiments. The results obtained have
clearly demonstrated inhibition of the infection through blockage
of the DC-SIGN receptor. The tetravalent systems 12 and 14
were very active in the lowmicromolar range, and themultivalent
systems G3(pseudosugar)32 showed a very strong inhibition
eﬀect with IC50 in the nanomolar range. These systems could
be considered as very potent inhibitors to be tested in further
experiments. On the other hand, relatively small diﬀerences were
observed between the two selected monovalent ligands the
pseudodi 13 and the pseudotrisaccharide 15.
In order to analyze this in more detail and to have additional
molecular-level data on the interaction of these compounds with
DC-SIGN, competition experiments using a biosensor with SPR
detection were performed. A chip functionalized with mannosy-
lated BSA was used to compete with our ligands for DC-SIGN.
Analysis of the results obtained in these competition experiments
demonstrates that the pseudosugars are good ligands for DC-
SIGN, and that the pseudotrisaccharide 15 is 1 order of
magnitude better than the pseudodisaccharide 13 when used as
monovalent units. Surprisingly, this trend was not observed when
the ligands are used in multivalent presentations: they both
present a similar aﬃnity when are exposed on the multivalent
scaﬀolds. A plausible explanation for these facts could be the loss
of diﬀerent binding modes of the ligands when they are linked to
a scaﬀold. In the particular case of DC-SIGN, it has been
experimentally determined by X-ray43 and also by NMR44 that
diﬀerent binding modes are possible for carbohydrate ligands.
These binding modes were observed for free ligands, but once
they are conjugated to scaﬀolds, some or all of these alternative
binding modes could become inaccessible; consequently, this
could notably inﬂuence binding aﬃnity. As a consequence,
despite the improved aﬃnity of the pseudomannotrioside at
the monovalent level, our data suggest that the pseudomanno-
bioside is the eﬀective lead compound to use for further
improvement of our multivalent pseudosaccharide compounds.
More structural experiments are currently being carried out
in our laboratory at the monovalent level to obtain more detailed
information and to investigate the factors that govern this
phenomenon.
In summary, we present in this work the preparation of
carbohydrate mimics on a tetra- and multivalent presentations
and the analysis of their antiviral activity using a pseudotyped
Ebola virus infection model. A strong inhibitory activity was
found for the higher valency compounds with IC50 in the
nanomolar range. Competition experiments using SPR have also
demonstrated the ability of these compounds to interact with
DC-SIGN and compete for this receptor. Our results conﬁrm
pseudoglycosylated multivalent systems as very promising anti-
viral drugs with strong activities and encourage us to pursuemore
in vitro and in vivo studies concerning the potential biomedical
applications.
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9.1. DEVELOPMENT OF MONOVALENT GLYCOMIMICS
9.1.4.3. Structural characterization of psDi binding to DC-SIGN and evaluation of its selectivity to
DC-SIGN versus langerin
After psDi and psTri were found as relatively eﬃcient DC-SIGN antagonists and psTri showed
already described discrepancy, it became important to characterize of their interaction with DC-
SIGN at a molecular level in order to find out, which of the two compounds is best to choose for
further improvements. The following article by Thépaut et al. sheds light on the structural basis of
psDi interaction with DC-SIGN: the crystal structure of DC-SIGN CRD in complex with psDi was
solved and the binding properties in solution were evaluated by NMR techniques. This compound
was found to have a sole binding mode, a desirable property for a molecule to be developed into
a drug candidate, and this binding mode was diﬀerent from its natural counterpart, Manα1-2Man
disaccharide. The revealed mode of psDi binding in the CRD of DC-SIGN gave the valuable
structural knowledge for further rational optimization of this ligand.
Additionally, the selectivity of psDi to DC-SIGN versus langerin was assessed by SPR com-
petition assay. When compared with Manα1-2Man, psDi had an improved selectivity to DC-SIGN
than langerin.
The main outcome of these studies: the structural properties of psDi interaction with DC-SIGN
present all required qualities (unique binding mode, good synthetic availability, good selectivity to
DC-SIGN) of a compound to be selected for further improvements.
Contributions:
DC-SIGN CRD was produced, the psDi/DC-SIGN co-crystals were obtained and the structure
was solved in our group (Dr. Michel Thépaut) before my PhD started. The characterization of psDi
interaction with DC-SIGN in solution was performed by a PhD student Cinzia Guzzi in the team of
Dr. P. Nieto. The compounds were synthesized by the teams of Pr. A. Bernardi and Dr. J. Rojo.
My contribution to this study:
I have performed the SPR assays comparing DC-SIGN and langerin selectivity, analyzed the
data, and participated in the preparation of the paper manuscript.
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Abstract 
In genital mucosa, different fates are described for HIV according to the sub-type of dendritic 
cells (DCs) involved in its recognition. This notably depends on the C-type lectin receptor, langerin or 
DC-SIGN, involved in gp120 interaction. Langerin blocks HIV transmission by its internalization in 
specific organelles of Langerhans cells. On the contrary DC-SIGN enhances HIV trans-infection of T 
lymphocytes. Thus, approaches aiming to inhibit DC-SIGN, without blocking langerin, represent 
attractive anti-HIV strategies. We previously demonstrated that dendrons bearing multiple copies of 
glycomimetic compounds were able to block DC-SIGN-dependent HIV infection in cervical explant 
models. Optimization of such ligand requires detailed characterization of its binding mode. In the 
present work we determined the first high-resolution structure of a glycomimetic/DC-SIGN complex 
by X-ray crystallography. This glycomimetic, pseudo-1,2-mannobioside, shares shape and 
conformational properties with Man!1-2Man, its natural counterpart. However, it uses the binding 
epitope previously described for Lewis X, a ligand specific for DC-SIGN among the C-type lectin 
family. Thus, selectivity gain for DC-SIGN vs langerin is observed with pseudo-1,2-mannobioside as 
shown by surface plasmon resonance analysis. In parallel, ligand binding was also analyzed by TR-
NOESY and STD NMR experiments, combined with the CORCEMA-ST protocol. These studies 
demonstrate that the complex, defined by X-ray crystallography, represents the unique binding mode of 
this ligand as opposed to the several binding orientations described for the natural ligand. This 
exclusive binding mode and its selective interaction properties position this glycomimetic as a good 
lead compound for rational improvement based on a structurally driven approach. 
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Introduction 
Dendritic cells (DCs) are key players in the initial response to pathogens as they are the first 
participants in the long series of events in host-pathogen interaction leading to activation of specific T-
cells.1,2 They are found in epidermal and mucosal tissues and are thus able to quickly recognize new 
invading pathogens through the identification of pathogen associated molecular patterns (PAMPs). The 
efficacy of DCs in their sentinel role is related to the wide diversity of pattern recognition receptors 
(PRRs) they express on their surface. Apart from the Toll Like receptors family of PRRs, they also 
possess C-type lectin receptors (CLRs) dedicated to the specific recognition of pathogen carbohydrate 
patterns.3 Among these CLRs, DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin) has 
attracted a great deal of attention during the past decade. Initially highlighted for its role in HIV 
transmission to T cells,4 it has then been identified as a PRR hijacked by many other pathogens, for 
instance some viruses, bacteria, fungi and parasites, to escape immune response in their infectious 
processes.5,6 More recently, DC-SIGN has also been involved in the modulation of the immune 
response.7 
DC-SIGN is a type II transmembrane protein with a short cytosolic region, a transmembrane 
segment and an extended extracellular domain (ECD) projecting its carbohydrate binding domain up to 
320 Å above the cell surface, as a bait to trap potential antigens.8 This extracellular domain is divided 
into two structurally and functionally distinct regions: a neck region, involved in the tetramerization of 
the receptor, and a calcium-dependent carbohydrate recognition domain (CRD), which is at the heart of 
the molecular recognition processes mediated by DC-SIGN. 
Therefore, many groups are developing strategies to block the sugar binding site within DC-
SIGN CRD to prevent its use by pathogens’ glycoproteins.9-12 DC-SIGN/pathogen interactions are 
complex and imply multipoint attachment benefiting from the DC-SIGN tetrameric state and from its 
organization into clustered patches at the cell membrane.13,14 For this reason almost all of these 
inhibition strategies exploit a multiple ligand presentation platform (polymers, dendrimers, or 
nanoparticles), on which the relevant ligands are presented for interaction with DC-SIGN CRD.15-18 
Several “proof of concept” studies have been performed using a simple mannose as grafted ligands 
onto these various display systems.9,11,19 Indeed, we initially demonstrated that dendrimers loaded with 
multiple copies of mannose were able to inhibit DC-SIGN/gp120 interaction.9 However, mannose, as 
natural ligand, is not specific enough for in vivo practical applications. The design of a ligand with 
good selectivity and basal affinity is of crucial importance. Several groups have invested efforts in DC-
SIGN ligand improvements by increasing the complexity of the oligosaccharide (reconstructing natural 
high mannose oligosaccharide for instance10,15,17), by selecting non-sugar molecules with high 
throughput screening20,21 or by designing new synthetic molecules mimicking natural sugar 
properties.22,23,24,25 
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Based on two natural ligands, Man!1-2Man disaccharide and Lewis X trisaccharide, we have 
developed glycomimetic compounds that have good affinity for DC-SIGN and low structural 
complexity. In the mannose series (Figure 1), we recently demonstrated that dendrons or dendrimers 
bearing multiple copies of pseudo-1,2-mannobioside (1) were able to block DC-SIGN-dependent HIV 
trans-infection of T cells,16 HIV infection in cervical explant models,26 and Ebola-pseudotyped viral 
infection.16,18 
 
Figure 1. Structure of compounds used in this study. 
 
We also developed a class of Lewis X mimics containing a fucosylamide anchor and 
demonstrated their potential in terms of specificity towards DC-SIGN relative to langerin, a related 
lectin.25 Due to their chemical stability, resistance to enzymatic degradation by glycosidases,27 and their 
rather simple and high yield synthetic route, these glycomimetics of first generation represent good 
candidates for optimization leading to efficient specific inhibitors for DC-SIGN. 
To enable ligand improvement, a good knowledge of the particular binding mode of model 
compounds is of the utmost importance. To achieve this goal, glycoscientists often face a particularly 
hard and specific task given by the nature of glycan/protein interactions. Indeed, oligosaccharide 
ligands often have several binding modes within a single binding site in Ca2+ dependent lectins. 28-30 
Moreover, computational tools are often of limited use in the prediction of sugar-lectin interaction 
modes due to the peculiar properties of lectin binding sites. As a consequence, ligand modifications 
aiming to improve one binding mode may disfavour another one, leading to unpredictable global 
effects on the affinity for the receptor. Therefore, the optimization process becomes a challenge. For 
DC-SIGN, it has been shown that the natural ligand Man!1-2Man disaccharide displays at least two 
different binding modes within the Ca2+ binding site28,29 : the major mode is achieved by coordination to 
the Ca2+ atom of the 3-OH and 4-OH equatorial groups of the reducing end mannose residue, the minor 
one occurs through the same groups of the non-reducing end mannose ring. The pseudo-1,2-
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mannobioside 1 and the natural mannobioside Man!1-2Man are known to share a similar shape and 
similar conformational properties.27 However, 1 contains a single mannose unit at the non-reducing 
end, and could be expected to bind DC-SIGN similarly to the minor binding mode of Man!1-2Man. 
Preliminary docking and NMR analysis of its binding properties to DC-SIGN suggested that several 
orientations of the ligand within the binding site were still possible and none could be selected based on 
the available data.22 
In the present work we describe the first high-resolution structure of a glycomimetic ligand in 
complex with DC-SIGN. Using X-ray crystallography on crystallized DC-SIGN CRD/1 complex, we 
have been able to characterize at a molecular level an unpredicted binding mode for such compound 
with the CRD. To obtain a dynamic picture of the interaction in solution, ligand binding was also 
analyzed by NMR spectroscopy. Transfer NOE (TR-NOESY) and Saturation Transfer Difference 
(STD) NMR experiments were used combined with the CORCEMA-ST protocol, which enables 
prediction of STD intensities from the Cartesian atomic coordinates of the ligand-receptor complex. 
These studies demonstrated that in solution 1 binds as observed in the solid state, and therefore the 
complex defined by X-ray represents the unique binding mode of this ligand in the Ca2+ binding site of 
DC-SIGN. Due to this exclusive binding mode, this ligand represents a good lead compound for a 
rational ligand optimization procedure and the X-ray structure reported here represents a powerful tool 
for virtual screening and docking as a guide to new chemical improvement of this compound. 
In addition, the structural analysis of this first high-resolution glycomimetics/DC-SIGN 
complex, as well as its comparison with other lectin binding sites, sets the basis for the design of 
efficient and specific DC-SIGN inhibitors. In particular, the interaction of 1 with langerin was also 
examined by SPR, leading to the satisfactory conclusion that 1 present improved selectivity for 
DC-SIGN. Langerin, a mannose binding C-type lectin expressed on Langerhans cells31 is present in the 
same mucosal environment as interstitial DCs expressing DC-SIGN, but it is known to possess a 
protective action against HIV infection, which should not be antagonized by therapeutic entities 
targeted against DC-SIGN.32 It was recently reported that langerin binds effectively to Man!1-2Man 
containing oligosaccharides, and the X-ray structure of this protein in complex with the Man!1-2Man 
disaccharide was described.33 Thus the conclusion that 1 is a selective DC-SIGN binder is non-trivial 
and of great importance for further improvement en route to a potential therapeutic use of these Man-
based glycomimetics in the prevention of sexually transmitted HIV infection. 
Results and discussion 
X-ray crystal structure of the complex of DC-SIGN CRD with pseudo-1,2-mannobioside 1a. 
In order to characterize the binding mode of the glycomimetics and to acquire structural data for 
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the optimization process, co-crystallization experiments of DC-SIGN CRD with some of the produced 
glycomimetic compounds were assayed. Crystals of monomeric DC-SIGN CRD in the presence of 
pseudo-1,2-mannobioside 1a (Figure 1) were obtained in crystallization conditions derived from those 
reported for the DC-SIGN CRD/Man!1-2Man.28 The crystals contain one copy of the CRD in the 
asymmetric unit with a P43212 space group. 
 
Figure 2. Electron density maps for bound pseudo-1,2-mannobioside. (a) and (b) correspond to two different views. The 
bound ligand is shown superimposed on the Fo-Fc electron density map (gray, 3 " contour). Residues involved in Ca2+ 
binding are visualized and labeled. V351 exhibits two alternative conformations with 50% occupancy in the crystal 
structure. Both of them are represented in b). 
 
After structure resolution from a model without sugar, an electron density was observed on the 
Ca2+ ion, confirming the presence of the pseudo-sugar in the canonical carbohydrate binding site of the 
CRD (Figure 2A). The structure of this complex has been solved at 1.42 Å resolution. Comparison with 
previously reported structures of DC-SIGN complexes, with natural ligands such as Man!1-2Man or 
Lewis X derivatives, shows that structure of the proteins, and more particularly residues involved in the 
binding site, are well conserved (see supporting information, Figure S1). As for many other mannose-
based ligands, 1a directly binds to the Ca2+ ion through coordination bonds with equatorial 3-OH and 4-
OH groups of the non-reducing mannose unit. The mannose unit, as well as the cyclohexane ring, is 
clearly visualized, as shown by the electron density map (Figure 2). On the contrary, the electron-
density of the dimethyl ester substituents on the cyclohexane moiety (Figure 2) as well as the 
ethylamine appendage are poorly or not visible suggesting that these parts of the molecule remain 
flexible within the complex. Three water molecules are associated to the ligand and only one of them 
connects the molecule to the protein (see supporting information, Figure S2). 
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Mannose 3-OH and 4-OH groups also interact with the Ca2+ ligand residues Glu 347, Asn 349, 
Glu 354 and Asn 365 through hydrogen bonds, and an additional interaction is observed between the 2-
OH group of the mannose unit and Asn 365. The cyclohexane ring of the ligand contributes exclusively 
to the binding through van der Waals contacts with Val 351 side chain. The conformation of the ligand 
corresponds to the extended conformation (phi O1-C1-O2’-C2’ is 66.3° ; psi’C1-O1-C2’-C1’ is -
141,11 °) that has been described as the most abundant in solution for the mimic.27 The ethylamine 
linker on the cyclohexane is free to move and oriented towards the solvent, far from the protein surface. 
This suggests that functionalization of the pseudo-1,2-mannobioside through this position onto 
multivalent presenting scaffolds should not affect the observed binding mode in solution. Indeed, the 
crystal structure of the DC-SIGN CRD/pseudo-1,2-mannobioside observed here may represent a good 
starting point for molecular improvement. 
NMR analysis of the interaction of pseudo-1,2-mannobioside with DC-SIGN in solution. 
Previous examples demonstrated that DC-SIGN recognizes carbohydrate ligands in a 
multimodal fashion, whereas X-ray diffraction studies can only show one of the possible bound poses, 
losing the structural information on other conformers and/or the other binding modes.28 Despite the 
high resolution of DC-SIGN/ligands complex structures solved by X-ray crystallography, additional 
approaches have been crucial to get a deeper structural insight to carbohydrate/lectin binding modes. 
Particularly, in a previous work, STD NMR enabled the characterization of both binding modes of a 
synthetic Man!1-2Man disaccharide,29 whilst the X-ray study was not able to fully determine the 
second binding mode.28 This multimodal binding feature seems to be a common characteristic of DC-
SIGN for its ligands, as NMR data on the molecular recognition between this lectin and other synthetic 
glycan mimics have also revealed multiple binding modes of the ligands.30 Taking into account the 
above considerations, a quantitative comparison between the X-ray data obtained for the DC-SIGN/1a 
complex with data from STD NMR studies in solution was planned. The binding of 1a has been 
previously studied by STD NMR techniques,22 but the epitope was not fully characterized due to a 
strong spectral overlap of the NMR signals. Namely, the methylene protons in the cyclohexane unit 
(H3 (C) and H6 (C), both axial and equatorial) appeared at degenerated chemical shifts, precluding 
individual integration of their STD signals. In the course of parallel studies in the laboratory, ligand 1c 
(R= CH2-CH2-N3) was used to prepare multivalent glycodendrimers via 1,3-dipolar cycloaddition 
catalyzed by Cu(I), a “click chemistry” reaction. This approach produced the formation of a triazole 
ring which induced a significant chemical shift variation of some key signals corresponding to the 
cyclohexane unit, leading to a better spectral dispersion. 
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 Figure 3. STD NMR study of the interaction of ligand 1b with DC-SIGN in solution. (a) 1H NMR reference spectrum (off-
resonance frequency 40 ppm) and (b) STD spectrum (on-resonance frequency 0 ppm) of a sample containing 1 mM of 1b 
and 19 µM of DC-SIGN ECD, at 25ºC (500 MHz). Key proton signals are labeled in (a). 
Thus, we modified the structure of 1 including a triazole ring in the spacer at the pseudo-
anomeric position, generating compound 1b. This modification was expected to help signal analysis, 
without modifying the interaction mode of the ligand with the protein. Indeed, the NMR data (Figure 3) 
support this hypothesis: the triazole residue did not affect binding to DC-SIGN neither in terms of 
affinity (STD NMR competition experiment, see Supporting Information) nor in terms of protein-
ligand contacts, (the STD signals of the triazole residue were basically null, and the pattern of 
intensities comparable to that of ligand 1a; compare Figure 4 and previously described STD signals for 
1a22). Furthermore, as expected, this monovalent compound showed chemical shifts similar to those 
observed in the multivalent systems with little signal overlapping in the 1H-NMR spectrum and, in 
particular, well-resolved signals for protons H3ax (C) and H6ax (C). Therefore, compound 1b turned 
out to be a very adequate model to study the binding process with DC-SIGN by STD NMR. 
The ability to distinguish both axial protons allowed us to demonstrate experimentally that 
proton H6ax received a considerably larger amount of saturation from the protein than H3ax (Figure 3). 
In fact, H3ax could not be integrated accurately in the STD spectrum due to its low signal-to-noise 
ratio, whilst H6ax showed the strongest STD intensity among the ligand protons, along with the 
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mannose proton H3 (M). This result indicated that H6ax (C) is in very close contact with non-
exchangeable protons of some side chains of the protein binding pocket in the bound state. 
Interestingly, inspection of the structure of the complex obtained by X-ray diffraction (Figure 2) leads 
to a straightforward explanation of the strong saturation transferred from the protein to H6ax (C) of 1b, 
as this proton sits on top of the methyl groups of the Val 351 side chain. In the experimental set-up, 
irradiation at 0 ppm leads to a very efficient saturation of these methyl protons of DC-SIGN, in 
agreement with the strong STD effect observed for the adjacent H6ax ligand proton. 
 (a)  
(b)  
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(c)  
Figure 4. STD growth curves and CORCEMA-ST analysis. (a) Ligand epitope map of 1b at 25º C. (b)  STD build-up 
curves of the mannose residue of 1b, (c) STD build-up curves of the cyclohexyl residue of 1b. Theoretical STD intensities 
predicted by CORCEMA-ST using the Cartesian coordinates of the X-ray structure are shown in dashed lines; experimental 
data in symbols. 
 
Having defined the binding epitope, a quantitative analysis of the agreement between the determined 
X-ray structure of the complex and the NMR data in solution was carried out using full matrix 
relaxation calculations and the Cartesian coordinates from X-ray diffraction (Figure 4). No refinement 
of the X-ray coordinates was carried out during CORCEMA-ST calculations, and only those protons 
with the most intense and well-isolated STD signals were considered in the analysis. Figure 4 
compares the experimental STD build-up curves with the corresponding theoretical predictions by 
CORCEMA-ST calculations for the mannose (Figure 4b) and cyclohexyl (Figure 4c) residues of 1b.34 
A good fit between theoretical and experimental curves is evident, quantitatively confirmed by the 
resulting low R-NOE factor of 0.2 (see Experimental Section).35,36 This demonstrates that the binding 
mode of the ligand in solution, as detected by NMR, is the same as the one observed in the crystal. This 
result strongly supports the notion that DC-SIGN binds this ligand in a single orientation, which 
corresponds to that observed in the X-ray structure. 
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 (a)  
(b)  
Figure 5. Expansions of NOESY experiments at 25ºC (500 MHz) of 1b. (a) Free state (1mM 1b) mixing time 600 ms. (b) 
In the presence of 19 µM DC-SIGN ECD, mixing time 300 ms. Labels indicate some key NOE peaks. 
NOESY experiments were also performed at different mixing times (see Experimental Section) 
to investigate the conformation of 1b in solution, both free and bound to DC-SIGN. The resulting 
spectra (Figure 5) suggested that no changes occur in ligand conformation upon binding to the protein 
receptor, as no significant differences in the NOE fingerprints were found. Signal overlap precludes a 
full analysis of residual conformational motion of the ligand in the protein binding site. However, some 
key cross peaks clearly observed in TR-NOESY spectra support the notion that conformation observed 
in the X-ray structure is well represented in solution. In fact, the experimental ligand interproton 
distances from NMR, calculated using the Isolated Spin Pair Approximation (ISPA), displayed good 
agreement with distances measured on the crystal structure (see Supporting Information Table S2). 
Binding mode comparison of pseudo-1,2-mannobioside with its natural model, Man!1-2Man. 
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From the combination of the two biophysical structural approaches described above (X-ray and 
NMR), we demonstrated a unique binding mode for pseudo-1,2-mannobioside 1 and provided a 
detailed molecular view of it. Initially, 1 was designed as a structural mimic of Man!1-2Man. Notably, 
both molecules exhibit an equilibrium between two conformations in solution (stacked and extended) 
with similar # and " angles around the glycosidic linkage.27 Two alternative binding modes were 
previously characterized for Man!1-2Man (Figure 6A)29 in DC-SIGN, each using a different mannose 
unit for Ca2+ coordination. The absence of hydroxyl groups in the cyclohexane moiety of 1 originally 
suggested that interaction would occur along the Man!1-2Man minor binding mode (Figure 6A), 
which involves the non-reducing end mannose and would possibly generate a favorable interaction 
between F313 of the secondary binding site and the cyclohexane moiety of 1. Surprisingly, 1 was found 
to interact through a third, distinct mode: the position of the Ca-binding diol (mannose 3-OH and 4-
OH) is swapped relative to the Man!1-2Man complex, so that the 3-OH group of 1 contacts E354 (as 
opposed to the 4-OH group of Man!1-2Man) and that the 4-OH group of 1 contacts E347 (as opposed 
to the 3-OH group of Man!1-2Man). The observed conformation of 1 is close to the extended one and 
the cyclohexane ring participates in the interaction through van der Waals contacts with V351. Thus, 
despite their largely documented structural similarity, 1 and Man!1-2Man have totally different DC-
SIGN binding modes (Figures 6A and 6B). On the contrary, strong similarity is observed with the 
binding epitope of Lewis X derivatives (lacto-N-fucopentaose III, 1SL5) (Figure 6B), which also 
exploits van der Waals contacts with V351. 
Interestingly, whilst several DC-SIGN related C-type lectins, such as DC-SIGNR and langerin, 
are capable to recognize mainly mannose-based oligosaccharides, DC-SIGN is specific for Lewis-type 
carbohydrates as well.37 In the case of DC-SIGNR, this difference has been previously attributed to the 
substitution of V351 in DC-SIGN by a serine in DC-SIGNR. Guo et al37 showed that a simple mutation 
reversing this serine to a valine can convert DC-SIGNR to a Lewis X binding lectin. This indicates that 
Val 351 represents a key residue modulating the specificity of the primary DC-SIGN binding site. The 
stabilization of 1 through V351 suggests that a similar selectivity exists for our compound. 
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Figure 6. Binding of pseudo-1,2-mannobioside to DC-SIGN and comparison with the binding of other mannose and fucose-
based oligosaccharides. (a) Comparison of pseudo-1,2-mannobioside 1a and Man!1-2Man binding modes. The protein is 
shown in olive, the pseudo-1,2-mannobioside is in yellow, Man!1-2Man in light grey, with nitrogen, oxygen, and calcium 
represented as blue, red, and green spheres, respectively. Hydrogen bonds are shown as dashed purple lines, Ca2+ 
coordination bonds are dashed black lines, and key van der Waals interactions are indicated by dashed blue lines. Both 
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Man!1-2Man binding modes are oriented highlighting the reducing (R) and non-reducing (NR) ends. (b) Comparison of 
carbohydrate binding surface epitope for LNFP III, pseudo-1,2-mannobioside 1a, and both binding modes of Man!1-2Man 
(see Figure S4 for structure of LNFP III). Residues common to binding of all carbohydrates and involved in Ca2+ chelation 
are in dark blue, residues specific for both Man!1-2Man binding modes are in green (F313, S360 and E358), K368 specific 
for Man!1-2Man minor binding mode is in pink, V351 involved in LNFPIII and pseudo-1,2-mannobioside 1a binding is in 
orange. (a) and (b) are representations with two opposite side views, V351 and P313 are highlighted in B) for appropriate 
orientation. In (a) only one of the two alternatives side chain conformations of V351 is represented for clarity. 
 
DC-SIGN/langerin specificity. 
As mentioned above, selectivity is a key concern in the selection of lead compounds for the 
development of DC-SIGN antagonists. The main issue involves selectivity versus langerin, a C-type 
lectin known to protect the host against HIV infection, which should not be antagonized by DC-SIGN 
targeting compounds.32,38 
The specificity of 1a for DC-SIGN and langerin was evaluated using a previously described 
surface plasmon resonance (SPR) competition assay.25,39 1a was compared to mannose and to the 
natural Man!1-2Man disaccharide for its ability to inhibit binding of the extracellular domains (ECD) 
of DC-SIGN or langerin to a mannosylated BSA (BSA-Man) surface (Figure 7A and 7B). In order to 
evaluate the interaction avidity effect for the lectins, we prepared two flow cells with different BSA-
Man density (Fc-HD and Fc-LD in Figure 7 corresponding respectively to flow cell of high density and 
low density). It is evident that BSA-Man density had virtually no effect on the inhibition of DC-SIGN 
binding, and for this lectin an improvement by a factor of 3 in the apparent affinity was obtained for 
both Man!1-2Man and 1a compared to mannose (Figure 7b, IC50 of 730 and 880 µM, respectively, 
compared to 2.4 mM for mannose). Thus the natural disaccharide and the mimic display same affinity 
for DC-SIGN in this assay. 
On the contrary, although the general pattern of the compound potencies remained the same for 
both surfaces (Figure 7B), it was harder to achieve inhibition of langerin binding to the Fc-HD surface 
(5000 RU) than to the Fc-LD (1350 RU), with a lower BSA-Man density,. For instance, at  lower Man-
BSA density Man!1-2Man and 1a have an IC50 of 1658 and 6553 µM, respectively, that become 562 
and 21,124 µM at higher density. This phenomenon depends on the fact that, as previously described 
and detailed in the experimental section,25 langerin displays a measurable affinity to the dextran matrix 
on the chip surface, and thus dextran/BSA-Man surface must be considered as a combined 
heterogenous ligand of langerin. The different ratios of dextran and BSA-Man, depending directly from 
the BSA-Man density, contribute to a complex relative affinity of the surface for langerin. 
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Figure 7. Specificity of pseudo1,2-mannobioside as a function of the C-type lectin. (a) SPR experiment results of the 
inhibition of DC-SIGN ECD and langerin ECD binding to BSA-Man/dextran surface by mannose, Man!1-2Man and 
pseudo-1,2-mannobioside. Results for higher BSA-Man density are represented. (b) Lectins selectivity : IC50 histograms for 
two different flow cells (Fc-HD – 5000 RU, Fc-LD – 1350 RU of immobilized BSA-Man). (c) Superposition of Man!1-
2Man/langerin and 1a/DC-SIGN complex structures. Langerin and D-SIGN backbones are in blue and yellow respectively. 
Man!1-2Man and 1a are represented in blue and yellow. Van der Waals interactions of Man!1-2Man, with A289 of 
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langerin, are represented as dashed blue lines while those of 1a, with V351 of DC-SIGN, are as dashed yellow lines. 
 
The dependence of the IC50 values on the BSA-Man surface-density in the langerin assay, 
prevented a straightforward comparison of the IC50 values obtained for the two lectins. However, 
comparison of the data in Figure 7b clearly shows that moving from Man!1-2Man to 1a a loss of 
affinity is observed for langerin while the affinity is conserved for DC-SIGN. An attempt of 
quantifying the selectivity effect in relative terms is proposed in the supporting information (Figure 
S5). This finding further supports the hypothesis of a relation between DC-SIGN selectivity and the use 
of a special binding region, shared by Lewis type derivatives. 
The crystal structure of a langerin CRD/Man!1-2Man complex has recently been published.33 
As for DC-SIGN, two binding modes have been observed with alternatively the reducing or the non 
reducing mannose involved in the primary binding through Ca2+ chelation (see supporting information, 
Figure S6). The major binding mode of Man!1-2Man to langerin is close to the binding mode of 1 to 
DC-SIGN (Figure 7c) and the main difference is the Val 351 of DC-SIGN, which is replaced by Ala 
289 in langerin (see Figure S6 and 7c). Comparing the major binding mode for the Man!1-
2Man/langerin complex and the 1/DC-SIGN structure, replacement of Ala 289 (in langerin) to Val 351 
(in DC-SIGN) significantly increases van der Waals contacts within the complex. Moreover, in 
langerin Man!1-2Man establishes a contact with Ala 289 through the hydroxyl group of the C-6 that 
fills the distance to the methyl of the alanine side chain. This requires previous desolvation of the 6-OH 
group, an energetically costly process. In the equivalent position, 1 does not have any substituent. 
Formation of a 1/langerin complex is disfavored simultaneously due to the loss of a bulky side chain in 
this position, valine to alanine, and to the absence of a group extending from the cyclohexane ring and 
capable to establish van der Waals contact with the alanine side chain. Therefore, as observed 
previously for the Lewis X DC-SIGN vs DC-SIGNR specificity, Val 351 is making the difference in 
the specificity of 1 for DC-SIGN, relative to langerin. The replacement by a serine in DC-SIGNR or an 
alanine in langerin, although being a moderate modification, is sufficient to lose Lewis X specificity in 
one case and to ensure here a preference of 1 for DC-SIGN with respect to langerin. 
Conclusions 
Multiple carbohydrate binding modes have been reported as a mechanism allowing improved 
affinity towards DC-SIGN.28 Indeed, it is interesting to note that in our assay 1 presents the same IC50 
as Man!1-2Man, while it has only an unique binding mode. This suggests that intrinsically 1 binds 
stronger than each individual binding mode of Man!1-2Man. Trying to mimic Man!1-2Man, which is 
also a good ligand of DC-SIGN, by using a pseudo-1,2-mannobioside, we finally discovered that this 
molecule mimics Lewis X binding mode to DC-SIGN, by exploiting lipophilic interactions with V351 
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side chain. Although this was not anticipated, it is a very interesting and convenient result considering 
that among a wide range of C-type lectins, DC-SIGN is the only one able to bind Lewis X.40 This result 
underlines that V351 is a key residue to target for the design of DC-SIGN specific inhibitors. Indeed, 
this structure suggests that addition of lipophilic groups to the cyclohexane scaffold of 1 should allow 
to extend contacts with the protein surface, which might improve the affinity and the DC-SIGN 
specificity to higher level. Each affinity improvement at the monovalent level will be even more 
amplified upon grafting onto multivalent presenting scaffolds. Future work in our network is going 
along this line: the development of DC-SIGN-adapted glycomimics based on a structurally driven 
approach. 
Experimental Procedures. 
Synthesis of compounds. 
Compound 1a. The synthesis of 1a was previously described by Sattin et al.16 
Compound 1b. Pseudo-1,2-mannobioside 1c (10 mg, 0.02 mmol), propargyl alcohol (1.8 mg, 
0.03 mmol), CuBr (2.2 mg, 0.015 mmol) and TBTA (1.6 mg, 0.03 mmol) were dissolved in 1 mL of 
THF/H2O (1:1). After 18 h, the solvent was evaporated and the resulting crude was purified by silica 
gel column chromatography (CH2Cl2/MeOH 9.5:0.5, 8.5:1.5, 8:2), affording 8.3 mg (75% yield) of 
compound 1b as an oil. 1H NMR (D2O) 300 MHz # ppm: 8.06 (s, 1H, Htriazol), 4.96 (d, 1H, J1-2 = 
1.64 Hz, H-1mann), 4.79 (s, 2H, CH2OH), 4.64 (t, J = 4.8 Hz, 2H, CH2N), 4.01-3.93 (m, 3H, OCH2CH2N, 
H-2mann), 3.90-3.84 (m, 2H, CHOCHmann, H-6mann), 3.83-3.78 (m, 1H, H-3mann), 3.76-3.66 (m, 8H, 
CHOCH2CH2N, H-6´mann, CH3), 3.63-3.57 (m, 2H, H-4mann, H-5mann), 2.90-2.79 (m, 1, CHCOOCH3), 
2.47-2.35 (m, 1, CHCOOCH3), 2.06-1.96 (m, 2H, CH2eqC, CH2eqC), 1.79-1.68 (m, 1H, CH2axC), 1.51-
1.39 (m, 1H, CH2axC). 13C NMR (D2O) 75 MHz # ppm: 177.4, 177.2 (C=O), 146.8 (Ctriazol), 124.6 
(CHtriazol), 98.5 (C-1mann), 73.7 (C-5mann), 73.4 (CHOCH2CH2N), 70.8 (C-3mann), 70.3 (OCH2CH2N, C-
2mann), 66.7 (C-4mann), 66.5 (CHOCH), 60.9 (C-6mann), 54.6 (CH2OH), 52.5 (CH3O), 50.3 (OCH2CH2N), 
38.8 (CHCOOCH3), 38.6 (CHCOOCH3), 26.5 (CCH2C), 26.4 (CCH2C). [!]25D = + 27.1° (c 0.6, MeOH). 
ESI-MS calc. for C21H33N3O12Na (m/z): 542.2; found: 541.9 [M+Na]+. HRMS (FAB) calc for 
C21H33N3O12Na (m/z): 542.1962 found: 542.1979 [M+Na]+. 
Cloning and expression of recombinant DC-SIGN S-CRD. 
The sequence coding for carbohydrate recognition domain of DC-SIGN, comprising amino 
acids 254 to 404, was obtained by PCR using the forward primer 
5'-gcattaggtctctgcgcatgcacccctgtccctggga-3' and the reverse primer 
5'-gcagcaggtctcttatcactacgcaggaggggggtttg-3'. The PCR template used was a previous construct for 
DC-SIGN ECD overexpression which has been described previously.8 The PCR product was inserted 
into pASK-IBA7plus vector (IBA GmbH), at the Bsa I sites, in phase with a Strep-Tag II sequence and 
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a factor Xa cleavage site, both located at N-terminal end of the protein (the CRD with this N-terminal 
tag will be called hereafter S-CRD). The resulting plasmid was sequence checked and used to 
transform calcium competent E. coli BL21(DE3). 
Culture was initiated from a 5% dilution of an overnight culture into LB medium with 
100 mg/L ampicillin. Cells were grown for 3 h at 37°C, and DC-SIGN S-CRD expression was induced 
by addition of 1 mg/L anhydrotetracycline for 4 additional hours. Cells were harvested by 
centrifugation at 5000 g for 20 min. The protein was expressed as inclusion bodies and then a refolding 
step was required prior to the purification procedures. 
Protein purification. 
The pellet, containing DC-SIGN S-CRD, obtained from a 1 L culture was resuspended in 
30 mL of buffer A (150 mM NaCl and 25 mM Tris pH 8). Cells were lysed by freezing at –20°C, 
thawing and sonication with addition of a tablet of protease inhibitors (Roche Diagnostics). Inclusion 
bodies were isolated by centrifugation at 100,000 g for 30 min at 4°C, and using a Potter-Elvehjem 
homogenizer were resuspended in 30 mL buffer A supplemented with 2 M urea and 1% Triton X-100, 
and recovered by a second centrifugation. Inclusion bodies were washed again with buffer A and 
solubilized in buffer A supplemented with 6 M guanidine hydrochloride and 0.01% 2-mercaptoethanol. 
Inclusion bodies solution was centrifuged at 100,000 g for 1 h at 4°C, supernatant was diluted in 
120 mL buffer of 1.25 M NaCl, 25 mM Tris pH 8 and 25 mM CaCl2, and the resulting solution was 
dialyzed overnight against 880 mL buffer of 25 mM Tris pH 8. Refolding of inclusion bodies was 
achieved by extensive dialysis in buffer A supplemented with 4 mM CaCl2 (buffer A'), and insoluble 
compounds were removed by the last centrifugation step at 100,000 g for 1 h at 4°C. 
Purification was then performed as previously described for langerin S-CRD41. Briefly, the first 
step of DC-SIGN S-CRD purification was performed by affinity chromatography on a 15 mL Strep-
Tactin superflow column (IBA GmbH) equilibrated in buffer A' and eluted in same buffer 
supplemented with 2.5 mM desthiobiotin. A second purification step was performed with DC-SIGN S-
CRD-containing fractions concentrated to 1.5 mL. Functional DC-SIGN S-CRD was separated from 
non-functional protein as it was delayed on a 15 mL mannose-agarose column equilibrated in buffer A'. 
Functional DC-SIGN S-CRD-containing fractions were concentrated to 11 mg/mL. 
DC-SIGN ECD and Langerin ECD were produced and purified as previously described8,42. 
DC-SIGN CRD crystallization. 
Crystallization assays were performed manually by hanging-drop vapor-diffusion method at 
293 K in EasyXtal plates (Qiagen) with protein-carbohydrate stock solution made by mixing 10 µL of 
concentrated DC-SIGN S-CRD with 1 µL of 100 mM pseudo-1,2-mannobioside 1a. Drops, prepared 
 19 
by mixing 1 µL reservoir solution with 1 µL protein-carbohydrate stock solution, were equilibrated 
against 1 mL reservoir solution. The best crystals appeared when reservoir solution was composed of 
20% PEG 3350, 100 mM cacodylate pH 6.5 and 200 mM NaCl. A 0.06 $ 0.06 $ 0.65 mm crystal was 
cryoprotected in Paratone-N (Hampton Research) and was flash-frozen in liquid nitrogen. 
Data collection and processing. 
X-ray diffraction data were collected at ID29 beamline at ESRF Grenoble. Two datasets were 
collected at a wavelength of 0.9809 Å, with a crystal-to-detector distance set to 197.89 mm and an X-
ray transmission of 8.1%. The first dataset was collected at maximal resolution and the second with 
reduced exposure time to minimize detector saturation at lower resolution. The first dataset, composed 
of 360 images, was collected with an oscillation range of 0.5° per image and an exposure time of 1 s. 
The second dataset, composed of 120 images, was collected with an oscillation range of 3° per image 
and an exposure time of 0.2 s. 
Datasets were processed and merged using the programs XDS and XSCALE, respectively.43 
Statistics of data processing are summarized in Table 1. Matthews coefficient was calculated using the 
program MATTHEWS_COEF.44 
Phasing, model building and structure refinement 
Phasing was performed by molecular replacement with a model built from a structure of DC-SIGN 
CRD (pdb code 2IT6) depleted of calcium ions, carbohydrate molecules and water molecules. The best 
solution resulting from molecular replacement was used as the starting model for structure refinement. 
The structure refinement was performed by cycling between manual building using the program 
COOT44 and energy minimization with the program REFMAC 5 from the CCP4 package.44 Statistics of 
structure refinement are summarized in Table 1. Crystal structure of DC-SIGN CRD/1a has been 
deposited in Protein Data Bank under PDB code 2xr5. 
Surface Plasmon Resonance experiments. 
Surface plasmon resonance experiments were performed on a Biacore 3000 using a CM4 chip, 
functionalized at 5 µL/min. Flow cells (Fc) 1, 2 and 3 were activated with 50 $L of an 0.2 M 
EDC/0.05 M NHS mixture, after this step Fc2 and Fc3 were functionalized with mannosylated bovine 
serum albumine (BSA-Man), and finally remaining activated groups of both flow cells were blocked 
with 30 $L of 1 M ethanolamine. After blocking, the three flow cells were treated with 10 µL of 
10 mM HCl to remove unspecific bound proteins and 20 µL of 50 mM EDTA to expose surface to 
regeneration protocol. After these steps 5000 RU and 1170 RU of BSA-Man were immobilized on the 
surfaces of Fc2 and Fc3, respectively. BSA-Man stock solution was prepared by dissolving the 
 20 
glycoprotein in water to final 1 mg/mL concentration, and for immobilization it was diluted to 
60 µg/mL in a buffer of 10 mM sodium acetate pH 4. 
To control surface activity and to determine optimal working protein concentration, 13 µL of 
samples of increasing concentrations of DC-SIGN and langerin ECDs (0.7–46.7 µM for DC-SIGN, and 
0.7–45.7 µM for langerin) were injected onto the surfaces. The selected concentration was 20 µM for 
both lectins. 
For inhibition studies, samples of each lectin mixed with increasing concentrations of inhibiting 
compounds were prepared in a running buffer (buffer A' supplemented with 0.005% P20 surfactant), 
and 13 µL of each sample was injected onto the surfaces at a 5 $L/min flow rate. Concentrations of 
inhibiting compounds ranged from 4.1 to 26,667 µM or from 3.1 to 20,000 µM for D-mannose, from 
4.1 to 8,889 µM or from 1.0 to 6,667 µM for Man!1-2Man, and from 1.3 µM to 8,782 µM or from 
1.0 µM to 6,587 µM for pseudo-1,2-mannobioside 1a mixed with DC-SIGN or langerin ECDs, 
respectively. The resulting sensorgrams were reference surface corrected, except in the case of 
langerin, since this lectin displayed affinity to the dextran matrix, and thus dextran/BSA-Man surface 
was considered as a combined ligand of langerin (as described previously in Andreini et al).25 
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The lectin binding responses were extracted from the sensorgrams, converted to percent residual 
activity values (y) with respect to lectin alone binding, and plotted against corresponding compound 
concentration. The 4-parameter logistic model (eq, 1) was fitted to the plots, and the IC50 values were 
calculated using the values of fitted parameters (Rhi, Rlo, A1, and A2) and equation 2. 
NMR spectroscopy experiments. 
NMR spectroscopy experiments were performed on a Bruker Avance DRX 500 MHz 
spectrometer equipped with a 5 mm inverse triple-resonance probe head. NMR samples were prepared 
in 550 $L of 99.9% D2O and for the experiments in presence of the receptor, in buffer D2O (150 mM 
NaCl, 4 mM CaCl2, 25 mM d-Tris, pD 8) and with 19 $M DC-SIGN ECD. The concentration of the 
ligand was 1.35 mM, and the same sample was used for both, STD NMR, and TR-NOESY 
 21 
experiments. For the two-ligand equimolar competition experiment, a concentration of 1.7 mM was 
employed. 
STD NMR experiments were carried out at 10, 25 and 35ºC, by using a train of Gaussian 
shaped pulses of 49 ms (field strength of ca. 80 Hz), an inter-pulse delay of 1 ms45 and 15 ms spin-lock 
pulse (field strength of 3.7 kHz) prior to acquisition. The on-resonance frequency was set to 0 ppm and 
the off-resonance frequency was 40 ppm. Appropriate blank experiments were used to ensure the lack 
of direct saturation of the ligand protons. Saturation times of 0.5, 1, 1.5, 2, 3, 4 and 5 s were used to 
obtain the STD build-up curves. 
The binding epitope was characterized by the analysis of initial slopes of the STD intensities at 
25º C 46: the experimental (I0 – Isat / I0) curves were fitted to an exponential function described by the 
equation: STD (tsat) = STDmax (1 – e –ksat·tsat), which allows to calculate STD at zero saturation time 
(initial slopes) by multiplying the resulting parameters STDmax and ksat.47 The epitope is obtained by 
normalization of the whole set of initial slopes against the highest value, and expressing the result in 
percentage. 
NOESY experiments were carried out using a phase sensitive pulse program with gradient 
pulses in the mixing time and with presaturation.48,49 Mixing times of 0.2, 0.3, 0.4, 0.5, 0.6, and 0.8 s 
were used for NOESY spectra and 0.1, 0.2, 0.3, and 0.5 s for TR-NOESY spectra. NOE build-up 
curves were obtained from the normalized cross-peak volumes (ratio cross peak over diagonal peak) as 
function of the mixing time. For TR-NOESY experiments the growth was approximately linear up to 
300 ms (see Figure S7 in the Supporting Information). Longitudinal cross-relaxation rates were 
obtained by averaging the ratio of the normalized volume and the mixing time, for mixing times 0.1, 
0.2, and 0.3 s. From them, intramolecular ligand proton-proton distances were obtained by using the 
ISPA approach (isolated spin pair approximation), and taking the distance H3eq - H3ax of the 
cyclohexyl ring as a reference. 
CORCEMA-ST: 
The Cartesian coordinates of the crystal structure of the complex DC-SIGN CRD/1a were 
employed for the full relaxation matrix calculations. As no chemical shift assignment of the protein 
protons was available, they were predicted by using the program SHIFTX.50 Although the experimental 
irradiation frequency for selective saturation was established at 0 ppm, all the protein protons with 
chemical shifts predicted to be within the [0.7, -0.7] ppm range were included, as SHIFTX does not 
consider the effects of line broadening under the experimental conditions. All exchangeable hydrogen 
atoms were excluded in the calculations, as the STD NMR experiments were performed in D2O. We 
assumed that pdb coordinates for the bound and free protein were identical and several cycles were 
performed to reach the optimized parameters. For this protein-ligand system, the classical assumption 
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of an association step limited by diffusion (on-rate 108 M-1s-1) was considered. The off-rate was varied 
within a range that yielded a final dissociation constant within the micromolar range, typical for this 
kind of ligands of DC-SIGN. No large variations were observed of the R-factor during this process, and 
the final off-rate was 40 kHz. Assuming a spherical shape for the protein tetramer, the correlation time 
of bound ligand was set to 115 ns whereas 0.5 ns was used for the free ligand, and 10 ps for the internal 
correlation time of methyl groups. This might be considered an oversized value for the correlation time 
of a protein of about 155 kDa (DC-SIGN tetramer). Nevertheless this seems to be not uncommon in 
CORCEMA-ST calculations, 51-53 particularly when the protein shape deviates from a perfect globular 
shape, as it is the case with the DC-SIGN tetramer. To reduce the dimensions of the matrices, a cut off 
of 8 Å from the ligand was used. The STD intensities for each binding mode were calculated as 
percentage fractional intensity changes, Scalc,k, from the intensity matrix I(t) (Scalc,k = (([(I0k – I(t)k)*100]/ 
I0k), where k is a particular proton in the complex, and I0k its thermal equilibrium value)34 and the 
calculation was carried out for the set of saturation times experimentally measured (0.5, 1, 1.5, 2, 3, 4 
and 5 s). The theoretical STD values were compared to the experimental ones using the NOE R-
factor35,36 defined as: 
 
In this equation  and  refer to experimental and calculated STD values for proton k. 
The best agreement with experimental data was achieved using the B chain of the residue V351. 
 
Acknowledgment 
For the financial support we are grateful to: Sidaction: Ensemble contre le SIDA for Michel 
Thépaut post-doctoral grant and support, EU ITN Marie-Curie program (CARMUSYS - Grant number 
213592) for funding Cinzia Guzzi, Ieva Sutkeviciute, Renato Ribeiro-Viana and Norbert Varga. J. A. 
acknowledges financial support from the MICINN through the Ramon y Cajal program. 
 
Reference 
 
(1) Banchereau, J.; Steinman, R. M. Nature 1998, 392, 245–252. 
(2) Bell, D.; Young, J. W.; Banchereau, J. Adv Immunol 1999, 72, 255–324. 
(3) van Kooyk, Y.; Engering, A.; Lekkerkerker, A. N.; Ludwig, I. S.; Geijtenbeek, T. B. Curr 
Opin Immunol 2004, 16, 488–493. 
(4) Geijtenbeek, T. B.; Kwon, D. S.; Torensma, R.; van Vliet, S. J.; van Duijnhoven, G. C.; 
 23 
Middel, J.; Cornelissen, I. L.; Nottet, H. S.; KewalRamani, V. N.; Littman, D. R.; Figdor, C. 
G.; van Kooyk, Y. Cell 2000, 100, 587–597. 
(5) van Kooyk, Y.; Geijtenbeek, T. B. Nat Rev Immunol 2003, 3, 697–709. 
(6) Geijtenbeek, T. B.; van Kooyk, Y. Apmis 2003, 111, 698–714. 
(7) Hodges, A.; Sharrocks, K.; Edelmann, M.; Baban, D.; Moris, A.; Schwartz, O.; Drakesmith, 
H.; Davies, K.; Kessler, B.; McMichael, A.; Simmons, A. Nat Immunol 2007, 8, 569–577. 
(8) Tabarani, G.; Thépaut, M.; Stroebel, D.; Ebel, C.; Vivès, C.; Vachette, P.; Durand, D.; Fieschi, 
F. J Biol Chem 2009, 284, 21229–21240. 
(9) Tabarani, G.; Reina, J. J.; Ebel, C.; Vivès, C.; Lortat-Jacob, H.; Rojo, J.; Fieschi, F. FEBS Lett 
2006, 580, 2402–2408. 
(10) Martínez-Avila, O.; Hijazi, K.; Marradi, M.; Clavel, C.; Campion, C.; Kelly, C.; Penadés, S. 
Chemistry 2009, 15, 9874–9888. 
(11) Becer, C. R.; Gibson, M. I.; Geng, J.; Ilyas, R.; Wallis, R.; Mitchell, D. A.; Haddleton, D. M. J 
Am Chem Soc 2010, 132, 15130–15132. 
(12) Ciobanu, M.; Huang, K.-T.; Daguer, J.-P.; Barluenga, S.; Chaloin, O.; Schaeffer, E.; Mueller, 
C. G.; Mitchell, D. A.; Winssinger, N. Chem Commun 2011, 47, 9321–9323. 
(13) Cambi, A.; de Lange, F.; van Maarseveen, N. M.; Nijhuis, M.; Joosten, B.; van Dijk, E. M.; de 
Bakker, B. I.; Fransen, J. A.; Bovee-Geurts, P. H.; van Leeuwen, F. N.; Van Hulst, N. F.; 
Figdor, C. G. J Cell Biol 2004, 164, 145–155. 
(14) de Bakker, B. I.; de Lange, F.; Cambi, A.; Korterik, J. P.; van Dijk, E. M.; Van Hulst, N. F.; 
Figdor, C. G.; Garcia-Parajo, M. F. Chemphyschem 2007, 8, 1473–1480. 
(15) Martínez-Avila, O.; Bedoya, L. M.; Marradi, M.; Clavel, C.; Alcamí, J.; Penadés, S. 
ChemBioChem 2009, 10, 1806–1809. 
(16) Sattin, S.; Daghetti, A.; Thépaut, M.; Berzi, A.; Sánchez-Navarro, M.; Tabarani, G.; Rojo, J.; 
Fieschi, F.; (null); Bernardi, A. ACS Chem Biol 2010, 5, 301–312. 
(17) Wang, S.-K.; Liang, P.-H.; Astronomo, R. D.; Hsu, T.-L.; Hsieh, S.-L.; Burton, D. R.; Wong, 
C.-H. Proc Natl Acad Sci USA 2008, 105, 3690–3695. 
(18) Luczkowiak, J.; Sattin, S.; Sutkeviciute, I.; Reina, J. J.; Sánchez-Navarro, M.; Thépaut, M.; 
Martinez-Prats, L.; Daghetti, A.; Fieschi, F.; Delgado, R.; Bernardi, A.; Rojo, J. Bioconjug 
Chem 2011, 22, 1354–1365. 
(19) Lasala, F.; Arce, E.; Otero, J. R.; Rojo, J.; Delgado, R. Antimicrob. Agents Chemother. 2003, 
47, 3970–3972. 
(20) Borrok, M. J.; Kiessling, L. L. J Am Chem Soc 2007, 129, 12780–12785. 
(21) Tran, T. H.; Baz, El, R.; Cuconati, A.; Arthos, J.; Jain, P.; Khan, Z. K. J Antivir Antiretrovir 
2011, 3, 49–54. 
(22) Reina, J. J.; Sattin, S.; Invernizzi, D.; Mari, S.; Martinez-Prats, L.; Tabarani, G.; Fieschi, F.; 
Delgado, R.; Nieto, P. M.; Rojo, J.; Bernardi, A. ChemMedChem 2007, 2, 1030–1036. 
(23) Mitchell, D. A.; Jones, N. A.; Hunter, S. J.; Cook, J.; Jenkinson, S. F.; Wormald, M. R.; Dwek, 
R. A.; Fleet, G. W. J. Tetrahedron: Asymmetry 2007, 18, 1502–1510. 
(24) Garber, K. C. A.; Wangkanont, K.; Carlson, E. E.; Kiessling, L. L. Chem Commun (Camb) 
2010, 46, 6747–6749. 
(25) Andreini, M.; Doknic, D.; Sutkeviciute, I.; Reina, J. J.; Duan, J.; Chabrol, E.; Thépaut, M.; 
Moroni, E.; Doro, F.; Belvisi, L.; Weiser, J.; Rojo, J.; Fieschi, F.; Bernardi, A. Org Biomol 
Chem 2011, 9, 5778–5786. 
(26) Berzi, A.; Reina, J. J.; Ottria, R.; Sutkeviciute, I.; Antonazzo, P.; Sánchez-Navarro, M.; 
Chabrol, E.; (null); (null); Cetin, I.; Rojo, J.; Fieschi, F.; Bernardi, A.; Clerici, M. AIDS 2012, 
26, 127–137. 
(27) Mari, S.; Posteri, H.; Marcou, G.; Potenza, D.; Micheli, F.; Jiménez-Barbero, J.; Bernardi, A. 
European Journal of Organic Chemistry 2004, 2004, 5119–5225. 
(28) Feinberg, H.; Castelli, R.; Drickamer, K.; Seeberger, P. H.; Weis, W. I. J Biol Chem 2007, 282, 
4202–4209. 
(29) Angulo, J.; Díaz, I.; Reina, J. J.; Tabarani, G.; Fieschi, F.; Rojo, J.; Nieto, P. M. ChemBioChem 
2008, 9, 2225–2227. 
(30) Guzzi, C.; Angulo, J.; Doro, F.; Reina, J. J.; Thépaut, M.; Fieschi, F.; Bernardi, A.; Rojo, J.; 
Nieto, P. M. Org Biomol Chem 2011, 9, 7705–7712. 
 24 
(31) Valladeau, J.; Ravel, O.; Dezutter-Dambuyant, C.; Moore, K.; Kleijmeer, M.; Liu, Y.; Duvert-
Frances, V.; Vincent, C.; Schmitt, D.; Davoust, J.; Caux, C.; Lebecque, S.; Saeland, S. 
Immunity 2000, 12, 71–81. 
(32) de Witte, L.; Nabatov, A.; Geijtenbeek, T. B. H. Trends Mol Med 2008, 14, 12–19. 
(33) Feinberg, H.; Taylor, M. E.; Razi, N.; Mcbride, R.; Knirel, Y. A.; Graham, S. A.; Drickamer, 
K.; Weis, W. I. J Mol Biol 2011, 405, 1027–1039. 
(34) Jayalakshmi, V.; Rama Krishna, N. J. Magn. Reson. 2004, 168, 36–45. 
(35) Xu, Y.; Sugár, I. P.; Krishna, N. R. J Biomol NMR 1995, 5, 37–48. 
(36) Krishna, N. R.; Agresti, D. G.; Glickson, J. D.; Walter, R. Biophys J 1978, 24, 791–814. 
(37) Guo, Y.; Feinberg, H.; Conroy, E.; Mitchell, D. A.; Alvarez, R.; Blixt, O.; Taylor, M. E.; Weis, 
W. I.; Drickamer, K. Nat Struct Mol Biol 2004, 11, 591–598. 
(38) de Witte, L.; Nabatov, A.; Pion, M.; Fluitsma, D.; de Jong, M. A. W. P.; de Gruijl, T.; Piguet, 
V.; van Kooyk, Y.; Geijtenbeek, T. B. H. Nat Med 2007, 13, 367–371. 
(39) Timpano, G.; Tabarani, G.; Anderluh, M.; Invernizzi, D.; Vasile, F.; Potenza, D.; Nieto, P. M.; 
Rojo, J.; Fieschi, F.; Bernardi, A. ChemBioChem 2008, 9, 1921–1930. 
(40) Lee, R. T.; Hsu, T.-L.; Huang, S. K.; Hsieh, S.-L.; Wong, C.-H.; Lee, Y. C. Glycobiology 
2011, 21, 512–520. 
(41) Thépaut, M.; Vivès, C.; Pompidor, G.; Kahn, R.; Fieschi, F. Acta Crystallogr F Struct Biol 
Cryst Commun 2008, 64, 115–118. 
(42) Thépaut, M.; Valladeau, J.; Nurisso, A.; Kahn, R.; Arnou, B.; Vivès, C.; Saeland, S.; Ebel, C.; 
Monnier, C.; Dezutter-Dambuyant, C.; Imberty, A.; Fieschi, F. Biochemistry 2009, 48, 2684–
2698. 
(43) Kabsch, W. J. Appl. Cryst. 1993, 26, 795–800. 
(44) Collaborative Computational Project, N. 4.  Acta Crystallogr. D 1994, 50, 760–763. 
(45) Mayer, M.; Bernd, M. Angew. Chem. Int. Ed. 1999, 38, 1784–1788. 
(46) Mayer, M.; Meyer, B. J Am Chem Soc 2001, 123, 6108–6117. 
(47) Mayer, M.; James, T. L. J Am Chem Soc 2004, 126, 4453–4460. 
(48) Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. J. Chem. Phys. 1979, 71, 4546–4553. 
(49) Wagner, R.; Berger, S. Journal of Magnetic Resonance, Series A 1996, 123, 119–121. 
(50) Neal, S.; Nip, A. M.; Zhang, H.; Wishart, D. S. J Biomol NMR 2003, 26, 215–240. 
(51) Yuan, Y.; Bleile, D. W.; Wen, X.; Sanders, D. A. R.; Itoh, K.; Liu, H.-W.; Pinto, B. M. J Am 
Chem Soc 2008, 130, 3157–3168. 
(52) Kemper, S.; Patel, M. K.; Errey, J. C.; Davis, B. G.; Jones, J. A.; Claridge, T. D. W. J. Magn. 
Reson. 2010, 203, 1–10. 
(53) Canales, A.; Rodríguez-Salarichs, J.; Trigili, C.; Nieto, L.; Coderch, C.; Andreu, J. M.; 
Paterson, I.; Jiménez-Barbero, J.; Díaz, J. F. ACS Chem Biol 2011, 6, 789–799. 
 
 25 
 
Table I: DC-SIGN CRD/pseudo-1,2-mannobioside 1a complex data 
collection and structure refinement statistics. 
Data collection statistics 
Wavelength (Å) 0.9809 
Space group P43 21 2 Unit cell parameters (Å) a = b = 71.45; c = 52.67 
Resolution (Å) 42.41-1.42 (1.46-1.42)a 
Measured reflections 658501 (12715) 
Unique reflections 25925 (1761) 
Completeness (%) 99.4 (92.4) 
I/% (I) 28.67 (5.56) 
Rmerge b (%) 13.0 (58.0) Structure refinement statistics 
Resolution (Å) 42.41-1.42 (1.46-1.42) 
Refinement factors  
Used reflections/free (%) 24628 / 5.0 
Rcrystc 0.145 Rfreec 0.172 rmsd from ideality  
Bond lengths (Å) 0.030 
Bond angles (deg) 2.413 
Ramachandran plot (%)  
Most favored regions 87.0 
Additional allowed regions 11.3 
Generously allowed regions 1.7 
Disallowed regions 0.0 
Average B-factor (Å2) 13.30 
a Values in parentheses are for the highest resolution shell. b Rmerge =&h&m%Im(h) - 
&I(h)'(&h&mIm(h). c Rcryst=&((F0(-(Fc((&(F0(, and Rfree= Rcryst calculated with 5% of 
F0 sequestered before refinement. 
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9.1. DEVELOPMENT OF MONOVALENT GLYCOMIMICS
9.1.4.4. Structural characterization of psTri interaction with DC-SIGN; comparison of thermodynamic
and hydrodynamic properties of psDi and psTri interaction with DC-SIGN
From the two mannose-based glycomimics psDi and psTri, the latter one was previously chosen as
the best lead due to its higher eﬃciency. However, recalling the data published by Luczkowiak et
al. (article n°3), a surprising discrepancy can be tracked when comparing the inhibitory potencies
of psDi and psTri in monovalent and multivalent presentations: the SPR data showed an order of
magnitude diﬀerence in monovalent psDi and psTri IC50 values in favor for psTri, but this diﬀerence
was lost comparing corresponding multivalent compounds. Moreover, monovalent and tetravalent
psTri had the same eﬃciency of inhibition of DC-SIGN binding to ManBSA surface. Although Ebola
infection inhibition assay yielded an order of magnitude diﬀerence of the potencies of tetravalent
presentations of psDi and psTri, however, it disappears for multivalent dendrimers.
The following paper manuscript aims to unravel the underlying reasons of this phenomenon.
Starting with the X-ray structure of psTri/DC-SIGN CRD, the further hydrodynamic and thermo-
dynamic characterization of psTri interaction with DC-SIGN is presented and compared with psDi.
The final outcome of these studies is an unexpected finding that a relatively small glycomimic psTri
is capable to bridge DC-SIGN tetramers and thus lead to an artificial overestimation of its eﬃcacy.
Therefore, the simpler and more readily to synthesize psDi ligand was approved to be as good as
psTri, which is confirmed by the fact that multivalent compounds with psDi and psTri tethers have
the same eﬃciency in cellular HIV trans infection inhibition assay.
The main outcome of these studies: the compound psTri has a unique intrinsic feature of
clustering DC-SIGN tetramers without any multivalent presentation.
Contributions:
The compounds were synthesized by the team of Pr. A. Bernardi. The X-ray structure of
psTri/DC-SIGN was solved by our group (Dr. Michel Thépaut). The initial DC-SIGN bridging
model was generated in our team by Dr. Michel Thépaut. The cell-based assays of HIV inhibition
were performed by a PhD student Angela Berzi in the group of Pr. Mario Clerici.
My contribution to this study:
✧ Prepared DC-SIGN CRD and performed its co-crystallization with psTri.
✧ Participated in X-ray data collection and structure solving.
✧ I have conducted the ITC experiments and analyzed the data with a technical support from
Dr. Aymeric Audfray.
✧ With the help of Pr. Christine Ebel and Aline Le Roy, I have performed AUC and DLS
experiments and analyzed the data.
✧ Prepared the initial version of the manuscript of the following paper.
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Abstract
DC-SIGN is a dendritic cell-specific C-type lectin receptor that recognizes highly glycosylated ligands ex-
pressed on the surfaces of various pathogens. It is known to be implicated in early stages of many viral in-
fections, including HIV, which makes it an interesting therapeutical target. Glycomimetic compounds are
good drug candidates for DC-SIGN inhibition due to their high solubility, resistance to glycosidases and
non-toxicity. In this work we studied the structural properties of DC-SIGN extracellular domain (ECD), a
tetrameric protein, interaction with two glycomimetic inhibitors, recently described pseudomannobioside
(psDi) and pseudomannotrioside (psTri). Though the inhibitory potency of psTri is significantly higher
than psDi, crystal structures of the complexes with DC-SIGN carbohydrate recognition domain show the
same binding mode for both compounds. Moreover, when coupled to multivalent scaﬀolds, the inhibitory
potencies of both compounds become uniform. Combining isothermal titration microcalorimetry, ana-
lytical ultracentrifugation and dynamic light scattering techniques to study DC-SIGN ECD interaction
with these glycomimetics, revealed that psTri is capable to bridge DC-SIGN tetramers. The results of
these studies allowed to select a compound for further improvements.
Keywords: DC-SIGN, HIV, glycomimetics, clustering
Introduction
Immature dendritic cells (DCs) are the major professional antigen presenting cells of the innate im-
munity. They routinely survey the peripheral tissues, capture and process the invading pathogens, and
finally, present the antigens to the T cells, which leads to the boost of pathogen specific adaptive immune
responses Banchereau & Steinman [4]. Pattern recognition receptors (PRRs) of DCs are instrumen-
tal in capturing pathogens through the recognition of so-called pathogen associated molecular patterns
(PAMPs). On their surface, DCs express a wide range of diﬀerent PRRs that include toll-like receptors
(TLRs) and C-type lectin receptors (CLRs), and this enables DCs to recognize the vast majority of in-
vading pathogens Figdor et al. [14], Geijtenbeek et al. [17]. One of these PRRs is DC-SIGN (Dendritic
Cell-Specific ICAM-3 Grabbing Non-integrin), a CLR that is abundantly expressed on immature DCs
and that has been extensively studied during the past decade because of its intriguing roles in immunity
Geijtenbeek et al. [15], Svajger et al. [28]. Apart from functioning as an adhesion molecule and a PRR,
DC-SIGN has been recognized as a receptor that is usurped by various dangerous pathogens, including
viruses such as HIV and Ebola, bacteria, fungi and parasites, to evade or modulate host immune responses
and thus enhance their infectivity van Kooyk & Geijtenbeek [34], Geijtenbeek et al. [16]. These findings
have highlighted DC-SIGN as an interesting therapeutical target and inspired many research groups to
attempt to design its antagonists that would prevent the infections.
DC-SIGN is a type II membrane protein with a cytosolic domain followed by a transmembrane region
and an extracellular domain (ECD). The latter is organized into an elongated neck region and a globular
C-terminal carbohydrate recognition domain (CRD) of the C-type lectin family, which binds fucose and
mannose containing carbohydrates in a calcium-dependent manner Feinberg et al. [13], Guo et al. [19].
The neck region is responsible for lectin oligomerization into tetramers and serves as a stalk that raises
CRDs well above the cell membrane (320Å) and presents them in a tetravalent manner with the distances
between vicinal binding sites being ca. 40Å Tabarani et al. [30]. These tetramers are further clustered
to microdomains at the cell membrane Cambi et al. [7], de Bakker et al. [10].
Although monosaccharide binding aﬃnity to DC-SIGN is very low, the described organization of DC-
SIGN together with clustered presentation of the glycans on the pathogens, greatly contributes to the
binding aﬃnity enhancement through the avidity eﬀects. Hence, the strategies of DC-SIGN inhibition
involve not only the design of various monovalent fucose and mannose-based glycomimetic or small non-
carbohydrate ligands with the goal to improve both aﬃnity and selectivity, but also include extensive
search for the proper scaﬀolds with multimeric ligand presentation that would ensure eﬃcient competition
with highly multivalent PAMPs (reviewed in Reina et al. [22] and Anderluh et al. [2]).
Our groups focus on the development of fucose- and mannose-based glycomimetic inhibitors of DC-
SIGN. We recently published series of LewisX trisaccharide mimics, which had slightly better aﬃnity as
compared to LewisX and an improved selectivity to DC-SIGN than langerin Andreini et al. [3], a C-type
lectin with a reported implication in the protection from HIV infection de Witte et al. [11]. We have also
developed two mannose type glycomimetics, corresponding to a terminal branch of high mannose glycan,
which are the target ligand for DC-SIGN on the gp120 HIV enveloped protein. Thus, we produced a
Manα1-2Man mimic pseudomannobioside (psDi) and a Manα1-2Manα1-6Man mimic pseudomannotrioside
(psTri) and evaluated them as DC-SIGN inhibitors. The initial SPR competition assay indicated psTri
to have an order of magnitude better aﬃnity (in terms IC50) than psDi Sattin et al. [24]. Hence, this
compound was selected to invest synthetic eﬀorts and generate a tetravalent dendron, which in turn was
tested for the capacity to inhibit HIV trans infection of T lymphocytes mediated by B-THP-1/DC-SIGN
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cells Sattin et al. [24] as well as HIV transmission inhibition in cervical explants Berzi et al. [5]. Indeed,
the psTri dendron displayed a very promising anti-HIV activity in these assays and was demonstrated to
be non-toxic.
Moreover, the third generation (G3) Boltorn type dendrimers bearing an average of 30-32 copies
of psDi (G3(pseudodi)32) or psTri (G3(pseudotri)32) were built and evaluated in SPR competition and
DC-SIGN-mediated Ebola infection assays Luczkowiak et al. [21]. Both dendrimers were highly active
in inhibiting Ebola infection, but surprisingly, no significant diﬀerences of their potencies were found
(IC50 ca. 20 nM). The SPR competition experiments gave the similar outcome: while the activities of
the monovalent compounds have almost 1 order of magnitude diﬀerence in favor for psTri, nearly the
same aﬃnities were observed for tetravalent psDi and psTri forms (Fig. 1) as well as for their multivalent
versions. Furthermore, the monovalent and tetravalent forms of psTri had basically the same activities.
Figure 1: The comparison of psDi and psTri inhibitory eﬃciencies at monovalent and multivalent presentations.
a) The structures of psDi and psTri, tetravalent dendron and multivalent Boltorn type dendrimer scaﬀolds; the
red frames highlight the portions of the molecules conjugated to the scaﬀolds; the structure of G3 Boltorn type
dendrimer, represented as a grey sphere, is shown in SI. b) The SPR competition assay results for the corresponding
compounds.
These findings have raised the question why the relatively high eﬃciency of psTri is lost when the
compound is tethered on the multivalent scaﬀolds and is psTri really the best lead compound. In order
to make a rational choice of one of those two compounds, to which synthetic eﬀorts should be invested
for further optimization, these questions had to be addressed.
Recently, we have structurally characterized the binding of psDi to DC-SIGN CRD Thepaut et al.
[31]. X-ray crystallography of co-crystallized DC-SIGN CRD/psDi complex revealed an unexpected
binding mode of the molecule, which was confirmed by solution studies using transfer NOE (tr-NOESY)
and saturation transfer diﬀerence (STD) NMR experiments. Although psDi and its natural counterpart
Manα1-2Man have similar aﬃnities to DC-SIGN as observed in surface plasmon resonance (SPR) com-
petition test (IC50 values 1.0mM and 0.9mM, respectively), our results indicated that psDi, contrary
to Manα1-2Man, has only a single binding mode within DC-SIGN CRD, a prerequisite for a good lead
compound for further chemical modifications to improve aﬃnity and selectivity. Furthermore, we also
found that psDi has an enhanced selectivity towards DC-SIGN compared to langerin. This is an impor-
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tant feature for the development of microbicides that shouldn’t interfere with the protective function of
langerin, especially because of its expression on Langerhans cells (LCs), which constitute the very first
barrier for invading HIV virions in genital and rectal mucosa.
Herein we describe our eﬀorts to unravel the underlying reasons for the above-described discrep-
ancy observed for the glycomimetic compound psTri. We have co-crystallized the latter glycomimics
with DC-SIGN CRD and solved the X-ray structure. Furthermore, we investigated the thermodynamic
and hydrodynamic properties of DC-SIGN extracellular domain (ECD) interaction with psDi and psTri
by isothermal titration microcalorimetry (ITC) and analytical ultracentrifugation (AUC). Our results
indicated that monovalent psTri in fact functions as a bivalent molecule capable to bridge DC-SIGN
tetramers, a very peculiar property for a rather small molecule with relatively not so high aﬃnity. Such
peculiarity of psTri resulted in an artifactual overestimation of its potency in competition assay where
soluble DC-SIGN tetramers are used, and thus misled us previously to select it as the best lead com-
pound. This work emphasizes the importance of thorough and critical investigation of the leads from the
primary screenings in order to avoid the “false positives” to be selected for further, rather void, attempts
to improve them.
Results and discussion
The X-ray structure of DC-SIGN CRD/psTri complex and comparison with psDi binding within DC-SIGN
CRD
In order to compare psDi and psTri binding modes within DC-SIGN and thus to shed light on the
underlying reasons for this discrepancy, we co-crystallized psTri with monomeric DC-SIGN CRD and
solved the X-ray crystal structure.
Similarly as the recently published structure, the crystals of psTri in complex with DC-SIGN CRD
had also a single copy of CRD in an asymmetric unit with P43212 space group. The structure was solved
by molecular replacement, at 1.35Å resolution (Table 1).
When the structure was solved using the model without sugar, an electron density was observed
on Ca2+ ion in the canonical carbohydrate binding site, indicating the presence of pseusomannotrioside
bound to DC-SIGN through a conventional Ca2+-coordination by 3-OH and 4-OH groups of non-reducing
mannose-moiety (Fig. 2a). The electron-density of the dimethyl ester substituents on the cyclohexane
moiety as well as the reducing mannose moiety were poorly or not visible suggesting that these parts of
the molecule remained flexible within the complex. In contrast to recently solved structure of pseudo-
mannobioside bound to DC-SIGN Thepaut et al. [31], where the electron density for ethylamine linker
was not visible, in the current case of psTri the density for the corresponding ethylazide linker was clearly
visible, suggesting that this appendage stayed stable due to contacts in the crystal packing.
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Table 1: DC-SIGN CRD/psTri complex data collection and structure refinement statistics.
Data collection statistics
Wavelength (Å) 0.9797
Space group P 43 21 2
Unit cell parameters (Å) a = b = 71.33; c = 52.67
Resolution (Å) 50.44-1.35 (1.43-1.35)a
Measured reflections 222778 (35175)
Unique reflections 30348 (4813)
Completeness (%) 99.9 (99.9)
I/σ￿ (I ) 20.13 (4.82)
Rmerge b (%) 6.5 (43.3)
Structure refinement statistics
Resolution (Å) 50.44-1.35 (1.39-1.35)
Refinement factors
Used reflections/free (%) 28812 / 5.1
Rcrystc 0.143
Rfreec 0.168
rmsd from ideality
Bond lengths (Å) 0.030
Bond angles (deg) 2.631
Average B-factor (Å2) 13.96
a Values in parantheses are for the highest resolution shell.
b Rmerge =
￿
h
￿
m
|Im(h)− ￿I(h)￿|
￿
h
￿
m
Im(h). cRcryst =
￿
||F0| − |Fc||
￿
|F0|, and Rfree = Rcryst
calculated with 5% of F0 sequestered before refinement.
It appeared that the binding mode of psTri within DC-SIGN CRD (Fig. 2a) is the same as that of
psDi, with exactly the same orientation of the psDi-corresponding portion of the molecule (Fig. 2b).
Figure 2: The binding mode of psTri within DC-SIGN CRD.
(a) The bound ligand superimposed with the Fo-Fc electron density map; the protein carbon backbone is rep-
resented in olive cartoon with amino acids contributing to binding highlighted by stick representation; psTri is
shown in yellow sticks. (b) The superimposition of psDi (black sticks) and psTri (yellow sticks) crystal structures
bound to DC-SIGN CRD (grey surface representation). Oxygen and nitrogen atoms are in red and blue, Ca2+
ion is an orange sphere.
To our surprise, no additional contacts (other than in psDi structure) with the protein were observed.
While non-reducing mannose moiety made coordination bonds with Ca2+ ion by its 3-OH and 4-OH
groups and the C6 methylene of the cyclohexane ring retained the van der Waals contact with Val351
side chain of the protein, the reducing mannose moiety was oriented away from the protein and apparently
didn’t make any contacts with the side chains. Moreover, the electron densities of this second mannose
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unit as well as of ethylazide linker were rather poorly defined suggesting a higher flexibility of these parts
(Fig. 2a). Thus the revealed structure of psTri within DC-SIGN was more puzzling than explanatory of
the described phenomenon, and prompted us to investigate the interaction further on to understand how
with the same binding mode a much higher aﬃnity might be achieved.
Thermodynamic characterization of psDi and psTri interaction with DC-SIGN
To inspect whether positive entropy contributions were responsible for the higher aﬃnity of monovalent
psTri with respect to psDi, we have analyzed the interaction of both psDi and psTri with tetrameric DC-
SIGN ECD by isothermal titration microcalorimetry. At the first set, the same experimental conditions
with identical concentrations of interaction components were used, and the pseudosaccharides (12.7mM)
were titrated into lectin solution (71µM with respect to binding sites).
Figure 3: The ITC results of psDi and psTri titrations to DC-SIGN ECD.
a) and b) show titrations of psDi and psTri, respectively, at 12.7mM to DC-SIGN ECD (71µM). c), psTri
(1.18mM) titratration to 214 µM DC-SIGN ECD. Upper panels show the titration thermograms and lower panels
the integration of data with fitted curves for “one binding site” model.
The ITC data (Fig. 3a and 3b) indicated the low aﬃnity of the ligands as the titration curves
did not adopt the full sigmoidal shape. Fitting one binding site model on the data with an assumed
stoichiometry value n fixed to 1 yielded the KD values of 990.10± 19.7µM and 75.76± 7.29µM for psDi
and psTri, respectively, but the low aﬃnity prevented the reliable interaction enthalpies and entropies
to be obtained and compared Turnbull & Daranas [33]. Nevertheless, an intriguing outcome could be
observed: the first injections of psTri to DC-SIGN solution resulted in more heat released while using
the same concentrations of both ligands and the same receptor concentration. This suggested the higher
aﬃnity of psTri than psDi to DC-SIGN, which was contradictory to the X-ray data since psTri didn’t
seem to make any other additional contacts compared to psDi structure.
Because psTri had apparently higher aﬃnity to DC-SIGN, we repeated the titration with adjusted
concentrations (1.18mM psTri titrated to 214 µM of DC-SIGN ECD) in order to perform titration in
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a more relevant concentration range (Fig. 3c). The fitting of the same model this time gave KD of
5.26± 0.29µM, ￿H =-15.80± 0.15 kcalmol-1, T￿S =-8.57 kcalmol-1, and ￿G of -7.20 kcalmol-1. Thus
a diﬀerence of 2 orders of magnitude between the KD values determined for psDi and psTri molecules (
990µM and 5µM, respectively), which is much higher compared to what could be initially expected from
the SPR data, highlights even a stronger diﬀerence in the activities of the two molecules.
Furthermore, the fitting yielded the stoichiometry value of 0.5. Because DC-SIGN ECD was extra-
purified for this experiment (see SI), the contribution of non-active binding sites to the n<1 value was
excluded. Interaction with stoichiometry of 0.5 in this case suggests that two DC-SIGN CRDs share
one psTri molecule, or in other words, two DC-SIGN ECD tetramers bind 4 psTri molecules in average.
Since psTri molecule is relatively small, its binding to 2 CRDs within the same tetramer is not likely
(the approximate distance between vicinal binding sites within the tetramer is 40Å Tabarani et al. [30]).
Hence, such a stoichiometry might mean that the same psTri molecule makes a bridge between two DC-
SIGN tetramers by simultaneously binding to a CRD in each one, and would explain why under the same
experimental conditions psTri titration released markedly more heat than psDi.
Analytical Ultracentrifugation analysis of psDi and psTri complexes with DC-SIGN ECD
To check the hypothesis of psTri capability to bridge DC-SIGN tetramers, as suggested by ITC data,
we performed the sedimentation velocity experiments on the samples retrieved from the first set of ITC
measurements. The deduced final concentrations of interacting components recovered from the cell were
the following: 62 µM DC-SIGN ECD (with respect to the binding sites), psDi and psTri at 1.63mM.
Thus the compounds were at the excess with respect to the lectin binding sites at a molar ratio of 26.
The sedimentation velocity was also recorded for compound-free DC-SIGN ECD (62µM) sample.
Figure 4 compares the sedimentation profiles registered at 42 000 rpm at the same time intervals (1 h)
for each of the three samples. Clearly, DC-SIGN alone (Fig. 4a) and incubated with psDi (Fig. 4b)
sediment similarly, while DC-SIGN incubated with psTri (Fig. 4c) moves faster, suggesting that the
association of DC-SIGN tetramers is induced by psTri but not psDi.
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Figure 4: Sedimentation velocity experiments of 62 ￿M DC-SIGN ECD alone and in presence of psDi or psTri at 1.63mM.
Experimental data showing concentration profiles of DC-SIGN alone (a), in the presence of psDi (b) and psTri
(c) recorded with time intervals between successive profiles of 40min for the two first ones, then 55min; the
first profiles at panels a), b) and c) were obtained 4, 10 and 14min, respectively, after the beginning of the
centrifugation. Sedimentation velocity was registered for 4 hours at 42 000 rpm, in 0.15 cm cells, at 20°C. d) and
e) shows the superimposition of the c(s) curves for DC-SIGN alone and with psDi (d) and psTri (e).
The data were treated in terms of size distribution analysis. The model considers that the solution
comprises a large number of species having the same frictional ratio, i.e. the same shape, characterized
by their sedimentation coeﬃcients, s, between a minimal and a maximal value. The result of the analysis
is a plot of the “concentration”, in terms of the signal at 280 nm, as a function of sedimentation coeﬃcient
s. The area under the peak gives the absorbance. The frictional ratio can be fitted, and a regularization
procedure can be applied, which allows smooth distributions to be obtained. Figure 4d shows a nearly
perfect superposition of the c(s) distributions obtained with DC-SIGN alone and in the presence of psDi.
On the other hand, psTri induces the formation of larger species (fig. 4e).
DC-SIGN alone and with psDi sediments at s20w=5.2 S, close to s20w=5.4 S previously published for
the tetramer at infinite dilution Tabarani et al. [29, 30]. The additional peak observed for DC-SIGN in the
presence of psTri is at s20w=6.5 S. This value may correspond to a more compact tetramer (f /f min=1.6
instead of 1.9 for DC-SIGN alone) or to a more elongated complex of two tetramers (f /f min=2.5). How-
ever, this experiment was done only at one ratio, and we cannot exclude that the 6.5 S peak corresponds
to an intermediate value between the s-value of the tetramer and of the larger complex. The shape of
the sedimentation boundary, thus the c(s), indeed depends on the kinetics and thermodynamics of the
interaction.
A second set of sedimentation velocity experiments was done with DC-SIGN ECD at 102 µM with
respect to monomer incubated with psTri at molar psTri/DC-SIGN ratios of 0, 0.25, 0.5, 1, 5, 11 and 27.
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Figure 5a shows the c(s) plots.
Figure 5: Sedimentation velocity experiments of 102 ￿M DC-SIGN ECD alone and in the presence of psTri at diﬀerent
psTri/DC-SIGN molar ratios.
a) The overlaid c(s) curves for DC-SIGN ECD alone and with psTri at diﬀerent ratios; sedimentation velocity
was registered at 42 000 rpm, in 1.5mm cells, at 20°C. b) The evolution of sw-values as a function of psTri
concentration; the line is shown to guide the eye.
DC-SIGN alone sediments at s20w=4.8 S, which is a lower value than measured with DC-SIGN at
62µM. This diﬀerence may be related to excluded volume eﬀects, which are expected to be noticeable at
this concentration (4mgmL-1) considering the elongated shape of DC-SIGN. The s-value of this peak is
slightly increasing up to the ratio of 5, as can be seen in figure 5a. Starting from ratio 1, an additional
peak emerges at approximately s20w=6.3 S. When adding psTri, the proportion of this peak increases up
to 80% of the total signal from ratios 11. The s-values for both peaks start to slightly decrease from the
experimental ratio 5: for the largest species the observed maximum of s20w is 6.3 S at ratio 5, and decreases
to 5.7 S at ratio 27; for the smallest species at the same ratios the corresponding s20w values are 5.2 and
4.7 S. Most likely this variation of the positions of the two peaks is related not to experimental errors,
but reflects the complexity of a reaction boundary: for fast reactions indeed, association-dissociation
processes aﬀect the sedimentation boundary Schuck [25], Zhao et al. [35]. The integration of each c(s)
curve under the two peaks gives, on one hand, the total absorbance reflecting DC-SIGN concentration,
which was similar at all ratios, and, on the other hand, the weight-average sedimentation coeﬃcient value
(sw) that does not depend on the kinetics of the interaction. The sw-isotherm was attempted to analyze
in SEDPHAT but fitting hetero-association models failed most likely due to more complicated system
and the non-ideality conditions. Nevertheless, the data analysis in terms of weight-average sw-value (Fig.
5b) clearly shows that the addition of psTri up to 500µM concentration to 102µM DC-SIGN solution
participates in the formation of higher macromolecular complexes as indicated by the increase of sw-
value, while further excess of the compound induces the disassembly of DC-SIGN complexes. Although
this type of sedimentation velocity data analysis can be used to extract the interaction aﬃnities Schuck
[26], Zhao et al. [35], our system apparently is more complicated (due to both, the tetravalent protein
and presumably bivalent small compound, and the presence of excluded volume eﬀects), therefore, no
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model could be fitted to the data.
Characterization of DC-SIGN/psTri interaction by static and dynamic light scattering
psTri-induced DC-SIGN association was also studied by Static (SLS) and Dynamic Light Scattering
(DLS) simultaneously. DLS allows to characterize the polydispersity of the sample and determine the
hydrodynamic radius (RH) of the macromolecules, while SLS gives independent values of MW in an
absolute way. The examined samples of DC-SIGN alone and in the presence of psTri were the same as
for AUC study. Correlation curves and RH distributions from DLS show the presence of one contribution
for most of the samples (an example is shown in the SI). Larger species (RH≈ 100 nm) were marginally
detected in negligible amounts of the peak intensity and are considered as irrelevant dust.
The RH and MW values were plotted against the psTri/DC-SIGN molar ratios (Fig. 6). SLS and
DLS do not allow distinguishing monomers and dimers. The measured MW and RH are mean values
dominated by the larger species, since scattered intensity is proportional to
￿
ciMW i2, ci and MW i
being the weight concentration and molar mass of species i. When increasing psTri/DC-SIGN ratio, MW
increases from 148 kDa for DC-SIGN alone and reaches a constant value of 350 kDa from ratio 5. RH
increases from 7.5 nm without psTri to a maximum value of 10.4 nm at ratio 11, followed by a slight and
perhaps irrelevant decrease to 10.2 nm at ratio 27.
Figure 6: Results of static and dynamic light scattering of 102 ￿M DC-SIGN ECD alone and in presence of psTri at diﬀerent
psTri/DC-SIGN molar ratios.
The dependencies of registered RH and MW on psTri/DC-SIGN ratio are plotted in green and red, respectively.
The error bars represent standard deviation values.
The evolution of MW and RH reflects the general behavior observed in AUC (Fig. 5b). We note
that in the absence of psTri, MW from SLS is close to the theoretical value for a tetramer (154.827 kDa);
RH is close to the value of 7.7 nm obtained from the combination of s20w=4.8 S and the theoretical
MW of a tetramer. The maximum MW value from SLS (350 kDa) is close to the expected value for
a dimer of tetramers (309.654 kDa), while the combination of s20w=6.3 S with MW=309.654 kDa gives
RH=11.7 nm, close to the experimental values from DLS above psTri/DC-SIGN ratio of 5.
The DLS and SLS data at high psTri ratio reflects imperfectly the changes observed in AUC. Apart
from experimental uncertainty, it may be related to the diﬀerent incubation times (one hour in SLS/DLS,
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one day in AUC). Altogether, AUC, DLS and SLS data support that psTri promotes the association of
two DC-SIGN tetramers when adding psTri up to ratio between 1 and 5, while higher excess of psTri
saturates all the binding sites and consequently the situation becomes less favorable for bridging to occur.
Figure 7: A possible structure of the assembly of DC-SIGN tetramers bridged by psTri molecule.
a) Positioning of two DC-SIGN tetramers resulting from superposition of X-ray structures of DC-SIGN CRD in
complex with mannose and psTri to each of the two envelopes of tetramers. b) The close-up of the area marked
by a black frame in panel (a). the color scheme used: carbons for one of the two DC-SIGN tetrames are pink, for
the other one cyan, for psTri carbons are yellow; oxygens and nitrogens are in read and blue colors; green spheres
are Ca2+ ions.
In order to get an insight to a structure of psTri-mediated DC-SIGN assembly, the molecular modeling
of the supramolecular complex was performed, and the resulting model apparently showed no steric clashes
(Fig. 7).
Finally, the constructed model was subjected to HydroPro calculations Torre et al. [32], and yielded
the theoretical s value for the model structure of 6.77 S, which in turn gives RH value of 10.3 nm. This
RH value corresponds perfectly with the experimentally measured RH maximum (Fig. 6). This suggests
that the supramolecular assembly indeed adopts such an elongated conformation. However, this model is
only a rough approximation of the real situation, since it assumes only one psTri molecule bound to two
tetramers (while ITC data suggested an average of 4 psTri molecules bridging two tetramers). It must
be kept in mind that such a system is presumably very dynamic due to relatively low aﬃnity of single
mannose residue, and thus possibly adopts diﬀerent conformations.
Comparison of the ability of psDi and psTri-bearing multivalent systems to inhibit HIV trans infection
Previously, due to the better activity of psTri as a monovalent compound observed in SPR competition
assay, only psTri was used to generate a tetravalent dendron and tested in cellular studies of HIV trans
infection inhibition Sattin et al. [24]. The promising results of these studies gave a feeling that psTri was
indeed the lead for further development. From the characterization of psDi and psTri binding mode to
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DC-SIGN (Thepaut et al. [31] and described in this work), it appeared that this initial selection might
not be correct. We decided to repeat these HIV trans infection inhibition studies this time including
tetravalent dendron of psDi for the comparison with previously generated psTri dendron. In addition to
tetravalent dendrons, 32-valent dendrimers bearing psDi or psTri pseudosaccharides (Fig. 1a) were also
included to the studies. The results showed that both dendrons were able to reduce HIV transmission
to CD4+ T cells by a very similar extent (Fig. 8): 5µM concentrations displayed around 50% infection
inhibition, while incubation with 50 µM dendrons reduced infection almost to 90%.
Figure 8: Comparison of HIV trans infection inhibition by psDi and psTri bearing multivalent systems.
Data obtained in triplicate, from 3 diﬀerent healthy donors. Values are mean± SD. After 30min of preincubation
with compounds or culture medium, B-THP-1/ DC-SIGN cells were incubated for 3 h with HIV-1 BaL in the pres-
ence of the indicated concentrations of the compounds, then washed and co-cultured with CD4+ T lymphocytes
for 3 days. Viral infection was assessed by measuring the concentration of p24 in the co-culture supernatants.
The dendrimers with both psDi and psTri had significantly higher eﬃciencies than dendrons and
reached nearly complete infection inhibition at 50µM concentration.
Despite slight diﬀerences of inhibitory eﬃciencies of psDi and psTri bearing dendrimers at lower
concentrations, these data correlate well with above described results and confirm once again that both
pseudosaccharide ligands have the same activity once they are tethered to multivalent scaﬀolds. It
definitely confirms that psDi is as eﬀective as psTri and gives a strong reasoning to select psDi for further
compound optimization.
Conclusions
The interactions of monosaccharides with the C-type lectins are of low aﬃnity with KD values in mM
range. Nature has overcome such low aﬃnity problems by clustering the interacting partners on both
sides: while the monosaccharide ligands are presented in high-density clusters such as polysaccharides
that usually exist in multiple copies on proteins or lipids, the sugar binding sites are also presented in
multiple copies per lectin. In order to eﬃciently compete such multivalent interactions, the strategies of
multivalent presentation of active ligands are developed. Our groups pursue DC-SIGN antagonists for
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the protection from HIV and other pathogen infections by employing two strategies, i.e. the glycomimetic
monovalent ligand development and the multivalent presentation of the selected monovalent leads. We
designed a small glycomimetic molecule, pseudomannotrioside, as a starting monovalent compound. To
our surprise, we discovered that this ligand possesses the bridging ability. Although the multivalent
bridging lectin-carbohydrate interactions are common and have a biological relevance Dam & Brewer
[9, 8], in biological systems the more common situation is glycoconjugate bridging by lectins allowing the
formation of the carbohydrate-lectin lattices Brewer [6]. On the other side, the lectin bridging property
of the small glycomimetic molecules has been engineered Gestwicki et al. [18], Sisu et al. [27], Lameignere
et al. [20]. In this aspect, our case is unique and unexpected, especially considering the size of the
molecule, the low aﬃnity of mannose residues to DC-SIGN and the arrangement of binding sites of DC-
SIGN that does not seem to allow the formation of the bridged lattices. However, such a property of psTri
is unfavorable in our course of the development of DC-SIGN inhibitors where we aim to design multivalent
platforms bearing multiple copies of glycomimetic leads: this ability was the underlying reason for the
overestimation of this compound in the competition assay and once it is tethered to multivalent scaﬀold
the second mannose moiety serves nothing but a part of a linker.
The competition assays are widely used in high-throughput screening of drug candidates, and this
study emphasizes the high probability of the selection of “false positives” arising from an artifactual
overestimation of the compound aﬃnity in the competition assay format.
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Experimental Procedures
Synthesis of compounds
Syntheses of psDi Reina et al. [23], psTri Sattin et al. [24] and psTri–bearing dendron Sattin et al.
[24] were described previously. The syntheses of multivalent 3rd generation Boltorn type dendrimers
functionalized with psDi and psTri are also described previously Luczkowiak et al. [21].
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DC-SIGN production and purification
The production and purification of DC-SIGN CRD containing StrepTag II (S-CRD) and ECD con-
structs was conducted as described previously Thepaut et al. [31] and Tabarani et al. [30], respectively.
Co-crystallization of DC-SIGN/psTri and data collection
Crystallization was performed at 20°C in EasyXtal plates (Qiagen) by hanging-drop vapor-diﬀusion
method. The drops were prepared combining 1µL of a purified DC-SIGN S-CRD (4.4mgmL-1 in 25mM
Tris-HCl pH 8, 150mM NaCl, 4mM CaCl2 buﬀer) and psTri (300mM) mixture (9:1, v/v) with 1 µL of
reservoir solution and equilibrated against 1 mL of reservoir solution. The best crystals were obtained with
the following reservoir solution composition: 35% PEG 3350, 100mM cacodylate pH 6.5, and 200mM
NaCl.
The X-ray diﬀraction data were collected from a single crystal cryprotected in Paraton-N (Hampton
Research) at the European Synchrotron Radiation Facility (Grenoble, France) at FIP BM30A beamline.
One dataset was collected at 0.9797Å wavelength, with a crystal-to-detector distance of 140.92mm. The
dataset, composed of 190 images, was collected with an oscillation range of 0.5° per image and an exposure
time of 30 s.
Structure solution and refinement
Phasing was performed by molecular replacement with a model built from a structure of DC-SIGN
CRD (pdb code 2XR5) depleted of calcium ions, carbohydrate molecules and water molecules. The best
solution resulting from molecular replacement was used as the starting model for structure refinement.
The structure refinement was performed by cycling between manual building using the program COOT
Emsley & Cowtan [12] and energy minimization with the program REFMAC 5 from the CCP4 package
4 [1]. Statistics of structure refinement are summarized in Table 1.
Isothermal titration microcalorimetry
ITC experiments were performed using Microcal VP-ITC microcalorimeter (Microcal, Northampton,
MA) with a cell volume of 1.409mL. All titration were accomplished at 25°C in Tris-HCl (25mM, pH
8) buﬀer containing 150mM NaCl and 4mM CaCl2. The pseudosaccharides and DC-SIGN ECD were
prepared in the same buﬀer, and the stepwise injections of 10 µL aliquots of pseudosaccharides to DC-
SIGN ECD solution were done using 5min intervals between injections. In the first set of experiments
the lectin concentration was 71µM (in terms of binding sites) and pseudosaccharides were prepared at
12.7mM, and in the second set of measurements 1.18mM psTri was titrated to 214 µM DC-SIGN ECD.
The blank titrations of the compounds to the buﬀer were done in order to subtract the heat of dilution
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from the integrated data. Subsequently, a built-in one site-binding model was fit to the data (Microcal
Origin 7) and yielded association constants (KA) and binding enthalpies (￿H ), which allowed to calculate
changes in free energy (￿G) and entropy (￿S ) using equation ∆G = ∆H − T∆S = −RT lnKA, where
T is the absolute temperature (K), and R=8.314 Jmol−1K−1.
Static and Dynamic Light Scattering
Static (SLS) and dynamic light scattering (DLS) measurements were performed using DynaPro Nanos-
tar instrument (Wyatt Technology Corp., Santa Barbara, USA) equipped with 658 nm “red” laser at a
scattering angle of 90°. Triplicate measurements of 10 scattering readings per sample in a carefully
cleaned quartz cuvette were recorded at 25°C. The samples contained DC-SIGN ECD alone (102µM with
respect to binding sites) or in presence of psTri at diﬀerent psTri/DC-SIGN molar ratios (0, 0.11, 0.25,
0.5, 1, 5, 11 and 27) and were prepared in Tris-HCl (25mM, pH 8) buﬀer containing 150mM NaCl and
4mM CaCl2 and centrifuged prior to analysis. The data were analyzed with Dynamics software version
7.1 (Wyatt Technology Corp.).
Analytical Ultracentrifugation
Sedimentation velocity experiments were performed in a Beckman XL-I analytical ultracentrifuge
using an AN-50 TI rotor (Beckman instruments), at 20°C. The experiments were carried out at 42 000 rpm,
using 55 ￿L samples, loaded into the two-channel 0.15 cm path length centerpieces equipped with sapphire
windows (Nanolytics GmbH), and the absorbance at 280 nm was monitored every 5 or 11 min for the
first and second set experiments, respectively, with a radial step size of 30 ￿m.
The samples were prepared Tris-HCl (25mM, pH 8) buﬀer containing 150mM NaCl and 4mM CaCl2.
The first set of experiments was done with the samples retrieved from first set ITC measurements and
contained DC-SIGN ECD alone at 62µM (with respect to binding sites) or in the presence of 1.63mM
psDi or psTri. Freshly prepared samples of the same concentrations were used for the control and identical
results were obtained.
The second set of experiments was carried out with the samples containing 102µM DC-SIGN ECD
alone or with psTri added at diﬀerent psTri/DC-SIGN binding site molar ratios (0, 0.25, 0.5, 1, 5, 11 and
27). These samples were incubated for one day as they were used for SLS/DLS measurements prior to
AUC experiments.
The molar mass (MW) and partial specific volume (v¯) of DC-SIGN ECD tetramers were estimated
from the amino acid composition using the SEDNTREP software and resulted in 154827Da and 0.733 cm3 g-1,
respectively. The values for psDi and psTri were considered equal to value of a hexose sugar (0.607 cm3 g-1).
Sedimentation velocity profiles were analyzed using the size distribution analysis Schuck [25] embedded
in the SEDFIT software (freely available at http://www.analyticalultracentrifugation.com), and
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for each analysis by global modeling taking typically 20 regularly spaced experimental profiles obtained
over a total 4 h. The c(s) analysis was performed considering 200 particles, and fitting the value of the
frictional ratio f /f min. For the regularization procedure a confidence level of 0.68 was used. All s-values
have been corrected for solvent density and viscosity and are therefore given as s20w values.
Construction of initial bridging model
To model the bridging of two DC-SIGN tetramers by a psTri molecule, the SAXS envelope of the
DC-SIGN ECD was used Tabarani et al. [30]. The solved X-ray structure of CRD in complex with psTri
was superimposed to the CRD part of the envelope of the tetramer, while in another tetramer the CRD in
complex with mannose (pdb code 2IT5) was overlaid, and the positioning of two tetramers was attempted
in a way that reducing mannose residue of psTri in one of the tetramers would superimpose with the
mannose in another tetramer.
Calculation of theoretical hydrodynamic radius from the model
HydroPro program Torre et al. [32] was used to obtain the theoretical sedimentation coeﬃcient value
for the constructed model of bridged DC-SIGN tetramers. The experimental values of solvent viscosity,
density and temperature were input: η=0.01024 poise, ρ=1.006 g cm-3, and the temperature was 293K.
The resulting sedimentation coeﬃcient value of 6.848 S was used to calculate theoretical RH according to
Svedberg’s equation:
s =
MW ·(1− ρ · v¯)
NA6πηRH
where s is the sedimentation coeﬃcient, MW the molecular mass of the assembly of two tetramers
(309.654 kDa), and v¯ is the partial specific volume of the dimer of tetramers (0.733 cm3 g-1); the same η
and ρ values were used as shown above.
Infection studies
The studies of HIV trans infection inhibition by psDi and psTri dendrons and dendrimers without
washing prior to virus inoculation were performed as described previously Sattin et al. [24].
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9.1.4.5. The bis-benzylamide derivatives of psDi to achieve better aﬃnity and selectivity to DC-SIGN
The mannose-based glycomimics development focused on the improvement of psDi molecule. The
solved structure of psDi in complex with DC-SIGN CRD (fig. 9.16) showed that the methyl groups
at cyclohexane ring of the compound are in a favorable position to be changed to more compli-
cated moieties that could extend over the protein surface by making additional contacts and thus
increasing the aﬃnity to the protein.
Figure 9.16.: psDi binding within DC-SIGN CRD.
The D-mannose moiety of the molecule is oriented to Ca2+ (a green sphere) in the CRD through 3-OH and 4-OH
groups, while the cyclohexane derivative is solution exposed, but still it makes Van der Waals contacts with Val351
residue of the protein. The cyan arrows point to the methyl groups that can be substituted to more complex moieties
in order to improve the aﬃnity of the molecule to DC-SIGN CRD. Color scheme: carbons of the protein and psDi
are white and yellow, respectively; oxygens and nitrogens are red and blue; sulfur of the protein is yellow.
A group of psDi-based compounds, bis-benzylamides, with a general formula shown in figure
9.17A have been synthesized by a PhD student Norbert Varga in the team of Pr. A. Bernardi. The
eﬃciency of these compounds to inhibit DC-SIGN and their selectivity to DC-SIGN versus langerin
was assessed, and the results are presented in the following article by Varga et al.
Figure 9.17.: The structure of new psDi-based compound series.
A, The general formula of bis-benzylamides; “Ar” stands for aromatic substituent. B, The “Ar” substituent of the
new lead compound 4h.
One of the compounds in this series, the bis-amide 4h (fig. 9.17B), showed a proper combina-
tion of such features as good aﬃnity and selectivity to DC-SIGN together with good water solubility
and synthetic accessibility. It was chosen for further aﬃnity improvement by mounting it on the
multivalent scaﬀolds. To get a better understanding of its interaction with DC-SIGN, the structural
analysis by NMR spectroscopy was performed. These NMR studies included the determination of
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the binding epitope of 4h and the estimation of the compound’s conformation in free and in the
bound states. I have been directly involved in these NMR experiments and data analysis during the
long-term secondment in the group of our collaborator Dr. P. Nieto, where I had an opportunity
for the first time to learn the basics of NMR and try to apply the knowledge to study DC-SIGN/4h
interaction. The stay supervised by Dr. Jesus Angulo and Dr. Pedro Nieto in the NMR laboratory
in Seville (Instituto de Investigaciones Químicas, CSIC) lasted for 2 months and a half starting 26th
September, 2011.
The saturation transfer diﬀerence (STD) NMR experiment was used to determine the 4h
binding epitope. Figure 9.18 summarizes the basic principle and the steps of STD NMR experiment,
which is based on Nuclear Overhauser Eﬀect (NOE) [171].
The first step is the so-called oﬀ-resonance experiment, which is done to record a standard
1D 1H spectrum, or a reference spectrum. Then the on-resonance experiment follows: some of the
protein protons are selectively irradiated, or saturated, (ligand protons remain unaﬀected) using a
low power radiofrequency for a specific period, i.e. saturation time. Subsequently, the intermolecular
NOE arise between protein and the bound ligand protons, that is the “magnetization” (perturbation,
or saturation, of protein proton polarization) from protein protons is transferred to the bound ligand
protons, which are in close proximity with the protein (<6Å).
Figure 9.18.: Schematic explanation of 1D STD NMR experiment.
The top part illustrates the experiment itself, while the bottom part shows the sample composed of a protein and a
pool of small test molecules in a molar excess with respect to the protein. (From [172])
The information about the binding appears in the saturated spectrum where the intensities
of the protons that were closer to the protein are reduced, while the intensities of the protons that
did not participate in binding are not aﬀected. The subtraction of the saturated spectrum from
reference spectrum yields a diﬀerence spectrum, where the STD intensities only of those protons
that were close to protein are visible, and the stronger intensities indicate the closer distance to
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the protein. Normalizing the intensities with respect to the most intense, to which 100% value is
assigned, the ligand epitope can be mapped.
Figure 9.19.: An illustration of the determination of a binding epitope of a small molecule.
A, An example of STD build-up curves with the relaxation times given for the corresponding protons A, B and C ;
without estimation of initial slopes and taking STD intensities at tsat of 4 s or 8 s, the epitope would be misinterpreted
putting the highest STD intensity possessing proton A closest to the protein (100% STD), then protons B and C .
B, A corresponding correct binding epitope deduced from initial slopes of shown STD build-up curves: when the
molecule is bound to the protein, proton B (highest value of initial slope, 100%) is closest to the protein and proton
C is further, while proton A takes the intermediate position with respect to protons B and C .
In order to avoid artifacts arising from the diﬀerent relaxation R1 (i.e. loss of magnetization)
rates for diﬀerent protons (fig. 9.19A), a proper ligand epitope map (fig. 9.19B) is obtained from
the STD intensity build-up curves (fig. 9.19A) [172]. For this reason, 1D STD NMR experiments
are performed at several diﬀerent saturation times, and after plotting the resulting STD intensities
against saturation time, the initial slopes are calculated by fitting mono-exponential function:
STD(tsat) = STDmax·(1− exp(−ksat·tsat)) (9.4)
where STD(tsat) is the observed STD intensity, STDmax is the asymptotic maximum of the
build-up curve, tsat is the saturation time, and k sat is a rate constant related to the relaxation
properties of a given proton that measures the speed of STD build-up. When k sat and STDmax are
derived by least-squares fitting, the initial slope may be calculated:
dSTD
dt(0)
= STDmax·ksat (9.5)
The calculated initial slopes for each interacting proton are normalized with respect to the
highest value, and thus the proper ligand epitope is determined.
The main outcome of these studies:
✧ Almost all of the bis-benzylamide derivatives of psDi yielded a better aﬃnity and selectivity
to DC-SIGN than langerin.
✧ A new lead compound, 4h, selected for further improvement by tethering on multivalent
scaﬀolds.
✧ 4h binds in the same binding mode as psDi validating the rational optimization approach.
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Contributions:
All psDi derivatives were synthesized by a PhD student Norbert Varga in the team of Pr. A.
Bernardi. The docking studies of 4h were performed by postdoctoral researcher John McGeagh in
the team of Dr. J. Weiser in order to envision the binding mode of 4h in DC-SIGN CRD.
My contribution to this study:
✧ Prepared DC-SIGN ECD required for SPR and NMR studies.
✧ Performed all of the described SPR assays, and analyzed the data for all psDi derivatives.
✧ Participated in STD NMR experiments and contributed to data analysis with the help of Dr.
Jesus Angulo and Cinzia Guzzi.
✧ Selection of a plausible 4h docking pose out of 60 calculated poses by checking it against STD
NMR data.
✧ Participated in article writing.
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Paper no6: Selective targeting of DC-SIGN with mannose-based glycomimetics. Synthesis and
interaction studies of bis-benzylamide derivatives of a pseudomannobioside
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Introduction
The dendritic cell (DC) membrane C-type lectin receptor
dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin (DC-SIGN) has been implicated in the
early stages of HIV infection and is, therefore, considered
an interesting target for the design of antiviral agents.[1,2] Im-
mature dendritic cells in mucosal tissue use DC-SIGN to
recognize high-mannose glycans present on the viral enve-
lope glycoprotein gp120 of HIV. This recognition event ap-
pears to contribute to infection by promoting viral transmis-
sion in a manner dependent on the composition of gp120
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Abstract: Dendritic cell-specific inter-
cellular adhesion molecule-3-grabbing
nonintegrin (DC-SIGN) and Langerin
are C-type lectins of dendritic cells
(DCs) that share a specificity for man-
nose and are involved in pathogen rec-
ognition. HIV is known to use DC-
SIGN on DCs to facilitate transinfec-
tion of T-cells. Langerin, on the contra-
ry, contributes to virus elimination;
therefore, the inhibition of this latter
receptor is undesired. Glycomimetic
molecules targeting DC-SIGN have
been reported as promising agents for
the inhibition of viral infections and for
the modulation of immune responses
mediated by DC-SIGN. We show here
for the first time that glycomimetics
based on a mannose anchor can be
tuned to selectively inhibit DC-SIGN
over Langerin. Based on structural and
binding studies of a mannobioside
mimic previously described by us (2), a
focused library of derivatives was de-
signed. The optimized synthesis gave
fast and efficient access to a group of
bis ACHTUNGTRENNUNG(amides), decorated with an azide-
terminated tether allowing further con-
jugation. SPR inhibition tests showed
improvements over the parent pseudo-
mannobioside by a factor of 3–4. A di-
meric, macrocyclic structure (11) was
also serendipitously obtained, which af-
forded a 30-fold gain over the starting
compound (2). The same ligands were
tested against Langerin and found to
exhibit high selectivity towards DC-
SIGN. Structural studies using satura-
tion transfer difference NMR spectro-
scopy (STD-NMR) were performed to
analyze the binding mode of one repre-
sentative library member with DC-
SIGN. Despite the overlap of some sig-
nals, it was established that the new
ligand interacts with the protein in the
same fashion as the parent pseudodi-
saccharide. The two aromatic amide
moieties showed relatively high satura-
tion in the STD spectrum, which sug-
gests that the improved potency of the
bis ACHTUNGTRENNUNG(amides) over the parent dimethyl
ester can be attributed to lipophilic in-
teractions between the aromatic groups
of the ligand and the binding site of
DC-SIGN.
Keywords: DC-SIGN · glycomi-
metics · HIV · NMR spectroscopy ·
proteins
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glycans.[3] Ligands that can be used to explore the multiple
functions of DC-SIGN and to inhibit DC-SIGN-mediated
pathogen binding, are actively pursued by different
groups.[4,5,6] Selective inhibition of DC-SIGN, however, has
rarely been addressed, despite the presence in the immune
system of many other C-type lectins that share DC-SIGNs
ability to bind high-mannose oligosaccharides. Among these,
Langerin, which is expressed on the surface of a different
subset of antigens presenting cells known as Langerhans
cells (LCs), has been suggested to have protective effects
against HIV infection.[7] Selective DC-SIGN ligands, which
interact only weakly with Langerin, are potentially useful
therapeutic tools against sexually transmitted HIV infec-
tion.[6d,8]
Glycomimetic structures designed to inhibit DC-SIGN
have been reported.[4a–c,6] In our previous work, we focused
on the design and synthesis of monovalent N-fucosylami-
des[6b,d] or on mannose conjugates, such as 1–3 (Fig-
ure 1).[6a,c,g] These molecules have been conceived to be met-
abolically more stable than native oligosaccharides and can
be equipped with reactive moieties that enable a multimeric
presentation on different scaffolds. Indeed, the pseudotrisac-
charide 1, mimicking the linear Man-a-1,2-Man-a-1,6-tri-
mannoside, the D3 arm of the high mannose structure Man9,
was found to inhibit DC-SIGN binding to mannosylated
BSA&&please define&& (Man-BSA) with an IC50 of
130 mm by surface-plasmon resonance (SPR).[6c] Moreover,
when presented on a tetravalent dendron, 1 was also found
to inhibit HIV transinfection of CD4+T lymphocytes[6c] and
of cervical tissue explants[6f] at micromolar concentrations.
We have also recently reported a small library of mannose
conjugates of general formula 3, which were tested by using
a dendritic cell adhesion assay to mannan-coated plates.[6 g]
The activity of these compounds was tuned by the nature of
the amide R group, but most of them efficiently inhibited
DC-SIGN-mediated adhesion. The data showed that the ac-
tivity increased if the R group was lipophilic. However,
most compounds in this series possess a low solubility in
aqueous media, which limits their applicability. Preliminary
NMR spectroscopic studies of their interaction with DC-
SIGN also indicated that some nonspecific association oc-
curred through the allyl linker.
Recently, structural studies combining X-ray crystallogra-
phy and NMR spectroscopic analysis allowed us to charac-
terize the binding mode of 2 within the DC-SIGN binding
site and to demonstrate that it corresponds to a unique well-
defined orientation, making 2 a good lead compound for
chemical improvement of the binding affinity and specificity
towards DC-SIGN.[8] Analysis of the X-ray structure showed
that the methyl ester groups of 2 in the complex extend to-
wards the DC-SIGN surface in an area in which larger sub-
stituents can be accommodated. Larger groups in this posi-
tion can be expected to reach the protein surface and make
additional contacts. These observations validated the initial
strategy that had led to the synthesis of bis ACHTUNGTRENNUNG(amides) 3 and
suggested that their structures should be reconsidered with
the goal of increasing water solubility and removing the
allyl group, as the source of undesired nonspecific interac-
tions with the protein. In the group of compounds previous-
ly examined, the best balance of synthetic accessibility, se-
lectivity, and solubility was achieved for benzylamides 3a–b,
which showed an IC50 in the mm range in the adhesion assay.
These molecules provided interesting leads, which could be
improved by optimizing the nature of the benzylamide sub-
stituents and by replacing their allylether appendage with a
functional tether, which would also allow multimeric presen-
tation of the ligands.
With these goals in mind, a group of functionalized bis(-
benzylamides) of general for-
mula 4 (Scheme 1) was synthe-
sized. They contain an azidoe-
thanol linker, which can be ex-
ploited for conjugation, and dif-
ferent polar groups on the
benzylamide ring, to increase
water solubility and possibly
improve affinity for the recep-
tor. These molecules were
tested for their activity as DC-
SIGN ligands by using an SPR
competition assay. Selectivity
against Langerin was also ad-
dressed. NMR spectroscopic
studies were performed to ana-
lyze the interaction of the li-
gands with DC-SIGN and es-
tablish the epitope region. Alto-
gether these results showed that
bis(benzylamido) pseudodiman-
nosides bind selectively to DC-
SIGN and allowed the selectionFigure 1. Structure of Man9 and of previously reported mannose-based DC-SIGN inhibitors 1–3.
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of 4h as the optimal ligand for
the future construction of mul-
tivalent systems. In the course
of this study a divalent macro-
cyclic ligand (11) was also ser-
endipitously obtained, which
showed a low mm affinity for
DC-SIGN in the SPR assay
used.
Results and Discussion
A high-yielding and flexible
synthesis of the entire library
was achieved by small modifica-
tions of the previously reported
procedure.[6g] By starting from
enantiomerically pure (1S,2S)-
diacid 5,[9] the bis(p-nitropheny-
lester) was synthesized and the double bond oxidized by
using mCPBA (meta-chloroperbenzoic acid), to afford epox-
ide 6. Copper-catalyzed epoxide opening[10] with azidoetha-
nol,[11] followed by mannosylation of alcohol 7 with trichlor-
oacetemidate 8[12] afforded the pseudodisaccharide 9 in only
four steps and with 42% overall yield. The two activated p-
nitrophenyl esters, used as acid-protecting groups through-
out the sequence so far, were transformed into amides by
reaction with an excess of the appropriate benzylamine (10),
yielding bis ACHTUNGTRENNUNG(amides) 4 after Zempl"n deprotection of the
sugar.
Docking studies[6g] had suggested that H-bond donors and
acceptors out of the plane of the aromatic ring could be
beneficial for interaction with the protein surface. This con-
sideration, together with water solubility and synthetic avail-
ability, drove the selection of benzylamines 10 and of the
group of 16 compounds 4a–o (Figure 2, Table 1) to be syn-
thesized, all bearing polar, oxygen-containing groups on the
aromatic ring. Bis(benzylamines) were also considered;
however, their reaction with 9
led mostly to complex mixtures.
By only using p-xylylendiamine
(10p, see Scheme S1 in the Sup-
porting Information) one major
product could be chromato-
graphically isolated in modest
yields (18%). MS and 13C NMR
spectroscopic analysis revealed
that the dimeric macrocyclic
structure 11 was assembled, as
a 1:1 mixture of inseparable di-
astereoisomers that was tested
as such in the following assays.
Finally, to analyze the effect of
the stereochemistry of the cy-
clohexane scaffold, compound 12, a stereoisomer of 4h, was
synthesized by starting from the (1R,2R)-enantiomer of 5
(see Scheme S8 in the Supporting Information). Analysis of
the 1H NMR spectra confirmed that all compounds share
the same chair conformation of the cyclohexane ring ob-
served in 2[13] (see Figure S1 in the Supporting Information).
The activity of these compounds as inhibitors of DC-
SIGN binding to mannosylated BSA (Man-BSA) was tested
by SPR (Figure 3). In the assay, Man-BSA was immobilized
on a CM4 chip and the extracellular domain (ECD) of DC-
SIGN was injected over the Man-BSA surface in the ab-
sence or in the presence of increasing concentrations of the
inhibitors. The obtained IC50 values are shown in Table 1&
&ok?&&. The parent pseudodisaccharide bis(methyl ester)
2 and the pseudotrisaccharide 1 are included in the Figure 3
data as reference compounds.&&ok?&& Many of the dia-
mides prepared showed a remarkable increase in inhibitory
activity compared to diester 2 and some approached the af-
finity observed for 1, a molecule of significantly higher
Figure 2. The bis-benzylamides 4a–o, 11 and 12 synthesized and tested in this work.
Scheme 1. Synthesis of bis(benzylamides) 4.
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structural and synthetic complexity. Low solubility remains
a problem for some of the structures (4a and 4d, shown in
light grey in Figure 3)&&ok?&&, but most compounds
displayed good solubility in water at the concentration re-
quired for the assay.
The group of diamides 4e–n, built upon the modeling sug-
gestion mentioned above, showed a remarkable activity, as
all the compounds were found to be only 2.5-fold less
potent than the pseudotrisaccharide 1 (Figure 1). Among
them, 4h, featuring a hydroxymethylene group in the para
position, was selected for structural modifications. The hy-
droxy group appears to play a role as a H-bond acceptor,
since the corresponding methyl ether shows the same inhibi-
tory potency (cf. 4h and 4 i). Addition of fluorine atoms on
the ring (4k–l) or additional lipophylic groups in the prox-
imity of the acceptor (4 j) did not significantly improve the
affinity. On the contrary, two methoxy substituents meta to
the hydroxymethylene group, as
in compound 4o, had a negative
effect, possibly as a result of a
different orientation of the aro-
matic residue around the N-
benzylic bond. Similarly, com-
pound 12, a diastereoisomer of
4h with the opposite configura-
tion (1R,2R) of the cyclohexane
ring, binds poorly to DC-SIGN,
which indicates that the design
of the pseudodisaccharide scaf-
fold is important to optimize in-
teraction with the protein as
suggested by the structure of
the 2/DC-SIGN complex.[8] Re-
markably, dimer 11 (1:1 mixture
of isomers) with an IC50 of
31 mm turned out to be the most
potent inhibitor of the series,
and one of the most effective
reported so far. The dimension
of the macrocycle in 11 (OH-4–
OH-4 distance: 22 %) is too
short to span two adjacent
binding sites of the DC-SIGN
tetramer (which are separated
by no less than 35 %),[14] thus
the potency of this compound
must derive from proximity ef-
fects (statistical rebinding) or
by aggregation of the protein,[15]
which, in turn, could block the
availability of DC-SIGN bind-
ing sites and thus effectively in-
hibit binding to immobilized
Man-BSA. Since the effect is
rather large, protein oligomeri-
zation under the assay condi-
tions appears to be the most
likely explanation. Protein aggregation by polyvalent carbo-
hydrates is very well documented;[16] however, given the het-
erogeneity of the compound and the low yield with which it
was synthesized, proving the mechanism underlying the ac-
tivity of 11 would be challenging. Furthermore, even if an
oligomerization mechanism could be demonstrated under
the conditions of the current assay (by using soluble DC-
SIGN extra-cellular domain (ECD)), it is very unlikely that
it will be operative in the biologically relevant conditions, in
which the protein would be membrane-bound. Thus the
issue was not pursued further.
In parallel, most of the library members were further
tested for inhibition of Langerin by using an SPR assay that
we have recently described.[6d] Selectivity for DC-SIGN
versus Langerin is particularly important to develop inhibi-
tors that would block sexually transmitted HIV infection.
As we have already remarked, while interaction with DC-
Table 1. Structure and activity of DC-SIGN ligands 4a–o, 11, and 12.
Structure
(R=)
Yield[a]
[%]
IC50[b]
[mm]
Structure
(R=)
Yield[a]
[%]
IC50[b]
[mm]
4a 67 296 4 j 65 367
4b 73 441[c] 4k 76 398
4c 75 814 4 l 64 335
4d 72 810[c] 4m 63 317
4e 60 324 4n 80 405
4 f 59 310 4o 28 1461
4g 65 356 11 dimer (Figure 2) – 31
4h 82 325 12 diastereoisomer of 4h (Figure 2) 65[d] 1421
4 i 78 290 2 see Figure 1 – 986
[a] Unoptimized overall yield from 9. [b] In SPR competition test with immobilized Man-BSA. [c] Low solubil-
ity in water. [d] Isolated as a byproduct from glycosylation of a batch of nonenantiomerically pure 7 (see the
Supporting Information for details).
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SIGN on mucosal DCs is used by the virus to invade the
host immune system, Langerin was shown to have protective
effects against HIV infection.[7] To get an insight into the se-
lectivity of ligands 1–4, they were tested in the same concen-
tration range as inhibitors of DC-SIGN (20 mm) and of Lan-
gerin (15.5 mm) binding to dextran/Man-BSA surface. As can
be seen from the inhibition curves (Figure 4a), none of the
tested compounds were able to fully inhibit Langerin bind-
ing to the surface, despite the lower concentration of Lan-
gerin used in the assay relative to DC-SIGN ECD concen-
tration (due to limited availability of the protein). The most
potent inhibitors were found to be dimer 11 and the referen-
ces 1 and 2. Because most of the compounds at the highest
concentration used did not reach 50% inhibition of Langer-
in, it was not possible to calculate their IC50 values. Never-
theless, to get a comparison of DC-SIGN versus Langerin
inhibition, the inhibition levels (%) achieved at three com-
pound concentrations, 0.5, 1.0, and/or 1.5 mm, were deter-
mined. Data obtained at 0.5 mm are plotted in Figure 4b
(see Figure S2 in the Supporting Information for DC-SIGN
and Langerin inhibition levels at 1 and 1.5 mm ligand con-
centration). The data show that the pseudo-disaccharide
bis(methylester) 2 is endowed with a modest selectivity for
DC-SIGN as previously reported.[8] The corresponding pseu-
dotrisaccharide 1 and many of the bis ACHTUNGTRENNUNG(amides) 4, that is, 4a,
4 f, 4h, and 4 i, were found to inhibit DC-SIGN with an im-
proved selectivity relative to Langerin, a very desirable fea-
ture for further development as antiviral agents. Fucose-
based ligands, both natural[17] and unnatural[6d] have been re-
ported to recognize DC-SIGN selectively. However, man-
nose-containing oligosaccharides appear to bind both lec-
tins[17,18] and it has long been believed that selectivity could
not be achieved with mannose-based ligands. Our current
results show that this goal can be reached.
With this information in hand, bis ACHTUNGTRENNUNG(amide) 4h was selected
for future development in multivalent constructs, since this
ligand appears to combine good affinity and selectivity for
DC-SIGN with good solubility, synthetic accessibility, and
atom efficiency. This ligand was therefore chosen for struc-
tural analysis by NMR spectroscopy to eventually identify
ligand-receptor contacts that are essential for complex for-
mation and compare its binding mode to that observed for 2
Figure 3. SPR results representing inhibition of DC-SIGN ECD binding
to Man-BSA surface by mannose-based compounds: inhibition curve-
s (top) and extracted corresponding IC50 values of mannose-based li-
gands (bottom). In dark grey: IC50 bars of the reference compounds 1
and 2. In light grey: compounds that displayed low solubility under the
assay conditions.
Figure 4. Inhibition of Langerin ECD binding to the Man-BSA/dextran
SPR surface by mannose-based compounds: inhibition curves (a), DC-
SIGN and langerin Inhibition level obtained for 0.5 mm of the com-
pounds (b).
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in the X-ray structure of its complex with DC-SIGN.[8] Ini-
tial attempts were frustrated because the high-field (500 and
600 MHz) 1H NMR spectrum of 4h showed some overlap-
ping of signals in areas crucial for our analysis. Previous
NMR work on the parent bis(methylester) 2 had shown that
its triazole derivative 14 (Scheme 2) is a better substrate for
spectroscopic analysis. The triazole residue in the linker of
14 did not affect binding to DC-SIGN ECD relative to 2,
neither in terms of affinity nor in terms of protein-ligand
contacts, but it significantly improved the dispersion of sig-
nals in the 1H NMR spectrum and allowed a full characteri-
zation of the binding epitope.[8] Thus, based on this experi-
ence, 4h was transformed into the corresponding triazole 13
(Scheme 2). For comparison, and to examine the role played
by the scaffold configuration in pseudomannobioside
mimics, the diastereomeric bis ACHTUNGTRENNUNG(amide) 12 was also trans-
formed into the corresponding triazole 15 and its interaction
with DC-SIGN was studied by NMR spectroscopy.
The spectrum of 13 is indeed more resolved than the spec-
trum of 4h, but not fully resolved. In particular the 6ax
proton of the cyclohexane ring (H6ax(C)) and the 3 proton
of mannose (H3(M)), both belonging to the epitope of 14,
overlap with protons 6eq (H6eq(C)) and 3eq (H3eq(C)) (m,
at d=1.89–1.82 ppm) and with proton 2 (H2(C)) (m, at d=
3.84 ppm) of the cyclohexane ring, respectively (Figure 5a,
see Scheme 2 for numbering of the cyclohexane ring).
Nonetheless saturation transfer difference (STD) NMR
spectroscopic studies could be performed and the data were
compared with those obtained for the reference ligand 14.
STD-NMR spectra is a useful and robust technique to
obtain structural information on molecular recognition proc-
esses within the range of fast exchange kinetics (KD from
the 0.1 to 10 mm range).[19] Attempts to resolve signal over-
lapping by varying the temperature were ineffective and
some of the most interesting signals could not be quantified.
The STD spectrum of 13 in the presence of DC-SIGN ECD
(50:1 ligand/protein ratio) at room temperature is reported
in Figure 5b.
To obtain information on the binding epitope, the initial
slope approximation (STD0)[20] was used, to reduce interfer-
ences from differences in relaxation properties of each
proton of the ligand and from rebinding processes.[21] The
experimental STD growth curves are collected in Figure 6.
Despite the signal overlap problems, a detailed compari-
son of the STD data obtained for 13 and 14 allows us to
qualitatively establish that the two molecules share the same
binding mode. For 14, quantitative analysis of the STD re-
sults had shown a very good match with the three-dimen-
sional structure of the DC-SIGN/2 complex determined by
X-ray crystallography (Figure 7a): binding occurs through
coordination of the calcium ion by OH-3 and OH-4 of the
mannose residue in an orientation which allows the cyclo-
hexane ring to establish a van der Waals contact with the
V351 side chain of the receptor; this results in important
Scheme 2. Triazole derivatives used for NMR spectroscopic interaction
studies.
Figure 5. STD NMR spectroscopic study of the interaction of ligand 13
with DC-SIGN in buffered D2O (150 mm NaCl, 4 mm CaCl2, 25 mm d-
Tris, pD 8). a) 1H NMR reference spectrum (off-resonance frequency
40 ppm) and b) STD spectrum (on-resonance frequency d=0 ppm) of a
sample containing 13 (1 mm) and DC-SIGN ECD (19 mm) at 25 8C
(500 MHz) and a saturation time of 0.5 s. Key proton signals are labeled.
Figure 6. Experimental STD growth curves of 13 as a function of satura-
tion time.
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STD signals for the mannose moiety and for all cyclohexane
protons, particularly H6ax(C) (see Figure S3 in the Support-
ing Information). Although no accurate integration of some
of the key protons was possible for 13, overall the same pat-
tern of STD intensities emerged (for a comparison of the
STD0 values, see the Table S1 in the Supporting Informa-
tion). For a comparison of the full STD spectra see Fig-
ure S3 in the Supporting Information) leaving little doubt
that 13 has the same binding mode as 14. Additionally, the
STD0 NMR spectroscopic signals obtained for 13 are higher
than those for the corresponding protons of 14 under the
same conditions (see Table S1 in the Supporting Informa-
tion). If both binding modes are the same, this is also indica-
tive of a higher affinity of 13 relative to the parent com-
pound. Indeed, the bis(benzylamido) moieties of 13 appear
to establish further contacts with the protein (H(Ar), Fig-
ures 5 and 6), which can explain the significant increase in
affinity for 13 compared to 14. Docking of mimic 13 in the
1L4 crystal structure[22] was carried out by using the quan-
tum polarized ligand docking (QPLD) workflow[23] based on
the docking algorithm Glide.[24] This procedure identified
poses consistent with the crystal structure of the DC-SIGN/
2 complex,[8] and also displayed additional interactions be-
tween the bis(benzylamido) moieties and the protein sur-
face. A docking pose that qualitatively accounts for the STD
data is shown in Figure 7b.
The STD spectra of the diastereomeric ligand 15 obtained
under the same conditions suggested a very different bind-
ing mode involving the mannose moiety (H3(M), H4(M),
and H2(M)), but showing only a single contact between the
protein and the cyclohexane ring, through the H4 proton
(H4(C); see Table S1 and Figure S3 in the Supporting Infor-
mation). These data are in agreement with the lower affinity
measured for 15 in the SPR experiments and further support
the notion that appropriate design of the cyclohexane ring
configuration is crucial to the activity of the mannobioside
mimics in this series.
Analysis of the NOESY spectra of 13 revealed the clear
existence of the same diagnostic cross-peaks critically defin-
ing inter-residue contacts (highlighted in Figure 8) in both
NOESY (Figure 8a, free-ligand state) and TR-NOESY (Fig-
ure 8b, bound ligand state). This suggests that there is no
major variation in the conformation of 13 upon binding to
DC-SIGN, or, in other words, that the lectin recognizes the
main conformation(s) existing in solution.
Figure 7. a) X-ray structure of the DC-SIGN/2 complex (from ref. [8]).
b) Docked pose of 13 that qualitatively accounts for the STD data.
Figure 8. Expansions of NOESY experiments at 25 8C (500 MHz) of 13.
a) Free state, mixing time 500 ms. b) In the presence of DC-SIGN ECD,
mixing time 500 ms. Labels indicate some key NOE peaks.
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Conclusion
We have shown here that benzylic bis ACHTUNGTRENNUNG(amides) of general
formula 4 bind to DC-SIGN with affinities approaching that
of the synthetically more demanding pseudotrisaccharide 1.
Replacement of an allylic linker and inclusion of substitu-
ents designed to increase water solubility afforded a class of
molecules that outperform the group of amides of general
formula 3[6 g] previously found to bind somewhat nonspecifi-
cally to the protein and to display low solubility. Indeed,
NMR interaction studies showed no sign of nonspecific asso-
ciation between DC-SIGN and compound 13, derived from
4h. These studies also allowed us to determine that 13 binds
to DC-SIGN with the same binding mode of the parent
pseudodisaccharide bis(methylester) 2, that was recently de-
termined by high-resolution X-ray analysis.[8] Among the
group of molecules synthesized, the dimeric structure 11 was
found to display the best affinity for DC-SIGN (31 mm).
However, this ligand was not pursued further, since its activ-
ity is likely to depend on its ability to cross-link the DC-
SIGN ECD tetramer, a feature that can contribute to in-
creased selectivity in the format of the assay performed (in-
hibition of DC-SIGN ECD binding to immobilized Man-
BSA), but might be not relevant in the real physiological sit-
uation (DC-SIGN “immobilized” on DC surface). Among
the molecules prepared here, ligand 4h was selected for fur-
ther studies, due to a combination of good solubility, syn-
thetic accessibility, activity, and selectivity. Polyvalent pre-
sentations of this ligand on dendrimeric scaffolds are pres-
ently being examined and will be reported in due course.
Probably the most important characteristic that we could
determine for compounds 4a–o is their selectivity for DC-
SIGN against a second mannose-binding lectin, Langerin,
also expressed by a (different) subset of dendritic cells and
endowed with protective properties against HIV infection.
Selective inhibition of DC-SIGN versus Langerin is consid-
ered an important requirement for the development of anti-
infective agents able to block the first stages of infection
during sexual transmission of the virus. The current observa-
tion that amides 4 display enhanced selectivity that remains
significant up to 100% DC-SIGN inhibition shows that the
goal of selective mannose-based DC-SIGN ligands can be
achieved. More generally, these results strongly suggest that
the activity and selectivity of glycomimetic molecules based
on a monosaccharide anchor can be tuned by structural
modifications of secondary elements in the molecule and
bode well for the development of selective low molecular
weight lectin ligands.
Experimental Section
DC-SIGN ECD protein (residues 66–404) were overexpressed and puri-
fied as described previously.[14] Langerin ECD construct, comprising resi-
dues 68–328, were overexpressed as inclusion body, then refolded and pu-
rified to homogeneity in a functional form as already described.[25] Sur-
face plasmon resonance experiments were performed on a Biacore 3000
by using a CM4 chip, functionalized at 5 mLmin!1. Flow cells (Fc) 1 and
2 were activated with 50 mL of an 0.2m EDC&&definition?&&/0.05m
NHS&&N-hydroxysuccinimide?&& mixture, then Fc2 was functional-
ized with mannosylated bovine serum albumin (Man-BSA) by injecting
protein (60 mgmL!1) prepared in sodium acetate (10 mm, pH 4). Finally,
the remaining activated groups of both flow cells were blocked with etha-
nolamine (30 mL, 1m). After blocking, the three flow cells were treated
with HCl (10 mL, 10 mm) to remove unspecific bound protein and then
EDTA (20 mL, 50 mm) to expose surface to regeneration protocol. After
these steps, BSA-Man (2000 RU, on average) was immobilized.&&ok?
&&
For inhibition studies, mixtures of each lectin (DC-SIGN ECD (20 mm)
or Langerin (15.5 mm)) with increasing concentrations of inhibiting com-
pounds were prepared in a running buffer composed of Tris (25 mm,
pH 8), NaCl (150 mm), CaCl2 (4 mm), and P20 surfactant (0.005%), and
each sample (13 mL) was injected onto the surfaces at a 5 mLmin!1 flow
rate. Concentrations of inhibiting compounds ranged from 0.7 to
4583 mm. The resulting sensorgrams were reference surface corrected,
except for the case of Langerin; because this lectin displayed high affinity
to the dextran matrix, a dextran/Man-BSA surface was considered as a
combined ligand of Langerin, as previously described.[6d] The lectin-bind-
ing responses were extracted from the sensorgrams, converted to percent
residual activity values (y) with respect to lectin-alone binding, and then
plotted against corresponding compound concentrations. The 4-parame-
ter logistic model [Eq. (1)] was fitted to the plots, and the IC50 values
were calculated by using the values of fitted parameters (Rhi, Rlo, A1, and
A2) and Equation (2).
y ¼ Rint! Rhi!Rlo
1þ
!
c
A1
"A2 ð1Þ
IC50 ¼ A1
!
Rhi!Rlo
Rhi!50 !1
" 1
A2 ð2Þ
NMR spectroscopy experiments : NMR spectroscopic experiments were
recorded on a Bruker Avance DRX 500 MHz instrument equipped with
a 5 mm inverse triple-resonance probe head. NMR samples were pre-
pared in D2O (550 mL, 99.9%) and, for the experiments in the presence
of the receptor, in the same amount of buffer D2O (NaCl (150 mm),
CaCl2 (4 mm), d-Tris (25 mm, pD&&pH?&& 8) and DC-SIGN ECD
(19 mm). The concentration of the ligand was 5 mm for assignment experi-
ments (1H, COSY, TOCSY, NOESY, HSQC) and 1 mm for both STD
NMR and transferred NOESY spectroscopic experiments.
STD NMR spectroscopic experiments were carried out at 10, 25, and
35 8C by using a train of Gaussian shaped pulses of 49 ms (field strength
of ca. 80 Hz), an interpulse delay of 1 ms[19] and 15 ms spin-lock pulse
(field strength of 3.7 kHz) prior to acquisition. The on-resonance fre-
quency was set to d=0 ppm&&not Hz for frequency?&& and the off-
resonance frequency was 40 ppm. Appropriate blank experiments were
performed to assure the lack of direct saturation of the ligand protons.
Saturation times of 0.5, 1, 1.5, 2, 3, 4, and 5 s were used to obtain the
STD build-up curves.
The binding epitope was characterized by the analysis of initial slopes of
the STD intensities[26]: the experimental (I0!Isat/I0) curves were fitted to
an exponential function described by the equation: STD (tsat)=STDmax
(1!e !ksat·tsat), which allows us to calculate STD at zero saturation time
(initial slopes) by the product of resulting parameters STDmax and ksat.[20]
NOESY experiments were carried out at 0.1, 0.2, 0.3, and 0.5 s, by using
a phase-sensitive pulse program with gradient pulses in the mixing time
and with presaturation.[27,28]
Docking studies
Protein setup: By starting from the crystal structure (resolution=1.55 %)
of human DC-SIGN in a complex with Man4 (PDB code 1L4),[22] a mo-
lecular model of the protein was constructed. By using the &Protein Prep-
aration Wizard! within the Maestro graphical interface,[29] the crystal
structure was modified by deleting all crystal waters, assigning bond
orders and adding hydrogen atoms. Protonation states of basic and acidic
residues were assigned by optimization of the hydrogen-bonding net-
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work. An Impref minimization was carried out on the final protein struc-
ture by using the OPLS2005 force field,[30] converging all heavy atoms to
a root-mean-squared deviation (RMSD) of 0.30 % of the crystallographic
positions.
Ligand conformational search : A conformational search was carried out
on each ligand by using a mixed torsional/low-mode sampling method.[31]
The conformational sampling was performed by using the OPLS2005
force field,[30] an implicit water model[32] with constant dielectric, and
with the van der Waals, electrostatic and hydrogen bond cutoffs set to 8,
20, and 4 %, respectively. Extended torsion sampling was used with the
maximum number of steps set to 1000. The energy window for saving
structures was set to 42 kJmol!1 (10.04 kcalmol!1). The resulting confor-
mations were clustered by using an average linkage clustering technique,
with representatives closest to the centroid of each cluster selected for
docking.
Docking : The protein structure described above was used to generate a
grid to be employed in the docking study. An &enclosing box! with dimen-
sions of 36%, centered on the ligand in the crystal structure, was set;
nonplanar conformations of amide bonds were penalized, and the partial
charge cutoff was set to 0.25. No constraints were used so as to allow li-
gands to freely explore the grid.
Docking studies were carried out by using the QPLD[23] workflow based
on Glide.[24] This technique allows for charge polarization of the ligands
induced by the protein environment, which is essential within highly
charged active sites, such as DC-SIGN. QPLD improves the partial
charges on the ligand atoms in Glide docking run by replacing them with
charges generated from a quantum-mechanical (QM) calculation on the
ligand in the field of the receptor. By using the previously described grid,
along with the input structures obtained from conformational clustering,
QPLD was performed. Initial charges for each ligand were generated
with a semi-empirical method and were rigidly docked in Glide Extra
Precision (XP) mode[33] with van der Waals radii scaled by 0.8. The QM
charges were calculated by using density functional theory at the B3LYP/
3-21g level of theory by using the Jaguar program.[34] The generated
poses from the initial docking stage were subsequently re-docked rigidly
in XP mode by using the calculated QM charges for the ligands.
Redundant binding modes, in which no calcium coordination was ob-
served, were removed by filtering docked poses by the OH-3–Ca2+ dis-
tance. Distances greater than 4 % were discarded and the remaining
poses were minimized, and binding energies estimated, with the Prime
MM-GBSA program.[35]
Synthesis
General: Dichloromethane, methanol, N,N-diisopropylethylamine
(DIPEA), and triethylamine (TEA) were dried over calcium hydride;
tetrahydrofuran (THF) was distilled over sodium, and N,N-dimethylace-
tamide (DMA) was dried over activated molecular sieves. Reactions re-
quiring anhydrous conditions were performed under nitrogen. 1H and 13C
spectra were recorded at 400 MHz on a Bruker AVANCE-400 instru-
ment. Chemical shifts (d) for 1H and 13C spectra are expressed in ppm
relative to the internal standard (CDCl3: d=7.24 ppm for 1H and d=
77.23 ppm for 13C; CD3OD: d=3.31 ppm for 1H and d=49.15 ppm for
13C). Signals were abbreviated as s, singlet; br s, broad singlet; d, doublet;
t, triplet; q, quartet; m, multiplet. Sugar signals were numbered as cus-
tomary; cyclohexane protons are indicated with the letter C followed by
numbers. The unusual numbering of the pseudodisaccharide derivatives
was adopted to facilitate the comparison with the native disaccharide.
Mass spectra were obtained with a ThermoFisherLCQapparatus (ESI
ionization), or iontrap ESI Esquire 6000 from Bruker, or a Microflex ap-
paratus (MALDI ionization) from Bruker, or Apex II ICR FTMS (ESI
ionization–HRMS). Specific optical rotation values were measured at
589 nm by using a Perkin–Elmer 241 with a 1 dm cell. TLC analysis was
carried out with pre-coated Merck F254 silica gel plates. Flash chroma-
tography (FC) was carried out with Macherey–Nagel silica gel 60 (230–
400 mesh). Amines 10a–e and 10p are commercially available. The syn-
thesis of amine 10 f–o is reported in the Supporting Information file. The
synthesis of 4h, 11, 13, and 15 is described below. The synthesis of all
other amides (4a–g, 4 i–o, and 12) are reported in the Supporting Infor-
mation.
4,5-Epoxy-cyclohexan-1,2-dicarboxylic acid bis(4-nitrophenyl)ester
(1S,2S) (6): EDC·HCl (394 mg, 2.05 mmol, 3.5 equiv) was added to a sol-
ution of the diacid 5[10] (100 mg, 0.59 mmol, 1 equiv) in dry THF (5.8 mL)
with stirring and under a nitrogen atmosphere. After 10 min, p-nitrophe-
nol (245 mg, 1.76 mmol, 3 equiv) was added. The solution was stirred at
room temperature for 2 h. After completion of the reaction, the solvent
was evaporated under reduced pres-
sure, the residue was taken up in Et2O,
washed with 1m HCl, saturated
Na2CO3 (3'), and water; the mixture
was then dried over sodium sulphate.
The solvent was evaporated under re-
duced pressure to yield 74% of pure
(1S,2S)-4-cyclohexen-1,2-dicarboxylic
acid bis(p-nitrophenyl) (PNP) ester as
a pale-yellow solid.
[a]20D= +129.6 (c=1 in CHCl3);
1H NMR (400 MHz, CDCl3): d=8.28–
8.22 (m, 4H; H10), 7.27–7.22 (m, 4H; H9), 5.83 (appd, J=2.8 Hz, 2H; H4,
H5), 3.27–3.19 (m, 2H; H1, H2), 2.78–2.68 (m, 2H; H3ps–eq, H6ps–eq), 2.48–
2.37 ppm (m, 2H; H3ps–ax, H6ps–ax); 13C NMR (100 MHz, CDCl3): d=172.8
(C7); 155.4 (C11); 145.7 (C8); 125.5 (C10); 124.9 (C5, C4); 122.5 (C9); 41.5
(C1, C2); 28.0 ppm (C3, C6).
mCPBA (77%, 891 mg, 3.98 mmol, 1.2 equiv) was added to a solution of
the PNP ester prepared in the previous step (1367 mg, 3.32 mmol,
1 equiv) in dry CH2Cl2 (11 mL) under stirring. The reaction was stirred
under nitrogen at room temperature
for 16 h. The solvent was evaporated
at reduced pressure and then the reac-
tion mixture was diluted with EtOAc
and washed with saturated NaHCO3
(3') and with water. The organic
phase was dried over sodium sulphate
and the solvent evaporated under re-
duced pressure to yield 91% of pure
product 6 as a white solid.
[a]20D= +82.2 (c=1.1 in CHCl3);
1H NMR (400 MHz, CDCl3): d=8.28–
8.22 (m, 4H; H10), 7.27–7.21 (m, 4H; H9), 3.43–3.36 (m, 1H; H4 or H5),
3.35–3.31 (m, 1H; H4 or H5), 3.32–3.24 (m, 1H; H1 or H2), 3.08–3.00 (m,
1H; H1 or H2), 2.79–2.71 (m, 1H, H3eq or H6eq), 2.63–2.54 (m, 1H; H3eq or
H6eq), 2.42–2.33 (m, 1H; H3ax or H6ax), 2.21–2.12 ppm (m, 1H; H3ax or
H6ax); 13C NMR (100 MHz, CDCl3): d=172.6, 171.5 (C7); 155.4, 155.3
(C8); 149.9 (C11); 125.5 (C10); 122.5, 122.6 (C9); 51.8, 50.3 (C4, C5); 40.1,
38.1 (C1, C2); 26.8, 26.3 ppm (C3, C6); MS (ESI): m/z (%): for
[C20H16N2O9Na]+ : 451.3; found: 452.0; HRMS: m/z calcd for
[C20H16N2O9Na]+ : 451.07480; found: 451.07525
1,2-Cyclohexanedicarboxylic acid, (1S,2S,4S,5S)-5-(2-azidoethoxy)-4-hy-
droxy-1,2-bis-p-nitrophenyl ester (7):&& Epoxide 6 (50 mg, 0.12 mmol,
1 equiv) and CuACHTUNGTRENNUNG(OTf)2 (4 mg, 0.01 mmol, 0.1 equiv) were added to a solu-
tion of 2-azidoethanol[11] (ca. 600 mg, 7 mmol, 58 equiv) in dichlorome-
thane (3 mL) and the mixture stirred under nitrogen at room tempera-
ture. After completion (16 h), the solvents were removed under reduced
pressure and the crude was purified by flash chromatography (hexane
with gradient of ethyl acetate from 20 to 50%) to yield 70% of pure
product 7 as a colorless wax.
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[a]20D= +33.8 (c=1.1 in CHCl3);
1H NMR (400 MHz, CDCl3): d=8.27–
8.17 (m, 4H; H12), 7.31–7.23 (m, 4H; H11), 4.19–4.14 (m, 1H; H2), 3.88–
3.82 (m, 1H; H7a), 3.73–3.63 (m, 2H; H7b, H1), 3.49–3.29 (m, 4H; H4, H5,
H8a,b), 2.40–2.10 ppm (m, 4H; H3, H6); 13C NMR (100 MHz, CDCl3): d=
172.7, 172.6 (C9); 155.5 (C10); 145.8, 145.7 (C13); 125.5 (C12); 122.6, 122.6
(C11); 76.5 (C1); 68.7 (C7); 66.3 (C2); 51.1 (C8); 39.4, 39.1 (C4, C5); 30.5,
27.0 ppm (C3, C6); MS (ESI): m/z calcd for [C22H21N3O10Na]+ : 512.4
[M+Na]+!N2&& ; found: 512.0.
1,2-Cyclohexanedicarboxylic acid, (1S,2S,4S,5S)-4-(2-azidoethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-a-d-mannopyranosyl)oxy]-1,2-bis(p-nitrophenyl
ester) (9): A mixture of the acceptor 7 (37 mg, 0.071 mmol, 1 equiv) and
the donor 8[12] (65 mg, 0.086 mmol, 1.2 equiv) was co-evaporated from
toluene three times. Powdered and activated 4% molecular sieves (acid
washed) were added; and the mixture was kept under vacuum for a few
hours and then dissolved with dry CH2Cl2 (1 mL). After cooling at
!20 8C, TMSOTf (3 mL, 0.014 mmol, 0.2 equiv) was added to the mixture
whilst stirring. The reaction was stirred at !20 8C for 1 h and was then
quenched with Et3N. The mixture was warmed to room temperature and
filtered over a Celite pad. The filtrate was evaporated at reduced pres-
sure and the crude product purified by flash chromatography (toluene
with a gradient of ethyl acetate from 0 to 10%) to yield 85% of pure
product 9 as a white foam.
[a]20D=!18.0 (c=0.5 in CHCl3); 1H NMR (400 MHz, CDCl3): d=8.30–
8.20 (m, 4H; H12), 8.09–8.00 (m, 4H; HBz), 7.99–7.94 (m, 2H; HBz,), 7.83–
7.79 (m, 3H; HBz), 7.63–7.48 (m, 3H; HBz), 7.46–7.20 (m, 12H; HBz, H11),
6.07 (t, 1H; H4, J4!3=J4!5=10.0 Hz), 5.90 (dd, 1H; H3, J3!4=10.0, J3!2=
3.3 Hz), 5.75 (dd, 1H; H2, J2!1=1.7, J2!3=3.3 Hz), 5.34 (d, 1H; H1, J1!2=
1.7 Hz), 4.73 (dd, 1H; H6b, J6b!5=2.9, J6a!6b=12.0 Hz), 4.53 (dd, 1H; H6a,
J6a!5=5.3, J6a!6b=12 Hz), 4.48–4.40 (m, 1H; H5), 4.23–4.18 (m, 1H; C2),
3.89–3.84 (m, 1H; C1), 3.74–3.67 (m, 1H; H7a), 3.60–3.52 (m, 1H; H7b),
3.44–3.34 (m, 2H; C4, C5), 3.35–3.23 (m, 2H; H8), 2.52–2.41 (m, 2H; C3eq,
C6eq), 2.25–2.09 ppm (m, 2H; C3ax, C6ax); 13C NMR (100 MHz, CDCl3):
d=172.3, 172.2 (C9); 166.3, 165.8, 165.7 (COBZ); 155.5, 155.4 (C10); 145.8
(C13); 133.9, 133.8, 133.6, 133.5 (CHBZ); 130.1, 130.1, 129.9, 129.9, 129.9
(CHBZ); 129.3, 129.2, 129.1, 129.0 (CquatBZ); 128.9, 128.7, 128.9, 128.4
(CHBZ); 125.5, 125.4 (C12); 122.7, 122.6 (C11); 96.8 (C1); 74.9 (CC1); 72.3
(CC2); 70.9 (C2); 70.1 (C5); 69.9 (C3); 68.7 (C7); 67.4 (C4); 63.5 (C6); 51.0
(C8); 39.4, 39.2 (CC4,CC5); 27.8 (CC3); 27.0 ppm (CC6); MS (ESI): m/z
calcd for [C56H47N5O19Na]+ : 1117.0; found 1116.1; HRMS: m/z calcd for
[C56H47N5O19Na]+ : 1116.27575; found: 1116.27734.
Synthesis of N1,N2-bis[4-(hydroxymethylene)benzyl]amide (4h): The
amine 10h (38 mg, 0.275 mmol, 3 equiv) was added to a 0.1m solution of
9 (100 mg, 0.091 mmol, 1 equiv) in dry acetonitrile (0.9 mL) whilst stir-
ring and under a nitrogen atmosphere at room temperature. After com-
pletion (3 h; TLC, hexane/EtOAc 1:1 and 2:8) the solvent was evaporat-
ed under reduced pressure. The crude product was dissolved in dry meth-
anol (c=0.1m), under nitrogen at room temperature and a 1m solution of
sodium methoxide in MeOH (2 equiv) was added. After reaction comple-
tion (1 h), the reaction mixture was diluted with MeOH and neutralized
with prewashed Amberlite IRA 120-H+ . The resin was filtered off and
the filtrate was concentrated under reduced pressure. The crude was pu-
rified by flash chromatography (CHCl3 with gradient of methanol from 0
to 20%).
Yield=82%; [a]20D= +12.1 (c=0.81 in CH3OH);
1H NMR (400 MHz,
CD3OD): d=7.29 (d, 4H; H12, J12!13=8 Hz), 7.23 (d, 4H; H13, J13!12=
8 Hz), 4.96 (d, 1H; H1, J1!2=1.6 Hz), 4.58 (s, 4H; H15a,b), 4.31 (s, 4H;
H10a,b), 4.08–4.03 (m, 1H; C2), 3.93–3.89 (m, 1H; H2), 3.89–3.84 (m, 1H;
H6a), 3.84–3.65 (m, 5H; C1, H6b, H7a,b, H3,), 3.64–3.54 (m, 2H; H4, H5),
3.47–3.35 (m, 2H; H8a,b), 3.02–2.85 (m, 2H; C4,C5), 2.06–1.86 ppm (m,
4H; C3, C6); 13C NMR (100 MHz, CD3OD): d=177.2, 177.0 (C9); 141.7
(C14); 139.2 (C11); 128.6, 128.7 (C12); 128.3 (C13); 100.4 (C1); 76.6 (C3);
75.7 (C5); 72.7 (CC1); 72.5 (C2); 72.4 ( CC2); 69.3 (C7); 68.9 (C4); 65.1
(C15); 63.2 (C6); 52.1 (C8); 43.8 (C10); 42.1, 41.9 (CC4, CC5); 29.9, 29.0 ppm
(CC3, CC6); HRMS: m/z calcd for: [C32H43N5O11Na]+ : 696.28568; found:
696.28423.
Synthesis of macrocycle 11: A solution of p-xylylbenzylamine 10p
(3.8 mg, 0.028 mmol, 0.5 equiv) in MeCN (0.55 mL) was added dropwise
under nitrogen to a flask charged with scaffold 9 (60 mg, 0.055 mmol,
1 equiv). The reaction was stirred for 5 h. TLC (dichloromethane/MeOH
9:1, dichloromethane/MeOH 9:1+1% TEA, hexane/AcOEt 6:4) indicat-
ed the presence of scaffold 9, whereas amine 10p was not observed.
Therefore, another portion of amine 10p (0.5 equiv) was added and the
reaction mixture was stirred for an additional 16 h after which TLC anal-
ysis indicated almost no 9 and a complex mixture of products. The sol-
vent was removed under reduced pressure and the crude was purified by
flash chromatography (silica, hexane with gradient of EtOAc from 30 to
70%) to afford 18.6 mg of benzoyl-protected intermediate (TLC, hexane/
EtOAc 2:8, Rf=0.33); MS (ESI): m/z calcd for [C104H98N10O26Na]+ :
1926.9; found: 1926.6.
A solution of sodium methoxide in MeOH (1m, 100 mL, 0.037 mmol,
4 equiv) was added to the solution of the product obtained in the previ-
ous reaction (18.6 mg, 0.0097 mmol, 0.18 equiv) in dry MeOH (0.7 mL).
After 45 min, the reaction mixture was diluted with methanol and neu-
tralized with prewashed Amberlite IRA 120-H+ . The resin was filtered
off and the filtrate was concentrated under reduced pressure. The crude
product was purified by flash chromatography (CHCl3 with a gradient of
MeOH from 0 to 20% with 10% water in methanol) to afford 8.7 mg of
product.
Yield=15%; 1H NMR (400 MHz, CD3OD): d=7.11 (s, 8H; H12), 4.96
(d, 2H; H1, J2!1=1.7 Hz), 4.72–4.65 (m, 4H; H10a), 4.05–4.02 (m, 2H;
C2), 3.91 (dd, 2H; H2, J2!1=1.7, J2!3=3.2 Hz), 3.88–3.81 (m, 2H; H6b),
3.80–3.62 (m, 14H; H10b, H3, H7, C1, H6b), 3.61–3.52 (m, 2H: H4, H5),
3.45–3.33 (m, 2H; H8), 2.98–2.81 (m, 2H; C4, C5), 2.00–1.86 ppm (m, 4H;
C3, C6); 13C NMR (100 MHz, CD3OD): d=177.1, 177.0, 176.8, 176.7 (C9);
138.9, 138.9 (C11); 128.9 (C12); 100.3 (C1); 76.7 (CC1); 75.7 (C5); 72.7 (C3);
72.6 (C2); 72.5 (CC2); 69.3 (C7); 68.9 (C4); 63.2 (C6); 52.2 (C8); 43.8 (C10);
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41.9, 41.8 (CC4, CC5); 30.0, 29.1 ppm (CC3, CC6); HRMS: m/z calcd for
[C48H66N10O18Na]+ : 1093.44543; found: 1093.44341.
Synthesis of 13 (triazol derivative of 4h): Bisamide 4h (20 mg,
0.030 mmol, 1 equiv), propargyl alcohol (5 mg, 0.090 mmol, 3 equiv), cop-
per(II) sulphate pentahydrate (0.7 mg, 0.003 mmol, 0.1 equiv), sodium as-
corbate (2.3 mg, 0.012 mmol, 0.4 equiv), and tris[(1-benzyl-1H-1,2,3-tria-
zol-4-yl)methyl]amine (TBTA, 3.1 mg, 0.006 mmol, 0.2 equiv) were dis-
solved in THF/H2O (1 mL, 1:1). After reaction completion (4 h; TLC,
CHCl3/MeOH 8:2) the solvent was removed under reduced pressure and
the resulting crude was purified by flash chromatography (silica, chloro-
form with gradient of MeOH from 10 to 30%) to afford 14.8 mg of pure
product.
Yield=70%; [a]20D= +11.7 (c=0.30 in CH3OH);
1H NMR (400 MHz,
CD3OD): d=8.00 (s, 1H; H16), 7.31–7.17 (m, 8H; H12, H13), 4.88 (br s,
1H; H1), 4.65 (s, 2H; H18), 4.59 (t, 2H; H8, J7!8=5.0 Hz), 4.56 (s, 4H;
H15), 4.32–4.23 (m, 4H; H10a,b), 3.98–3.86 (m, 3H; H7, C2), 3.88–3.81 (m,
2H; H2, H6a), 3.72–3.61 (m, 3H; C1, H6b, H3,), 3.58–3.48 (m, 2H; H4, H5),
2.88–2.77 (m, 1H; C4), 2.72–2.60 (m, 1H; C5), 1.94–1.64 ppm (m, 4H; C3,
C6); 13C NMR (100 MHz, CD3OD): d=177.0, 176.9 (C9); 141.7 (C14);
139.2 (C11); 128.5 (C12); 128.3 (C13); 125.5 (C16); 100.4 (C1); 76.1 (C3);
75.7 (C5); 72.7 (CC1); 72.5 (C2); 72.2 (D2); 69.0 (C4); 68.3 (C7); 65.1 (C15);
63.2 (C6); 56.7 (C18); 51.8 (C8); 43.8 (C10); 41.9, 41.8 (CC4, CC5); 29.6,
28.9 ppm (CC3, CC6); HRMS: m/z calcd for [C35H47N5O12Na]+ : 752.31189;
found: 752.31099.
Synthesis of 15 (triazol derivative of 12): Bisamide 12 (see Scheme S8 in
the Supporting Information, 11 mg, 0.016 mmol, 1 equiv), propargyl alco-
hol (4.6 mg, 0.081 mmol, 5 equiv), copper(II) sulphate pentahydrate
(0.4 mg, 0.001 mmol, 0.1 equiv), sodium ascorbate (1.3 mg, 0.006 mmol,
0.4 equiv), and TBTA (1.72 mg, 0.003 mmol, 0.2 equiv) were dissolved in
THF/H2O (1 mL, 1:1). After reaction completion (12 h; TLC, CHCl3/
MeOH 8:2), the solvent was removed under reduced pressure and the re-
sulting crude was purified by flash chromatography (silica, chloroform
with gradient of methanol from 10 to 30%) to afford 4.2 mg of pure
product.
Yield=35%; [a]20D= +30.1 (c=0.20 in CH3OH);
1H NMR (400 MHz,
CD3OD): d=8.00 (s, 1H; H16), 7.31–7.14 (m, 8H; H12, H13), 4.84 (br s,
1H; H1), 4.88 (br s, 1H; H1), 4.65 (s, 2H; H18), 4.59 (t, 2H; H8, J7!8=
5.0 Hz), 4.56 (s, 2H; H15), 4.56 (s, 2H; H15), 4.29 (s, 2H; H10), 4.27 (s, 2H;
H10), 3.99–3.92 (m, 1H; H7a), 3.90–3.84 (m, 2H; H7b, C2), 3.84–3.80 (m,
1H; H6a), 3.78–3.71 (m, 2H; H2, H4), 3.71–3.59 (m, 2H; H5, H6b), 3.59–
3.49 (m, 2H; C1, H3), 2.94–2.84 (m, 1H; C4), 2.70–2.59 (m, 1H; C5), 1.98–
1.71 ppm (m, 4H; C3, C6); 13C NMR (100 MHz, CD3OD): d=177.0 (C9);
141.7, 141.6 (C14); 139.2, 139.2 (C11); 128.6 128.5 (C12); 128.3, 128.3 (C13);
125.7 (C16); 101.8 (C1); 75.8 (C5); 75.2 (D1); 73.9 (CC2); 72.6, 72.5 (C2,
C4); 69.0 (C3); 68.3 (C7); 65.1 (C15); 63.3 (C6); 56.7 (C18); 51.9 (C8); 43.8,
43.7 (C10); 42.3, 41.7 (CC4, CC5); 31.0, 29.2 ppm (CC3, CC6); HRMS: m/z
calcd for [C35H47N5O12Na]+ : 752.31189; found: 752.31123
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Studies of Bis(benzylamide) Deriva-
tives of a Pseudomannobioside
Receptor targeting : We show here for
the first time that glycomimetics based
on a mannose anchor can be tuned to
selectively inhibit DC-SIGN (dendritic
cell-specific intercellular adhesion mol-
ecule-3-grabbing nonintegrin) over
Langerin. Based on structural and
binding studies of a mannobioside
mimic previously described by us, a
focused library of derivatives was
designed (see figure).
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9.1. DEVELOPMENT OF MONOVALENT GLYCOMIMICS
The additional data not presented in the article.
1) Evaluation of selectivity gain for bis-benzylamide compound series. The selectivity gain
values achieved by modifying psDi scaﬀold to obtain the compounds of bis-benzylamide series were
calculated (sel.gpsDi→psDi derivative). For comparison psTri was also included. After extrapolating
the IC50 values for langerin using eq. 6.2 on page 114, the sel.gpsDi→psDi derivative values were
calculated as described in sub-subsection 9.1.1.4 on page 150. and the results are shown in figure
9.20.
Figure 9.20.: The comparison of the selectivity gains of bis-benzylamides and psTri with respect
to psDi as a reference compound.
The error bar for 4h is the SD value from two measurements in this experiment.
With an exception for compound 4o, all other compounds yielded improved selectivity to DC-
SIGN versus langerin. The outstanding selectivity gain for compound 11, a dimeric macrocyclic
structure of two diastereoisomers (fig. 9.21), was observed.
Figure 9.21.: The structure of compound 11.
Taking into account a relatively very high aﬃnity to DC-SIGN of this compound (in terms
of IC50 , 31 ￿M, which is even better than for psTri) that might suggest a psTri-like ability to
bridge DC-SIGN tetramers, such high selectivity gain could indicate that 11 is able to bridge only
DC-SIGN tetramers and not langerin trimers. Whereas a comparison with the result obtained for
psTri may suggest that psTri bridges both DC-SIGN and langerin, but in addition has intrinsically
higher aﬃnity to DC-SIGN than langerin (thereof the selectivity gain, which is very similar to the
gain for bis-benzylamide compound series). It is also possible that 11 bridges langerin, but in that
case it has much higher intrinsic aﬃnity to DC-SIGN than langerin.
One of the highest selectivity gains (apart from 11) belonged to compound 4h.
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2) Eﬀorts to resolve the overlap of the key protons in 4h 1D 1H NMR spectrum. The compound
4h exhibited an overlap of the key protons, shown in figure 9.22, necessary for the comparison of its
binding to DC-SIGN properties with those of psDi, i.e. the protons that had highest initial slope
values in STD build-up curves.
Figure 9.22.: 1D 1H NMR spectra of 4h and psDi comparing the signals of the key protons in the
two molecules.
The protons are indicated on 4h structure on top.
It was attempted to resolve these overlaps (mainly the C3eq-C6ax-C6eq overlap since C6ax
in psDi had the highest initial slope value) by lowering the temperature of the experiment from
25°C to 10°C and by adding DMSO to the sample. I was involved in these experiments during the
long-term secondment in Seville.
Lowering the temperature not only didn’t improve the resolution of C3eq-C6ax-C6eq overlap,
but also turned to be even more disadvantageous because at 10°C anomeric proton of mannose (M1)
fused with water signal and mannose protons M6 and C1 were worse resolved (fig. 9.23).
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Figure 9.23.: 1D 1H NMR spectra of 4h at 10°C and 25°C.
The changes of proton signals are indicated in the figure by blue the frames: at 10°C anomeric proton of mannose
(M1) fused with water signal, mannose protons M6 and C1 were worse resolved and no change for C3eq-C6ax-C6eq
overlap was observed.
Likewise, the second approach of adding DMSO up to 31% did not give any favorable results
– there were virtually no changes to the spectra (fig. 9.24).
Figure 9.24.: 1D 1H NMR spectra of 4h in presence of diﬀerent DMSO concentrations, at 25°C.
Hence STD experiments were performed at 25°C with no DMSO in the sample, and conse-
quently 4h binding epitope was qualitatively compared with that of psDi as described in the article
and the following supplementary information.
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9.1.4.6. The second type of psDi optimization to achieve better selectivity to DC-SIGN
The new series of psDi-based compounds were generated with a purpose to reduce their recognition
by langerin and thus improve the selectivity to DC-SIGN. The rationale of this series design was the
structural knowledge about the ability of langerin CRD to recognize galactose residues sulphated
at position 6 (fig. 2.19 on page 78B), where the negatively charged sulphate group is in a favorable
position to make electrostatic contacts with positively charged side chain of the protein (Lys313,
see DC-SIGN and langerin binding site comparison in fig. 2.23 on page 81). Therefore, diﬀerent
substituents at position 6 of non-reducing mannose of psDi were introduced and the corresponding
structures are shown in figure 9.25. These studies were performed by master-1 student Vanessa
Porkolab under my supervision.
Figure 9.25.: The structures of psDi derivatives with diﬀerent substituents at position 6 of non-
reducing mannose compared to 4h structure.
The synthesis of these compounds was carried out in the team of Pr. A. Bernardi by Norbert
Varga. In these series the compound with the best inhibitory capacity towards DC-SIGN was
NV243, although previously selected new lead 4h remained the best among all the tested compounds
(fig. 9.26 left panel).
Figure 9.26.: The activities of new psDi derivatives to inhibit DC-SIGN and langerin.
DC-SIGN inhibition was performed using surface with 1900RU of ManBSA immobilized; inhibition of langerin
binding to reference (Fc1, activated/deactivated CM-dextran) and ManBSA/dextran (Fc2, ManBSA immobilized to
1600RU) surfaces was measured.
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The same compounds were tested for their capability to inhibit langerin ECD binding to
ManBSA/dextran surface. Since langerin exhibits measurable aﬃnity for dextran surface, the IC50
values were determined for the inhibition of both, binding to reference (activated/deactivated CM-
dextran) and ManBSA/dextran surfaces (fig. 9.26 right panel). As expected, the absolute IC50
values were diﬀerent for these two surfaces, but the general pattern of the activities of the compounds
was the same. Acetyl (NV233) and methyl sulfone (NV253) groups at position 6 did not change
compounds’ relative aﬃnity to langerin as compared to psDi. However, NV243 and NV270 with
amino and triazole groups, respectively, appeared to have lower activity to inhibit lagerin.
To have a more quantitative evaluation of the selectivity of these compounds, the sel.g values
were calculated as described in sub-subsection 9.1.1.4 on page 150. and compared (fig. 9.27).
Figure 9.27.: The comparison of the selectivity gains with respect to psDi as a reference compound.
Fc1 and Fc2 surfaces are the same as described in fig. 9.26.
As can be seen in figure 9.27, the psDi modifications leading to compounds NV233 and NV253
did not yield selectivity gain to DC-SIGN, and very slight sel.g was observed for compound NV270.
The highest improvement was reached for compound NV243, which possesses NH2 group at position
6 of non-reducing mannose, which confirms the assumption that adding there a positive charge would
impair compound’s interaction with langerin. The previously chosen lead 4h had the best selectivity
in the group of the tested compounds.
These results suggest that the combination of compounds 4h and NV243 might lead to even
more stronger and more selective inhibitor of DC-SIGN than the current lead 4h. The synthesis
of this compound, combining 4h and NV243 features, is a direct perspective of this collaborative
work.
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9.2. THE DEVELOPMENT OF MULTIVALENT GLYCOMIMETIC DC-SIGN
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9.2. The development of multivalent glycomimetic DC-SIGN
antagonists
9.2.1. The structures of all tested multivalent compounds
The first attempts to design multivalent DC-SIGN inhibitors were made before my PhD project
by our group in collaboration with Dr. J. Rojo group. The second (G2) and third generation
(G3) Boltorn type dendrimers functionalized with D-mannose residues were generated and assessed
for the capacity to inhibit DC-SIGN binding to gp120 surface [158]. The resulting activities of
these dendrimers were encouraging, thus G3 Boltorn type dendrimers were functionalized with
the selected mannose-based glycomimics psDi and psTri (fig. 9.15 on page 191). The evaluation
of these dendrimers to inhibit DC-SIGN in SPR competiton assay as well as DC-SIGN-mediated
Ebola infection assay is described in article n°3 (see sub-subsection 9.1.4.2 on page 191).
The strategies of multivalent presentation of DC-SIGN ligands were further explored by the
group of Dr. J. Rojo, and various glycodendrimers were generated by a PhD student Renato Ribeiro-
Viana using an eﬃcient convergent strategy, which employs a click chemistry reaction based on the
Cu(I) catalyzed azide−alkyne cycloaddition (CuAAC) (fig. 9.28) [173, 174, 175], a very versatile and
popular reaction allowing preparation of high diversity of compounds (small molecules, polymers,
hydrogels, etc.) and bioconjugates.
Figure 9.28.: The principal scheme of CuAAC reaction.
(Adapted from [176])
These dendrimers, shown in figure 9.29, allowed the ligand presentation at diﬀerent valences
as well as diﬀerent spatial conformations.
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Figure 9.29.: The structures of diﬀerent multivalent flexible scaﬀolds generated by CuAAC reac-
tions.
The scaﬀolds are named according to their valence (e.g. S4 means 4-valent Scaﬀold) and additional number marks
the alternative scaﬀold with the same valence. The orange spheres represent diﬀerent ligands conjugated to the
scaﬀolds, as shown in table 9.2.
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Whereas the dendrimers shown in figure 9.29 have flexible backbones, the multivalent platform
of a diﬀerent type with a rigid (“rod-like”) backbone was also synthesized (fig. 9.30, R3 ) by Norbert
Varga. The R3 scaﬀold was generated in order to obtain the presentation of conjugated ligands at
fixed distance and in this way to target the compound for binding to vicinal CRDs within the same
DC-SIGN tetramer. The other two compounds, R1 and R2 , are the control compounds to test
the intermediate stages of R3 development.
Figure 9.30.: The structure of rod-like scaﬀold and the control compounds R1 and R2 .
The predicted distance between the two branches of the ligands in scaﬀold R3 corresponded
to a 40Å spacing to reach the binding sites within a single DC-SIGN tetramer, as suggested by
molecular modeling performed in the group of Pr. Anna Bernardi (fig. 2.11 on page 70).
Diﬀerent mannose-based ligands, including the new lead compound 4h, were conjugated to
these newly generated multivalent scaﬀolds (fig. 9.29 and 9.30). Table 9.2 lists all mannose-based
compounds that were attached to the dendrimers and the corresponding multivalent compound
names used further in this thesis.
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Table 9.2.: Mannose-based ligands conjugated to the multivalent scaﬀolds and the corresponding
names of the compounds.
Ligand Scaﬀold Valence Compound name
D-mannose S4 4 S4-Oman
S6-1 6 S6-1-Oman
S9-1 9 S9-1-Oman
S9-2 9 S9-2-Oman
S12 12 S12-Oman
S18-1 18 S18-1-Oman
S18-2 18 S18-2-Oman
D-mannose C-glycoside S9-1 9 S9-1-Cman
S12 12 S12-Cman
psDi S4 4 S4-psDi
S6-1 6 S6-1- psDi
S6-2 6 S6-2- psDi
S9-1 9 S9-1- psDi
psTri S4 4 S4-psTri
S6-1 6 S6-1- psTri
4h S4 4 S4-4h
S6-1 6 S6-1-4h
S9-1 9 S9-1-4h
R1 6 R1
R2 6 R2
R3 6 R3
Scaﬀ. stands for “scaﬀold”
Ligand structures:
On the side of polyvalent fucose-based glycomimics development, several multivalent com-
pounds were also synthesized (table 9.3). The compounds listed in table 9.3 were synthesized
by PhD students Benedetta Bertolotti (L-fucose C-glycosides), Renato Ribeiro-Viana (S12-Ofuc,
S18-1-Ofuc), Daniela Doknic (S4-fucβAla , S4-10b-azide1 ) and a post-doctoral researcher Mar-
tino Ambrosini (S4-Ofuc, S6-1-Ofuc compounds).
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Table 9.3.: The list of fucose-based ligands conjugated to multivalent scaﬀolds and the correspond-
ing names of the compounds.
Ligand Scaﬀold Valence Compound name
L-fucose S4 4 S4-Ofuc
S6-1 6 S6-1-Ofuc
S12 12 S12-Ofuc
S18-1 18 S18-1-Ofuc
L-fucose C-glycoside S4 4 S4-Cfuc
S6-1 6 S6-1-Cfuc
S9-1 9 S9-1-Cfuc
S12-1 12 S12-1-Cfuc
L-fucose β-Ala+ S4 4 S4-fucβAla
10b-azide1 S4 4 S4-10b-azide1
Scaﬀ. stands for “scaﬀold”
Ligand structures:
All of these compounds were analyzed in SPR competition assay, and some of them were tested
for binding to DC-SIGN in SPR direct interaction assay.
9.2.2. The results of multivalent compound analysis by SPR competition assay
The multivalent compounds were tested in SPR competition assay in the same manner as described
earlier for monovalent compounds (subsection 9.1.1 on page 147). The below presented results are
divided to three parts according to compound, i.e. mannose or fucose-based, and scaﬀold type, i.e.
flexible or rod-like.
9.2.2.1. The evaluation of mannose-based compounds tethered to flexible multivalent scaﬀolds
The SPR competition assay results for the most of multivalent compounds on flexible scaﬀolds
showed a gradual increase of their activity as a function of the scaﬀold valence increment (fig. 9.31).
The only exception was psTri as monovalent and tetravalent presentation yielded same activity, the
reason for this is previously described ability of “monovalent” psTri to bridge DC-SIGN tetramers.
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Figure 9.31.: DC-SIGN inhibition activities of multivalent manoose-based compounds on flexible
scaﬀolds.
“Mono” stands for monovalent and “Mannose (C-glyc.)” means C-glycoside of mannose. IC50 values for Mono
compounds are from table 9.1 on page 149, except mannose C-glycoside, for which the value is the same as in fig. 9.7
on page 154). Compounds with 4h on all scaﬀold were assayed in presence of 4% DMSO.
Comparing the activities of the compounds with diﬀerent ligands but same scaﬀolds, it is
obvious that tethering selected lead 4h on each of the tested scaﬀold gives the best activity in
the group. It is also noticeable that 4h activity dramatically increases switching from monovalent
to tetravalent compound and a slight improvement is still achieved when valence increases to 6,
however, the nonavalent presentation gives no further improvement. It is possible that the spatial
presentation of the ligands on a nonavalent scaﬀold does not favor the accessibility of individual
ligands to DC-SIGN. The other, more plausible reason is the overestimation of the concentration
of this compound due to the lower solubility (the compounds are sent lyophilized, and it was not
possible to fully solubilize this particular compound).
Significantly higher activity of mannose C-glycosides as compared to mannose on the same
scaﬀolds, despite that the corresponding monovalent ligands have the same activities, is a strange
outcome with no rational explanation. All of the obtained IC50 values are listed in table 9.4.
Table 9.4.: The IC50 ± SD values (￿M) obtained for multivalent mannose-based compounds on
flexible scaﬀolds.
Ligand
Mannose Mannose (C-glyc.) psDi psTri 4h
Sc
aﬀ
ol
d
Mono* 3292 ± 337 3324 ± 74 1018 ± 109 145 ± 83 308 ± 40
S4 767 ± 20 - 136 ± 23 112 12 ± 3
S6-1 800 - 39 51 5.7 ± 1.6
S6-2 - - 32 - -
S9-1 128 24 ± 0.2 14 - 8.2 ± 0.2
S9-2 107 ± 10 - - - -
S12 67 12 ± 0.1 - - -
S18-1 36 - - - -
S18-2 38 - - - -
*values for monovalent ligands, except mannose C-glycoside (value same as in fig. 9.7 on page 154), were taken from table 9.1 on
page 149. For other compounds SD values obtained due to the analysis using two or three diﬀerent flow cells with ManBSA, and
some of the compounds were analyzed 2 or 3 times.
To better visualize the eﬀect of compound clustering relative to the activity of monovalent
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compound, the activity/aﬃnity improvement factor β was calculated using the following equation:
β =
IC50monovalent
valence·IC50multivalent
(9.6)
The values of β > 1 mean the improvement of the multivalent compound activity with respect
to monovalent ligand, and β < 1 – the decline of the activity. Figure 9.32 represents the calculated
β factors for the compounds, except mannose C-glycosides, which were likely overestimated.
Figure 9.32.: DC-SIGN inhibition activity improvement factors for the multivalent compounds on
flexible scaﬀolds with respect to corresponding monovalent ligands.
Tethering mannose on tetravalent and hexavalent scaﬀolds did not yield any activity improve-
ment, but mannose on the scaﬀolds with the higher valence show the gradual improvement β. Such
gradual improvement eﬀect is even more profound for psDi. The best improvement of factor β was
obtained for 4h with hexavalent scaﬀold. The overestimation of the concentration of the nonava-
lent compound is most likely the reason why no further increase of β factor is observed for this
compound.
However, psTri clustering on both tetra- and hexavalent scaﬀolds resulted in the decrease of
compound’s activity relative to the “monovalent” ligand because of its unique property to cluster
DC-SIGN tetramers.
It must be kept in mind that in the SPR competition assay the soluble tetramers of DC-
SIGN are used, therefore the β >1 values most likely show a combined eﬀect: 1) concentrating
the monovalent ligands on the scaﬀold mimics high concentration of ligand; 2) possibly increased
intrinsic aﬃnity of the multivalent compound to DC-SIGN tetramer due to binding to several CRDs
within the same tetramer; 3) the ability of multivalent compounds to cluster DC-SIGN tetramers
[158]. Considering the small size of S4 and S6-1 scaﬀolds from the proposed aﬃnity improvement
mechanisms 2) and 3), only the third case may be expected.
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9.2.2.2. The evaluation of fucose-based compounds tethered to flexible multivalent scaﬀolds
The multivalent forms of L-fucose O- and C-glycosides, and a new fucose-based lead compound
10b-azide1 (table 9.3) were analyzed in SPR competition assay. In addition to these compounds,
in order to evaluate the eﬀect of the linker in the multivalent compound, the L-fucose with a linker
of β-alanine with or without additional ethylenglycol (fig. 9.33) were also tested and appeared to
have no eﬀect when comparing both monovalent and tetravalent derivatives of L-fucose (fig. 9.34
and table 9.5).
Figure 9.33.: The structures of L-fucose with β-alanine/ethylene glycol linkers.
As in case of mannose-based multivalent compounds, the results for multivalent fucose-based
compounds showed generally the same tendency of activity increase as a function of the valence
(fig. 9.34A and table 9.5).
Figure 9.34.: DC-SIGN inhibition activities of multivalent fucose-based compounds on flexible scaf-
folds.
A, The IC50 values. B, The inhibition activity improvement factors β. “L-fucose (C-glyc.)” means C-glycoside of
L-fucose. IC50 values for Mono compounds are from table 9.1 on page 149.
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Table 9.5.: The IC50 ± SD values (￿M) obtained for multivalent fucose-based compounds on flexible
scaﬀolds.
Ligand
L-fucose L-fucose β-Ala L-fucose β-Ala+ L-fucose (C-glyc.) 10b-azide1
Sc
aﬀ
ol
d
Mono* 2061 ± 182 1445 ± 52 1682 ± 61 1020 ± 225 328 ± 43
S4 375 ± 3.2 - 306 ± 19 212 ± 4 39 ± 1.3
S6-1 392 ± 1.3 - - 97 ± 0.3 -
S9-1 - - - 41 ± 0.6 -
S12 4.7 ± 0.04 - - 17 ± 0.1 -
S18-1 3.1 ± 0.1 - - - -
*values for monovalent L-fucose and 10b-azide were taken from table 9.1 on page 149; for monovalent L-fucose C-glycoside value is
the same as in fig. 9.7 on page 154. For other compounds SD values obtained due to the analysis using two or three diﬀerent flow
cells with ManBSA, and some of the compounds were analyzed 2 or 3 times.
The relationship between valence and compound activity is best illustrated for L-fucose C-
glycoside derivatives: a proportional increase of both aﬃnity (in terms of IC50 value, fig. 9.34A) and
β factor (fig. 9.34B) is observed. Strangely, L-fucose O-glycosides did not show such a proportional
evolution: while the 4-valent and 6-valent compounds had virtually the same aﬃnity and no activity
improvement, these terms dramatically increased for the 12-valent and 18-valent forms. The latter
multivalent forms had the same, relatively high, aﬃnity and β factors, probably suggesting the
maximal valence for L-fucose derivative achieved, with which the aﬃnity is maximal under the used
experimental conditions. The experimental errors cannot be excluded as well (compounds of only
a single batch were tested using two ManBSA surfaces in the same run).
Additionally, comparing L-fucose O- and C- glycosides, their activity was alternating: the
monovalent C-fucose has twice better aﬃnity than O-fucose, which becomes the same when ligands
are presented on 4-valent scaﬀold. Comparing hexavalent forms, C-fucose has again better aﬃnity (4
times) than O-fucose, whereas 12-valent O-fucose becomes regains the better aﬃnity than C-fucose
(3 times). It is not clear what was the origin of such an alternation.
The best compound in these series, in terms of both IC50 value and the activity improvement
factor β (fig. 9.34B), appeared to be the selected lead compound 10b-azide1. Considering that
10b-azide1 was tethered only to a tetravalent scaﬀold, even better aﬃnity and factor β values can
be expected if the compound was tethered to the higher valence scaﬀolds.
9.2.2.3. The evaluation of mannose-based compounds tethered to rod-like multivalent scaﬀolds
The third type of multivalent presentation, i.e. the rod-like hexavalent scaﬀold, which was designed
in an attempt to target binding to two CRDs within the same DC-SIGN tetramer, was used to tether
the mannose-based lead compound 4h. Figure 9.35 and table 9.6 show the results obtained for the
rod-like scaﬀold presenting 4h, compared to the monovalent ligand and other related hexavalent
compounds with 4h, i.e. R1 and R2 , and the previously presented S6-1 scaﬀold with 4h.
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Figure 9.35.: DC-SIGN inhibition activities of diﬀerent hexavalent scaﬀolds with 4h.
A, The IC50 values. B, The inhibition activity improvement factors β. IC50 value for monovalent 4h is from table 9.1
on page 149, and for S6-1 with 4h from table 9.4. Compounds R1 and R2 were assayed in presence of 4% DMSO,
while R3 was assayed in presence of 4.2% DMSO. The error bars show SD values from 3 measurements.
Table 9.6.: The IC50 obtained for rod-like and other hexavalent scaﬀolds.
Scaﬀold IC50 ± SD, ￿M
R1 7.81 ± 0.09
R2 6.10 ± 0.09
R3 5.55 ± 0.04
SD values calculated from three measurement in the same test performed using 3 diﬀerent ManBSA
surfaces on sensor chip flow cells 2, 3, and 4.
It turned out that all of the hexavalent 4h variants have the same the aﬃnity (fig. 9.35A) as
well as the same β factors (fig. 9.35B). However, the latter three compounds, and especially R3,
had significant solubility problems, which led to the overestimation of their concentration. Hence,
the real aﬃnity of these compounds might be stronger.
It is not possible to answer the question, if R3 is able to bind several CRDs within the same
DC-SIGN tetramer from the SPR competition assay results, because the higher observed aﬃnity
may result from two phenomena (as already pointed above): the intrinsically increased aﬃnity of
the compound due to binding to several CRDs within the same tetramer, and due to increased
capability to cluster DC-SIGN tetramers. It is not possible to discriminate, which of the two
phenomena occurs, or do both of them occur simultaneously.
9.2.3. The results of multivalent compound analysis by SPR direct interaction
assay
The SPR competition assay is suitable for eﬃcient compound activity screening, but does not reflect
the real situation since DC-SIGN tetramers are in solution and not surface-attached. This point
was clearly illustrated by psTri interaction studies with DC-SIGN, where its interaction in solution
induced bridging between the lectin tetramers that is not awaited if the lectin receptor is membrane-
bound. Therefore the SPR direct interaction assay was designed, where DC-SIGN tetramers are
immobilized to the sensor chip surface.
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Additionally to screening by SPR competition assay, some of the multivalent compounds were
tested in SPR direct interaction assay in three separate experiments:
1. The first tested compounds were Boltorn type dendrimers and dendrons with psDi and psTri
(fig. 9.36).
2. In the second experiment mannose-based compounds from table 9.2 were analyzed, except
mannose C-glycosides, S9-1-4h , and R1 , R2 , R3 compounds.
3. Compounds S4-4h , S6-1-4h , S9-1-4h , andR1 ,R2 ,R3 compounds from table 9.2 together
with fucose based compounds S4-fucβAla and S4-10b-azide1 (table 9.3) were tested in the
third direct interaction SPR experiment.
Figure 9.36.: The structures of psDi and psTri functionalized Boltorn type dendrons and dendrimers
that were analyzed in SPR direct interaction assay.
Unfortunately, the monovalent ligands could not be assayed in this set-up due to their low
aﬃnity and low molecular weight: the injected high concentrations cause too strong bulk responses,
which do not allow discriminating the real binding response from the SPR signal error.
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9.2.3.1. The set-up of the direct interaction assay
DC-SIGN surface preparation.
Due to the following reasons, the standard amine coupling procedure could not be used to
generate surfaces with “oriented” functional DC-SIGN tetramers, meaning that all 4 CRDs of the
tetramer are available for interaction. The protein to be immobilized by amine coupling should have
a positive net charge; since DC-SIGN ECD has a pI of 5.16, the positive net charge can be achieved
only by preparing the protein sample in a buﬀer with an acidic pH. However, the previous studies
in our group [80] indicated that acidic pH induces irreversible dissociation of DC-SIGN tetramers,
therefore preparing DC-SIGN ECD in acidic pH for amine coupling would lead to immobilization
of unfolded monomeric ECDs.
To overcome this problem, DC-SIGN ECD construct with a StrepTag II in its N-terminus
was generated previously (see subsection 8.1.2 on page 126). The latter tag allows the biospecific
capture by StrepTactin at pH compatible with the stable structure of tetrameric DC-SIGN ECD.
StrepTactin can be covalently immobilized to CM-dextran matrix on sensor chip by amine coupling.
Figure 9.37 schematically illustrates the principal set-up of the direct interaction assay.
Figure 9.37.: A schematic illustration of the SPR direct interaction assay.
A, DC-SIGN S-ECD is captured by a covalently immobilized StrepTactin, then the multivalent glycomimetic
compounds are flown over the prepared surface. B, The binding responses of the compounds, injected in increasing
concentration order, can be measured at the indicated interval. C, The obtained binding responses can be plotted
against compound concentration and the KD values can be calculated using eq. 9.1 on page 148 (the shown example
plot in panel C does not correspond to the sensorgrams shown in panel B). Alternatively (if possible), the interaction
aﬃnity could be determined by evaluating kinetic parameters, i.e. association and dissociation rate constants kon
and koﬀ.
In order to determine the suitability of DC-SIGN S-ECD capturing to immobilized StrepTactin
surface, the aﬃnity of this DC-SIGN construct to StrepTactin was estimated (fig. 9.38), and resulted
in a reasonable apparent KD value of 57 nM. This is a higher value than the KD of 1 ￿M indicated by
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the manufacturer for StrepTag II/StrepTactin interaction, which likely resulted due to the avidity
eﬀect: because DC-SIGN ECD is tetrameric, StrepTag II is concentrated, and on the other side,
StrepTactin is also tetrameric protein.
Figure 9.38.: DC-SIGN S-ECD aﬃnity to StrepTactin.
The left panel shows the sensorgrams for the injections of a range of DC-SIGN S-ECD concentrations
(0.62 nM–622 nM of DC-SIGN S-ECD tetramers prepared in HBS-P buﬀer) over covalently immobilized StrepTactin
surface (2700RU), and the right panel represents the corresponding binding responses as a function of DC-SIGN
concentration. The injection point of the indicated regeneration solution (20 ￿L at 100 ￿L/min) is indicated above.
The flow rate of 5 ￿L/min of HBS-P buﬀer was maintained.
The next step was to test the activity of the prepared surface. For this reason, the dendrimer
G3(pseudotri)32 (see fig. 9.36) was injected over DC-SIGN surface (fig. 9.39).
Figure 9.39.: The activity of oriented DC-SIGN surface.
A, The sensorgrams showing two subsequent injections of G3(pseudotri)32 (10 ￿L of 20 ￿M at 5 ￿L/min) over the
reference (red) and DC-SIGN S-ECD surface (green) followed by the running buﬀer flow (25mM Tris-HCl pH8,
150mM NaCl, 4mM CaCl2, 5 ￿L/min). B and C, The insets, highlighted in panel A by a black and blue frames,
showing the two injections of G3(pseudotri)32 over DC-SIGN (panel B) and StrepTactin (panel C) surfaces; the
injection of regeneration solution (50mM EDTA pH8, 5 ￿L at 5 ￿L/min) followed each injection of the compound,
as indicated. D, Reference surface corrected overlaid sensorgrams corresponding to the first (pink) and the second
(green) injections of G3(pseudotri)32. 25mM Tris-HCl pH8, 150mM NaCl, 4mM CaCl2 was used as the running
buﬀer.
The prepared DC-SIGN surface was indeed active as the dendrimer bound (about 200RU)
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in a Ca2+-dependent manner (interaction could be abolished by EDTA). Moreover, the compound
did not bind to the reference surface, which showed that the observed interaction is specific to
DC-SIGN.
However, a rapid dissociation of DC-SIGN S-ECD from StrepTactin surface was observed,
as indicated by the drifting baseline, despite the reasonable apparent aﬃnity determined for DC-
SIGN S-ECD / StrepTactin interaction. Such an unstable surface could not be used for the DC-
SIGN/compound interaction studies: the compounds should be injected multiple times, making the
comparison between injections impossible due to continuously decreasing amount of DC-SIGN. As
illustrated in fig. 9.39D, the binding responses of two subsequent injections of the same sample are
markedly diﬀerent.
Therefore, the stabilization of DC-SIGN S-ECD surface had to be explored, and the approach
of covalent stabilization of captured DC-SIGN S-ECD was chosen. For this reason, after cova-
lently immobilizing StrepTactin, an additional injection of EDC/NHS mixture was done in order
to activate carboxyl groups on StrepTactin and/or residual carboxyl groups on CM-dextran. Then
DC-SIGN S-ECD, prepared in HBS-P buﬀer, was injected over such a reactivated surface (fig.
9.40A). To control the binding specificity, DC-SIGN ECD, i.e. without a construct without Strep-
Tag II, prepared at the same concentration as S-ECD construct, was also injected over reactivated
dextran/StrepTactin surface (fig. 9.40B).
Figure 9.40.: The sensorgrams showing the immobilization of DC-SIGN constructs on reactivated
dextran/StrepTactin surface.
The dextran/StrepTactin surface was reactivated by 50 ￿L injection EDC/NHS mixture. Then DC-SIGN S-ECD
(panel A) or DC-SIGN ECD (panel B) constructs prepared at 60 ￿g/mL concentration in HBS-P buﬀer were injected
(150 ￿L/min) over reactivated surface at a flow rate of 5 ￿L/min of HBS-P running buﬀer. The remaining activated
–COOH groups were blocked by 30 ￿L injection of 1M ethanolamine pH8.
The latter experiment confirmed that DC-SIGN S-ECD is indeed covalently immobilized
through StrepTactin/StrepTag II interaction, thus in a well-oriented way, since DC-SIGN ECD
construct without StrepTag II did not bind to the reactivated surface. The stability of the surface
as shown by later experiments was indeed much better (see figure 9.43 on page 308).
DC-SIGN surface regeneration optimization and stability.
The first compounds tested by the direct interaction assay were the Boltorn type dendrimers
and dendrons functionalized with psDi and psTri (see fig. 9.36 for the structures). This initial test
indicated the inability to fully remove DC-SIGN-bound dendrons by EDTA injection (fig. 9.41).
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Figure 9.41.: Reference surface corrected overlaid sensorgrams showing the inability to regenerate
DC-SIGN surface with EDTA.
The sensorgrams showing injections of psDi and psTri functionalized compounds are on left and right, respectively,
and the tetravalent dendrons and 32-valent dendrimers are on top and bottom, respectively. The compounds were
injected (15 ￿L at 5 ￿L/min flow rate) at a concentration range of 3 ￿M–2400 ￿M for dendrons and 0.38 ￿M–93.3 ￿M
for dendrimers. The injection points of 50mM EDTA pH8 (5 ￿L at 5 ￿L/min each) are marked.
Such an inability to regenerate DC-SIGN surface with EDTA was not only a technical problem
of the assay: it indicates that these compounds, for which the interaction is not abolished by
EDTA, bind to DC-SIGN not only through a conventional sugar recognition site, but have Ca2+-
independent interaction with other unknown parts of the protein (no binding to the reference surface
was observed, data not shown). However, better regeneration conditions were explored.
After screening eight diﬀerent regeneration solutions (as listed in sub-subsection 6.2.5.2 on
page 115; the sensorgrams of the screening are shown in Appendix), a mixture consisting of 50mM
Gly-NaOH pH11.9 / 0.15% TritonX100 / 25mM EDTA pH8, was found to eﬃciently remove the
bound compounds from DC-SIGN surface (fig.9.42).
Figure 9.42.: An example of reference surface corrected overlaid sensorgrams showing improved
compound detachment from DC-SIGN surface.
Tetravalent dendron functionalized with psDi was injected (15 ￿L at 5 ￿L/min flow rate) at a concentration range of
22 ￿M–2400 ￿M over covalently stabilized DC-SIGN S-ECD surface. The injection point of regeneration mix (8 ￿L
of 50mM Gly-NaOH pH11.9 / 0.15% TritonX100 / 25mM EDTA pH8, at 100 ￿L/min flow rate) is marked.
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This solution was further tested in order to find out if using it does not lead to the loss of
DC-SIGN surface activity. For this reason, ManBSA (0.56 ￿M) was used to monitor DC-SIGN
surface activity, and 10 cycles1 of ManBSA injections followed by regeneration (8 ￿L injection at
100 ￿L/min) were performed (fig. 9.43).
Figure 9.43.: The evaluation of DC-SIGN surface stability.
A, Reference surface corrected overlaid sensorgrams showing 10 subsequent injections of ManBSA (10 ￿L of 0.56 ￿M)
over DC-SIGN surface. Each injection was followed by regeneration with a mix consisting of 50mMGly-NaOH pH11.9
/ 0.15% TritonX100 / 25mM EDTA pH8, injected (8 ￿L) at 100 ￿L/min flow rate. B, The corresponding binding
responses measured after each injection and plotted against cycle number (i.e. injection number). C, Reference
surface corrected overlaid sensorgrams showing two injections of ManBSA (0.48 ￿M), the first (blue) and the last
(red) in the series of 44 cycles in total.
Indeed, using the latter regeneration conditions, a reasonable DC-SIGN surface stability was
maintained as ManBSA binding responses remained very similar (fig. 9.43B). Even more, the
later tests where 44 injections were performed and ManBSA was injected first and last in the run,
indicated a remarkable stability of the surface as the binding responses of ManBSA remained the
same (fig. 9.43C).
9.2.3.2. The studies of multivalent compound interaction with oriented DC-SIGN surface
The results of the first SPR direct interaction experiment.
When the optimal surface regeneration conditions were found, the psDi and psTri functional-
ized dendrons and dendrimers were analyzed again. Figures 9.44 and 9.45 shows the sensorgrams
and corresponding plots of binding responses as a function of compound concentration.
1The term “cycle” here means the injection of an analyte followed by surface regeneration and corresponds to one
sensorgram
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Figure 9.44.: The interaction of tetravalent dendrons with oriented DC-SIGN surf ace.
The left and the right plots show respectively the reference surface corrected sensorgrams and corresponding binding
responses of psDi (panel A) and psTri (panel B) functionalized dendrons. Both dendrons were injected at the
concentration range of 22 ￿M-2400 ￿M. The solid lines in the left panels represent the fitted curve of 4-parameter
model (eq. 6.1 on page 114).
Figure 9.45.: The interaction of G3(pseudodi)32 and G3(pseudotri)32 dendrimers with oriented DC-
SIGN surface.
The left and the right plots show respectively the reference surface corrected sensorgrams and corresponding binding
responses of G3(pseudodi)32 (panel A) and G3(pseudotri)32 (panel B) dendrimers. Both compounds were injected at
the concentration range of 0.38 ￿M-93.3 ￿M. The solid line in the left of panel A represent the fitted curve of steady
state aﬃnity model (eq. 9.1 on page 148), and in panel B the line simply connects the data points.
Surprisingly, the tetravalent dendrons appeared to have more stable binding to DC-SIGN, as
the dissociation phases were apparently slower than those for 32-valent dendrimers. Moreover, the
binding responses of lower molecular weight dendrons were much higher than for the dendrimers
that have higher molecular weights. Therefore it was interesting to check the observed maximal
binding responses with the theoretically calculated Rmax values that could be expected for the
corresponding compounds.
Rmax =
MWanalyte
MWligand
· Rligand·n (9.7)
where MW analyte and MW ligand are the molecular weight of the injected analyte (i.e. com-
pound) and the immobilized ligand (i.e. DC-SIGN S-ECD, MW=161.6 kDa of a tetramer), Rligand
is the quantity (in RU) of the immobilized ligand, and n is ligand:analyte interaction stoichiome-
try. The results of the experiments shown in figures 9.44 and 9.45 were obtained with the surface
where 3000RU of DC-SIGN S-ECD tetramers were immobilized. Table 9.7 shows the comparison of
theoretical and experimental Rmax values calculated assuming two limiting cases: 1) one DC-SIGN
tetramer binds only one molecule of the compound, i.e. n=1; 2) one DC-SIGN tetramer binds four
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molecules of the compound, i.e. n=4.
Table 9.7.: The comparison of calculated Rmax values with the experimentally observed maximal
binding responses of Boltorn type dendrimers and dendrons functionalized with psDi
or psTri.
Calculated Rmax, RU Maximal observed response, RU
MW, kDa n=1 n=4
psDi dendron 2.513 47 187 2550
psTri dendron 3.162 59 235 1970
G3(pseudodi)32 19.592 364 1455 50
G3(pseudotri)32 24.618 457 1828 123
The observed maximal binding responses for both dendrimers were lower than the calculated
values even for the case when one tetramer binds one molecule. It might suggest that only a
part of the CRDs in DC-SIGN tetramers is active due to the following reasons: 1) a part of the
CRDs is not well-folded and therefore not active, or 2) considering that DC-SIGN surface density
is high, one molecule of the dendrimer may bind several tetramers and thus block binding site
availability for other dendrimer molecules. However, it must be noticed that the sensorgrams
representing the highest compound concentration injected did not reach the equilibrium, therefore
the real experimental Rmax is higher than the observed maximal binding response.
On the other hand, the maximal binding responses for both dendrons were significantly higher
than the calculated Rmax, and considering that the binding did not reach equilibrium, the real
experimental Rmax would be even higher. In the first tests of direct interaction with compounds
shown in fig. 9.36, only the dendrons could not be removed from DC-SIGN surface by EDTA
(fig. 9.41), which indicated that they additionally interact with DC-SIGN in a Ca2+-independent
manner. Combining this observation and much higher experimental Rmax values for the dendrons,
it is possible to envision that several dendrons bind one DC-SIGN tetramer at multiple sites, in
addition to the conventional Ca2+-dependent sugar binding site. Since the major part of the bound
dendrons could be removed by EDTA (fig. 9.41), the reason of the much higher experimental Rmax
values could also be the formation of compound aggregates, which would cause the higher binding
responses due to increased molecular weight of the binding entity. It is likely that both of these
phenomena occur simultaneously.
The compound aggregation, although in a much lesser extent than for dendrons, could be
tracked also for G3(pseudotri)32 dendrimer, as at the higher injected concentrations the response
increased disproportionally2 (fig. 9.45B).
2The term “disproportional(ly)” will be used to define a situation where binding occurs without and even above the
saturation awaited for a standard ligand-receptor interaction, whereas in this context the term “proportional(ly)”
will refer to the standard case of receptor saturation by the increased ligand concentration.
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Because of the high DC-SIGN surface density, which creates conditions for mass transfer, the
interaction of the tested compounds could not be evaluated in kinetic terms. Nevertheless, the
measured binding responses as a function of compound concentration could be used to calculate
the apparent equilibrium aﬃnity values (KD) using eq. 9.1 on page 148. Because of the unexpected
above described behavior of the dendrons, this latter data analysis approach could be applied only
for the dendrimers, and the calculated KD values are listed in table 9.8.
Table 9.8.: The calculated apparent KD values for psDi and psTri functionalized 3rd generation
Boltorn type dendrimers.
Apparent KD ± SD*, ￿M
G3(pseudodi)32 7.6 ± 0.5
G3(pseudotri)32** 2.4 ± 0.1
*SD is calculated from two measurements on the same surface and same samples. ** The two highest concentrations were excluded
for the KD calculation (fig. 9.45B).
Both dendrimers have very similar apparent aﬃnities to immobilized DC-SIGN. In order to
get a more quantitative evaluation of dendron interaction with DC-SIGN, the EC50 (concentration,
with which half of maximal binding response is reached) were calculated using equation 6.2 on
page 114, where 50 was exchanged to the half of the observed corresponding Rmax value. The EC50
values of 925 ￿M and 730 ￿M for psDi and psTri dendrons, respectively, were found. These values
do not correlate with and are 4 and 6 times (for psDi and psTri dendrons, respectively) higher
than the IC50 values determined in SPR competition assay. Such a diﬀerence arose most likely due
to the strange behavior of the dendrons, i.e. a possible compound aggregation, which led to the
artificially high concentration for which the maximal binding is observed, thus the overestimation
of EC50 value.
The results of the second SPR direct interaction experiment.
The new type dendrimers, built by the click chemistry reactions, with mannose-based com-
pounds were tested in the second SPR direct interaction experiment. Firstly, all of the compounds
listed in table 9.2 were analyzed, except mannose C-glycosides, S9-1-4h , and R1 , R2, R3 com-
pounds. These dendrimers were prepared at concentration ranges of 4 ￿M – 2.5mM in running buﬀer
without DMSO, and injected (15 ￿L, 5 ￿L/min) over the surface with DC-SIGN S-ECD (3000RU)
covalently captured to StrepTactin. Sensor chip CM5 was used. The majority of the compounds
bound to DC-SIGN surface as can be seen in the represented sensorgrams (fig. 9.46).
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Figure 9.46.: Reference surface corrected sensorgrams showing the binding of flexible dendrimers
with mannose-based compounds to DC-SIGN surface.
As it can be noticed from the sensorgrams, the binding equilibrium was far from being reached
for the majority of the tested compounds, probably with the exception for compounds S6-1-4h , S9-
1-Oman and S9-1-Oman . Regarding the observable kinetic aspect of the compound interaction
with DC-SIGN, nearly all of them had a slow association phase followed by very slow dissociation,
which indicated a stable binding.
The hexavalent dendrimer with the selected lead 4h, S6-1-4h , showed an exceptional be-
havior: the association was rather fast and the binding equilibrium was reached rapidly, while the
dissociation had two phases, the rapid one followed by a very slow dissociation. Also the sensorgrams
corresponding to the last two (highest) concentrations injected deviated from the general pattern
for lower concentrations, as the binding appeared to continue further without reaching equilibrium.
Unfortunately, during this set of experiments DC-SIGN surface was not as stable as observed
before: only 10% of its prior activity remained as judged by ManBSA binding responses in the
beginning and the end of the experiments. Measuring absolute responses of the baseline at the
beginning of each cycle, showed a significant loss of immobilized DC-SIGN, i.e. about 8RU per
cycle. Therefore the loss of absolute surface activity most likely resulted from the dissociation of
DC-SIGN than the deactivation of binding sites. It is not possible to tell the reason why DC-
SIGN S-ECD tetramers, captured by StrepTactin and covalently stabilized, were still dissociating,
especially because in the previous experiment the surface displayed a remarkable stability. Therefore,
the interaction of the compounds could be evaluated only qualitatively.
The binding responses of the compounds were plotted against corresponding concentration as
shown in figure 9.47.
312
9.2. THE DEVELOPMENT OF MULTIVALENT GLYCOMIMETIC DC-SIGN
ANTAGONISTS
Figure 9.47.: DC-SIGN surface titration with flexible dendrimers.
The binding responses were measured after injections for the most of the compounds, except S6-1-4h , for which
binding responses were collected just before the end of injections.
All of the compounds with the scaﬀold valence lower than 9 displayed a disproportional increase
of the binding responses with the higher concentrations injected.
Even though DC-SIGN density was decreasing during the course of the experiment, the ob-
served maximal binding responses for all of the compounds were roughly compared with the cal-
culated Rmax values using the value of 3000RU of immobilized DC-SIGN (table 9.9, for a better
comparison, the compounds are listed in the order as they were analyzed).
Table 9.9.: The comparison of calculated Rmax values with the experimentally observed maximal
binding responses of the flexible dendrimers.
MW, kDa
Calculated Rmax, RU Maximal observed response, RU
Rmax, n=1 Rmax, n=4
S4-psDi 2.156 40 160 251
S9-1-Oman 3.573 66 265 125
S9-2-Oman 3.7 69 275 170
S18-1-Oman 7.149 133 531 600
S18-2-Oman 7.325 136 544 1550
S4-Oman 1.285 24 95 120
S6-1-psDi 3.263 61 242 90
S4-psTri 2.791 52 207 15
S4-4h 2.983 55 222 480
S6-1-4h 4.525 84 336 60
S12-Oman 4.733 88 351 40
Compounds, for which the observed binding responsesare higher than calculated Rmax, are highlighted in red.
In fact, those compounds, for which disproportional binding response increase was observed,
had also higher maximal binding responses than could be expected. Although S4-psTri , S6-1-
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psDi and S6-1-4h did not demonstrate higher experimental binding than the expected one, it must
be kept in mind that they were analyzed using DC-SIGN surface with a decreased activity, hence the
higher binding responses could be expected with the fully active freshly prepared DC-SIGN surface.
As discussed earlier, the higher experimental binding responses than calculated Rmax values may
indicate the aggregation of the compounds. Combining the latter result with the observation of the
disproportional increase of the signal when increasing concentration, it can be speculated that these
compounds start to aggregate (or aggregation becomes more favored) only at the higher compound
concentrations.
Although for the compounds S18-1-Oman and S18-2-Oman the binding responses in-
creased proportionally3 to the change of concentration, they also had significantly higher experi-
mentally observed binding than the calculated one (table 9.9). This case could be explained by
envisioning that these two compounds at all concentrations in water-based solution exist as larger
aggregates and not monomeric molecules, for which the MW values were determined, and/or they
bind to other sites on DC-SIGN, additionally to conventional sugar binding site.
The compounds S9-1-Oman and S9-2-Oman were the only ones, for which the binding re-
sponses increased proportionally to the concentration change, they had lower than expected maximal
binding responses when analyzed with freshly prepared DC-SIGN surface, and in the sensorgrams
observed the binding seemed to approach equilibrium. For those two compounds the apparent KD
values could be determined using steady state aﬃnity model (eq. 9.1 on page 148), and resulted in
97 ￿M and 189 ￿M for S9-1-Oman and S9-2-Oman , respectively. However, the 2-fold diﬀerence
in aﬃnity between these two nonavalent dendrimers with D-mannose is strange, and might be a
result of measuring binding responses prior to reaching equilibrium (it was not possible to reach the
binding equilibrium because of the high required compound volumes to be injected, thus the high
amount of the compound, which was very limited).
Figure 9.48.: The example sensorgrams showing a stronger interaction of the flexible dendrimer
with StrepTactin than DC-SIGN surface.
A, Raw sensorgrams showing the binding of S9-1-psDi to immobilized StrepTactin (reference) surface. B, Refer-
ence surface corrected sensorgrams showing S9-1-psDi injections over DC-SIGN surface. The concentration range
of S9-1-psDi was used as indicated.
The other compounds, analyzed in this first set included S6-1-Oman , S6-1-psTri , S6-2-
psDi , and S9-1-psDi . All these four compounds had stronger, concentration-dependent inter-
action with the reference (StrepTactin) surface than DC-SIGN (fig. 9.48), which led to negative
binding responses observed in reference surface corrected sensorgrams. No further analysis of these
compounds could be performed.
3The term “proportional(ly)” refers to the standard case of receptor saturation by the increased ligand concentration
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The results of the third SPR direct interaction experiment.
In this experiment the multivalent compounds functionalized with 4h were analyzed. They
included newly synthesized S4-4h and S6-1-4h dendrimers, and compounds S9-1-4h , R1 , R2
and R3 from table 9.2 on page 296. The fucose-based dendrimers S4-fucβAla and S4-10b-azide1
(table 9.3 on page 297) were also analyzed in the same experiment.
The priority of this run was to determine if the rod-like dendrimer R3 is capable to bind to
two CRDs within the same DC-SIGN tetramer. The underlying idea for the experiment (illustrated
in figure 9.49) was the following: the interaction of R3 with DC-SIGN should be investigated
using the surfaces with DC-SIGN tetramers covalently captured at low and high densities. If the
compound is indeed capable to bind to two CRDs within the same DC-SIGN tetramer, the surface
density should not have an eﬀect to the compound’s aﬃnity, thus the determined apparent aﬃnities
for all the three surfaces should be the same. Whereas, if one molecule of the compound binds to
one CRDs of the tetramer, the aﬃnity for the densely populated DC-SIGN surface would be higher:
the close proximity of DC-SIGN tetramers would allow the bridging to occur, which would not be
possible on the low density surface.
Figure 9.49.: The experimental set-up of SPR direct interaction assay to determine if the compound
binds to 2 CRDs within the same DC-SIGN tetramer.
A, The case when compound is capable to bind to 2 CRDs within the same tetramer. B, The case when one
molecule of the compound binds only to one CRD of the tetramer.
DC-SIGN S-ECD was covalently captured to three StrepTactin surfaces, immobilized to about
2800RU by amine coupling procedure using sensor chip CM3 (procedure: 80 ￿L EDC/NHS, 100 ￿L
of 100 ￿g/mL StrepTactin in sodium acetate pH4, 80 ￿L ethanolamine, running buﬀer HBS-P at
5 ￿L/min). After reactivating CM-dextran/StrepTactin surfaces with 50 ￿L EDC/NHS injection,
315
CHAPTER 9. THE RESULTS OF THE DEVELOPMENT OF GLYCOMIMETIC DC-SIGN
ANTAGONISTS
three diﬀerent DC-SIGN densities were achieved (the approximate required DC-SIGN S-ECD con-
centrations were estimated from StrepTactin surface titration with DC-SIGN S-ECD, shown in
figure 9.38 on page 305):
✧ DCSIGN-LD: 230RU captured after injecting 15 ￿L of 0.35 ￿g/mL DC-SIGN S-ECD;
✧ DCSIGN-MD: 2030RU captured after injecting 7 ￿L of 50.27 ￿g/mL DC-SIGN S-ECD;
✧ DCSIGN-HD: 3820RU captured after injecting 50 ￿L of 696 ￿g/mL DC-SIGN S-ECD.
The non-reacted carboxyl groups were blocked by ethanolamine (50 ￿L injection). In order to
remove non-covalently bound DC-SIGN S-ECD, which might improve DC-SIGN surface stability,
the prepared surfaces were rinsed with 1M NaCl / 50mM NaOH solution (20 ￿L at 100 ￿L/min).
The example sensorgram of this DC-SIGN S-ECD covalent capture is shown in figure 9.50.
Figure 9.50.: The example sensorgram DC-SIGN S-ECD covalent capture followed by surface rins-
ing to remove non-covalently bound protein.
As usually, flow cell 1 was used as a reference surface and contained immobilized StrepTactin
(2800RU).
Mass transfer eﬀect evaluation for DC-SIGN surfaces. The kinetic parameters of R3 interaction
with diﬀerent density DC-SIGN surfaces could be also helpful: on a low density surface, faster
dissociation could be predicted in the case where R3 molecule binds one CRD of the tetramer (fig.
9.49B), and it would become slower when the surface density increases. Therefore, the prepared
surfaces were tested for the mass transfer eﬀect [177].
The recommended procedure for testing mass transfer eﬀect consists of several injections of
the same analyte at diﬀerent flow rates and comparison of the shape of association and dissociation
phases. If these shapes superimpose at all flow rates, the mass transfer is not significant.
In order to test this, ManBSA (27 ￿M) prepared in the running buﬀer consisting of 24mM
Tris-HCl pH 8, 144mM NaCl, 3.8mM CaCl2, 0.005% P20 and 4% DMSO (also used for all of
the below described tests), was injected over the surfaces at flow rates of 5, 30 and 80 ￿L/min.
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The injected volumes corresponded to the association for 1min, i.e. 5, 30 and 80 ￿L were injected,
respectively. The obtained sensorgrams are compared in figure 9.51.
Figure 9.51.: The results of mass transfer test for diﬀerent density DC-SIGN S-ECD surfaces.
ManBSA (27 ￿M) was injected over the above indicated surfaces at flow rates of 5 ￿L/min (cycle 1), 30 ￿L/min (cycle
2) and 80 ￿L/min (cycle 3). All the upper panels show reference surface corrected overlaid sensorgrams obtained for
the above-indicated surfaces, and all the lower panels represent the corresponding normalized sensorgrams.
For some reason ManBSA injection at 5 ￿L/min flow rate resulted in higher binding response
than the other two injections, which gave very comparable ManBSA binding responses. In order to
compare the association and dissociation phases obtained at all three flow rates, the sensorgrams
were normalized (fig. 9.51, lower panels). Even if the first injection (at 5 ￿L/min) is not taken into
account for comparison, it is obvious that the mass transfer eﬀect is significant for the high DC-SIGN
density surface (DCSIGN-HD), as association phases for injections at 30 ￿L/min and 80 ￿L/min
do not superimpose. Even higher mass transfer eﬀect could be expected for the glycomimetic
dendrimers, since they have much lower MW than ManBSA, thus their diﬀusion to the surface
would be much slower than that of ManBSA.
Evaluation of ManBSA interaction with DC-SIGN surfaces. In order to better characterize DC-SIGN
surfaces prior the compound analysis, ManBSA titration was performed. Despite the observed
mass transfer eﬀect, the experiment was done in a kinetic regime, i.e. at a flow rate of 30 ￿L/min.
ManBSA samples were prepared in the running buﬀer with the concentrations ranging from 2.7 nM
to 266 nM. The injections of 30 ￿L of each sample were made and followed by 200 s dissociation phase.
The binding was abolished with 50mM EDTA pH 8 (5 ￿L, 5 ￿L/min). The resulting sensorgrams
are shown in the upper panels of figure 9.52.
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Figure 9.52.: The interaction of ManBSA with DC-SIGN surfaces of diﬀerent densities.
Upper panels show reference surface corrected sensorgrams obtained by ManBSA titration over the indicated den-
sity DC-SIGN surfaces. Lower panels represent the titration curves obtained by plotting binding responses at the
respective density surfaces against ManBSA concentration.
None of the available interaction kinetic models fitted the data. However, the interaction
kinetics could be qualitatively evaluated by visually inspecting the dissociation phases observed for
diﬀerent density surfaces. Clearly, the dissociation slows down with an increase of DC-SIGN surface
density, which is particularly visible for the lowest concentration ManBSA sample (fig. 9.52, upper
panels).
The interaction was evaluated quantitatively by fitting steady state aﬃnity model (eq. 9.1
on page 148) to the plots of ManBSA binding responses against concentration, and the obtained
apparent aﬃnity values are displayed on the plots of lower panels of figure 9.52. The latter model
obviously did not fit well the data indicating that the system is more complicated than assumed by
this simple 1:1 binding model.
The apparent aﬃnity values of KD of about 10 nM were similar to all DC-SIGN surfaces with
slightly lower aﬃnity for low density DC-SIGN surface. It is also noteworthy that the aﬃnity
measured with immobilized DC-SIGN is much higher (2 orders of magnitude) than when ManBSA
is immobilized. This could be expected because the absolute aﬃnity of this interaction is determined
by the avidity, which is more favorable when the binding partner with lower number of binding sites
(i.e. DC-SIGN, 4 CRDs) is immobilized on the surface while the partner with more binding sites
(ManBSA, 12 site of glycosylation) is free in the solution.
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Multivalent compound analysis using diﬀerent density DC-SIGN surfaces. Hence, it was chosen to
perform the further experiment with the multivalent compounds using steady state interaction set-
up, since the presence of mass transfer would prevent the reliable evaluation of kinetic parameters.
The compounds were prepared at the concentration ranges similar to those used in SPR competition
assay: 0.38 ￿M – 2.5mM for compounds S4-4h and S6-1-4h , 0.15 ￿M–1mM for compounds S9-1-
4h , R1 and R2 , 0.3 ￿M–2mM for compounds S4-fucβAla and S4-10b-azide1 , and compound
R3 was prepared at 0.03 ￿M–185 ￿M range. The prepared samples were injected (120 ￿L, 5 ￿L/min)
over the surfaces and the binding was abolished by the injection (8 ￿L, 100 ￿L/min) of the previously
optimized surface regeneration mix (50mM Gly-NaOH pH12 / 0.15% TritonX100 / 25mM EDTA
pH8). The activity of DC-SIGN surfaces during the run was controlled by the injections (30 ￿L,
5 ￿L/min) of ManBSA (10 nM). The obtained sensorgrams are presented in the Appendix. The
binding responses measured at the end of compound injections were plotted against compound
concentration and are represented in figures 9.53, 9.54 and 9.55.
Figure 9.53.: The results of the interaction of 4h functionalized dendrimers with DC-SIGN surfaces
of diﬀerent density.
The plots in each row correspond to the indicated compound, and the plots in each column correspond to the indicated
diﬀerent DC-SIGN surface densities. The insets show the first portion of the curves with 4 parameter logistic model
(eq. 6.1 on page 114) fits.
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Figure 9.54.: The results of the interaction of 4h functionalized rod-like and related dendrimers
with DC-SIGN surfaces of diﬀerent density.
The plots in each row corresponds to the indicated compound, and the plots in each column correspond to the
indicated diﬀerent DC-SIGN surface densities. The insets show the first portion of the curves with 4 parameter
logistic model (eq. 6.1 on page 114) fits; for compound R3 , the fitting was performed all of the data points obtained
for all concentrations used.
Figure 9.55.: The results of the interaction of tetravalent fucosylated dendrimer with DC-SIGN
surfaces of diﬀerent density.
Apparently, the results were very similar to the previously observed behavior of the flexible
dendrimers: most of the compounds displayed the disproportional binding response increase at the
higher injected concentrations. As previously, the theoretical Rmax values were calculated for all of
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the compounds and compared with the maximal binding responses observed (table 9.10).
Table 9.10.: The comparison of calculated Rmax values with the experimentally observed maximal
binding responses for the tested dendrimers.
With the only exception for the rod-like dendrimer R3 , all other compounds had higher
binding responses than the expected Rmax, with the most significant increase in maximal binding
response for compounds S6-1-4h for S4-fucβAla . Again, such a disproportional binding response
suggests that these dendrimers form aggregates at higher concentrations, and the proportional
evolution of too high binding responses observed for S4-fucβAla may mean that this dendrimer
binds to additional sites on DC-SIGN other than Ca2+-dependent sugar recognition site, or that it
exists as higher molecular weight aggregates at all concentrations, or both.
Although the binding responses for R3 did not exceed the calculated Rmax, they are very close
to the theoretical value, calculated with an assumption that four molecules of the compound bind to
the same DC-SIGN tetramer. In practice, the experimental Rmax values are usually lower than the
calculated ones because of the surface activity loss during experiment and/or ligand immobilization
in an orientation not favorable for the interaction. In this experiment the control injections of
ManBSA indicated a loss of surface activity (about 66%, 86% and 89% of primary activity of
DCSIGN-LD, DCSIGN-MD and DCSIGN-HD surfaces remained after all tests). Therefore it is
more likely that the rod-like dendrimer R3 also forms aggregates (or binds DC-SIGN to additional
sites), especially considering its low water solubility, than that all of the CRDs of immobilized DC-
SIGN tetramers are active and each is occupied by one R3 molecule. Even though all of the studied
dendrimers had this unexpected behavior, a rough estimation of the aﬃnities for their interaction
with diﬀerent density DC-SIGN surfaces was attempted. For this reason, the 4 parameter logistic
model (eq. 6.1 on page 114) was fit to the selected first portion of the curves until the concentration,
with which the rapid increase of the signal was obtained (the insets in figures 9.53 and 9.54). The
apparent EC50 values were calculated as described above and compared as shown in figure 9.56.
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Figure 9.56.: A relative comparison of EC50 values obtained for 4h functionalized series of den-
drimers.
Although the reliable aﬃnity of these compounds to DC-SIGN surfaces could not be deter-
mined, the relative comparison of the calculated EC50 values showed a general tendency: for four
compounds the apparent aﬃnity increased with the DC-SIGN surface density increase. The other
two compounds, namely S9-1-4h and R3 , appeared to have similar aﬃnities to the surfaces of
all three diﬀerent densities. This might indicate that the two latter compounds bind to several
CRDs within the same DC-SIGN tetramer, a result initially anticipated for compound R3 , and
the probable ability of S9-1-4h to bind to several CRDs of same tetramer may suggest that this
compound in solution adopts a conformation favorable for such a binding. However, this is just a
qualitative comparison of the compounds, which may only give a clue of the real situation.
The estimation of an apparent EC50 value for the dendrimer S4-fucβAla was not possible
because of a nearly linear concentration-binding relationship.
Regarding fucosed-based dendrimer S4-10b-azide1 , it was analyzed after S4-fucβAla den-
drimer, which had very strong binding to the surfaces and could not be fully regenerated by the
used regeneration solution. Thus the compound S4-10b-azide1 was injected to the surfaces that
still contained S4-fucβAla , which made the comparison of S4-10b-azide1 binding responses im-
possible.
The failure to fully remove S4-fucβAla dendrimer from DC-SIGN surfaces with 50mM Gly-
NaOH pH12 / 0.15% TritonX100 / 25mM EDTA pH8 solution, indicated that the binding of
this compound is in part Ca2+-independent. Therefore the test of DC-SIGN surface regeneration
was performed with all of the compounds in order to determine if the binding could be abolished
by EDTA, i.e. the compounds interacted in a Ca2+-dependent manner. For this reason, each
compound was injected (5 ￿L, 5 ￿L/min) over the DC-SIGN surfaces. The tested compounds and
their concentrations are shown in table 9.11.
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Table 9.11.: The list of multivalent compounds, which were tested for ability to be removed from
DC-SIGN surface by EDTA.
Cycle Compound Concentration
1 ManBSA 17 nM
2 S4-4h 1 mM
3 S6-1-4h 1 mM
4 S9-1-4h 1 mM
5 R1 1 mM
6 R2 1 mM
7 R3 185 ￿M
8 S4-psDi 1 mM
9 S4-fucβAla 2 mM
10 S4-10b-azide1 2 mM
11 ManBSA 17 nM
After the compound injection, two subsequent regeneration solutions were injected: at first
50mM EDTA pH8 was injected (5 ￿L, 5 ￿L/min), then the previously optimized surface regeneration
mix was injected (8 ￿L, 100 ￿L/min). The baseline responses (AbsResp) were measured in the
beginning of each cycle (i.e. before the compound injection), after the first regeneration with
EDTA, after the second regeneration and were plotted against cycle number (fig. 9.57).
Figure 9.57.: The results of the test of DC-SIGN S-ECD surface regeneration after multivalent
compound binding.
The three panels correspond to the results obtained with diﬀerent DC-SIGN density surfaces, as indicated. Pink,
blue and green data points correspond to baseline responses before compound injection, after EDTA injection and
after the injection of the second regeneration mix (50mM Gly-NaOH pH12 / 0.15% TritonX100 / 25mM EDTA
pH8), respectively.
The results of this test indicated two compounds (cycles 3 and 9), which failed to be removed
from DC-SIGN surface by EDTA. These compounds were S6-1-4h , and as expected, S4-fucβAla .
Recalling that for both of those compounds the experimentally observed maximal binding responses
exceeded theoretical ones most significantly, it can be assumed that they interact with DC-SIGN
at multiple sites in addition to Ca2+-dependent sugar binding site.
In summary, the majority of the tested multivalent compounds display a complicated behavior:
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aggregation, interaction with other sites than Ca2+-dependent sugar binding site. Unfortunately,
these phenomena make the quantitative evaluation of the compound interaction with DC-SIGN and
an accurate comparison of the individual compounds barely feasible, and only the general tendencies
can be tracked. Due to the significant mass transfer eﬀect, even the qualitative comparison of the
association and dissociation phases of the compound interaction with diﬀerent density DC-SIGN
surfaces would not be reliable.
On the other hand, this SPR direct interaction assay showed that most of the compounds
interact with DC-SIGN in a Ca2+-dependent manner, with only two above indicated exceptions.
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10. The newly identified monovalent lead
compounds as DC-SIGN antagonists.
Three diﬀerent types of monovalent DC-SIGN ligands were developed including mannose-
based glycomimics, fucose-based LewisX trisaccharide mimics and various C-glycosidic compounds.
In the pool of these monovalent compounds, two new leads, namely 4h and 10b (fig. 10.1), were
identified by SPR competition assay among the bis-benzylamide derivatives of previously designed
pseudodisaccharide psDi (fig. 9.14 on page 173) and the LewisX mimicking compounds (LewisX
structure may be found in fig. 2.9 on page 68).
Figure 10.1.: The new identified glycomimetic leads.
Although both of these compounds have similar activities to inhibit DC-SIGN, the activity im-
provement comparing to their parental compounds is slightly better for mannose-based glycomim-
ics 4h. While fucose-based compound 10b has an improvement of relative aﬃnity compared to
LewisX trisaccharide by a factor of 1.9, the comparison of 4h with its predecessors psDi and natural
Manα1-2Man disaccharide shows slightly more than a 3-fold aﬃnity improvement. Furthermore, the
LewisX-type compounds displayed a remarkable selectivity to DC-SIGN compared with langerin, as
could be expected knowing that langerin does not bind LewisX trisaccharide [57, 113]. On the other
hand, langerin is known to bind mannosylated carbohydrates [60, 113, 115], therefore the selectivity
improvement for mannose-based compounds is a more challenging task in the course of the devel-
opment of mannose-based DC-SIGN antagonists. Indeed, the selectivity gain of a factor of ≈ 6 was
reached for compound 4h as compared to its predecessor psDi. Knowing that psDi already had the
selectivity improvement of sel.g = 3.5 compared to natural disaccharide Manα1-2Man, even much
higher sel.g value (compared to Manα1-2Man) for 4h may be predicted. Finally, the slightly better
activity of 4h than 10b could be also observed for the multivalent forms of these two compounds:
the tetravalent dendrimer with 4h had about 3 times better activity than 10b (IC50 values 39 ￿M
and 12 ￿M, respectively).
327
CHAPTER 10. THE NEWLY IDENTIFIED MONOVALENT LEAD COMPOUNDS AS
DC-SIGN ANTAGONISTS.
The design of 4h and its identification as a new lead compound became possible only after the
previous lead compound pseudotrisaccharide psTri (fig. 9.14 on page 173) was discovered to possesses
the ability to cross-link two DC-SIGN tetramers (figure 7 in paper n°5). This unique feature of
psTri ligand led to artificial overestimation of its activity in SPR competition assay where soluble
DC-SIGN tetramers are used allowing the cross-linking to occur, which has an important eﬀect on
IC50 value estimation. Along the latter discovery, a shorter analogue of psTri, the above-mentioned
compound psDi, was found to have the required qualities for further development as a drug candidate
(paper n°4). Therefore, the further development focused on psDi scaﬀold and yielded the lead
compound 4h. However, the detection of the cross-linking phenomenon characteristic to psTri,
highlights the importance of testing the selected leads in multiple biophysical techniques in order
to avoid the false positives identified due to the particular set-up of the competition experiment.
The activity and selectivity of 4hmay be further improved. The second type of psDi derivatives
with substituents introduced at carbon 6 of the non-reducing mannose moiety of psDi molecule were
designed in order to decrease the recognition by langerin. Among these derivatives, one compound,
with an amino group instead of hydroxyl at carbon 6 (NV243, fig. 9.25 on page 290), exhibited an
improved selectivity to DC-SIGN as compared to langerin (sel.g of ≈ 5 comparing to psDi). This
compound also had a better activity of DC-SIGN inhibition than psDi. Therefore, combining the
structural features of both 4h and NV243 may lead to the design of a compound (fig. 10.2) with a
much better activity and much higher selectivity.
Figure 10.2.: A perspective mannose-based compound with combined features of the lead 4h and
compound NV243.
The structural basis of the improvement of the selectivity to DC-SIGN vs langerin with this
new compound (fig. 10.2) could be also anticipated. In addition to the previous discovery that
langerin is able to bind galactose with a sulphate group at position 6 [115], our group found that
GlcNAc with an analogous sulphation at position 6 is also recognized by langerin, and as in the case
of 6SO4-Gal, the sulphate group makes electrostatic contacts with Lys313 side chain (fig. 10.3A).
If this sulphate was replaced by a group carrying a positive charge at a respective position, an
electrostatic repulsion of the resulting compound could be expected.
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Figure 10.3.: The anticipated structural basis for the improvement of the selectivity to DC-SIGN
vs langerin by the perspective mannose-based compound.
A, The structure of langerin in complex with 6SO4-GlcNAc and important lysines indicated (non-published data:
the complex was obtained and the structure was solved in our group by a PhD student Eric Chabrol, and is described
in his PhD thesis). B, DC-SIGN binding site in complex with psDi; 6-OH group on mannose moiety, which is replaced
by amino group in NV243, is highlighted by a blue circle. Langerin (A) and DC-SIGN (B) binding sites are arranged
in similar respective positions, Ca2+ ions are shown as green spheres and polar contacts are represented by dashed
lines.
The selectivity may be gained not only by decreasing the aﬃnity to langerin but also by
increasing it to DC-SIGN. The crystal structure of psDi binding mode in DC-SIGN CRD (fig. 10.3B)
allows to predict that amino group instead of 6-OH of mannose may interact through electrostatic
contact and/or H-bond with the neighboring surface of the lectin and notably carbonyl of Glu347.
Indeed, the psDi derivative with NH2 instead of 6-OH (NV243) showed improved aﬃnity compared
to psDi, and the additional aromatic groups of 4h would improve the aﬃnity even further.
In order to further improve LewisX mimics, the structural knowledge of the lead compound
interaction with DC-SIGN would be helpful. Therefore, co-crystallizing this compound with DC-
SIGN CRD and solving the X-ray structure of the complex could be a future perspective for this
project.
Regarding the C-glycosidic compounds, an interesting result was found: a simple L-fucose
with a short alkyl-azide appendage linked to an anomeric carbon by C-glycosidic bond (compound
BB133, fig. 9.6 on page 153) has twice higher activity than the natural L-fucose, whereas the anal-
ogous D-mannose C-glycoside (compound BB112, fig. 9.6 on page 153) had the same activity as
natural D-mannose. Comparing the latter two C-glycosidic monosaccharides, L-fucose has 3 times
better activity than D-mannose. The underlying reason for this aﬃnity improvement observed for
L-fucose C-glycoside could be investigated further by other biophysical techniques, such as ITC
combined with structural studies of the interaction by NMR or X-ray crystallography. However, it
may be speculated that the alkyl-azide linker of L-fucose is in a favorable position to make addi-
tional contacts in the binding site of DC-SIGN, while this is not possible in case of D-mannose with
the same linker. Indeed, when the C-glycosidic L-fucose was tethered to the dendrimeric scaﬀolds
(fig. 9.29 on page 294 and table 9.3 on page 297), the activity of the resulting compounds was com-
parable or even lower than of the corresponding dendrimers with O-glycosidic L-fucose (fig. 9.34 on
page 300), suggesting that the contribution of the alkyl-azide linker to aﬃnity improvement may
have been lost in the multivalent presentation. On the contrary, the multivalent platforms with
the C-glycosidic D-mannose for some reason appeared to have a better aﬃnity than corresponding
dendrimers with O-glycosidic D-mannose (fig. 9.31 on page 298). Finally, when the corresponding
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dendrimers with C-glycosidic L-fucose and C-glycosidic D-mannose are compared, a switch in activ-
ities can be noticed: while C-glycosidic L-fucose had higher aﬃnity than C-glycosidic D-mannose as
a monosaccharide, the multivalent presentation results in favor for C-glycosidic D-mannose and a
slightly higher aﬃnity is observed for the dendrimers with mannose than corresponding compounds
with fucose (fig. 10.4).
Figure 10.4.: The comparison of DC-SIGN inhibition activities of the corresponding multivalent
compounds with C-glycosidic L-fucose and C-glycosidic D-mannose.
On the other side, when Manα1-3Man-mimicking C-glycosidic disaccharides were built (com-
pounds ZL1(D), ZL2(L), BB207, BB213, fig. 9.6 on page 153), it appeared that their activities were
even worse than the natural Manα1-3Man sugar, and one of these compounds (ZL2(L)) possessed
a bizarre ability to induce DC-SIGN aﬃnity to the dextran. Considering that even the natural
Manα1-3Man disaccharide has an activity twice lower than the Manα1-2Man disaccharide, it can
be concluded that it is not a good idea to design Manα1-3Man mimics as DC-SIGN antagonists.
The disaccharide of the other type, i.e. the artificial dimannoside with mannose moieties
linked through C1α carbons by an alkyl chain (compound BB203, fig. 9.6 on page 153), were found
to have 2 times better activity as compared to D-mannose monosaccharide. The similar result was
found also for the analogous disaccharide with C-glycosidic L-fucose (compound BB178, fig. 9.6 on
page 153): it had twice better activity than the corresponding C-glycosidic L-fucose monosaccharide.
Thus such a 2-fold improvement of the activity for the disaccharides may result from the ligand
concentration eﬀect. The other three L-fucose C-glycosidic disaccharides (compounds BO, BO2
and BO3, fig. 9.6 on page 153) had the same activity as the corresponding C-glycosidic L-fucose
monosaccharide.
Although these results give a first insight to the aﬃnities of the C-glycosides to DC-SIGN,
more importantly these compounds should be evaluated in the enzymatic digestion assay to test
their resistance to glycosidases and compare it with corresponding O-glycosides.
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Several series of multivalent scaﬀolds with diﬀerent valences and ligand presentation in space
were produced. Functionalizing them with simple monosaccharides such as D-mannose or L-fucose
allowed a preliminary evaluation of the eﬃciencies of the scaﬀolds themselves (fig. 11.1).
Figure 11.1.: The comparison of DC-SIGN inhibition activities of the corresponding multivalent
compounds with O-glycosidic L-fucose and D-mannose.
Left and right panels show IC50 and β factor values, respectively. The IC50 values (￿M) are displayed on each bar
in the left panel.
Generally, the activity of the compounds increased with the increase of the scaﬀold valence.
Fucosylated compounds had better activity at all valences than the mannose-bearing compounds,
and the activity improvement factor β was much stronger for fucosylated compounds. It is interesting
to notice that, for both mannose and fucose, there was no activity improvement achieved when the
valence is raised from 4 to 6, and the same absence of activity increase also found changing valence
from 12 to 18. This might suggest that the configuration of tetravalent scaﬀold is more favorable
in terms of ligand presentation than that of the hexavalent one in case of these two simple O-
glycosidic monosaccharide ligands, while for 12-valent and 18-valent scaﬀolds either the maximal
eﬃciency with these ligands has been already reached (compared to IC50 value of 50 ￿M for 32-
valent 3rd generation Boltorn type dendrimer functionalized with mannose was found previously
[158]) or also the configuration (folding) of 18-valent scaﬀold is not favorable for further aﬃnity
improvement as compared to 12-valent scaﬀold. However, no definite conclusion can be drawn
from this observation because a very smooth eﬃciency increase with valence increase was found for
dendrimers with C-glycosidic L-fucose (fig. 9.34 on page 300).
The dendrimers with glycomimetic ligands, which have higher aﬃnity compared to natural
sugars, had higher activity than the same scaﬀolds with natural monosaccharides. This indicates
that tethering to multivalent platforms conserved their initially better aﬃnity to DC-SIGN. Even
more, this better initial aﬃnity was further amplified by the multivalent presentation, as could be
seen from β > 1 values for all of the dendrimers with the glycomimics, except psTri.
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Among the glycomimetic compounds, comparing the same scaﬀolds the best activity and β
factor values were achieved for the new lead compound 4h, even though the LewisX mimics 10b-
azide1 displayed the same activity as 4h at the monovalent presentation (fig. 11.2).
Figure 11.2.: The comparison of DC-SIGN inhibition activities of all glycomimetic compounds on
tetravalent dendrimer scaﬀolds.
Left and right panels show IC50 and β factor values, respectively.
As discussed above, for psTri multivalent presentation resulted in unfavorable β factor < 1 due
to actually bivalent nature of this compound when not on the multivalent scaﬀold. The comparison
of these tetravalent dendrimer scaﬀolds with previously designed tetravalent dendrons (fig. 11.3),
indicated that a new type of tetravalent presentation was beneficial for the activity of psDi, while it
had no eﬀect for psTri. Again this could be related to scaﬀold configuration/folding, which might
also be ligand-dependent.
Figure 11.3.: The comparison of DC-SIGN inhibition activities of tetravalent psDi and psTri den-
drimers and dendrons.
The most potent DC-SIGN antagonists identified up to now are the 32-valent Boltorn type
dendrimers with psDi and psTri with the IC50 values of 2 ￿M and 1.25 ￿M, respectively. They
were also showed to be good inhibitors of HIV trans infection in a cell-based assay (paper n°5).
However, a new lead compound 4h had a rather close activity when presented only on a hexavalent
dendrimer scaﬀold, giving a promising perspective to acquire even higher potencies with higher
valence scaﬀolds. Morever, the Boltorn type dendrimers are built based on ester bonds, which are
less stable than ether and triazole bonds in new type dendrimers, which is one more advantage to
further develop this new type multivalent platforms.
The only drawback observed for some of these dendrimers was their low solubility, namely
for compounds S4-Oman , S4-psTri , S4-fucβAla , S6-1-Oman , S9-1-Cfuc, and for all 4h
functionalized compounds, in particular rod-like dendrimer R3 . This limited solubility first of all
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aﬀects the accurate determination of the IC50 values due to overestimated compound concentration,
which is why the further increase of 4h activity on a 9-valent scaﬀold was not observed (fig. 9.31
on page 298). The limited solubility may also be related with the anticipated aggregation phenom-
ena observed in SPR direct interaction assay (it must be noted that the compounds before SPR
experiments were centrifuged, and only soluble part of the samples was analyzed). However, the
aggregation was observed also for those compounds (S4-psDi and S6-1-psDi), which did not have
any apparent water solubility problems. All these presumably aggregating compounds comprised
all of the tetra- and hexavalent dendrimers, in addition to all 4h-functionalized dendrimers. For the
lower valence compounds it could be that the aggregation is driven by the scaﬀold folding in a way,
where hydrophobic parts become exposed and available for formation of the aggregates. Whereas
for 4h multivalent compounds the nature of the ligand, i.e. probably the presence of two aromatic
rings on each ligand molecule, also plays a role in aggregation process, and for this reason the
solubility of the latter compounds is particularly lower. Such aggregation phenomenon most likely
has also an eﬀect on compound analysis in SPR competition assay, as described below.
The second presumable phenomenon observed in SPR direct interaction assay was the ability
of some compounds to interact with DC-SIGN in Ca2+-independent manner. These compounds
included:
✧ dendrons with psDi and psTri since EDTA failed to fully remove them from DC-SIGN surface
(fig. 9.41 on page 307)
✧ S6-1-4h and S4-fucβAla as seen in surface double regeneration assay (fig. 9.57 on page 323,
EDTA also didn’t fully remove these compounds from DC-SIGN)
✧ compounds S18-1-Oman , S18-2-Oman , S4-Oman and S4-4h can be predicted to bind
DC-SIGN in other than Ca2+-dependent sugar recognition site from the observation that after
using the regeneration solution (composed of 50mM Gly-NaOH pH11.9 / 0.15% TritonX100
/ 25mM EDTA pH8) still part of the compounds stayed bound on DC-SIGN surface (data
not shown).
Possibly, the initial binding of these compounds occurs through Ca2+-dependent interaction in the
conventional sugar binding site of DC-SIGN, but then is stabilized by additional, probably hy-
drophobic, compound-protein interactions. Since the double regeneration assay was not performed
with all of the tested dendrimers, it is possible that there were more compounds binding to DC-SIGN
in Ca2+-independent manner.
Finally, the third unexpected behavior of some of the dendrimers (i.e. compounds S6-1-
Oman , S6-1-psTri , S6-2-psDi , and S9-1-psDi) was an apparently higher aﬃnity to StrepTactin
than to DC-SIGN. The latter eﬀect, together with ability of some other compounds to interact in
Ca2+-independent manner, should be taken with caution considering cellular assays since such
unspecific compound-protein interaction might have an eﬀect to the course and the results of these
assays, where many diﬀerent protein receptors are available for interaction.
All of these observed phenomena for the compounds are summarized in table 12.2.
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12. Does the shape of the inhibition curve
indicate “the mode of action” of the
compound?
After performing multiple SPR competition experiments, I have noticed that the shapes of the
inhibition curves, in terms of the slope, for some compounds vary significantly. It is obvious that
the same IC50 value may be achieved from the curves with diﬀerent slopes as shown in figure 12.1.
Figure 12.1.: The comparison of three inhibition curves with diﬀerent slopes, for which IC50 values
are the same.
It raised the question whether the slope of the curve could indicate a particular mechanism
of how the compound interacts with DC-SIGN. One of the first observations was that for psTri the
slope values were always lower than for the majority of other compounds. When it was found that
psTri is capable to cross-link DC-SIGN tetramers, it gave an idea how to interpret such a lower
slope value, which is illustrated in the middle panel of figure 12.2 and compared to a “normal”
non-bridging compound (figure 12.2, left panel). At low psTri concentrations (the top of the curve),
DC-SIGN tetramers are in excess, which makes bridging favorable. At this point, psTri displays
an activity characteristic so higher aﬃnity compounds, which in turn forces the inhibition curve
to start to incline at low psTri concentrations. Increasing psTri concentration further, the binding
sites of DC-SIGN gradually become saturated, which makes bridging less and less favored, and this
way aﬀects the appearance of the curve to have a milder slope than for the “normal” compound.
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Figure 12.2.: Possible mechanisms of how compounds inhibit DC-SIGN in the SPR competition
assay.
The curves with the evolutions of compound and DC-SIGN states for the three indicated cases are shown. The
compound evolution is illustrated on the left, and the change of DC-SIGN state is shown on the right of each curve.
A compound, which neither cross-links DC-SIGN nor aggregates, is referred as “normal”.
However, for some of the compounds the slope value was obviously higher than for the “nor-
mal” compounds. Thinking of this case, I considered the following situation (fig. 12.2, right panel):
since the slope is steep, it might suggest that the compound exhibits higher aﬃnity at higher con-
centrations. This could be possible only if the compound at higher concentrations forms aggregates,
which display more ligands on their surface in a favorable manner for DC-SIGN binding. This way
the clustering of even more DC-SIGN tetramers becomes possible. In competition assay the binding
of DC-SIGN is measured, so such an aggregation of the compounds at higher concentrations would
reduce the amount of free DC-SIGN more eﬃciently forcing the steepness of the curve.
I have selected six monovalent compounds (L-fucose, LewisX, Manα1-2Man, Manα1-3Man,
psDi and D-mannose), which are expected to behave “normally”, i.e. they don’t bridge DC-SIGN
nor they aggregate. I calculated the mean slope (parameter A2 in eq. 6.1 on page 114) and SD
values from multiple SPR competition experiments (table 12.1).
Table 12.1.: The determination of upper and lower A2 limits for the “normal” compound.
Mean A2 SD
D-mannose 1.24 0.17
Manα1-2Man 1.17 0.11
Manα1-3Man 1.03 0.06 0.97 ←lower limit
psDi 1.16 0.15
L-fucose 1.25 0.18 1.43 ←upper limit
LewisX 1.21 0.15
By subtracting the SD value from the lowest observed A2 (for Manα1-3Man) and by adding
SD value to the highest observed A2 (for L-fucose), I defined the approximate lower and upper slope
limits for the “normal” mode of inhibition: the compounds that lie below the lower limit would be
likely to cross-link DC-SIGN tetramers, while the compounds that go above the upper limit are
probably aggregating, and all others that are in-between the two limits are “normal”.
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Figure 12.3.: The analysis of all the tested compounds in terms of the slope of the inhibition curve.
Fucose-based, mannose-based and all multivalent compounds are shown in top, middle and bottom panels, respec-
tively.
Such an analysis of all the tested compounds in terms of the inhibition curve slope value
showed that all fucose-based (fig. 12.3 top panel) and most of the mannose-based compounds (fig.
12.3 middle panel) behave in a “normal” mode. Among mannose-based compound series, psTri
was found to be below the lower limit indicating its ability to cross-link DC-SIGN. The second
compound slightly below the lower limit was NV253. However, this compound was tested only
once and considering relatively high variation of slope values, it behaves most likely like a “normal”
compound. Similarly, there were several mannose-based compounds above the upper limit, which
were measured also only once, thus possibly behaving as “normal” ones as well (although the lower
solubility displayed by 4a and 4d might be related with aggregation).
A very diﬀerent result is seen for multivalent compounds (fig. 12.3 bottom panel): part
of them (S6-2-psDi , S6-1-4h , S9-1-4h , R1 , R2, R3 and G3(pseudotri)32) demonstrated a
significant sign of aggregation, which correlates well with SPR direct interaction assay. The others
(S4-Oman , S9-1-Oman , S9-2-Oman , S9-1-Cman , S9-1-psDi , S12-Oman , S12-Cman ,
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S12-Ofuc, S4-fucβAla , S18-1-Oman and S18-2-Oman) displayed the ability to cross-link
DC-SIGN, an expected behavior for the multivalent compounds. The rest of the compounds were
in-between the two limits. It may suggest the “normal” mode of their interaction with DC-SIGN,
however, considering that multivalent compounds are likely to bridge DC-SIGN, these observed
slope values between the limits might likely result from the cross-linking eﬀect compensated by
aggregation eﬀect, and thus the slopes do not cross either limit.
Table 12.2.: The summary of all observed and assumed characteristics of all multivalent com-
pounds.
Although this type of analysis may give a clue, it does not provide a definite answer about
what is really happening in solution. The other biophysical assays, such as DLS and/or AUC,
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should be performed on the compounds alone in order to track and characterize their aggregation.
Performing the same experiment in the presence of DC-SIGN would indicate which of the compounds
are able to cross-link DC-SIGN. These experiments would also answer the question if the higher
maximal binding responses observed in SPR direct interaction assay indicate compound aggregation
or binding to other sites on DC-SIGN.
In summary, the low solubility of the compounds is problematic for both performing the assay
and interpreting the results. It could be a good idea to determine water solubility of the compounds
and provide as a guideline in order to avoid the misevaluation of their activities. Moreover and
most importantly, the solubility problem is a drawback for development of the compounds as the
drug substances. When tethered to multivalent scaﬀolds, a new perspective ligand with combined
features of 4h and NV243 (fig. 10.2) could be predicted to induce the electrostatic repulsion between
the molecules due to the presence of positively charged amino group, and lead to both increased
solubility and reduced aggregation.
In general, the strategy of using multivalent glycomimetic compounds for protection from
HIV trans infection has been proved promising (article n°2), and the further improvement of the
scaﬀolds may possibly lead to a successful drug substance discovery for the development of vaginal
microbicides.
The closest way to achieve that may be envisioned: after synthesizing and tethering on mul-
tivalent scaﬀolds a new ligand with combined 4h and NV243 features, it should be analyzed in
proposed biophysical assays (DLS, AUC and SPR) to control its behavior in solution and activity.
In case of positive results, it should be tested for HIV trans infection inhibition in cell-based or ex
vivo assays together with toxicity determination. The good results of the latter tests would pave
a way for such compound to be tested in preclinical animal studies. Only the confirmed positive
tendency of the resistance to infection in monkeys may approve the further investigation of this
molecule in clinical trials.
Finally, even if the use of such molecule for protection from HIV infection wasn’t approved,
it may find other applications in inhibiting infections and/or blocking the hijack of DCs by other
pathogens. This type of molecule may also be used for the development of synthetic vaccines to
target DCs specifically through the interaction with DC-SIGN.
339

Part V.
Bibliography
341

 
 
 
 
 
 
Bibliography 
 
 
 
[1] He, J. & Deem, M. W. (2010) Heterogeneous diversity of spacers within CRISPR (Clustered 
Regularly Interspaced Short Palindromic Repeats). Physical Review Letters 105, 128102. 
 
[2]  Rowley, A. F. & Powell, A. (2007) Invertebrate immune systems specific, quasi-specific, or nonspecific? 
Journal of Immunology 179, 7209–7214. 
 
[3] Goldsby, R.; Kindt, T.; Osborne, B.; & Kuby, J. Book: Immunology. 5th edition. W. H. Freeman. 
2002. 
 
[4] Parham, P. Elements of the immune system and their roles in defense. In book: The Immune System. 3rd 
edition. Garland Science. 2009. 
 
[5]  Miller, L. S & Cho, J. S. (2011) Immunity against Staphylococcus aureus cutaneous infections. Nature Reviews 
Immunology 11, 505–518. 
 
[6] Murphy, K.; Geha, R. & Notarangelo, L. Innate immunity: The first lines of defense. In book: 
Janeway’s Immunobiology. 8th edition. Garland Science. 2011. 
 
[7]  Pathak, S. & Palan, U. Book: Immunology: Essential And Fundamental. 2nd edition. Science Publishers. 
2005. 
 
[8] DeFranco, A.; Locksley, R. & Robertson, M. Book: Immunity:  The Immune Response in Infectious and 
Inflammatory Disease. New Science Press. 2007. 
 
[9] Paul, W. E. Book: Fundamental Immunology. 6th edition. Lippincott Williams & Wilkins. 2008. 
 
[10] Bedard, K. & Krause, K.-H. (2007) The NOX family of ROS-generating NADPH oxidases: physiology 
and pathophysiology. Physiological Reviews  87, 245–313. 
 
[11] Janeway, C. A. & Medzhitov, R.  (2002) Innate immune recognition.  Annual Review of Immunology 
20, 197–216. 
 
[12] Kishore, U. Book: Target pattern recognition in innate immunity. Springer. 2009. 
 
[13] Peiser, L.; Mukhopadhyay, S. & Gordon, S. (2002) Scavenger receptors in innate immunity. Current 
Opinion in Immunology 14, 123–128. 
 
[14] Lombardi, G. & Ri!o-Vasquez, Y. Book: Dendritic Cells: Handbook of Experimental Pharmacology. 
Springer. 2008. 
 
[15] Elgert, K. D. Book: Immunology: Understanding the immune system.  2nd edition. John Wiley & Sons. 
2009. 
 
343 
Bibliography 
344 
!
!
 
 
[16] Chen, G.; Shaw, M. H.; Kim, Y.-G. & Nuñez, G. (2009) NOD-like receptors: role in innate 
immunity and inflammatory disease. Annual Review of Pathology: Mechanisms of Disease 4, 365–398. 
 
[17] Zelensky, A. N. & Gready, J. E. (2005) The C-type lectin-like domain superfamily. The FEBS journal   
272, 6179–6217. 
 
[18] van den Berg, L. M.; Gringhuis, S. I. & Geijtenbeek, T. B. H. (2012) An evolutionary per- spective 
on C-type lectins in infection and immunity. Annals of the New York Academy of Sciences. doi: 
10.1111/j.1749-6632.2011.06392.x 
 
[19] Geijtenbeek, T. B. H. & Gringhuis, S. I. (2009) Signalling through C-type lectin receptors: shaping 
immune responses. Nature Reviews Immunology 9, 465–479. 
 
[20] Redelinghuys, P. & Brown, G. D. (2011) Inhibitory C-type lectin receptors in myeloid cells. 
Immunology Letters 136, 1–12. 
 
[21] de Jong, M. A. W. P.; Vriend, L. E. M.; Theelen, B.; Taylor, M. E.; Fluitsma, D.; Boekhout, T. & 
Geijtenbeek, T. B. H. (2010) C-type lectin langerin is a !-glucan receptor on human Langerhans cells 
that recognizes opportunistic and pathogenic fungi. Molecular Immunology  47, 1216– 1225. 
 
[22] Stoitzner, P. & Romani, N. (2011) Langerin, the "catcher in the rye": an important receptor for 
pathogens on Langerhans cells. European Journal of Immunology  41, 2526–2529. 
 
[23] Bashirova, A. A.; Geijtenbeek, T. B.; van Duijnhoven, G. C.; van Vliet, S. J.; Eilering, J. B.; 
Martin, M. P.; Wu, L.; Martin, T. D.; Viebig, N.; Knolle, P. A.; KewalRamani, V. N.; van Kooyk, Y. 
& Carrington, M. (2001) A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes 
HIV-1 infection. Journal of Experimental Medicine 193, 671–678. 
 
[24] Snyder, G. A.; Ford, J.; Torabi-Parizi, P.; Arthos, J. A.; Schuck, P.; Colonna, M. & Sun, P. D. (2005) 
Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and 
ICAM molecules favors the receptor’s role as an antigen-capturing rather than an adhesion receptor. 
Journal of Virology  79, 4589–4598. 
 
[25] Yabe, R.; Tateno, H. & Hirabayashi, J. (2010) Frontal a!nity chromatography analysis of constructs 
of DC-SIGN, DC-SIGNR and LSECtin extend evidence for a!nity to agalactosylated N-glycans. 
FEBS J  277, 4010–4026. 
 
[26] Kolatkar, A. R.; Leung, A. K.; Isecke, R.; Brossmer, R.;  Drickamer,  K.  &  Weis,  W.  I. (1998) 
Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition 
domain. Journal of Biological Chemistry  273, 19502–19508. 
 
[27] Williams, A. Book: Immunology: Mucosal and Body Surface Defences. 2nd edition. John Wiley & Sons. 
2011. 
 
[28] Gessani, S. & Belardelli, F. Book: The Biology of Dendritic Cells and HIV Infection. Springer. 2007. 
Bibliography 
345 
!
!
 
 
[29] Geijtenbeek, T. B. H.; den Dunnen, J. & Gringhuis, S. I. (2009) Pathogen recognition by DC-
SIGN shapes adaptive immunity. Future Microbiology  4, 879–890. 
 
[30] Bleijs, D. A.; Geijtenbeek, T. B.; Figdor, C. G. & van Kooyk, Y. (2001) DC-SIGN and LFA-1: a battle 
for ligand.  Trends i n  Immunology 22, 457–463. 
 
[31] Dustin, M. L.; Tseng, S.-Y.; Varma, R. & Campi, G. (2006) T cell-dendritic cell immunological 
synapses. Current Opinion in Immunology 18, 512–516. 
 
[32] Wilen, C. B.; Tilton, J. C. & Doms, R. W. (2012) HIV: Cell binding and entry. Cold Spring 
Harbor Perspectives in Medicine  2. doi: 10.1101/cshperspect.a006866 
 
[33] Saphire, A. C.; Bobardt, M. D.; Zhang, Z.; David, G. & Gallay, P. A. (2001) Syndecans serve as 
attachment receptors for human immunodeficiency virus type 1 on macrophages. Journal of Virology 75, 
9187–9200. 
 
[34] Arthos, J.; Cicala, C.; Martinelli, E.; Macleod, K.; Ryk, D. V.; Wei, D.; Xiao, Z.; Veenstra, T. D.; 
Conrad, T. P.; Lempicki, R. A.; McLaughlin, S.; Pascuccio, M.; Gopaul, R.; Mcnally, J.; Cruz, C. 
C.; Censoplano, N.; Chung, E.; Reitano, K. N.; Kottilil, S.; Goode, D. J. & Fauci, A. S. (2008) HIV-1 
envelope protein binds to and signals through integrin "4!7, the gut mucosal homing receptor for 
peripheral T cells. Nature Immunology  9, 301–309. 
 
[35] Cicala, C.; Martinelli, E.; McNally, J. P.; Goode, D. J.; Gopaul, R.; Hiatt, J.; Jelicic, K.; Kottilil, S.; 
Macleod, K.; O’Shea, A.; Patel, N.; Ryk, D. V.; Wei, D.; Pascuccio, M.; Yi, L.; McKinnon, L.; 
Izulla, P.; Kimani, J.; Kaul, R.; Fauci, A. S. & Arthos, J. (2009) The integrin "4!7 forms a complex 
with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. PNAS 
106, 20877–20882. 
 
[36] Geijtenbeek, T. B.; Kwon, D. S.; Torensma, R.; van Vliet, S. J.; van Duijnhoven, G. C.; Middel, J.; 
Cornelissen, I. L.; Nottet, H. S.; KewalRamani, V. N.; Littman, D. R.; Figdor, C. G. & van 
Kooyk, Y. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-
infection of T cells. Cell 100, 587–597. 
 
[37] Orlo!, G. M.; Orlo!, S. L.; Kennedy, M. S.; Maddon, P. J. & McDougal, J. S. (1991) Penetration of 
CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal 
transduction events are not required for entry. Journal of Immunology 146, 2578–2587. 
 
[38] Sherer, N. M.; Jin, J. & Mothes, W. (2010) Directional spread of surface-associated retroviruses regulated by 
di!erential virus-cell interactions. Journal of Virology 84, 3248–3258. 
 
[39] Miyauchi, K.; Kim, Y.; Latinovic, O.; Morozov, V. & Melikyan, G. B. (2009) HIV enters cells via 
endocytosis and dynamin-dependent fusion with endosomes. Cell 137, 433–444. 
 
[40] Melikyan, G. B. (2008) Common principles and intermediates of viral protein-mediated fusion: the HIV-1 
paradigm. Retrovirology 5. doi:10.1186/1742-4690-5-111 
 
[41] Cameron, P. U.; Freudenthal, P. S.; Barker, J. M.; Gezelter, S.; Inaba, K. & Steinman, R. M. (1992) 
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic 
infection to CD4+ T cells. Science 257, 383–387. 
Bibliography 
346 
!
!
 
 
[42] Pope, M.; Betjes, M. G.; Romani, N.; Hirmand, H.; Cameron, P. U.; Ho!man, L.; Gezelter, S.; 
Schuler, G. & Steinman, R. M. (1994) Conjugates of dendritic cells and memory T lymphocytes from skin 
facilitate productive infection with HIV-1. Cell  78, 389–398. 
 
[43] Hladik, F. & McElrath, M. J. (2008) Setting the stage: host invasion by HIV. Nature Reviews 
Immunology 8, 447–457. 
 
[44] Hladik, F. & Hope, T. J. (2009) HIV infection of the genital mucosa in women. Current HIV/AIDS 
Reports   6,  20–28. 
 
[45] Felts, R. L.; Narayan, K.; Estes, J. D.; Shi, D.; Trubey, C. M.; Fu, J.; Hartnell, L. M.; Ruthel, G. 
T.; Schneider, D. K.; Nagashima, K.; Bess, J. W.; Bavari, S.; Lowekamp, B. C.; Bliss, D.; Lifson, J. 
D. & Subramaniam, S. (2010) 3D visualization of HIV transfer at the virological synapse between 
dendritic cells and T cells. PNAS  107, 13336–13341. 
 
[46] Kwon, D. S.; Gregorio, G.; Bitton, N.; Hendrickson, W. A. & Littman, D. R. (2002) DC-SIGN-
mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16, 135–
144. 
 
[47] Sol-Foulon, N.; Moris, A.; Nobile, C.; Boccaccio, C.; Engering, A.; Abastado, J.-P.; Heard, J.-M.; van 
Kooyk, Y. & Schwartz, O. (2002) HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells 
promotes lymphocyte clustering and viral spread. Immunity 16, 145–155. 
 
[48] Gurney, K. B.; Elliott, J.; Nassanian, H.; Song, C.; Soilleux, E.; McGowan, I.; Anton, P. A. & Lee, 
B. (2005) Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal 
mucosa. Journal of Virology 79, 5762–5773. 
 
[49] Sattin, S.; Daghetti, A.; Thépaut, M.; Berzi, A.; Sánchez-Navarro, M.; Tabarani, G.; Rojo, J.; 
Fieschi, F.; Clerici, M. & Bernardi, A. (2010) Inhibition of DC-SIGN-mediated HIV infection by a 
linear trimannoside mimic in a tetravalent presentation. ACS Chemical Biology  5, 301–312. 
 
[50] Berzi, A.; Reina, J. J.; Ottria, R.; Sutkeviciute, I.; Antonazzo, P.; Sanchez-Navarro, M.; Chabrol, E.; 
Biasin, M.; Trabattoni, D.; Cetin, I.; Rojo, J.; Fieschi, F.; Bernardi, A. & Clerici, M. (2012) A 
glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant 
models. AIDS (London, England) 26, 127–137. 
 
[51] de Witte, L.; Nabatov, A. & Geijtenbeek, T. B. H. (2008) Distinct roles for DC-SIGN+-dendritic cells 
and Langerhans cells in HIV-1 transmission. Trends in Molecular Medicine  14, 12–19.  
 
[52]  Burleigh, L.; Lozach, P.-Y.; Schi!er, C.; Staropoli, I.; Pezo, V.; Porrot, F.; Canque, B.; Virelizier, J.-L.; 
Arenzana-Seisdedos, F. & Amara, A. (2006) Infection of dendritic cells (DCs), not DC-SIGN-mediated 
internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. 
Journal of Virology 80, 2949–2957. 
 
[53] Gringhuis, S. I.; van der Vlist, M.; van den Berg, L. M.; den Dunnen, J.; Litjens, M. & 
Geijtenbeek, T. B. H. (2010) HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive 
infection of dendritic cells. Nature Immunology 11, 419–426. 
Bibliography 
347 
!
!
 
 
[54] Hladik, F.; Sakchalathorn, P.; Ballweber, L.; Lentz, G.; Fialkow, M.; Eschenbach, D. & McElrath, M. J. 
(2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. 
Immunity  26, 257–270. 
 
[55] Turville, S. G.; Cameron, P. U.; Handley, A.; Lin, G.; Pöhlmann, S.; Doms, R. W. & Cunningham, A. L. 
(2002) Diversity of receptors binding HIV on dendritic cell subsets. Nature Immunology 3, 975– 983. 
 
[56] Hussain, L. A. & Lehner, T. (1995) Comparative investigation of Langerhans’ cells and potential receptors 
for HIV in oral, genitourinary and rectal epithelia. Immunology  85, 475–484. 
 
[57] de Witte, L.; Nabatov, A.; Pion, M.; Fluitsma, D.; de Jong, M. A. W. P.; de Gruijl, T.; Piguet, V.; 
van Kooyk, Y. & Geijtenbeek, T. B. H. (2007) Langerin is a natural barrier to HIV-1 
transmission by Langerhans cells. Nature Medicine  13, 367–371. 
 
[58] de Jong, M. A. W. P.; de Witte, L.; Taylor, M. E. & Geijtenbeek, T. B. H. (2010) Herpes simplex 
virus type 2 enhances HIV-1 susceptibility by a!ecting Langerhans cell function. Journal of 
Immunology  185, 1633–1641. 
 
[59] Ballweber, L.; Robinson, B.; Kreger, A.; Fialkow, M.; Lentz, G.; McElrath, M. J. & Hladik, F. 
(2011) Vaginal Langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. 
Journal of Virology 85, 13443–13447. 
 
[60] Chatwell, L.; Holla, A.; Kaufer, B. B. & Skerra, A. (2008) The carbohydrate recognition domain of 
langerin reveals high structural similarity with the one of DC-SIGN but an additional, calcium- 
independent sugar-binding site. Molecular Immunology  45, 1981–1994. 
 
[61] Curtis, B. M.; Scharnowske, S. & Watson, A. J. (1992) Sequence and expression of a membrane- associated C-
type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope 
glycoprotein gp120. PNAS  89, 8356–8360. 
 
[62] Geijtenbeek, T. B.; Torensma, R.; van Vliet, S. J.; van Duijnhoven, G. C.; Adema, G. J.; van Kooyk, 
Y. & Figdor, C. G. (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 
receptor that supports primary immune responses. Cell  100, 575–585. 
 
[63] Granelli-Piperno, A.; Pritsker, A.; Pack, M.; Shimeliovich, I.; Arrighi, J.-F.; Park, C. G.; Trumpfheller, 
C.; Piguet, V.; Moran, T. M. & Steinman, R. M. (2005) Dendritic cell-specific intercellular adhesion 
molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node 
and is not required for dendritic cell stimulation of the mixed leukocyte reaction. Journal of Immunology 
175, 4265–4273. 
 
[64] Lee, B.; Leslie, G.; Soilleux, E.; O’doherty, U.; Baik, S.; Levroney, E.; Flummerfelt, K.; Swiggard, W.; 
Coleman, N.; Malim, M. & Doms, R. W. (2001) cis expression of DC-SIGN allows for more e"cient 
entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. Journal of Virology 75, 
12028–12038. 
 
[65] Soilleux, E. J.; Morris, L. S.; Leslie, G.; Chehimi, J.; Luo, Q.; Levroney, E.; Trowsdale, J.; Montaner, 
L. J.; Doms, R. W.; Weissman, D.; Coleman, N. & Lee, B.  (2002) Constitutive and 
Bibliography 
348 
!
!
 
 
induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. 
Journal of Leukocyte Biology 71, 445–457. 
 
[66] Krutzik, S. R.; Tan, B.; Li, H.; Ochoa, M. T.; Liu, P. T.; Sharfstein, S. E.; Graeber, T. G.; Sieling, P. A.; 
Liu, Y.-J.; Rea, T. H.; Bloom, B. R. & Modlin, R. L. (2005) TLR activation triggers the rapid 
di!erentiation of monocytes into macrophages and dendritic cells. Nature Medicine 11, 653–660. 
 
[67] Rappocciolo, G.; Piazza, P.; Fuller, C. L.; Reinhart, T. A.; Watkins, S. C.; Rowe, D. T.; Jais, M.; 
Gupta, P. & Rinaldo, C. R. (2006) DC-SIGN on B lymphocytes is required for transmission of HIV-1 
to T lymphocytes. PLoS Pathogenes  2, 691-704. 
 
[68] Mummidi, S.; Catano, G.; Lam, L.; Hoefle, A.; Telles, V.; Begum, K.; Jimenez, F.; Ahuja, S. S. & Ahuja, 
S. K. (2001) Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing 
nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms. Inter-individual variation in expression of DC-
SIGN transcripts. Journal of Biological Chemistry  276, 33196–33212. 
 
[69] Martinez, O.; Brackenridge, S.; El-Idrissi, M. E.-A. & Prabhakar, B. S. (2005) DC-SIGN, but not sDC-
SIGN, can modulate IL-2 production from PMA- and anti-CD3-stimulated primary human CD4 T 
cells. International Immunology  17, 769–778. 
 
[70] Plazolles, N.; Humbert, J.-M.; Vachot, L.; Verrier, B.; Hocke, C. & Halary, F. (2011) Pivotal 
advance: The promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of 
cytomegalovirus-mediated cis-infection of myeloid dendritic cells. Journal of Leukocyte Biology 89, 329–
342. 
 
[71] Soilleux, E. J.; Barten, R. & Trowsdale, J. (2000) DC-SIGN; a related gene, DC-SIGNR; and CD23 
form a cluster on 19p13. Journal of Immunology 165, 2937–2942. 
 
[72] Svajger, U.; Anderluh, M.; Jeras, M. & Obermajer, N. (2010) C-type lectin DC-SIGN: an adhesion, 
signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cellular Signalling 22, 
1397–1405. 
 
[73] Feinberg, H.; Mitchell, D. A.; Drickamer, K. & Weis, W. I. (2001) Structural basis for selective 
recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science   294, 2163–2166. 
 
[74] Guo, Y.; Feinberg, H.; Conroy, E.; Mitchell, D. A.; Alvarez, R.; Blixt, O.; Taylor, M. E.; Weis, W. I. & 
Drickamer, K. (2004) Structural basis for distinct ligand-binding and targeting properties of the 
receptors DC-SIGN and DC-SIGNR. Nature Structural & Molecular Biology  11, 591–598. 
 
[75] Mitchell, D. A.; Fadden, A. J. & Drickamer, K. (2001) A novel mechanism of carbohydrate 
recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to 
multivalent ligands. Journal of Biological Chemistry 276, 28939–28945. 
 
[76] Frison, N.; Taylor, M. E.; Soilleux, E.; Bousser, M.-T.; Mayer, R.; Monsigny, M.; Drickamer, K. & 
Roche, A.-C. (2003) Oligolysine-based oligosaccharide clusters: selective recognition and endocytosis by 
the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing 
nonintegrin. Journal of Biological Chemistry 278, 23922–23929. 
Bibliography 
349 
!
!
 
 
[77] Dam, T. K. & Brewer, C. F. (2010) Lectins as pattern recognition molecules: the e!ects of epitope 
density in innate immunity. Glycobiology  20, 270–279. 
 
[78] Lupas, A. (1996) Coiled coils: new structures and new functions. Trends in Biochemical Sciences 21, 
375–382. 
 
[79] Feinberg, H.; Guo, Y.; Mitchell, D. A.; Drickamer, K. & Weis, W. I. (2005) Extended neck 
regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR. Journal of Biological Chemistry 
280, 1327–1335. 
 
[80] Tabarani, G.; Thépaut, M.; Stroebel, D.; Ebel, C.; Vivès, C.; Vachette, P.; Durand, D. & Fi- 
eschi, F. (2009) DC-SIGN neck domain is a pH-sensor controlling oligomerization: SAXS and 
hydrodynamic studies of extracellular domain. Journal of Biological Chemistry 284, 21229–21240. 
 
[81] Menon, S.; Rosenberg, K.; Graham, S. A.; Ward, E. M.; Taylor, M. E.; Drickamer, K. & Leckband, D. E. 
(2009) Binding-site geometry and flexibility in DC-SIGN demonstrated with surface force measurements. 
PNAS 106, 11524–11529. 
 
[82] Cambi, A.; de Lange, F.; van Maarseveen, N. M.; Nijhuis, M.; Joosten, B.; van Dijk, E. M. H. P.; de 
Bakker, B. I.; Fransen, J. A. M.; Bovee-Geurts, P. H. M.; van Leeuwen, F. N.; Hulst, N. F. V. & Figdor, 
C. G. (2004) Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic 
cells. Journal of Cell Biology 164, 145–155. 
 
[83] de Bakker, B. I.; de Lange, F.; Cambi, A.; Korterik, J. P.; van Dijk, E. M. H. P.; Hulst, N. F. V.; 
Figdor, C. G. & Garcia-Parajo, M. F. (2007) Nanoscale organization of the pathogen receptor DC-SIGN 
mapped by single-molecule high-resolution fluorescence microscopy. European Journal of Chemical Physics and 
Physical Chemistry  8, 1473–1480. 
 
[84] Koopman, M.; Cambi, A.; de Bakker, B. I.; Joosten, B.; Figdor, C. G.; van Hulst, N. F. & Garcia- 
Parajo, M. F. (2004) Near-field scanning optical microscopy in liquid for high resolution single molecule 
detection on dendritic cells. FEBS Letters 573, 6–10. 
 
[85] Neumann, A. K.; Thompson, N. L. & Jacobson, K. (2008) Distribution and lateral mobility of DC-
SIGN on immature dendritic cells–implications for pathogen uptake. Journal of Cell Science 121, 634–643. 
 
[86] Itano, M. S.; Neumann, A. K.; Liu, P.; Zhang, F.; Gratton, E.; Parak, W. J.; Thompson, N. L. & 
Jacobson, K. (2011) DC-SIGN and influenza hemagglutinin dynamics in plasma membrane 
microdomains are markedly di!erent. Biophysical Journal  100, 2662–2670. 
 
[87] Itano, M. S.; Steinhauer, C.; Schmied, J. J.; Forthmann, C.; Liu, P.; Neumann, A. K.; Thompson, N. L.; 
Tinnefeld, P. & Jacobson, K. (2012) Super-resolution imaging of C-type lectin and influenza 
hemagglutinin nanodomains on plasma membranes using blink microscopy. Biophysical Journal  102, 
1534–1542. 
 
[88] Liu, P.; Wang, X.; Itano, M. S.; Neumann, A. K.; Jacobson, K. & Thompson, N. L. (2012) The 
formation and stability of DC-SIGN microdomains require its extracellular moiety. Tra!c 13, 715-
726. 
Bibliography 
350 
!
!
 
 
[89] Gringhuis, S. I.; den Dunnen, J.; Litjens, M.; van der Vlist, M. & Geijtenbeek, T. B. H. (2009) 
Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium 
tuberculosis, HIV-1 and Helicobacter pylori. Nature Immunology  10, 1081–1088. 
 
[90] Cambi, A.; Koopman, M. & Figdor, C. G. (2005) How C-type lectins detect pathogens. Cellular 
microbiology 7, 481–488. 
 
[91] Bogoevska, V.; Nollau, P.; Lucka, L.; Grunow, D.; Klampe, B.; Uotila, L. M.; Samsen, A.; Gahmberg, 
C. G. & Wagener, C. (2007) DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes 
through Lewis X residues. Glycobiology  17, 324–333. 
 
[92] Geijtenbeek, T. B.; Krooshoop, D. J.; Bleijs, D. A.; van Vliet, S. J.; van Duijnhoven, G. C.; Grabovsky, 
V.; Alon, R.; Figdor, C. G. & van Kooyk, Y. (2000) DC-SIGN-ICAM-2 interaction mediates dendritic 
cell tra!cking. Nature Immunology  1, 353–357. 
 
[93] García-Vallejo, J. J.; van Liempt, E.; da Costa Martins, P.; Beckers, C.; van het Hof, B.; 
Gringhuis, S. I.; Zwaginga, J.-J.; van Dijk, W.; Geijtenbeek, T. B. H.; van Kooyk, Y. & van Die, 
I. (2008) DC-SIGN mediates adhesion and rolling of dendritic cells on primary human umbilical vein 
endothelial cells through LewisY antigen expressed on ICAM-2. Molecular Immunology  45, 2359–2369. 
 
[94] van Gisbergen, K. P. J. M.; Sanchez-Hernandez, M.; Geijtenbeek, T. B. H. & van Kooyk, Y. 
(2005) Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent 
interactions between MAC-1 and DC-SIGN. Journal of Experimental Medicine  201, 1281–1292. 
 
[95] van Gisbergen, K. P. J. M.; Ludwig, I. S.; Geijtenbeek, T. B. H. & van Kooyk, Y. (2005) 
Interactions of DC-SIGN with MAC-1 and CEACAM1 regulate contact between dendritic cells and 
neutrophils. FEBS Letters  579, 6159–6168. 
 
[96] van Gisbergen, K. P. J. M.; Aarnoudse, C. A.; Meijer, G. A.; Geijtenbeek, T. B. H. & van Kooyk, 
Y. (2005) Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on 
colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin. Cancer Research  65, 5935–5944. 
 
[97] Sabatte, J.; Faigle, W.; Ceballos, A.; Morelle, W.; Rodrígues, C. R.; Lenicov, F. R.; Thépaut, M.; Fieschi, 
F.; Malchiodi, E.; Fernández, M.; Arenzana-Seisdedos, F.; Lortat-Jacob, H.; Michalski, J.-C.; Ge"ner, J. 
& Amigorena, S. (2011) Semen clusterin is a novel DC-SIGN ligand. Journal of Immunology 187, 
5299–5309. 
 
[98] Pöhlmann, S.; Baribaud, F. & Doms, R. W. (2001) DC-SIGN and DC-SIGNR: helping hands for 
HIV. Trends in Immunology  22, 643–646. 
 
[99] Ludwig, I. S.; Geijtenbeek, T. B. H. & van Kooyk, Y. (2006) Two way communication between 
neutrophils and dendritic cells. Current Opinion in Pharmacology  6, 408–413. 
 
[100] Engering, A.; Geijtenbeek, T. B. H.; van Vliet, S. J.; Wijers, M.; van Liempt, E.; Demaurex, N.; 
Lanzavecchia, A.; Fransen, J.; Figdor, C. G.; Piguet, V. & van Kooyk, Y. (2002) The dendritic 
cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. Journal of 
Immunology  168, 2118–2126. 
Bibliography 
351 
!
!
 
 
[101] van Kooyk, Y. & Geijtenbeek, T. B. H.  (2003) DC-SIGN: escape mechanism for pathogens. Nature 
Reviews Immunology 3, 697–709. 
 
[102] Cambi, A.; Beeren, I.; Joosten, B.; Fransen, J. A. & Figdor, C. G. (2009) The C-type lectin DC-
SIGN internalizes soluble antigens and HIV-1 virions via a clathrin-dependent mechanism. Journal of 
Immunology  39, 1923–1928. 
 
[103] Tacken, P. J.; Ginter, W.; Berod, L.; Cruz, L. J.; Joosten, B.; Sparwasser, T.; Figdor, C. G. & Cambi, 
A. (2011) Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early 
endosomes, delayed lysosomal degradation and cross-presentation. Blood 118, 4111-4119. 
 
[104] Engering, A.; Geijtenbeek, T. B. H. & van Kooyk, Y. (2002) Immune escape through C-type lectins on 
dendritic cells. Trends in Immunology 23, 480–485. 
 
[105] Valladeau, J.; Ravel, O.; Dezutter-Dambuyant, C.; Moore, K.; Kleijmeer, M.; Liu, Y.; Duvert- 
Frances, V.; Vincent, C.; Schmitt, D.; Davoust, J.; Caux, C.; Lebecque, S. & Saeland, S. (2000) 
Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the 
formation of Birbeck granules. Immunity 12, 71–81. 
 
[106] Romani, N.; Clausen, B. E. & Stoitzner, P. (2010) Langerhans cells and more: langerin-expressing 
dendritic cell subsets in the skin. Immunological Reviews  234, 120–141. 
 
[107] Idoyaga, J.; Suda, N.; Suda, K.; Park, C. G. & Steinman, R. M. (2009) Antibody to lan- 
gerin/CD207 localizes large numbers of CD8"+ dendritic cells to the marginal zone of mouse spleen. 
PNAS  106, 1524–1529. 
 
[108] Hunger, R. E.; Sieling, P. A.; Ochoa, M. T.; Sugaya, M.; Burdick, A. E.; Rea, T. H.; Brennan, P. J.; 
Belisle, J. T.; Blauvelt, A.; Porcelli, S. A. & Modlin, R. L. (2004) Langerhans cells utilize CD1a and 
langerin to e!ciently present nonpeptide antigens to T cells. Journal of Clinical Investigation 113, 
701–708. 
 
[109] Girolomoni, G.; Caux, C.; Lebecque, S.; Dezutter-Dambuyant, C. & Ricciardi-Castagnoli, P. (2002) 
Langerhans cells: still a fundamental paradigm for studying the immunobiology of dendritic cells. 
Trends in Immunology 23, 6–8. 
 
[110] Cunningham, A. L.; Carbone, F. & Geijtenbeek, T. B. H. (2008) Langerhans cells and viral 
immunity. European Journal of Immunology  38, 2377–2385. 
 
[111] Stambach, N. S. & Taylor, M. E. (2003) Characterization of carbohydrate recognition by langerin, a 
C-type lectin of Langerhans cells. Glycobiology  13, 401–410. 
 
[112] Thépaut, M.; Valladeau, J.; Nurisso, A.; Kahn, R.; Arnou, B.; Vivès, C.; Saeland, S.; Ebel, C.; 
Monnier, C.; Dezutter-Dambuyant, C.; Imberty, A. & Fieschi, F. (2009) Structural studies of 
langerin and Birbeck granule: a macromolecular organization model. Biochemistry 48, 2684–2698. 
 
[113] Feinberg, H.; Powlesland, A. S.; Taylor, M. E. & Weis, W. I. (2010) Trimeric structure of 
langerin. Journal of Biological Chemistry 285, 13285–13293. 
Bibliography 
352 
!
!
 
 
[114] Tateno, H.; Ohnishi, K.; Yabe, R.; Hayatsu, N.; Sato, T.; Takeya, M.; Narimatsu, H. & Hirabayashi, 
J. (2010) Dual specificity of langerin to sulfated and mannosylated glycans via a single C-type 
carbohydrate recognition domain. Journal of Biological Chemistry 285, 6390–6400. 
 
[115] Feinberg, H.; Taylor, M. E.; Razi, N.; Mcbride, R.; Knirel, Y. A.; Graham, S. A.; Drickamer, K. & 
Weis, W. I. (2011) Structural basis for langerin recognition of diverse pathogen and mammalian 
glycans through a single binding site. Journal of Molecular Biology 405, 1027– 1039. 
 
[116] Ward, E. M.; Stambach, N. S.; Drickamer, K. & Taylor, M. E. (2006) Polymorphisms in human langerin 
a!ect stability and sugar binding activity. Journal of Biological Chemistry 281, 15450–15456. 
 
[117] Drickamer, K. (1999) C-type lectin-like domains. Current Opinion in Structural Biology 9, 585–590. 
 
[118]  UNAIDS. (2011) UNAIDS world AIDS day report 2011. 1–52. 
 
[119] Hester, E. K. (2012) HIV medications: an update and review of metabolic complications. Nutrition in 
Clinical Practice 27, 51–64. 
 
[120] Subbaraman, R.; Chaguturu, S. K.; Mayer, K. H.; Flanigan, T. P. & Kumarasamy, N. (2007) Adverse 
e!ects of highly active antiretroviral therapy in developing countries. Clinical Infectious Diseases 45, 1093–
1101. 
 
[121] d’Arminio Monforte, A.; Lepri, A. C.; Rezza, G.; Pezzotti, P.; Antinori, A.; Phillips, A. N.; 
Angarano, G.; Colangeli, V.; Luca, A. D.; Ippolito, G.; Caggese, L.; Soscia, F.; Filice, G.; Gritti, F.; 
Narciso, P.; Tirelli, U. & Moroni, M. (2000) Insights into the reasons for discontinuation of the first 
highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. 
I.CO.N.A. study group. Italian cohort of antiretroviral-naïve patients. AIDS (London, England) 14, 
499–507. 
 
[122] Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; 
Namwat, C.; de Souza, M.; Adams, E.; Benenson, M.; Gurunathan, S.; Tartaglia, J.; McNeil, J. G.; Francis, 
D. P.; Stablein, D.; Birx, D. L.; Chunsuttiwat, S.; Khamboonruang, C.; Thongcharoen, P.; Robb, M. 
L.; Michael, N. L.; Kunasol, P. & Kim, J. H. (2009) Vaccination with ALVAC and AIDSVAX to 
prevent HIV-1 infection in Thailand. New England Journal of Medicine 361, 2209–2220. 
 
[123] Moscicki, A. B. (2008) Vaginal microbicides: where are we and where are we going? Journal of Infection 
and Chemotherapy 14, 337–341. 
 
[124] Stein, Z. A. (1990) HIV prevention:  the  need  for  methods  women  can  use.  American  Journal  of Public  
            Health  80, 460–462. 
 
[125] Cutler, B. & Justman, J. (2008) Vaginal microbicides and the prevention of HIV transmission. The 
Lancet Infectious Diseases 8, 685–697. 
 
[126] Mâsse, B. R.; Boily, M.-C.; Dimitrov, D. & Desai, K. (2009) E"cacy dilution in randomized 
placebo-controlled vaginal microbicide trials. Emerging Themes in Epidemiology 6, doi:10.1186/1742-
7622-6-5. 
Bibliography 
353 
!
!
 
 
[127] Huskens, D. & Schols, D. (2012) Algal lectins as potential HIV microbicide candidates. Marine Drugs 10, 
1476–1497. 
 
[128] Reina, J. J.; Bernardi, A.; Clerici, M. & Rojo, J. (2010) HIV microbicides: state-of-the-art and new 
perspectives on the development of entry inhibitors. Future Medicinal Chemistry 2, 1141–1159. 
 
[129] Obiero, J.; Mwethera, P. G. & Wiysonge, C. S. (2012) Topical microbicides for prevention of sexually 
transmitted infections. Cochrane Database of Systematic Reviews 6, doi: 10.1002/14651858.CD007961.pub2. 
 
[130] Karim, Q. A.; Karim, S. S. A.; Frohlich, J. A.; Grobler, A. C.; Baxter, C.; Mansoor, L. E.; 
Kharsany, A. B. M.; Sibeko, S.; Mlisana, K. P.; Omar, Z.; Gengiah, T. N.; Maarschalk, S.; 
Arulappan, N.; Mlotshwa, M.; Morris, L. & Taylor, D. (2010) E!ectiveness and safety of Tenofovir 
gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–
1174. 
 
[131]  Kelly, C. G. & Shattock, R. J.  (2011) Specific microbicides in the prevention of HIV infection. Journal 
of Internal Medicine 270, 509–519. 
 
[132] Anderluh, M.; Jug, G.; Svajger, U. & Obermajer, N. (2012) DC-SIGN antagonists, a potential new 
class of anti-infectives. Current Medicinal Chemistry 19, 992–1007. 
 
[133] Ernst, B. & Magnani, J. L. (2009) From carbohydrate leads to glycomimetic drugs. Nature Reviews 
Drug Discovery  8, 661–677. 
 
[134] Magnani, J. L. & Ernst, B. (2009) Glycomimetic drugs–a new source of therapeutic opportunities. 
Discovery Medicine 8, 247–252. 
 
[135] Rojo, J. & Delgado, R. (2004) Glycodendritic structures: promising new antiviral drugs. 
Journal of Antimicrobial Chemotherapy  54, 579–581. 
 
[136] Marradi, M.; García, I. & Penadés, S. (2011) Carbohydrate-based nanoparticles for potential 
applications in medicine. Progress in Molecular Biology and Translational Science  104, 141–173. 
 
[137] Nierengarten, J.-F.; Iehl, J.; Oerthel, V.; Holler, M.; Illescas, B. M.; Muñoz, A.; Martín, N.; Rojo, J.; 
Sánchez-Navarro, M.; Cecioni, S.; Vidal, S.; Bu!et, K.; Durka, M. & Vincent, S. P. (2010) Fullerene 
sugar balls. Chemical Communications  46, 3860–3862.  
 
[138] Gómez-García, M.; Benito, J. M.; Butera, A. P.; Mellet, C. O.; Fernández, J. M. G. & Blanco, J. L. J. 
(2012) Probing carbohydrate-lectin recognition in heterogeneous environments with monodisperse 
cyclodextrin-based glycoclusters. Journal of  Organic Chemistry  77, 1273–1288. 
 
[139] André, S.; Sansone, F.; Kaltner, H.; Casnati, A.; Kopitz, J.; Gabius, H.-J. & Ungaro, R. (2008) 
Calix[n]arene-based glycoclusters: bioactivity of thiourea-linked galactose/lactose moieties as inhibitors of 
binding of medically relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity 
among human adhesion/growth-regulatory galectins. ChemBioChem  9, 1649–1661. 
 
[140] Bossu, I.; Šulc, M.; Křenek, K.; Dufour, E.; Garcia, J.; Berthet, N.; Dumy, P.; Křen, V. & Renaudet, O. 
(2011) Dendri-rafts: a second generation of cyclopeptide-based glycoclusters. Organic & Biomolecular 
Chemistry 9, 1948–1959. 
Bibliography 
354 
!
!
 
 
[141] Blanco, J. L. J.; Mellet, C. O. & Fernández, J. M. G. (2013) Multivalency in heterogeneous 
glycoenvironments: hetero-glycoclusters, -glycopolymers and -glycoassemblies. Chemical Society Reviews, doi: 
10.1039/C2CS35219B. 
 
[142]  Mitchell, D. A.; Jones, N. A.; Hunter, S. J.; Cook, J.; Jenkinson, S. F.; Wormald, M. R.; Dwek, R. A. 
& Fleet, G. W. J. (2007) Synthesis of 2-C-branched derivatives of D-mannose: 2-C- aminomethyl-D-
mannose binds to the human C-type lectin DC-SIGN with a!nity greater than an order of 
magnitude compared to that of D-mannose. Tetrahedron: Asymmetry 18, 1502– 1510. 
 
[143] Reina, J. J.; Sattin, S.; Invernizzi, D.; Mari, S.; Martínez-Prats, L.; Tabarani, G.; Fieschi, F.; 
Delgado, R.; Nieto, P. M.; Rojo, J. & Bernardi, A. (2007) 1,2-mannobioside mimic: synthesis, DC-
SIGN interaction by NMR and docking, and antiviral activity. ChemMedChem 2, 1030–1036. 
 
[144] Obermajer, N.; Sattin, S.; Colombo, C.; Bruno, M.; Svajger, U.; Anderluh, M. & Bernardi, A.  
(2010) Design, synthesis and activity evaluation of mannose-based DC-SIGN antagonists. Molecular 
diversity 15, 347-360. 
 
[145] Timpano, G.; Tabarani, G.; Anderluh, M.; Invernizzi, D.; Vasile, F.; Potenza, D.; Nieto, P. M.; Rojo, 
J.; Fieschi, F. & Bernardi, A. (2008) Synthesis of novel DC-SIGN ligands with an "-fucosylamide 
anchor. ChemBioChem 9, 1921–1930. 
 
[146] Garber, K. C. A.; Wangkanont, K.; Carlson, E. E. & Kiessling, L. L. (2010) A general gly- 
comimetic strategy yields non-carbohydrate inhibitors of DC-SIGN. Chemical Communications 46, 6747–
6749. 
 
[147] Prost, L. R.; Grim, J. C.; Tonelli, M. & Kiessling, L. L. (2012) Noncarbohydrate glycomimetics and 
glycoprotein surrogates as DC-SIGN antagonists and agonists. ACS Chemical Biology 7, 1603–1608. 
 
[148] Borrok, M. J. & Kiessling, L. L. (2007) Non-carbohydrate inhibitors of the lectin DC-SIGN. 
Journal of the American Chemical Society 129, 12780–12785. 
 
[149] Mangold, S. L.; Prost, L. R. & Kiessling, L. L. (2012) Quinoxalinone inhibitors of the lectin DC-
SIGN. Chemical Science 3, 772–777. 
 
[150] Scanlan, C. N.; O"er, J.; Zitzmann, N. & Dwek, R. A. (2007) Exploiting the defensive sugars of HIV-1 
for drug and vaccine design. Nature  446, 1038–1045. 
 
[151] Martínez-Avila, O.; Hijazi, K.; Marradi, M.; Clavel, C.; Campion, C.; Kelly, C. & Penadés, S. (2009) 
Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-
SIGN. Chemistry 15, 9874–9888. 
 
[152] Gianvincenzo, P. D.; Chiodo, F.; Marradi, M. & Penadés, S. (2012) Gold manno- glyconanoparticles for 
intervening in HIV gp120 carbohydrate-mediated processes. Methods in Enzymology 509, 21–40. 
 
[153] Arnáiz, B.; Martínez-Ávila, O.; Falcon-Perez, J. M. & Penadés, S. (2012) Cellular uptake of gold 
nanoparticles bearing HIV gp120 oligomannosides. Bioconjugate Chemistry 23, 814-825. 
Bibliography 
355 
!
!
 
 
[154] Martínez-Avila, O.; Bedoya, L. M.; Marradi, M.; Clavel, C.; Alcamí, J. & Penadés, S. (2009) 
Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T 
cells. ChemBioChem 10, 1806–1809. 
 
[155] Wang, S.-K.; Liang, P.-H.; Astronomo, R. D.; Hsu, T.-L.; Hsieh, S.-L.; Burton, D. R. & Wong, C.-
H. (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human 
monoclonal antibody 2G12 and DC-SIGN. PNAS 105, 3690–3695. 
 
[156] Becer, C. R.; Gibson, M. I.; Geng, J.; Ilyas, R.; Wallis, R.; Mitchell, D. A. & Haddleton, D. M. 
(2010) High-a!nity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN in- 
teractions with HIV envelope glycoprotein. Journal of the American Chemical Society 132, 15130–
15132. 
 
[157] Lasala, F.; Arce, E.; Otero, J. R.; Rojo, J. & Delgado, R. (2003) Mannosyl glycodendritic structure 
inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans. Antimicrobial Agents and Chemotherapy 
47, 3970–3972. 
 
[158] Tabarani, G.; Reina, J. J.; Ebel, C.; Vivès, C.; Lortat-Jacob, H.; Rojo, J. & Fieschi, F. (2006) Mannose 
hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 
binding. FEBS Letters 580, 2402–2408. 
 
[159] Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680–685. 
 
[160] Powlesland, A. S.; Fisch, T.; Taylor, M. E.; Smith, D. F.; Tissot, B.; Dell, A.; Pöhlmann, S. & 
Drickamer, K. (2008) A novel mechanism for LSECtin binding to Ebola virus surface glycoprotein through 
truncated glycans. Journal of Biological Chemistry 283, 593–602. 
 
[161] Dominguez-Soto, A.; Aragoneses-Fenoll, L.; Martin-Gayo, E.; Martinez-Prats, L.; Colmenares, M.; 
Naranjo-Gomez, M.; Borras, F. E.; Munoz, P.; Zubiaur, M.; Toribio, M. L.; Delgado, R. & Corbi, 
A. L. (2007) The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by 
human myeloid cells. Blood 109, 5337–5345. 
 
[162] Domínguez-Soto, A.; Aragoneses-Fenoll, L.; Gómez-Aguado, F.; Corcuera, M. T.; Clária, J.; García-
Monzón, C.; Bustos, M. & Corbí, A. L. (2009) The pathogen receptor liver and lymph node sinusoidal 
endotelial cell C-type lectin is expressed in human Kup"er cells and regulated by PU.1. Hepatology 49, 
287–296. 
 
[163] Gramberg, T.; Hofmann, H.; Möller, P.; Lalor, P. F.; Marzi, A.; Geier, M.; Krumbiegel, M.; 
Winkler, T.; Kirchho", F.; Adams, D. H.; Becker, S.; Münch, J. & Pöhlmann, S. (2005) LSECtin 
interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 340, 224–236. 
 
[164] Gramberg, T.; Soilleux, E.; Fisch, T.; Lalor, P. F.; Hofmann, H.; Wheeldon, S.; Cotterill, A.; 
Wegele, A.; Winkler, T.; Adams, D. H. & Pöhlmann, S. (2008) Interactions of LSECtin and DC-
SIGN/DC-SIGNR with viral ligands: Di"erential pH dependence, internalization and virion 
binding. Virology 373, 189–201. 
Bibliography 
356 
!
!
 
 
[165] Suzuki, N.; Yamamoto, K.; Toyoshima, S.; Osawa, T. & Irimura, T. (1996) Molecular cloning and 
expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding 
specificity for Tn antigen. Journal of Immunology 156, 128–135. 
 
[166] Denda-Nagai, K.; Aida, S.; Saba, K.; Suzuki, K.; Moriyama, S.; Oo-Puthinan, S.; Tsuiji, M.; 
Morikawa, A.; Kumamoto, Y.; Sugiura, D.; Kudo, A.; Akimoto, Y.; Kawakami, H.; Bovin, N. V. & 
Irimura, T. (2010) Distribution and function of macrophage galactose-type C-type lectin 2 
(MGL2/CD301b): e!cient uptake and presentation of glycosylated antigens by dendritic cells. Journal of 
Biological Chemistry 285, 19193–19204. 
 
[167] Iida, S.; Yamamoto, K. & Irimura, T. (1999) Interaction of human macrophage C-type lectin with O-
linked N-acetylgalactosamine residues on mucin glycopeptides. Journal of Biological Chemistry 274, 
10697–10705. 
 
[168] van Vliet, S. J.; van Liempt, E.; Saeland, E.; Aarnoudse, C. A.; Appelmelk, B.; Irimura, T.; 
Geijtenbeek, T. B. H.; Blixt, O.; Alvarez, R.; van Die, I. & van Kooyk, Y. (2005) Carbohydrate 
profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth 
parasites and tumor antigens by dendritic cells. International Immunology 17, 661–669. 
 
[169] Takada, A.; Fujioka, K.; Tsuiji, M.; Morikawa, A.; Higashi, N.; Ebihara, H.; Kobasa, D.; Feldmann, H.; 
Irimura, T. & Kawaoka, Y. (2004) Human macrophage C-type lectin specific for galactose and N-
acetylgalactosamine promotes filovirus entry. Journal of Virology 78, 2943–2947. 
 
[170] Upham, J. P.; Pickett, D.; Irimura, T.; Anders, E. M. & Reading, P. C. (2010) Macrophage receptors 
for influenza a virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry. 
Journal of Virology 84, 3730–3737. 
 
[171] Mayer, M. & Meyer, B. (1999) Characterization of ligand binding by saturation transfer di"erence 
NMR spectroscopy. Angewandte Chemie International Edition 38, 1784–1788. 
 
[172] Angulo, J. & Nieto, P. M. (2011) STD-NMR: application to transient interactions between 
biomolecules-a quantitative approach. European Biophysoical Journal  40, 1357–1369. 
 
[173] Kolb, H. C.; Finn, M. G. & Sharpless, K. B. (2001) Click chemistry: Diverse chemical function from a 
few good reactions. Angewandte Chemie International Edition 40, 2004–2021. 
 
[174] Rostovtsev, V. V.; Green, L. G.; Fokin, V. V. & Sharpless, K. B. (2002) A stepwise huisgen 
cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. 
Angewandte Chemie International Edition 41, 2596–2599. 
 
[175] Tornøe, C. W.; Christensen, C. & Meldal, M. (2002) Peptidotriazoles on solid phase: [1,2,3]- triazoles by 
regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. Journal of 
Organic Chemistry 67, 3057–3064. 
 
[176] Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, K. B. & Fokin, V. V. 
(2005) Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and 
intermediates. . Journal of the American Chemical Society 127, 210–216. 
Bibliography 
357 
!
!
 
[177] Kortt, A. A.; Gruen, L. C. & Oddie, G. W. (1997) Influence of mass transfer and surface ligand 
heterogeneity on quantitative biacore binding data. Analysis of the interaction of NC10 Fab with an 
anti-idiotype Fab’. Journal of Molecular Recognition 10, 148–158. 

Part VI.
Appendices
359

13. Supplementary information to paper no1
361
CHAPTER 13. SUPPLEMENTARY INFORMATION TO PAPER NO1
362
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1
,
!"
#$
%&
'(
"%
")
*+
,$
%'
$-
'.
/#
$0
"1
2*
0"
&'
'3
4
1!
56
7
'8,
(*
%&
0'9
'*
--
,%
,+:
',;
<)
$=
";
"%
+'*
%&
'
0<
"#
,-,
#,
+:
'!
"#
$%
$'>
*%
("
),
%'
2
)'
"%
$,3
'4
*%
0'
05)
6,7
8,9
)'
0%
$)
,9
/:
'0
;5
)6
,7
8,-
%<
),
!"
(:
%<
0;
0"
(%
5=
68,
5%
6,7
8,>
/?
@,
>A,
B
%0
')
5)
6 8,
>)
'C
0'
,9
")
'5
;6
8,D
*0;
,
E
F)
=*
/$
5=
68,
5%
6 8,
,2
0;
F%
$,G
F%
#)
"(
5=
68,
5%
68,
5.
6 8,
D$
0?
)=
%(
()
,2
/*
/'
05)
6 8,
H)
=0
/,
9
/*
/5
)6
8,I
)"
*)
,J
%$
<0
?0
5)
6 8,
>/
%*
K,
L
%0
?%
*5;
6 8,
>)
<0
%*
,B
/M
/5
46
8,H
*)
';
:,
H0
%?
;F
0N
5=
68,
5%
68,
5K
6 8,
3
''
),
J
%*
')
*4
0N
5)
6 ,
7,
(F
%?
%,
)"
(F
/*
?8,
$0?
(%
4,
0'
,)
$#
F)
=%
(0;
)$
,/
*4
%*
8,;
/'
(*0
="
(%
4,
%O
")
$$+
,(/
,(F
0?
,P
/*
: !
"#
!$
%&
'(
)*
&+"
,!-
(.
/&!
0+
1-
&!-
&!2
&/"
%3
4!!
5
&6
")
+&7
(%
+3
!-
&!8
9&
7
&:
"!
;
).
"%
&:
"!
(!
<%
-1
*+
)&
"/
(!
"%
-!
8
<0
<4!
!'
&"
!
=(
%(
>&
"%
!?
@4
!?
A@
BB
!2
&/"
%3
4!<
+"
/C
4!!
"%
%"
DE
()
%"
)-
&F
1%
&7
&D&
+!
E#
!<%
*+
&+1
+!-
(!
G&
3/
3.
&(
!0
+)1
:+
1)
"/
(4
!$
%&
'(
)*
&+H
!I
)(
%3
E/
(!
<4!
J@
!)1
(!
K1
/(
*!L
3)
3M
&+>
4!B
NA
?O
!I
)(
%3
E/
(4
!
P)
"%
:(
4!Q
&(
*:
9&
F
&E
*DQ
)!
:#
!R
%+
()
&3
!:
3%
*1
/+S
)(
*(
")
:9
4!R
1.
1*
+"
"%
/"
.(
!?
B4
!5
TU
N@
UV
!2
"%
%9
(&
7
4!I
()
7
"%
C!
-#
!I
/C
:3
*C
*+
(7
*!W
"E
3)
"+
3)
C4
!!<
%*
+&+
1+
3!
-(
!<%
'(
*+
&.
":
&3
%(
*!X
1Y
7
&:
"*
4!8
0<
8
!Z
!$
%&
'(
)*
&-
"-
!-
(!
0(
'&
//"
4!!
R7
H)
&:
3!
=(
*6
1:
&3
!J
[4
!J
@A
[?
!0
('
&//
"!
\0
6"
&%
#!
(#
!8
]
^0
4!$
2
^!
VA
OV
4!I
)(
%3
E/
(4
!P
)"
%:
(!
Q#!
8
_R
4!I
)(
%3
E/
(4
!P
)"
%:
(!
.#
!<%
*+
&+1
+!$
%&
'(
)*
&+"
&)
(!
-(
!P
)"
%:
(4
!@
AB
!E
31
/(
'"
)-
!0
"&
%+
T2
&:
9(
/!O
VA
AV
!`
")
&*
4!P
)"
%:
(!
' ' '
?@
'!
/<
<8
";
"%
+*
):
'5%
-$
);
*+
,$
%'
A'
!:
%+
B"
+,#
'<
)$
#"
&/
)"
0'
'
'
'
'
'
<'
'?
'1'
CD
'
E@
'!
/<
<8
";
"%
+*
):
'5%
-$
);
*+
,$
%'
A'
!/
)-
*#
"'
F8
*0
;
$%
'G
"0
$%
*%
#"
'H
I<
")
,;
"%
+0
'
'
<'
C?
'1'
CJ
'
'
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Q
?@
'!
/<
<8
";
"%
+*
):
'5%
-$
);
*+
,$
%'
A'
!:
%+
B"
+,#
'<
)$
#"
&/
)"
0,
GF
%,
$0=
*)
*0%
?,P
%*
%,
?+
'(
F%
?0
R%
4,
(F
*/
"K
F,
(F
%,
;/
&
&
/'
,)
##
*/
);
F,
?F
/P
',
0'
,!
;F
%&
%,
1A
1 ,
,
,
!5
1!
#B
";
"'
?@
,S
%'
%*
)$
,)
##
*/
);
F,
./
*,(
F%
,?+
'(
F%
?0
?,/
.,(
F%
,$0
K)
'4
?,
, , 9
%!
F/
'K
,*
%)
;(
0/
'Q
,/
.,
(*0
T;
T)
;%
(+
$T.
";
/?
+$
)R
04
%,
K'
P
0(F
,(F
%,
)#
#*
/#
*0)
(%
,]
TE
=R
T#
*/
(%
;(
%4
,E
T)
&
0'
/)
;0
4,
UL
8,
?C
1?
J8
,)
'4
,]
TE
=R
T3
$)
V,+
0%
$4
%4
,D
T]
T.
";
/?
+$
)&
04
%?
A,3
.(%
*,E
=R
,*%
&
/<
)$
8,(
F%
,.*
%%
,)
&
0'
%?
,P
%*
%,
;/
"#
$%
4,
P
0(F
,
(F
%,
);
04
,#
)*
('
%*
?,
UB
E
W
QX
V,P
0(F
/"
(,#
*%
<0
/"
?,
#"
*0.
0;
)(
0/
'A
,G
F%
,?
+'
(F
%?
0?
,/
.,
,C
*8
1,
U(F
*/
"K
F,
0'
(%
*&
%4
0)
(%
?,
L,
)'
4,
J,
V,,
)'
4,
M*
Y 'U
(F
*/
"K
F,
EL
V,F
)<
%,
=%
%'
,*%
#/
*(%
4,
%$
?%
P
F%
*%
@'
' !:
%+
B"
0,
0'*
%&
'*
#+
,=
*+
,$
%'
$-
'+B
"'
E1
*;
,%
$*
#,
&0
@,
E
)*
=/
=%
'R
+$
/C
+T
ET
)$
)'
0'
%,
0?
,;
/&
&
%*
;0
)$
$+
,)
<)
0$)
=$
%A
,G
F%
,?
+'
(F
%?
0?
,/
.,
U1
08
Q^
VT
!]
TE
)*
=/
=%
'R
+$
/C
+T
QT
)&
0'
/T
;+
;$
/F
%C
)'
%;
)*
=/
C+
$0;
,
);
04
,
L,
F)
?,
=%
%'
,
4%
?;
*0=
%4
A1,
GF
%,
?+
'(
F%
?0
?,
/.
,
(F
%,
0?
/&
%*
0;
,
]
T
;)
*=
/=
%'
R+
$/
C+
TQ
T)
&
0'
/T
;+
;$
/F
%C
)'
%;
)*
=/
C+
$0;
,)
;0
4?
,?
C1
?J
,P
)?
,#
%*
./
*&
%4
,)
?,
?F
/P
',
0'
,!
;F
%&
%,
Q8
,
?(
)*
(0'
K,
.*
/&
,(
F%
,:
&*
,&
/'
/)
;0
4?
,?
K,
)'
4,
EE
@Z,
GF
%+
,P
%*
%,
%0
(F
%*
,(
*)
'?
./
*&
%4
,4
0*%
;(
$+
,0
'(
/,
(F
%,
:&
*,
]
TE
=R
T
#*
/(
%;
(%
4,
ET
)&
0'
/)
;0
4?
,?
C,
)'
4,
L8
,*
%?
#%
;(
0<
%$
+8
,"
?0
'K
,)
,E
"*
(0"
?,
*%
)*
*)
'K
%&
%'
(,
./
$$/
P
%4
,=
+,
I0
W
X
,
F+
4*
/$
+?
0?
8,/
*,P
%*
%,
(*)
'?
./
*&
%4
,0'
,(F
%,
+)
"%
*!0
?/
&
%*
?,
?M
,)
'4
,E
C,
=+
,=
)?
%T
#*
/&
/(
%4
,%
O"
0$0
=*
)(
0/
'Z
= ,U
!;
F%
&
%,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Y
QV
A,
E
"*
(0"
?,
*%
)*
*)
'K
%&
%'
(,
/.
,(
F%
,+
)"
%*
!&
/'
/)
;0
4?
,?
M,
)'
4,
EC
,)
..
/*
4%
4,
(F
%,
;/
**
%?
#/
'4
0'
K,
+)"
%*
,]
TE
=R
T
#*
/(
%;
(%
4,
ET
)&
0'
/)
;0
4?
,?
N,
)'
4,
?J
,)
.(%
*,I
0W
X
,F
+4
*/
$+
?0
?,/
.,%
?(
%*
?,E
D,
)'
4,
EN
@,
' ' !5
1!
#B
";
"'
E@
,!
+'
(F
%?
0?
,/
.,(
F%
,E
T)
&
0'
/)
;0
4?
,L
O'?
C1
?J
,)
'4
,)
;(
0<
)(
0/
',
)?
,#
+*
04
+$
,(F
0/
$%
?(
%*
?,
, , 3
$$,
E
=R
T#
*/
(%
;(
%4
,)
&
0'
/)
;0
4?
8,
0'
;$
"4
0'
K,
;/
&
&
%*
;0
)$
$+
,)
<)
0$)
=$
%,
E
=R
TE
T3
$)
8,
P
%*
%,
);
(0<
)(
%4
,)
?,
#+
*04
+$
,
(F
0/
$%
?(
%*
?,
U?
PO
'E
?O
'E
J'
)'
4,
EK
8,!
;F
%&
%,
Q,
)'
4,
YV
,)
'4
,"
?%
4,
0'
,(F
%,
9
%!
F/
'K
,*
%)
;(
0/
'?
,P
0(F
,K
,U
!;
F%
&
%,
YV
A,,
GF
%,
#+
*04
+$
,(F
0/
$%
?(
%*
?,/
.,E
=R
TE
T3
$)
,E
K,
0?
,)
,:
'/
P
',
;/
&
#/
"'
4A
[ ,,
M
eO
2C
H
O
2C
16
M
eO
2C
C
bz
H
N
H
O
2C
C
bz
H
N
P
yS
O
C
C
bz
H
N
17
13
18
28
10
a-
d
b
c
d
M
eO
2C
H
O
2C
a
+
16
19
5
:
1
b,
e
M
eO
2C
C
bz
H
N
H
O
2C
C
bz
H
N
Py
S
O
C
C
bz
H
N
14
21
29
11
a-
c
c
d
20
a)
tA
m
O
K
,T
H
F;
b)
C
ur
tiu
s
re
ar
ra
ng
em
en
t;
c)
Li
O
H
;d
)P
h 3
P
,P
yS
S
P
y;
e)
fla
sh
ch
ro
m
at
og
ra
ph
y
M
eO
2C
H
O
2C
22
H
O
2C
C
bz
H
N
7
3a
-v
M
eO
2C
H
O
2C
a
+
22
23
5
:
1
b,
e
M
eO
2C
C
bz
H
N
H
O
2C
C
bz
H
N
Py
S
O
C
C
bz
H
N
15
25
30
12
a
c
d
24
se
e
re
f.
1
C
bz
N
H
C
O
O
H
C
bz
- E
-A
la
C
bz
N
H
C
O
S
P
y
S
P
y
=
N
S
d
26
27
9
a-
h
5
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Z
,
' ' !5
1!
#B
";
"'
CA
,9
%!
F/
'K
,*%
);
(0/
'?
,)
'4
,?+
'(
F%
?0
?,/
.,(
F%
,$0
=*
)*
0%
?,
, ,
GF
0?
,?
(%
#,
#*
/4
";
%4
,(F
%,
."
;/
?+
$)
&
04
%?
,J
81 ,
EL
8Y '
)'
4'
EP
1C
D8
,P
F0
;F
,P
%*
%,
(*)
'?
./
*&
%4
,0'
,(F
%,
.0'
)$
,$0
K)
'4
?,
).
(%
*,
E
=R
,*%
&
/<
)$
,UX
Q\]
4V
,)
'4
,;
/"
#$
0'
K,
P
0(F
,(F
%,
);
04
,#
)*
('
%*
A,,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
[
,
H
I<
")
,;
"%
+*
8'
!/
$<
%'
(?
,P
%*
%,
4*
0%
4,
=+
,?
()
'4
)*
4,
#*
/;
%4
"*
%?
^,4
0;
F$
/*
/&
%(
F)
'%
8,&
%(
F)
'/
$8,
]8
]T
40
0?
/#
*/
#+
$%
(F
+$
)&
0'
%,
)'
4,
(*0
%(
F+
$)
&
0'
%,
P
%*
%,
4*
0%
4,
/<
%*
,;
)$
;0
"&
,F
+4
*04
%8
,;
F$
/*
/.
/*
&
,)
'4
,#
+*
04
0'
%,
P
%*
%,
4*
0%
4,
/<
%*
,)
;(
0<
)(
%4
,
&
/$
%;
"$
)*
,?
0%
<%
?A,
B
%)
;(
0/
'?
,*
%O
"0
*0'
K,
)'
F+
4*
/"
?,
;/
'4
0(0
/'
?,
P
%*
%,
#%
*.
/*
&
%4
,"
'4
%*
,'
0(*
/K
%'
A,1
X
8,1
Y E
,)
'4
,
Y1
]T
_
2
B
,?
#%
;(
*)
,P
%*
%,
*%
;/
*4
%4
,)
(,Z
``
,2
X
R,
/'
,)
,J
*"
:%
*,3
a
3
_
E
DT
Z`
`,
0'
?(
*"
&
%'
(A,
E
F%
&
0;
)$
,?
F0
.(?
,Uį
#,
./
*,
1 X
,)
'4
,1
Y E
,?
#%
;(
*)
,)
*%
,%
C#
*%
??
%4
,0
',
##
&
,*
%$
)(
0<
%,
(/
,0
'(
%*
')
$,
2
% Z
!0
,)
?,
?(
)'
4)
*4
A,
!0
K'
)$
?,
P
%*
%,
)=
=*
%<
0)
(%
4,
)?
,?8
,?0
'K
$%
(b,
=?
8,=
*/
)4
,?0
'K
$%
(b,
48
,4
/"
=$
%(
b,(
8,(
*0#
$%
(b,
O8
,O
")
*(%
(b,
&
8,&
"$
(0#
$%
(A,
2
)?
?,?
#%
;(
*)
,P
%*
%,
/=
()
0'
%4
,P
0(F
,)
,J
*"
:%
*,
0/
'T
(*)
#,
D?
O"
0*%
,Y
``
`,
)#
#)
*)
("
?,
UD
!-
,0
/'
0R
)(
0/
'V
,/
*,
)'
,3
"(
/?
#%
;,
H0
??
0/
',
-'
?(
*"
&
%'
(,U
H3
J
,0/
'0
R)
(0/
'V
A,G
F0
',
$)
+%
*,
;F
*/
&
)(
/K
*)
#F
+,
UG
IE
V,
P
)?
,;
)*
*0%
4,
/"
(,P
0(F
,#
*%
T;
/)
(%
4,
2
%*
;:
,
H Q
[Z
,?
0$0
;)
,K
%$
,#
$)
(%
?A,
H$
)?
F,
;F
*/
&
)(
/K
*)
#F
+,
UH
E
V,P
)?
,;
)*
*0%
4,
/"
(,P
0(F
,2
);
F%
*%
+T
_
)K
%$
,?
0$0
;)
,K
%$
,c
`,
UQ
Y`
T
Z`
`,
&
%?
FV
A,G
F%
,:
&*
,&
/'
/)
;0
4?
,?
K,
)'
4,
EE
,)
*%
,:
'/
P
',
)'
4,
P
%*
%,
?+
'(
F%
?0
?%
4,
)?
,4
%?
;*
0=
%4
,0'
,(F
%,
$0(
%*
)(
"*
%A
Z,
GF
%,
?+
'(
F%
?0
?,
/.
,C
*,
.*
/&
,E
E,
(F
*/
"K
F,
J,
)'
4,
L,
F)
?,
)$
*%
)4
+,
=%
%'
,*%
#/
*(%
4A
1 ,G
F%
,#
+*
04
+$
,(F
0/
$%
?(
%*
?,
/.
,E
=R
TE
T
3
$)
,E
K[
,)
'4
,(F
%,
;/
**
%?
#/
'4
0'
K,
."
;/
?+
$)
&
04
%,
EL
8Y'
)*
%,
:'
/P
',
;/
&
#/
"'
4?
A, ,
, !:
%+
B"
0,
0'$
-'+
B"
'&#
'(
$';
$%
$*
#,
&0
'?
M'
*%
&'
EC
'
Qd
,&
I,
/.
,]
/(
)?
?0
"&
,+(
)+
T3
&
+$
)(
%,
U1
Ae
2
,0'
,G
/$
"%
'%
V,P
%*
%,
40
$"
(%
4,
0'
,Z
`,
&
I,
/.
,(/
$"
%'
%,
"'
4%
*,_
QA,
GF
%,
?/
$"
(0/
',
P
)?
,
;/
/$
%4
,
(/
,
f1
[,
gE
A,
GF
%'
,
),
?/
$"
(0/
',
/.
,
(F
%,
:&
*,
&
/'
/)
;0
4,
?K
,
U/
*,
EE
V,
UY
A[
,
K8
,,
1d
,&
&
/$
V,0
',
(/
$"
%'
%,
UQ
`,
&
IV
,P
)?
,)
44
%4
,4
*/
#P
0?
%A
,G
F%
,*%
);
(0/
',
&
0C
("
*%
,P
)?
,?
(0*
*%
4,
./
*,Z
,F
/"
*?
,)
(,T
,1
[,
gE
A,
GF
%,
*%
);
(0/
',
P
)?
,O
"%
';
F%
4,
P
0(F
,c
`,
&
I,
X
E
$,U
12
V8,
40
$"
(%
4,
P
0(F
,%
(F
+$
,)
;%
()
(%
,)
'4
,P
)?
F%
4,
P
0(F
,P
)(
%*
A,G
F%
,
/*
K)
'0
;,
#F
)?
%,
P
)?
,4
*0%
4,
/<
%*
,_
) Q
!W
Z,)
'4
,(F
%,
?/
$<
%'
(,P
)?
,%
<)
#/
*)
(%
4,
(/
,)
..
/*
4,
),
&
0C
("
*%
,/
.,#
*/
4"
;(
,?
M,
)'
4,
?K
,U/
*,E
C,
)'
4,
EE
V,)
?,)
,;
/$
/"
*$%
??
,/
0$A
,,
h
0%
$4
,U?
K\
?M
,&
0C
("
*%
V^,
YA
Y,
K,
Ud
Z,
i
V,0
',
),
1^
[,
*)
(0/
A,
h
0%
$4
,UE
E\
EC
,&
0C
("
*%
V^,
QA
d,
K,
Uj
Z,
i
V,0
',
),
1^
Z,
*)
(0/
A,
GF
%,
&
0C
("
*%
?,
?K
\?
M,
U/
*,
EC
\E
EV
,P
%*
%,
"?
%4
,0
',
(F
%,
K%
'%
*)
$,
#*
/;
%4
"*
%,
./
*,
(F
%,
8
1)
+&1
*,
*%
)*
*)
'K
%&
%'
(,
)'
4,
(F
%,
0?
/&
%*
?,P
%*
%,
?%
#)
*)
(%
4,
)(
,(F
)(
,$%
<%
$A,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
c
6
"%
")
*8
'<
)$
#"
&/
)"
'-$
)'
+B
"'
)%
#&*
%$
')
"*
))
*%
("
;
"%
+'A
'!
:%
+B
"0
,0
'$
-'?
LO
'E
D'
*%
&'
EN
'
9
]]
3
,U
1A
`,
&
/$
,%
O"
0<
)$
%'
(V,
)'
4,
D(
Y_
,U
1,
&
/$
,%
O"
0<
)$
%'
(V,
P
%*
%,
)4
4%
4,
(/
,)
,`
AY
,2
,?
/$
"(
0/
',
/.
,(
F%
,)
;0
4,
0'
,
(/
$"
%'
%A
,3
.(%
*,(
F%
,)
44
0(0
/'
,/
.,=
%'
R+
$,)
$;
/F
/$
,U1
Aj
,&
/$
,%
O"
0<
)$
%'
(V,
(F
%,
*%
);
(0/
',
&
0C
("
*%
,P
)?
,*%
.$"
C%
4,
./
*,[
,F
8,
(F
%'
,0(
,P
)?
,4
0$"
(%
4,
P
0(F
,%
(F
+$
,)
;%
()
(%
,)
'4
,%
C(
*)
;(
%4
,P
0(F
,X
E
$,U
[,
i
V8,
?)
("
*)
(%
4,
_
)X
E
W
Y,
?/
$"
(0/
',
)'
4,
=*
0'
%A
,
GF
%,
?/
$<
%'
(,P
)?
,%
<)
#/
*)
(%
4,
)'
4,
(F
%,
]
TE
=R
T#
*/
(%
;(
%4
,E
T)
&
0'
/)
;0
4?
,P
%*
%,
#"
*0.
0%
4,
=+
,.
$)
?F
T;
F*
/&
)(
/K
*)
#F
+,
/*
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
/'
,?0
$0;
),
K%
$,(
/,
K0
<%
,)
,P
F0
(%
,?/
$04
A,
?L
A''
W
=(
)0
'%
4,
.*
/&
'E
"*
(0"
?,*
%)
**
)'
K%
&
%'
(,/
.,?
KZ
')
'4
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U(/
$"
%'
%\
%(
F+
$,)
;%
()
(%
,
1[
^1
V8,
B
.,k
,`
AY
1b
,h
0%
$4
,U?
LV
^,Z
Ae
,K
,Ue
[,
i
V,
? Q
17
R
G
'SN
DD
'R
Q
TO
'4
3
4
8 CU
9,Q
A1
Z,
f,
QA
QQ
,U&
8,1
X
8,X
YV
8,Q
AQ
j,
fQ
AZ
1,
U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
AZ
c,
f,
QA
[Z
,U&
8,1
X
8,
X
cV
8,Q
Ae
d,
f,
QA
jY
,U&
8,1
X
8,X
1V
8,Y
Ac
e,
U?
8,Y
X
8,E
W
W
2
(V
8,Z
AQ
1,
f,
ZA
Qe
,U&
8,1
X
8,X
QV
8,[
A`
[,
f,
[A
`j
,U&
8,Q
X
8,8
L
?]
FV
8,
[A
Yj
,U=
*4
8,1
X
8,_
X
V8,
[A
[c
T[
Ac
e,
U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
j,
f,
eA
Yc
,U&
8,[
X
8,R
)V
A,?
C 4
17
R
G
,S?
DD
'R
Q
TO
'4
3
4
8 CU
9,
Q[
Ae
,UE
cV
8,Y
`A
j,
UE
YV
8,Z
QA
Y,
UE
1V
8,Z
eA
`,
UE
QV
8,[
QA
1,
UE
W
W
2
(V
8,c
cA
d,
U8
L
?]
FV
8,1
QZ
Ad
,UE
Z,
/*
,E
[V
8,1
Q[
AQ
,UE
X
8,E
Z,
/*
,E
[V
8,1
Qj
AY
,UE
X
8,3
*V
8,1
Qj
Ae
,UE
X
8,3
*V
8,1
Yc
Ae
,UE
O"
)*
(A8
,3
*V
A,D
!-
T2
!,
7
a>
,k
,Y
1Q
,5U
2
,l
,_
)V
l 8,
1`
`,
i
6A,
, ED
@''
W
=(
)0
'%
4,
.*
/&
,E
"*
(0"
?,
*%
)*
*)
'K
%&
%'
(,/
.,
),
[^
1,
?M
9?
K'
&
0C
("
*%
,)
'4
'?
%#
)*
)(
%4
,.
*/
&
,(F
%,
:&
*!
0?
/&
%*
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
U(/
$"
%'
%\
%(
F+
$,)
;%
()
(%
,P
0(F
,)
,K
*)
40
%'
(,.
*/
&
,`
,i
,(/
,1
`,
i
,%
(F
+$
,)
;%
()
(%
V8,
B
.,
k,
`A
Y1
,U(
/$
"%
'%
\D
(W
3
;,
1d
^1
VA,
h
0%
$4
,UE
DV
^,1
Ae
,K
,UY
j,
i
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
Ad
Q,
fQ
A`
`,
U&
8,1
X
8,X
YV
8,Q
AQ
Z,
f,
QA
Y1
,U&
8,1
X
8,X
cV
8,Q
AZ
[,
f,
QA
[Q
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
Ac
e,
f,
QA
eY
,U&
8,1
X
8,X
1V
8,Y
Ac
Y,
U?
8,Y
X
8,E
W
W
2
(V
8,Z
A`
Z,
f,
ZA
1Q
,U&
8,1
X
8,X
QV
8,Z
Aj
c,
U=
*?
8,1
X
8,_
X
V8,
[A
`j
,U?
8,
QX
8,8
L
?]
FV
8,[
A[
c,
f,
[A
[d
,U
&
8,1
X
8,X
ZV
8,[
Ac
Q,
f,
[A
cc
,U
&
8,1
X
8,X
[V
8,e
AQ
e,
f,
eA
Y[
,U
&
8,[
X
8,R
)V
A,?
C 4
17
R
G
,S
?D
D'
R
Q
TO
'4
3
4
8 CU
^,Q
cA
j,
UE
cV
8,Y
1A
Y,
UE
YV
8,Z
ZA
c,
UE
1V
8,Z
jA
1,
UE
QV
8,[
QA
1,
UE
W
W
2
(V
8,c
cA
d,
U8
L
?]
FV
8,1
QZ
AY
,UE
ZV
8,1
Q[
AQ
,
UE
[V
8,1
Qj
AY
,U3
*V
8,1
Qj
Ae
,U3
*V
8,1
Qj
Ae
,U3
*V
8,1
Yc
Ae
,UE
O"
)*
(A8
,3
*V
8,1
[[
Ae
,U_
X
E
W
V8,
1e
ZA
1,
UE
W
W
2
%V
A,D
!-
T2
!,
7
a>
,
k,
Y1
Q,
5U
2
,l
,_
)V
l 8,
1`
`,
i
6,
EN
@',
W
=(
)0
'%
4,
.*
/&
,E
"*
(0"
?,*
%)
**
)'
K%
&
%'
(,/
.,)
,[
^1
,E
C9
EE
,&
0C
("
*%
,)
'4
,?%
#)
*)
(%
4,
.*
/&
,(F
%,
:&
*!0
?/
&
%*
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
U(/
$"
%'
%\
%(
F+
$,)
;%
()
(%
,P
0(F
,)
,K
*)
40
%'
(,.
*/
&
,`
,i
,(/
,1
`,
i
,%
(F
+$
,)
;%
()
(%
V8,
B .
,k
,`
AY
1,
U(/
$"
%'
%\
D(
W
3
;,
1d
^1
Vb,
h
0%
$4
,UE
NV
^,1
A1
,K
,UY
Q,
i
VA,
,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
e
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
Ad
Q,
f,
QA
``
,U&
8,1
X
8,X
YV
8,Q
AQ
Z,
f,
QA
YQ
,U&
8,1
X
8,X
cV
8,Q
AZ
c,
f,
QA
[1
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
Ac
e,
f,
QA
eY
,U&
8,1
X
8,X
1V
8,Y
Ac
Q,
U?
8,Y
X
8,E
W
W
2
(V
8,Z
A`
c,
f,
ZA
1Y
,U&
8,1
X
8,X
QV
8,Z
Aj
Z,
U=
*?
8,1
X
8,_
X
V8,
[A
`j
,U?
8,
QX
8,8
L
?]
FV
8,[
A[
c,
f,
[A
[d
,U&
8,1
X
8,X
ZV
8,[
Ac
Y,
f,
[A
cc
,U&
8,1
X
8,X
[V
8,e
AQ
c,
f,
eA
Yc
,U&
8,[
X
8,3
*V
A,?
C 4
17
R
G
'S?
DD
'
R
Q
TO
'4
3
4
8 CU
^,Q
cA
j,
UE
cV
8,Y
1A
Q,
UE
YV
8,Z
ZA
c,
UE
1V
8,Z
jA
1,
UE
QV
8,[
QA
Q,
UE
W
W
2
(V
8,c
cA
d,
U8
L
?]
FV
8,1
QZ
AY
,UE
ZV
8,1
Q[
AQ
,
UE
[V
8,1
Qj
AZ
,U3
*V
8,1
Qj
Ae
,U3
*V
8,1
Qj
Aj
,U3
*V
8,1
Yc
Ac
,UE
O"
)*
(A8
,3
*V
8,1
eZ
A1
,UE
W
W
2
%V
A,D
!-
T2
!,
7
a>
,k
,Y
1Q
,5U
2
,l
,
_
)V
l 8,
1`
`,
i
6,
, H
0+
")
'B
:&
)$
8:
0,
0'A
'!
:%
+B
"0
,0
'$
-'+
14
2T
1E
1*
;
,%
$*
#,
&0
'?
C'
1'?
J'
3
,`
A1
e,
2
,?
/$
"(
0/
',
/.
,E
T)
&
0'
/,
%?
(%
*,?
L,
U/
*,E
D,
/*
,E
NV
,0'
,2
%W
X
\X
QW
,UZ
^1
V,P
)?
,#
*%
#)
*%
4A
,I
0W
X
NX
QW
,UQ
AZ
,&
/$
,
%O
"0
<)
$%
'(
?V
,P
)?
,)
44
%4
,(/
,(F
%,
?/
$"
(0/
',
)(
,`
,gE
,)
'4
,(F
%,
&
0C
("
*%
,P
)?
,?(
0**
%4
,./
*,1
Q,
F,
)(
,*/
/&
,(%
&
#%
*)
("
*%
A,3
.(%
*,
(F
%,
*%
);
(0/
',
P
)?
,;
/&
#$
%(
%4
8,;
)A
,Q
\Y
,/
.,
(F
%,
?/
$<
%'
(,P
)?
,%
<)
#/
*)
(%
4,
)'
48
,0.
,'
%;
%?
?)
*+
8,(
F%
,#
X
,/
.,
(F
%,
&
0C
("
*%
,
P
)?
,)
4M
"?
(%
4,
(/
,#
X
,d
,P
0(F
,_
)X
E
W
YA,
G/
,*
%&
/<
%,
=%
'R
+$
,)
$;
/F
/$
,(F
)(
,P
)?
,/
;;
)?
0/
')
$$+
,?
(0$
$,#
*%
?%
'(
,)
.(%
*,
(F
%,
#*
%<
0/
"?
,*%
);
(0/
',
?(
%#
8,(
F%
,&
0C
("
*%
,P
)?
,%
C(
*)
;(
%4
,P
0(F
,4
0%
(F
+$
,%
(F
%*
A,G
F%
',
(F
%,
0'
/*
K)
'0
;,
#F
)?
%,
P
)?
,)
;0
40
.0%
4,
(/
,#
X
,1
,P
0(F
,X
E
$,U
c2
V,)
'4
,%
C(
*)
;(
%4
,P
0(F
,%
(F
+$
,)
;%
()
(%
A,G
F%
,/
*K
)'
0;
,#
F)
?%
?,
P
%*
%,
;/
&
=0
'%
4,
)'
4,
(F
%,
?/
$<
%'
(,
P
)?
,%
<)
#/
*)
(%
4,
(/
,)
..
/*
4,
(F
%,
);
04
,U?
C'
/*
,?
N,
/*
,?
JV
,)
?,)
,P
F0
(%
,?/
$04
A,
?C
'h
0%
$4
,U?
CV
^,Z
AQ
d,
K,
Ud
Y,
i
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,Q
A1
c,
f,
QA
QY
,U&
8,1
X
8,X
YV
8,Q
AY
Z,
f,
QA
Yd
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
AZ
j,
f,
QA
[[
,U&
8,1
X
8,
X
cV
8,Q
Aj
[,
f,
QA
d`
,U
&
8,1
X
8,X
1V
8,Z
A1
e,
f,
ZA
Qj
,U
&
8,1
X
8,X
QV
8,[
A`
Y,
f,
[A
11
,U
&
8,Q
X
8,8
L
?]
FV
8,[
AZ
c,
U=
*4
8,1
X
8,_
X
V8,
[A
[d
,T
,[
Ac
e,
U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
e,
f,
eA
Y[
,U
&
8,[
X
8,3
*V
A,?
C 4
17
R
G
,S
?D
D'
R
Q
TO
'4
3
4
8 CU
^,Q
cA
1,
UE
cV
8,Y
`A
c,
UE
YV
8,Z
QA
1,
UE
1V
8,Z
cA
d,
UE
QV
8,c
eA
1,
U8
L
?]
FV
8,1
Q[
A`
,UE
Z,
/*
,E
[V
8,1
Q[
A1
,UE
Z,
/*
,E
[V
8,1
Qj
AZ
,UE
X
8,3
*V
8,1
Qj
Aj
,UE
X
8,
3
*V
8,1
ej
Ac
,UE
W
W
X
VA,
D!
-T
2
!,
7
a>
,k
,Q
dj
,5U
2
,l
,_
)V
l 8,
[d
,i
6A,
?N
'h
0%
$4
,U?
NV
^,`
Ac
Z,
K,
Uj
Y,
i
V'
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
Ad
c,
T,Q
A`
[,
U&
8,1
X
8,X
YV
8,Q
AY
1,
f,
QA
Z`
,U&
8,1
X
8,X
cV
8,Q
AZ
c,
f,
QA
[c
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
Ae
c,
f,
QA
j1
,U
&
8,1
X
8,X
1V
8,Z
A1
`,
f,
ZA
1[
,U
&
8,1
X
8,X
QV
8,Z
Ad
e,
U=
*4
8,1
X
8,_
X
V8,
[A
`Z
,f
,[
A1
Z,
U&
8,Q
X
8,8
L
?]
FV
8,
[A
[d
,f
,[
Ac
d,
U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
d,
f,
eA
Yj
,U
&
8,[
X
8,3
*V
A,?
C 4
17
R
G
,S
?D
D'
R
Q
TO
'4
3
4
8 CU
^,Q
cA
Z,
UE
cV
8,Y
`A
d,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
j
UE
YV
8,Z
YA
d,
UE
1V
8,Z
eA
e,
UE
QV
8,c
eA
`,
U8
L
?]
FV
8,1
QZ
AZ
,U
E
Z!
/*
,E
[V
8,1
Q[
A1
,U
E
Z,
/*
,8
VV
8,1
Qj
AY
j,
U3
*V
8,1
Qj
Ae
[,
U3
*V
8,
1Y
cA
[,
UE
O"
)*
(A8
,3
*V
8,1
cY
A[
,U_
X
E
W
V8,
1e
jA
[,
UE
W
W
X
VA,
D!
-T
2
!,
7
a>
,k
,Q
dj
,5U
2
,l
,_
)V
l 8,
11
,i
6,
' ?J
'h
0%
$4
,U?
JV
^,c
ZY
,&
K,
,UZ
Yi
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
Ad
Y,
f,
QA
`Y
,U&
8,1
X
8,X
YV
8,Q
AQ
j,
f,
QA
Z1
,U&
8,1
X
8,X
cV
8,Q
AZ
Q,
f,
QA
[e
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
Ae
Y,
f,
QA
j1
,U
&
8,1
X
8,X
1V
8,Z
A`
c,
f,
ZA
1c
,U
&
8,1
X
8,X
QV
8,Z
Ad
Q,
U=
*4
8,1
X
8,_
X
V8,
[A
`Y
,f
,[
A1
Y,
U&
8,Q
X
8,8
L
?]
FV
8,
[A
[[
,f
,[
Ac
`,
U&
8,1
X
8,X
ZV
8,[
Ac
Q,
f,
[A
ce
,U&
8,1
X
8,X
[V
8,e
AQ
j,
f,
eA
Yj
,U&
8,[
X
8,3
*V
A,?
C 4
17
R
G
,S?
DD
'R
Q
TO
'4
3
4
8 CU
^,
Qc
AY
,U
E
cV
8,Y
`A
e,
UE
YV
8,Z
YA
e,
UE
1V
8,Z
eA
[,
UE
QV
8,c
cA
d,
U8
L
?]
FV
8,1
QZ
AQ
,U
E
Z,
/*
,E
[V
8,1
QZ
Ad
,U
E
Z,
/*
,8
VV
8,1
Qj
AQ
,U
3
*V
8,
1Q
jA
[c
,U3
*V
8,1
Qj
Ac
,U3
*V
A,D
!-
T2
!,
7
a>,
k,
Qd
j,
5U
2
,l
,_
)V
l 8,
11
,i
6,
, !:
%+
B"
0,
0'$
-'<
:)
,&
:8
'+B
,$
8"
0+
")
0'?
PO
'E
?O
''E
J'
'
]]
F Y
,U1
AY
,&
/$
,%
O"
0<
)$
%'
(V,
)'
4,
40
#+
*04
+$
,4
0?
"$
.04
%,
U1
AY
,&
/$
,%
O"
0<
)$
%'
(V,
P
%*
%,
)4
4%
4,
(/
,)
,`
A1
,2
,?
/$
"(
0/
',
/.
,?
C,
U/
*,?
N'
/*
,?
JV
,0'
,E
X
YE
_
A,G
F%
,*%
);
(0/
',
&
0C
("
*%
,P
)?
,*%
.$"
C%
4,
./
*,Q
,F
8,(
F%
',
(F
%,
?/
$<
%'
(,P
)?
,%
<)
#/
*)
(%
4,
)'
4,
(F
%,
#*
/4
";
(,U
?P
,/
*,E
?,
/*
,E
JV
,P
)?
,0?
/$
)(
%,
=+
,.$
)?
F,
;F
*/
&
)(
/K
*)
#F
+,
/'
,)
,?
F/
*(,
#)
(F
,/
.,!
0W
Q,
U%
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,
c^
Z,
/*
,e
^Y
VA,
?P
'h
0%
$4
,U?
PV
^,j
Y`
,&
K,
Ue
d,
i
V8,
B
.,k
,`
AQ
[,
U'
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,e
^Y
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,Q
AQ
1,
f,
QA
Yj
,U&
8,1
X
8,X
YV
8,Q
AY
j,
f,
QA
Zj
,U&
8,Q
X
8,X
Y,
)'
4,
X
cV
8,Q
A[
c,
f,
QA
c[
,U&
8,1
X
8,
X
cV
8,Y
A1
e,
f,
YA
Q1
,U&
8,1
X
8,X
1V
8,Z
AY
Y,
f,
ZA
Yd
,U&
8,1
X
8,X
QV
8,[
A`
e,
U?
8,Q
X
8,8
L
?]
FV
8,[
AQ
c,
U=
*4
8,1
X
8,_
X
V8,
[A
c1
T[
Ae
Q,
U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
[,
f,
eA
YZ
,U&
8,c
X
8,3
*!)
'4
!]
+*
V8,
eA
[[
,f
,e
A[
j,
U&
8,1
X
8,]
+*
V8,
eA
ce
,f
,e
Ae
1,
U&
8,1
X
8,]
+*
V8,
jA
[j
,f
,j
Ac
1,
U&
8,1
X
8,]
+*
V,
' E?
,h
0%
$4
,UE
?V
^,[
Qj
,&
K,
Ue
d,
i
V8,
B
.,k
,`
AQ
[,
U'
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,e
^Y
V,
? Q
17
R
G
,S?
DD
'R
Q
TO
'4
3
4
8 CU
^,Q
A`
Z,
f,
QA
1Y
,U&
8,1
X
8,X
cV
8,Q
AY
j,
f,
QA
[Z
,U&
8,Y
X
8,X
Y,
)'
4,
X
cV
8,Y
A`
c,
f,
YA
1Z
,U&
8,1
X
8,
X
1V
8,Z
A1
Q,
f,
ZA
1d
,U&
8,1
X
8,X
QV
8,Z
Ad
d,
U=
*4
8,1
X
8,_
X
V8,
[A
`d
,U?
8,Q
X
8,8
L
?]
FV
8,[
A[
j,
T,[
Ac
d,
U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
c,
f,
eA
Y[
,U&
8,c
X
8,3
*,)
'4
,#
+*
!V8
,e
A[
1,
T,A
[Y
,U&
8,1
X
8,#
+*
V8,
eA
cc
,f
,e
Ae
`,
U&
8,1
X
8,#
+*
V8,
jA
[e
,f
,j
Ac
`,
U&
8,1
X
8,#
+*
VA,
'
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
d
EJ
'h
0%
$4
,UE
JV
^,Y
YZ
,&
K,
Uj
Y,
i
V8,
B
.,k
,`
AY
Y,
U'
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,c
^Z
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
9,Q
A`
Y,
f,
QA
1Z
,U&
8,1
X
8,X
cV
8,Q
AY
d,
f,
QA
[Z
,U&
8,Y
X
8,X
Y,
)'
4,
X
cV
8,Y
A`
e,
f,
YA
1Z
,U&
8,1
X
8,
X
1V
8,Z
A1
Q,
f,
ZA
1d
,U&
8,1
X
8,X
QV
8,Z
Ad
c,
f,
[A
`Y
,U=
*4
8,1
X
8,_
X
V8,
[A
`j
,U?
8,Q
X
8,8
L
?]
FV
8,[
A[
j,
f,
[A
cd
,U&
8,Q
X
8,X
Z,
)'
4,
X
[V
8,e
AQ
Z,
f,
eA
YZ
,U&
8,c
X
8,3
*,)
'4
,#
+*
!V8
,e
A[
1,
f,
eA
[Y
,U&
8,1
X
8,#
+*
V8,
eA
cc
,f
,e
Ae
1,
U&
8,1
X
8,#
+*
V8,
jA
[j
,f
,j
Ac
1,
U&
8,1
X
8,
#+
*V
A,
, 3
"!
B$
%(
')
"*
#+
,$
%@
'!
:%
+B
"0
,0
'$
-'+
B"
'D
1-/
#$
0:
8*
;
,&
"0
'E
P1
CD
,
G/
,)
,`
A`
e,
2
,?
/$
"(
0/
',
/.
,."
;/
?+
$,)
R0
4%
,K
,0'
,D
(_
W
Q,K
*/
"'
4%
4,
&
/$
%;
"$
)*
,?
0%
<%
?,
)'
4,
),
`A
`j
,2
,?
/$
"(
0/
',
/.
,]
]F
Y,
U1
A1
,&
/$
,%
O"
0<
)$
%'
(V,
0'
,D
(_
W
Q,P
%*
%,
)4
4%
4A
,G
F%
,*%
);
(0/
',
&
0C
("
*%
,P
)?
,*%
.$"
C%
4,
./
*,1
Z,
FA
,3
.(%
*,;
//
$0'
K,
(/
,*/
/&
,
(%
&
#%
*)
("
*%
8,
),
`A
[,
2
,?
/$
"(
0/
',
/.
,#
+*
04
+$
,(
F0
/$
%?
(%
*,
?P
,U
/*
,E
?,
/*
,E
JV
,U
1A
Y,
&
/$
,%
O"
0<
)$
%'
(V,
0'
,D
(_
W
Q,
)'
4,
E
"E
$ QN
X
QW
U1
AY
,&
/$
,%
O"
0<
)$
%'
(V,
P
%*
%,
)4
4%
4,
(/
,(F
%,
*%
);
(0/
',
&
0C
("
*%
A,G
F%
,&
0C
("
*%
,P
)?
,?
(0*
*%
4,
)(
,Z
`,
gE
,./
*,Q
Z,
F,
&
/'
0(/
*0'
K,
=+
,G
IE
A,3
.(%
*,;
/&
#$
%(
0/
'8
,&
/$
%;
"$
)*
,?
0%
<%
?,
)'
4,
;)
()
$+
?(
,P
%*
%,
.0$
(%
*%
4,
/'
,)
,;
%$
0(%
,#
)4
,P
)?
F0
'K
,
P
0(F
,%
(F
+$
,)
;%
()
(%
8,
(F
%,
/*
K)
'0
;,
#F
)?
%,
P
)?
,%
C(
*)
;(
%4
,P
0(F
,_
X
Y\_
X
ZE
$,
U1
^1
V,
)'
4,
P
)?
F%
4,
P
0(F
,P
)(
%*
A,
GF
%,
/*
K)
'0
;,
#F
)?
%,
P
)?
,4
*0%
4,
/<
%*
,_
) Q
!W
Z,
)'
4,
(F
%,
?/
$<
%'
(,P
)?
,%
<)
#/
*)
(%
4A
,G
F%
,/
=(
)0
'%
4,
;*
"4
%,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
T;
F*
/&
)(
/K
*)
#F
+,
/'
,!
0W
Q,U
%T
F%
C)
'%
\%
(F
+$
,)
;%
()
(%
,c
^Z
VA,
' EP
'h
0%
$4
,UE
PV
^,Y
Q`
,&
K,
UY
1,
i
V8,
B
.,k
,`
AQ
Q,
U%
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,c
^Z
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
A1
[,
U4
8,K
VT
U,
k,
cA
Z,
X
R8
,X
Hc
V8,
1A
dZ
,U?
8,Y
X
8,H
";
T3
;V
8,1
Ad
c,
U?
8,Y
X
8,H
";
T3
;V
8,Q
A`
[,
f,
QA
1Z
,U&
8,1
X
8,X
E
+Y
)C
V8,
QA
1[
,U?
8,Y
X
8,H
";
TR
:V
8,Q
A1
d,
f,
QA
Q[
,U&
8,1
X
8,X
E
+c
)C
V8,
QA
ZY
,f
,Q
A[
1,
U&
8,1
X
8,X
E
+Y
%O
V8,
QA
[Z
,f
,
QA
cY
,U&
8,1
X
8,X
E
+c
%O
V8,
QA
e`
,f
,Q
Ae
[,
U&
8,1
X
8,X
E
+1
V8,
ZA
`Q
,f
,Z
A`
j,
U&
8,1
X
8,X
H[
V8,
ZA
YQ
,f
,Z
AY
j,
U&
8,1
X
8,X
E
+Q
V8,
[A
`c
,U4
8,
K,
k,
1Q
AQ
,X
R8
,1
X
8,8
L
?]
FV
8,[
A1
c,
U4
8,K
,k
,1
QA
Q,
X
R8
,1
X
8,8
L
?]
FV
8,[
AQ
d,
T,[
AY
c,
U&
8,Z
X
8,X
HZ
8,X
HY
8,E
+T
]
L
8,X
HQ
V8,
[A
cQ
,
f,
[A
j`
,U&
8,Q
X
8,X
E
+Z
,)
'4
,X
E
+[
V8,
[A
dZ
,U4
48
,K
,k
,Z
AY
,X
R8
,K
,k
,j
A1
,X
R8
,1
X
8,X
H1
V8,
eA
Qj
,f
,e
AY
c,
U&
8,[
X
8,3
*V
8,e
A[
[,
U=
*?
8,
1X
8,H
";
T]
L
VA,
?C
4
17
R
G
,S?
DD
'R
Q
TO
'4
3
4
8 CU
^,1
cA
[,
UE
Hc
V8,
Q`
Aj
,UH
";
T3
;T
2
%V
8,Q
`A
d,
UH
";
T3
;T
2
%V
8,Q
[A
c,
UE
E
+c
V8,
YQ
AZ
,UE
E
+Y
V8,
ZZ
A1
,UE
E
+1
V8,
Zc
AQ
,UE
E
+Q
V8,
cc
AY
,UX
H[
V8,
cc
AZ
,UE
HQ
V8,
ce
Ac
,UE
X
Q8,
8L
?]
FV
8,c
jA
Y,
UE
HY
V8,
e`
Ad
,UE
HZ
V8,
eZ
Ac
,
UE
H1
V8,
1Q
ZA
Z,
UE
E
+Z
,/
*,
E
E
+[
V8,
1Q
cA
Z,
UE
E
+Z
,/
*,
E
E
+[
V8,
1Q
jA
Z,
U3
*V
8,1
Qj
A[
,U
3
*V
8,1
Qj
Aj
,U
3
*V
8,1
Yc
AY
,U
E
O"
)*
(A8
,3
*V
8,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1`
1[
eA
Z,
UE
O"
)*
(AV
8,1
cd
Ae
,UE
O"
)*
(AV
8,1
e`
AQ
,UE
O"
)*
(V8
,1
e`
Ad
,UE
O"
)*
(AV
8,1
eY
AZ
,UE
O"
)*
(AV
A,D
!-
T2
!,
&
\R
,k
,[
cd
,5U
2
,l
,
_
)V
l 8,
1`
`,
i
6A,
5D
6 9
,k
,T1
eA
j,
U;
,k
,1
A[
`8
,D
(W
X
V,
,
' EM
'h
0%
$4
,UE
MV
^,Q
1`
,&
K,
UZ
c,
i
V8,
B
.,k
,`
A1
[,
U%
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,c
^Z
V,
? Q
17
R
G
,SN
DD
'R
Q
TO
'4
3
4
8 CU
^,1
A`
Q,
U4
8,Y
X
8,K
VT
U!
!k
,c
AY
,X
R8
,X
Hc
V8,
1A
dj
,U?
8,c
X
8,H
";
T3
;V
8,Q
A1
Q,
U?
8,Y
X
8,H
";
T3
;V
8,
QA
1Z
,f
,Q
AQ
`,
U&
8,1
X
8,X
E
+Y
)C
V8,
QA
Q1
,f
,Q
AZ
[,
U&
8,1
X
8,X
E
+c
)C
8,X
E
+Y
%O
8,X
E
+c
%O
V8,
QA
jY
,f
,Q
Aj
d,
U&
8,1
X
8,X
E
+1
V8,
YA
jQ
,f
,
YA
jd
,U&
8,1
X
8,X
E
+Q
V8,
YA
jd
,f
,Y
Ad
j,
U&
8,1
X
8,X
H[
V8,
[A
``
,f
,[
A`
d,
U&
8,Q
X
8,8
L
?]
FV
8,[
A1
d,
f,
[A
QQ
,U&
8,1
X
8,X
HZ
V8,
[A
Qe
,f
,
[A
Y[
,U&
8,1
X
8,E
+T
]L
8,X
HY
8,X
HQ
V8,
[A
[[
,f
,[
Ac
`,
U&
8,1
X
8,X
E
+Z
V8,
[A
cY
,f
,[
Ac
j,
U&
8,1
X
8,X
E
+[
V8,
[A
d1
,U4
48
,K
,k
,Z
Ac
,X
R8
,K
,
k,
jA
1,
X
R,
1X
8,X
H1
V,e
AQ
c,
f,
eA
YZ
,U&
8,[
X
8,3
*V
8,e
AZ
Q,
U=
*?
8,1
X
8,H
";
T]
L
VA,
?C
4
17
R
G
,S?
DD
'R
Q
TO
'4
3
4
8 CU
^,1
cA
Y,
UE
Hc
V8,
Q`
Aj
,UH
";
T3
;T
2
(V
8,Q
`A
d,
UH
";
T3
;T
2
(V
8,Q
1A
`,
UH
";
T3
;T
2
(V
8,Q
jA
e,
UE
E
+c
V8,
Y1
AY
,UE
E
+Y
V8,
Zc
AY
,UE
E
+1
V8,
Zd
A1
,
UE
E
+Q
V8,
c[
Aj
,UE
H[
V8,
cc
AY
,UE
HQ
V8,
ce
AQ
,U8
L
?]
FV
8,c
jA
Z,
UE
HY
V8,
e`
Ad
,UE
HZ
V8,
eZ
Ac
,UE
H1
V8,
1Q
ZA
c,
U,E
E
+Z
V8,
1Q
[A
c,
UE
E
+[
V8,
1Q
jA
Q,
U3
*V
8,1
Qj
A[
,U3
*V
8,1
Qj
Aj
,U3
*V
8,1
Yc
AY
,UE
O"
)*
(8,
3
*,V
8,1
[c
Ac
,UE
O"
)*
(AV
8,1
cd
Ae
,UE
O"
)*
(AV
8,1
e`
Ac
,UE
O"
)*
(AV
8,
1e
1A
`,
UE
O"
)*
(AV
8,1
eZ
8e
,UE
O"
)*
(AV
,D
!-
T2
!,
&
\R
,k
,[
cd
,5U
2
,l
,_
)V
l 8,
1`
`,
i
6A,
5D
6 9
,k
,Td
YA
e,
U;
,k
,`
A[
`8
,2
%W
X
V,
, CD
'h
0%
$4
,UC
DV
^,Q
``
,&
K,
U[
Qi
V8,
B
.,k
,`
A1
[,
U%
TF
%C
)'
%\
%(
F+
$,)
;%
()
(%
,c
^Z
V,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
4
8 CU
9,į
,U#
#&
V,k
,1
A`
Z,
U4
8,Y
X
8,K
V!
Z!
U,k
,c
AZ
,X
R8
,X
Hc
V8,
1A
dc
,U?
8,Y
X
8,W
3
;V
8,1
Ad
j,
U?
8,Y
X
8,
W
3
;V
8,Q
A`
[,
f,
QA
1Q
,U&
8,1
X
8,X
E
Y)
CV
8,Q
A1
[,
U?
8,Y
X
8,W
3
;V
8,Q
AQ
Z,
f,
QA
Zj
,U&
8,Y
X
8,X
E
Y%
O,)
'4
,X
E
cV
8,Q
Ae
Z,
f,
QA
je
,U&
8,1
X
8,
X
E
+1
V8,
YA
jj
,f
,Y
Ad
d,
U&
8,Q
X
8,X
E
+Q
,)
'4
,X
H[
V8,
[A
`Y
,f
,[
A1
Q,
U&
8,Y
X
8,8
L
?]
F,
)'
4,
E
+;
T]
L
V8,
[A
QY
,f
,[
AQ
[,
U&
8,1
X
8,X
HQ
V8,
[A
YQ
,f
,[
AY
j,
U&
8,Q
X
8,X
HY
,)
'4
,X
HZ
V8,
[A
[e
,f
[A
cQ
,U&
8,1
X
8,X
E
+Z
,/
*,X
E
+[
V8,
[A
cZ
,f
,[
Te
`,
U&
8,1
X
8,X
E
+Z
,/
*,X
E
+[
V8,
[A
j[
,f
,
[A
d1
,U
&
8,1
X
8,X
H1
V8,
eA
Qe
,f
,e
AY
c,
U&
8,c
X
8,3
*,
)'
4,
H"
;T
_
X
VA,
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
4
8 CU
9,
į,
U#
#&
V,
k,
1c
AY
,
UE
Hc
V8,
Q`
Aj
,U
H"
;T
W
3
;T
2
%V
8,Q
`A
d,
UH
";
TW
3
;T
2
%V
8,Q
`A
d,
UH
";
TW
3
;T
2
%V
8,Q
dA
[,
UE
E
+c
V8,
YQ
A`
,U
E
E
+Y
V8,
Ze
AZ
,U
E
E
+1
V8,
Zj
Ae
,U
E
E
+Q
V8,
cc
A`
Q,
UE
H[
V8,
cc
AZ
,U
E
HY
,/
*,
E
HZ
V8,
ce
AZ
,U
8L
?T
]F
V8,
cj
AY
,U
E
HY
,/
*,
E
HZ
V8,
e`
Ad
,U
E
HQ
V8,
eZ
Aj
,U
E
H1
V8,
1Q
ZA
Z,
UE
E
+Z
,/
*,E
E
+[
V8,
1Q
[A
j,
UE
E
+Z
,/
*,E
E
+[
V8,
1Q
jA
Y,
U3
*V
8,1
Qj
Ac
,U3
*V
8,1
Qj
Ad
,U3
*V
8,1
Yc
A1
,UE
O"
)*
(A8
,3
*V
8,1
[c
Aj
,UE
O"
)*
(AV
8,
1c
dA
e,
UE
O"
)*
(AV
8,1
e`
AZ
,UE
O"
)*
(AV
8,1
e`
Ad
,UE
O"
)*
(AV
8,1
eZ
AZ
,UE
O"
)*
(AV
A,D
!-
T2
!,
7
a>
,k
,[
cd
,5U
2
,l
,_
)V
l 8,
1`
`,
i
6A,
, '
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
11
!:
%+
B"
0,
0'$
-'+
B"
'8,
(*
%&
0'C
O'M
1?
E'
'
GF
%,
."
;/
?+
$)
&
04
%?
,0?
/$
)(
%4
,)
.(%
*,(
F%
,9
%!
F/
'K
,*%
);
(0/
',
P
%*
%,
(*%
)(
%4
,P
0(F
,X
Q,)
'4
,]
4\
E
,0'
,2
%W
X
,U`
A`
[,
2
V,.
/*
,
QF
,)
(,
*/
/&
,(
%&
#%
*)
("
*%
A,G
F%
,;
*"
4%
,P
)?
,.
0$(
%*
%4
,(
F*
/"
KF
,;
%$
0(%
,)
'4
,"
?%
4,
./
*,
(F
%,
;/
"#
$0'
K,
*%
);
(0/
'?
8,P
F0
;F
,
P
%*
%,
*"
',
"?
0'
K,
(F
%,
K%
'%
*)
$,
#*
/;
%4
"*
%?
,.
/*
,;
/"
#$
0'
K,
*%
#/
*(%
4,
=%
$/
P
,.
/*
,)
&
0'
%,
J@
,G
F%
,.
0'
)$
,)
&
04
%?
,P
%*
%,
4%
);
%(
+$
)(
%4
,"
?0
'K
,(F
%,
K%
'%
*)
$,#
*/
;%
4"
*%
,./
*,m
%&
#$
%'
n?
,4
%#
*/
(%
;(
0/
',
4%
?;
*0=
%4
,=
%$
/P
,./
*,;
/&
#/
"'
4,
PA
,
,
"(
"#
'-
./
#0
1"
2%
#"
.0
3.'
1"
&4
-'
&*0
(.
5*
&6
.7
1 8
9
.
G/
,)
,?/
$"
(0/
',
/.
,J
,U`
A`
eQ
,&
&
/$
8,1
,%
O"
0<
V,0
',
E
X
QE
$ Q,
UQ
,&
IV
8,#
+*
04
0'
%,
U`
A`
1,
&
I8
,1
AY
,%
O"
0<
V,)
'4
,3
;Q
W
,U`
A`
1,
&
I8
,1
AY
,%
O"
0<
V,P
%*
%,
)4
4%
4,
)'
4,
(F
%,
?/
$"
(0/
',
P
)?
,?
(0*
*%
4,
/<
%*
'0
KF
(A,
GF
%,
&
0C
("
*%
,P
)?
,4
0$"
(%
4,
P
0(F
,E
X
QE
$ Q8
,
%C
(*)
;(
%4
,P
0(F
,P
)(
%*
8,4
0$"
(%
4,
X
E
$8,
P
)(
%*
A,G
F%
,/
*K
)'
0;
,#
F)
?%
,P
)?
,4
*0%
4,
/<
%*
,_
) Q
!W
Z,)
'4
,%
<)
#/
*)
(%
4A
,
,
"(
"#
'-
./
#0
1"
2%
#"
.0
3.1
0%
/-
*(
:.
%$
*(
:.
;
<=
>
.
G/
,)
,?
/$
"(
0/
',
/.
,J
,U
`A
`Q
,&
&
/$
V,
0'
,`
AQ
,&
I,
/.
,E
X
QE
$ Q8
,D
( Y_
,U
`A
`e
Q,
&
&
/$
8,Y
,%
OA
V,
)'
4,
;)
*=
/C
+$
0;
,#
)*
('
%*
,
U`
A`
Yc
,&
&
/$
8,1
A[
,%
OA
V,0
',
`A
Q,
&
I,
/.
,E
X
QE
$ Q,
P
%*
%,
)4
4%
4A
,!
"=
?%
O"
%'
($+
8,X
J
Go
,U`
A`
Yc
,&
&
/$
8,1
A[
,%
OA
V,P
)?
,
)4
4%
4,
)'
4,
*%
);
(0/
',
&
0C
("
*%
,?
(0*
*%
4,
)(
,*/
/&
,(%
&
#%
*)
("
*%
A,3
.(%
*,1
j,
F8
,1
`,
&
I,
/.
,E
X
QE
$ Q,
P
%*
%,
)4
4%
4,
(/
,(F
%,
*%
);
(0/
',
&
0C
("
*%
,)
'4
,/
*K
)'
0;
,#
F)
?%
,P
)?
,P
)?
F%
4,
P
0(F
,`
A[
,2
,_
)W
X
,U1
`,
&
IV
8,1
2
,p
X
!W
Z,U
1`
,&
IV
8,P
)(
%*
,
U1
`,
&
IV
,)
'4
,=
*0'
%,
U1
`,
&
IV
A,G
F%
,/
*K
)'
0;
,#
F)
?%
,P
)?
,4
*0%
4,
/<
%*
,_
) Q
!W
Z8,
.0$
(%
*%
4,
)'
4,
(F
%,
?/
$<
%'
(,%
<)
#/
*)
(%
4,
"'
4%
*,<
);
""
&
A,G
F%
,*%
?0
4"
%,
P
)?
,#
"*
0.0
%4
,<
0)
,J
0/
()
K%
,"
?0
'K
,(F
%,
)#
#*
/#
*0)
(%
,?/
$<
%'
(,K
*)
40
%'
(A,
,
,
"(
"#
'-
./
#0
1"
2%
#"
.0
3.1
0%
/-
*(
:.
%$
*(
:.
'1
*2
.1
6-
0#
*2
".
GF
%,
;)
*=
/C
+$
0;
,#
)*
('
%*
,U1
AQ
,&
&
/$
8,1
AQ
,%
OA
V,P
)?
,*%
.$"
C%
4,
0'
,1
,&
I,
/.
,(/
$"
%'
%,
0'
,#
*%
?%
';
%,
/.
,/
C)
$+
$,;
F$
/*
04
%,
UY
,&
&
/$
8,Y
AY
,%
OA
V,4
"*
0'
K,
Y,
FA
,G
F%
,?
/$
"(
0/
',
P
)?
,(F
%'
,%
<)
#/
*)
(%
4,
)'
4,
)4
4%
4,
(/
,)
,?
/$
"(
0/
',
/.
,J
,U1
,&
&
/$
V,)
'4
,
D(
Y_
,U
Q,
&
&
/$
8,
Q,
%O
AV,
0'
,1
,&
I,
/.
,G
X
HA
,G
F%
,?
/$
"(
0/
',
P
)?
,?
(0*
*%
4,
)(
,*
//
&
,(
%&
#%
*)
("
*%
,.
/*
,1
j,
FA
,3
.(%
*,
;/
&
#$
%(
0/
'8
,(
F%
,?
/$
<%
'(
,P
)?
,%
<)
#/
*)
(%
4A
,G
F%
,;
*"
4%
,P
)?
,(
):
%'
,"
#,
P
0(F
,E
X
QE
$ Q8
,P
)?
,P
)?
F%
4,
P
0(F
,)
,
?)
("
*)
(%
4,
?/
$"
(0/
',
/.
,_
)X
E
W
Y8,
1`
i
,;
0(*
0;
,)
;0
48
,)
'4
,)
',
)O
"%
/"
?,
?)
("
*)
(%
4,
_
)E
$,?
/$
"(
0/
'A
,!
%#
)*
)(
0/
'?
,F
)<
%,
=%
%'
,4
/'
%,
"?
0'
K,
0?
/$
"(
%,
;/
$"
&
',
?%
#)
*)
(0<
%,
#F
)?
%A
,G
F%
,?
/$
<%
'(
,P
)?
,%
<)
#/
*)
(%
4,
"'
4%
*,
<)
;"
"&
,)
'4
,(
F%
,
*%
?0
4"
%,
P
)?
,#
"*
0.0
%4
,<
0)
,J
0/
()
K%
,"
?0
'K
,(F
%,
)#
#*
/#
*0)
(%
,?/
$<
%'
(,K
*)
40
%'
(A,
. .
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1Q
,
"(
"#
'-
./
#0
1"
2%
#"
.0
3.1
0%
/-
*(
:.
%$
*(
:.
?@
)A
;
9
<&
.
G/
,(F
%,
&
0C
("
*%
,/
.,
(F
%,
);
04
0;
,#
)*
('
%*
,U
`A
`e
,&
&
/$
8,1
A1
,%
OA
V,
0'
,1
A[
,&
I,
/.
,E
X
QE
$ Q,
P
%*
%,
)4
4%
4,
X
W
J
(,U
`A
1`
,
&
&
/$
8,1
AZ
,%
OA
V,
)'
4,
;/
&
#/
"'
4,
J,
U`
A`
e,
&
&
/$
8,1
,%
OA
VA,
GF
%,
&
0C
("
*%
,P
)?
,?
(0*
*%
4,
)(
,`
gE
,.
/*
,[
,&
0'
,(
F%
',
),
?/
$"
(0/
',
/.
,D
9
E
AX
E
$,U
`A
`d
,&
&
/$
8,1
AY
,%
OA
V,
)'
4,
(*0
%(
F+
$)
&
0'
%,
U`
A`
d,
&
&
/$
8,1
AQ
,%
OA
V,
0'
,`
A[
,&
I,
/.
,E
X
QE
$ Q,
P
)?
,)
44
%4
A,G
F%
,*%
?"
$(0
'K
,&
0C
("
*%
,P
)?
,)
$$/
P
%4
,(/
,P
)*
&
,)
(,*
A(,
)'
4,
?(
0**
%4
,)
(,*
A(,
/<
%*
'0
KF
(A,
GF
%,
*%
);
(0/
',
P
)?
,
(F
%'
,P
)?
F%
4,
P
0(F
,_
)X
E
W
Y8,
1`
i
,;
0(*
0;
,)
;0
48
,)
'4
,)
',
)O
"%
/"
?,
?)
("
*)
(%
4,
_
)E
$,?
/$
"(
0/
'A
,!
%#
)*
)(
0/
'?
,P
%*
%,
#%
*.
/*
&
%4
,"
?0
'K
,0
?/
$"
(%
,;
/$
"&
',
?%
#)
*)
(0<
%,
#F
)?
%A
,G
F%
,?
/$
<%
'(
,P
)?
,%
<)
#/
*)
(%
4,
"'
4%
*,
<)
;"
"&
,)
'4
,(
F%
,
*%
?0
4"
%,
P
)?
,#
"*
0.0
%4
,<
0)
,J
0/
()
K%
,"
?0
'K
,(F
%,
)#
#*
/#
*0)
(%
,?/
$<
%'
(,K
*)
40
%'
(A,
,
"(
"#
'-
./
#0
1"
2%
#"
.0
3.B
"C
/-
"(
D$
.2
"/
#0
&"
1&
*0
(.
G/
,)
,?
/$
"(
0/
',
/.
,#
*/
(%
;(
%4
,)
&
04
%,
P,
U`
A`
e,
&
&
/$
V,0
',
1A
[,
&
I,
/.
,4
*+
,2
%W
X
8,_
)W
2
%,
U`
A`
1,
&
&
/$
V,P
)?
,)
44
%4
,
)'
4,
(F
%,
?/
$"
(0/
',
P
)?
,?
(0*
*%
4,
)(
,*
//
&
,(%
&
#%
*)
("
*%
A,3
.(%
*,
;/
&
#$
%(
0/
'8
,)
&
=%
*$0
(%
,-
B
3
,1
Q`
l ,
P
)?
,)
44
%4
,"
'(
0$,
#X
,e
,)
'4
,(
F%
,=
%)
4?
,P
%*
%,
.0$
(%
*%
4,
/.
.A,
GF
%,
?/
$<
%'
(,
P
)?
,%
<)
#/
*)
(%
4,
"'
4%
*,
<)
;"
"&
,)
'4
,(
F%
,*
%?
04
"%
,P
)?
,
#"
*0.
0%
4,
=+
,*%
<%
*?
%,
#F
)?
%,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
"?
0'
K,
(F
%,
)#
#*
/#
*0)
(%
,?/
$<
%'
(,K
*)
40
%'
(A,
' S?
EO
EF
U1
E1
V
;
,%
$#
:#
8$
B"
I*
%"
#*
)2
$I
:8
,#
'*
#,
&'
0"
),
"0
9'>
,(
*%
&0
'C
'
+
1W
S?
EO
EF
U1
E1
SC
1Q
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
2U
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,Y
T)
;%
(/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(F
%,
K%
'%
*)
$,X
J
Go
,#
*/
;%
4"
*%
A,G
F%
,;
*"
4%
,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
^Z
,F
%C
)'
%^
3
;W
D(
,8,
B
.,k
,`
Ac
Y8
,e
Qi
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y^
2
%W
X
8,B
.,k
,`
AQ
1V
,)
..
/*
4%
4,
C2
,U
O"
)'
(VA
,?
Q
17
R
G
''
SN
DD
'R
Q
TO
'
4
3
CY
3
U9
,į
,U#
#&
V,k
,`
Aj
j,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
Hc
V8,
1A
Y1
TQ
A1
e,
U&
8,j
X
8,E
X
QE
+V
8,Q
Ad
Z,
U&
8,1
X
8,X
E
+1
V8,
YA
[Z
,
U&
8,1
X
8,X
HZ
V8,
YA
[d
,U&
8,1
X
8,X
H[
V8,
YA
e[
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
AY
,X
R8
,X
HY
V8,
YA
dY
,U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QH
V8,
ZA
Ye
,U
&
8,1
X
8,X
E
+Q
V8,
[A
[`
,U
48
,1
X
8,X
H1
V8,
cA
dZ
,U
&
8,1
X
8,X
3
*V8
,e
A1
dT
eA
Qe
,U
&
8,Y
X
8,X
3
*Vb
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
1c
Aj
,U
E
Hc
V8,
QY
AY
8,Q
YA
[8
,Q
cA
Q8
,Y
`A
e,
UZ
uE
X
QE
+V
8,Z
cA
`,
UE
E
+1
V8,
[`
AY
,U
E
E
+Q
V8,
cj
A`
,UE
HQ
V8,
cj
AZ
,UE
H[
V8,
e1
A[
,UE
HY
V8,
eY
AZ
,UE
HZ
V8,
ej
A[
,UE
H1
V8,
11
[A
Z,
UE
X
3
*V8
,1
1d
AZ
,UE
X
3
*V8
,1
1d
Aj
,UE
X
3
*V8
,1
Y`
Aj
,
UE
X
3
*V8
,1
Ye
AZ
,UE
3
*V8
,1
[d
A`
,UE
3
*V8
,1
e`
AQ
,UE
kW
V8,
1e
eA
j,
UE
kW
VA,
B
.,k
,`
AQ
1,
UZ
^1
,E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1Y
k,
Yd
1,
5U
2
TW
X
Vl
8,1
``
i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
Q`
X
Qj
_
QW
e,5
2
l_
)6
l ^,
ZY
1A
1e
jj
eb
,./
"'
4,
52
l_
)6
l ^
,
Zj
cA
1e
j[
1A
,
. +
1W
S?
EO
EF
U1
E1
SC
OJ
13
,B
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
#U
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,Y
8[
T4
0)
;%
(/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(
F%
,K
%'
%*
)$
,X
J
Go
,#
*/
;%
4"
*%
A,
GF
%,
;*
"4
%,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
^1
A[
,F
%C
)'
%T
3
;W
D(
8,
B
.,
k`
AY
Y8
,[
[,
i
,+
0%
$4
V,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y,
^,2
%W
X
8,B
.,k
,`
A1
jV
,)
..
/*
4%
4,
C#
'UO
")
'(
VA'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,,`
Aj
d,
U4
8,1
X
8,K
[T
c!k
,c
AZ
,X
R8
,X
Hc
V8,
1A
ej
T1
AQ
d,
U&
8,c
X
8,X
E
+Y
8,Q
X
E
+Z
8,Q
X
E
+[
8,
X
E
+c
V8,
1A
dc
T1
Aj
[,
U&
8,1
X
8,X
E
+c
V8,
QA
1c
TQ
A`
e,
U&
8,1
X
8,X
E
+Y
V8,
QA
jd
,U
(4
8,1
X
8,K
!k
,j
AZ
,q
,Z
AQ
,X
R8
,X
E
+1
V8,
YA
[Y
,U
48
,
1X
8,K
YT
Z,k
,Y
AQ
,X
R8
,X
HZ
V8,
YA
[e
,UO
8,1
X
8,K
[T
c,k
,c
Ac
,X
R8
,X
H[
V8,
YA
eY
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
!K
YT
Z,k
,,Y
AZ
,X
R8
,X
HY
V8,
YA
d1
,U4
48
,1
X
8,K
QT
Y,
k,
1`
AY
,X
R8
,K
1T
Q,
k,
[A
c,
X
R8
,X
HQ
V8,
ZA
YQ
TZ
AQ
[,
U&
8,1
X
8,X
E
+Q
V8,
[A
Z[
,U4
8,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
H1
V8,
cA
Ye
,U(
8,1
X
8,K
!k
,Q
AQ
,X
R8
,E
X
3
*V8
,c
Ac
Z,
U4
8,Q
X
8,K
!k
,Q
AQ
,X
R8
,Q
E
X
3
*Vb
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,
k,
1c
Ae
,U
E
Hc
V8,
QY
AQ
,U
E
E
+Z
V8,
QZ
AY
,U
E
E
+[
V8,
Qc
A1
,U
E
E
+c
V8,
Y`
Ac
,U
E
E
+Y
V8,
Z[
Aj
,U
E
E
+1
V8,
[`
AQ
,U
E
E
+Q
V8,
ce
Ad
,U
E
HQ
V8,
cj
AZ
,
UE
H[
V8,
e1
AZ
,UE
HY
V8,
eY
AY
,UE
HZ
V8,
ej
AZ
,UE
H1
V8,
1`
cA
e,
UE
X
3
*V8
,1
`c
Aj
,UE
X
3
*V8
,1
Qe
Ae
,UE
X
3
*G
*#
V8,
1Y
jA
`,
UE
3
*V8
,1
c`
A`
,
UQ
CE
3
*V8
,1
e`
AQ
,U
E
kW
V8,
1e
eA
e,
UE
kW
VA,
B
.,
k,
`A
1e
,U
Z^
1,
E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>,
k,
ZZ
eA
Z,
5U
2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
Q`
X
Qj
_
QW
j,5
2
l_
)6
l ^,
ZZ
eA
1e
Yd
eb
,./
"'
4,
52
l_
)6
l ^,
Zj
cA
1e
Z`
`A
,
. +
1W
S?
EO
EF
U1E
1SC
1F
:)
,&
,%
"#
*)
2$
I*
;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
&U
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,'
0;
/(
0'
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
X
J
Go
,#
*/
;%
4"
*%
A,
GF
%,
;*
"4
%,
P
)?
,
#"
*0.
0%
4,
=+
,.
$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U3
;W
D(
8,
B
.,
k,
`A
Y`
8,
ee
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
2
%W
X
8,B
.,k
,`
AY
YV
,)
..
/*
4%
4,
C&
'Ud
[i
,+
0%
$4
VA,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'3
EY
U'9
,į
,
U#
#&
V,k
,`
Ae
`,
UY
X
8,4
8,K
[T
c,k
,c
A[
,X
R8
,X
Hc
V8,
1A
Y[
T1
Ad
1,
U&
8,j
X
8,E
X
QE
+V
8,Q
Ad
1,
U&
8,1
X
8,X
E
+1
V8,
YA
[[
,U&
8,1
X
8,X
H[
V8,
YA
Yc
,U
#?
%"
4/
T4
81
X
8,K
ZT
[,
k,
YA
Z,
X
R8
,X
HZ
V8,
YA
ee
,U
44
8,1
X
8,K
QT
Y,
k,
1`
Ac
,X
R8
,X
HY
V8,
YA
dQ
,U
44
8,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,
X
HQ
V8,
ZA
Ze
,U&
8,1
X
8,X
E
+Q
V8,
[A
ZY
,U4
8,1
X
8,X
H1
V8,
eA
[Q
,U4
48
,1
X
8,K
,k
,[
A`
,X
R8
,K
,k
,e
Ae
,X
R8
,X
3
*V8
,j
A`
[,
U4
8,1
X
8,K
,k
,j
A`
,
X
R8
,X
3
*V8
,j
Ac
d,
U&
8,
QX
8,
X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'3
EY
U'9
,į
,U
##
&
V,
k,
1c
AQ
,U
E
Hc
V8,
Q`
Ac
8,
QY
Ac
8,
Y`
AY
,
UZ
CE
X
QE
+V
8,Z
[A
c,
UE
E
+1
V8,
Zd
Ae
,UE
E
+Q
V8,
cc
Ae
,UE
HQ
V8,
ce
Ad
,UE
H[
V8,
e`
AY
,UE
HY
V8,
eQ
A1
,UE
HZ
V8,
ee
A[
,UE
H1
V8,
1Y
eA
18
,1
Zj
AQ
8,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1Z
1[
QA
Z,
UZ
CE
3
*V8
,1
cd
A1
,U
E
kW
V8,
1e
jA
c,
UE
kW
VA,
B
.,
k,
`A
YY
,U
E
X
E
$ Y\
2
%W
X
,k
,Z
\1
VA,
D!
-T
2
!^
,7
a>
,k
,Y
dZ
AZ
,
5U
2
lX
Vl
8,
ZY
i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,.
/*
,E
1d
X
Qe
_
YW
c,
52
l_
)6
l ^,
Z1
cA
1e
dQ
1b
,.
/"
'4
,5
2
l_
)6
l ^
,
Z1
cA
1e
d`
cA
,
, +
1W
S?
EO
EF
U1
E1
SC
1R
"+
B$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
"U
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,Y
T&
%(
F/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(F
%,
K%
'%
*)
$,X
J
Go
,#
*/
;%
4"
*%
A,G
F%
,;
*"
4%
,P
)?
,
#"
*0.
0%
4,
=+
,.
$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
^1
A[
,F
%C
)'
%T
3
;W
D(
8,B
.,k
`A
Y1
8,c
Z,
i
,+
0%
$4
V,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y,
^,
2
%W
X
8,
B
.,
k,
`A
Y`
V,
).
./
*4
%4
,C
"'
UO
")
'(
VA'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'
4
3
CY
3
U'9
,į
,U#
#&
V,k
,`
Aj
Y,
U4
8,1
X
8,K
[T
c,k
,c
A[
,X
R8
,X
Hc
V8,
1A
ed
T1
AY
Z,
,U&
8,c
X
8,X
E
+Y
8,Q
X
E
+Z
8,Q
X
E
+[
8,X
E
+c
V8,
QA
`Q
T1
Aj
d,
U&
8,1
X
8,X
E
+c
V8,
QA
1j
TQ
A1
`,
U&
8,1
X
8,X
E
+Y
V8,
QA
dQ
,U(
48
,1
X
8,K
!k
,j
Ac
,q
,Z
AY
,X
R8
,X
E
+1
V8,
YA
[1
,U4
8,1
X
8,K
YT
Z,k
,Q
A[
,X
R8
,X
HZ
V8,
YA
[c
,UO
8,1
X
8!K
[T
c,k
,c
A[
,X
R8
,X
H[
V8,
YA
eY
,U4
48
,1
X
8,K
QT
Y!k
,1
`A
Z,
X
R8
,K
YT
Z!k
,Y
AZ
,X
R8
,X
HY
V8,
YA
jY
,U?
8,Y
X
8,W
2
%V
8,Y
Ad
1,
U4
48
,
1X
8,K
QT
Y,k
,1
`A
Z,
X
R8
,K
1T
Q,k
,[
Ac
,X
R8
,X
HQ
V8,
ZA
Z`
TZ
AY
Y,
U&
8,1
X
8,X
E
+Q
V8,
[A
Zc
,U4
8,1
X
8,K
1T
Q,k
,[
Ac
,X
R8
,X
H1
V8,
eA
`e
,U(
48
,1
X
8,
K!
k,
cA
`,
q
,Q
Ae
,X
R8
,X
3
*V8
,e
AY
[,
U&
8,Y
X
8,Y
X
3
*Vb
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
1c
Aj
,U
E
Hc
V8,
QY
AQ
,
UE
E
+[
V8,
QZ
AY
,UE
E
+Z
V8,
Qc
A`
,UE
E
+c
V8,
Y`
Ae
,UE
E
+Y
V8,
Z[
Ad
,UE
E
+1
V8,
[`
AY
,UE
E
+Q
V8,
[[
Ad
,UW
2
%V
8,c
eA
d,
UE
HQ
V8,
cj
AY
,UE
H[
V8,
e1
AZ
,
UE
HY
V8,
eY
AY
,U
E
HZ
V8,
ej
AZ
,U
E
H1
V8,
11
YA
d,
UE
X
3
*V8
,1
1j
A[
,U
E
X
3
*V8
,1
Q`
Ac
,U
E
X
3
*V8
,1
Y`
Ae
,U
E
X
3
*V8
,1
Ye
AZ
,U
E
3
*V8
,1
c1
AY
,
UE
3
*W
2
%V8
,1
cd
Ad
,U
E
kW
V8,
1e
eA
e,
UE
kW
VA,
B
.,k
,`
AZ
`,
UE
X
E
$ Y\
2
%W
X
,k
,Z
\1
VA,
D!
-T
2
!^
,7
a>
,k
,Z
Z[
AY
,5
U2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
Q1
X
Y`
_
QW
e,5
2
l_
)6
l ^,
ZZ
[A
1d
Z[
Qb
,./
"'
4,
52
l_
)6
l ^,
ZZ
[A
1d
Z`
1A
,
, +
1W
S?
EO
EF
U1
E1
SS
EF
U1E
1Q
:&
)$
I:
1<
B"
%:
8*
#"
+*
;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
-U'
E
/&
#/
"'
4,
J5
1Y
6 ,
P
)?
,;
/"
#$
%4
,P
0(F
,U
^V
TU
íV
TĮ
T)
;%
(/
C+
#F
%'
+$
);
%(
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
);
04
,;
F$
/*
04
%,
#*
/;
%4
"*
%A
,G
F%
,;
*"
4%
,P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
^Z
,F
%C
)'
%^
3
;W
D(
8,B
.,k
,`
Ac
8,c
`i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AQ
[V
,)
..
/*
4%
4,
C-
'UO
")
'(
VA,
? Q
1
7
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,`
Ad
c,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
Hc
V8,
1A
Z`
TQ
A`
j,
U&
8,j
X
8,E
X
QE
+V
8,Q
Ae
c,
U&
8,1
X
8,X
E
+1
V8,
YA
[e
,U&
8,1
X
8,X
HZ
V8,
YA
c[
,U4
O8
,1
X
8,K
ZT
[,r
,1
X
R8
,X
H[
V8,
YA
eY
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
Ac
,
X
R8
,X
HY
V8,
YA
d[
,U
44
8,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
HQ
V8,
ZA
1c
,U
&
8,1
X
8,X
E
+Q
V8,
ZA
dj
,U
?8,
1X
8,T
E
L
UW
X
V]
FV
8,[
A[
1,
U4
8,1
X
8,
X
H1
V8,
eA
Qc
Te
AZ
Q,
U&
8,[
X
8,X
3
*VA
,?
C 4
17
R
G
'S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
1e
A1
,U
E
Hc
V8,
QY
AY
8,Q
ZA
Y8
,Q
cA
e8
,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1[
Y`
Ad
,UZ
CE
X
QE
+V
8,Z
cA
Z,
UE
E
+1
8,E
E
+Q
V8,
cj
AQ
,UE
HQ
V8,
cj
A[
,UE
H[
V8,
e1
Ac
,UE
HY
V8,
eY
A[
,UE
HZ
V8,
e[
Ae
,UT
8X
UW
X
V]
FV
8,e
jA
Z,
UE
H1
V8,
1Q
jA
c,
UQ
CE
X
3
*V8
,1
Qd
AQ
,UE
X
3
*V8
,1
Qd
Ac
,UQ
uE
X
3
*V8
,1
Z1
Aj
,UE
3
*V8
,1
eZ
Ac
8,1
ee
A[
,UQ
uE
kW
VA,
B
.,k
,`
AQ
[,
UZ
^1
,
E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>
,k
,Z
Z[
,5U
2
l_
)V
l 8,
Q[
i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
Q1
X
Y`
_
QW
e,5
2
l_
)6
l ^,
ZZ
[A
1d
Z[
Qb
,./
"'
4,
52
l_
)6
l ^,
ZZ
[A
1d
Z`
cA
,
, +
1W
S?
EO
EF
U1
E1
S3
1+
D1V
#"
+:
81+
),
<+
$<
B*
%$
:8
U#
:#
8$
B"
I*
%"
#*
)2
$I
:8
X1D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
(U
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,9
T_
T)
;%
(+
$T(
*0#
(/
#F
)'
%,
"?
0'
K,
(F
%,
K%
'%
*)
$,X
J
Go
,#
*/
;%
4"
*%
A,G
F%
,;
*"
4%
,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
``
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AQ
j8
,j
[i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AQ
YV
,)
..
/*
4%
4,
C(
,U
O"
)'
(VA
,?
Q
17
R
G
''
SN
DD
'R
Q
TO
'
4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
e,
U4
8,1
X
8,K
[T
c!k
,c
A[
,X
R8
,X
Hc
V8,
1A
Yc
T1
A1
QU
&
,Z
X
8,E
X
QE
+V
8,1
Ae
YT
1A
[Z
,U&
8,Z
X
8,E
X
QE
+V
8,
1A
d[
,U
?8,
YX
8,E
X
YE
W
_
X
TV
8,Q
Ae
`T
QA
cY
,U
&
8,1
X
8,X
E
+1
V8,
YA
`d
,U
44
8,1
X
8,K
!k
,1
ZA
Z,
q
,e
AZ
,X
R8
,E
X
QG
*#
V8,
YA
QY
,U
44
8,
1X
8,K
!k
,1
ZA
Z,
q
,e
AQ
,X
R8
,E
X
QG
*#
V8,
YA
cZ
,U
48
,1
X
8,K
YT
Z!k
,Y
A`
,X
R8
,X
ZH
V8,
YA
j`
TY
Ae
Z,
U&
8,Q
X
8,X
HY
8,X
H[
V8,
YA
d[
,U
44
8,
1X
8,K
QT
Y,k
,1
`A
Y8
,K
1T
Q,k
,[
Ac
,X
R8
,X
HQ
V8,
ZA
1c
TZ
A1
`,
U&
8,1
X
8,X
E
+Q
V8,
ZA
cc
,U(
8,1
X
8,K
!k
,e
AY
,X
R8
,E
X
G*
#V
8,[
AZ
j,
U4
8,1
X
8,
K 1
TQ
,k
,[
Ac
,X
R8
,X
H1
V8,
eA
`Q
,U(
8,1
X
8,K
!k
,e
A`
,X
R8
,E
X
3
*G
*#
V8,
eA
1Q
Te
A`
c,
U&
8,Q
X
8,Q
E
X
3
*G
*#
V8,
eA
YY
,U4
8,Q
X
8,K
!k
,j
A1
,X
R8
,
E
X
3
*G
*#
V8,
eA
c`
,U4
8,1
X
8,K
!k
,e
Aj
,X
R8
,E
X
3
*G
*#
Vb,
?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,,1
eA
1,
UE
Hc
V8,
QQ
Ac
,
UE
E
+Z
,/
*,E
E
+[
V8,
QQ
Ae
,UE
X
YE
W
_
X
TV
8,Q
ZA
[,
UE
E
+Z
,/
*,E
E
+[
V8,
Q[
Ac
,UE
E
+c
V8,
Qd
AY
,UE
X
QG
*#
V8,
Y`
Ae
,UE
E
+Y
V8,
Zc
AZ
,UE
E
+1
V8,
Zd
A1
,U
E
E
+Q
V8,
[c
A1
,U
E
X
G*
#V
8,c
jA
`,
UE
HQ
V8,
cj
Ac
,U
E
H[
V8,
e1
AZ
,U
E
HY
V8,
eY
AY
,U
E
HZ
V8,
ej
AY
,U
E
H1
V8,
11
1A
1,
UE
3
*G
*#
V8,
11
QA
Y,
UE
X
3
*G
*#
V8,
11
dA
Z,
UE
X
3
*G
*#
V8,
11
dA
j,
UE
X
3
*G
*#
V8,
1Q
`A
Z,
UE
X
3
*G
*#
V8,
1Q
QA
[,
UE
X
3
*G
*#
V8,
1Q
ZA
[,
UE
X
3
*G
*#
V8,
1Q
jA
d,
UE
3
*G
*#
V8,
1Y
jA
1,
UE
3
*G
*#
V8,
1e
YA
1,
UE
kW
V8,
1e
YA
Q,
UE
kW
V8,
1e
eA
Y,
UE
kW
VA,
B
.,k
,`
AY
`,
UZ
^1
,E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,
7
a>
,k
,[
Yd
AZ
,5
U2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,.
/*
,E
Qc
X
Yc
_
ZW
e,
52
l_
)6
l ^,
[Y
dA
QZ
eQ
cb
,.
/"
'4
,
52
l_
)6
l ^,
[Y
dA
QZ
e[
ZA
,
. +
1W
S?
EO
EF
U1
E1
S'3
1+
D1V
#"
+:
81<
B"
%:
8*
8*
%:
8U#
:#
8$
B"
I*
%"
#*
)2
$I
:8
X1D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SC
BU
'
E
/&
#/
"'
4,
J5
1Y
6 ,P
)?
,;
/"
#$
%4
,P
0(F
,9
T_
T)
;%
(+
$T#
F%
'+
$)
$)
'0
'%
,"
?0
'K
,(F
%,
K%
'%
*)
$,X
J
Go
,#
*/
;%
4"
*%
A,G
F%
,;
*"
4%
,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U1
^d
,F
%C
)'
%^
,3
;W
D(
8,B
.,k
,`
AY
Y8
,j
ji
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y^
,2
%W
X
8,
B
.,
k,
`A
YQ
V,
).
./
*4
%4
,C
B,
UO
")
'(
V@'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1c
4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
c,
U4
8,1
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
Hc
V8,
1A
Zj
T1
AQ
e,
U&
8,Z
X
8,E
X
QE
+V
8,1
Ae
`T
1A
[Z
,U&
8,Q
X
8,E
X
QE
+V
8,
1A
jY
T1
Ae
1,
U&
8,Q
X
8,E
X
QE
+V
8,1
Ad
1,
U?
8,Y
X
8,E
X
YE
W
_
X
TV
8,Q
Ae
QT
QA
c[
,U&
8,1
X
8,X
E
+1
V8,
QA
j[
,U4
48
,1
X
8,K
!k
,1
YA
e,
q
,j
Ac
,
X
R8
,E
X
Q]
F%
V8,
YA
`j
,U
44
8,1
X
8,K
!k
,1
YA
e,
q
,c
AZ
,X
R8
,E
X
Q]
F%
V8,
YA
cQ
,U4
8,1
X
8,K
YT
Z!k
,Q
AY
,X
R8
,X
HZ
V8,
YA
ed
TY
Ae
1,
U&
8,Q
X
8,
X
HY
8,X
H[
V8,
YA
dY
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y8
!K
1T
Q,k
,[
Ac
,X
R8
,X
HQ
V8,
ZA
QQ
TZ
A1
Z,
U&
8,1
X
8,X
E
+Q
V8,
ZA
c`
,U4
48
,1
X
8,K
!k
,j
A[
,q
,c
A[
,
X
R8
,E
X
]F
%V8
,[
AZ
e,
U4
8,1
X
8,K
1T
Q!k
,[
Ac
,X
R8
,X
H1
V8,
eA
Qd
Te
A1
c,
U&
8,[
X
8,[
X
3
*]
F%
Vb,
?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,
U#
#&
V,
k,
,1
eA
1,
UE
Hc
V8,
QQ
Ac
,U
E
X
YE
W
_
X
TV
8,,
QQ
Ae
,U
E
E
+[
V8,
QZ
A[
,U
E
E
+Z
V8,
Q[
Ac
,U
E
E
+c
V8,
Y`
Ad
,U
E
E
+Y
V8,
Yd
AY
,U
E
X
Q]
F%
V8,
Zc
AZ
,U
E
E
+1
V8,
Zd
A1
,U
E
E
+Q
V8,
[c
AZ
,U
E
X
]F
%V8
,c
jA
`,
UE
HQ
V8,
cj
Ac
,U
E
H[
V8,
e1
AZ
,U
E
HY
V8,
eY
AY
,U
E
HZ
V8,
ej
AY
,U
E
H1
V8,
1Q
eA
j,
UE
X
3
*]
F%
V8,
1Q
dA
[,
UQ
uE
X
3
*]
F%
V8,
1Y
`A
Y,
UQ
uE
X
3
*]
F%
V8,
1Y
jA
c,
UE
3
*]
F%
V8,
1e
QA
e,
UE
kW
V8,
1e
YA
1,
UE
kW
V8,
1e
eA
Y,
UE
kW
VA,
B
.,
k,
`A
Z1
,U
Z^
1,
E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>
,k
,[
``
AZ
,5
U2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,.
/*
,
E
QZ
X
Y[
_
YW
e,5
2
l_
)6
l ^,
[`
`A
QY
ce
Qb
,./
"'
4,
52
l_
)6
l ^,
[`
`A
QY
cZ
cA
,
, +
1W
S?
EO
EF
U1
E1
SE
1V
;
,%
$2
"%
T*
;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C,
'
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,]
TQ
TJ
/;
T)
&
0'
/=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
X
J
Go
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,#
*/
4"
;(
,U
1^
1,
F%
C)
'%
^,
3
;W
D(
8,B
.,k
,`
AZ
QV
,P
)?
,#
"*
0.0
%4
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
U[
[,
i
,+
0%
$4
VA,
GF
%,
)&
04
%,
P
)?
,4
0?
?/
$<
%4
,0
',
),
&
0C
("
*%
,/
.,
E
X
QE
$ Q\
GH
3
,U
1A
[,
&
I8
,[
\1
VA,
GF
%,
*%
);
(0/
',
&
0C
("
*%
,P
)?
,?(
0**
%4
,)
(,*
A(A
,4
"*
0'
K,
Q,
F,
)'
4,
P
)?
,;
/'
;%
'(
*)
(%
4,
"'
4%
*,<
);
""
&
A,m
%&
#$
%'
,
4%
#*
/(
%;
(0/
',
/.
,(
F0
?,
;*
"4
%,
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,
B
.,
k,
`A
Q[
V,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,Ud
ei
VA,
, ? Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
1A
`Q
,U
48
,Y
X
8,K
[T
c,
k,
cA
Y,
X
R8
,X
cV
8,1
AQ
QT
QA
`c
,U
&
8,j
X
8,E
X
Q;
+;
$V8
,
QA
jZ
,U&
8,1
X
8,X
dV
8,Y
Ac
1,
U#
?%
"4
/T
48
,1
X
8,K
YT
Z,k
,Q
Ac
,X
R8
,X
ZV
8,Y
Ae
[T
YA
j1
,U&
8,Q
X
8,X
Y8,
X
[V
8,Y
Ad
c,
U4
48
,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,K
QT
Y,k
,1
`A
Q,
X
R8
,X
QV
8,Z
A[
Q,
U&
8,1
X
8,X
1`
V8,
[A
[`
,U&
8,1
X
8,X
1V
8,[
Ad
d,
U?
8,1
X
8,T
E
X
UW
3
;V
V8,
eA
`Y
,U4
8,1
X
8,K
1`
T
_
X
,k
,j
Ac
,X
R8
,_
X
11
V8,
eA
`j
,U4
8,1
X
8,_
X
eV
8,e
A1
`T
eA
jQ
,U&
8,Z
X
8,X
3
*VA
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,
k,
1c
A`
c,
UE
cV
8,Q
QA
QQ
8,Q
ZA
jc
8,Q
[A
1[
8,Y
`A
d`
,UZ
CE
X
Q;
+$
V8,
Zc
Ad
c,
UE
dV
8,Z
dA
Ye
,UE
1`
V8,
ce
Aj
j,
UE
[V
8,c
jA
[c
,UE
QV
8,e
1A
Zc
,
O
O
H
H
O
O
H
N
H
O H
N
O
N
H
2
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1e
UE
YV
8,
eY
AY
c,
UE
ZV
8,
ej
AQ
j,
UE
1V
8,
1e
eA
de
,U
QC
E
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
`e
,5
U2
l_
)V
l 8,
1`
`i
6A,
B
.,
k,
`A
Q[
,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
EO
EF
U1
E1
S>
1Q
$;
$<
B"
%:
8*
8*
%:
8U#
:#
8$
B"
I*
%#
*)
2$
I:
8X1
D
1>
1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
CZ
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,]
TJ
/;
TF
/&
/#
F%
'+
$)
$)
'0
'%
,"
?0
'K
,(
F%
,K
%'
%*
)$
,
X
J
Go
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,#
*/
4"
;(
,U
B .
,k
,`
Ae
[8
,
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Ue
Q,
i
,+
0%
$4
VA,
GF
%,
)&
04
%,
P
)?
,
40
??
/$
<%
4,
0'
,)
,&
0C
("
*%
,/
.,
E
X
QE
$ Q\
GH
3
,U
1A
[,
&
I8
,[
\1
VA,
GF
%,
*%
);
(0/
',
&
0C
("
*%
,P
)?
,
?(
0**
%4
,
)(
,
*A(
A,
4"
*0'
K,
Q,
F,
)'
4,
P
)?
,
;/
';
%'
(*)
(%
4,
"'
4%
*,
<)
;"
"&
A,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
/.
,(
F0
?,
;*
"4
%,
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,
`A
QV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,Ue
[i
VA,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'3
EY
U9
,į
,U#
#&
V,k
,1
A1
c,
U4
8,Y
X
8,K
[T
c,k
,c
A[
,X
R8
,X
cV
8,1
AZ
ZT
1A
ec
,U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Ac
j,
U4
48
,1
X
8,
> K
%&
,k
,1
cA
`,
X
R8
,>
E
X
QT
E
X
,k
,e
A[
,X
R8
,T
E
L
X
nE
X
_
X
QT
V8,
QA
ec
,U
44
8,
1X
8,
> E
X
QT
E
X
,k
,e
A[
,X
R8
,T
E
X
L
,E
X
_
X
QT
V8,
QA
j[
,U&
8,1
X
8,X
dV
8,Y
A1
`,
U4
8,Q
X
8,>
E
X
TE
X
Q,k
,e
AZ
,X
R8
,TE
X
E
X
Q]
FV
8,Y
Aj
YT
YA
je
,U&
8,Q
X
8,X
Z8,
X
[V
8,
YA
dQ
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
c,
X
R8
,K
YT
Z,k
,Y
AZ
,X
R8
,X
YV
8,Y
Ad
e,
U&
8,1
X
8,T
E
L
E
X
Q]
FV
8,Z
A`
e,
U4
48
,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,X
QV
8,
ZA
Zc
,U
&
8,1
X
8,X
1`
V8,
[A
[e
,U
&
8,1
X
8,X
1V
8,e
AZ
`T
eA
[[
,U
&
8,[
X
8,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'3
EY
U9
,į
,U
##
&
V,
k,
1c
AZ
j,
UE
cV
8,Q
`A
j`
8,Q
YA
11
8,Q
YA
ZY
8,Y
`A
Ze
,UZ
CE
X
Q;
+$
V8,
Yc
Ad
j,
UT
E
X
8X
Q]
FV
8,Y
jA
Zc
,UT
8X
QE
X
_
X
QT
V8,
Zc
A1
j,
UE
dV
8,
Zj
AQ
`,
UE
1`
V8,
[`
Ad
j,
UT
E
X
Q8
X
_
X
QT
V8,
cc
Ac
c,
UE
QV
8,c
jA
`1
,U
E
[V
8,e
`A
1d
,U
E
YV
8,e
QA
11
,U
E
ZV
8,e
eA
1Q
,U
E
1V
8,1
Qj
AY
j8
,
1Q
dA
j[
8,1
Y`
A1
`,
U[
CE
3
*V8
,1
Y[
Ae
d,
UE
0#
?/
V8,
1e
1A
Zc
8,1
ej
AZ
Q,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
[`
A[
,5
U2
l1
Vl
8,1
``
i
6A,
B
.,k
,`
AQ
`,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
. +
1W
S?
EO
EF
U1
E1
S[
"%
T*
;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
'C
\'
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
);
04
,;
F$
/*
04
%,
#*
/;
%4
"*
%,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,#
*/
4"
;(
,U
B .
,k
,`
Aj
e8
,3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Uj
`,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
O
O
H
H
O
O
H
N
H
O H
N
O
N
H
2
P
h O
O
H
H
O
O
H
N
H
O H
N
O
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1j
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
eV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
`A
eY
,U
48
,Y
X
8,K
[T
c,
k,
cA
Z,
X
R8
,X
cV
8,1
A1
YT
QA
`c
,U
&
8,j
X
8,E
X
Q;
+;
$V8
,
QA
jY
,U&
8,1
X
8,X
dV
8,Y
AZ
Q,
U#
?%
"4
/T
48
,1
X
8,K
YT
Z,k
,Q
Ac
,X
R8
,X
ZV
8,Y
AZ
e,
U&
8,1
X
8,X
[V
8,Y
Ac
Z,
U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,
K Y
TZ
,k
,Y
AY
,X
R8
,X
YV
8,Y
Aj
Q,
U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QV
8,Z
AY
`,
U&
8,1
X
8,X
1`
V8,
[A
Ye
,U&
8,1
X
8,X
1V
8,e
AY
YT
eA
ZY
,U&
8,Y
X
8,
X
3
*V8
,e
Ac
[T
eA
eQ
,U&
8,Q
X
8,X
3
*VA
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,1
cA
jc
,UE
cV
8,Q
YA
QQ
8,Q
ZA
ZZ
8,Q
cA
`Z
8,
Y`
Aj
Z,
UZ
CE
X
Q;
+$
V8,
Zc
A`
c,
UE
dV
8,
[`
AY
Q,
UE
1`
V8,
cj
A`
`,
UE
QV
8,
cj
AY
c,
UE
[V
8,
e1
A[
Z,
UE
YV
8,
eY
AY
c,
UE
ZV
8,
ej
A[
`,
UE
1V
8,
1e
`A
1Z
8,1
ee
Ad
e,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
1[
,5U
2
l_
)V
l 8,
Q`
i
6A,
B
.,k
,`
A1
e,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
EO
EF
U1E
1SC
1SF
B"
%:
80
/8
-$
%:
8U<
)$
<*
%*
;
,&
$U
#:
#8
$B
"I
*%
#*
)2
$I
:8
U1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C8
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,U
#F
%'
+$
?"
$./
'+
$V#
*/
#0
/'
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
);
04
,;
F$
/*
04
%,
#*
/;
%4
"*
%,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,#
*/
4"
;(
,U
B
.,k
,
`A
[d
8,1
^Z
,F
%C
)'
%^
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
UZ
e,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
[V
,
).
./
*4
%4
,(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'3
EY
U9
,į
,U#
#&
V,k
,1
A1
Q,
UY
X
8,4
8,K
[T
c,k
,c
A[
,X
R8
,X
cV
8,1
AY
`T
1A
jQ
,
U&
8,j
X
8,E
X
QE
h
E
IV
8,Q
Ac
jT
QA
jQ
,U&
8,Y
X
8,X
d8,
TE
X
Q!
W
Q]
FV
8,Y
Ac
[,
U&
8,1
X
8,T
E
L
X
nE
X
Q!
W
Q]
FV
8,Y
Ae
cT
YA
jQ
,U&
8,Y
X
8,
X
Z8,
X
[8,
TE
X
L
,E
X
Q!
W
Q]
FV
8,Y
Ad
1,
U4
48
,1
X
8,K
QT
Y,
k,
1`
A[
,X
R8
,K
YT
Z,
k,
YA
Z,
X
R8
,X
YV
8,Z
A`
j,
U4
48
,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,
X
QV
8,[
A[
c,
U4
8,1
X
8,X
1V
8,e
Ae
[T
jA
`1
,U&
8,[
X
8,X
3
*VA
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'3
EY
U9,
į,
U#
#&
V,k
,1
cA
Z`
,UE
cV
8,Q
1A
11
8,
QY
Ad
,
UY
CE
X
QE
h
E
IV
8,
Qd
AY
Z,
UT
E
X
Q!
W
Q]
FV
8,
Y`
AQ
e,
UE
X
QE
h
E
IV
8,
Z[
Ac
Y,
UE
dV
8,
Zj
Ac
j,
UE
1`
V8,
[1
Ae
[,
UT
8X
QE
X
Q!
W
Q]
FV
8,
cc
Ac
Z,
UE
QV
8,
ce
A[
j,
UE
[V
8,
cd
Aj
c,
UE
YV
8,
eQ
A`
d,
UE
ZV
8,
ee
AQ
Z,
UE
1V
8,
1Q
jA
[e
8,
1Y
`A
Z[
8,
1Y
[A
c[
,
UY
CE
3
*V8
,1
Ye
A1
`,
UE
0#
?/
V8,
1e
1A
``
,U
E
1Q
V8,
1e
jA
YY
,U
E
jV
A,
D!
-T
2
!^
,7
a>
,k
,Z
j[
,5
U2
l1
Vl
8,
Q[
i
6A,
B
.,
k,
`A
1[
,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, . . .
O
O
H
H
O
O
H
N
H
O H
N
O
S
P
h O
O
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
1d
+
1W
S?
EO
EF
U1E
1SE
1Q
:&
)$
I:
1E
1;
"+
B:
8<
)$
<*
%*
;
,&
$U
#:
#8
$B
"I
*%
#*
)2
$I
:8
X1
D
1>
1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
C;
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Q
T)
;%
(/
C+
QT
&
%(
F+
$#
*/
#)
'/
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
);
04
,;
F$
/*
04
%,
#*
/;
%4
"*
%,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,#
*/
4"
;(
,U
B
.,
k,
`A
[d
8,1
^Z
,F
%C
)'
%^
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
UZ
c,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
[V
,
).
./
*4
%4
,(F
%,
(0(
$%
,#
*/
4"
;(
,Ud
[i
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,1
A1
e,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
cV
8,1
AY
c,
U?
8,
cX
8,T
E
UE
X
YV
QV
8,1
AY
1T
QA
`Y
,U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Aj
`,
U&
8,1
X
8,X
dV
8,Y
Ac
Z,
U&
8,1
X
8,X
ZV
8,Y
Ae
c,
U&
8,1
X
8,X
[V
8,Y
Ae
d,
U4
48
,
1X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
AZ
,X
R8
,X
YV
8,Y
Ad
c,
U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QV
8,Z
A1
Z,
U&
8,1
X
8,X
1`
V8,
[A
[`
,U4
8,1
X
8,X
1V
A,
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
1[
Ac
1,
UE
cV
8,Q
1A
Zc
8,Q
YA
``
8,Q
ZA
dc
8,Q
dA
Zc
,U
ZC
E
X
Q;
+$
V8,
Qc
AY
[8
,
Qc
AZ
c,
UQ
CT
E
U8
X
YV
QV
8,Z
ZA
jZ
,UE
d8,
E
1`
V8,
cc
A[
[,
UE
QV
8,c
eA
``
,UE
[V
8,e
`A
`Y
,UE
YV
8,e
1A
d1
,UE
ZV
8,e
YA
Q,
UT
8
UE
X
YV
QV
8,e
cA
jj
,
UE
1V
8,1
ee
AY
d8
,1
ej
Aj
d,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Y
de
,5U
2
l_
)V
l 8,
Yj
i
6A,
B
.,k
,`
A1
[,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
EO
EF
U1
E1
S]
/,
%$
8,%
"1
C1
#*
)2
$I
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C%
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,O
"0
'/
$0'
%T
YT
;)
*=
/C
+$
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,)
;0
4,
;F
$/
*04
%,
#*
/;
%4
"*
%,
)'
4,
(F
%,
#*
/4
";
(,U
B
.,k
,`
AZ
[8
,1
^Z
,F
%C
)'
%^
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,
;F
*/
&
)(
/K
*)
#F
+,
UZ
j,
i
,
+0
%$
4V
A,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AQ
QV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,`
Ae
Z,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
cV
8,1
1A
Zc
T
QA
1[
,U
&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Ad
c,
U&
8,1
X
8,X
dV
8,Y
A[
Y,
U&
8,1
X
8,X
ZV
8,Y
Ac
1,
U&
8,1
X
8,X
[V
8,Y
Ae
e,
U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
AY
,X
R8
,X
YV
8,Y
Ad
Y,
U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QV
8,Z
A[
e,
U&
8,1
X
8,X
1`
V8,
[A
[`
,U4
8,1
X
8,
X
1V
8,e
Ae
Q,
U&
8,1
X
8,X
1d
V8,
eA
d1
,U&
8,1
X
8,X
1j
V8,
jA
`j
8,j
A1
`,
UQ
C&
8,Q
X
8,X
1e
8,X
Q`
V8,
jA
ej
,U&
8,1
X
8,X
QQ
V8,
dA
Q`
,U&
8,1
X
8,
X
1Z
VA,
?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,1
cA
jd
,UE
cV
8,Q
QA
d1
8,Q
ZA
c[
8,Q
[A
[[
8,Y
1A
1Q
,UZ
CE
X
Q;
+$
V8,
Zc
AY
`,
UE
dV
8,[
`A
YZ
,U
E
1`
V8,
cj
A`
`,
UE
QV
8,c
jA
Yj
,U
E
[V
8,e
1A
[[
,U
E
YV
8,e
YA
Y`
,U
E
ZV
8,e
jA
Zc
,U
E
1V
8,1
Qj
A[
j,
UE
Q1
V8,
1Q
dA
1[
,U
E
1Y
V8,
1Q
dA
`c
8,1
Qd
AY
Q8
,1
Y`
AZ
[8
,1
YQ
Ad
c8
,1
Yj
A`
Q,
UE
1e
8,E
1j
8,E
1d
8,E
Q`
8,E
QQ
V8,
1Z
dA
jQ
,UE
1c
V8,
1[
`A
QQ
,UE
1Z
V8,
1c
jA
`Q
,UE
1Q
V8,
1e
eA
eY
,UE
jV
A,D
!-
T2
!^
,7
a>
,k
,Z
ZZ
,5U
2
lX
Vl
8,1
``
i
6A,
B
.,k
,`
AQ
Q,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
O
O
H
H
O
O
H
N
H
O H
N
O
H
O O
O
H
H
O
O
H
N
H
O H
N
O
N
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Q`
, +
1W
S?
EO
EF
U1
E1
SN
17
,+)
$2
"%
T"
%"
0/
8-$
%*
;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8U1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C$
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Z
T'
0(*
/=
%'
R%
'%
?"
$./
'+
$,;
F$
/*
04
%,
)'
4,
(F
%,
#*
/4
";
(,U
B .
,
k,
`A
cj
8,
1^
Z,
F%
C)
'%
^3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Uc
d,
i
,
+0
%$
4V
A,m
%&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,
`A
Q1
V,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,Uc
Yi
VA'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
1A
1d
,U
48
,Y
X
8,K
[T
c,
k,
cA
Z,
X
R8
,X
cV
8,1
AY
1T
1A
jc
,U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Ae
Y,
U&
8,1
X
8,X
dV
8,Y
Ac
jT
YA
eQ
,U&
8,Q
X
8,X
Z8,
X
1`
V8,
YA
ed
,U4
48
,1
X
8,
K Q
TY
,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
AZ
,X
R8
,X
YV
8,Y
Ad
Y,
U&
8,1
X
8,X
[V
8,Y
Ad
c,
U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QV
8,[
A[
`,
U4
8,1
X
8,X
1V
8,j
A1
Z8
,
jA
Z1
,U
QC
4,
ZX
8,K
,k
,j
AZ
,X
R8
,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
1c
Aj
j,
UE
cV
8,Q
QA
cQ
8,Q
YA
de
8,
Qc
A1
18
,Y
`A
j[
,UZ
CE
X
Q;
+$
V8,
Ze
AQ
Z,
UE
dV
8,[
YA
d1
,UE
1`
V8,
cj
A`
1,
UE
QV
8,c
jA
[`
,UE
[V
8,e
1A
Zj
,UE
YV
8,e
YA
Qd
,UE
ZV
8,e
jA
QY
,UE
1V
8,
1Q
[A
Y[
8,1
Qd
AZ
1,
UZ
CE
3
*V8
,1
Zj
Ae
Z8
,1
[1
AY
Y,
UQ
CE
0#
?/
V8,
1e
eA
``
,UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
eZ
,5U
2
lX
Vl
8,e
ji
6A,
B
.,
k,
`A
Q1
,UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
EO
EF
U1E
1SC
15
%&
$8
*#
"+
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8U1
D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C<
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Y
T0'
4/
$)
;%
(0;
,)
;0
4,
);
04
,"
?0
'K
,(F
%,
K%
'%
*)
$,X
J
Go
,
#*
/;
%4
"*
%,
)'
4,
(F
%,
#*
/4
";
(,
UB
.,
k,
`A
cj
8,
3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,
;F
*/
&
)(
/K
*)
#F
+,
UZ
j,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
1V
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,1
A1
Z,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
cV
8,1
AY
`T
1A
jZ
,U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Aj
Z,
U&
8,1
X
8,X
dV
8,Y
Ae
ZT
YA
d1
,U&
8,[
X
8,E
X
Q-
_
9
W
I8,
X
Y8,
X
Z8,
X
[V
8,
ZA
`e
,U
44
8,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,K
QT
Y,
k,
1`
Ac
,X
R8
,X
QV
8,Z
AY
d,
U&
8,1
X
8,X
1`
V8,
[A
[c
,U
48
,1
X
8,X
1V
8,e
AQ
ZT
eA
Yd
,U
&
8,Y
X
8,
X
3
*V8
,e
Ac
1,
U4
8,1
X
8,K
,k
,j
AQ
,X
R8
,X
3
*V8
,e
Ae
`,
U4
8,1
X
8,K
,k
,e
Ad
,X
R8
,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,
U#
#&
V,
k,
1c
A[
`,
UE
cV
8,
Q1
A`
18
,Q
YA
cQ
8,
QY
Aj
18
,Y
`A
[[
,U
ZC
E
X
Q;
+$
V8,
YY
AQ
Q,
UE
X
Q-
_
9
W
IV
8,
Z[
Ae
Y,
UE
dV
8,
Zj
Aj
1,
UE
1`
V8,
cc
Aj
`,
UE
QV
8,
ce
Ad
c,
UE
[V
8,
e`
AY
Z,
UE
YV
8,
eQ
AQ
Y,
UE
ZV
8,
ee
AZ
c,
UE
1V
8,
1`
jA
Yj
,U
E
0#
?/
T1
ZV
8,
11
QA
ce
8,
11
dA
Q[
8,
1Q
`A
Qj
8,
O
O
H
H
O
O
H
N
H
O H
N S
O
O
O
2N
O
O
H
H
O
O
H
N
H
O H
N
O
H N
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Q1
1Q
QA
jj
8,
1Q
[A
c`
,U
[C
E
3
*V8
,1
Qj
A[
c8
,1
Ye
A`
e,
UQ
CE
0#
?/
V8,
1e
ZA
jZ
,U
E
1Q
V8,
1e
jA
Yd
,U
E
jV
A,
D!
-T
2
!^
,7
a>
,k
,Z
Zc
AY
,
5U
2
lX
Vl
8,1
``
i
6AA
,B
.,k
,`
A1
1,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
EO
EF
U1
E1
SS
EU
1E
1Q
:&
)$
I:
<B
"%
:8
*#
"+
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C^
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,U
0V
TU
lV
TD
T)
;%
(/
C+
#F
%'
+$
);
%(
0;
,)
;0
4,
"?
0'
K,
(F
%,
K%
'%
*)
$,
);
04
,;
F$
/*
04
%,
#*
/;
%4
"*
%,
)'
4,
(F
%,
#*
/4
";
(,
UB
.,k
,`
AY
j8
,1
^1
,F
%C
)'
%^
3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
UZ
e,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
Ae
QV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,
UO
")
'(
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'3
EY
U9
,į
,U#
#&
V,k
,1
A1
j,
U4
8,Y
X
8,K
[T
c,k
,c
AZ
,X
R8
,X
cV
8,1
AZ
`T
1A
dY
,
U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Ad
Z,
U&
8,1
X
8,X
dV
8,Y
Ae
jT
YA
j1
,U&
8,Q
X
8,X
Z8,
X
[V
8,Y
Ad
Y,
U4
48
,1
X
8,K
QT
Y,k
,
1`
Ac
,X
R8
,K
YT
Z,k
,Y
AZ
,X
R8
,X
YV
8,Z
A`
c,
U4
48
,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,X
QV
8,Z
AY
j,
U&
8,1
X
8,X
1`
V8,
[A
Q1
,U?
8,1
X
8,T
E
L
UW
X
V]
FV
8,
[A
[j
,U
48
,1
X
8,X
1V
8,e
AZ
[T
eA
[Q
,U
&
8,[
X
8,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'3
EY
U9
,į
,U
##
&
V,
k,
1c
AQ
d,
UE
cV
8,Q
`A
e1
8,
QY
AY
c8
,Q
YA
ce
8,Y
`A
Q[
,U
ZC
E
X
Q;
+$
V8,
Z[
AZ
Z,
UE
dV
8,Z
jA
Z1
,U
E
1`
V8,
cc
AZ
e,
UE
QV
8,c
eA
jQ
,U
E
[V
8,e
`A
`e
,U
E
YV
8,e
1A
de
,U
E
ZV
8,
eZ
A[
Q,
UT
8X
UW
X
V]
FV
8,e
eA
1Z
,U
E
1V
8,1
Qe
Ac
18
,1
Qd
A[
j,
U[
CE
3
*V8
,1
Yd
A1
c,
UE
0#
?/
V8,
1e
ZA
ZQ
8,1
ej
AQ
[,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
`[
A[
,5U
2
TW
X
Vl
8,Q
[i
6A,
B
.,k
,`
Ae
Q,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1S
S?
EO
EF
U1
E1
SE
1Q
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8U1
D
1 >
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C)
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Q
T)
;%
(/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(
F%
,K
%'
%*
)$
,)
;0
4,
;F
$/
*04
%,
#*
/;
%4
"*
%,
)'
4,
(F
%,
#*
/4
";
(,U
B
.,k
,`
AY
8,1
^1
,F
%C
)'
%^
3
;W
D(
V,
P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,
;F
*/
&
)(
/K
*)
#F
+,
U[
`,
i
,
+0
%$
4V
A,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
Ae
[V
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'3
EY
U9
,į
,U
##
&
V,
k,
`A
ej
,U
48
,Y
X
8,K
[T
c,
k,
cA
[,
X
R8
,X
cV
8,1
AZ
jT
QA
`[
,
U&
8,j
X
8,E
X
Q;
+;
$V8
,Y
A`
`,
U&
8,1
X
8,X
dV
8,Y
Ac
1,
U4
O8
,1
X
8,K
ZT
[,r
,1
,X
R8
,X
[V
8,Y
Ac
e,
U4
48
,1
X
8,K
YT
Z,
k,
YA
Z,
X
R8
,X
ZV
8,Y
Aj
Y,
U4
48
,1
X
8,K
QT
Y,k
,1
`A
c,
X
R8
,X
YV
8,Z
A`
`,
U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
QV
8,Z
A[
c,
U&
8,1
X
8,X
1V
8,[
AZ
j,
U4
8,
1X
8,X
1V
8,e
A`
j8
,e
AZ
d8
,e
Aj
Z,
UY
C&
8,Z
X
8,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'3
EY
U9,
į,
U#
#&
V,
k,
1c
A1
`,
UE
cV
8,Q
1A
cQ
8,
O
O
H
H
O
O
H
N
H
O H
N
O
H
O O
O
H
H
O
O
H
N
H
O H
N
O
H
O
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
QQ
QY
Ad
`8
,Q
ZA
Q1
8,Y
`A
Yd
,U
ZC
E
X
Q;
+$
V8,
Z[
A[
d,
UE
dV
8,Z
dA
[j
,U
E
1`
V8,
cc
Aj
Q,
UE
QV
8,c
eA
jd
,U
E
[V
8,e
`A
ZY
,U
E
YV
8,e
QA
Qe
,U
E
ZV
8,
ee
Ac
c,
UE
1V
8,1
1e
Ad
c,
UE
3
*V8
,1
1j
AQ
`,
UE
0#
?/
V8,
1Q
1A
Y1
8,1
Y`
AY
c8
,1
YZ
Ad
d,
UY
CE
3
*V8
,1
[e
AQ
j,
UE
0#
?/
V8,
1c
dA
`e
8,1
ej
Ac
Y,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
Y1
A[
,5U
2
l_
)V
l 8,
Y`
i
6A,
B
.,k
,`
Ae
[,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
, +
1W
S?
.E
OE
FU
1E
1S
N1
Q
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D
1>
'1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
C0
'''
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Z
T)
;%
(/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(F
%,
K%
'%
*)
$,)
;0
4,
;F
$/
*04
%,
#*
/;
%4
"*
%,
)'
4,
(F
%,
#*
/4
";
(,U
B
.,k
,`
AY
`8
,1
^1
,F
%C
)'
%^
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,=
+,
)"
(/
&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
U[
[,
i
,+
0%
$4
VA,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
^Q
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AZ
cV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
VA'
'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'3
EY
U9
,į
,U
##
&
V,
k,
`A
cc
,U
48
,Y
X
8,K
[T
c,
k,
cA
[,
X
R8
,X
cV
8,1
AY
1T
1A
d[
,U&
8,j
X
8,E
X
Q;
+;
$V8
,Q
Ad
Z,
U&
8,1
X
8,X
dV
8,Y
AZ
c,
U&
8,1
X
8,X
[V
8,Y
A[
d,
U#
?%
"4
/T
48
,1
X
8,
K Y
TZ
,k
,Y
AZ
,X
R8
,X
ZV
8,Y
Ae
c,
U4
48
,1
X
8,K
QT
Y,k
,1
`A
c,
X
R8
,X
YV
8,Y
Ad
Q,
U4
48
,1
X
8,K
1T
Q,
k,
[A
e,
X
R8
,
X
QV
8,Z
AZ
`,
U&
8,1
X
8,X
1`
V8,
[A
ZQ
,U
48
,1
X
8,X
1V
8,c
Ad
18
,e
Ac
`,
UQ
C4
8,Z
X
8,X
3
*VA
,?
C 4
17
R
G
''
S?
DD
'R
Q
TO
'3
EY
U9,
į,
U#
#&
V,k
,1
cA
`Z
,UE
cV
8,Q
1A
[j
8,Q
YA
[e
8,Q
YA
dQ
8,Y
`A
Q[
,UZ
CE
X
Q;
+$
V8,
Z[
AY
e,
UE
dV
8,Z
dA
e[
j,
UE
1`
V8,
cc
Ac
e,
UE
[V
8,c
eA
jQ
,U
E
QV
8,e
`A
Qe
,U
E
YV
8,e
QA
1[
,U
E
ZV
8,e
eA
[Q
,
UE
1V
8,1
1c
A`
d,
UQ
CE
3
*V8
,1
Qc
AZ
c,
UE
0#
?/
V8,
1Y
`A
Yj
,UQ
CE
3
*V8
,1
[d
Ad
c,
UE
0#
?/
V8,
1e
`A
jj
8,1
ej
Ae
[,
UQ
CE
kW
VA,
D!
-T
2
!^
,7
a>,
k,
ZY
1A
[,
5U
2
l_
)V
l 8,
Y`
i
6A,
B
.,k
,`
AZ
c,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
. +
1W
S?
EO
EF
U1
E1
S3
1+
GV
#"
+:
81G
*+
#(
/#
F)
'/
+$
U#
:#
8$
B"
I*
%"
#*
)2
$I
:8
X1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C+
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,_
T)
;%
(+
$T9
T(*
+#
(/
#F
)'
,"
?0
'K
,(
F%
,K
%'
%*
)$
,
X
J
Go
,#
*/
;%
4"
*%
,)
'4
,(F
%,
#*
/4
";
(,U
B
.,k
,`
AZ
j8
,1
^d
,F
%C
)'
%^
3
;W
D(
V,P
)?
,0?
/$
)(
%4
,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
UZ
^1
,E
X
E
$ Y^
,2
%W
X
8,
B
.,
k,
`A
QQ
V,
).
./
*4
%4
,(
F%
,(
0($
%,
#*
/4
";
(,
UO
")
'(
AVA
'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,1
A1
e,
U4
8,1
X
8,K
kc
A[
,X
R8
,Y
X
cH
V8,
1A
Yc
T
O
O
H
H
O
O
H
N
H
O H
N
O
H
O
O
O
H
H
O
O
H
N
H
O H
N
O
N H
N
H
A
c
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
QY
1A
1Q
U&
,Z
X
8,E
X
Q;
+;
$V8
,1
Ae
YT
1A
[Z
,U&
8,Z
X
8,E
X
Q;
+;
$V8
,1
Ad
[,
U?
8,Y
X
8,E
X
YE
W
_
X
TV
8,Q
Ae
`T
QA
cY
,U&
8,1
X
8,X
1V
8,Y
A`
d,
U4
48
,
1X
8,K
k1
ZA
Z,
q
,e
AZ
,X
R8
,E
X
QG
*#
V8,
YA
QY
,U
44
8,1
X
8,K
k1
ZA
Z,
q
,e
AQ
,X
R8
,E
X
QG
*#
V8,
YA
cZ
,U
48
,1
X
8,K
kY
A`
,X
R8
,X
ZH
V8,
YA
j`
T
YA
eZ
,U&
8,Q
X
8,K
kQ
Aj
,X
R8
,X
YH
,l
,X
[H
V8,
YA
d[
,U4
48
,1
X
8,K
k1
`A
Y,
q
,[
Ac
,X
R8
,X
QH
V8,
ZA
1c
TZ
A1
`,
U&
8,1
X
8,X
QV
8,Z
Ac
c,
U(8
,1
X
8,
Kk
eA
Y,
X
R8
,E
X
G*
#V
8,[
AZ
j,
U4
8,1
X
8,K
k[
Ac
,X
R8
,X
1H
V8,
eA
`Q
,U(
8,1
X
8,K
ke
A`
,X
R8
,E
X
3
*G
*#
V8,
eA
1Q
Te
A`
c,
U&
8,Q
X
8,Q
E
X
3
*G
*#
V8,
eA
YY
,U4
8,Q
X
8,K
kj
A1
,X
R8
,E
X
3
*G
*#
V8,
eA
c`
,U4
8,1
X
8,K
ke
Aj
,X
R8
,E
X
3
*G
*#
VA,
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9,
į,
U#
#&
V,
k,
,1
eA
1,
UE
cH
V8,
QQ
Ac
,UE
Z,/
*,E
[V
8,Q
QA
e,
UE
X
YE
W
_
X
TV
8,Q
ZA
[,
UE
Z,/
*,E
[V
8,Q
[A
c,
UE
cV
8,Q
dA
Y,
UE
X
QG
*#
V8,
Y`
Ae
,UE
YV
8,Z
cA
Z,
UE
1V
8,Z
dA
1,
UE
QV
8,[
cA
1,
UE
X
G*
#V
8,c
jA
`,
UE
QH
V8,
cj
Ac
,UE
[H
V8,
e1
AZ
,UE
YH
V8,
eY
AY
,UE
ZH
V8,
ej
AY
,UE
1H
V8,
11
1A
1,
UE
3
*G
*#
V8,
11
QA
Y,
UE
X
3
*G
*#
V8,
11
dA
Z,
UE
X
3
*G
*#
V8,
11
dA
j,
UE
X
3
*G
*#
V8,
1Q
`A
Z,
UE
X
3
*G
*#
V8,
1Q
QA
[,
UE
X
3
*G
*#
V8,
1Q
ZA
[,
UE
X
3
*G
*#
V8,
1Q
jA
d,
UE
3
*G
*#
V8,
1Y
jA
1,
UE
3
*G
*#
V8,
1e
YA
1,
UE
kW
V8,
1e
YA
Q,
UE
kW
V8,
1e
eA
Y,
UE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,[
Yd
AZ
,5U
2
l_
)V
l 8,
1`
`i
6A,
, +
1W
S?
.E
OE
FU
1E
1S
>
G+
1V
#"
+:
81+
):
<+
$<
B*
%$
:8
U#
:#
8$
B"
I*
%"
#*
)2
$I
:8
X1
'D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C/
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,]
T)
;%
(+
$TI
T(*
+#
(/
#F
)'
,"
?0
'K
,(F
%,
K%
'%
*)
$,X
J
Go
,#
*/
;%
4"
*%
,)
'4
,(F
%,
#*
/4
";
(,
UB
.,
k,
`A
Qc
8,
1^
d,
F%
C)
'%
^3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Ue
1i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
UZ
^1
,E
X
E
$ Y^
,
2
%W
X
8,B
.,k
,`
AY
QV
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,UO
")
'(
AVA
'
? Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U9
,į
,U
##
&
V,
k,
,1
A1
`,
U4
8,1
X
8,K
kc
AZ
,X
R8
,Y
X
cH
V8,
1A
eY
T
1A
QY
,U&
8,e
X
8,X
Y,l
,Q
X
Z,l
,Q
X
[,l
,Q
X
cV
8,1
Aj
e,
U?
8,Y
X
8,E
X
YE
W
_
X
TV
8,,
QA
`Y
T1
Aj
1,
U&
8,1
X
8,
X
YV
8,Q
Ae
[T
QA
cd
,U&
8,1
X
8,X
1V
8,Y
A`
c,
U4
48
,1
X
8,K
k1
ZA
d,
q
,d
A1
,X
R8
,E
X
QG
*#
V8,
YA
QQ
,U4
48
,1
X
8,
Kk
1Z
Ad
,q
,Z
Aj
,X
R8
,E
X
QG
*#
V8,
YA
[d
,U
48
,1
X
8,K
kY
A`
,X
R8
,X
ZH
V8,
YA
ed
TY
Ae
`,
U&
8,Q
X
8,X
YH
,l
,
X
[H
V8,
YA
dY
,U4
48
,1
X
8,K
k1
`A
Y,
q
,[
Ac
,X
R8
,X
QH
V8,
ZA
QZ
TZ
A1
c,
U&
8,1
X
8,X
QV
8,Z
Ac
e,
U4
48
,1
X
8,K
kd
A`
,q
,Z
Ad
,X
R8
,E
X
G*
#V
8,[
A[
`,
U4
8,1
X
8,K
k[
Ac
,X
R8
,X
1H
V8,
cA
dd
,U(
8,1
X
8,K
ke
A`
,X
R8
,E
X
3
*G
*#
V8,
eA
11
Te
A`
Z,
U&
8,Q
X
8,Q
E
X
3
*G
*#
V8,
eA
Y1
,U4
8,Q
X
8,K
kj
A1
,X
R8
,
E
X
3
*G
*#
V8,
eA
c1
,U4
8,1
X
8,K
ke
Aj
,X
R8
,E
X
3
*G
*#
VA,
,
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,,1
eA
1,
UE
cH
V8,
QQ
A[
,UE
Z,/
*,E
[V
8,Q
YA
`,
UE
X
YE
W
_
X
TV
8,Q
ZA
Z,
UE
Z,/
*,E
[V
8,
Qc
AY
,UE
cV
8,Q
dA
`,
UE
X
QG
*#
V8,
Y`
Aj
,UE
YV
8,Z
cA
Z,
UE
1V
8,Z
dA
Y,
UE
QV
8,[
[A
e,
UE
X
G*
#V
8,c
jA
1,
UE
QH
V8,
cj
Ac
,UE
[H
V8,
e1
A[
,UE
YH
V8,
eY
AY
,
UE
ZH
V8,
ej
AY
,U
E
1H
V8,
11
1A
Y,
UE
X
3
*G
*#
V8,
11
QA
Q,
UE
X
3
*G
*#
V8,
11
dA
[,
UE
X
3
*G
*#
V8,
11
dA
j,
UE
X
3
*G
*#
V8,
1Q
QA
Z,
UE
X
3
*G
*#
V8,
1Q
ZA
Z,
O
O
H
H
O
O
H
N
H
O H
N
O
N H
N
H
A
c
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
QZ
UE
X
3
*G
*#
V8,
1Q
jA
d,
UE
3
*G
*#
V8,
1Y
jA
1,
UE
3
*G
*#
V8,
1e
YA
Y,
UE
kW
V8,
1e
YA
e,
UE
kW
V8,
,1
ee
AZ
,U
E
kW
VA,
D!
-T
2
!^
,7
a>
,k
,[
Yd
AZ
,
5U
2
l_
)V
l 8,
1`
`i
6A,
. +
1W
S?
EO
EF
U1
E1
SC
OJ
13
,;
"+
B$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
C=
''
E
/&
#/
"'
4,
J,
P
)?
,;
/"
#$
%4
,P
0(F
,Y
8[
T4
0&
%(
F/
C+
=%
'R
/0
;,
);
04
,"
?0
'K
,(
F%
,K
%'
%*
)$
,X
J
Go
,#
*/
;%
4"
*%
,)
'4
,(
F%
,
#*
/4
";
(,
UB
.,
k,
`A
YQ
8,
1^
1A
[,
F%
C)
'%
^3
;W
D(
V,
P
)?
,0
?/
$)
(%
4,
=+
,)
"(
/&
)(
%4
,;
F*
/&
)(
/K
*)
#F
+,
Uj
e,
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
UZ
^1
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
Ac
1V
,)
..
/*
4%
4,
(F
%,
(0(
$%
,#
*/
4"
;(
,
UO
")
'(
AVA
'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U9
,į
,U#
#&
V,k
,`
Aj
[,
U4
8,1
X
8,K
kc
AZ
,X
R8
,Y
X
cH
V8,
1A
j1
T1
AY
Z,
,
U&
8,c
X
8,X
Y,l
,Q
X
Z,l
,Q
X
[,l
,X
cV
8,Q
A`
`T
1A
d`
,U&
8,1
X
8,X
cV
8,Q
A1
dT
QA
1`
,U&
8,1
X
8,X
YV
8,Q
Ad
Y,
U(4
8,1
X
8,K
kj
A[
,q
,Z
AZ
,X
R8
,X
1V
8,Y
A[
1,
U4
8,1
X
8,K
kQ
Ac
,X
R8
,X
ZH
V8,
YA
[[
,U
O8
,1
X
8,K
kc
Ac
,X
R8
,
X
[H
V8,
YA
eY
,U
44
8,1
X
8,K
k1
`A
Y,
q
,Y
AZ
,X
R8
,X
YH
V8,
YA
j1
,U
?8,
cX
8,Q
,C
,W
2
%V
8,Y
Ad
1,
U4
48
,1
X
8,
Kk
1`
AY
,q
,[
Ac
,X
R8
,X
QH
V8,
ZA
Ye
TZ
AY
1,
U&
8,1
X
8,X
QV
8,[
AZ
e,
U4
8,1
X
8,K
k[
Ac
,X
R8
,X
1H
V8,
cA
c1
,U(
8,
1X
8,K
kQ
AQ
,X
R8
,X
3
*V8
,c
Ad
1,
U4
8,Q
X
8,K
kQ
AQ
,X
R8
,Q
X
3
*VA
,,?
C 4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U9
,
į,
U#
#&
V,
k,
1c
Ae
,U
E
cH
V8,
QY
AQ
,U
E
[V
8,Q
ZA
Q,
UE
ZV
8,Q
cA
`,
UE
cV
8,Y
`A
c,
UE
YV
8,Z
[A
j,
UE
1V
8,[
`A
Z,
UE
QV
8,[
cA
1,
UQ
,C
,W
2
%V
8,c
eA
d,
UE
QH
V8,
cj
AY
,U
E
[H
V8,
e1
AZ
,U
E
YH
V8,
eY
AY
,U
E
ZH
V8,
ej
AZ
,U
E
1H
V8,
1`
ZA
[,
U1
E
X
3
*V8
,1
`c
A[
,U
QE
X
3
*V8
,1
cQ
AZ
,U
QE
3
*W
2
%V8
,1
cd
Ad
,
UE
kW
V8,
1e
eA
e,
UE
kW
VA,
D!
-T
2
!^
,7
a>
,k
,Z
e[
AY
,5U
2
l_
)V
l 8,
1`
`i
6A,
, , S?
EO
EE
U1
E1
V
;
,%
$#
:#
8$
B"
I*
%"
#*
)2
$I
:8
,#
'*
#,
&'
0"
),
"0
9'>
,(
*%
&0
'?
?'
+
1S
S?
EO
EE
U1E
1V
#"
+*
;
,&
$1
#:
#8
$B
"I
*%
"#
*)
2$
I:
8U1
D1
>
1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
S?
?*
U'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,
/.
,E
M,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,"
?%
4,
0'
,(
F%
,
K%
'%
*)
$,
);
%(
+$
)(
0/
',
&
%(
F/
4,
U?
%%
,
!"
##
$%
&
%'
()
*+
,
-'
./
*&
)(
0/
'V
A,
GF
%,
#*
/4
";
(,
P
)?
,
#"
*0.
0%
4,
=+
,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U
3
;W
D(
8,B
.,k
,`
AQ
1V
A,h
0%
$4
^,
1c
,&
K,
Ue
Y,
i
VA,
,G
F%
,m
%&
#$
%'
,4
%#
*/
(%
;(
0/
',
P
)?
,
#%
*.
/*
&
%4
,)
'4
,(F
%,
#*
/4
";
(,P
)?
,'
/(
,."
*(F
%*
,#
"*
0.0
%4
A,U
B
.,k
,`
A1
`8
,E
X
E
$ Y\
2
%W
X
,Z
^1
V,h
0%
$4
,U?
?*
V^,
c,
&
K,
U[
[,
i
V''
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
eU
48
,Y
X
8,K
[T
c,k
,c
A[
,X
R8
,X
Hc
V8,
1A
Q1
,f
,1
AY
[,
U&
8,Q
X
8,X
E
+Y
)C
,)
'4
,
O
O
H
H
O
O
H
N
H
O H
N
O
M
eO
O
M
e
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Q[
X
E
+[
)C
V8,
1A
Y[
,f
,1
AZ
[,
U&
8,1
X
8,X
E
+Z
)C
V8,
1A
Ze
,f
,1
A[
e,
U&
8,1
X
8,X
E
+c
)C
V8,
1A
e1
,f
,1
Ae
d,
U&
8,Q
X
8,X
E
+Z
%O
,)'
4,
X
E
+[
%O
V8,
1A
jj
,
U?
8,Y
X
8,3
;T
2
%V
8,1
Aj
d,
f,
1A
dc
,U&
8,Q
X
8,X
E
+Y
%O
,)
'4
,X
E
+c
%O
V8,
QA
Yc
,U(
48
,1
X
8,K
@T
U"
!!
k,
YA
c,
X
R8
,K
@T
UE
!!
k,
11
Ae
,X
R8
,K
@T
?!
!k
,
11
Ae
,X
R,
8,X
E
+1
!V8
,Y
Ac
Y,
f,
YA
cc
,U&
8,1
X
8,X
HZ
V8,
YA
eY
,U4
48
,K
BT
J,k
,Y
AZ
,X
R8
,K
?T
B,k
,1
`A
Y,
X
R8
,1
X
8,X
HY
V8,
YA
ee
,UO
8,K
VT
U,k
,c
A[
,
X
R,
81
X
8,
X
H[
V8,
YA
je
,f
,Y
Ad
c,
U&
8,
QX
8,
X
E
Q8,
X
HQ
V8,
[A
Ze
,U
48
,1
X
8,
K @
T?
,k
,[
Ac
,X
R8
,X
H 1
V,
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'
4
3
CY
3
U'9
,į
,U
##
&
V,
k,
1e
A1
,U
E
Hc
V8,
QY
A`
,U
3
;T
E
X
YV
8,Q
cA
1,
UE
E
+Z
,/
*,
E
E
+[
V8,
Qc
AQ
,U
E
E
+Z
,/
*,
E
E
+[
V8,
Y`
Ad
,U
E
E
+c
V8,
YY
Aj
,
UE
E
+Y
V8,
[1
AQ
,U
E
E
+Q
V8,
[1
Ae
,U
E
E
+1
V8,
cj
A1
,U
E
HQ
V8,
cj
Ac
,U
E
H[
V8,
e1
Ae
,U
E
HY
V8,
eY
AY
,U
E
HZ
V8,
ej
Ac
,U
E
H1
V8,
1e
QA
Z,
U_
X
E
W
V8,
1e
eA
j,
U_
X
E
W
VA,
X
B
2
!,
UH
GT
-E
B
8,D
!-
V^,
7
a>
,;
)$
;4
,./
*,E
1[
X
Qc
_
QW
c^,
Y[
YA
1c
jY
1,
52
,l
,_
)6
l b,
./
"'
4^
,Y
[Y
A1
cj
YQ
A,
5D
6 9
,k
,T1
Z`
Aj
,U;
,,`
A`
[8
,2
%W
X
VT
,
. +
1W
S?
EO
EE
U1
E1
SC
1Q
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
S?
?2
U'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,E
M,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,Y
T
F+
4*
/C
+=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(F
%,
#*
/4
";
(,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
U3
;W
D(
8,
B
.,
k,
`A
1[
8,
e1
i
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
UZ
^1
,;
F$
/*
/.
/*
&
^&
%(
F)
'/
$8,
B
.,k
,`
A1
[V
,)
..
/*
4%
4,
??
2A
,?
Q
17
R
G
''
SN
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,
U#
#&
V,k
,`
A[
d,
U4
8,Y
X
8,K
VT
U,k
,c
A[
,X
R8
,X
Hc
V8,
1A
Q[
,f
,1
AY
`,
U&
8,1
X
8,X
E
+Z
)C
,/
*,X
E
+[
)C
V8,
1A
Yc
,f
,1
AZ
Q,
U&
8,1
X
8,X
E
+Y
)C
,)'
4,
X
E
+Z
)C
,/
*,
X
E
+[
)C
V8,
1A
[1
,f
,1
Ac
Z,
U&
8,1
X
8,X
E
+c
)C
V8,
1A
cd
,f
,1
Ae
d,
U&
8,Q
X
8,X
E
+Z
%O
,)
'4
,X
E
+[
%O
V8,
1A
j1
,f
,1
Aj
d,
U&
8,1
X
8,
X
E
+c
%O
V8,
1A
d1
,f
,1
Ad
j,
U&
8,1
X
8,X
E
+Y
%O
V8,
QA
Zj
,U(
48
,1
X
8,K
@T
U"
,k
,Y
A[
,X
R8
,K
@T
UE
,k
,1
1A
e,
X
R8
,K
@T
?,k
,1
1A
e,
X
R8
,X
E
+1
V8,
YA
YQ
,f
,
YA
YZ
,U&
8,1
X
8,X
HZ
V8,
YA
Z`
,UO
8,K
VT
U,k
,c
AY
,X
R8
,1
X
8,X
H[
V8,
YA
cQ
,U4
48
,1
X
8,K
BT
J,k
,Y
AZ
,X
R8
,K
?T
B,k
,1
`A
Z,
X
R8
,X
HY
V8,
YA
j1
,U4
48
,
1X
8,K
@T
?,k
,[
Ac
,X
R8
,K
?T
B,k
,1
`A
Y,
X
R8
,X
HQ
V8,
ZA
`1
,f
,Z
A`
d,
U&
8,1
X
8,X
E
QV
8,[
AY
1,
U4
8,1
X
8,K
@T
?,k
,[
Ac
,X
R8
,X
H1
V8,
cA
eZ
,f
,c
Ae
j,
U&
8,1
X
8,X
3
*V8
,e
A`
1,
f,
eA
`j
,U&
8,Y
X
8,3
*V
A,?
C 4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
cA
[,
UE
Hc
V8,
Q[
Ad
,UE
E
+Z
,/
*,
E
E
+[
V8,
Qc
AY
,UE
E
+Z
,/
*,E
E
+[
V8,
Y`
AQ
,UE
E
+c
V8,
YY
Ad
,UE
E
+Y
V8,
[1
AY
,UE
E
+1
V8,
[Q
A`
,UE
E
+Q
V8,
ce
Ad
,UE
HQ
V8,
cj
Ac
,UE
H[
V8,
e1
A[
,UE
HY
V8,
eY
AQ
,UE
HZ
V8,
ej
Aj
,UE
H1
V8,
11
cA
[,
U3
*V
8,1
1c
Ae
,U3
*V
8,1
QQ
AY
,U3
*V
8,1
Y`
AZ
,U3
*V
8,1
Yc
AY
e,
UE
O"
)*
(A8
,3
*AV
8,1
cZ
A[
d,
UE
O"
)*
(A8
,
3
*AV
8,1
cd
Aj
1,
UE
O"
)*
(AV
8,1
ej
A1
Y,
UE
O"
)*
(AV
A,X
B
2
!,
UH
GT
-E
B
8,D
!-
V^,
7
a>
,;
)$
;4
,./
*,E
Q`
X
Qj
_
QW
e^,
ZY
1A
1e
jj
e,
52
,l
,
_
)6
l b,
./
"'
4^
,Z
Y1
A1
ed
[1
A,5
D6
9
,k
,TQ
1A
`,
U;
,k
,`
AQ
[8
,2
%W
X
VA,
,
. .
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Qc
+
1W
S?
EO
EE
U1
E1
SC
OJ
13
,B
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>1
-/
#$
<:
)*
%$
0:
8*
;
,%
"'
'S?
?#
U'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,
EM
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,
Y8
[T
40
F+
4*
/C
+=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,
#*
/4
";
(,P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Ue
^Y
,%
(F
+$
,)
;%
()
(%
^%
TF
%C
)'
%8
,B
.,k
,`
AQ
YV
A,h
0%
$4
^,1
d,
&
K,
UQ
c,
i
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
UZ
^1
,;
F$
/*
/.
/*
&
^&
%(
F)
'/
$8,
B
.,k
,`
A1
ZV
,)
..
/*
4%
4,
??
#A
,h
0%
$4
^,d
,
&
K,
Uc
d,
i
VT
,? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,`
Ae
Y,
U4
8,Y
X
8,K
[T
c,k
,c
A[
,X
R8
,X
Hc
V8,
1A
Qj
,f
,1
AZ
c,
U&
8,Y
X
8,
X
E
+[
)C
8,X
E
+Z
)C
8,X
E
+Y
)C
V8,
1A
[1
,f
,1
Ac
1,
U&
8,1
X
8,X
E
+c
)C
V8,
1A
cd
,f
,1
Ae
j,
U&
8,1
X
8,X
E
+[
%O
8,X
E
+Z
%O
V8,
1A
jZ
,f
,1
Ad
`,
U&
8,1
X
8,
X
E
+c
%O
V8,
1A
d`
,
f,
1A
de
,
U&
8,
1X
8,
X
E
+Y
%O
V8,
QA
[[
,
U(4
8,
K @
TU
",
k,
YA
[,
X
R8
,,
K @
T?
,k
,1
1A
c,
X
R8
,K
@T
UE
,k
,1
1A
c,
X
R8
,1
X
8,X
E
+1
V8,
YA
Z`
,f
,Y
AZ
Q,
U&
8,1
X
8,X
HZ
V8,
YA
Zd
,UO
8,K
VT
U,k
,c
A[
,X
R8
,1
X
8,X
H[
V8,
YA
cZ
,U4
48
,
1X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
YT
Z,k
,Y
AZ
,X
R8
,X
HY
V8,
YA
ed
,U4
48
,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,K
QT
Y,
k,
1`
AY
,X
R8
,X
HQ
V8,
YA
dd
,U(
48
,K
?T
B"
,k
,Z
A`
,
X
R8
,K
?T
BE
,k
,1
1A
1,
X
R8
,K
@T
?,k
,1
1A
1,
X
R8
,1
X
8,X
E
+Q
V8,
[A
Y[
,U4
8,1
X
8,K
@T
?,k
,[
Ac
,X
R8
,X
H1
V8,
cA
Y[
,U(
8,1
X
8,K
J ,k
,Q
AQ
,X
R8
,X
3
*Z
V8,
cA
ce
,U4
8,Q
X
8,K
J ,k
,Q
AQ
,X
R8
,X
3
*Q
,)
'4
,X
3
*c
,VA
,?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
cA
c,
UE
Hc
V8,
Q[
Ad
,UE
E
+[
V8,
Qc
AY
,U
E
E
+Z
V8,
Y`
AZ
,U
E
E
+c
V8,
YY
A[
,U
E
E
+Y
V8,
[1
A1
,U
E
E
+1
V8,
[Q
AY
,U
E
E
+Q
V8,
cj
A`
,U
E
HQ
V8,
cj
Ac
,U
E
H[
V8,
e1
Ac
,U
E
HY
V8,
eY
AY
,U
E
HZ
V8,
ej
Ae
,U
E
H1
V8,
1`
cA
e,
U3
*V
8,1
`c
Ad
,U
3
*V
8,1
Ye
Aj
,U
E
O"
)*
(AV
,1
c`
A`
,U
E
O"
)*
(AV
8,1
cd
AY
,U
E
W
_
X
V8,
1e
jA
`,
UE
W
_
X
VA,
X
B
2
!,
UH
GT
-E
B
8,D
!-
V^,
7
a>
,;
)$
;4
,./
*,E
Q`
X
Qj
_
QW
j^,
ZZ
eA
1e
Ye
d,
52
,l
,_
)6
l b,
./
"'
4^
,Z
Ze
A1
eY
cd
A,5
D6
9
,k
,Te
cA
Q,
U;
,k
,`
AQ
`8
,
2
%W
X
VA,
' S?
EO
EE
U1
E1
V
;
,%
$#
:#
8$
B"
I*
%"
#*
)2
$I
:8
,#
'*
#,
&'
0"
),
"0
9'>
,(
*%
&0
'?
E'
+
1W
S?
FO
EF
U1
E1
SC
1Q
:&
)$
I:
2"
%T
*;
,&
$U
#:
#8
$B
"I
*%
"#
*)
2$
I:
8X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
S?
E2
U'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,C
D,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,
YT
F+
4*
/C
+=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
,)
'4
,(
F%
,
#*
/4
";
(,P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uc
^Z
,,%
(F
+$
,)
;%
()
(%
^#
%(
*/
$%
"&
,%
(F
%*
,B
.,k
,`
A1
eV
A,h
0%
$4
^,Q
j,
&
K,
U[
Y,
i
V,m
%&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,;
F$
/*
/.
/*
&
^&
%(
F)
'/
$8,
B
.,k
,`
A1
`V
,)
..
/*
4%
4,
?E
2A
,h
0%
$4
^,e
,&
K,
U[
`,
i
VA'
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,`
Ad
Y,
U4
8,Y
X
8,K
VT
U,k
,c
A[
,X
R8
,X
Hc
V8,
1A
QZ
,
f,
1A
cY
,U
&
8,Z
X
8,X
E
+Y
)C
8,X
E
+c
)C
,)
'4
,X
E
+Z
,)
'4
\/
*,
X
E
+[
,V8
,1
Ae
c,
f,
1A
ej
,U
&
8,Q
X
8,X
E
+Z
,)
'4
\/
*,
X
E
+[
V8,
1A
dY
,f
,Q
A`
Q,
U&
8,Q
X
8,X
E
+Y
%O
,)
'4
,X
E
+c
%O
V8,
QA
Ze
,U(
48
,1
X
8,K
@T
UE
!,k
,Y
Ac
,X
R8
,K
@T
?,k
,1
1A
d,
X
R8
,K
@T
UE
,k
,1
1A
d,
X
R8
,X
E
+1
V8,
YA
[Z
,f
,Y
A[
[,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Qe
U&
8,1
X
8,X
HZ
V8,
YA
c`
,UO
8,K
VT
U,k
,c
AZ
,X
R8
,1
X
8,X
H[
V8,
YA
ej
,U4
48
,1
X
8,K
BT
J,k
,Y
AZ
,X
R8
,K
?T
B,k
,1
`A
Z,
X
R8
,X
HY
V8,
YA
jd
,U4
48
,
1X
8,K
@T
?,k
,[
Ac
,X
R8
,K
?T
B,k
,1
`A
Z,
X
R8
,X
HQ
V8,
ZA
1e
,U(
48
,K
?T
B,k
,Z
A`
,X
R8
,K
@T
?,k
,1
1A
Y,
X
R8
,K
?T
B,k
,1
1A
Y,
X
R8
,1
X
8,X
E
+Q
V8,
[A
Z1
,U4
8,1
X
8,K
@T
?,k
,[
Ae
,X
R8
,X
H1
V8,
cA
j[
,f
,c
Ad
`,
U&
8,1
X
8,X
3
*Q
V8,
eA
1Q
,f
,e
AQ
`,
U&
8,Y
X
8,X
3
*Z
8[
8c
VA,
?C
4
17
R
G
'S?
DD
'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
cA
jZ
,UE
Hc
V8,
Qc
AQ
Q,
UE
E
+Z
,/
*,E
E
+[
V8,
Qc
AZ
Q,
UE
E
+Z
,/
*,E
E
+[
V8,
Y`
1A
e`
,UE
E
+c
V8,
YY
Ae
j,
UE
E
+Y
V8,
[1
A`
`,
UE
E
+Q
V8,
[Q
AQ
[,
UE
E
+1
V8,
ce
Ad
d,
UE
HQ
V8,
cj
AZ
Z,
UE
H[
V8,
e1
AZ
e,
UE
HY
V8,
eY
AY
Q,
UE
HZ
V8,
ej
Ac
Y,
UE
H1
V8,
11
[A
[[
,
U3
*T
E
X
V8,
11
dA
[Q
,U
3
*T
E
X
V8,
11
dA
c1
,U
3
*V
8,
1Y
`A
cc
,U
3
*V
8,
1Y
eA
Y1
,U
E
O"
)*
(A8
V8,
1[
jA
jj
,U
E
O"
)*
(AV
8,
1c
dA
d[
,
UE
O"
)*
(AV
8,
1e
jA
`e
,U
E
O"
)*
(AV
A,
X
B
2
!,
UH
GT
-E
B
8,
D!
-V
^,
7
a>
,;
)$
;4
,.
/*
,E
Q`
X
Qj
_
QW
e^,
ZY
1A
1e
jj
e,
52
,l
,_
)6
l b
,
./
"'
4^
,Z
Y1
A1
ed
cY
A,,
5D
6 9
,k
,Tc
[A
`,
U;
,k
,`
AQ
`8
,2
%W
X
V,.
/*
,)
,?)
&
#$
%,
;/
'(
)0
'%
4,
ji
,/
.,(
F%
,=
%(
),
)'
/&
%*
A,
 E1
V
8*
%,
%"
'0"
),
"0
9'>
,(
*%
&0
'M
'
+
1S
+
ƍ1V
#"
+:
81ȕ
1*
8*
%:
8U1
D1
>
1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
SM
*U
'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,
/.
,E
L,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,"
?%
4,
0'
,(
F%
,
K%
'%
*)
$,
);
%(
+$
)(
0/
',
&
%(
F/
4,
U?
%%
,
!"
##
$%
&
%'
()
*+
,
-'
./
*&
)(
0/
'V
A,
GF
%,
#*
/4
";
(,
P
)?
,
#"
*0.
0%
4,
=+
,
.$)
?F
,
;F
*/
&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U
3
;W
D(
8,B
.,k
,`
A1
e8
,O
")
'(
AVA
,m
%&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
UZ
^1
,E
X
E
$ Y^
2
%W
X
8,B
.,k
,`
AQ
V,)
..
/*
4%
4,
M*
'UO
")
'(
AVA
,? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
Ad
`,
U4
8,Y
X
8,
K c
T[
,k
,[
Ac
,X
R8
,X
Hc
V8,
1A
dY
,U?
8,Y
X
8,_
X
E
UW
VE
X
YV
8,Q
A[
`,
U(8
,Q
X
8,K
,k
,c
A`
,X
R8
,E
UW
VE
X
QE
X
Q_
X
3
;V
8,Y
AZ
Y,
U(8
,Q
X
8,K
,k
,
cA
`,
X
R8
,E
UW
VE
X
QE
X
Q_
X
3
;V
8,Y
Ac
[,
U=
*,
?8,
1X
8,X
HZ
V8,
YA
eY
fY
Aj
`,
U=
*,
?8,
QX
8,X
H[
8,X
HY
V8,
YA
dY
fZ
A1
`,
U&
8,1
X
8,X
HQ
V8,
[A
[[
,U4
48
,1
X
8,K
1T
Q,k
,[
Ac
,X
R8
,K
1T
_
X
,k
,e
Ac
,X
R8
,X
H1
V8,
jA
`[
,U=
*,?
8,1
X
8,E
UW
VE
X
QE
X
Q_
X
3
;V
8,j
AY
[,
U4
8,1
X
8,K
1T
_
X
,k
,e
Ac
,
X
R8
,Į
T_
X
E
UW
VV
b,
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
1[
A[
,U
E
Hc
V8,
Q1
A1
,U
_
X
E
UW
VE
X
YV
8,
Y[
A1
,
UE
UW
VE
X
QE
X
Q_
X
3
;V
8,Y
[A
Z,
UE
UW
VE
X
QE
X
Q_
X
3
;V
8,c
cA
[,
UE
HQ
V8,
ee
AQ
8,e
`A
`8
,U
E
HY
8,
E
H[
V8,
eQ
AY
,U
E
HZ
V8,
ee
A1
,U
E
H1
V8,
1e
QA
`,
UE
kW
V8,
1e
YA
c,
UE
kW
Vb,
B
.,k
,`
AQ
,UZ
^1
,E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>
,k
,Q
ee
AY
,5U
2
lX
Vl
8,1
``
i
6A,
,
. +
1W
+
ƍ1S
C1
Q
:&
)$
I:
2"
%T
$:
8U1
ȕ1
*8
*%
:8
X1D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SM
2U
'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,E
L,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,Y
T
);
%(
/C
+=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,&
%(
F/
4,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
A,G
F%
,#
*/
4"
;(
,P
)?
,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Qj
#"
*0.
0%
4,
=+
,.
$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U
1^
Z,
F%
C)
'%
^,
3
;W
D(
8,
B
.,
k,
`A
Q[
8,
[`
i
,+
0%
$4
VA,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Ud
^1
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
eV
,)
..
/*
4%
4,
M2
'UO
")
'(
AVA
,,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
Q,
U4
8,Y
X
8,K
cT
[,k
,c
A[
,X
R8
,X
Hc
V8,
QA
e`
TQ
A[
Z,
U&
8,Q
X
8,_
X
W
E
TE
X
QT
V8,
,
YA
cj
TY
A[
d,
U&
8,Y
X
8,X
H[
,l
,T8
L
?_
X
E
W
TV
8,,
YA
ec
TY
Ae
`,
U&
8,1
X
8,X
HZ
V8,
YA
ec
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Z,
X
R8
!K
YT
Z,k
,Y
A[
,X
R8
,
X
HY
V8,
YA
dc
,U4
48
,1
X
8,K
QT
Y,k
1`
AZ
,X
R8
,K
1T
Q,k
,[
Ac
,X
R8
,X
HQ
V8,
[A
[e
,U4
8,1
X
8!K
1T
Q,k
,[
Ac
,X
R8
,X
H1
V8,
cA
dc
Tc
Ad
1,
U&
8,1
X
8,X
3
*V8
,
eA
Qe
Te
AQ
`,
U&
8,Y
X
8,Y
CX
3
*Vb
'?
C 4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
cA
d,
UE
Hc
V8,
Yc
Ae
,U_
X
W
E
TE
X
QT
V8,
,Y
eA
Z,
UT
E
X
Q_
X
E
W
TV
8,,
cj
A`
,U
E
HQ
V8,
cj
Ac
8,e
1A
[,
UE
YH
8,E
ZH
V8,
eY
AY
,U
E
H[
V8,
ej
AY
,U
E
H1
V8,
11
[A
Y,
UE
X
3
*V8
,1
1d
A1
,U
E
X
3
*V8
,1
Q`
Aj
,
UE
X
3
*V8
,1
Y`
Ac
,U
E
X
3
*V8
,1
Ye
A`
,U
E
3
*V8
,1
[d
A`
,U
E
3
*V8
,1
e`
AZ
,U
E
kW
V8,
1e
[A
Y,
UE
kW
Vb,
B
.,k
,`
AQ
Z,
UZ
^1
,E
X
E
$ Y^
2
%W
X
VT
,,
D!
-T
2
!^
,7
a>
,k
,Y
ee
A[
,5U
2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
1c
X
Q1
_
QW
e,5
2
T1
6T ^
,Y
[Y
A1
Y[
ZQ
b,.
/"
'4
,
52
T1
6T ^
,Y
[Y
A1
Y[
c[
A,
, +
1W
+
ƍ1S
CO
J1
3
,B
:&
)$
I:
2"
%T
$:
8U1
ȕ1
*8
*%
:8
X1D
1>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SM
#U
'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,
EL
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,
Y8
[T
40
);
%(
/C
+=
%'
R/
0;
,)
;0
4,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
'V
A,G
F%
,#
*/
4"
;(
,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U
1^
Z,
F%
C)
'%
^,
3
;W
D(
8,
B
.,k
,`
AY
8,
[[
i
,+
0%
$4
VA,
m%
&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
AQ
YV
,)
..
/*
4%
4,
M#
'UO
")
'(
AVA
,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
Q,
U4
8,Y
X
8,K
cT
[,k
,c
A[
,X
R8
,X
Hc
V8,
QA
cd
TQ
A[
Y,
U&
8,Q
X
8,T
_
X
W
E
8L
?T
V8,
YA
c[
TY
A[
d,
U&
8,Y
X
8,X
HZ
,l
,T
8L
?_
X
E
W
TV
8,Y
Aj
`T
YA
e`
,U&
8,Q
X
8,X
HY
8,X
H[
V8,
YA
dc
,U4
48
,1
X
8,K
QT
Y,k
1`
AY
,X
R8
,K
1T
Q,k
,[
Ac
,
X
R8
,X
HQ
V8,
[A
[c
,U4
8,1
X
8,K
1T
Q,k
[A
c,
X
R8
,X
1H
V8,
cA
Z`
,U4
(8,
1X
8,K
!k
,Q
A1
,q
,`
Ad
,X
R8
,X
3
*V8
,c
Ae
1T
cA
cj
,U&
8,Q
X
8,Q
X
3
*Vb
,?C
4
1
7
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
,1
cA
d,
UE
Hc
V8,
Yc
Ac
,U
_
X
W
E
TE
X
QT
V8,
,Y
eA
Z,
UT
E
X
Q_
X
E
W
TV
8,,
cj
A`
,U
E
HQ
V8,
cj
Ae
8,e
1A
[,
UE
HY
8,E
H[
V8,
eY
AY
,UE
HZ
V8,
ej
AZ
,UE
H1
V8,
11
cA
j,
UY
uE
X
3
*V8
,1
Ye
Ae
,UE
3
*V8
,1
[d
Ad
,UQ
uE
3
*V8
,1
e`
Ac
,UE
kW
V8,
1e
[A
Y,
UE
kW
Vb,
B
.,k
,`
AY
,UZ
^1
,E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>
,k
,Y
dY
A[
,5U
2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,
E
1c
X
Q1
_
QW
j,5
2
T1
6T ^
,Y
cd
A1
Y`
YZ
b,.
/"
'4
,52
T1
6T ^
,Y
cd
A1
Y`
jd
A,,
. . .
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Qd
+
1W
+
ƍ1S
3
1V
#"
+:
81+
),
<+
$<
B*
%:
8U1
ȕ1
*8
*%
:8
X1
D'
1>
1-
/#
$<
:)
*%
$0
:8
*;
,%
"'
SM
(U
'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,E
L,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,9
T
]T
);
%(
+$
T(*
0#
(/
#F
)'
%,
"?
0'
K,
(F
%,
X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
'V
A,G
F%
,#
*/
4"
;(
,P
)?
,
#"
*0.
0%
4,
=+
,.
$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U
3
;W
D(
8,B
.,k
,`
Ac
e8
,Z
ei
,+
0%
$4
VA,
m%
&
#$
%'
,4
%#
*/
(%
;(
0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Uj
[^
1[
,E
X
E
$ Y^
,2
%W
X
8,
B
.,
k,
`A
1[
V,
).
./
*4
%4
,M
('
UO
")
'(
AVA
,?
Q
17
R
G
''
SN
DD
'R
Q
TO
'
4
3
CY
3
U'9
,į
,U#
#&
V,k
,,1
A1
c,
U4
8,Y
X
8,K
cT
[,k
,c
AZ
,X
R8
,X
Hc
V8,
1A
dQ
,U?
8,Y
X
8,E
X
YE
W
_
X
TV
8,Q
AZ
[T
QA
Qe
,U&
8,Q
X
8,_
X
W
E
T
E
X
QT
V8,
YA
`d
,U4
48
,1
X
8,K
!k
,1
ZA
[,
q
,e
Ac
,X
R8
,E
X
QG
*#
V8,
YA
QQ
,U4
48
,1
X
8,K
!k
,1
ZA
Z,
q
,c
A[
,X
R8
,E
X
QG
*#
V8,
YA
ZZ
TY
AY
`,
U&
8,1
X
8,
T8
L
?_
X
E
W
TV
8,Y
Ac
[T
YA
cQ
,U&
8,1
X
8,X
HZ
V8,
YA
j1
TY
Ae
Y,
U&
8,Q
X
8,X
HY
8,X
H[
V8,
YA
d[
,U4
48
,1
X
8,K
QT
Y,k
,1
`A
Y,
X
R8
,K
1T
Q,k
,[
Ac
,
X
R8
,X
HQ
V8,
ZA
[c
,U
(8,
1X
8,K
!k
,e
A1
,X
R8
,E
X
G*
#V
8,[
A[
Z,
U4
8,1
X
8,K
1T
Q,
k,
[A
c,
X
R8
,X
H1
V8,
eA
`1
,U
(8,
1X
8,K
!k
,e
AZ
,X
R8
,X
3
*G
*#
V8,
eA
11
Te
A`
[,
U&
8,Q
X
8,Q
X
3
*]
F%
V8,
eA
YQ
,U4
8,1
X
8,K
!k
,j
A`
,X
R8
,X
3
*G
*#
V8,
eA
[j
,U4
8,1
X
8,K
!k
,e
Aj
,X
R8
,X
3
*G
*#
Vb'
?C
4
17
R
G
''S
?D
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
,1
cA
d,
UE
Hc
V8,
QQ
Ac
,U
E
X
YE
W
_
X
TV
8,
,Q
dA
`,
UE
X
QG
*#
V8,
Yc
A[
,U
_
X
W
E
TE
X
QT
V8,
Yc
Aj
,U
T
E
X
Q_
X
E
W
TV
8,
[c
A1
,U
E
X
G*
#V
8,
cj
A1
,U
E
HQ
V8,
cj
Ae
8,
e1
A[
,U
E
HY
8,
E
H[
V8,
eY
AY
,U
E
HZ
V8,
ej
AY
,U
E
H1
V8,
,1
`1
AZ
,U
E
3
*V8
,1
11
A`
,
UQ
CE
3
*V8
,1
1Q
AY
,U
E
X
3
*V8
,1
1d
AZ
,U
E
X
3
*V8
,1
1d
Aj
,U
E
X
3
*V8
,1
QQ
A[
,U
E
X
3
*V8
,1
QZ
A[
,U
E
X
3
*V8
,1
Qj
Ad
,U
E
3
*V8
,1
Yj
A1
,U
E
3
*V8
,
1e
YA
Q,
UE
kW
V8,
1e
ZA
Y,
UE
kW
V8,
1e
[A
1,
UE
kW
Vb,
B
.,k
,`
AQ
[,
UE
X
E
$ Y^
2
%W
X
,Z
^1
VA,
D!
-T
2
!^
,7
a>
,k
,Z
j[
Ac
,5
U2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,E
QQ
X
Y`
_
ZW
e_
),
52
l_
)6
l ^
,Z
j[
AQ
``
ce
b,.
/"
'4
,52
l_
)6
l ^,
Zj
[A
Q`
`[
eA
,,,
. +
1W
+
ƍ1S
3
1+
1V
#"
+:
81<
B"
%:
8*
8*
%:
8U1
ȕ1
*8
*%
:8
X1
D1
>
1-/
#$
<:
)*
%$
0:
8*
;
,%
"'
SM
BU
'
GF
%,
;*
"4
%,
F+
4*
/K
%'
)(
0/
',
#*
/4
";
(,/
.,E
L,
U?
%%
,!
"#
#$
%&
%'
()
*+
,-'
./
*&
)(
0/
',
f,
!-
T!
;F
%&
%,
YV
,P
)?
,;
/"
#$
%4
,P
0(F
,9
T
]T
);
%(
+$
T#
F%
'+
$)
$)
'0
'%
,"
?0
'K
,(
F%
,X
J
Go
,K
%'
%*
)$
,#
*/
;%
4"
*%
,U
?%
%,
!"
##
$%
&
%'
()
*+
,-
'.
/*
&
)(
0/
'V
A,G
F%
,#
*/
4"
;(
,
P
)?
,#
"*
0.0
%4
,=
+,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
/'
,?
0$0
;)
,K
%$
,U1
``
^Q
8,3
;W
D(
^2
%W
X
8,B
.,k
,`
A1
Q8
,c
`i
,+
0%
$4
VA,
,m
%&
#$
%'
,
4%
#*
/(
%;
(0/
',
)'
4,
.$)
?F
,;
F*
/&
)(
/K
*)
#F
+,
Ud
^1
,E
X
E
$ Y^
,2
%W
X
8,B
.,k
,`
A1
YV
,)
..
/*
4%
4,
MB
'UO
")
'(
AVA
,
? Q
17
R
G
''S
ND
D'
R
Q
TO
'4
3
CY
3
U'9
,į
,U#
#&
V,k
,1
A1
e,
U4
8,Y
X
8,K
[T
c,k
,c
A[
,X
R8
,X
cH
V8,
1A
d`
,U?
8,Y
X
8,E
X
YE
W
_
X
TV
8,Q
A[
1T
QA
Y[
,U
&
8,Q
X
8,_
X
W
E
T8
L
?T
V8,
,Q
Aj
c,
U4
48
,1
X
8,K
!k
,1
YA
j,
q
,j
Ad
,X
R8
,E
X
Q]
F%
V8,
YA
`j
,U
44
8,1
X
8,K
!k
,1
YA
j,
q
,c
AQ
,X
R8
,
E
X
Q]
F%
V8,
YA
[`
TY
AY
`,
U&
8,Q
X
8,T
8L
?_
X
E
W
TV
8,Y
Ac
cT
YT
cY
,U&
8,1
X
8,X
HZ
V8,
YA
j1
TY
Ae
Z,
U&
8,Q
X
8!X
HY
8,X
H[
V8,
YA
dc
,U4
48
,1
X
8,
K Q
TY
,k
,1
`A
Y,
X
R8
!K
1T
Q,k
,[
Ac
,X
R8
,X
HQ
V8,
ZA
ZQ
,U4
48
,1
X
8,K
!k
,j
Aj
,q
,c
AY
,X
R8
,E
X
]F
%V8
,,[
A[
c,
U4
8,1
X
8,K
1T
Q,k
,[
Ac
,X
R8
,X
H1
V8,
eA
Y1
Te
A1
e,
U&
8,[
X
8,[
X
3
*]
F%
Vb,
?C
4
17
R
G
''
S?
DD
'R
Q
TO
'4
3
CY
3
U'9
,į
,U
##
&
V,
k,
,1
eA
c,
UE
Hc
V8,
QQ
AZ
,U
E
X
YE
W
_
X
TV
8,,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Y`
Yc
Ae
,U_
X
W
E
TE
X
QT
V8,
Yc
Aj
,UT
E
X
Q_
X
E
W
TV
8,,
Yd
A`
,UE
X
Q]
F%
V8,
[j
A[
,UE
X
]F
%V8
,c
jA
1,
UE
HQ
V8,
cj
Ae
8,e
1A
[,
UE
HY
8,E
H[
V8,
eY
AY
,
UE
HZ
V8,
ej
AY
,UE
H1
V8,
1Q
eA
j,
UE
X
3
*V8
,1
Qd
A[
,UE
X
3
*V8
,1
Y`
AY
,UE
X
3
*V8
,1
Yj
A[
,UE
3
*V8
,1
eY
AQ
,UE
kW
V8,
1e
YA
j,
UE
kW
V8,
1e
[A
1,
UE
kW
Vb,
B
.,k
,`
AQ
`,
UZ
^1
,E
X
E
$ Y^
2
%W
X
VA,
D!
-T
2
!^
,7
a>
,k
,Z
Zc
A[
,5U
2
l_
)V
l 8,
1`
`i
6A,
X
B
T2
!,
UD
!-
V^,
;)
$;
"$
)(
%4
,./
*,
E
Q`
X
Qd
_
YW
e_
),
52
l_
)6
l ^
,Z
Zc
A1
jd
ee
b,.
/"
'4
,52
l_
)6
l ^,
ZZ
cA
1d
``
[A
,,,
,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,
1 ,,
S
A,G
0&
#)
'/
8,S
A,G
)=
)*
)'
08,
2
A,3
'4
%*
$"
F8
,9
A,-
'<
%*
'0
RR
08,
HA
,a
)?
0$%
8,9
A,]
/(
%'
R)
8,]
A,2
A,_
0%
(/
8,>
A,B
/M
/8
,H
A,H
0%
?;
F0
8,3
A,
J
%*
')
*4
08,
8
9(
7
G&
38
9(
7
,E
DD
P8
,[
8,1
dQ
1T
1d
Y`
,
Q ,,
HA
,9
)&
:)
;0
8,,
]A
,9
%!
F/
'K
8,K
D!R
7
D!8
9(
7
D!0
3:
D,E
DD
C8
,@
?V
8,Z
Z`
jT
ZZ
`d
,
Y ,,
,2
A,3
'4
*%
0'
0,8
,2
A,3
'4
%*
$"
F,
8,3
A,3
"4
.*
)+
,8,
3
A,J
%*
')
*4
0,8
,3
A,-
&
=%
*(+
8,8
")
ED
!^
(*
D!E
D?
D8
,B
JV
8,1
Z`
`T
1Z
`e
,
Z ,,
,)
V,E
A,J
/$
&
8,-
A,,
!;
F0
..
%*
?8,
E
A,I
A,9
0'
(%
*8,
3
A,,
S
%*
$)
;F
8,K
D!;
).
D!8
9(
7
D!E
DD
D8
,U
V8
,c
dj
ZT
cd
d1
b,=
V,3
A,J
%*
')
*4
08,
9
A,3
*/
?0
/8
,
9
A,9
%$
$)
<%
;;
F0
)8
,H
A,2
0;
F%
$08
,b
(+
)"
9(
-)
3%
c!R
*C
7
7
D,?
MM
M8
,@
A8
,Y
Z`
Y,
f,
YZ
`e
,
[ ,,
2
A,3
4)
&
;R
+:
8,>
A,B
A,,
H0
?F
#)
"K
F8
,,b
(+
)"
9(
-)
3%
!W
(+
+D,
?M
MK
8,B
O8
,Z
Y`
[f
ZY
`j
,
, , , , ,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Y1
E@
'!
/<
<8
";
"%
+*
):
'5%
-$
);
*+
,$
%'
A'
!/
)-
*#
"'
F8
*0
;
$%
'G
"0
$%
*%
#"
'H
I<
")
,;
"%
+0
'
' HI
.J
#0
/"
#&*
"$
.0
3..
K'
(:
"#
*(
.L
*(
2*
(:
.&0
.<
E7
GM
'(
.E
JF
.$%
#3
'1
"$
.'
(2
.$"
&.%
/.
03
.&6
".
*(
6*
L*
&*0
(.
&"
$&I
.
3
?,
./
*,9
E
T!
-S
_
8,(
F%
,)
=0
$0(
+,
/.
,I
)'
K%
*0'
,(/
,=
0'
4,
(/
,?
"*
.)
;%
,."
';
(0/
')
$0R
%4
,P
0(F
,2
)'
TJ
!3
,P
)?
,(%
?(
%4
A,-
',
(F
%,
;)
?%
,/
.,
I)
'K
%*
0'
8,?
(*/
'K
,=
0'
40
'K
,(/
,(F
%,
*%
.%
*%
';
%,
?"
*.
);
%,
P
)?
,/
=?
%*
<%
48
,4
"%
,(/
,(F
%,
#*
%?
%'
;%
,/
.,
(F
%,
4%
C(
*)
',
#/
$+
&
%*
,U!
-T
H0
KA
1V
A,G
F0
?,
0?
,$0
&
0(%
4,
="
(,'
/(
,?
"#
#*
%?
?%
4,
=+
,"
?0
'K
,)
,*%
.%
*%
';
%,
?"
*.
);
%,
."
';
(0/
')
$0R
%4
,P
0(F
,'
/'
T
K$
+;
/?
+$
)(
%4
,J
!3
,U!
-T
H0
KA
1V
A,G
F%
*%
./
*%
8,(
F%
,4
%C
(*)
'\
2
)'
TJ
!3
,?"
*.
);
%,
P
)?
,;
/'
?0
4%
*%
4,
)?
,)
,;
/&
=0
'%
4,
$0K
)'
4,
/.
,I
)'
K%
*0'
,D
E
9
,)
'4
,(F
"?
,=
0'
40
'K
,*%
?#
/'
?%
?,P
%*
%,
'/
(,*
%.
%*
%'
;%
,?"
*.
);
%,
;/
**
%;
(%
4A
,
.
0510152025
0
10
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
M
an
-B
S
A
 s
ur
fa
ce
C
M
-d
ex
tra
n 
su
rfa
ce
Response, kRU
Ti
m
e,
 s
,
,
!5
1.
,(
/)
"'
?@
,I
)'
K%
*0'
,0
'(
%*
);
(0/
',
P
0(F
,*
%.
%*
%'
;%
,?
"*
.)
;%
A,9
)(
),
P
%*
%,
/=
()
0'
%4
,P
0(F
,[
,P
$\&
0'
,.
$/
P
,*
)(
%,
/.
,
*"
''
0'
K,
="
..
%*
,UQ
[,
&
2
,G
*0?
TX
E
$,#
X
,j
8,1
[`
,&
2
,_
)E
$8,
Z,
&
2
,E
)E
$ Q8
,`
A`
`[
i
,?
"*
.)
;(
)'
(,]
Q`
VA,
I%
.(,
#)
'%
$,3
V8,
*%
.%
*%
';
%,
.$/
P
,;
%$
$,
;/
**
%?
#/
'4
?,
(/
,;
)*
=/
C+
&
%(
F+
$)
(%
4,
4%
C(
*)
',
?"
*.
);
%A
,B
0K
F(
,#
)'
%$
,J
V8,
*%
.%
*%
';
%,
?"
*.
);
%,
."
';
(0/
')
$0R
%4
,P
0(F
,"
'K
$+
;/
?+
$)
(%
4,
J
!3
A,
,
,,,
!5
1.
,(
/)
"'
E9
,I
)'
K%
*0'
,(0
(*)
(0/
',
/'
,)
,2
)'
TJ
!3
,?
"*
.)
;%
A,3
V,I
)'
K%
*0'
,;
/'
;%
'(
*)
(0/
'?
,*)
'K
%,
.*
/&
,[
`A
Y[
,P
2
,(/
,
`A
`e
,P
2
,=
+,
YT
./
$4
,4
0$"
(0/
'?
A,B
%K
%'
%*
)(
0/
',
0?
,#
%*
./
*&
%4
,"
?0
'K
,1
T&
0'
"(
%,
#"
$?
%,
0'
M%
;(
0/
',
/.
,[
`,
&
2
,D
9
G3
,#
X
,
j8
,)
(,Z
``
,?%
;A
,,J
V,G
0(*
)(
0/
',
;"
*<
%,
4%
*0<
%4
,.*
/&
,?%
'?
/*
K*
)&
?,3
VA,
, ,
J
,
-50510152025
0
10
0
20
0
30
0
40
0
50
0
60
0
70
0
Response, kRU
Ti
m
e,
 s
l
3
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
YQ
,
,
!5
1.
,(
/)
"'
C9
,9
E
T!
-S
_
,D
E
9
,(0
(*)
(0/
',
/'
,)
,2
)'
TJ
!3
,?
"*
.)
;%
A,3
V,9
E
T!
-S
_
,D
E
9
,;
/'
;%
'(
*)
(0/
'?
,*)
'K
%,
.*
/&
,
[`
AY
[,
P2
,(/
,`
A`
e,
P2
,=
+,
YT
./
$4
,4
0$"
(0/
'?
A,B
%K
%'
%*
)(
0/
',
0?
,#
%*
./
*&
%4
,"
?0
'K
,1
,&
0'
"(
%,
#"
$?
%,
0'
M%
;(
0/
',
/.
,[
`,
&
2
,D
9
G3
,#
X
,j
8,)
(,Z
``
,?%
;A
,J
V,G
0(*
)(
0/
',
;"
*<
%,
4%
*0<
%4
,.*
/&
,?%
'?
/*
K*
)&
?,3
VA,
' ' ' '
'
!5
1.
,(
/)
"'
N9
'B
%.
%*
%'
;%
,?
"*
.)
;%
,;
/*
*%
;(
%4
,/
<%
*$)
+,
?%
'?
/*
K*
)&
?,
*%
#*
%?
%'
(0'
K,
0'
F0
=0
(0/
',
/.
,9
E
T!
-S
_
,D
E
9
,
=0
'4
0'
K,
(/
,2
)'
TJ
!3
,?"
*.
);
%,
=+
,;
/&
#/
"'
4?
,C
,)
'4
,I
%s
A,
,
3
J
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
YY
, ,
,
!5
1.
,(
/)
"'
J9
'B
%.
%*
%'
;%
,?
"*
.)
;%
,;
/*
*%
;(
%4
,/
<%
*$)
+,
?%
'?
/*
K*
)&
?,
*%
#*
%?
%'
(0'
K,
0'
F0
=0
(0/
',
/.
,9
E
T!
-S
_
,D
E
9
,
=0
'4
0'
K,
(/
,2
)'
TJ
!3
,?"
*.
);
%,
=+
,;
/&
#/
"'
4?
,C
8'?
D8
'?
?8
,?
E8
,I
T.
";
/?
%8
,)
'4
,I
%s
A,
,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
YZ
,
, , ,
,
,
!5
1.
,(
/)
"'
K9
'W
<%
*$)
+,
*)
P
,?
%'
?/
*K
*)
&
?,
*%
#*
%?
%'
(0'
K,
0'
F0
=0
(0/
',
/.
,I
)'
K%
*0'
,D
E
9
,=
0'
40
'K
,(
/,
2
)'
T
J
!3
\4
%C
(*)
',
?"
*.
);
%,
=+
,;
/&
#/
"'
4?
,C
8'?
D8
'?
?8
,?
E8
')
'4
,I
%s
A,
,,,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
!"
##
$%
&
%'
()
*+
,-'
./
*&
)(
0/
',
,
Y[
,
8I
.?
!'
-%
'&
*0
(.
03
.<
E7
GM
'(
.E
JF
.$%
#3
'1
".
$&'
L*
-*&
4I
.
,
GF
%,
?(
)=
0$0
(+
,/
.,
(F
%,
?"
*.
);
%,
P
)?
,%
<)
$"
)(
%4
,0
',
(P
/,
)?
#%
;(
?^
,)
..
0'
0(+
,)
'4
,=
0'
40
'K
,;
)#
);
0(+
A,!
-T
,H
0K
"*
%,
e)
,
?F
/P
?,
(F
%,
%<
/$
"(
0/
',
/.
,9
E
T!
-S
_
,=
0'
40
'K
,$
%<
%$
,/
'(
/,
/'
%,
/.
,(
F%
,;
F0
#?
,"
?%
48
,#
$/
((%
4,
)?
,)
,.
"'
;(
0/
',
/.
,(
F%
,
'"
&
=%
*,/
.,;
+;
$%
?,
#%
*.
/*
&
%4
,/
'(
/,
(F
%,
;F
0#
A,G
F%
,=
0'
40
'K
,$%
<%
$,0
?,
<%
*+
,*%
#*
/4
";
0=
$%
,P
0(F
,)
,4
%<
0)
(0/
',
/.
,)
=/
"(
,Z
,
B
o
,#
%*
,;
+;
$%
,UH
0K
"*
%,
e=
V,(
/,
;/
&
#)
*%
,(/
,)
,=
0'
40
'K
,$%
<%
$,;
$/
?%
,(/
,e
``
`,
B
o
,U?
/,
),
$/
??
,/
.,)
*/
"'
4,
`A
`c
,i
VA,
,
,
D
C
S
IG
N 
bi
nd
in
g 
Fc
4-
Fc
3
-1
0
99
0
19
90
29
90
39
90
49
90
59
90
69
90
79
90
0
20
0
40
0
60
0
Ti
m
e,
 s
RelResp, RU
cy
cl
e 
1
cy
cl
e 
29
cy
cl
e 
57
,
S
lo
pe
 -4
,3
52
5 
R
U
/c
yc
le
68
50
69
00
69
50
70
00
70
50
71
00
71
50
0
20
40
60
C
yc
le
Req, RU
,
*@
'
2@
'
' !5
1'.
,(
/)
"'
L@
'*
@'9
E
T!
-S
_
,=
0'
40
'K
,(/
,J
!3
T2
)'
,;
F0
#8
,)
?,)
,."
';
(0/
',
/.
,4
0..
%*
%'
(,;
+;
$%
?,#
%*
./
*&
%4
,/
',
(F
%,
;F
0#
8,,
=A
,B
o
,<
)*
0)
(0/
',
)?
,)
,."
';
(0/
',
/.
,4
0..
%*
%'
(,;
+;
$%
?,
, H0
')
$$+
8,)
,;
/&
#$
%(
%,
(0(
*)
(0/
',
/.
,2
)'
TJ
!3
,?
"*
.)
;%
,P
0(F
,9
E
T!
-S
_
,P
)?
,#
%*
./
*&
%4
8,(
/,
4%
(%
*&
0'
%,
)#
#)
*%
'(
,
p
48
,)
(,
(F
%,
=%
K0
''
0'
K,
)'
4,
%'
4,
/.
,%
);
F,
!]
B
,;
)&
#)
0K
',
U'
%P
,?
"*
.)
;%
,%
);
F,
(0&
%V
A,
a
%*
+,
?0
&
0$)
*,
<)
$"
%?
,P
%*
%,
/=
()
0'
%4
,%
);
F,
(0&
%,
UZ
AQ
,P
2
,;
/&
#)
*%
4,
(/
,Y
AY
P
2
b,/
*,c
A1
,P
2
,;
/&
#)
*%
4,
(/
,[
A[
,P
2
VA,
, ,
El
ec
tro
nic
 S
up
ple
m
en
ta
ry
 M
at
er
ial
 (E
SI
) f
or
 O
rg
an
ic 
an
d 
Bi
om
ole
cu
lar
 C
he
m
ist
ry
Th
is 
jou
rn
al 
is 
© 
Th
e 
Ro
ya
l S
oc
iet
y o
f C
he
m
ist
ry
 2
01
1
14. Supplementary information to paper no3
381
CHAPTER 14. SUPPLEMENTARY INFORMATION TO PAPER NO3
382
!
"
#$
%%
&'
(
')
*+
,-
!.)
/0
,(
+*
10
)!
 
Ps
eu
do
sa
cc
ha
ri
de
 fu
nc
tio
na
liz
ed
 d
en
dr
im
er
s a
s p
ot
en
t i
nh
ib
ito
rs
 o
f D
C
-S
IG
N
 
de
pe
nd
en
t E
bo
la
 p
se
ud
ot
yp
ed
 v
ir
al
 in
fe
ct
io
n 
! 20
+)
)+
!3
$4
56
07
1+
68
4 !
#+
,+
!#
+*
*1)
89 !
.'
:+
!#
$*
6'
:1
þ1
ǌ*
ơ8
;8
/  
20
<=
!2
$+
)!
>
'1
)+
89 !
?
+4
+,
')
+!
#@
)4
A'
5B
C
+:
+,
,0
8+!
?
14
A'
&!
DA
=%
+$
*8;
8'
!3
0,
')
+!
?
+,
*E)
'5
BF
,+
*<
84 !
G
))
+!
H
+I
A'
**1
89 !
J,
+)
46
!J
1'
<4
A1
8;8
'8
/8K
!>
+/
+'
&!
H
'&
I+
;0
48
K !G
))
+!
L
',
)+
,;
189
8K
!2+
:1
',
!>
0M
08
+8
K!
! !
a !G
ru
po
 C
ar
bo
hi
dr
at
os
, I
ns
tit
ut
o 
de
 In
ve
st
ig
ac
io
ne
s 
Q
uí
m
ic
as
, C
S
IC
 –
 U
ni
ve
rs
id
ad
 d
e 
S
ev
ill
a,
 A
m
ér
ic
o 
V
es
pu
ci
o 
49
, 4
10
92
 S
ev
ill
e,
 
S
pa
in
N T
el
: 9
54
48
95
68
; F
ax
: 9
54
46
05
65
 
b 
U
ni
ve
rs
ità
 d
eg
li 
S
tu
di
 d
i M
ila
no
, D
ip
ar
tim
en
to
 d
i C
hi
m
ic
a 
O
rg
an
ic
a 
e 
In
du
st
ria
le
, M
ila
no
, I
ta
ly
 
c  L
ab
or
at
or
io
 d
e 
M
ic
ro
bi
ol
og
ía
 M
ol
ec
ul
ar
- H
os
pi
ta
l U
ni
ve
rs
ita
rio
 1
2 
de
 O
ct
ub
re
, M
ad
rid
, S
pa
in
 
d 
In
st
itu
t d
e 
B
io
lo
gi
e 
S
tru
ct
ur
al
e,
 C
N
R
S
, U
M
R
 5
07
5,
 4
1 
ru
e 
Ju
le
s 
H
or
ow
itz
 3
80
27
 G
re
no
bl
e 
Fr
an
ce
 
e 
C
E
A
, D
S
V
,  
38
02
7 
G
re
no
bl
e 
Fr
an
ce
  
f  U
ni
ve
rs
ité
 J
os
ep
h 
Fo
ur
ie
r, 
38
00
0 
G
re
no
bl
e,
 F
ra
nc
e 
 
!
O
! "N
!#
F>
!<
')
<0
,I
,+
(
<!
/0
,!
*A
'!
1)
A1
91
*10
)!
4$
,:
'<
!,
'%
0,
*'
;!
1)
!J
1I
$,
'!
PN
!D
A'
!+
,,
07
<!
;'
)0
*'
!Q
H
DG
!
1)
M'
4*
10
)<
!/0
,!L
#G
B?
+)
)0
*,1
0<
'!
<$
,/+
4'
!,'
I'
)'
,+
*10
)!
9'
*7
''
)!
'+
4A
!4
-4
&'
N!
!
Ps
eu
do
m
an
no
bi
os
id
e 
!
Ps
eu
do
m
an
no
tr
io
si
de
 
!
C
om
po
un
d 
12
 
!
C
om
po
un
d 
14
 
!
G
3(
ps
eu
do
di
) 3
2 
!
G
3(
ps
eu
do
tr
i) 3
2 
!
!
P
! ON
!?
+<
<!<
%'
4*
,+
!/0
,!(
$&
*1:
+&
')
*!4
0(
%0
$)
;<
!7
1*A
!I
&-
40
(
1(
'*
14
<!1
3!
+)
;!
15
N!
!
!
M
A
LD
I m
as
s s
pe
ct
ru
m
 o
f 3
G
(p
se
ud
od
i) 3
2. 
M
at
ri
x:
 S
A
. 
! !
!
M
A
LD
I m
as
s s
pe
ct
ru
m
 o
f 3
G
(p
se
ud
ot
ri
) 32
. M
at
ri
x:
 S
A
. 
 
 
E
qu
at
io
n 
1 
(;
'*
',
(
1)
+*
10
) 
0/
!,'
&+
*1:
'!
.R
ST
!:
+&
$'
<U
 
y
 b
ot

to
p
b
ot
"
x IC
ST
§ ©¨
· ¹¸sl
op
e
!
!
!!
7
A'
,'
! y
!1<
!*A
'!
%'
,4
')
*!+
4*
1:
1*-
8!x
!1<
!*A
'!
40
,,
'<
%0
);
1)
I!
40
)4
')
*,+
*10
)8
!b
ot
 +
);
!to
p!
+,
'!
*A
'!
&0
7
'<
*!+
);
!
*A
'!
A1
IA
'<
*!:
+&
$'
<!0
/!%
',
4'
)*
!+
4*
1:
1*-
8!,
'<
%'
4*
1:
'&
-N
!
!
15. Supplementary information to paper no4
385
CHAPTER 15. SUPPLEMENTARY INFORMATION TO PAPER NO4
386
 Su
pp
or
tin
g 
in
fo
rm
at
io
ns
 
 
!"
#$
%"
$#
&'
()
'*
'+
,-
%(
.
/.
&"
/%
',/
+*
01
'/0
'"
2&
'3
*#
4(
2-
1#
*"
&'
5&
%(
+0
/"
/(
0'
6
(.
*/
0'
()
'3
7"
-8
&'
,&
%"
/0
'6
37
!9
:
;
<'!
"#
$%
"$
#*
,'#
&=
$/
#&
.
&0
">
')(
#'
>&
,&
%"
/?
/"
-'
*0
1'
,/+
*0
1'
1&
>/
+0
<'
   
!
"#
$%
&'(
$)
*+
,-
./
0/
12
/'3
"4
5"
+'
6
,5
5"
72
/'8
%9
+'
:,
-;
%9
"#
",
-%
./
0/
1 /
':
+<
+'
:+
--
"4
= /
'
>%
4+
-?
'>
"@
%"
<?
AB
"+
4+
7 /
'C
?<
@%
<-
'B
+<
D+
= /
'E
<"
#'
3$
+@
<?
&./
0/
1 /
'F+
9"
%<
'>
?G
?7
/'H
44
+'
I%
<4
+<
J"
= /
'F%
K,
K'
H
4D
,&
?7
/'L
%J
<?
'!
M'C
"%
-?
7 /
'+
4J
'N
<+
4#
;'
N"
%K
#$
"./
0/
OP
'
 
! "
#$
%&%
'%
()
*(
+&
,-
,.
&*
(/
%0
'1
%'
02
-*
3(4
#&
5*
0$
&%6
(7
0*
#,
8-
*(
"3(
9!
(0'
*(
:'
-*
$(
;
,0
,<
&%=
3(7
0*
#,
8-
*3
(>
?
@A
BC
D3
(>
02
#1
*E
(C F
G
H/
3(4
I
H(
JB
DJ
3(7
0*
#,
8-
*3
(>
?@
AB
BB
3(>
02
#1
*E
(@ F
KL
3(M
/N
3(7
0*
#,
8-
*3
(>
?@
AB
BB
3(
>0
2#
1*
E(9
4
#&
5*
0$
&%2
O()
&(I
&-2
#,
3(M
&P
20
%&Q
*#
%,
()
&(F
R&
Q
&1
2(
S
0.
2#
&1
2(
*(
"#
)'
$%
0&
2-
*3
(5
&2
(N
*#
*=
&2
#(
C!
3(
CB
!@
@(
I
&-2
#,
(?(
"%
2-
TE
(J 7
-T
1,
$T
$%
*Q
$(
U2
8,
02
%,
0T
3("
#$
%&%
'%
,(
)*
("#
5*
$%
&.
21
&,
#*
$(
V
'W
Q
&1
2$
(X"
"V
Y3(
F/
"F
(?(
4
#&
5*
0$
&)
2)
()
*(
/*
5&
--2
3(L
Q
60
&1
,(
N*
$P
'1
&,
(9
Z3
(9
!B
ZC
(/
*5
&--
2?
/P
2&
#E
([ "
#$
%&%
'%
(4
#&
5*
0$
&%2
&0*
(
)*
(>
02
#1
*3
 !B
@(
8,
'-
*5
20
)(
/2
&#
%?
I
&1
R*
-(D
JB
BJ
(\
20
&$
?>
02
#1
*]
(
  
    
 
    
 
Fi
gu
re
 S
1.
 S
tru
ct
ur
al
 a
lig
nm
en
t 
of
 D
C
-S
IG
N
 C
R
D
 f
ro
m
 2
X
R
5,
 2
IT
6 
an
d 
1S
L5
 s
tru
ct
ur
e 
co
rr
es
po
nd
in
g 
re
sp
ec
tiv
el
y 
to
 
th
e 
pd
b 
co
de
 
of
 
D
C
-S
IG
N
 
co
m
pl
ex
ed
 
w
ith
 
ps
eu
do
-1
,2
-
m
an
no
bi
os
id
e 
(th
is
 
st
ud
y,
 
gr
ee
n)
, 
M
an
!
1,
2M
an
 
(m
ag
en
ta
), 
an
d 
La
ct
o-
N
-fu
co
pe
nt
ao
se
 
III
 
(y
el
lo
w
). 
Li
ga
nd
s 
ar
e 
no
t r
ep
re
se
nt
ed
 fo
r c
la
rit
y 
(s
ee
 F
ig
ur
e 
6a
 to
 s
ee
 th
ei
r b
in
di
ng
 m
od
e)
. 
 
C
om
pa
ris
on
 o
f t
he
 g
lo
ba
l D
C
-S
IG
N
 C
R
D
 b
ac
kb
on
es
 in
 e
ac
h 
co
m
pl
ex
 r
ev
ea
ls
 a
 g
lo
ba
l 
id
en
tic
al
 s
tru
ct
ur
e.
 W
he
n 
ex
am
in
in
g 
m
or
e 
pr
ec
is
el
y 
th
e 
si
de
 c
ha
in
 o
f 
re
si
du
es
 (
se
e 
ab
ov
e)
 
in
vo
lv
ed
 i
n 
th
e 
bi
nd
in
g 
si
te
 (
C
a2
+  
an
d/
or
 l
ig
an
d 
bi
nd
in
g)
, 
ag
ai
n,
 m
os
t 
of
 t
he
m
 a
re
 p
er
fe
ct
ly
 
su
pe
rim
po
se
d.
 O
nl
y 
4 
re
si
du
es
 p
re
se
nt
 s
om
e 
sl
ig
ht
 d
iff
er
en
ce
s 
an
d 
ar
e 
la
be
le
d 
in
 t
he
 f
ig
ur
e 
ab
ov
e:
 F
31
3,
 R
34
5,
 V
35
1 
an
d 
K3
68
. 
Fo
r F
31
3,
 th
e 
di
ffe
re
nc
e 
is
 w
ith
 2
IT
6 
st
ru
ct
ur
e 
(c
om
pl
ex
 w
ith
 M
an
!
1-
2M
an
) w
he
re
 th
e 
F3
13
 s
id
e 
ch
ai
n 
is
 d
oi
ng
 a
 s
lig
ht
 r
ot
at
io
n 
ca
us
ed
 b
y 
hy
dr
op
ho
bi
c 
in
te
ra
ct
io
n 
w
ith
 m
an
no
se
 r
in
g.
 N
o 
m
ov
em
en
t 
of
 t
hi
s 
re
si
du
e 
w
ith
 p
se
ud
o-
1,
2-
m
an
no
si
de
 a
nd
 L
ew
is
 X
 w
hi
ch
 a
re
 n
ot
 in
te
ra
ct
in
g 
w
ith
 F
31
3.
 
Fo
r 
R
34
5,
 t
he
 s
id
e 
ch
ai
n 
is
 in
 d
iff
er
en
t 
or
ie
nt
at
io
n 
in
 a
ll 
th
re
e 
st
ru
ct
ur
es
 b
ut
 is
 n
ot
 in
vo
lv
ed
 in
 
lig
an
d 
bi
nd
in
g.
 I
t 
is
 o
rie
nt
ed
 t
ow
ar
ds
 s
ol
ve
d 
an
d 
di
ffe
re
nt
 o
rie
nt
at
io
n 
ar
e 
m
or
e 
re
la
te
d 
to
 t
he
 
va
rio
us
 c
ry
st
al
 s
tru
ct
ur
es
 p
ac
ki
ng
 (
no
t 
ex
ac
tly
 s
am
e 
sp
ac
e 
gr
ou
ps
). 
O
nl
y,
 t
he
 C
O
 o
f 
th
e 
ba
ck
bo
ne
 o
f 
R
34
5,
 w
hi
ch
 i
s 
ap
pr
ox
im
at
el
y 
in
 t
he
 s
am
e 
or
ie
nt
at
io
n 
in
 a
ll 
st
ru
ct
ur
es
, 
ca
n 
be
 
in
di
re
ct
ly
 i
nv
ol
ve
d 
in
 i
nt
er
ac
tio
n 
w
ith
 l
ig
an
ds
 t
hr
ou
gh
 a
 b
rid
gi
ng
 w
at
er
 m
ol
ec
ul
e 
(n
ot
 s
ho
w
n 
he
re
). 
Fo
r 
K
36
8,
 
di
ffe
re
nc
es
 
ar
e 
m
or
e 
si
gn
ifi
ca
nt
 
an
d 
im
pl
ic
at
e 
m
ov
em
en
ts
 
of
 
th
e 
si
de
-c
ha
in
. 
D
ep
en
di
ng
 o
f 
th
e 
ca
se
, 
th
e 
la
te
ra
l 
ch
ai
ns
 a
re
 f
ac
in
g 
th
e 
lig
an
d 
or
 s
ol
ve
nt
. 
In
 2
IT
6 
te
rm
in
al
 
am
in
e 
of
 s
id
e 
ch
ai
n 
is
 i
nv
ol
ve
d 
in
 h
yd
ro
ge
n 
bo
nd
 w
ith
 h
yd
ro
xy
l 
fu
nc
tio
n 
of
 C
6 
of
 t
he
 n
on
-
re
du
ci
ng
 m
an
no
se
 o
f m
in
or
 o
rie
nt
at
io
n.
 In
 1
S
L5
 a
n 
in
te
ra
ct
io
n 
w
ith
 th
e 
hy
dr
ox
yl
 g
ro
up
 o
n 
C
2 
of
 
fu
co
se
 m
ig
ht
 a
ls
o 
be
 p
os
si
bl
e.
 In
 2
X
R
5 
st
ru
ct
ur
e 
th
er
e 
is
 n
o 
gr
ou
p 
fro
m
 th
e 
lig
an
d 
av
ai
la
bl
e 
fo
r 
in
te
ra
ct
io
n 
an
d 
K
36
8 
si
de
 c
ha
in
 is
 o
rie
nt
ed
 to
 s
ol
ve
nt
. 
Fo
r 
V
35
1,
 th
e 
di
ffe
re
nc
es
 a
re
 s
m
al
l a
nd
 li
m
ite
d 
to
 v
ar
io
us
 o
rie
nt
at
io
ns
 o
f s
id
e 
ch
ai
n 
ar
ou
nd
 th
e 
C
A
-C
B
 b
on
d 
in
 o
rd
er
 t
o 
fit
 t
o 
th
e 
co
rr
es
po
nd
in
g 
lig
an
d.
 I
n 
2X
R
5 
st
ru
ct
ur
e 
(th
is
 s
tu
dy
) 
w
e 
id
en
tif
ie
d 
tw
o 
al
te
rn
at
e 
co
nf
or
m
at
io
ns
, 
on
e 
th
at
 is
 t
he
 s
am
e 
co
nf
or
m
at
io
n 
as
 in
 2
IT
6 
st
ru
ct
ur
e 
an
d 
a 
se
co
nd
 w
hi
ch
 is
 a
 9
0°
 r
ot
at
io
n.
 T
he
se
 tw
o 
co
nf
or
m
at
io
ns
 e
st
ab
lis
h 
co
nt
ac
ts
 w
ith
 h
ex
an
e 
rin
g 
of
 p
se
ud
om
an
no
bi
os
id
e.
 In
 1
S
L5
 s
tru
ct
ur
al
 o
rie
nt
at
io
n 
of
 th
e 
si
de
 c
ha
in
 is
 in
 b
et
w
ee
n 
th
e 
tw
o 
al
te
rn
at
e 
co
nf
or
m
at
io
ns
 w
e 
id
en
tif
ie
d 
in
 2
X
R
5 
st
ru
ct
ur
e 
an
d 
es
ta
bl
is
h 
co
nt
ac
ts
 w
ith
 h
yd
ro
xy
l 
gr
ou
p 
an
d 
C
2 
of
 th
e 
fu
co
se
 ri
ng
 o
f L
ew
is
 X
. 
      
 
Fi
gu
re
 S
2.
 C
ry
st
al
lo
gr
ap
hi
c 
w
at
er
 m
ol
ec
ul
e 
in
 d
ire
ct
 c
on
ta
ct
 w
ith
 p
se
ud
o-
1,
2-
m
an
no
bi
os
id
e.
 
O
nl
y 
on
e 
of
 t
he
se
 t
hr
ee
 m
ed
ia
te
s 
an
 i
nt
er
ac
tio
n 
w
ith
 a
 p
ro
te
in
 r
es
id
ue
, 
D
36
7.
 W
at
er
 a
re
 
re
pr
es
en
te
d 
as
 r
ed
 s
ph
er
e,
 C
a2
+  
as
 g
re
en
 s
ph
er
e.
 H
yd
ro
ge
n 
bo
nd
s 
in
vo
lv
in
g 
w
at
er
 m
ol
ec
ul
es
 
ar
e 
re
pr
es
en
te
d 
as
 d
ot
te
d 
lin
e.
 
  (a
) 
  
 
(b
) 
 
Fi
gu
re
 S
3.
 Z
oo
m
 o
f a
no
m
er
ic
 re
gi
on
 o
f S
TD
 s
pe
ct
ra
 re
gi
st
er
ed
 a
t 2
5 
ºC
 (5
00
 M
H
z)
 a
nd
 
sa
tu
ra
tio
n 
tim
e 
of
 2
.0
 s
.  
(o
ff-
re
so
na
nc
e 
fre
qu
en
cy
 4
0 
pp
m
, o
n-
re
so
na
nc
e 
fre
qu
en
cy
 0
 
pp
m
). 
 (
a)
 1
H
 N
M
R
 r
ef
er
en
ce
 s
pe
ct
ru
m
 (
ab
ov
e)
 a
nd
 S
TD
 s
pe
ct
ru
m
 (
bo
tto
m
) 
of
 a
 
sa
m
pl
e 
co
nt
ai
ni
ng
 1
.7
 m
M
 o
f 1
b 
an
d 
19
 µ
M
 o
f D
C
-S
IG
N
 E
C
D
. (
b)
 1
H
 N
M
R
 r
ef
er
en
ce
 
sp
ec
tru
m
 (a
bo
ve
) a
nd
 S
TD
 s
pe
ct
ru
m
 (b
ot
to
m
) o
f t
he
 s
am
e 
sa
m
pl
e 
af
te
r a
dd
iti
on
 o
f 1
.7
 
m
M
 o
f 1
a.
 T
he
 d
ec
re
as
e 
in
 S
TD
 a
ro
un
d 
50
 %
 in
di
ca
te
s 
th
at
 th
e 
tw
o 
lig
an
ds
 h
av
e 
th
e 
sa
m
e 
af
fin
ity
 a
nd
 th
en
 th
e 
tri
az
ol
 m
oi
et
y 
do
es
 n
ot
 a
ffe
ct
 b
in
di
ng
 to
 D
C
-S
IG
N
. 
  
  
Ta
bl
e 
S
1.
 C
he
m
ic
al
 s
hi
fts
 o
f 1
b 
(5
00
 M
H
z,
D
2O
, 2
5 
ºC
, H
D
O
 re
si
du
al
 a
t 4
.7
 p
pm
) 
  
Pr
ot
on
s 
! 
1 H
 
(p
pm
) 
H
-1
 M
 
4.
89
 
H
-2
 M
 
3.
88
 
H
-3
 M
 
3.
72
 
H
-4
 M
 
3.
52
 
H
-5
 M
 
3.
51
 
H
-6
a 
M
 
3.
78
 
H
-6
b 
M
 
3.
65
 
M
e 
3.
62
 
H
-1
ax
 C
 
3.
65
 
H
-2
eq
 C
 
3.
79
 
H
-3
ax
 C
 
1.
38
 
H
-3
eq
 C
 
1.
95
 
H
-4
ax
 C
 
2.
77
 
H
-5
ax
 C
 
2.
33
 
H
-6
ax
 C
 
1.
66
 
H
-6
eq
 C
 
1.
92
 
O
-C
H
2-
C
H
2 
3.
86
 
O
-C
H
2-
C
H
2 
3.
92
 
O
-C
H
2-
C
H
2 
4.
56
 
C
H
2-
O
H
 
4.
65
 
H
 T
ria
zo
l 
7.
98
 
' ' ' ' ' ' ' ' '
' ' Ta
bl
e 
S
2.
'C
om
pa
ris
on
 o
f i
nt
er
pr
ot
on
 d
is
ta
nc
es
 o
f 1
b 
in
 b
ou
nd
 s
ta
te
 o
bt
ai
ne
d 
fro
m
 N
M
R
 
da
ta
 in
 s
ol
ut
io
n,
 a
nd
 fr
om
 m
ea
su
re
m
en
t o
n 
th
e 
cr
ys
ta
l s
tru
ct
ur
e 
(p
db
 c
od
e 
 2
xr
5)
. 
  
'
D
is
ta
nc
es
 fr
om
 
 
Pr
ot
on
 p
ai
r 
TR
-N
O
ES
Y 
(@
) a
 
X-
R
ay
 (@
) 
H
-3
ax
 C
 / 
H
-3
eq
 C
  
1.
7 
1.
8 
H
-1
 M
 / 
H
-3
eq
 C
 
2.
6 
2.
3 
H
-1
 M
 / 
H
-4
 C
 
3.
3 
3.
5 
H
-2
 M
 / 
H
-6
ax
 C
 
4.
2 
4.
3 
H
-2
 M
 /H
-3
eq
 C
 
3.
2 
3.
9 
H
-2
 M
 / 
H
-4
 C
 
3.
1 
3.
3 
H
-3
 M
 / 
H
-6
ax
 C
 
3.
4 
3.
4 
H
-3
 M
 / 
H
-4
 C
 
4.
4 
4.
0 
H
-5
 C
 / 
H
-1
 C
 
3.
5 
3.
7 
H
-6
eq
 C
 / 
H
-1
 C
 
2.
5 
2.
5 
H
-6
ax
 C
 / 
H
-1
 C
 
2.
4 
2.
4 
a '
D
is
ta
nc
es
 d
er
iv
ed
 u
si
ng
 th
e 
is
ol
at
ed
 s
pi
n-
pa
ir 
ap
pr
ox
im
at
io
n 
(IS
P
A
) b
y 
co
m
pa
rin
g 
re
la
tiv
e 
N
O
E
 in
te
ns
iti
es
 w
ith
 th
at
 o
f t
he
 re
fe
re
nc
e 
(H
3a
x-
H
3e
q 
of
 c
yc
lo
he
xy
l r
in
g 
of
 1
b)
 
 ' ' '
Q+
R'
'
Q@
R'
'
Fi
gu
re
 S
4:
 S
tru
ct
ur
e 
of
 L
ew
is
 X
 (a
) a
nd
 L
ac
to
-N
-fu
co
pe
nt
ao
se
 II
I (
b)
 
O
H
OO
H
O
H
O
O
O
O
H N
H
AcO
H
O
O
H
H
OH
O
O
H
O
H
OO
H
O
H
O
O
O
O
H N
H
A
cO
O
O
H
H
OH
O
O
H
O
H
O
O
H O
H
O
H
O
O
H
O
H O
H
O
' ' ' Ta
bl
e 
S
3.
'C
on
ta
ct
 d
is
ta
nc
es
 b
et
w
ee
n 
ps
eu
do
-1
,2
-m
an
no
bi
os
id
e 
an
d 
V
35
1 
si
de
 c
ha
in
 
in
 b
ot
h 
co
nf
or
m
at
io
n 
A
 a
nd
 B
. 
 
D
is
ta
nc
es
 (@
)'
C
on
ta
ct
 
#?
4S
'H
 a
 
#?
4S
'I
 
B+
&'1
7.
'3
6
0'
A'T
UI
'V
H
( 
3.
8 
3.
0 
B+
&'1
7.
'3
6
0'
A'T
UI
'3
H
> 
3.
9 
3.
7 
B+
&'1
7.
'3
6
.'
A'T
UI
'3
H
> 
- 
4.
2 
B+
&'1
7.
'3
6
.'
A'!
H
C
'3
1 
- 
3.
9 
B+
&'1
7.
'3
6
0'
A'!
H
C
'3
1 
3.
9 
- 
' H
-?
W
'4
+W
%K
'+
<%
'-$
?K
%'
S<
?W
'-$
%'
*J
@'
S"&
%'
0X
>7
'?
S'-
$%
'K
-<
,#
-,
<%
'J
%K
#<
"@
%J
'"4
'-$
"K
'K
-,
JY
M'
!
H
C
'3
1Z
'3
1'
?S
'-$
%'
4?
4'
<%
J,
#"
4D
'W
+4
4?
K%
'*
K%
,J
?A
./
0A
W
+4
4?
@"
?K
"J
%'
TU
I'
3H
>Z
'3
+<
@?
4'
?S
'-$
%'
-$
%'
#Y
#&
?$
%[
+4
'<
"4
D'
*K
%,
J?
A.
/0
AW
+4
4?
@"
?K
"J
%'
TU
I'
V
H
('
Z'V
[Y
D%
4'
?S
'W
%-
$Y
&%
K-
%<
'@
?4
J'
K,
@K
-"-
,%
4-
'?
4'
-$
%'
#Y
#&
?$
%[
+4
%'
<"
4D
'?
S'*
K%
,J
?A
./
0A
W
+4
4?
@"
?K
"J
%'
'
'   Pr
op
os
ed
 fo
rm
al
is
m
 to
 q
ua
nt
ify
, /
0'
#&
,*
"/
?&
'"
&#
.
>A
'"
2&
'>
&,
&%
"/
?/
"-
'&
))
&%
"<
 
 
'
Fi
gu
re
 S
5.
 H
is
to
gr
am
s 
sh
ow
in
g 
th
e 
co
m
pa
ris
on
 o
f 
M
an
!
1-
2M
an
 a
nd
 1
a 
se
le
ct
iv
iti
es
, 
an
d 
th
e 
se
le
ct
iv
ity
 g
ai
n 
ob
ta
in
ed
 fo
r b
ot
h 
flo
w
 c
el
ls
 (F
c-
H
D
 –
 5
00
0 
R
U
, F
c-
LD
 –
 1
35
0 
R
U
 o
f i
m
m
ob
ili
ze
d 
B
S
A
-M
an
). 
 
84
'?
<J
%<
'-
?'
\,
+4
-"S
Y'
-$
%'
K%
&%
#-
"9
"-Y
'%
SS
%#
-/
'+
'<
%&
+-
"9
%'
%9
+&
,+
-"?
4'
$+
J'
-?
'@
%'
%W
*&
?Y
%J
M'
($
%'
+@
K?
&,
-%
'K
%&
%#
-"9
"-Y
'?
S'
+'
*+
<-
"#
,&
+<
'#
?W
*?
,4
J'
Q$
*-
#?
W
*M
R'
S?
<'
]
3A
:8
6
C
'5
$'
&+
4D
%<
"4
'#
+4
'@
%'
J%
S"4
%J
'+
K'
+'
<+
-"?
'?
S'-
$%
'83
7T
'9
+&
,%
K'
S?
<'
&+
4D
%<
"4
'+
4J
']
3A
:8
6
C
'Q$
*-
#?
W
*M
^'
83
7T
'&+
4D
%<
"4
'_'
83
7T
']
3A
:8
6
C
R/'
K?
'
-$
+-
'$
*-
#?
W
*M
'`
'.
'W
%+
4K
'+
'K
%&
%#
-"9
"-Y
'?
S'
-$
%'
#?
W
*?
,4
J'
"4
'S
+9
?,
<'
?S
']
3A
:8
6
C
M'
(?
'%
[#
&,
J%
'-
$%
'
%S
S%
#-
'?
S'
-$
%'
K,
<S
+#
%'
J%
4K
"-Y
'Q
N"
D,
<%
':
7M
R/'
+'
K%
&%
#-
"9
"-Y
'D
+"
4'
Q$
*-
.R
'+
#$
"%
9%
J'
@Y
'K
a
"-#
$"
4D
'S
<?
W
'
?4
%'
#?
W
*?
,4
J'
-?
'+
4?
-$
%<
'#
+4
'@
%'
#?
4K
"J
%<
%J
/'
$*
-.
#?
W
*M
. !
#?
W
*M
0'
^'
$*
- #?
W
*M
0'
_'
$*
- #?
W
*M
.M
'(
$"
K'
-%
<W
'
*<
?9
"J
%K
'+
'<
%&
+-
"9
%'
#?
W
*+
<"
K?
4'
?S
'-
$%
'"
W
*<
?9
%W
%4
-'
?S
'K
%&
%#
-"9
"-Y
'@
%-
a
%%
4'
-$
%'
-a
?'
&%
#-
"4
K'
a
$%
4'
Ka
"-#
$"
4D
'S
<?
W
'?
4%
'#
?W
*?
,4
J'
-?
'+
4?
-$
%<
M'8
4J
%%
J/
'$
*-
. #
?W
*M
. !
#?
W
*M
0'
`'
.'
W
%+
4K
'+
'D
+"
4'
?S
'
]
3A
:8
6
C
'K
%&
%#
-"9
"-Y
'5
$M
'&+
4D
%<
"4
'S
?<
'#
?W
*?
,4
J'
0'
#?
W
*+
<%
J'
-?
'#
?W
*?
,4
J'
.'
@Y
'+
'#
?<
<%
K*
?4
J"
4D
'
S+
#-
?<
/'
a
$"
&%
'9
+&
,%
K'
b.
'W
%+
4K
'+
'&
?K
K'
?S
'K
%&
%#
-"9
"-Y
'S
?<
']
3A
:8
6
C
M'
($
"K
'+
**
<?
+#
$'
?S
'+
'<
%&
+-
"9
%'
#?
W
*+
<"
K?
4'
<%
9%
+&
%J
'-
$+
-'
-$
%'
K%
&%
#-
"9
"-Y
'D
+"
4'
"K
'"
4J
%%
J'
K,
<S
+#
%'
J%
4K
"-Y
A"4
J%
*%
4J
%4
-'
QN
"D
,<
%'
:7
RM'
84
-%
<%
K-
"4
D&
Y/
'-
$"
K'
S?
<W
+&
"K
W
'+
&&?
a
K'
\,
+4
-"S
Y"
4D
'-
$%
'"
W
*<
?9
%W
%4
-'
?S
'K
%&
%#
-"9
"-Y
'-
$+
-'
a
+K
'
\,
+&
"-+
-"9
%&
Y'
?@
K%
<9
%J
'"4
'N
"D
,<
%'
UI
M'c
$"
&%
'!
+4
!
.A
0!
+4
'$
+K
'4
?'
#&
%+
<'
K%
&%
#-
"9
"-Y
'@
%-
a
%%
4'
-$
%'
-a
?'
&%
#-
"4
K/
'B
*'
*<
%K
%4
-K
'+
'K
*%
#"
S"#
"-Y
'"W
*<
?9
%W
%4
-'
-?
a
+<
JK
']
3A
:8
6
C
'a
"-$
'+
'K
%&
%#
-"9
"-Y
'D
+"
4'
@Y
'+
'
S+
#-
?<
'?
S'+
@?
,-
'1
M7
'Q@
%-
a
%%
4'
1M
O1
'+
4J
'1
M1
0R
'?
9%
<'
!
+4
!
.A
0!
+4
M'
!"#"$"%"&"'"(")"*"
+,
-"
.
/0
1#
2$
.
/0
"
3"
#/
"
4"
.
#$
.
25
#/
"
67
28
9
"
67
2:
9
"
!"
# !
"#
$
%&
'!
"#
(
!"
# %
"(
!"
#$
!
"#
$
%&
'!
"#
!
%"
(
'
 
Fi
gu
re
 S
6.
'M
an
!
1-
2M
an
 b
in
di
ng
 m
od
es
 i
n 
la
ng
er
in
. 
M
in
or
 a
nd
 m
aj
or
 b
in
di
ng
 m
od
es
 a
re
 
re
pr
es
en
te
d 
in
 c
ya
n 
an
d 
da
rk
 b
lu
e 
re
sp
ec
tiv
el
y.
 V
an
 d
er
 W
aa
ls
 i
nt
er
ac
tio
ns
 w
ith
 A
28
9 
ar
e 
re
pr
es
en
te
d 
as
 d
as
he
d 
bl
ue
 li
ne
. 
' '
'  
'
Fi
gu
re
 S
7.
 (
<+
4K
S%
<<
%J
'C
V
E'
@,
"&J
A,
*'
#,
<9
%K
'?
S'K
%&
%#
-%
J'
#<
?K
K'
*%
+;
K'
?S
'B
4M
'(
$%
'D
<?
a
-$
'?
S'C
V
E'
4?
<W
+&
"5
%J
'9
?&
,W
%K
'Q#
<?
KK
'*
%+
;'
_'
J"
+D
?4
+&
'*
%+
;R
'a
+K
'a
%&
&'J
%K
#<
"@
%J
'@
Y'
+'
&"4
%+
<'
@%
$+
9"
?<
'S?
<'
W
"[
"4
D'
-"W
%K
'@
%&
?a
'T
M1
'K
M'
' ' '  
16. Supplementary information to paper no5
393
CHAPTER 16. SUPPLEMENTARY INFORMATION TO PAPER NO5
394
SU
P
P
L
E
M
E
N
T
A
R
Y
IN
F
O
R
M
A
T
IO
N
T
O
:L
ec
tin
cl
us
te
rin
g
by
a
gl
yc
om
im
et
ic
w
ith
ou
t
an
y
m
ul
tiv
al
en
t
pr
es
en
ta
tio
n:
a
ca
se
st
ud
y
in
D
C
-S
IG
N
an
ta
go
ni
st
de
ve
lo
pm
en
t
Ie
va
Su
tk
ev
ič
iu¯
te˙
1,
2,
3 ,
M
ic
he
lT
hé
pa
ut
1,
2,
3 ,
Sa
ra
Sa
tt
in
4 ,
A
ng
el
a
B
er
zi
5 ,
Jo
hn
M
cG
ea
gh
6 ,
A
lin
e
Le
R
oy
1,
2,
3 ,
M
ac
ar
en
a
Sa
nc
he
z
N
av
ar
o7
,J
av
ie
r
R
oj
o7
,M
ar
io
C
le
ri
ci
8 ,
A
nn
a
B
er
na
rd
i4
,C
hr
is
ti
ne
E
be
l1
,2
,3
,
Fr
an
ck
Fi
es
ch
i1
,2
,3
*
1
In
st
it
ut
de
B
io
lo
gi
e
St
ru
ct
ur
al
e,
U
ni
ve
rs
it
é
G
re
no
bl
e
I,
41
ru
e
Ju
le
s
H
or
ow
it
z,
G
re
no
bl
e,
F
-3
80
27
,
Fr
an
ce
;
2
C
N
R
S,
U
M
R
50
75
,
G
re
no
bl
e,
F
-3
80
00
,
Fr
an
ce
;
3
C
E
A
,
D
SV
,
G
re
no
bl
e,
F
-3
80
00
,
Fr
an
ce
;
4
U
ni
ve
rs
it
a’
di
M
ila
no
,
D
ip
ar
ti
m
en
to
di
C
hi
m
ic
a,
vi
a
G
ol
gi
19
,
20
13
3
M
ila
no
-
It
al
y;
5
C
ha
ir
of
Im
m
un
ol
og
y,
D
ep
ar
tm
en
t
of
C
lin
ic
al
Sc
ie
nc
es
L
.
Sa
cc
o,
U
ni
ve
rs
it
y
of
M
ila
n,
Se
gr
at
e;
6
A
nt
er
io
C
on
su
lt&
R
es
ea
rc
h
G
m
bH
,
A
ug
us
ta
an
la
ge
23
,
D
-6
81
65
M
an
nh
ei
m
-G
er
m
an
y;
7
G
ly
co
sy
st
em
s
La
bo
ra
to
ry
,
In
st
it
ut
o
de
In
ve
st
ig
ac
io
ne
s
Q
uí
m
ic
as
(I
IQ
),
C
SI
C
-
U
ni
ve
rs
id
ad
de
Se
vi
lla
,
A
m
ér
ic
o
V
es
pu
ci
o
49
,
41
09
2
Se
vi
lla
-S
pa
in
;
8
C
ha
ir
of
Im
m
un
ol
og
y,
D
ep
ar
tm
en
t
of
B
io
m
ed
ic
al
Sc
ie
nc
es
an
d
T
ec
hn
ol
og
ie
s,
U
ni
ve
rs
it
y
of
M
ila
n,
Se
gr
at
e.
Su
pp
le
m
en
ta
l
fig
ur
e
S1
.
T
he
st
ru
ct
ur
e
of
th
e
G
3
B
ol
to
rn
ty
pe
de
nd
ri
m
er
.
D
C
-S
IG
N
E
C
D
ex
tr
a-
pu
ri
fic
at
io
n
D
C
-S
IG
N
E
C
D
pu
ri
fie
d
by
aﬃ
ni
ty
ch
ro
m
at
og
ra
ph
y
us
in
g
m
an
na
n-
ag
ar
os
e
co
lu
m
n,
w
hi
ch
al
lo
w
s
to
se
le
ct
on
ly
th
os
e
te
tr
am
er
st
ha
th
av
e
at
le
as
tt
w
o
ac
ti
ve
C
R
D
s,
an
d
su
bs
eq
ue
nt
ge
l-fi
lt
ra
ti
on
(a
sd
es
cr
ib
ed
in
Ta
ba
ra
ni
et
al
.
[1
],
w
as
re
-in
je
ct
ed
to
m
an
na
n-
ag
ar
os
e
co
lu
m
n
m
ai
nt
ai
ni
ng
th
e
sa
m
e
co
nd
it
io
ns
as
al
re
ad
y
de
sc
ri
be
d
Ta
ba
ra
ni
et
al
.[
1]
,e
xc
ep
t
th
at
el
ut
io
n
w
as
pe
rf
or
m
ed
by
m
an
no
se
gr
ad
ie
nt
(0
-3
0
m
M
,
20
0
m
L
le
ng
th
,1
m
L/
m
in
flo
w
ra
te
),
an
d
at
th
e
en
d
th
e
flo
w
of
m
an
no
se
co
nt
ai
ni
ng
bu
ﬀe
r
w
as
sw
it
ch
ed
to
1
m
M
E
D
TA
to
el
ut
e
an
y
re
si
du
al
pr
ot
ei
n
th
at
w
as
at
ta
ch
ed
to
th
e
co
lu
m
n.
Su
pp
le
m
en
ta
lfi
gu
re
S2
.
E
xt
ra
-p
ur
ifi
ca
ti
on
of
D
C
-S
IG
N
E
C
D
.A
ch
ro
m
at
og
ra
m
of
D
C
-S
IG
N
E
C
D
in
je
ct
io
n
to
m
an
na
n-
ag
ar
os
e
an
d
el
ut
io
n
by
m
an
no
se
gr
ad
ie
nt
(p
in
k
lin
e)
.
A
bs
or
pt
io
n
ch
an
ge
s
at
λ
=
28
0
nm
ar
e
sh
ow
n
by
a
bl
ue
lin
e.
G
re
en
fr
am
e
de
pi
ct
s
co
lle
ct
ed
fr
ac
ti
on
s
fo
r
fu
rt
he
r
us
e
in
IT
C
ex
pe
ri
m
en
ts
.
Si
nc
e
D
C
-S
IG
N
E
C
D
ha
s
be
en
al
re
ad
y
pu
ri
fie
d,
ea
ch
te
tr
am
er
m
us
t
ha
ve
at
le
as
t
2
C
R
D
s
fu
nc
ti
on
al
(C
R
D
m
on
om
er
ha
s
no
t
en
ou
gh
of
aﬃ
ni
ty
to
bi
nd
to
th
e
co
lu
m
n,
th
us
it
is
de
la
ye
d
an
d
el
ut
io
n
is
no
t
re
qu
ir
ed
(d
es
cr
ib
ed
in
T
he
pa
ut
et
al
.
[2
])
.
T
he
el
ut
ed
pe
ak
in
Fi
g.
S1
is
co
m
po
se
d
of
3
su
b-
pe
ak
s,
in
w
hi
ch
th
e
ea
rl
ie
st
el
ut
ed
ha
ve
lo
w
es
t
aﬃ
ni
ty
an
d
m
us
t
co
rr
es
po
nd
to
te
tr
am
er
s
w
it
h
2
fu
nc
ti
on
al
C
R
D
s,
su
bs
eq
ue
nt
su
b-
pe
ak
ss
ho
ul
d
co
nt
ai
n
3
an
d
4
fu
nc
ti
on
al
C
R
D
sp
os
se
ss
in
g
te
tr
am
er
s,
re
sp
ec
ti
ve
ly
.
O
ve
ra
ll,
th
e
ap
pr
ox
im
at
el
y
es
ti
m
at
ed
pe
rc
en
ta
ge
of
ac
ti
ve
C
R
D
s
pe
r
in
je
ct
ed
sa
m
pl
e
is
95
%
.
T
he
co
lle
ct
ed
3r
d
su
b-
pe
ak
w
it
h
4
fu
nc
ti
on
al
C
R
D
s
w
as
fu
rt
he
r
tr
ea
te
d
to
el
im
in
at
e
th
e
ex
ce
ss
of
m
an
no
se
:
E
D
TA
w
as
ad
de
d
to
th
e
co
nc
en
tr
at
ed
sa
m
pl
e
of
th
e
pr
ot
ei
n
(8
m
g/
m
L)
to
fin
al
co
nc
en
tr
at
io
n
of
16
m
M
in
or
de
r
to
di
sr
up
t
m
an
no
se
/D
C
-S
IG
N
co
m
pl
ex
es
,
ce
nt
ri
fu
ge
d
an
d
su
bj
ec
te
d
to
ge
l-fi
lt
ra
ti
on
(S
up
er
os
e1
2)
to
el
im
in
at
e
E
D
TA
an
d
m
an
no
se
,a
nd
re
ch
ar
ge
th
e
pr
ot
ei
n
w
it
h
C
a2
+
.
T
he
el
ut
ed
pr
ot
ei
n
w
as
co
nc
en
tr
at
ed
an
d
us
ed
in
IT
C
ex
pe
ri
m
en
t.
2
A
n
ex
am
pl
e
of
ps
Tr
i/
D
C
-S
IG
N
E
C
D
sa
m
pl
e
po
ly
di
sp
er
si
ty
in
D
LS
m
ea
su
re
m
en
ts
T
he
co
rr
el
at
io
n
cu
rv
es
an
d
th
e
co
rr
es
po
nd
in
g
R
H
di
st
ri
bu
ti
on
s
fr
om
th
re
e
m
ea
su
re
m
en
ts
of
a
sa
m
pl
e
co
nt
ai
ni
ng
10
2
µM
D
C
-S
IG
N
E
C
D
an
d
10
9
µM
ps
Tr
ia
re
pr
es
en
te
d
be
lo
w
.
3
R
ef
er
en
ce
s
[1
]
Ta
ba
ra
ni
,G
.,
T
hé
pa
ut
,M
.,
St
ro
eb
el
,D
.,
E
be
l,
C
.,
V
iv
ès
,C
.,
V
ac
he
tt
e,
P.
,D
ur
an
d,
D
.,
&
Fi
es
ch
i,
F.
(2
00
9)
.
J
B
io
lC
he
m
,
28
4
(3
2)
,2
12
29
–4
0.
[2
]
T
he
pa
ut
,M
.,
G
uz
zi
,C
.,
Su
tk
ev
ic
iu
te
,I
.,
Sa
tt
in
,S
.,
R
ib
ei
ro
-V
ia
na
,R
.,
V
ar
ga
,N
.,
C
ha
br
ol
,E
.,
R
oj
o,
J.
,A
ng
ul
o,
J.
,B
er
na
rd
i,
A
.,
N
ie
to
,P
.M
.,
&
Fi
es
ch
i,
F.
(2
01
2)
.
su
bm
itt
ed
,
,1
–2
8.
4
17. Supplementary information to paper no6
397
CHAPTER 17. SUPPLEMENTARY INFORMATION TO PAPER NO6
398
!"
"
!"
##
$%
&
%'
()
*+
,'
-.
*&
)(
/.
'
(.
0

!%
$%
1(
/2
%
()
*3
%(
/'
3
.-
4
5Ͳ
!,
67
8
/(9
&
)'
'.
:%
Ͳ;
):
%<
3
$+
1.
&
/&
%(
/1
:=
!
+'
(9
%:
/:

)'
<
/'
(%
*)
1(
/.
'
:(
"<
/%
:.
-;
/:
Ͳ;
%'
>+
$)
&
/<
%
<%
*/2
)(
/2
%:
.
-)
#
:%
"<
.Ͳ
&
)'
'.
;/
.:
/<
%=

!
"#
$%
#&
'
(#
)(
*+*
, -
%.
(
/0
&1
%.
23
20
&%
*4*
5*
6*
, 7
28
92(
:
09
92*
; <
"=
8
>
3:
%(
)=
*? 
-@
($
%A
A%
B
%&
2&Ͳ
C(
%#
&A%
28
*4
*5
*6

/%
#%
8(
:
0)
A2"
&&
(*
+ <
D#
)
E
%2
@%
#*?
<%
@F
@G
8)
0A
"*
; H
#(
83
1
H2
%@
3=
2*4
*5
*I
G
88
(
J%
#8
(#
K2
+L

! "
#$
%&
'(
$)*
+,
$-
$.*
#/
01
$2
*'
)$3
&#
)/
,
$4
5$
3
$6
*
0%
$*
7
/.
8$
!
90
:
;!
<<
-
$.*
#/
Ͳ
=)*
.>
 ?
: =#
()
$)@
),
&
A$
/.
/8
$&

B)
'@
6)
@'
*.
&0
"
#$
%&
'(
$)C
7
'&
#/
D.
&
=0
E!
'@
&
F@
.&
(
G/
'/
H
$)I
07
'&
#/
D.
&0
J
Ͳ<
K;
:L
0J
'*
#6
&
?<
4M
NB
0"
-
N
O;
LO
0
7'
&#
/D
.&
0J
Ͳ<
K;
;;
0J
'*
#6
&?
E 4
PQ
01
BR
07
'&
#/
D.
&0
J
Ͳ<
K;
;;
0J
'*
#6
&?
O 7
.>
6/
(>
()
&3
(S
*D
/'
*)
/'
>0
=#
()
$)@
)/
,
&
=#
%&
()
$8
*6
$/
#&
(
T
@U
3
$6
*(
V=
=T
W0
4B
=4
Ͳ
"
#$
%&
'(
$,
*,
,
&
B&
%$
..*
0Q
3
C'
$6
/
R&
(2
@6
$/
E
90
E
!;
9:
B
&%
$..
*Ͳ
B2
*$
#?

X A
nt
er
io
 
C
on
su
lt&
Re
se
ar
ch
 
G
m
bH
, 
Au
gu
sta
an
la
ge
 
23
, 
D
-6
81
65
 
M
an
nh
ei
m
-G
er
m
an
y?

L =#
()
$)@
)
"#
$%
&'
($)
*$
'&
,
&
J'
*#
6&
0 !
;<
D
/@
.&
%*
',
B
*$
#)
Ͳ-
$65
&.
L
O;
;O
Y
*'
$(Ͳ
J'
*#
6&
Z
,
M=
%@
%
&N
"
(0
&=
"#
@3
"8
&#
2$
0&
%K
%
O0
(A
AP
&"
&=
2@
Q(
Q%
#
  !"
##
$%
&
%'
()
*+
,'
-.
*&
)(
/.
'
 + C
Ͳ(
8K
+5
7Ͳ
!
>
R
@Q
%3
&#
(
"S
?
@
(8
K
?A
T;
UU
>
C9
*V
4W
X
B)
;$
%
!,
Ͳ?
=/
MV
U.
(A
0%
@S
"#
&=
%
Q#
"&
"8
@"
S?
@Ͳ
?A

/P
8&
=%
@2@
"
S$
%8
9P
A(
Y
28
%@
?
C
/P
8&
=%
@2@
"
S(
Y
2K
%@
D
)Ͳ
.*
?
?
(8
K
?E
  
/P
8&
=%
@2@
"
S!
+ *!
4 Ͳ
$2
@T
6Ͳ
T=
PK
#"
ZP
Y
%&
=P
A%
8%
X$
%8
9P
AX(
Y
2K
%
?E

F/
3"
*%
!
,Ͳ?
[
7
"8
S"
#Y
(&
2"
8
"S
&=
%
Q@
%0
K"
Ͳ@
0)
(#
#2
8)
\@
&(
31
%K
+
C
!
>
R
@Q
%3
&#
(
F/
3"
*%
!
,ͲE
Ͳ
/B
R
(K
K2
&2"
8(
AK
(&
(
"8
V
7Ͳ
/-
:!
(
8K
]
(8
)%
#28
28
=2
$2
&2"
8
3"
Y
Q(
#2@
"8
^
F/
3"
*%
!
,Ͳ@
Ͳ
/M
V
!
>
R
@Q
%3
&#
(
"S
&=
%
28
&%
#(
3&
2"
8
"S
A2
)(
8K
@?
@
T(
X*
?A
T$
X(
8K
?
D
T3
XN
2&=
V
7Ͳ
/-
:!

#"
" 7G
H
:#
%1
(*
)
.-
?
@
)'
<
?A
IA
CC
G
J>
K4
EL
M
 7"
Y
Q"
08
K
?@
=
? J
7
G
H
T;
UU
>
C9
*V
4W
*4
;
_7
*C
VW
#
%@
2K
0(
A(
&
6^
II
Q
QY
X
\
ɷ
`
a^
U6
T
@*
+
C*
C

M#
2(
9"
A%
Xb
I^
5+
TY
*6
C*
C
Y
%&
(T
G#
XXb
I
^4
TY
*6
C*
C
"#
&"
TG
#X
Xb
6^
c5
TK
*+
C*
C
+
T>
Xb
6^
?6
[
6
^;
c
TY
*6
C*
W
Ͳ
7C
4Ͳ
7C
4*
7C
4Ͳ
W
C
TM
#2(
9"
A%
XXb
6
^;
I*
T$
@*
6
C*
7
C 4
ͲW
C
TG
#X
Xb6
^4
c
[
6^
+c
TY
*6
C*
7
C 4
Ͳ!
C
TG
#X
Xb
6^
U4
[

5^
c+
TY
*4
C*
W
Ͳ7
C 4
(*
$Ͳ
7C
4
TM
#2(
9"
A%
XXb
5
^c
;
TY
*+
C*
C
4
T>
XXb
5
^a
?
T$
@*
+
C*
C
? (
T>
XXb
5
^a
6
TY
*4
C*
C
5
T>
X*
C4
T7
XXb
5
^I
+
TY
*+
C*
C
? $
T>
XXb
5
^?
?
TY
*+
C*
C
+
T7
XXb
5
^?
;
[
5^
;?
TY
*4
C*
C
6*
C
;
T>
XXb
4
^I
?
TY
*
+C
*C
6
T7
XXb
4
^;
4
TY
*+
C*
C
;
T7
XXb
+
^a
c
[
+^
a4
TY
*5
C*
C
5 %
O*
C?
%O
*C
? (
Z
T7
XXb
+
^;
6
TY
*+
C*
C
5 (
ZT
7X
X^
?@
5
IJ
!N
5M
7
G
H
T;
UU
>
C9
*V
4W
*4
;
_7
X\
+4
I^
?
T7
Y
%&
(
TG
#X
Xb
+4
I^
4
T7
"#
&"
TG
#X
Xb
+4
6^
a
T7
TM
#2(
9"
A%
XXb
c
a^
I
T7
+
T>
XXb
I
5^
6
T7
;
T>
XXb
I
U^
a
T7
5
T>
XX*
7
4
T7
XXb
I
U^
4
T7
+
T7
XXb
?
?^
a
TW
Ͳ7
C 4
Ͳ7
C 4
TM
#2(
9"
A%
XXb
?
?^
I
T7
6
T>
XXb
?
5^
;
T7
C 4
ͲW
C
TG
#X
Xb
?U
^c
T7
?
T>
XXb
;
6^
?
T7
C 4
ͲW
C
TM
#2(
9"
A%
XXb
;
U^
5
TW
Ͳ7
C 4
Ͳ7
C 4
TM
#2(
9"
A%
XXb
6
4^
6
7C
4Ͳ
!
C 
TG
#X
Xb
6U
^?
T7
;
T7
XXb
6
U^
;
T7
6
T7
XXb
4
I^
;
T7
?
T7
XXb
4
I^
+
T7
5T
7X
X^
 7"
Y
Q"
08
K
?A
=?
J
7
G
H
T;
UU
>
C9
*V
4W
*4
;
_7
*C
VW
#%
@2K
0(
A(
&6
^I
I
QQ
Y
X\
a
^U
6
T@
*+
C*
C
M
#2(
9"
A%
Xb
I^
5+
TY
*6
C*
C
Y
%&
(
TG
#X
Xb
I^
4
TY
*6
C*
C
"#
&"
TG
#X
Xb
6^
ac
TK
*+
C*
C
+
T>
Xb
6^
?6
[
6
^?
U
TY
*6
C*
W
Ͳ7
C 4
Ͳ7
C 4
*
7C
4Ͳ
W
C
TM
#2(
9"
A%
XXb
6
^;
I
TK
*6
C*
7
C4
ͲW
C
TG
#X
Xb
6^
5U
[
6
^+
a
TY
*6
C*
7
C 4
Ͳ!
C
TG
#X
Xb
6^
U5
[
5
^c
+
TY
*4
C*

W
Ͳ7
C 4
(*
$Ͳ
7C
4
TM
#2(
9"
A%
XXb
5
^c
U
TY
*+
C*
C
4
T>
XXb
5
^a
?
TY
*+
C*
C
5 
T>
XXb
5
^a
U
TY
*4
C*
C
? (
T>
X*
C4
T7
XXb

5^
?a
TY
*+
C*
C
? $
T>
XXb
5
^?
I
[
5^
;a
TY
*5
C*
C
+T
7X
*C
6*
C
;
T>
XXb
4
^I
a
TY
*+
C*
C
6
T7
XXb
4
^6
c
TY
*+
C*
C
;
T7
XXb
+
^a
c
[
+^
I;
TY
*5
C*
C
5 %
O*
C?
%O
*C
? (
Z
T7
XXb
+
^?
5
TY
*+
C*
C
5 (
Z
T7
XX^
?
@ 5
IJ
!N
5M
7
G
H
T;
UU
>
C9
*
V 4
W
*4
;
_7
X\
+4
I^
;
T7
Y
%&
(
TG
#X
Xb
+4
I^
4
T7
"#
&"
TG
#X
Xb
+4
6^
a
T7
TM
#2(
9"
A%
XXb
c
c^
;
T7
+
T>
XXb
I
5^
+
T7
;
T>
XXb

I5
^U
T7
+
T7
XXb
I
+^
6
T7
4
T7
XXb
I
U^
5
T7
5
T>
XXb
I
U^
4
T7
4
T>
Xb
??
^c
TW
Ͳ7
C 4
Ͳ7
C 4
TM
#2(
9"
A%
XXb
?
?^
I
T7
6
T>
XXb

?5
^;
T7
C 4
ͲW
C
TG
#X
Xb
?U
^I
T7
?
T>
XXb
;
6^
;
T7
C 4
ͲW
C
TM
#2(
9"
A%
XXb
;
U^
;
TW
Ͳ7
C 4
Ͳ7
C 4
TM
#2(
9"
A%
XXb
6
4^
6
7C
4Ͳ
!
C 
TG
#X
Xb
6+
^U
T7
6
T7
XXb
6
U^
;
T7
;
T7
XXb
4
c^
U
T7
5
T7
XXb
4
I^
5
T7
?
T7
XX^

  
 
$"
" B)
;$
%
!,
Ͳ?
=/
MV
U.
(A
0%
@S
"#
&=
%
Q#
"&
"8
@"
S?
D
3"
Y
Q(
#%
K
&"
N
2&=
&=
%
/M
V U
.
(A
0%
@"
S&
=%
Q
#"
&"
8@
"
S?
@
(8
K
2&@

K2
(@
&%
#%
"2
@"
Y
%#
?
A
T;
UU
>
C9
*V
4W
*8
"8
Ͳ"
.%
#A(
QQ
28
)
@2)
8(
A@X


Pr
ot
on
s 
ST
D
0 
13
"
ST
D
0
14
 
ST
D
0
15
 
%
"&'
()*
+,
-.
/"
!0
1"
20
3"
20
45
"
%
6
.7
*"&
8
(/
"
50
!"
9"
!0
:4
"
%
,(
7,
"&8
(/
"
40
$"
9"
!0
4:
"
;
%
#9<
%
"&8
(/
"
40
1"
9"
9"
%
!"
&=
/"
30
:"
!0
#"
9"
%
#"
&=
/"
:0
2"
#0
5"
10
#"
%
$"
&=
/">
"%
#"
&;
/"
?0
:"
"3
0:
"&%
$&
=
//
"
40
?"
&%
$"
&=
//
"
%
3"
&=
/""
9"
9""
?0
3"
%
3"
&;
/"
:0
!"
#0
1"
30
4"
%
1"
&;
/"
40
4"
#0
2"
9"
%
$*
@"
&;
/"
50
:"
#0
5"
9"
%
$.
A>
%
5.
A>
%
5*
@"
&;
/"
!2
0!
"
1"
&%
5*
@"
&;
//
"
9"
     
3"
" Sy
nt
he
si
s o
f b
en
zy
la
m
in
es
 1
0 
8
6
)B
.C
"1
0a
-e
,p
"D
.(
."
E,
6
6
.(
E)
*-
-F
"*
G*
)-*
H-
.0
"I
.B
+F
-*
6
)B
.C
"1
0g
-h
,k
-m
"D
.(
."
J(
.J
*(
.K
"*
EE
,(
K)
BL
"
7,
"7
M.
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"O
(,
6
"E
,6
6
.(
E)
*-
-F
"*
G*
)-*
H-
."
6
*7
.(
)*
-C
P"
D
M)
-.
"E
,6
J,
NB
KC
"
10
f,I
,j,
n,
o"
D
.(
."
J(
.J
*(
.K
")B
"6
N-
7)C
7.
J"
CF
B7
M.
C)
C0"
"
"
"
!"
#$
%
$&
!'
:A
m
in
es
 '
()
*+
 u
se
d 
fo
r t
he
 sy
nt
he
si
s o
f p
se
ud
o-
di
m
an
no
si
de
  
ba
se
d 
D
C
-S
IG
N
 li
ga
nd
s ,
)*
-,
 '
' 
an
d 
'.
. 
& /
$0
$1
)2
&+
1-
"$
34
1$
&'
5&&
1$
34
"6
7-
0&
48
70
9&
:7
;2
<
,&
',
"*
"2
01
"=
"C
,-
N7
),
B"
,O
"Q
)8
-%
3"&
#"
.A
"J
.(
"ON
BE
7),
B*
-"L
(,
NJ
/")
B"
K(
F"
'%
R"
*"
20
1"
=
"C
,-
N7
),
B"
,O
"C
7*
(7)
BL
"
6
*7
.(
)*
-"
&!
".
A/
")
B"
K(
F"
'%
R"
D
*C
"*
KK
.K
"*
7"
2S
;
"K
(,
JD
)C
."
NB
K.
("
B)
7(,
L.
B"
*7
6
,C
JM
.(
.0
"8
O7.
("
7M
."
1"
"E,
6
J-
.7
."
*K
K)
7),
B"
7M
."
(.
*E
7),
B"
6
)@
7N
(.
"D
*C
"M
.*
7.
K"
NJ
"7,
"(
.O
-N
@"
O,
("
$"
M0
"'
M.
"(
.*
E7
),
B"
D
*C
"E
,,
-.
K"
K,
D
B"
7,
"2
S;
"*
BK
"D
,(
T.
K"
NJ
"H
F"
*K
K)
7),
B"
,O
"D
*7
.(
"&!
".
A"
J.
("Q
)8
-%
3/
P"!
1U
"<
*V
%
"C
,-
N7
),
B"
&!
".
A"
J.
("
Q)
8
-%
3/
"*
BK
"D
*7
.(
"&$
".
A"
J.
("Q
)8
-%
3/
"*
L*
)B
0"'
M.
"J
(.
E)
J)
7*
7.
"D
*C
"O)
-7.
(.
K"
,O
O"*
BK
"D
*C
M.
K"
D
)7M
"'
%
R0
"
'M
."
O)-
7(*
7.
"
D
*C
"
E,
BE
.B
7(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"
'M
."
J(
,K
NE
7"
D
*C
"
JN
()O
).
K"
HF
"
O-*
CM
"
EM
(,
6
*7
,L
(*
JM
F"
&W
;
=
"D
)7M
"L
(*
K)
.B
7",
O"6
.7
M*
B,
-"O
(,
6
"2
"7,
"#
2U
/",
("N
C.
K"
D
)7M
,N
7"J
N(
)O)
E*
7),
B"
)O"
7M
."
JN
()7
F"
D
*C
"CN
OO
)E
).
B7
0""
"
" =,
*=.
*%
$6
#>
2*'
?@
*3
7-
A-
2)
0*
.*
>2
B+
#$
0>
2B%
$6
#)
0)
%
70
$&
='
(C
B&
"
!"
#$
%
$&
!.
5&s
yn
th
es
is
 o
f '
(C
&
"
,*
=.
*%
$6
#>
2*'
?@
*3
7-
A-
2)
0*
.*
>2
BD
$0
E-
07
617
2$
&='
FB
G'
H 5&
',
"7
M.
"C
,-
N7
),
B"
,O
"3
9*
E.
7F
-H
.B
+,
B)
7()
-.
"1
6"
&$
22
"6
LP
"#
02
5"
6
6
,-
P"
!"
.A
/"
)B
"H
.B
+.
B.
"&
1"
6
-/"
NB
K.
("
B)
7(,
L.
B"
*7
6
,C
JM
.(
."
.7
MF
-.
B.
L-
FE
,-
"&
20
$1
"6
-P"
50
#2
"6
6
,-
P"
$"
.A
/"
"D
*C
"*
KK
.K
")
B"
,B
."
J,
(7)
,B
"*
BK
"
I
R $
0X
7 $"
&2
02
?"
6
-P"
20
5#
"6
6
,-
P"2
0$
".
A/
"K
(,
JD
)C
.0
"'
M.
"C,
-N
7),
B"
D
*C
"C7
)((
.K
"*
7"(
,,
6
"7.
6
J.
(*
7N
(.
"O,
("!
"M
"
7M
.B
"M
.*
7.
K"
NJ
"7,
"(.
O-N
@"
O,
("1
"M
0"'
M.
"(.
*E
7),
B"
D
*C
"A
N.
BE
M.
K"
HF
"*
KK
)7)
,B
",
O"7
().
7M
F-
*6
)B
."
&O
.D
"K
(,
JC
/"
*B
K"
7M
.B
"K
)-N
7.
K"
D
)7M
"K
).
7M
F-
".
7M
.(
0"'
M.
"6
)@
7N
(.
"D
*C
"7(
*B
CO
.(
(.
K"
7,
"*
"C.
J*
(*
7,
(F
"ON
BB
.-
P"D
*C
M.
K"
D
)7M
"
D
*7
.(
"*
BK
"H
()B
.P
"K
().
K"
,G
.(
"C
,K
)N
6
"C
N-
JM
*7
."
*B
K"
E,
BE
.B
7(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"'
M.
"E
(N
K.
"
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&C
)-)
E*
P"M
.@
*B
.Y
K)
.7
MF
-"
.7
M.
("
Z"
4Y
$/
"7
,"
F)
.-
K"
3!
"U
",
O"
JN
(.
"
J(
,K
NE
7"1
70
"&
N
O
O
1 2
3 4
5 6
7
8
9
17
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
05
3"
["
40
15
"&6
P"3
%
P"%
$P"
%
3/
P"3
02
:"
["
$0
::
"&6
P"#
%
P"%
?P"
%
:/
P"$
04
?"
["
$0
5?
"&
6
P"#
%
P"%
?P"
%
:/
P"!
05
!"
&C
P"$
%
P"%
4/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"!
3?
0:
"&
;
1/
\"!
$#
03
"&
;
$/
\"
!#
50
3"
&;
3/
\ !
!:
02
"&;
!/
\"!
!#
02
"&;
#/
\"!
2?
03
"&;
5/
\"5
30
:"
&;
?P"
;
:/
\"#
40
5"
&;
4/
"
5"
"" &=,
*=.
*%
$6
#>
2*'
?@
*3
7-
A-
2)
0*
.*
>2
B+
#$
0>
2B%
$6
#)
0)
%
70
$&
='
(C
BG.
H 5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"
O(
,6
"B
)7(
)-.
"1
7\
"F
).
-K
Y":
1"
U
0&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
03
1"
["
40
#!
"&6
P"3
"%
P"%
$P"
%
3/
P"3
02
5"
["
$0
:5
"&6
P"#
%
P"%
?P"
%
:/
P"$
0?
1"
&C
P"
#%
P"%
!/
P"$
0?
2"
["
$0
42
"&
6
P"#
%
P"%
?P"
%
:/
P"!
05
$"
&C
P"$
%
P"%
4/
\"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"!
3#
05
P"
!3
#0
2"
&;
#P"
;
1/
\"!
#4
0#
"&;
$/
\"!
#1
04
"&;
3/
\ !
2:
02
"&;
5/
\"5
30
5"
&;
?P"
;
:/
\"3
50
$"
&;
!/
\"#
40
?"
&;
4/
0"
" =@
*=)
%
70
-%
$6
#>
2B+
#$
0>
2B%
$6
#)
0-
2&
'(
9G
@H
5&
]
C)
BL
"
L.
B.
(*
-"
J(
,E
.K
N(
."
!"
C7
*(
7)B
L"
O(
,6
"
$9
O,
(6
F-
H.
B+
,B
)7(
)-.
\"F
).
-K
Y":
#U
0&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
3!
"[
"4
0#
?"
&6
P"3
"%
P"%
$P"
%
1P"
%
5P"
%
4/
P"3
05
?"
&C
P"#
%
P"%
?/
P"$
0?
1"
&C
P"
#%
P"%
!/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"!
3$
0:
P"!
3$
0#
"&
;
#P"
;
3/
\"!
#:
04
&;
$/
\"!
#4
03
P"!
#4
0!
P"!
#5
04
"
&;
1P"
;
5P"
;
4/
\P"
51
0$
"&;
?/
\"3
50
?"
&;
!/
0"
& =,
*=)
%
70
-%
$6
#>
2B+
#$
0>
2B%
$6
#)
0-
2&=
'(
#B
G@
H 5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C7
*(
7)B
L"
O(
,6
"6
.7
MF
-"3
9
&*
6
)B
,6
.7
MF
-/H
.B
+,
*7
."
MF
K(
,E
M-
,(
)K
.\
"F
).
-K
Y":
1"
U
0" 
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
$#
"&C
P"3
%
P"%
$P"
%
3/
P"3
01
?"
&C
P"#
%
P"%
5/
P"$
04
?"
&C
P"#
%
P"%
!/
0"
"
4"
"& =,
*=%
$6
#-
A>
%
$6
#>
2B+
#$
0>
2B%
$6
#)
0)
%
70
$&
='
(7
B&
"
"
!"
#$
%
$&
!@
5&s
yn
th
es
is
 o
f '
(7
"
" 1-
(c
hl
or
om
et
hy
l)-
4-
(m
et
ho
xy
m
et
hy
l)b
en
ze
ne
&=
'I
BG,
H 5&
',
"*
"C
,-
N7
),
B"
,O
"!
P3
H)
C&
EM
-,
(,
6
.7
MF
-/H
.B
+.
B.
"
18
"&#
22
6
LP
"!
0!
3"
6
6
,-
P"!
0!
".
A/
")B
"K
(F
"'
%
R"
&!
0$
"6
-/"
*"
!"
=
"C
,-
N7
),
B"
,O
"=
.V
<
*"
)B
"6
.7
M*
B,
-"&
20
:"
6
-P"
!0
2!
6
6
,-
P"
!"
.A
/"
D
*C
"*
KK
.K
""
K(
,J
D
)C
."
*7
"2
S;
"N
BK
.(
"B
)7(
,L
.B
"*
76
,C
JM
.(
.0
"8
O7.
("
7M
."
E,
6
J-
.7
."
*K
K)
7),
B"
7M
."
(.
*E
7),
B"
D
*C
"C
7)(
(.
K"
*7
"(
,,
6
"7
.6
J.
(*
7N
(.
"O
,(
"!
5"
M0
"'
M.
"(
.*
E7
),
B"
D
*C
"K
)-N
7.
K"
D
)7M
"
K)
.7
MF
-.
7M
.(
"D
*C
M.
K"
D
)7M
"D
*7
.(
"*
BK
"H
()B
.P
"K
().
K"
,G
.(
"C
,K
)N
6
"C
N-
JM
*7
."
*B
K"
E,
BE
.B
7(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"'
M.
"E
(N
K.
"J
(,
KN
E7
"D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&M
.@
*B
."
D
)7M
"L
(*
K)
.B
7",
O"
W
;
=
"O(
,6
"#
2U
"7,
"1
2U
/"7
,"
F)
.-
K"
31
U
",
O"J
N(
."
J(
,K
NE
7"1
90
"&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0$
:"
&K
P"#
%
P"%
$P"
J"
Z"
?0
#"
%
+/
P"4
0$
3"
&K
P"#
%
P"%
3P"
J"
Z"
?0
#"
%
+/
P"3
05
2"
&C
P"
#%
P"%
!/
P"3
03
?"
&C
P"#
%
P"%
5/
P"$
03
!"
&C
P"$
%
P"%
4/
0""
" 1-
(a
zi
do
m
et
hy
l)-
4-
(m
et
ho
xy
m
et
hy
l)b
en
ze
ne
&=
.(
B5&
',
"*
"C
,-
N7
),
B"
,O
"1
9"
&5
1"
6
LP
"2
0$
?"
6
6
,-
P"!
".
A/
")B
"
W
=
R"
&!
0$
"6
-/"
<
*<
$"
&!
:?
"6
LP
"$
02
1"
6
6
,-
P"?
".
A/
"*
BK
"'
I
8
^"&
!3
"6
LP
"2
02
3"
6
6
,-
P"2
0!
".
A/
"D
*C
"*
KK
.K
0"
'M
."
(.
*E
7),
B"
D
*C
"M
.*
7.
K"
NJ
"7,
"1
2S
;
"*
BK
"C
7)(
(.
K"
O,
("
!5
"M
0"'
M.
"C
,-
G.
B7
"D
*C
"(
.6
,G
.K
"N
BK
.(
"(
.K
NE
.K
"
J(
.C
CN
(.
"*
BK
"7M
."
(.
C)
KN
."
D
*C
"7*
T.
B"
NJ
"D
)7M
".
7M
.(
P"D
*C
M.
K"
D
)7M
"D
*7
.(
"*
BK
"H
()B
.P
"K
().
K"
,G
.(
"C
,K
)N
6
"
CN
-J
M*
7.
"*
BK
"E
,B
E.
B7
(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"
'M
."
E(
NK
."
J(
,K
NE
7"
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"
EM
(,
6
*7
,L
(*
JM
F"
&M
.@
*B
."
D
)7M
"L
(*
K)
.B
7",
O"W
;
=
"O(
,6
"$
2"
U
"7,
"4
2"
U
/"7
,"
F)
.-
K"
?2
"U
",
O"J
N(
."
J(
,K
NE
7"
20
0"&
?"
"
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0$
1"
&K
P"#
%
P"%
$P"
J"
Z"
?0
!"
%
+/
P"4
0#
:"
&K
P"#
%
P"%
3P"
J"
Z"
?0
!"
%
+/
P"3
03
1"
&C
P"
#%
P"%
5/
P"3
0$
!"
&C
P"#
%
P"%
!/
P"$
0$
?"
&C
P"$
%
P"%
4/
"13
C
 N
M
R
"&!
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"!
$?
05
"&;
#/
\"!
$3
0:
"&;
1/
\"
!#
?0
3P
"!
#?
0#
"&;
$P"
;
3/
\ 4
30
3"
&;
5/
\"1
?0
$"
&;
4/
\"1
30
4"
&;
!/
0"
" (4
-(
m
et
ho
xy
m
et
hy
l)p
he
ny
l)m
et
ha
na
m
in
e&
='
(7
BGJ
H 5&
',
"*
"C,
-N
7),
B"
,O
"2
0"
&1
2"
6
LP
"2
0#
?"
6
6
,-
P"!
".
A/
")B
"
.7
M*
B,
-"&
:"
6
-/"
!2
"U
"_
K`
;
"D
*C
"*
KK
.K
")B
"E
*7
*-
F7
)E
"*
6
,N
B7
0"'
M.
"(.
*E
7),
B"
D
*C
"C7
)((
.K
"N
BK
.(
"%
#"&
!"
*7
6
/"
*7
"(,
,6
"7.
6
J.
(*
7N
(.
"O,
("#
"M
0"'
M.
"E
*7
*-
FC
7"D
*C
"O)
-7.
(.
K"
,O
O"7
M(
,N
LM
"*
"E
.-
)7.
"J
*K
0"'
M.
"O)
-7(
*7
."
D
*C
"
E,
BE
.B
7(*
7.
K"
NB
K.
("(
.K
NE
.K
"J
(.
CC
N(
."
7,
"F
).
-K
"?
2"
U
",
O"J
N(
."
J(
,K
NE
7"1
0i
"&
"
1 H
 N
M
R
"&
32
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0$
2"
9"
40
#3
"&
6
P"3
%
P"%
$P"
%
3/
P"3
03
!"
&C
P"#
%
P"%
5/
P"$
0?
$"
&C
P"#
%
P"%
!/
P"
$0
$1
"&C
P"$
%
P"%
4/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"!
3#
0:
"&;
#/
\"!
$5
0:
"&;
1/
\"!
#?
0#
P"!
#4
0$
"&;
$P"
;
3/
\ 
43
05
"&;
5/
\"1
?0
#"
&;
4/
\"3
50
3"
&;
!/
0""
" .*
=,
*=)
%
70
-%
$6
#>
2B+
#$
0>
2B+
1-
+)
0*
.*
-2
&='
(K
B&
"
"
!"
#$
%
$&
!,
5&S
yn
th
es
is
 o
f '
(K
"
 
:"
"4-
(2
-h
yd
ro
xy
pr
op
an
-2
-y
l)b
en
zo
ni
tr
ile
&=.
'B
GF
H 5&
',
"*
"C
,-
N7
),
B"
,O
"=
.=
LI
("&
$"
=
")B
"X
7 #V
P"#
0$
"6
-P"
50
??
"
6
6
,-
P"1
".
A/
")B
"'
%
R"
&1
"6
-/"
*"
C,
-N
7),
B"
,O
"3
9*
E.
7F
-H
.B
+,
B)
7()
-.
"1
6"
&#
22
6
LP
"!
0$
?"
6
6
,-
P"!
".
A/
"D
*C
"
*K
K.
K"
K(
,J
D
)C
."
*7
"2
S;
"N
BK
.(
"B
)7(
,L
.B
"*
76
,C
JM
.(
.0
"'
M.
"(
.*
E7
),
B"
D
*C
"C
7)(
(.
K"
O,
("
#"
M"
*7
"(
,,
6
"
7.
6
J.
(*
7N
(.
P"7
M.
B"
E,
,-
.K
"K
,D
B"
7,
"2
S;
"*
BK
"A
N.
BE
M.
K"
HF
"*
KK
)7)
,B
",
O"D
*7
.(
0"'
M.
"(.
*E
7),
B"
D
*C
"K
)-N
7.
K"
D
)7M
".
7M
.(
P"D
*C
M.
K"
D
)7M
"D
*7
.(
"*
BK
"H
()B
.0
"'
M.
",
(L
*B
)E
"J
M*
C.
"D
*C
"K
().
K"
,G
.(
"C
,K
)N
6
"C
N-
JM
*7
."
*B
K"
E,
BE
.B
7(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"
'M
."
E(
NK
."
J(
,K
NE
7"
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&M
.@
*B
."
D
)7M
"L
(*
K)
.B
7",
O".
7M
F-
"*
E.
7*
7.
"O(
,6
"!
2U
"9"
$2
U
/"7
,"
F)
.-
K"
54
"U
",
O"J
N(
."
J(
,K
NE
7"2
10
"&
&
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
05
1"
["
40
11
"&6
P"3
"%
P"%
!P"
%
#/
P"!
01
4"
&C
P"5
%
P"%
$/
0"
& 2-
(4
-(
am
in
om
et
hy
l)p
he
ny
l)p
ro
pa
n-
2-
ol
&=
'(
KBI
5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"O
(,
6
"2
1\
"a
).
-K
Y"
42
"U
0&
 
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
35
"&K
P"#
%
P"%
3P"
J"
Z"
?0
3"
%
+/
P"4
0#
:"
&K
P"#
%
P"%
$P"
J"
Z"
?0
3"
%
+/
P"$
04
:"
&C
P"#
%
P"%
!/
P"!
01
#"
&C
P"5
%
P"%
4/
0"1
3 C
 N
M
R
"&!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!3
:0
#"
&;
#P"
;
1/
\"!
#?
03
"&;
$/
\P"
!#
50
2"
&;
3/
\"4
$0
2"
&;
5/
\"3
40
$"
&;
!/
\"$
#0
!"
&;
4/
0&
" =,
*=)
%
70
-%
$6
#>
2B*
@*
C24
-1
-+
#$
0>
2B%
$6
#)
0-
2&=
'(
LB
5&]
C)
BL
"7M
."
L.
B.
(*
-"J
(,
E.
KN
(.
"!
"C7
*(
7)B
L"
O(
,6
"#
9
O-N
,(
,9
39
O,
(6
F-
H.
B+
,B
)7(
)-.
P"F
).
-K
Y"1
$"
U
0&
"
!2
"
"1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
32
"&7
P"!
%
P"%
$P 
J 4
95
"Z
 J
$9
R"
Z"
40
?"
%
+/
P"4
0!
:"
"9"
40
2:
"&6
P"#
%
P"%
5P"
%
3/
P"
30
5$
"&C
P"#
%
P"%
?/
P"$
0?
5"
&C
P"#
%
P"%
!/
0"1
3 C
 N
M
R
"&!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!5
#0
3"
&K
P";
$P 
J ;
$9
R"
Z 
#3
3"
%
+/
\""
!3
30
4"
&K
P";
1P 
J ;
19
R"
Z 
40
#"
%
+/
\"!
$2
04
"&K
P";
4P 
J ;
49
R"
Z 
10
2"
%
+/
\"!
#:
0!
4"
&K
P";
#P 
J ;
#9
R"
Z 
!1
01
"%
+/
\""
!#
$0
4"
&K
P"
;
3P 
J ;
39
R"
Z"
$0
##
"%
+/
\"!
!3
01
"&K
P";
5P 
J ;
59
R"
Z 
##
03
"%
+/
\""
53
03
"&K
P";
?P 
J ;
?9
R"
Z 
!0
5"
%
+/
\"3
20
$"
&K
P";
!P 
J ;
!9
R"
Z 
$0
:"
%
+/
0"
" =,
*=)
%
70
-%
$6
#>
2B*
.*
C24
-1
-+
#$
0>
2B%
$6
#)
0-
2&=
'(
2B5
&]
C)
BL
"7M
."
L.
B.
(*
-"J
(,
E.
KN
(.
"!
"C7
*(
7)B
L"
O(
,6
"3
9
EF
*B
,9
#9
O-N
,(
,H
.B
+,
)E
"*
E)
K\
"F
).
-K
Y"4
2"
U
0&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
33
"&7
P"!
%
P"%
3P 
J 3
9$
"Z
 J
39
R"
Z"
40
?"
%
+/
P"4
0!
:"
"9"
40
2:
"&6
P"#
%
P"%
$P"
%
4/
P"
30
5?
"&C
P"#
%
P"%
?/
P"$
0?
!"
&C
P"#
%
P"%
!/
"13
C
 N
M
R
"&!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!5
#0
!"
&K
P";
5P 
J ;
59
R"
Z 
#3
1"
%
+/
\""
!3
10
?"
&K
P";
#P 
J ;
#9
R"
Z 
40
!"
%
+/
\"!
$2
04
"&K
P";
3P 
J ;
39
R"
Z 
30
:"
%
+/
\"!
#?
0!
"&K
P";
1P 
J ;
19
R"
Z 
!1
0#
"%
+/
\""
!#
30
#"
&K
P"
;
$P 
J ;
$9
R"
Z"
$0
!5
"%
+/
\"!
!1
02
"&K
P";
4P 
J ;
49
R"
Z 
##
02
"%
+/
\""
1?
0?
"&K
P";
?P 
J ;
?9
R"
Z 
30
3"
%
+/
\"3
50
#"
&K
P";
!P 
J ;
!9
R"
Z 
!0
1"
%
+/
0"
" &=J
*=)
%
70
-%
$6
#>
2B*
'?
@*
+#
$0
>2
$0
$B
37
%
$6
#)
0-
2&
='
(%
B5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"O
(,
6
"1
9
EF
*B
,)
C,
JM
7M
*-
)E
"*
E)
KP
"F
).
-K
Y"$
1"
U
0&
 
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#5
"&C
P"!
%
P"%
1/
P"4
0#
$"
&C
P"#
%
P"%
$/
P"3
05
#"
&C
P"3
%
P"%
5/
P"$
0?
?"
&C
P"#
%
P"
%
!/
0"1
3 C
 N
M
R
"&!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!3
$0
5"
&;
3/
\"!
3!
01
"&;
#/
\"!
#5
03
"&;
$/
\"!
#1
0:
"&;
1/
\"5
10
#"
&;
5/
\"
35
0!
"&;
!/
0"
" =,
*=)
%
70
-%
$6
#>
2B*
.*
%
$6
#-
A>
+#
$0
>2
B%
$6
#)
0-
2&=
'(
0B
&
!!
"
"
"
!"
#$
%
$&
!J
5&S
yn
th
es
is
 o
f '
(0
"
"
M
et
hy
l 4
-c
ya
no
-2
-m
et
ho
xy
be
nz
oa
te
&=
.@
B5&
R-
*C
T"
EM
*(
L.
K"
D
)7M
"6
.7
MF
-"3
9H
(,
6
,9
#9
6
.7
M,
@F
H.
B+
,*
7.
"
22
"&
#2
2"
6
LP
"2
0?
#"
6
6
,-
P"!
".
A/
P"b
3c
R.
&;
<
/ 5
d0$
%
#V
"&
45
"6
LP
"2
0!
?"
6
6
,-
P"2
0#
#"
.A
/P"
<
* #
;
V
$"
&?
4"
6
LP
"
20
?#
"6
6
,-
P"!
".
A/
P"_
K&
V
8
E/
#"&
!"
6
LP
"2
02
3"
6
6
,-
P"2
02
1"
.A
/"D
*C
"K
.L
*C
C.
K"
*B
K"
B)
7(,
L.
B"
*7
6
,C
JM
.(
."
D
*C
"
)B
7(,
KN
E.
K"
&$
"E
FE
-.
/P"
7M
.B
"7
M.
"(
.*
L.
B7
C"
D
.(
."
K)
CC
,-
G.
K"
HF
"*
KK
)7)
,B
",
O"
K(
F"
W
=
8
;
"&
!0
3"
6
-/0
"'
M.
"
(.
*E
7),
B"
6
)@
7N
(.
"D
*C
"M
.*
7.
K"
NJ
"7,
"?
2S
;
"*
BK
"C
7)(
(.
K"
NB
K.
("
B)
7(,
L.
B"
*7
6
,C
JM
.(
."
O,
("
#3
"M
0"'
M.
"'
Q;
"
&M
.@
*B
."
Y"
8
EV
X7
"
Z"
?Y
#/
P"
)B
K)
E*
7.
K"
J(
.C
.B
E.
"
,O
"
C7
*(
7)B
L"
6
*7
.(
)*
-"
C,
"
*B
,7
M.
("
J,
(7)
,B
"
,O
"
b
3c
R.
&;
<
/ 5
d0$
%
#V
"&!
4#
"6
LP
"2
03
2?
"6
6
,-
P"2
01
".
A/
P"<
* #
;
V
$"&
?4
".
AP
"2
0?
#"
6
6
,-
P"!
".
A/
P"_
K&
V
8
E/
#"&
!"
6
LP
"2
02
3"
6
6
,-
P"2
02
1"
.A
/P"
*B
K"
!6
Q"
,O
"W
=
8
;
"D
*C
"*
KK
.K
0"
'M
."
(.
*E
7),
B"
6
)@
7N
(.
"D
*C
"C
7)(
(.
K"
O,
("
*K
K)
7),
B*
-"
#3
"M
"*
7"
42
S;
"7
M.
B"
E,
,-
.K
"K
,D
B"
7,
"(
,,
6
"7
.6
J.
(*
7N
(.
P"
K)
-N
7.
K"
D
)7M
".
7M
F-
"*
E.
7*
7.
"*
BK
"
O)-
7.
(.
K"
7M
(,
NL
M"
*"
CM
,(
7"
C)
-)E
*"
J*
K0
"'
M.
"O
)-7
(*
7.
"D
*C
"E
,B
E.
B7
(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
"*
BK
"7
M.
"
E(
NK
."
(.
C)
KN
."
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&C
)-)
E*
P"M
.@
*B
.Y
X7
V
8
E"
Z"
:Y
!/
""7
,"
F)
.-
K"
13
"U
",
O"
JN
(.
"J
(,
KN
E7
"2
30
"&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0?
$"
&K
P"!
%
P"%
3P"
J 4
-3
 "Z
"4
0:
"%
+/
P"4
0#
:"
&K
KP
"!
%
P"%
$P"
J 3
-4
 =
"4
0:
"%
+P
"J
3-
7 
=
"!
0$
"%
+ 
/P"
40
#5
"&
KP
"!
%
P"%
4P"
J 7
-3
 "Z
"!
0$
"%
+/
P"$
0:
1"
&C
P"$
%
P"%
!2
/"
$0
:$
"&
CP"
!%
P"%
:/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
;
- $/
Y"
į"
Z"
!5
10
$"
&;
?/
\"
!1
:0
2"
&;
#/
\"
!$
#0
#"
&;
3/
\"
!#
30
?"
&;
1/
\"
!#
30
2"
&;
$/
\"
!!
?0
2"
&;
!/
\"
!!
50
5"
&;
5/
\"!
!1
03
"&;
4/
\"1
50
$"
&;
:/
\"1
#0
4"
&;
!2
/0"
" &(4
-(
am
in
om
et
hy
l)-
2-
m
et
ho
xy
ph
en
yl
)m
et
ha
no
l&=
'(
0B
5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"O
(,
6
"2
3\
"
F)
.-
KY
"4
2"
U
0&
!#
"
"
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
$2
"&K
P"!
%
P"%
3P"
J 4
-3
 "Z
"4
05
"%
+/
P"5
0:
5"
&C
P"!
%
P"%
4/
P"5
0:
!"
&K
P"!
%
P"%
$P"
J 3
-4
 "Z
"4
05
"%
+/
P"3
05
2"
&C
P"#
%
P"%
?/
"$
0?
?"
&C
P"$
%
P"%
:/
P"$
0?
#"
&C
P"$
%
P"%
!/
0 1
3 C
 N
M
R
"&!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!1
?0
?"
&;
5/
\"!
3$
0?
"&;
#/
\"!
#:
05
"&;
1/
\"!
#:
03
"&;
3/
\"!
#2
01
"&;
$/
\"!
!2
05
"&;
4/
\"5
20
1"
&;
?/
\"1
50
!"
&;
:/
\"3
50
?"
&;
!/
0"
" =,
*=)
%
70
-%
$6
#>
2B*
@?
J*
37
%
$6
#-
A>
+#
$0
>2
B%
$6
#)
0-
2&=
'(
-B
&
"
!"
#$
%
$&
!F
5&s
yn
th
es
is
 o
f '
(-
"
" M
et
hy
l 
4-
br
om
o-
3,
5-
di
m
et
ho
xy
be
nz
oa
te
&
=.
JB
5&
',
"
*"
C,
-N
7),
B"
,O
"
6
.7
MF
-"
39
H(
,6
,9
$P
19
K)
6
.7
M,
@F
H.
B+
,*
7.
"2
4"
&!
P2
2"
LP
"$
0?
$"
6
6
,-
P"!
".
A/
")B
"6
.7
M*
B,
-"&
3"
6
-/"
%
#e
V
3"
&#
1"
fQ
P"2
03
5"
6
6
,-
P"
20
!#
".
A/
0D
*C
"*
KK
.K
0"'
M.
"(.
*E
7),
B"
D
*C
"C
7)(
(.
K"
NB
K.
("(
.O
-N
@"
O,
("!
5"
M0
"'
M.
"C
,-
G.
B7
"D
*C
"(.
6
,G
.K
"N
BK
.(
"
(.
KN
E.
K"
J(
.C
CN
(.
"*
BK
"7
M.
"E
(N
K.
"(
.C
)K
N.
"D
*C
"K
)C
C,
-G
.K
")
B"
W
;
=
P"
D
*C
M.
C"
D
)7M
"C
*7
N(
*7
.K
"<
*%
;
V
$"
C,
-N
7),
B"
*B
K"
D
*7
.(
0"
'M
."
,(
L*
B)
E"
JM
*C
."
D
*C
"K
().
K"
,G
.(
"C
,K
)N
6
"C
N-
JM
*7
."
*B
K"
E,
BE
.B
7(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
"7,
"*
OO
,(
K"
7M
."
JN
(.
"J
(,
KN
E7
"2
5"
)B
"A
N*
B7
)7*
7)G
."
F)
.-
K0
"&
"
!$
"
"1 H
 N
M
R
"&
32
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0#
1"
&C
P"#
%
P"%
$/
P"$
0:
5"
&C
P"5
%
P"%
4/
P"$
0:
3"
&C
P"$
%
P"%
5/
0"1
3 C
 N
M
R
"
&!
22
"=
%
+P
";
W
;
- $/
Y"į
"!
55
0?
"&
;
1/
\"!
14
0$
"&
;
#/
\"!
$2
0#
"&
;
3/
\"!
24
02
"&
;
!/
\"!
21
05
"&
;
$/
\"1
50
:"
&;
4/
\"1
#0
5"
&;
5/
0"
& M
et
hy
l 4
-c
ya
no
-3
,5
-d
im
et
ho
xy
be
nz
oa
te
&=
.F
B5&
R-
*C
T"
EM
*(
L.
K"
D
)7M
"2
5"
&#
22
"6
LP
"2
04
$"
"6
6
,-
P"!
".
A/
P"
b
3c
R.
&;
<
/ 5
d0$
%
#V
"&$
24
"6
LP
"2
04
$"
6
6
,-
P"!
".
A/
P"<
* #
;
V
$"&
44
"6
LP
"2
04
#4
"6
6
,-
P"!
".
A/
"*
BK
"_
K&
V
8
E/
#"
&$
91
U
/"
D
*C
"K
.L
*C
C.
K"
*B
K"
B)
7(,
L.
B"
*7
6
,C
JM
.(
."
D
*C
")
B7
(,
KN
E.
K"
&$
"E
FE
-.
/P"
7M
.B
"7
M.
"(
.*
L.
B7
C"
D
.(
."
K)
CC
,-
G.
K"
HF
"*
KK
)7)
,B
",
O"
K(
F"
W
=
8
;
"&
!"
6
-/0
"'
M.
"(
.*
E7
),
B"
6
)@
7N
(.
"D
*C
"M
.*
7.
K"
NJ
"7
,"
!$
2S
;
"*
BK
"
C7
)((
.K
"N
BK
.(
"B
)7(
,L
.B
"*
76
,C
JM
.(
."
O,
("
#3
"M
0"'
M.
"(
.*
E7
),
B"
D
*C
"E
,,
-.
K"
K,
D
B"
7,
"(
,,
6
"7
.6
J.
(*
7N
(.
P"
K)
-N
7.
K"
D
)7M
".
7M
F-
"*
E.
7*
7.
"*
BK
"O)
-7.
(.
K"
7M
(,
NL
M"
*"
CM
,(
7"C
)-)
E*
"J
*K
0"'
M.
"O)
-7(
*7
."
D
*C
"E
,B
E.
B7
(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
"*
BK
"7M
."
E(
NK
."
(.
C)
KN
."
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&M
.@
*B
."
Y".
7M
F-
*E
.7
*7
."
Z"
:"
Y"!
/""
7,
"F
).
-K
"3
5"
U
",
O"J
N(
."
J(
,K
NE
7"2
60
"&
"
1 H
 N
M
R
"&
32
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"4
0#
#"
&C
P"#
%
P"%
3/
P"$
0:
?"
&C
P"5
%
P"%
?/
P"$
0:
5"
&C
P"$
%
P"%
4/
0"1
3 C
 N
M
R
"
&!
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"!
55
03
"&;
5/
\"!
5#
05
"&;
$/
\"!
$5
0!
"&;
1/
\"!
!$
05
"&;
!/
\"!
21
02
"&;
3/
\"1
50
:"
&;
?/
\"1
$0
#"
&;
4/
0""
" (4
-(
am
in
om
et
hy
l)-
3,
5-
di
m
et
ho
xy
ph
en
yl
)m
et
ha
no
l 
='
(-
B5&
]
C)
BL
"L
.B
.(
*-
"J
(,
E.
KN
(.
"!
"C
7*
(7)
BL
"O
(,
6
"
26
\"F
).
-K
Y"#
?"
U
0&
"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"5
05
5"
&C
P"#
%
P"%
3/
P"3
05
!"
&C
P"#
%
P"%
5/
P"$
0:
$"
&C
P"#
%
P"%
!/
P"$
0?
1"
&C
P"5
%
P"
%
4/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
;
- $/
Y"į
"Z
"!
1:
0?
"&
;
$/
\"!
31
03
"&
;
1/
\"!
!$
0?
"&
;
#/
\"!
2$
02
"&
;
3/
\"5
10
3"
&;
5/
\"
15
05
"&;
4/
"$
30
!"
&;
!/
0"
 Sy
nt
he
si
s o
f a
m
id
es
 4
a-
o,
 1
1 
an
d 
12
 
!3
"
"/
$0
$1
)2
&+
1-
"$
34
1$
&.
5&
&!
>0
6#
$8
78&
-C
&'
?.
*M
>"
2-
#$
A)
0$
37
")
1D
-A
)%
73
$?
&,
*=.
*)
E73
-$
6#
-A
>B
*J
*=Į
*N
*
%
)0
0-
+>
1)
0-
8>
2-
A>
B?*
&='
!?
.!
?,
!?
J!
B?,
)*
$?
9*
-?
&'
'&
)0
3&
&'
.&
'M
."
*6
)B
."
10
"&$
".
A/
"D
*C
"*
KK
.K
"7,
"*
"2
0!
"=
"_
<
_9
CE
*O
O,
-K
"9
"&!
".
A/
")B
"K
(F
"=
.;
<
"N
BK
.(
"C
7)(
()B
L"
*B
K"
NB
K.
("B
)7(
,L
.B
"*
76
,C
JM
.(
."
*7
"(,
,6
"7.
6
J.
(*
7N
(.
0"8
O7.
("E
,6
J-
.7
),
B"
&!
9#
3"
M\
"'
Q;
P"M
.@
YX
7V
8
E"
Z"
!Y
!"
,(
"#
Y?
/"7
M.
"C
,-
G.
B7
"D
*C
".
G*
J,
(*
7.
K"
NB
K.
("(
.K
NE
.K
"J
(.
CC
N(
.0
"'
M.
"E
(N
K.
"J
(,
KN
E7
"D
*C
"K
)C
C,
-G
.K
")B
"K
(F
"
6
.7
M*
B,
-"&
E"
Z"
20
!"
=
/P"
NB
K.
("B
)7(
,L
.B
"*
7"(
,,
6
"7.
6
J.
(*
7N
(.
P"*
BK
"!
=
"C,
-N
7),
B"
,O
"C,
K)
N6
"6
.7
M,
@)
K.
")B
"
=
.V
%
"&#
".
A/
"D
*C
"*
KK
.K
0"8
O7.
("(
.*
E7
),
B"
&!
"M
\"'
Q;
P";
%
;
- $Y
=
.V
%
"Z
":
Y!
",
("?
Y#
/"7
M.
"(.
*E
7),
B"
6
)@
7N
(.
"
D
*C
"K
)-N
7.
K"
D
)7M
"6
.7
M*
B,
-"*
BK
"B
.N
7(*
-)+
.K
"D
)7M
"J
(.
D
*C
M.
K"
8
6
H.
(-)
7.
"^
g
8
"!
#2
9%
> 0"
'M
."
(.
C)
B"
D
*C
"
O)-
7.
(.
K"
,O
O"
*B
K"
7M
."
O)-
7(*
7.
"D
*C
"E
,B
E.
B7
(*
7.
K"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"'
M.
"E
(N
K.
"D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&;
%
;
- $"
D
)7M
"L
(*
K)
.B
7",
O"=
.V
%
"O(
,6
"2
"7,
"#
2U
/0"
"
"
G
en
er
al
 st
ru
ct
ur
e 
an
d 
nu
m
be
ri
ng
 o
f p
se
ud
o-
di
m
an
no
si
de
 b
is
-a
m
id
es
 ,
)*
- 
"
N
' ?N
. *D
78=
@*
%
$6
#-
A>
D$
0E
>2
B)
%
73
$&=
,)
B&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
a.
"
"
Y
ie
ld
"Z
"5
4"
U
\"[
D]
D
20
""
Z"
>"
!5
0#
"&
E"
20
4?
P"=
.V
%
/\"
1 H
 N
M
R
"&
32
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#2
"&
7P"
#%
P"
%
!1
P"J
"Z
"?
02
"%
+/
P"5
0?
1"
["
50
41
"&6
P"5
%
P"%
!#
P"%
!3
P"%
!5
/P"
30
:5
"&H
("C
P"!
%
P"%
!/
P"3
0#
?"
&C
P"3
%
P"%
!2
*P
H/
P"3
02
:"
9"
30
2$
"&6
P"!
%
P";
#/
P"$
0:
3"
9"$
0:
2"
&6
P"!
%
P"%
#/
P"$
0:
2"
["
$0
?3
"&6
P"!
%
P"%
5*
/P"
$0
?$
"[
"$
05
1"
&6
P"!
!%
P";
!P"
%
!4
P"
%
5H
P"%
4*
PH
P"%
$/
P"$
05
3"
9"
$0
13
"&
6
P"#
%
P"%
3P
"%
1/
P"$
03
4"
["
$0
$!
"&
6
P"#
%
P"%
?/
P"$
02
$"
9"
#0
?1
"&
6
P"#
%
P";
3P"
;
1/
P"
#0
2?
"9
"!
0:
2"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
#P
"!
44
02
"&
;
:/
\"!
5!
01
"&
;
!$
/\"
!3
!0
?"
&;
!!
/\"
!$
20
5"
&;
!1
/\"
!#
20
4P
"!
#2
04
"&;
!5
/\"
!!
30
2P
"!
!$
0:
P"!
!$
04
P"!
!$
P4
"&;
!3
P";
!#
/\"
!2
20
3"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
4"
&;
;
!/
\"4
#0
1"
&;
#/
\"4
#0
3"
&;
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
10
?"
&;
!4
/\"
1#
0!
"
!1
"
"&;
?/
\"
33
02
"&
;
!2
/\"
3#
0!
P"
3!
0:
"&
;
;
3P"
;
;
1/
\"
#:
0:
P"
#:
02
"&
;
;
$P"
;
;
5/
0"
M
S 
&%
g
=
e/
Y"
E*
-E
N-
*7
.K
"O
,(
"
c;
$#
%
3$
<
1V
!!
<
*d
> Y"
5:
50
#?
15
?\
"O,
NB
KY
"5
:5
0#
?1
::
"
" N
' ?N
. *D
78=
,*
%
$6
#-
A>
D$
0E
>2
B)
%
73
$&=
,D
B&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
b.
"
&
"
& Y
ie
ld
"Z
"4
$"
U
\"[
D]
D
20
""
Z"
>"
!0
?!
"&
E"
"2
0!
1P
"X
7V
%
/\"
1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#2
"&
KP
"3
%
P"
%
!#
P"J
!#
9!
$"Z
"?
"%
+/
P"5
0?
?"
&K
P"3
%
P"%
!$
P"J
!$
9!
#"Z
"?
"%
+/
P"3
0:
:"
&K
P"!
%
P"%
!P
/P"
30
#5
"&K
P"3
%
P"%
!2
*P
HP"
J !
2*
9!
2H
"Z
"
#0
3"
%
+/
P"3
0!
2"
9"3
02
5"
&6
P"!
%
P";
#/
P"$
0:
1"
&K
KP
"!
%
P"%
#P
"J
#9
!"Z
"!
05
"%
+P
"J
#9
$"Z
"$
0#
"%
+/
P"$
0:
$"
["
$0
?4
"&6
P"!
%
P"
%
5*
/P"
$0
?5
"[
"$
05
:"
&6
P"!
!%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P"
%
!1
"/P
"$
01
!"
9"$
04
"&6
P"#
%
P"%
3P
"%
1/
P"$
03
:"
["
$0
$1
"&6
P"#
%
P"
%
?*
PH
/P"
$0
2!
"9"
#0
?5
"&6
P"#
%
P";
3P;
1/
P"#
02
?"
9"!
0:
2"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
2P
"!
45
0?
"&
;
:/
\"!
52
03
"&
;
!3
/\"
!$
#0
#"
&;
!!
/\"
!#
:0
:P
"!
#:
0?
"&
;
!#
/\"
!!
10
2"
&;
!$
/\"
!2
20
3"
&;
!/
\"4
50
5"
&;
$/
\"
41
05
"&;
1/
\"4
#0
#"
&;
;
!/
\"4
#0
1"
&;
#/
\"4
#0
1"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
10
?"
&;
!1
/\"
1#
0#
"&;
?/
\"
3$
05
"
&;
!2
/\"
3#
0!
P"
3#
02
"
&;
;
3P"
;
;
1/
\"
#:
0?
P"
#:
02
"
&;
;
$P"
;
;
5/
0"
M
S 
&%
g
=
e/
Y"
E*
-E
N-
*7
.K
"
O,
(Y"
c;
$#
%
3$
<
1V
!!
<
*d
> Y"
5:
50
#?
15
?\
"O,
NB
KY
"5
:5
0#
?3
51
"
" N
' ?N
. *D
78=
=:
B*+
#$
0>
2)
2)
07
0-
2B)
%
73
$&
=,
"B
&&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
c.
"
" &
"
& Y
ie
ld
"Z
"4
1"
U
\"[
D]
D
20
""
Z"
>"
!4
0?
"&E
20
1P
"=
.V
%
/\"
1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
$!
"9"
40
!2
"&6
P"
!2
%
P"%
!3
P"%
!1
P"%
!5
/P"
30
:5
"&C
P"!
%
P"%
!/
P"3
0!
#"
9"3
02
2"
&6
P"#
%
P"%
!2
/P"
$0
??
"&K
KP
"!
%
P"%
#, 
J #
9!
""Z
"!
05
"%
+P
"J
#9
$"
"
Z"
$0
!"
%
+/
P"$
0?
5"
&K
KP
"#
%
P"%
1P"
%
5H
P"J
59
1"
"Z
"#
0!
"%
+P
"J
59
5"
"Z
"!
!0
4"
%
+/
P"$
04
#0
"9"
$0
5$
"&6
P"3
%
P";
#P"
%
5*
P"%
4/
P"
10 11
12
13
14
15
H
N
R:
O
!5
"
"$0
5$
"9"
$0
1:
"&6
P"#
%
P"%
3P"
;
!/
P"$
01
?"
9"$
01
3"
&6
P"!
%
P"%
$/
P"$
03
4"
&K
P"3
%
P"%
!!
P"J
!!
9!
2Z
"1
03
/P"
$0
$:
"9"
$0
$$
"&6
P"
#%
P"%
?/
P"$
02
2"
9"#
0?
?"
&6
P"#
%
P"%
!#
/P"
#0
4!
"9"
#0
14
"&6
P"3
%
P"%
!!
P";
3P"
;
1/
P"!
05
$"
9"!
03
2"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 
N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
#P
"!
44
0!
"&;
:/
\"!
32
0!
"&;
!$
/\"
!$
20
5P
"!
#:
01
P"!
#:
03
P"!
#4
03
"&;
!3
P";
!1
P"
;
!5
/\"
!2
20
#"
&;
!/
\"4
50
1"
&;
$/
\"4
10
5"
&;
;
!/
\"4
#0
?"
&;
;
#/
\"4
#0
5"
&;
1/
\"4
#0
!"
&;
#/
\"5
:0
$"
&;
4/
\"5
?0
?"
&;
3/
\"5
30
?"
&;
!!
/\"
5$
0#
"&;
5/
\"1
$0
:"
&;
!2
/\"
1#
0!
"&;
?/
\"3
!0
:P
"3
!0
4"
&;
;
3P"
;
;
1/
\"$
?0
!"
&;
!#
/\"
#:
0:
01
P"#
?0
4"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
Y"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$3
%
34
<
1V
!!
<
*d
> Y"
4#
30
$!
5:
?\
"O,
NB
KY
"4
#3
0$
!5
:?
"
" N
' ?N
. *D
78=
,*
07
61-
D$
0E
>2
B)
%
73
$&
=,
3B
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
d.
"
&
"
& Y
ie
ld
"Z
"4
#"
U
\"[
D]
D
20
"" Z
"9"
#!
01
"&E
""2
0#
P"=
.V
%
/\"
1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
::
"&K
P"3
%
P"%
!$
P"
J!
$9
!#
"Z
"4
03
"%
+/
P"4
03
2"
&K
P"3
%
P"%
!#
P"J
!#
9!
$"
Z"
40
3"
%
+/
P"3
0:
:"
&C
P"!
%
P"%
!/
P"3
05
2"
&K
P"#
%
P"%
!2
*P"
J !
2*
9!
2H
"Z
"!
50
3"
%
+/
P"3
0$
2"
&K
P"#
%
P"%
!2
HP"
J !
2H
9!
2*
"Z
"!
50
3"
%
+/
P"3
0!
2"
9"3
02
5"
&6
P"!
%
P";
#/
P"$
0:
3"
9"$
0:
!"
&6
P"!
%
P"%
#/
P"$
0?
:"
["
$0
?3
"&6
P"!
%
P"%
5*
/P"
$0
?3
"[
"$
05
5"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P"
/P"
$0
51
"9"
$0
15
"&6
P"#
%
P"%
3P"
%
1/
P"$
03
:"
9"$
0$
1"
&6
P"
#%
P"
%
?*
PH
/P"
$0
!2
"9
"#
0:
1"
&6
P"
#%
P"
;
3P;
1/
P"
#0
!2
"9
"!
0:
#"
&6
P"
3%
P"
;
$P"
;
5/
0"
!3
C
 N
M
R
"&
!2
2"
=
%
+P
"
;
W
$V
W
/Y"
į"
Z"
!4
40
?P
"!
44
05
"&;
:/
\"!
3?
0$
"&;
!3
/\"
!3
?0
!"
&;
!!
/\"
!#
?0
?"
&;
!#
/\"
!#
30
1"
&;
!$
/\"
!2
20
5"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
?"
&;
;
!/
\"4
#0
5"
&;
#/
\"4
#0
5"
&;
;
#/
\"5
:0
3"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
#0
#"
&;
?/
\"3
$0
$"
&;
!2
/\"
3!
0:
P"3
!0
?"
&;
;
3P"
;
;
1/
\"$
20
!P
"#
:0
$"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$2
%
$4
<
4V
!$
<
*d
> Y
"
4#
50
#$
34
2\
"O,
NB
KY
"4
#5
0#
$1
#5
"
& N
' ?N
. *D
78=
,*
")
1D
-%
$6
#-
A>
D$
0E
>2
B)
%
73
$&
=,
$B
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
e.
"
&
"
 
!4
"
"Y
ie
ld
"Z
"5
2"
U
\"[
D]
D
20
"" Z
">
13
0$
"&E
"Z
"2
01
1"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
40
?!
"&K
P"3
%
P"
%
!$
P"J
!$
9!
#"Z
"?
"%
+/
P"4
0#
?"
&K
P"3
%
P"%
!#
P"J
!#
9!
$"Z
"?
"%
+/
P"3
0:
5"
&C
P"!
%
P"%
!/
P"3
01
!"
9"3
0#
!"
&6
P"3
%
P"%
!2
*P
H/
P"3
02
?"
9"3
02
$"
&6
P"!
%
P";
#/
P"$
0:
#"
9"$
0?
:"
&6
P"!
%
P"%
#/
P"$
0?
?"
["
$0
?$
"&6
P"4
%
P"%
5*
P"%
!5
/P"
$0
?$
"[
"$
05
3"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
05
#"
9"$
01
#"
&6
P"#
%
P"%
3P
"%
1/
P"$
03
1"
["
$0
$$
"&6
P"#
%
P"%
?*
PH
/P"
$0
21
"9"
#0
:2
"&6
P"#
%
P";
3P;
1/
P"
#0
1#
"&
CP"
$%
P"%
!5
/P"
#0
25
"9
"!
0:
!"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
";
W
$V
W
/Y"
!4
40
1P
"!
44
0$
"&
;
:/
\"
!5
?0
1"
&;
!1
/\"
!3
10
:"
&;
!!
/\"
!$
20
?"
&;
!$
/\"
!$
20
2"
&;
!3
/\"
!#
?0
#P
"!
#?
0!
"&
;
!#
/\"
!2
20
1"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
4"
&;
;
!/
\"4
#0
5"
&;
#/
\"4
#0
1"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
#0
4"
&;
!5
/\"
1#
0#
"&;
?/
\"3
$0
5"
&;
!2
/\"
3#
02
P"3
!0
:"
&;
;
3P"
;
;
1/
\"$
20
2P
"#
:0
#"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$3
%
3$
<
1V
!$
<
*d
> Y
""
41
#0
#4
11
!\
"O,
NB
KY
"4
1#
0#
43
!?
"
" N
' ?N
. *D
78=
,*
)"
$6
>2
D$
0E
>2
B)
%
73
$&
=,
CB&
'M
)C
"E
,6
J,
NB
K"
D
*C
"J
(.
J*
(.
K"
HF
"7M
."
O,
--,
D
)B
L"
J(
,E
.K
N(
.Y
" 
"
"
Sc
he
m
e 
S7
Y"C
FB
7M
.C
)C
",
O"4
f"
 <
1 ,<
2 -
bi
s(
4-
(2
-m
et
hy
l-1
,3
-d
io
xo
la
n-
2-
yl
)b
en
zy
l)a
m
id
e&
=.
OB
5"
'M
."
*6
)B
."
10
f"
"&
$:
"6
LP
"#
"6
6
,-
P"#
01
"
.A
/"
D
*C
"*
KK
.K
"7,
"*
"7M
."
_<
_9
CE
*O
O,
-K
"9
"&
?4
"6
LP
"2
02
?"
6
6
,-
P"!
.A
/"
)B
"K
(F
"=
.;
<
"N
BK
.(
"C
7)(
()B
L"
*B
K"
NB
K.
("B
)7(
,L
.B
"*
76
,C
JM
.(
."
*7
"(,
,6
"7.
6
J.
(*
7N
(.
0"8
O7.
("E
,6
J-
.7
),
B"
&#
"M
/"7
M.
"C
,-
G.
B7
"D
*C
".
G*
J,
(*
7.
K"
!?
"
"NB
K.
("(
.K
NE
.K
"J
(.
CC
N(
.0
"'
M.
"E
(N
K.
"D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&M
.@
*B
."
D
)7M
"L
(*
K)
.B
7",
O"
X7
V
8
E"
O(
,6
"#
2"
U
"7,
"5
2"
U
/"7
,"
F)
.-
K"
?2
"U
",
O"J
(,
KN
E7
"2
70
"
 
 
1H
 N
M
R
"&3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"?
02
5"
["
?0
2#
"&6
P"#
%
P"%
I
+/P
"?
02
!"
["
40
:5
"&6
P"3
%
P"%
I
+P/
P"4
04
1"
["
40
42
"
&6
P"#
%
P"%
I
+/P
"4
05
2"
["
40
35
"&
6
P"$
%
P"%
I
+/P
"4
03
$[
40
$#
"&
6
P"!
!%
P"%
I
+P"
%
!#
/P"
40
#5
"[
"4
0!
:"
&6
P"5
%
P"%
I
+P"
%
!$
/P"
50
?!
"&7
P"!
%
P"%
<
%
P"J
<
%
9!
2"
Z"
10
?"
%
+/
P"5
0#
!"
&7P
"!
%
P"%
<
%
P"J
<
%
9!
2"
Z"
10
?"
%
+/
P"5
0!
2"
&7P
"!
%
P"%
3P"
J 3
9$
"Z
"J
39
1Z
"!
20
2"
%
+/
P"1
0?
5"
&K
KP
"!
%
P"%
$P"
J $
93
"Z
"!
20
2"
%
+P
"J
$9
#Z
"$
0$
/P"
10
55
"&
KK
P"!
%
P"%
#P"
J #
9!
"Z
"!
04
"%
+P
"J
#9
$Z
"$
0$
"
%
+/
P"1
0#
3"
&K
P"!
%
P"%
!P"
J !
9#
Z"
!0
4"
%
+/
P"3
04
2"
["
30
53
"&6
P"!
%
P"%
5*
/P"
30
1$
"[
"3
0#
2"
&6
P"5
%
P"%
5H
P"%
!2
*P
HP"
%
1/
P"
30
2:
"9"
30
23
"&6
P"!
%
P";
#/
P"3
02
$"
9"$
0:
!"
&6
P"3
%
P"%
!5
*P
"!
4*
/P"
$0
4?
"[
"$
04
3"
&6
P"!
%
P";
!/
P"$
04
3"
9"$
05
$"
&6
P"3
%
P"
%
!5
HP
"!
4H
/P"
$0
5!
"[
"$
01
#"
&6
P"#
%
P"%
4/
P"$
0$
3"
9"$
0!
4"
&6
P"#
%
P"%
?/
P"$
02
$"
["
#0
?4
"&6
P"#
%
P";
3P"
;
1/
P"#
0$
2"
9"#
0!
2"
&6
P"#
%
P";
$.
AP"
;
5.
A/
P"#
0!
2"
9"#
0:
1"
&6
P"#
%
P";
$*
@P"
;
5*
@/
P"!
05
2"
&C
P"$
%
P"%
!5
/P"
!0
11
"&C
P"$
%
P"%
!5
/0"
13
C
 N
M
R
"
&!
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"!
43
0#
P"!
4#
0#
"&
;
:/
\"!
55
0$
P"!
51
0:
P"!
51
0:
P"!
51
0?
"&
;
V
I
h/
\"!
3#
04
P"!
3#
05
"&
;
!!
/\"
!$
?0
!"
&;
!3
/\"
!$
$0
:P
"!
$$
0?
P"!
$$
05
P"!
$$
03
"&
;
%
I
h/
\"
!$
20
!P
"!
$2
02
P"!
#:
0:
"&
;
%
I
h/
\"
!#
:0
#P
"!
#:
02
P"!
#:
02
"
&;
AN
*7
I
h/
\"
!#
?0
?P
"!
#?
04
P"!
#?
04
P"!
#?
01
"&
;
%
I
h/
\"
!#
40
4"
&;
!$
/\"
!#
10
?P
"!
#1
0?
"&
;
!#
/\"
!2
?P
:"
&;
!1
/\"
:4
0$
"
&;
!/
\"4
10
1"
&;
;
!/
\"4
30
#"
&;
;
#/
\"4
!0
1"
&;
#/
\"4
20
$"
&;
$/
\"4
20
!"
&;
1/
\"5
?0
4"
&;
4/
\"5
50
?"
&;
3/
\"5
30
5P
"5
30
5"
&;
!5
P"
;
!4
/\"
5$
0!
"&;
5/
\"1
20
:"
&;
?/
\"3
$0
$"
&;
!2
/\"
"3
!0
?P
"3
!0
!"
&;
;
3P"
;
;
1/
\"#
?0
?"
&;
;
$/
\"#
?0
5"
&;
;
5/
\"#
40
?P
"#
40
?"
&;
!5
/\"
"
M
S"
&X
e^
/"E
*-
EN
-*
7.
K"
O,
("c
;
55
%
54
<
1V
!4
<
*d
> Y"
!#
#1
0#
\"O
,N
BK
Y"!
##
30
:0
"
" <
1 ,<
2 -
bi
s(
4-
ac
et
yl
be
nz
yl
)a
m
id
e&
=.
PB
5"
'M
."
*E
.7
*-
"2
7"
&5
2"
6
LP
"2
P2
16
6
,-
P"!
".
A/
"D
*C
"K
)C
C,
-G
.K
")
B"
*"
6
)@
7N
(.
",
O"
*E
.7
,B
."
*B
K"
D
*7
.(
"&
!2
`!
P"
20
16
-/"
*B
K"
7,
"7
M)
C"
C,
-N
7),
B"
JF
()K
)B
)N
6
"3
97,
-N
.B
.C
N-
O,
B*
7.
"
&_
_'
eP
"!
0#
"6
LP
"2
02
21
"6
6
,-
P"2
0!
".
A/
"D
*C
"*
KK
.K
0"'
M.
"(
.*
E7
),
B"
D
*C
"C
7)(
(.
K"
*7
"1
2S
;
"O
,(
"3
"M
0"'
M.
"
C,
-G
.B
7"D
*C
".
G*
J,
(*
7.
K"
NB
K.
("(
.K
NE
.K
"J
(.
CC
N(
."
*B
K"
7M
."
E(
NK
."
D
*C
"J
N(
)O)
.K
"H
F"
O-*
CM
"E
M(
,6
*7
,L
(*
JM
F"
&M
.@
*B
.Y
"X
7V
8
E"
Z"
$Y
4/
"7,
"F
).
-K
"":
2"
U
",
O"J
(,
KN
E7
"2
80
 
!:
"
" 
 
1H
 N
M
R
 &3
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"?
02
3"
&K
P"#
%
P"%
I
+P"
J "Z
"?
0$
"%
+/
P"4
0:
?"
&K
P"#
%
P"%
I
+P"
J "Z
"?
0$
"%
+/
P"4
0:
$"
&K
P"#
%
P"%
I
+P"
J "Z
"?
0$
"%
+/
P"4
0?
1"
&K
P"#
%
P"%
!$
P"J
!$
9!
#"
Z"
?0
!"
%
+/
P"4
0?
2"
&K
P"#
%
P"%
!$
P"J
!$
9!
#"
Z"
?0
!"
%
+/
P"4
05
1"
&K
P"
#%
P"%
I
+P"
J "Z
"?
0$
"%
+/
P"4
0:
2"
["
40
31
"&6
P"$
%
P"%
I
+/P
"4
03
!"
["
40
#?
"&6
P"!
!%
P"%
!#
P"%
I
+/P
"4
0#
#"
["
40
!5
"&6
P"#
%
P"
%
I
+/P
"4
02
2"
&7P
"!
%
P"%
<
%
P"J
<
%
9!
2"
Z"
10
?"
%
+/
P"5
0$
#"
&7P
"!
%
P"%
<
%
P"J
<
%
9!
2"
Z"
10
?"
%
+/
P"5
0!
#"
&7P
"!
%
P"%
3P"
J 3
9$
"Z
"J
39
1Z
"!
20
2"
%
+/
P"1
0?
5"
&K
KP
"!
%
P"%
$P"
J $
93
"Z
"!
20
2"
%
+P
"J
$9
#Z
"$
0#
/P"
10
55
"&6
P"!
%
P"%
#/
P"1
0#
3"
&H
("C
P"!
%
P"%
!/
P"3
04
$"
["
30
5$
"&6
P"!
%
P"%
5*
/P"
30
1$
"[
"3
0$
#"
&6
P"5
%
P"%
5H
P"%
!2
*P
HP"
%
1/
P"3
0!
$"
9"3
02
5"
&6
P"!
%
P";
#/
P""
$0
4:
"[
"$
04
3"
&6
P"!
%
P"
;
!/
P"$
05
5"
["
$0
13
"&6
P"#
%
P"%
4/
P"$
0$
3"
9"$
0!
4"
&6
P"#
%
P"%
?/
P"$
02
:"
["
#0
??
"&6
P"#
%
P";
3P"
;
1/
P"#
01
$"
&C
P"$
%
P"%
!5
/P"
#0
31
"&C
P"$
%
P"%
!5
/P"
#0
#5
"9"
#0
2$
"&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
;
- $/
Y"į
"Z
"!
:4
0?
P"!
:4
0?
"&;
!1
/\"
!4
30
1P
"!
43
01
"&;
:/
\"!
55
0$
P"!
55
0!
P"!
55
0!
P"!
51
04
"&;
V
I
h/
\"!
33
02
P"!
33
0:
"&;
!!
/\"
!$
50
3P
"!
$5
0$
"&;
!3
/\"
!$
30
2P
"
!$
$0
?P
"!
$$
05
P"
!$
$0
3"
&;
%
I
h/
\"
!$
20
!P
"!
$2
02
P"
!#
:0
:P
"!
#:
0:
"&
;
%
I
h/
\"
!#
:0
!P
"!
#?
0:
P"
!#
:0
2"
&;
AN
*7
I
h/
\"
!#
?0
:P
"!
#?
0:
P"!
#?
04
P"!
#?
01
"&
;
%
I
hP"
;
!$
/\"
!#
40
4P
"!
#4
P5
"&
;
!#
/\"
:4
0#
"&
;
!/
\"4
10
$"
&;
;
!/
\"4
30
$"
&;
;
#/
\"4
!0
1"
&;
#/
\"4
20
3"
&;
$/
\"4
20
#"
&;
1/
\"5
?0
?"
&;
4/
\"5
50
4"
&;
3/
\"5
$0
2"
&;
5/
\"1
20
:"
&;
?/
\"3
$0
$P
"3
$0
#"
&;
!2
/\"
"3
!0
4P
"3
!0
2"
&;
;
3P;
;
1/
\"
#:
02
"&
;
;
$/
\"
#?
0:
"&
;
;
5/
\"
#5
0?
P"
#5
04
"&
;
!5
/0"
M
S"
&X
e^
/"
E*
-E
N-
*7
.K
"O
,(
"c
; 5
#%
1:
<
1V
!1
<
*d
> Y
"
!!
$4
0!
\"O
,N
BK
Y"!
!$
50
$0
"
" <
1 ,<
2 -
bi
s(
4-
ac
et
yl
be
nz
yl
)a
m
id
e&
=,
CB5
&;
,6
J,
NB
K"
27
"&
$2
"6
LP
"2
02
#5
"6
6
,-
P"!
.A
0/"
D
*C
"K
)C
C,
-G
.K
")
B"
K(
F"
6
.7
M*
B,
-"&
20
$"
6
-/P
"N
BK
.(
"B
)7(
,L
.B
"*
7"(
,,
6
"7.
6
J.
(*
7N
(.
P"*
BK
"!
=
"C
,-
N7
),
B"
,O
"C
,K
)N
6
"6
.7
M,
@)
K.
"
)B
"=
.V
%
"&
20
21
"6
-P"
#"
.A
0/"
D
*C
"*
KK
.K
0"8
O7.
("
(.
*E
7),
B"
E,
6
J-
.7
),
B"
7M
."
(.
*E
7),
B"
6
)@
7N
(.
"D
*C
"K
)-N
7.
K"
D
)7M
"6
.7
M*
B,
-"*
BK
"B
.N
7(*
-)+
.K
"D
)7M
"J
(.
D
*C
M.
K"
8
6
H.
(-)
7.
"^
g
8
"!
#2
9%
> 0"
'M
."
(.
C)
B"
D
*C
"O
)-7
.(
.K
",
OO
"
*B
K"
7M
."
C,
-G
.B
7"
.G
*J
,(
*7
.K
"
NB
K.
("
(.
KN
E.
K"
J(
.C
CN
(.
0"
'M
."
E(
NK
."
D
*C
"
JN
()O
).
K"
HF
"
O-*
CM
"
EM
(,
6
*7
,L
(*
JM
F"
&;
%
;
- $"
D
)7M
"L
(*
K)
.B
7",
O"6
.7
M*
B,
-"O
(,
6
"1
U
"7,
"#
2U
/"7
,"
F)
.-
K"
?$
"U
",
O"J
(,
KN
E7
"4
g0
&
 
#2
"
"
&
[D
] D
20
"" Z
"9"
3#
0?
"&E
"Z
"2
0!
")B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
?#
"&K
P"3
%
P"%
!$
P"J
!$
9!
#"Z
"
40
$"
%
+/
P"4
0$
$"
&K
P"3
%
P"%
!#
P"J
!#
9!
$"
Z"
?0
!"
%
+/
P"3
0:
?"
&K
P"!
%
P"%
!P"
J !
9#
"Z
"!
05
"%
+/
P"3
01
3"
9"
30
#5
"&
6
P"3
%
P"
%
!2
*P
H/
P"3
0!
2"
9"3
02
1"
&6
P"!
%
P";
#/
P"$
0:
3"
9"$
0:
2"
&6
P"!
%
P"%
#/
P"$
0:
2"
["
$0
?3
"&6
P"!
%
P"%
5*
/P"
$0
?3
"[
"$
05
5"
&6
P"
1%
P";
!P"
%
5H
P"%
4*
PH
P"%
$/
P"$
05
3"
9"$
01
4"
&6
P"#
%
P"%
1P"
%
3/
P"$
03
4"
["
$0
$1
"&6
P"#
%
P"%
?*
PH
/P"
$0
2?
"9"
#0
:#
"&6
P"#
%
P"
;
3P;
1/
P"#
01
#"
&C
P"$
%
P"%
!5
/P"
#0
1#
"&
CP"
$%
P"%
!5
/P"
#0
2?
"9
"!
0:
#"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
"&
!2
2"
=
%
+P
"
;
W
$V
W
/Y"
į"
Z"
#2
20
#"
&;
!1
/\"
!4
40
1P
"!
44
0$
"&
;
:/
\"
!3
50
#"
&;
!3
/\"
!$
40
!"
&;
!!
/\"
!#
:0
?"
&;
!$
/\"
!#
?0
$"
&;
!#
/\"
!2
20
1"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
?"
&;
;
!/
\"4
#0
5"
&;
#/
\"4
#0
5"
&";
;
#/
\"5
:0
3"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"
1#
0#
"&
;
?/
\"
3$
05
"&
;
!2
/\"
3#
02
P"
3!
0:
"&
;
;
3P"
;
;
1/
\"
$2
02
P"
#:
0#
"&
;
;
$P"
;
;
5/
\"
#5
0?
"&
;
!5
/0"
M
S"
&%
g
=
e/
"
E*
-E
N-
*7
.K
"O,
(Y"
c;
$3
%
3$
<
1V
!!
<
*d
> Y"
4#
20
#?
15
?\
"O,
NB
KY
"4
#2
0#
?1
1#
"
" N
' ?N
. *D
78=
@*
=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
9B
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
g.
"
"
"
" & Y
ie
ld
 Z
"5
1"
U
\"[
D]
D
20
  
Z"
>"
#!
01
"&E
"Z
"2
0$
$"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
$1
"[
"
40
!?
"&6
P"?
%
P"%
!#
P"%
!$
P"%
!3
P"%
!5
/P"
10
2!
"&K
P"!
%
P"%
!P"
J !
9#
"Z
"!
P5
"%
+/
P"3
P5
!"
&C
P"3
%
P"%
!4
*P
H/
""3
03
!"
["
30
$!
"&6
P"
3%
P"%
!2
*P
H/
P"3
0!
$"
9"3
02
?"
&6
P"!
%
P";
#/
P"$
0:
5"
&K
KP
"!
%
P"%
#P
"J
#9
!"Z
"!
05
"%
+P
"J
#9
$"Z
"$
0#
"%
+/
P"$
0:
3"
["
$0
?:
"&6
P"
!%
P"%
5*
/P"
$0
??
"[
"$
04
!"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
04
!"
9"$
01
:"
&6
P"#
%
P"%
3P"
%
1/
P"$
01
!"
["
$0
$?
"&6
P"#
%
P"
%
?*
PH
/P"
$0
25
"[
"#
0:
#"
&6
P"#
%
P";
3P;
1/
P"#
02
:"
9"!
0:
1"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
#P
"!
44
02
"&
;
:/
\"!
3$
0!
"&
;
!1
/\"
!3
20
$"
&;
!!
/\"
!#
:0
4"
&;
!5
/\"
!#
40
4P
"!
#4
0!
P"!
#5
0?
"&
;
!#
P";
!$
P";
!3
/\"
!2
20
1"
&;
!/
\"4
50
4"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
?"
&;
;
!/
\"4
#0
5"
&;
#P"
";
;
#/
\""
5:
0$
"&
;
4/
\"5
:0
2"
&;
3/
\"5
10
$"
&;
!4
/\"
5$
0#
"&
;
5/
\"
1#
0#
"&
;
?/
\"
33
02
"&
;
!2
/\"
3#
0!
P"
3!
0:
"&
;
;
3P"
;
;
1/
\"
#:
0:
P"
#:
0!
"&
;
;
$P"
;
;
5/
0"
M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$#
%
3$
<
1V
!!
<
*d
> Y"
5:
50
#?
15
?\
"O,
NB
KY
"5
:5
0#
?1
4?
"
"
#!
"
"N
' ?N
. *D
78=
,*
=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
#B
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
h.
"
&
"
Y
ie
ld
"Z
"?
#"
U
\"[
D]
D
20
"" Z
">
"!
#0
!"
&E
"Z
"2
0?
!"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#:
"&K
P"
3%
P"%
!#
P"J
!#
9!
$"Z
"?
"%
+/
P"4
0#
$"
&K
P"3
%
P"%
!$
P"J
!$
9!
#"Z
"?
"%
+/
P"3
0:
5"
&K
P"!
%
P"%
!P"
J !
9#
"Z
"!
P5
"%
+/
P"3
P1
?"
&C
P"3
%
P"
%
!1
*P
H/
P""
30
$!
"&C
P"3
%
P"%
!2
*P
H/
P"3
02
?"
9"3
02
$"
&6
P"!
%
P";
#/
P"$
0:
$"
9"$
0?
:"
&6
P"!
%
P"%
#/
P"$
0?
:"
["
$0
?3
"&6
P"!
%
P"
%
5*
/P"
$0
?3
"[
"$
05
1"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
05
3"
9"$
01
3"
&6
P"#
%
P"%
3P"
%
1/
P"$
03
4"
["
$0
$1
"&6
P"#
%
P"%
?*
PH
/P"
$0
2#
"9"
#0
?1
"&6
P"#
%
P";
3P;
1/
P"#
02
5"
9"!
0?
5"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
#P
"
!4
40
2"
&;
:/
\"
!3
!0
4"
&;
!3
/\"
!$
:0
#"
&;
!!
/\"
!#
?0
5P
"!
#?
04
"&
;
!#
/\"
!#
?0
$"
&;
!$
/\"
!2
20
3"
&;
!/
\"
45
05
"&
;
$/
\"
41
04
"
&;
1/
\"4
#0
4"
&;
;
!/
\"4
#0
1"
&;
#/
\"4
#0
3"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
10
!"
&;
!1
/\"
5$
0#
"&;
5/
\"1
#0
!"
&;
?/
\"3
$0
?"
&;
!2
/\"
3#
0!
P"3
!0
:"
&;
;
3P"
;
;
1/
\"#
:0
:P
"#
:0
2"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$#
%
3$
<
1V
!!
<
*d
> Y
"
5:
50
#?
15
?\
"O,
NB
KY
"5
:5
0#
?3
#$
0"
N
' ?N
. *D
78=
,*
=%
$6
#-
A>
%
$6
#>
2$
0$
BD
$0
E>
22B
)%
73
$&
=,
7B&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
i."
&
&
Y
ie
ld
 Z
"4
?"
U
\"[
D]
D
20
  
Z"
>"
10
#"
&E
"Z
"2
0#
#"
)B
"6
.7
M*
B,
-/\
"1
H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#?
"[
"
40
!?
""&
6
P"?
%
P"%
!#
P"%
!$
/P"
"3
0:
3"
&H
("C
P"!
%
P"%
!/
P"3
03
2"
&C
P"3
%
P"%
!1
/P"
30
#1
"&H
("C
P"3
%
P"%
!2
/P"
30
25
93
02
!"
&6
P"
!%
P";
#/
P"$
0:
!"
9"$
0?
4"
&6
P"!
%
P"%
#/
P"$
0?
4"
["
$0
?#
"&6
P"!
%
P"%
5*
/P"
$0
?2
"[
"$
05
3"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"
$0
5!
"9"
$0
13
"&6
P"#
%
P"%
3P
"%
1/
P"$
03
3"
["
$0
$#
"&6
P"?
%
P"%
?*
PH
P"%
!5
/P"
$0
:?
"9"
#0
?$
"&6
P"#
%
P";
3P;
1/
P"#
02
#"
9"!
0?
4"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &
!2
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
#P
"!
44
02
"&
;
:/
\"!
$:
0?
"&
;
!3
/\"
!$
?0
3P
"!
$?
0$
"
&;
!!
/\"
!#
:0
$"
&;
!$
/\"
!#
?0
5P
"!
#?
01
"&;
!#
/\"
!2
20
3"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
10
1"
&;
!1
/\"
4#
04
"&;
;
!/
\"4
#0
1"
##
"
"&;
#/
\"4
#0
3"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
?0
3"
&;
!5
/\"
1#
0!
"&;
?/
\"3
$0
?"
&;
!2
/\"
3#
0!
P"3
!0
:"
&;
;
3P"
;
;
1/
\"
#:
0:
P"
#:
02
"&
;
;
$P"
;
;
5/
0"
M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$3
%
34
<
1V
!!
<
*d
> Y"
4#
30
$!
5:
?\
"O
,N
BK
Y"
4#
30
$!
15
1"
" N
' ?N
. *D
78=
,*
=#
>3
1-
A>
=D
?D
*3
7%
$6
#>
2B%
$6
#>
2$
0B
D$
0E
>2
B)
%
73
$&
=,
KB&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
j."
&
"
"
Y
ie
ld
"Z
"5
1"
U
\"[
D]
D
20
  Z
">
"1
0$
"&E
"Z
"2
03
?"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
32
"&K
P"
3%
P"%
!#
P"J
!#
9!
$"Z
"?
0!
"%
+/
P"4
0!
?"
&K
P"3
%
P"%
!$
P"J
!$
9!
#"Z
"?
0!
"%
+/
P"3
0:
$"
&H
("C
P"!
%
P"%
!/
P"3
0#
5"
&C
P"3
%
P"%
!2
*P
H/
P"
30
23
"9"
$0
22
"&6
P"!
%
P";
#/
P"$
0?
?"
9"$
0?
5"
&6
P"!
%
P"%
#/
P"$
0?
5"
["
$0
4:
"&6
P"!
%
P"%
5*
/P"
$0
4?
"[
"$
05
!"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
01
:"
9"$
01
2"
&6
P"#
%
P"%
1P "
%
3P
/P"
$0
3$
"[
"$
0$
#"
&6
P"#
%
P"%
?*
PH
/P"
#0
:?
"9"
#0
?#
"&6
P"#
%
P";
3P;
1/
P"
#0
22
"9
"!
0?
3"
&6
P"3
%
P";
$P"
;
5/
P"!
03
4"
&C
P"!
#%
P"%
!5
/0"
13
C
 N
M
R
 &
!2
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
!P
"!
45
0:
"
&;
:/
\"!
3:
0:
"&;
!3
/\"
!$
?0
#"
&;
!!
/\"
!#
?0
$P
"!
#?
0#
"&;
!#
/\"
!#
10
:"
&;
!$
/\"
!2
20
3"
&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
$0
2"
&;
!1
/\"
4#
04
"&;
;
!/
\"4
#0
1"
&;
#/
\"4
#0
3"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"1
#0
!"
&;
?/
\"3
$0
?"
&;
!2
/\"
3#
0!
P"
3#
02
"&
;
;
3P"
;
;
1/
\"$
#0
!"
&;
!5
/\"
#:
0:
P"#
:0
2"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$5
%
1!
<
1V
!!
<
*d
> Y"
41
#0
$3
?#
?\
"O,
NB
KY
"4
1#
0"$
34
2#
0"
 N
' ?N
. *D
78=
.*
C24
-1
-*
,*
=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
LB
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
k.
"
&
&
#$
"
"Y
ie
ld
"Z
"4
5"
U
\"[
D]
D
20
  
Z"
>"
:0
$"
&E
"Z
"2
03
3"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
##
"&7
P"
#%
P"%
!5
P"J
!5
9!
1"Z
"4
04
"%
+P
"J
!5
9R
"Z
"4
04
"%
+/
P"4
02
1"
&K
P"#
%
P"%
!$
P"J
!$
9R
"Z
"!
!0
1"
%
+/
P"4
02
3"
&K
P"#
%
P"%
!1
P"J
!1
9!
5"Z
"
40
4"
%
+/
P"3
0:
3"
&H
("
CP"
!%
P"%
!/
P"3
P1
1"
&C
P"3
%
P"%
!4
*P
H/
P""
30
$4
"[
"3
0#
5"
&6
P"3
%
P"%
!2
*P
H/
P"3
02
3"
9"
30
22
"&
6
P"!
%
P"
;
#/
P"$
0?
:"
&K
KP
"!
%
P"%
#P"
J #
9!
"Z
"!
05
"%
+P
"J
#9
$"Z
"$
0!
"%
+"
/P"
$0
?4
"[
"$
0?
!"
&6
P"!
%
P"%
5*
/P"
$0
?!
"[
"$
05
$"
&6
P"1
%
P"
;
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
05
#"
9"
$0
1!
"&
6
P"#
%
P"%
3P"
%
1/
P"$
03
3"
["
$0
$!
"&
6
P"#
%
P"%
?*
PH
/P"
#0
::
"9
"#
0?
$"
&6
P"#
%
P"
;
3P;
1/
P"#
02
!"
9"!
0?
5"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
$P
"!
44
0!
"&;
:/
\"!
5#
0!
"&K
P"
;
!#
P"J
!#
9R
"Z
"#
12
"%
+/
\"!
33
0?
P"!
33
04
"&K
P";
!3
P"J
!3
9R
"Z
"3
0$
"%
+/
\"!
$2
05
P"!
$2
01
"&K
P";
!5
P"J
!5
9R
"Z
"3
01
"%
+/
\"!
#1
01
"
&K
P";
!!
P"J
!!
9R
"Z
"!
$0
?"
%
+/
\"!
#$
01
"&K
P";
!1
P"J
!1
9R
"Z
"$
0!
"%
+/
\"!
!3
0$
"&K
P";
!$
P"J
!$
9R
"Z
"#
#0
!"
%
+/
\"!
22
03
"&;
!/
\"
45
05
"&;
$/
\"4
10
4"
&;
1/
\"4
#0
4"
&;
;
!/
\"4
#0
1"
&;
#/
\"4
#0
1"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
30
$"
&;
!4
/\"
5$
0!
"&;
5/
\"
1#
0!
"&
;
?/
\"3
#0
2P
"3
!0
?"
&;
;
3P"
;
;
1/
\"$
40
4"
&K
P";
!2
P"J
!2
9R
"Z
"3
05
"%
+/
\"#
:0
?P
"#
:0
2"
&;
;
$P"
;
;
5/
0"M
S"
&%
g
=
e/
"
E*
-E
N-
*7
.K
"O,
(Y"
c;
$#
%
3!
R #
<
1V
!!
<
*d
> Y"
4$
#0
#5
5?
$\
"O,
NB
KY
"4
$#
0#
55
:!
0"
" N
' ?N
. *D
78=
@*
C24
-1
-*
,*
=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$?
&=,
2B&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
"N
C)
BL
"*
6
)B
."
10
l."
&
&
Y
ie
ld
"Z
"5
3"
U
\"[
D]
D
20
"" Z
">
"5
0:
"&E
"Z
"2
0$
$"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
44
0#
#"
&7P
"
#%
P"%
!1
P"J
!1
9!
5"Z
"4
04
"%
+P
"J
!1
9R
"Z
"4
04
"%
+/
P"4
0!
#"
&K
P"#
%
P"%
!5
P"J
!5
9!
1"Z
"4
04
"%
+/
P"4
02
3"
&K
P"#
%
P"%
!#
P"J
!#
9R
"Z
"
!!
01
"%
+/
P"1
02
3"
&K
P"!
%
P"%
!P"
J !
9#
"Z
"!
05
"%
+/
P"3
05
:"
&C
P"3
%
P"%
!4
*P
H/
""3
03
3"
["
30
$$
"&6
P"3
%
P"%
!2
*P
H/
P"3
0!
1"
9"3
0!
!"
&6
P"!
%
P";
#/
P"$
0:
:"
&K
KP
"!
%
P"%
#P"
J #
9!
"Z
"!
05
"%
+P
"J
#9
$"Z
"$
0!
"%
+"
/P"
$0
:5
"[
"$
0:
!"
&6
P"!
%
P"%
5*
/P"
$0
:2
"9"
$0
4$
"
&6
P"1
%
P";
!P"
%
5H
P"%
4*
PH
P"%
$P
"/P
"$
04
$"
9"$
05
#"
&6
P"#
%
P"%
3P"
%
1/
P"$
01
$"
["
$0
3!
"&6
P"#
%
P"%
?*
PH
/P"
$0
2?
"9"
#0
:$
"&6
P"
#%
P";
3P;
1/
P"#
0!
$"
9"
!0
:5
"&
6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &
!2
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
$P
"!
44
0!
"&
;
:/
\"
!5
#0
2"
&K
P";
!$
P"J
!$
9R
"Z
"#
31
02
"%
+/
\"!
3#
0!
"&K
P";
!!
P"J
!!
9R
"Z
"4
0$
"%
+/
\"!
$2
05
"&K
P";
!1
P"J
!1
9R
"Z
"1
02
"%
+/
\"!
#?
03
P"
!#
?0
$"
&K
P";
!3
P"J
!3
9R
"Z
"!
10
#"
%
+/
\"!
#3
0#
P"!
#3
0!
"&K
P";
!5
P"J
!5
9R
"Z
"3
04
"%
+/
\"!
!1
0!
P"!
!1
02
"&K
P";
!#
P"J
!$
9R
"Z
"#
#0
1"
%
+/
\"!
22
01
"&;
!/
\"4
50
5"
&;
$/
\"4
10
4"
&;
1/
\"4
#0
?"
&;
;
!/
\"4
#0
5"
&;
#/
\"4
#0
1"
&";
;
#/
\"5
:0
$"
&;
4/
\"5
:0
2"
&;
3/
\"5
$0
#"
&;
5/
\"1
?0
?"
&K
P";
!4
P"J
!4
9R
"Z
"3
0$
"%
+/
\"1
#0
#"
&;
?/
\"3
$0
3"
&;
!2
/\"
3#
0!
P"3
#0
2"
&;
;
3P"
;
;
1/
\"#
:0
:P
"#
:0
2"
&;
;
$P"
;
;
5/
0"
M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$#
%
3!
R #
<
1V
!!
<
*d
> Y"
4$
#0
#5
5?
$\
"O,
NB
KY
"4
$#
0#
51
#:
0"
 
#3
"
"N
' ?N
. *D
78=
,?
J*
37
*=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
%
B&&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
P"N
C)
BL
"*
6
)B
."
10
m
."
&
"
" & Y
ie
ld
"Z
"5
$"
U
\"[
D]
D
20
"" Z
">
":
03
"&E
"Z
"2
0#
")B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#2
"&C
P"#
%
P"
%
!3
/P"
40
!$
"&C
P"#
%
P"%
!#
/P"
30
:1
"&C
P"!
%
P"%
!/
P"3
05
4"
9"3
03
5"
&6
P"?
%
P"%
!1
/P"
30
$5
"9"
30
#3
"&6
P"3
%
P"%
!2
/P"
"3
02
!"
&K
P"
!%
P"%
1P"
J "
"Z
"#
04
"%
+/
P"$
0:
2"
&K
KP
"!
%
P"%
#, 
J #
9!
""
Z"
!0
4"
%
+P
"J
#9
$"
"Z
"$
0#
"%
+/
P"$
0?
?"
&K
P"!
%
P"%
5H
P""
J 5
95
""
Z"
!!
0$
"
%
+/
P"$
0?
$"
9"
$0
45
&6
P"!
%
P"%
$/
P"$
04
5"
9"
$0
5$
"&
6
P"3
%
P";
#P
"%
5*
P"%
4/
P"$
05
#"
9"
$0
1#
"&
6
P"#
%
P"%
3P"
;
!/
P"$
03
1"
9"
$0
$$
"&
6
P"#
%
P"%
?/
P"$
02
3"
9"
#0
?3
"&
6
P"#
%
P";
3P"
;
1/
P"#
02
4"
9"
!0
:2
"&
6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &
!2
2"
=
%
+P
"
;
W
$V
W
/Y"
į"
Z"
!4
40
:P
"!
44
P4
"&
;
:/
\"!
3$
0?
P"&
;
!$
/\"
!3
20
:"
&;
!!
/\"
!#
50
3P
"!
#5
0$
"&
;
!#
/\"
!#
10
?"
&;
!3
/\"
!2
20
2"
&;
!/
\"4
40
#"
&;
$/
\"4
50
#"
&;
;
!/
\"4
$0
#"
&;
;
#/
\"4
$0
!"
&;
1/
\"4
#0
:"
&;
#/
\"5
:0
?"
&;
4/
\"5
:0
3"
&;
3/
\"5
10
#&
;
!1
/\"
5$
05
"
&;
5/
\"1
#0
#"
&;
?/
\"3
30
3"
&;
!2
/\"
3#
01
P"3
#0
$"
&;
;
3P"
;
;
1/
\"$
20
1P
"#
:0
5"
&;
;
$P"
;
;
5/
0 M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$3
%
34
<
1V
!$
<
*d
> Y"
41
50
$2
5?
!\
"O,
NB
KY
"4
15
0$
21
45
0 "
& N
' ?N
. *D
78=
@*
%
$6
#-
A>
*,
*=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
0B
&&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
P"N
C)
BL
"*
6
)B
."
10
n.
"
& &
"
" & Y
ie
ld
"Z
"?
2"
U
\"[
D]
D
20
  Z
"9"
#3
0$
"&E
"Z
"2
0!
1"
)B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#$
"&K
P"
#%
P"%
!1
P"J
15
-1
6 
"Z
"4
05
"%
+/
P"5
0?
!"
&C
P"#
%
P"%
!#
/P"
50
?2
"&K
P"#
%
P"%
!5
P"J
15
-1
6 
"Z
"4
05
"%
+/
P"3
0:
3"
&C
P"!
%
P"%
!/
P"3
01
1"
&C
P"3
%
P"%
!?
/P"
30
#4
"&6
P"3
%
P"%
!2
/P"
30
23
"&K
P"!
%
P"%
1P"
J 5
91
"Z
"#
04
"%
+/
P"$
0:
!"
&K
KP
"!
%
P"%
#, 
J #
9!
""Z
"!
04
"%
+P
"J
#9
$"
"Z
"
#1
"
"$0
#"
%
+/
P"$
0?
4"
9"$
0?
!"
&6
P"!
%
P"%
5H
/P"
$0
4:
"9"
$0
45
"&6
P"5
%
P"%
!4
/P"
$0
45
"9"
$0
4#
"&6
P"#
%
P"%
$P"
;
#/
P"$
04
#0
"9"
$0
53
"
&6
P"$
%
P"%
5*
P"%
4/
P"$
01
:"
9"$
01
3"
&6
P"#
%
P"%
3P"
;
!/
P"$
03
3"
9"$
0$
$"
&6
P"#
%
P"%
?/
P"$
02
?"
9"#
04
4"
&6
P"3
%
P";
3P"
;
1/
P"
#0
21
"9
"!
0?
#"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &
!2
2"
=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
40
$P
"!
44
02
"&
;
:/
\"!
1?
05
"&
;
!$
/\"
!3
20
:P
"!
32
0?
"&;
!!
/\"
!#
:0
1"
&;
!3
/\"
!#
:0
!"
&;
!1
/\"
"!
#2
0#
P"!
#2
0!
"&;
!5
/\"
!!
20
3P
"!
!2
0$
"&;
!#
/\"
!2
20
3"
&;
!/
\"4
50
4"
&;
$/
\"4
10
4"
&;
;
!/
\"4
#0
4"
&;
;
#/
\"4
#0
1"
&;
1/
\"4
#0
3"
&;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
$0
#"
&;
5/
\"5
20
3"
&;
!?
/\"
15
02
"
&;
!4
/\"
1#
0!
"&
;
?/
\"3
$0
:"
&;
!2
/\"
3#
02
P"3
!0
:"
&;
;
3P"
;
;
1/
\""
$2
02
P"#
:0
!"
&;
;
$P"
;
;
5/
0 M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$3
%
34
<
1V
!$
<
*d
> Y"
41
50
$2
5?
!\
"O,
NB
KY
"4
15
0$
21
54
"
& N
' ?N
. *D
78=
.?
F*
37
%
$6
#-
A>
*,
*=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
=,
-B
&
8
EE
,(
K)
BL
"7,
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
P"N
C)
BL
"*
6
)B
."
10
o.
"
&
"
"
Y
ie
ld
"Z
"#
?"
U
\"[
D]
D
20
  
Z"
>"
$5
01
"&E
"Z
"2
0!
")B
"6
.7
M*
B,
-/\
"1 H
 N
M
R
 &3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
50
5$
"&C
P"
3%
P"%
!$
/P"
30
:4
"&C
P"!
%
P"%
!/
P"3
05
$"
&C
P"3
%
P"%
!5
/P"
30
35
"&K
KP
"#
%
P"%
!2
*P
""J
!2
*9
<
%
"Z
"4
05
"%
+P
"J
!2
*9
!2
H Z
"!
$0
3"
%
+/
P"
30
!4
"&K
KP
"#
%
P"%
!2
HP"
J !
2H
9<
%
 Z
"1
0?
"%
+/
P"$
0:
4"
&K
P"!
%
P"%
1P"
J 5
91
"Z
"#
05
"%
+/
P"$
0:
2"
9"$
04
5"
&6
P"!
3%
P"%
!1
iP"
%
#P"
%
5H
/P"
$0
43
"9"
$0
1:
"&6
P"1
%
P"%
4P"
%
5*
P"%
$P"
;
#/
P"$
01
:"
9"$
03
?"
&6
P"#
%
P"%
3P
";
!/
P"$
0$
1"
9"$
0$
#"
&6
P"3
%
P"%
?/
P"#
0?
!"
9"#
05
#"
&6
P"#
%
P";
3P"
;
1/
P"!
0:
?"
9"!
04
#"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
 &!
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
!4
50
3P
"!
45
0!
"
&;
:/
\"!
52
0#
P"!
52
0!
"&
;
!#
/\"
!3
30
4"
&;
!!
/\"
!#
:0
!"
&;
!3
/\"
!2
$0
$"
&;
!$
/\"
!2
20
3"
&;
!/
\"4
50
?"
&;
$/
\"4
10
5"
&;
;
!/
\"
4#
04
"&
;
;
#/
\"4
#0
1"
&;
1/
\"4
#0
#"
&;
#/
\"5
:0
$"
&;
4/
\"5
?0
:"
&;
3/
\"5
10
3"
&;
!5
/\"
5$
0#
"&
;
5/
\"1
50
3"
&;
!1
/\"
1#
0!
"&
;
?/
\"
3#
0!
P"
3#
02
"&
;
;
3P"
;
;
1/
\"
$$
01
P"
$$
0$
"&
;
!2
/\"
#:
01
P"
#?
05
"&
;
;
$P"
;
;
5/
0"
M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$5
%
1!
<
1V
!1
<
*d
> Y"
?!
50
$#
4:
3\
"O,
NB
KY
"?
!5
0$
#5
22
"
" !>
06
#$
878
&-
C&Q
' ?Q
. *D
78=
,*
=#
>3
1-
A>
%
$6
#>
2$
0$
BD
$0
E>
2B)
%
73
$&
'.
&=3
7)
86$
1$
-7
8-
%
$1
&-
C&,
#B
&
W
N(
)B
L"
7M
."
-*
(L
."
CE
*-
."
"C
FB
7M
.C
)C
",
O"
4h
P"7
M.
"K
)*
E)
K"
5"
D
*C
"N
C.
K"
*C
"7M
."
E,
6
6
.(
E)
*-
-F
"*
G*
)-*
H-
."
3Y
!"
6
)@
7N
(.
",
O"&
>/
95
"*
BK
"&9
/9
50
"R
,-
-,
D
)B
L"
7M
."
(.
*E
7),
B"
J*
7M
"K
.C
E(
)H
.K
")B
"C
EM
.6
."
!"
&J
*J
.(
/P"
*"
6
)@
7N
(.
",
O"
K)
*C
7.
(.
,)
C,
6
.(
C"
9"
*B
K"
9a
"D
*C
",
H7
*)
B.
KP
"D
M)
EM
"D
*C
"7(
.*
7.
K"
D
)7M
"*
6
)B
."
10
h"
*E
E,
(K
)B
L"
7,
"7M
."
O)(
C7
"
J*
(7"
,O
"L
.B
.(
*-
"J
(,
E.
KN
(.
"#
0"
'M
)C
"-
.K
"7
,"
7D
,"
K)
*C
7.
(.
,)
C,
6
.(
C"
29
"*
BK
"2
9a
"D
M)
EM
"D
.(
."
J*
(7)
*-
-F
"
C.
J*
(*
H-
."
HF
"O-
*C
M"
EM
(,
6
*7
,L
(*
JM
F"
&X
7 #V
"D
)7M
"L
(*
K)
.B
7",
O"X
7V
8
E"
O(
,6
"$
2U
"7,
"4
2U
/0"
#5
"
"" "
"
"
Sc
he
m
e 
S8
Y"C
FB
7M
.C
)C
",
O"1
2"
W
.J
(,
7.
E7
),
B"
,O
"E
,6
J,
NB
KC
"2
9"
*B
K"
29
a 
D
)7M
"=
.V
<
*"
O,
--,
D
)B
L"
7M
."
C.
E,
BK
"J
*(
7"
,O
"7
M.
"L
.B
.(
*-
"
J(
,E
.K
N(
."
#P
"L
*G
."
7M
."
O)B
*-
"W
;
9e
^j
<
"-)
L*
BK
C"4
h"
*B
K"
12
, (
.C
J.
E7
)G
.-
F0
"" &
 
#4
"
"12
: [
D]
D
20
"" Z
">
"$
50
:"
&E
"2
0#
$P
"=
.V
%
/\"
1 H
 N
M
R
"&3
22
"=
%
+P
";
W
$V
W
/Y"
į"
Z"
40
#4
"&K
P"3
%
P"%
!#
P"J
!#
9!
$"Z
"
?0
2"
%
+/
P"4
0#
#"
&K
P"3
%
P"%
!$
P"J
!$
9!
#"Z
"?
"%
+/
P"3
0:
!"
&K
P"!
%
P"%
!P"
J !
9#
"Z
"!
P1
"%
+/
P"3
01
5"
&C
P"3
%
P"%
!1
*P
H/
""3
0$
2"
["
30
#4
"&
6
P"3
%
P"%
!2
*P
H/
P"3
02
!"
["
$0
:4
"&
6
P"!
%
P";
#/
P"$
0?
?"
["
$0
?#
"&
6
P"!
%
P"%
5*
/P"
$0
?#
"[
"$
04
3"
&6
P"$
%
P"%
#P"
%
4*
PH
P"/
P"$
04
3"
9"$
05
:"
&6
P"!
%
P"%
$/
P"$
05
:"
9"$
05
!"
&6
P"$
%
P" "
;
!P "
%
1P"
%
5H
/P"
0$
05
2"
["
$0
13
"&6
P"!
%
P"%
3/
P"$
03
1"
["
$0
$$
"&6
P"#
%
P"%
?*
PH
/P"
$0
2!
"9"
#0
?3
"&6
P"#
%
P";
3P;
1/
P"#
02
4"
9"!
0?
?"
&6
P"3
%
P";
$P"
;
5/
0"1
3 C
 N
M
R
"&!
22
"=
%
+P
"
;
W
$V
W
/Y"
į"
Z"
!4
40
#P
"!
44
02
"&
;
:/
\"!
3!
04
P"!
3!
05
"&
;
!3
/\"
!$
:0
$P
"!
$:
0#
"&
;
!!
/\"
!#
?0
1"
!#
?0
1"
&;
!#
/\"
!#
?0
$P
"
!#
?0
$"
&;
!$
/\"
!2
!0
:"
&;
!/
\"4
10
?P
"4
10
4"
&;
$P"
;
1/
\"4
30
3"
&;
;
#/
\"4
#0
4"
&;
#/
\"4
#0
3"
&;
!/
\"5
:0
#"
&;
4/
\"5
:0
2"
&;
3/
\"
51
0!
P"5
10
!"
&;
!1
/\"
5$
0$
"&;
5/
\"1
#0
#"
&;
?/
\"3
$0
?P
"3
$0
4"
&;
!2
/\"
3#
01
P"3
!0
?"
&;
;
3P"
;
;
1/
\"$
!0
!P
"#
:0
1"
&;
;
$P"
;
;
5/
0"
M
S"
&%
g
=
e/
"E
*-
EN
-*
7.
K"
O,
(Y"
c;
$#
%
3$
<
1V
!!
<
*d
> "Z
""5
:5
0?
15
?P
"O,
NB
KY
"5
:5
0?
15
2"

#?
"
"F/3
"*
%
!,
Ͳ?
[
7
"8
S"
#Y
(&
2"
8
"S
&=
%
Q@
%0
K"
Ͳ@
0)
(#
#2
8)
\@
&(
31
%K
+
C
!
>
R
@Q
%3
&#
(
T6
UU
>
C9
*7
V 5
W
V*
Y
%&
=(
8"
A#
%S
%#
%8
3%
Q
%(
1
(&
5
^5
+
QQ
Y
X

#:
"
"/&
(3
1%
K
+C
!
>
R
@Q
%3
&#
(
"S
E
*D
)Ͳ
D.
*?
?
(8
K
?E
^M
=%
K
2(
)8
"@
&23
Q
%(
1@
S"
#
T(
Z2
(A
XQ
#"
&"
8@
C
6T
7X
(
8K
C
;T
7X

(#
%
@=
"N
8^
V
%Q
%8
K2
8)
"
8
&=
%
(3
&0
(A
@
&#
03
&0
#%
"
S
&=
%
A2)
(8
K*
@
2)
8(
A@
3(
8
$%
@
=2
S&
%K
0
QS
2%
AK
"
#
K"
N
8S
2%
AK

#%
A(
&2.
%
&"
&=
%
#%
S%
#%
83
%
Q#
"&
"8
@
28
E
T4
^a
Ͳ5
^U
Q
QY
X*
$0
&&
=%
 @
=(
Q%
"
S&
=%
Y
0A
&2Q
A%
&@
#%
Y
(2
8@
&=
%
@(
Y
%
T(
A@"

@%
%
&=
%
%Z
Q(
8@
2"
8
$%
A"
N
X^

M=
%
C6
T7
X(
8K
C
;T
7X
3
P3
A"
=%
Z(
8%
@2
)8
(A
@"
S&
=%
K
2(
@&
%#
%2
@"
Y
%#
?
E
(#
%
2@"
3=
#"
8"
0@
T4
^c
;
QQ
Y
X*
$0
&(
8(
AP
@2@

"S
&=
%
@Q
%3
&#
0Y
"
S2
&@
K
%#
2.
(&
2.
%
?A
T@
%%
H
2)
0#
%
/-
Ͳ5
X3
A%
(#
AP
@=
"N
@&
=%
&N
"
Q#
"&
"8
@(
#%
(
Z2
(A
^

$2
"
" !O
H
)<
</
(/.
')
$<
)(
)
.'
4
5Ͳ
!,
6
7
)
'<
P
)'
3%
*/'
/'
9/
;/
(/.
'
1.
&
#)
*/:
.'
=
 QM


RM


!"
##
$%
&
%'
()
$F
/3
"*
%
!,
ͲE
=/
BR
#%
@0
A&@
#%
Q#
%@
%8
&28
)
28
=2
$2
&2"
8
"S
]
(8
)%
#28
d
7V
$
28
K2
8)
&"
>
(8
ͲJ
/G
eK
%Z
&#
(8

@0
#S
(3
%
$P
Y
(8
8"
@%
Ͳ$
(@
%K
3
"Y
Q"
08
K@
\V
7Ͳ
/-
:!
(
8K
A(
8)
%#
28
-8
=2
$2
&2"
8
A%
.%
A"
$&
(2
8%
K
S"
#
+
Y
>
TG
X(
8K

+^
;
>
>
TJ
X3
"8
3%
8&
#(
&2"
8
"S
&=
%
3"
Y
Q"
08
K@
^
$!
"
"
      )M
?
@
;M
?
A
1M
?
D
F/
3"
*%
!
,Ͳ@
=/
MV
!
>
R
@Q
%3
&#
(
"S
&=
%
28
&%
#(
3&
2"
8
"S
A2
)(
8K
@
?@
T(
X*
?A
T$
X(
8K
?
D
T3
*S
#"
Y
'&
[K
XN
2&=
V
7Ͳ
/-
:!

28
$
0S
S%
#%
K
V 4
W
T+
;U
Y
>
!
(7
A*
6
Y
>
7
(7
A 4*
4
;
Y
>
K
ͲM
#2@
*Q
V
aX
^f
QQ
%#
&#
(3
%\
+ C
!
>
R
#%
S%
#%
83
%
@Q
%3
&#
0Y

$#
"
"T"
SSͲ
#%
@"
8(
83
%
S#
%O
0%
83
P
6U
Q
QY
Xb
]"
N
%#
&
#(
3%
\
/M
V
@Q
%3
&#
0Y
T"
8Ͳ
#%
@"
8(
83
%
S#
%O
0%
83
P
U
QQ
Y
X^
+
Y
>

A2)
8(
K*
V
7Ͳ
/-
:!
d
7V
T+
c
P>
X*
(&
4
;
g7
T;
UU
>
C9
X*
@(
&0
#(
&2"
8
&2Y
%
"S
+
@^
h
%P
Q
#"
&"
8
@2)
8(
A@
(#
%
A(
$%
A%
K^

  i+
jk
^C
PK
%#
*<
^E
^R
0(
8
(8
K
<^
]^
l
2(
"*
4
5&
3
$()
'>
Ͳ*
P
@'
/2
&*
# 
F/
@'
#*
.E
CC
S*
!
E*
;
;;
;Ͳ
;;
??
^
i4
jC
^]
(8
)=
(A
@*
G
^W
$%
#Y
%2
%#
*m
^H
A"
#%
K"
*G
^k
(8
%A
A2
(8
K
]^
H
A(
Y
2)
82
*4
5&
3
$()
'>
Ͳ*
P
@'
/2
&*
#
F/
@'
#*
.E
CC
T*
!
O*

+4
I5
5Ͳ
+4
I6
6^

i5
j<
^R
^>
(#
&28
%A
A2*
V
^G
^E
(&
@"
8*
V
^>
^>
^H
#%
31
Y
(8
8*
M
^d
^J
(#
K%
#(
8K
/
^]
^J
03
=N
(A
K*
F/
@'
#*
./
[\
'8
*#
$6

45
&3
$()
'>
E
CC
S*
L
<*
I
+U
4Ͳ
I+
UI
^
i6
jB
^m
^h
%8
)*
-^
/
=2
Y
*J
^V
^h
"#
&=
*<
^H
^V
"0
)A
(@
(
8K
<^
B
P0
8*
Q
6(
M
*#
/
EC
CU
*!
*4
Ic
Ͳ4
c4
^
i;
j7
^/
(A
"Y
%*
d
^/
(A
"Y
%Ͳ
:#
"@
n%
(8
*h
^V
^B
(#
1*
B
^>
"#
2%
0Z
*R
^/
N
%8
K2
Y
(8
*d
^V
%>
(#
3"
*<
^B
^/
&(
$A
%@
(
8K
C
^
h"
=8
*F
/@
'#
*.
/
[-
&,
$6$
#*
.4
5&
3
$()
'>
E
C?
C*
O
<*
+
4a
aͲ
+5
U;
^
i?
j<
^]
^M
03
1%
#*
>
^7
"0
&0
#2%
#*
>
^<
^7
(@
&(
AK
2*
7^
h
^H
^7
=2
0
(8
K
V^
:
%@
&Y
(8
8*
B
>#
)5
&)
$6
4
/3
3
@#
$6
*)
$/
#(
E
CC
V*

<X
*4
+6
;Ͳ
4+
;U
^
 
18. The list of compounds and their names
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CHAPTER 18. THE LIST OF COMPOUNDS AND THEIR NAMES USED IN THIS THESIS
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!"#$%&'(&)*+$*,'#-$)-#+$.*$/"#-.-$,*+$%&00#-(&*+.*1$.*./.,2$*,'#-$
&3$/"#$-,'#$%&'(&)*+-$!
Compound name 
in thesis/papers 
Compound name as the received 
samples 
3a Fuc 1-02 
3f Fuc 1-09 
3b Fuc 1-14 
3d Fuc 1-19 
3g Fuc 1-28 
3h Fuc 1-30 
3c Fuc 1-31 
3e Fuc 1-32 
10a Fuc4-2 
10c Fuc4-3 
10d Fuc4-4 
11b Fuc5-1 
11c Fuc5-2 
11a Fuc5-3 
- Fuc5-4 
12b Fuc6-1 
10b Fuc 4-1 
10b-azide1 Fuc4-1 azide 
10b-azide2 Fuc4-1 azide-2 
L fucose L fucose 
Lewis X Lewis X 
BB178 BB178 
BB203 BB203 
BB213 BB213 
BB207 BB207 
BO2 BO2 
BO3 BO3 
BB112 BB112 
BB133 BB133 
ZL1(D) ZL1(D) 
Man!1-3Man Man!1-3Man 
Man!1-2Man Man!1-2Man 
NV233 NV233 
NV243 NV243 
NV253 NV253 
NV270 NV270 
-  Man-029 
4j Man-031 
4f Man-032 
4i Man-033 
4e Man-035 
4b Man-036 
4d Man-037 
4a Man-038 
4g Man-039 
4k Man-040 
4l Man-041 
- Man-042 
- Man043 !
Compound name 
in thesis/papers 
Compound name as the received 
samples 
4m Man044 
4n Man045 
4o Man046 
4c Man047 
12 Man048 
11 Man049 
4h Man-030 
psDi psDi/Man002/Man001 
Mannose Mannose 
psTri psTri/Man005 
psDi dendron poly001 (Polymann001)/SARA127 
psTri dendron poly002 (Polymann002)/SARA133 
S6-1-Oman poly006 (Polymann006) 
S4-Oman poly005 (Polymann005) 
S4-psDi Poly008 (Polymann008) 
S6-1- psDi poly009 (Polymann009) 
S9-1-Oman poly012 (Polymann012) 
S9-2-Oman poly013 (Polymann013) 
S12-Oman poly014 (Polymann014) 
S18-1-Oman poly015 (Polymann015) 
S18-2-Oman poly016 (Polymann016) 
S4-psTri poly017 (Polymann017) 
S4-4h poly018 (Polymann018) 
S6-1-4h poly019 (Polymann019) 
S9-1- psDi poly-020 (Polymann020) 
S6-1- psTri poly021 (Polymann021) 
S6-2- psDi poly022 (Polymann022) 
S9-1-4h PM023 
R1 PM024 
R2 PM025 
R3 PM026 
L-fucose !-Ala 9a 
L-fucose !-Ala+ L-fuc b-Ala (Fuc "-Ala azide) 
S4-fuc!Ala Dendri b-Ala fuc (Dendrimer Fuc "-Ala) 
S4-10b-azide1 Dendri Fuc4-1 (Dendrimer Fuc4-1) 
S6-1-Cfuc BB02 
S4-Ofuc MA05 
S6-1-Ofuc MA07 
S18-1-Ofuc RCF-26 
S12-Ofuc RR390b 
S4-Cfuc BB01 
S9-1-Cfuc BB013 
S12-Cfuc BB014 
S9-1-Cman BB015 
S12-Cman BB016 
BO BO 
G3(pseudodi)32 Dendri-Man-003 
G3(pseudotri)32 Dendri-Man-004 !!
!
19. The list of IC50 values for all compounds
419
CHAPTER 19. THE LIST OF IC50 VALUES FOR ALL COMPOUNDS
420
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! "!
#
#
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#
#
Date Compound IC50, µM A2 Rhi Rlo A1 
psDi Fc2 1252 1.3467 -0.79138 99.208 1282.1 
psTri Fc2 166 1.0517 0.6077 100.61 162.65 
psDi Fc3 1193 1.3491 -0.75415 99.245 1219.6 
psTri Fc3 168 1.0597 0.60731 100.61 164.31 
Dendri-Nan004 fc2 1 1.573 -0.7239 99.275 1.3158 
Dendri-Man004 fc3 1 1.5926 -1.0721 98.927 1.2556 
Dendri-Man003 fc2 2 1.2108 -0.7727 99.226 2.2628 
Dendri-Man003 fc3 2 1.2099 -0.87759 99.121 2.1015 
dendri-G3 fc2 20 1.1132 -1.2221 98.777 20.471 
dendri-G3 fc3 18 1.0387 -0.85847 99.141 18.858 
SARA133 fc2 118 1.2282 -0.5601 99.439 120.33 
SARA133 fc3 115 1.2163 -0.55428 99.445 116.76 
SARA127 fc2 225 1.3654 -1.5647 98.434 235.13 
SARA127 fc3 214 1.3287 -1.9026 98.096 226.95 
MS517 fc2 898 1.0951 -1.4972 98.502 948.72 
MS517 fc3 824 1.0765 -2.1316 97.867 892.07 
mannose fc2 2850 1.2995 -1.2833 98.716 2965 
N
ov
em
be
r 2
00
9 
mannose fc3 2728 1.3987 -1.2966 98.702 2831.2 
Fuc5-2 Fc2-Fc3 444 1.5 0.00525 99 450 
Fuc4-1 Fc2-Fc3 394 1.46 0.00284 99.5 397 
Fuc4-2 Fc2-Fc3 1080 1.4 0.00996 100 1080 
Fuc4-3 Fc2-Fc3 376 1.46 0.00184 99.5 379 
Fuc4-4 Fc2-Fc3 515 1.42 0.0000817 99.6 518 
Fuc6-1 Fc2-Fc3 966 1.42 0.998 100 952 
Fuc1-2 Fc2-Fc3 480 1.44 0.428 99.3 482 
LewisX Fc2-Fc3 684 1.37 0.0951 99.1 692 
Man005 Fc2-Fc3 109 0.881 0.1 104 99.7 
Fuc5-2 Fc4-Fc3 524 1.67 7.66E-04 98.2 536 
Fuc4-1 Fc4-Fc3 468 1.58 0.379 98.2 477 
Fuc4-2 Fc4-Fc3 1493 1.48 0.0636 97.7 1540 
Fuc4-3 Fc4-Fc3 459 1.5 0.241 98.2 469 
Fuc4-4 Fc4-Fc3 625 1.47 0.88 98.1 634 
Fuc6-1 Fc4-Fc3 1286 1.43 0.0596 98.1 1320 
Fuc1-2 Fc4-Fc3 596 1.47 1.82 98.3 595 
LewisX Fc4-Fc3 833 1.47 4.03 98.8 800 
13
 S
ep
te
m
be
r 2
01
0 
Man005 Fc4-Fc3 155 0.946 5.55 102 131 
Fuc4-1 Fc2-Fc3 382 1.5 1.23E-01 98.5 389 
L-fucose Fc2-Fc3 1814 1.43 0.293 99.1 1830 
Fuc1-14 Fc2-Fc3 595 1.52 0.0718 98.3 608 
Fuc5-1 Fc2-Fc3 845 1.47 2.11E-01 98.6 859 
Fuc5-3 Fc2-Fc3 742 1.47 0.182 98.2 759 
Fuc5-4 Fc2-Fc3 776 1.5 0.184 97.9 797 
Fuc4-1 Fc4-Fc3 438 1.62 4.81E-04 97.8 450 
L-fucose Fc4-Fc3 2043 1.56 0.0118 97.9 2100 
Fuc1-14 Fc4-Fc3 672 1.65 7.35E-03 96.9 698 
Fuc5-1 Fc4-Fc3 954 1.58 0.0198 96.6 997 
Fuc5-3 Fc4-Fc3 828 1.59 0.0208 96 872 
14
 S
ep
te
m
be
r 2
01
0 
Fuc5-4 Fc4-Fc3 869 1.61 1.69E-02 95.4 922 !!!!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! #!
!
Date Compound IC50, µM A2 Rhi Rlo A1 
Fuc 1-02 596 1.49 0.0138 99.3 602 
Fuc 1-09 757 1.52 0.565 98.9 762 
Fuc 1-14 592 1.45 0.0139 98.6 604 
Fuc 1-19 554 1.45 0.0178 98.4 566 
Fuc 1-28 657 1.4 0.0072 99.1 666 
Fuc 1-30 609 1.41 0.042 99.4 614 
Fuc 1-31 490 1.36 0.00616 99 497 
Fuc 1-32 545 1.42 0.0138 99 553 
Lewis X 750 1.35 0.00901 99.2 759 
Man 005 114 1 0.276 97.9 118 
Man 002 774 1.37 0.0471 95.4 830 
Fuc 4-1 347 1.53 0.00481 97.6 358 
10
 M
ar
ch
 2
01
0 
Man-030 291 1.54 0.000161 97.8 300 
Man-035 324 1.6085 -1.2626 98.736 334.51 
Man-036 441 1.5596 -1.5425 98.456 459.07 
Man-002 830 1.4248 -1.2203 98.779 858.69 
Man-005 101 1.0629 0.013663 100.01 101.09 
mannose 79 1.62 12 94.9 71.7 
Man-030 325 1.561 -1.3005 98.699 335.6 
Man-031 367 1.5355 -1.1181 98.881 378.07 
Man-032 310 1.545 -1.432 98.567 321.44 
19
 Ju
ly
 2
01
0 
Man-033 290 1.5416 -1.4121 98.587 301.23 
man-040 398 1.5495 -1.2961 98.703 411.54 
man-041 335 1.5618 -1.3352 98.664 347.16 
man-042 5283 2.24 43.8 92.8 2230 
man-001 1054 1.4834 -0.93711 99.062 1081.5 
RR122 159 1.5 0.179 90.5 183 
man-029 797 1.34 0.00537 96.9 836 
man-037 810 1.6584 -1.2391 98.76 834.48 
man-038 296 1.6134 -1.3499 98.649 305.77 
20
 Ju
ly
 2
01
0 
man-039 356 1.5434 -1.2866 98.712 368.49 
ZL2(1) 3275 1.21 20.1 106 1950 
psDi 1056 1.1 -16.8 105 1260 
mannose 2982 1.11 -14.1 104 3480 
BB112 3272 1.11 -13.8 105 3740 
BB133 1179 1.23 -5.46 106 1170 15
 M
ar
ch
 2
01
1 
ZL1(D) 4540 1.05 7.26 106 3510 
BB112 3376 1.1 -14 101 4150 
ZL1(D) 4587 0.982 -2.67 101 4740 
ZL2(L) #NOMBRE! 1.49 57 99.8 1010 
Man1-2Man 915 1.09 -14.4 99.7 1160 
Man1-3Man 2341 1.07 -15.8 101 2970 16
 M
ar
ch
 2
01
1 
psDi 1012 1.07 -16.1 101 1290 
Man1-3Man-DC 2245 0.989 -28.9 101 3490 
ZL2(L)-DC 8840 1.53 48.2 99 1020 
Fucose-DC 3157 1.06 -14 98.9 4070 
17
 M
ar
ch
 
20
11
 
BB133-DC 862 1.15 -4.64 98.6 954 !!!!!!!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! $!
Date Compound IC50, µM A2 Rhi Rlo A1 
dcsign-mannose-FC2-1 3050 1.28 -7.46 100 3400 
dcsign-man12man1-FC2-1 901 1.23 -7.4 99.9 1010 
dcsign-psDi-FC2-1 1020 1.19 -9.46 100 1180 
dcsign-psTri-FC2-1 246 1.01 -3.31 102 252 
dcsign-man12man2-FC2-1 869 1.22 -7.35 99.9 974 
dcsign-mannose-FC3-1 3722 1.29 -7.01 100 4120 
dcsign-man12man1-FC3-1 1119 1.28 -6.89 99.9 1240 
dcsign-psDi-FC3-1 1289 1.22 -9.16 100 1480 
dcsign-psTri-FC3-1 319 1.01 -3.74 101 336 
dcsign-man12man2-FC3-1 1096 1.29 -6.78 100 1210 
Lg mannose Fc2 10300 0.916 0 100 10300 
Lg man12man Fc2 1630 0.988 0 99.7 1640 
Lg psDi Fc2 6827 1.03E+00 0 99.6 6880 
Lg psTri Fc2 5050 0.881 0 100 5050 
Lg mannose Fc3 4107 1.1 0 99.7 4130 
Lg man12man Fc3 713 1.19 0 98.8 728 
Lg psDi Fc3 2760 1.21 0 98.1 2850 
15
 Ju
ne
 2
01
1 
Lg psTri Fc3 1669 1.09 0 99 1700 
Man030 Fc2-1 1 261 1.28 -3.82 101 272 
Man030 Fc2-1 2 258 1.3 -3.7 98.9 277 
Man043 Fc2-1 4288 1.05 -50.1 101 8150 
Man044 Fc2-1 234 1.33 0.443 99.6 234 
Man045 Fc2-1 300 1.36 0.539 98.9 303 
Man046 Fc2-1 1080 1.23 1.43 99.7 1060 
Man047 Fc2-1 610 1.22 -7.37 99.2 692 
Man048 Fc2-1 1047 1.23 -3.07 99.4 1110 
Man049 Fc2-1 24 1.43 1.75 98.9 23.8 
Man030 Fc3-1 1 352 1.38 -4.04 99.8 374 
Man030 Fc3-1 2 351 1.36 -4.17 98.5 381 
Man043 Fc3-1 5850 1.03 -71.6 101 13600 
Man044 Fc3-1 326 1.35 -3.25 99.9 342 
Man045 Fc3-1 418 1.35 -4.4 99.7 447 
Man046 Fc3-1 1527 1.1 -31.1 100 2370 
Man047 Fc3-1 844 1.23 -11.1 99.6 1000 
Man048 Fc3-1 1491 1.12 -23.3 99.7 2110 
Man049 Fc3-1 32 1.39 0.31 98.4 32.5 
Man030 Fc4-1 1 340 1.33 -5.11 102 355 
Man030 Fc4-1 2 322 1.32 -5.03 97.2 362 
Man043 Fc4-1 5490 0.999 -80.6 102 13800 
Man044 Fc4-1 308 1.31 -4.88 101 326 
Man045 Fc4-1 392 1.31 -5.81 100 426 
Man046 Fc4-1 1395 1.09 -30.5 100 2160 
Man047 Fc4-1 784 1.2 -12.1 99.3 950 
Man048 Fc4-1 1350 1.1 -25.5 99 2000 
19
 Ju
ly
 2
01
1 
Man049 Fc4-1 30 1.35 -0.691 97.6 31.7 
Fuc4-1 Fc2-1 1 367 1.13 -25.2 99.6 530 
Fuc4-1 Fc2-1 2 372 1.13 -25.5 100 535 
Fuc4-1 azide Fc2-1 227 1.28 -3.05 99.3 240 
Lewis X Fc2-1 628 1.15 -11.7 100 754 
Fuc4-1 Fc3-1 1 527 1.29 -6.29 99.6 581 
Fuc4-1 Fc3-1 2 529 1.29 -6.2 99.4 585 
Fuc4-1 azide Fc3-1 311 1.36 -3.59 99.3 331 
Lewis X Fc3-1 886 1.18 -13 99.9 1080 
Fuc4-1 Fc4-1 1 529 1.05 -37 101 879 
Fuc4-1 Fc4-1 2 524 1.04 -38.3 99.8 908 
Fuc4-1 azide Fc4-1 304 1.32 -4.41 99.5 327 
21
 Ju
ly
 2
01
1 
Lewis X Fc4-1 856 1.15 -14.5 99.9 1070 !!!!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! %!
!
Date Compound IC50, µM A2 Rhi Rlo A1 
poly-020 14 0.956 6.98 100 12 
psDi 943 1.11 -10.5 101 1100 
Man030 226 1.22 -1.22 100 231 
poly008 113 1.11 -1.75 100 117 
poly009 39 1.04 2.12 100 37.6 
poly015 36 0.867 3.54 100 33.5 
poly016 38 0.74 0.774 101 36.6 
poly018 8 1.5 6.53 99.4 6.89 
1 
Fe
br
ua
ry
 2
01
1 
poly019 4 2.12 7.45 97.3 3.37 
psTri 81 0.637 -7.87 120 60.4 
poly005 753 0.999 5.37 101 659 
poly006 800 1.14 -2.53 100 835 
poly012 128 0.903 6.2 101 108 
poly013 114 0.924 3.83 100 105 
poly014 67 0.873 4.76 101 58.8 
poly017 112 1.12 -0.267 99.8 113 
poly021 51 1.1 3.24 99.6 48.5 
2 
Fe
br
ua
ry
 2
01
1 
poly022 32 0.986 2.83 100 30.6 
poly002 55 0.916 -3.19 102 56.5 
man a1-2man 869 1.04 -15.8 101 1110 
psDi 1023 1 -18.8 101 1380 
psTri 113 0.776 -3.68 105 110 
Man030 254 1.19 -2.47 100 265 
poly018 10 1.5 4.45 99.9 9.19 
poly019 4 2.14 1.37 98.1 4.41 
3 
Fe
br
ua
ry
 2
01
1 
poly005 781 0.867 -9.04 102 904 
Poly001 164 0.977 -13 99.9 208 
Poly008 136 0.987 -12.2 99.9 170 
psDi 896 0.994 -17.7 98.6 1250 
Man1-2Man 905 1.04 -15.6 98.5 1210 
psTri 68 0.802 -4.7 102 72.2 
Poly013 101 0.797 -2.44 98.8 110 7
 F
eb
ru
ar
y 
20
11
 
Mannose 2825 1.01 -18.8 97.7 4060 
psDi 1 994 1.06 -18.2 99.3 1350 
psDi 2 918 1.07 -17.1 94.4 1350 
NV233 1235 0.981 -29.3 98 2060 
NV243 481 1.04 -8.96 96.8 601 
NV253 703 0.927 -21.2 96.6 1110 
NV270 1366 1.03 -27.8 96.1 2270 2
4 
Ja
nu
ar
y 
20
12
 
Man030 298 1.31 -4.37 94.3 348 !!!!!!!!!!!!!!!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! &!
!!
Date Compound IC50, µM A2 Rhi Rlo A1 
L-fucose Fc2 11760 1.09 -22.8 100 16600 
BB01 211 1.21 -7.01 100 235 
MA05 Fc2 378 1.28 -7.36 101 414 
BB02 Fc2 96 1.19 -3.29 101 100 
MA07 Fc2-1 391 1.15 -15.3 101 485 
BB014 Fc2-1 17 0.997 -1.34 102 17 
RR390b Fc2-1 5 0.854 -0.152 109 3.94 
BB01 Fc2-1 2 215 1.21 -7.05 100 240 
L fucose Fc3-1 11743 1.09 -9.15 100 13700 
BB01 Fc3-1 1 211 1.15 -8.38 100 241 
MA05 Fc3-1 373 1.23 -8.16 100 422 
BB02 Fc3-1 97 1.16 -4.17 101 102 
MA07 Fc3-1 393 1.1 -16.6 101 501 
BB014 Fc3-1 17 0.96 -1.98 102 17.1 
RR390b Fc3-1 5 0.818 -0.468 110 3.81 
BB01 Fc3-1 2 217 1.17 -8.33 100 248 
L-fucose Fc2-1 7348 1.06 -29.9 99.7 11500 
BB013 Fc2-1 1 40 1.08 -1.93 100 41.4 
RCF-26 Fc2-1 3 1.15 1.61 102 2.89 
BB01 Fc2-1 206 1.24 -5.93 100 225 
D-mannose Fc2-1 3220 1.22 -11.2 100 3800 
BB015 Fc2-1 24 0.679 -1.15 106 20.6 
BB016 Fc2-1 12 0.758 -1.12 106 10.8 
BB013 Fc2-1 2 41 1.1 -1.86 99.9 42.3 
L-fucose Fc3-1 7465 1.05 -30.70 99.90 11800 
BB013 Fc3-1 1 41 1.07 -2.73 100.00 42.8 
RCF-26 Fc3-1 3 1.13 1.50 102.00 2.9 
BB01 Fc3-1 210 1.23 -6.65 100.00 232 
D-mannose Fc3-1 3273 1.20 -11.90 100.00 3910 
BB015 Fc3-1 24 0.67 -2.39 106.00 21.6 
BB016 Fc3-1 12 0.75 -1.95 106.00 11.1 
BB013 Fc3-1 2 41 1.08 -2.58 99.90 43.5 
BO Fc2-1 985 1.36 -2.41 99.3 1030 
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BO Fc3-1 998 1.37 -3.66 99.4 1060 
PM008 FC2-1 219 1.16 -15 99.6 277 
PM018 FC2-1 14 1.21 -0.755 101 14.2 
PM019 FC2-1 7 1.72 0.444 98.9 6.99 
PM023 FC2-1 8 2.02 -0.629 98.6 8.43 
PM024 FC2-1 8 2.04 0.107 98.8 7.94 
PM025 FC2-1 6 1.86 0.0434 97.7 6.29 
PM026 FC2-1 26 2.13 -1.14 98.5 26.7 
Man30 FC2-1 344 1.26 -4.9 99.1 376 
PM008 FC3-1 219 1.15 -15.5 99.7 279 
PM018 FC3-1 14 1.2 -0.811 101 14.2 
PM019 FC3-1 7 1.71 0.356 99 7 
PM023 FC3-1 8 2.01 -0.564 98.6 8.41 
PM024 FC3-1 8 2.02 0.0122 98.9 7.95 
PM025 FC3-1 6 1.83 -0.065 97.8 6.31 
PM026 FC3-1 26 2.13 -0.985 98.5 26.7 
man30 FC3-1 344 1.25 -5.15 99.1 378 
PM008 FC4-1 213 1.11 -14.4 100 267 
PM018 FC4-1 13 1.17 -0.453 101 13.3 
PM019 FC4-1 7 1.64 0.491 99.4 6.71 
PM023 FC4-1 8 1.95 -0.51 98.4 8.11 
PM024 FC4-1 8 2.05 0.249 96.8 7.93 
PM025 FC4-1 6 1.9 0.307 93.4 6.44 
PM026 FC4-1 25 2.17 -0.823 96.1 26.6 
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man30 FC4-1 324 1.2 -5.26 97.9 365 !!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! '!
!!
Date Compound IC50, µM A2 Rhi Rlo A1 
PM008 Fc2-1 217 1.18 -16.1 97 290 
MAN30 Fc2-1 259 1.41 -3.08 99.6 272 
PSDi Fc2-1 1100 1.05 -22.6 101 1540 
PM008 Fc3-1 218 1.17 -15 96.8 289 
MAN30 Fc3-1 258 1.4 -2.89 99.4 271 
PSDi Fc3-1 1076 1.05 -21.4 100 1510 
PM008 Fc4-1 194 1.11 -14.1 94.5 270 
man30 fc 4-1 256 1.45 -2.32 99.4 266 
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PSDi Fc4-1 1037 1.14 -14.7 100 1300 
FC4-1 man30 134 1.28 -2.29 99.6 140 
FC4-1 PM026 8 2.54 -1.33 97.3 7.83 
FC3-1 man30 137 1.25 -2.41 99.1 144 
FC3-1 PM026 8 2.64 0.0646 96.5 7.99 
FC2-1 Man030 139 1.26 -2.43 99.6 145 27
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FC2-1 PM026 8 2.72 0.641 96.7 7.98 
9a Fc4-1 1504 1.04 -25.4 101 2190 
Dendri b-Ala fuc Fc4-1 327 0.918 -9.28 101 385 
Dendri Fuc4-1 Fc4-1 41 1.3 0.0829 99.3 41 
L-fucose Fc4-1 2281 1.12 -18.2 100 3010 
LewisX Fc4-1 1490 1.06 -28.5 100 2280 
Fuc4-1 azide old Fc4-1 2 364 1.33 -4.48 99.2 393 
LewisX Fc2-1 1420 1.1 -25.7 100 2070 
Fuc4-1 azide old Fc2-1 2 344 1.38 -4.43 99.1 371 
Fuc4-1 azide old Fc3-1 1 348 1.36 -3.97 99.3 372 
Fuc4-1 azide-2 Fc3-1 2755 1.08 -41.5 99.9 4830 
L-fuc b-Ala Fc3-1 1660 1.07 -33.5 100 2680 
9a Fc3-1 1427 1.08 -22.8 100 2020 
Dendri b-Ala fuc Fc3-1 300 0.96 -8.41 99.6 356 
Dendri Fuc4-1 Fc3-1 39 1.34 0.0995 99 39.5 
L-fucose Fc3-1 2196 1.15 -15.7 99.9 2790 
LewisX Fc3-1 1427 1.08 -29 100 2180 
Fuc4-1 azide old Fc3-1 2 352 1.36 -3.92 99.2 376 
Fuc4-1 azide old Fc4-1 1 362 1.34 -4.02 99.4 387 
Fuc4-1 azide-2 Fc4-1 2910 0.88 -131 99.5 12700 
L-fuc b-Ala Fc4-1 1750 1.03 -36.4 101 2920 
Fuc4-1 azide old Fc2-1 1 342 1.37 -4.57 99.5 367 
Fuc4-1 azide-2 Fc2-1 2656 1.21 -20.8 100 3540 
L-fuc b-Ala Fc2-1 1635 1.08 -34.9 100 2670 
9a Fc2-1 1404 1.1 -23.4 100 1990 
Dendri b-Ala fuc Fc2-1 291 0.97 -9.24 99.5 350 
Dendri Fuc4-1 Fc2-1 38 1.33 -0.842 99 39.1 
2 
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L-fucose Fc2-1 2143 1.17 -16.4 99.8 2740 
Man030 DCSIGN 1 319 1.4 -3.94 99.1 341 
Man030 DCSIGN 2 326 1.39 -4.09 99.3 349 
psDi Lg Fc1 1008 1.68 9.21 99 904 
Man030 Lg Fc1 1725 1.37 -0.516 98.4 1780 
NV233 Lg Fc1 1302 1.29 1.87 99.7 1270 
NV243 Lg Fc1 2432 1.25 -18.4 99.3 3160 
NV253 Lg Fc1 877 1.5 3.55 101 824 
NV270 Lg Fc1 2880 1.26 -18.9 99.4 3750 
psDi Lg Fc2 1474 1.51 20.4 99.4 1050 
Man030 Lg Fc2 2556 1.28 14.2 98.7 2010 
NV233 Lg Fc2 1933 1.22 15.3 99.7 1440 
NV243 Lg Fc2 3440 1.16 -4.94 99.7 3750 
NV253 Lg Fc2 1263 1.29 10.8 101 1030 
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NV270 Lg Fc2 4035 1.26 3.5 99.5 3840 !!!
!""#$%&'()*+#,-./#0$"'*1#23)#$""#%3453'6+1#+')(67#89*#89*1(1#! (!
!!
Date Compound IC50, µM A2 Rhi Rlo A1 
PM026 fc2-1 6 3.03 1.18 93.6 5.79 
man030 fc2-1 348 1.35 -2.68 99.5 364 
PM026 FC3-1 6 3 0.21 93.6 5.82 
MAN030 FC3-1 348 1.34 -3.55 99.9 367 
PM026 FC4-1 6 2.97 -0.689 94.3 5.76 3
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MAN030 FC4-1 348 1.39 -3.63 99.7 368 
D-mannose 1 3597 1.23 -8.73 99.7 4120 
L-fucose 1886 1.28 -4.51 99.6 2030 
BB178 435 1.27 -5.93 99.7 477 
BB203 2000 1.19 -19 99.8 2630 
BB213 3430 1.15 -27.3 100 5010 
BB207 3154 1.19 -22.5 100 4310 
BO2 1108 1.33 -10.1 99.6 1280 
BO3 1170 1.26 -10.9 99.9 1370 
30
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D-mannose 2 3667 1.23 -9.13 99.9 4210 
Man038 Lg 5788 1.0167 -4.7854 95.213 6990.9 
Man039 Lg 8128 0.85874 -5.0693 94.93 10301 
Man040 Lg 7625 0.90671 -4.8698 95.129 9459.6 
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Man041 Lg 6629 0.85703 -4.5188 95.48 8190.9 
Man 002 Lg 2915 1.0322 2.9381 102.94 2600.6 
Man 005 Lg 2037 0.96396 3.6266 103.63 1751.8 
Man 029 Lg 3083 1.1661 -2.933 97.066 3410.3 
Man 030 Lg 7467 0.8808 -3.0726 96.927 8586.7 
Man 031 Lg 6410 1.0516 -4.0032 95.996 7466.5 
Man 032 Lg 5061 1.2031 -3.4695 96.529 5681 
Man 033 Lg 4668 1.1664 -4.5742 95.425 5463.1 
Man 036 Lg 4504 2.117 -4.4524 95.547 4900.7 
Man 035 Lg 3680 1.2217 -5.1281 94.871 4354.9 
Man-038 Lg 5788 1.0167 -4.7854 95.213 6990.9 
Man-039 Lg 8128 0.85874 -5.0693 94.93 10301 
Man-040 Lg 7625 0.90671 -4.8698 95.129 9459.6 
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Man-041 Lg 6629 0.85703 -4.5188 95.48 8190.9 
psDi Lg 4849 0.70 0.73 100.73 4651.20 
Man044 Lg 9244 0.82 0.42 100.42 9056.60 
Man045 Lg 11298 0.79 0.82 100.82 10839.00 
Man046 Lg 3747 1.68 -0.45 99.55 3786.70 
Man047 Lg 10457 0.75 0.78 100.78 10032.00 
Man048 Lg 12323 0.95 0.14 100.14 12251.00 
Man049 Lg 2045 1.02 0.31 100.31 2020.40 
Man030 Lg 10111 0.75 0.79 100.79 9692.70 
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psDi 2 Lg 4534 0.77 0.71 100.71 4369.70 !
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Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition by various dendrimers with mannose, psDi, psTri and 4h 1 
Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition 
by various dendrimers with mannose, psDi, psTri and 4h 
 
 
 
 
 
 
 
   
Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition by various dendrimers with mannose, psDi, psTri and 4h 2 
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Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition by various dendrimers with mannose, psDi, psTri and 4h 3 
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Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition by various dendrimers with mannose, psDi, psTri and 4h 4 
   
 
   
   
   
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference surface corrected sensorgrams and inhibition curves for DC-SIGN inhibition by various dendrimers with mannose, psDi, psTri and 4h 5 
Inhibition curves : 
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Reference surface corrected sensorgrams of double regeneration test 
of DC-SIGN surfaces 
 
Fc1 = StrepTactin; Fc2 = DC-SIGN-LD; Fc3 = DC-SIGN-MD; Fc4 = DC-SIGN-HD 
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Abstract  
An amazing defense system, the immunity, protects most of the living organisms from harmful pathogens. The innate and 
acquired immunity components work together to provide efficient protection of humans as well as all other jawed vertebrates. 
Dendritic cells, the component of the innate immunity, routinely survey the peripheral tissues, capture and process the invading 
pathogens, and finally, present the antigens to the T cells to boost the pathogen specific adaptive immune responses. These 
cells recognize the foreign organisms with the help of multiple pattern recognition receptors (PRRs), which specifically bind 
molecules on the pathogen surfaces, so-called pathogen associated molecular patterns (PAMPs).  
Among PRRs, the C-type lectin receptors (CLRs) have an important role in pathogen recognition and capturing. However, 
one of these CLRs, DC-SIGN, has been shown to be hijacked by many dangerous pathogens, including HIV, to promote 
their infection. 
This work aims to develop the antagonists of the C-type lectin receptor DC-SIGN, which would be able to block the use of 
this receptor by pathogens. To achieve that, the strategy of the development of glycomimetic ligands of DC-SIGN and the 
multivalent presentation of the selected monovalent glycomimics has been employed.  
The presented studies were accomplished in collaboration with several chemists groups, who have designed and synthesized 
different glycomimetic compounds as well as different multivalent platforms. The mannose-based, fucose-based and the C-
glycosidic compounds were explored as monovalent DC-SIGN ligands, and multivalent platforms with different valence as 
well as ligand presentation in space were investigated. 
Using surface plasmon resonance (SPR), the activity of the compounds to inhibit DC-SIGN was estimated. Moreover, the 
compounds were evaluated for their selectivity to DC-SIGN vs langerin, another CLR with a protective role from HIV 
infection. Some of the compounds were structurally characterized by X-ray crystallography and NMR spectrometry studies. The 
SPR studies of multivalent compounds confirmed the improved activity, but also revealed possible complications. 
Overall, these studies allowed to identify two new monovalent leads and to draw perspectives for their further improvement, 
and suggested the improvement of multivalent presentation platforms.  
Keywords: dendritic cells, DC-SIGN, langerin, HIV, glycomimetics, dendrimers, inhibition, selectivity, clustering, surface 
Plasmon resonance, analytical ultracentrifugation, dynamic light scattering, X-ray crystallography, nuclear magnetic resonance. 
 
Résumé 
L'immunité, un système de défense incroyable, protège la plupart des organismes vivants des pathogènes nuisibles. Les 
composantes innée et acquise de l'immunité travaillent ensemble pour assurer une protection efficace de l'homme ainsi que de 
tous les autres vertébrés à mâchoires. 
Les cellules dendritiques, la composante de l'immunité innée, passent régulièrement en revue les tissus périphériques, 
capturent et traitent les agents pathogènes envahisseurs et enfin, présentent les antigènes aux lymphocytes T pour stimuler les 
réponses immunitaires adaptatives spécifiques. Ces cellules reconnaissent les organismes étrangers à l'aide de plusieurs "Pattern 
Recognition Receptors" (PRRs), qui se lient spécifiquement à des molécules à la surface des agents pathogènes, dits 
"Pathogen Associated Molecular Patterns (PAMPs). 
Parmi les PRR, les récepteurs lectine de type C (CLRs) ont un rôle important dans la reconnaissance et dans la capture des 
pathogènes. Cependant, DC-SIGN, l'un de ces CLR, peut être détourné par de nombreux agents pathogènes dangereux, y 
compris le VIH, afin de promouvoir leur infection. 
Ce travail vise à développer des antagonistes de DC-SIGN, qui serait en mesure de bloquer l'utilisation de ce récepteur par des 
agents pathogènes. Pour atteindre cet objectif, la stratégie du développement de ligands glycomimétique de DC-SIGN et la 
présentation multivalente des glycomimétiques monovalents sélectionnés a été employée. 
Les études présentées ont été réalisées en collaboration avec plusieurs groupes de chimistes, qui ont conçu et synthétisé 
différents composés glycomimétiques ainsi que différentes plates-formes multivalentes. Des ligands monovalents de DC-
SIGN basés sue le mannose, le fucose et sur les composés C-glycosidiques ont été explorés et différentes plates-formes de 
valence avec différents modes de présentation dans l'espace ont été étudiées. 
En utilisant la résonance plasmonique de surface (SPR), l'activité des composés à inhiber DC-SIGN a été estimée. De plus, 
les composés ont été évalués pour leur sélectivité pour DC-SIGN par rapport à la Langerine, un autre CLR ayant un rôle 
protecteur contre l'infection par le VIH. Certains de ces composés ont été caractérisés par cristallographie aux rayons X et par 
spectrométrie RMN. Les études de SPR de composés multivalents ont confirmé l'amélioration de l'activité, mais a également 
révélé des complications possibles. 
Dans l'ensemble, ces études ont permis d'identifier les deux meilleurs nouveaux composés et de suggérer des perspectives pour 
l'amélioration de ces composés et des plates-formes de présentation multivalentes. 
Mots-clés: cellules dendritiques, DC-SIGN, langerin, VIH, glycomimetiques, dendrimères, inhibition, selectivité, clustering, 
résonance plasmonique de surface, ultracentrifugation analytique, diffusion dynamique de la lumière, cristallographie aux rayons 
X, résonance magnétique nucléaire. 
